Clustering O 0 2.5344341338495724e-05
of O 0 8.315139155001816e-08
missense O 0 4.5915810915175825e-05
mutations O 0 1.3872386261937208e-05
in O 0 3.48186404153239e-08
the O 0 2.5927863589458866e-07
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999997615814209
telangiectasia I-Disease 1 1.0
gene O 0 6.832415965618566e-05
in O 0 5.180240236768441e-08
a O 0 7.308026539476487e-08
sporadic B-Disease 0 0.0003646227123681456
T I-Disease 1 0.9999299049377441
- I-Disease 1 0.860854983329773
cell I-Disease 0 0.01613699086010456
leukaemia I-Disease 0 0.48142990469932556
. O 0 2.4369639959331835e-06

Ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.024789977818727493
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 4.809146858519853e-09
is O 0 5.744943964991478e-10
a O 0 1.7246499783851732e-09
recessive B-Disease 0 0.000927816319745034
multi I-Disease 1 0.9885298609733582
- I-Disease 1 0.9999681711196899
system I-Disease 0 0.41492730379104614
disorder I-Disease 1 0.5166865587234497
caused O 0 6.43607549477565e-08
by O 0 1.1274732258925724e-09
mutations O 0 1.663060231749114e-07
in O 0 1.2769465485007458e-09
the O 0 8.865079781372742e-10
ATM O 0 2.588889742582978e-07
gene O 0 1.1754350737191999e-07
at O 0 1.689642026292404e-08
11q22 O 0 1.1252458307353663e-06
- O 0 1.0693944432205171e-06
q23 O 0 1.1210096317881835e-06
( O 0 6.3062817190484566e-09
ref O 0 9.556016493661446e-07
. O 0 3.078657773158966e-09
3 O 0 7.4307147102103954e-09
) O 0 1.3781912500121507e-08
. O 0 1.7596083523585548e-07

The O 0 2.3324740539010236e-07
risk O 0 3.141617298751953e-06
of O 0 2.386018715938576e-09
cancer B-Disease 0 8.588731361669488e-07
, O 0 9.94005322496605e-10
especially O 0 6.016199094460717e-09
lymphoid B-Disease 0 3.5314857882440265e-07
neoplasias I-Disease 0 5.453396170196356e-06
, O 0 3.0029903008710335e-09
is O 0 1.0626476365516169e-09
substantially O 0 2.4670814724458978e-08
elevated O 0 1.3180277846913668e-07
in O 0 2.6094078009464283e-08
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 4.04028469347395e-06
and O 0 1.5027580291260278e-09
has O 0 4.247482365826727e-09
long O 0 8.730490996811113e-09
been O 0 1.0718613552285206e-08
associated O 0 3.7291805199402006e-08
with O 0 1.3494332051777747e-07
chromosomal O 1 1.0
instability O 1 1.0
. O 0 6.281198693613987e-06

By O 0 3.5056882552453317e-07
analysing O 0 1.194130709336605e-05
tumour B-Disease 1 0.9999946355819702
DNA O 0 5.83566418299597e-07
from O 0 2.4770903106485775e-09
patients O 0 1.6092570831460762e-08
with O 0 6.265180041431506e-10
sporadic B-Disease 0 1.3343252248887438e-05
T I-Disease 1 0.9993867874145508
- I-Disease 0 0.01115246582776308
cell I-Disease 0 0.00010759283759398386
prolymphocytic I-Disease 0 0.006009221076965332
leukaemia I-Disease 0 0.015276686288416386
( O 0 9.316933891057033e-09
T B-Disease 0 1.1290498150628991e-05
- I-Disease 0 2.599899744382128e-07
PLL I-Disease 0 1.5362924159489921e-06
) O 0 1.693884477127483e-09
, O 0 1.134262683777365e-10
a O 0 1.6377900424746628e-10
rare O 0 6.797978180372866e-09
clonal B-Disease 0 3.505327015318471e-07
malignancy I-Disease 0 3.423991074669175e-05
with O 0 3.471595233506264e-10
similarities O 0 1.7947490604797167e-08
to O 0 1.948337047252835e-09
a O 0 3.4014193683873373e-09
mature B-Disease 0 2.109965606678088e-07
T I-Disease 0 8.103939035208896e-05
- I-Disease 0 1.565825414218125e-06
cell I-Disease 0 1.3425059250948834e-06
leukaemia I-Disease 0 0.0001441142667317763
seen O 0 3.285578316081228e-07
in O 0 8.086129099638129e-09
A B-Disease 1 0.9999994039535522
- I-Disease 1 0.9999785423278809
T I-Disease 1 1.0
, O 0 1.5260794850036064e-09
we O 0 4.5737649778665457e-10
demonstrate O 0 5.542548642267775e-10
a O 0 1.9962977104714952e-10
high O 0 2.22199592059269e-09
frequency O 0 2.9093673248326013e-08
of O 0 9.851399696003682e-10
ATM O 0 1.0662172371667111e-06
mutations O 0 9.926701522999792e-07
in O 0 3.464699460664633e-08
T B-Disease 0 0.0011661113239824772
- I-Disease 0 2.543371192587074e-05
PLL I-Disease 0 0.00034068903187289834
. O 0 6.416017868104973e-07

In O 0 8.980405397096547e-08
marked O 0 2.9302736237468707e-08
contrast O 0 1.126304560727931e-08
to O 0 6.42640385351001e-10
the O 0 6.802565732932919e-10
ATM O 0 1.1289305348327616e-06
mutation O 0 2.8438896038096573e-07
pattern O 0 1.0183816812059376e-06
in O 0 2.2962444745644461e-07
A B-Disease 1 1.0
- I-Disease 1 0.9999996423721313
T I-Disease 1 1.0
, O 0 6.822342690782079e-10
the O 0 7.784344696615264e-11
most O 0 1.5490468630030563e-10
frequent O 0 1.3902798912113212e-09
nucleotide O 0 1.744714062112962e-08
changes O 0 3.052975428019522e-09
in O 0 9.432401526510148e-10
this O 0 6.92182977601874e-09
leukaemia B-Disease 0 2.1607245798804797e-05
were O 0 3.544461790738751e-08
missense O 0 1.9316321413498372e-05
mutations O 0 1.3003159438085277e-05
. O 0 7.198225944193837e-07

These O 0 5.019826687657769e-08
clustered O 0 2.72479638852019e-07
in O 0 7.621539843682967e-09
the O 0 1.610754751801835e-09
region O 0 1.2818373917866666e-08
corresponding O 0 1.1419897916198352e-08
to O 0 1.1043044256808798e-09
the O 0 3.1553276658158325e-10
kinase O 0 1.4628213307332771e-08
domain O 0 9.348619656179835e-09
, O 0 8.32722613086645e-10
which O 0 1.6604407848674896e-09
is O 0 4.04662470199213e-10
highly O 0 7.394798662296864e-10
conserved O 0 1.4140172366339243e-09
in O 0 8.392392891742873e-10
ATM O 0 6.445713438552048e-07
- O 0 1.4290120020632457e-07
related O 0 1.331464360987411e-08
proteins O 0 3.035272477802664e-09
in O 0 9.68733426809365e-10
mouse O 0 1.2533030258055078e-07
, O 0 4.250302332309275e-09
yeast O 0 3.2596989285593736e-07
and O 0 4.9565958448738456e-08
Drosophila O 0 5.472649604598701e-07
. O 0 2.492031967449293e-07

The O 0 1.377314049477718e-07
resulting O 0 2.1546857453813573e-07
amino O 0 2.8522200068437087e-07
- O 0 3.0343136359078926e-07
acid O 0 2.4782730534411712e-08
substitutions O 0 6.8942527242654705e-09
are O 0 5.307077000082927e-10
predicted O 0 4.130250363942878e-09
to O 0 6.413913844482977e-10
interfere O 0 9.372007170327379e-09
with O 0 1.654150372232266e-09
ATP O 0 1.7520949313620804e-07
binding O 0 1.2816424543871108e-07
or O 0 5.575880379637965e-08
substrate O 0 6.949725502636284e-06
recognition O 0 2.0546053747239057e-06
. O 0 2.632087671372574e-06

Two O 0 1.5312460277527862e-07
of O 0 6.287521170378341e-09
seventeen O 0 1.5584197399221011e-07
mutated O 0 2.3024006168270716e-06
T B-Disease 0 1.2231726032041479e-05
- I-Disease 0 1.979903885285239e-07
PLL I-Disease 0 1.0252165338897612e-06
samples O 0 1.6914478706553382e-08
had O 0 3.309716056776324e-09
a O 0 4.957205201883141e-10
previously O 0 1.3134852849816525e-07
reported O 0 9.064615369425155e-06
A B-Disease 1 0.9999995231628418
- I-Disease 1 0.9999974966049194
T I-Disease 1 1.0
allele O 0 0.00039328119601123035
. O 0 2.2631152205576655e-06

In O 0 5.4837311580513415e-08
contrast O 0 1.4443696727539646e-07
, O 0 2.0987576121456186e-09
no O 0 4.142937104489874e-09
mutations O 0 5.355168397613852e-08
were O 0 2.8604170143609053e-09
detected O 0 5.139789749364354e-08
in O 0 9.898449837564272e-10
the O 0 3.539803172802891e-10
p53 O 0 6.229578630723154e-09
gene O 0 6.558257936717382e-09
, O 0 1.435700724972122e-10
suggesting O 0 1.741395361243292e-09
that O 0 2.2796696474980394e-10
this O 0 2.5347786092311253e-09
tumour B-Disease 1 1.0
suppressor O 0 9.73273358795268e-07
is O 0 6.2969669478718515e-09
not O 0 3.3830440671067663e-09
frequently O 0 1.8988318473134314e-08
altered O 0 1.620697958060191e-07
in O 0 1.5290520849475797e-08
this O 0 7.387856015839134e-08
leukaemia B-Disease 0 0.0005038076778873801
. O 0 7.430575692524144e-07

Occasional O 0 4.581154644256458e-05
missense O 0 6.439208664232865e-05
mutations O 0 4.3704130803234875e-06
in O 0 4.146913923364082e-09
ATM O 0 2.6739726877167413e-07
were O 0 5.298674832232564e-09
also O 0 2.4986430702256257e-09
found O 0 5.3192712456962e-09
in O 0 1.2843606178591926e-08
tumour B-Disease 1 1.0
DNA O 0 6.639561433985364e-07
from O 0 2.1926014337481092e-09
patients O 0 1.6469449803935277e-08
with O 0 1.0515823767320853e-09
B B-Disease 0 6.005601790093351e-06
- I-Disease 0 1.6143715129146585e-06
cell I-Disease 0 3.228376226616092e-05
non I-Disease 0 5.619659714284353e-05
- I-Disease 0 0.1055944487452507
Hodgkins I-Disease 1 0.9177430868148804
lymphomas I-Disease 0 7.370068487944081e-05
( O 0 7.383978317676565e-09
B B-Disease 0 2.629199968851026e-07
- I-Disease 0 8.379861071716732e-08
NHL I-Disease 0 1.7196645885064754e-08
) O 0 4.218165539082719e-10
and O 0 4.811621101552532e-10
a O 0 4.397114672372027e-09
B B-Disease 0 1.8884354631154565e-06
- I-Disease 0 3.7965290289321274e-07
NHL I-Disease 0 1.6204599262437114e-07
cell O 0 7.945550919430389e-07
line O 0 2.959328867291333e-06
. O 0 8.260238359980576e-07

The O 0 2.205592508630616e-08
evidence O 0 1.6101534328072376e-08
of O 0 2.6109486794823056e-10
a O 0 4.722508495369482e-10
significant O 0 3.869383480292754e-09
proportion O 0 6.280380659973162e-08
of O 0 2.198014409371396e-10
loss O 0 1.2639836199923593e-07
- O 0 1.689133739546378e-07
of O 0 4.739816872323388e-10
- O 0 1.266576987291046e-06
function O 0 2.1844503095280743e-08
mutations O 0 7.221989761774239e-08
and O 0 1.3355409000936902e-09
a O 0 4.943684350777744e-10
complete O 0 1.4826377903176535e-09
absence O 0 1.1059232418730858e-09
of O 0 2.2677469277421203e-11
the O 0 1.2231039792087728e-10
normal O 0 7.994738759897757e-10
copy O 0 3.464142750431165e-09
of O 0 3.8537797952820085e-11
ATM O 0 1.9262158090782577e-08
in O 0 3.025410200141465e-10
the O 0 7.336244944866621e-10
majority O 0 2.0415599877310342e-08
of O 0 2.5227449018672132e-09
mutated O 0 0.0010633750353008509
tumours B-Disease 1 1.0
establishes O 0 4.7054842866600666e-07
somatic O 0 4.0896856035033124e-07
inactivation O 0 7.251652505146922e-07
of O 0 1.67155220220927e-10
this O 0 1.3536614884568365e-10
gene O 0 5.60292434670373e-09
in O 0 5.62719038033066e-10
the O 0 4.252392604708888e-10
pathogenesis O 0 3.2051055143256235e-08
of O 0 6.566153176734701e-10
sporadic B-Disease 0 9.78170101006981e-06
T I-Disease 1 0.9452997446060181
- I-Disease 0 1.0396970537840389e-05
PLL I-Disease 0 1.0816165740834549e-05
and O 0 2.355078798643717e-09
suggests O 0 2.9581537219769416e-09
that O 0 1.2541502558693907e-10
ATM O 0 2.5529848457495063e-08
acts O 0 5.955483661779226e-09
as O 0 7.252022982129347e-09
a O 0 1.0056925248136395e-07
tumour B-Disease 1 0.9999998807907104
suppressor O 0 0.00018299593648407608
. O 0 3.953924988309154e-06

As O 0 5.7802431285836064e-08
constitutional O 0 1.243480518553497e-08
DNA O 0 7.642009336450428e-08
was O 0 4.0185370586698355e-09
not O 0 3.371743440006014e-10
available O 0 1.0043114118118979e-09
, O 0 1.8074580721005873e-10
a O 0 1.2113661185253477e-09
putative O 0 1.1853384194182581e-06
hereditary O 0 0.003929182421416044
predisposition O 0 4.44999432147597e-06
to O 0 2.0638140085793566e-08
T B-Disease 0 0.007191547192633152
- I-Disease 0 9.856573797151214e-07
PLL I-Disease 0 1.91233993973583e-06
will O 0 6.057440105067258e-10
require O 0 9.613981832856666e-10
further O 0 7.348119890338012e-10
investigation O 0 1.1946762690229207e-08
. O 0 6.947768138587662e-09
. O 0 1.3210730287482875e-07

Myotonic B-Disease 1 0.9999620914459229
dystrophy I-Disease 1 0.9996380805969238
protein O 0 8.540690032532439e-06
kinase O 0 1.554251866764389e-05
is O 0 2.0041284187755082e-08
involved O 0 7.53122364471892e-09
in O 0 7.504548094061647e-10
the O 0 4.886060445130624e-10
modulation O 0 7.208860353102864e-08
of O 0 1.2485562583819387e-09
the O 0 2.3050178654671072e-08
Ca2 O 0 1.0906302122748457e-05
+ O 0 5.396734195528552e-06
homeostasis O 0 2.0787054381798953e-05
in O 0 1.1338598682186785e-07
skeletal O 0 5.900928590563126e-05
muscle O 0 3.0336355848703533e-05
cells O 0 5.284056896925904e-06
. O 0 5.616777798422845e-07

Myotonic B-Disease 1 0.9999979734420776
dystrophy I-Disease 1 0.9999988079071045
( O 0 1.4703632587043103e-05
DM B-Disease 1 1.0
) O 0 3.645762447490597e-08
, O 0 3.718955421394554e-10
the O 0 2.4988086599897485e-10
most O 0 3.295919759338517e-09
prevalent O 0 6.5709591581253335e-06
muscular B-Disease 0 1.5375970178865828e-05
disorder I-Disease 0 0.003995838575065136
in O 0 7.319476136302683e-09
adults O 0 3.5975574519397924e-07
, O 0 2.6049209456147082e-09
is O 0 3.827777650400321e-09
caused O 0 8.491906733354426e-09
by O 0 6.311127731528643e-10
( O 0 1.1109719810775687e-09
CTG O 0 3.336411680265883e-07
) O 0 8.334519185915212e-10
n O 0 1.0180500709111584e-07
- O 0 1.9293969444333925e-07
repeat O 0 2.71119318995261e-07
expansion O 0 3.4197311649108997e-09
in O 0 1.8007308144607492e-10
a O 0 2.542971111463288e-10
gene O 0 7.792642087167678e-09
encoding O 0 1.2587022979460016e-08
a O 0 4.794721064627083e-09
protein O 0 1.2464849419302482e-07
kinase O 0 5.459890417114366e-06
( O 0 8.48190708779839e-08
DM B-Disease 1 0.9999990463256836
protein O 0 1.7631947457630304e-07
kinase O 0 4.382414715564664e-07
; O 0 6.669278462823058e-09
DMPK O 0 4.0766795450508653e-07
) O 0 7.974620408468525e-10
and O 0 2.1427118412908897e-10
involves O 0 1.5595333913154263e-09
changes O 0 4.562605848690282e-09
in O 0 1.893146084341879e-09
cytoarchitecture O 0 9.810303254198516e-07
and O 0 2.4234696027747304e-08
ion O 0 2.2007238840160426e-06
homeostasis O 0 3.9587703213328496e-05
. O 0 9.602433692634804e-07

To O 0 3.2037490882430575e-08
obtain O 0 2.5383407376011746e-08
clues O 0 2.8016922115625675e-08
to O 0 7.699750281808804e-10
the O 0 2.1191061405634315e-10
normal O 0 5.050325047051274e-09
biological O 0 2.9603507201159118e-08
role O 0 1.2117873815498115e-08
of O 0 5.33418309522915e-10
DMPK O 0 5.403261411629501e-07
in O 0 2.817913236086156e-09
cellular O 0 1.1231386309873415e-07
ion O 0 7.778167088190457e-08
homeostasis O 0 3.805224935149454e-07
, O 0 2.065762227942969e-09
we O 0 3.320218100455463e-09
have O 0 6.503594884854635e-10
compared O 0 2.513039110141335e-09
the O 0 1.0750466072906306e-09
resting O 0 1.848340787091729e-07
[ O 0 7.292194936781016e-08
Ca2 O 0 3.205656469162932e-07
+ O 0 9.898835173771658e-08
] O 0 3.414929139466949e-08
i O 0 1.6327543761462948e-08
, O 0 8.061527140279523e-11
the O 0 6.518742490246865e-11
amplitude O 0 4.790625673933846e-09
and O 0 2.0556572000174356e-09
shape O 0 7.77565958287596e-08
of O 0 1.3862420100707595e-09
depolarization O 0 2.4634377382426464e-07
- O 0 4.059402726852568e-06
induced O 0 1.504039687461045e-06
Ca2 O 0 4.2728692051241524e-07
+ O 0 4.552680721303659e-08
transients O 0 1.8819724800778204e-07
, O 0 6.052139345236185e-10
and O 0 1.3336616533354828e-10
the O 0 5.846485101601573e-11
content O 0 5.090078358804817e-10
of O 0 7.703536419878532e-11
ATP O 0 4.8284967135714396e-08
- O 0 8.344690627382079e-08
driven O 0 5.6604370968216244e-08
ion O 0 1.3227624151568307e-07
pumps O 0 2.943118602161121e-07
in O 0 5.749638987140315e-09
cultured O 0 4.2644344944164914e-07
skeletal O 0 1.6359455230485764e-06
muscle O 0 3.2424725304736057e-07
cells O 0 1.51715013885223e-08
of O 0 6.345718395195377e-11
wild O 0 5.356187493532616e-09
- O 0 3.770977173189749e-06
type O 0 4.457775958144339e-06
and O 0 7.313280203646855e-09
DMPK O 0 8.4723336613024e-07
[ O 0 4.8961780407807964e-08
- O 0 6.984754463701393e-07
/ O 0 1.1194274520676117e-06
- O 0 2.6017405616585165e-06
] O 0 7.337621923397819e-07
knockout O 0 1.5040274774946738e-05
mice O 0 8.709705070941709e-06
. O 0 6.249038051464595e-07

In O 0 2.0543535583783523e-07
vitro O 0 1.3817578292218968e-05
- O 0 9.46537602430908e-06
differentiated O 0 2.596980721136788e-06
DMPK O 0 3.730771140908473e-06
[ O 0 1.3541011867346242e-07
- O 0 5.673851433130039e-07
/ O 0 6.422898763958074e-07
- O 0 2.2307919778086216e-07
] O 0 2.2172171654233352e-08
myotubes O 0 9.011805701675257e-08
exhibit O 0 1.1687056655773631e-08
a O 0 4.8145616382555545e-09
higher O 0 2.686079092484306e-08
resting O 0 1.3571431622949603e-07
[ O 0 4.338700065886769e-08
Ca2 O 0 3.1116607601688884e-07
+ O 0 8.660901329449189e-08
] O 0 1.738177424215337e-08
i O 0 5.53687717896878e-09
than O 0 1.0563139252184328e-10
do O 0 6.595335388936974e-10
wild O 0 1.5199355107853307e-09
- O 0 5.391459367842799e-08
type O 0 9.265986733453246e-08
myotubes O 0 2.974036306113703e-07
because O 0 3.6070888498329623e-09
of O 0 2.1276222103572273e-11
an O 0 1.1054144405386879e-10
altered O 0 2.4382691421465097e-08
open O 0 2.3994191522547226e-08
probability O 0 4.410537268739745e-09
of O 0 2.963743417350173e-10
voltage O 0 2.367453134866082e-06
- O 0 1.8645718228071928e-05
dependent O 0 3.982011094194604e-06
l O 0 7.013559661572799e-05
- O 0 2.140134256478632e-06
type O 0 1.411254288541386e-06
Ca2 O 0 1.5342176311605726e-06
+ O 0 3.1345524575954187e-07
and O 0 3.33854046630222e-08
Na O 0 1.9937863271479728e-06
+ O 0 4.543511522570043e-07
channels O 0 2.1973874027025886e-06
. O 0 9.157718068308895e-07

The O 0 1.0368905378754789e-07
mutant O 0 2.203546500822995e-06
myotubes O 0 1.8860847603718867e-06
exhibit O 0 5.9512057504207405e-08
smaller O 0 4.2308442971261684e-08
and O 0 1.4682274063204659e-08
slower O 0 3.629811260452698e-07
Ca2 O 0 3.0329097171488684e-06
+ O 0 3.2238091307590366e-07
responses O 0 2.9469314100083466e-08
upon O 0 3.1195919181215004e-09
triggering O 0 3.6982125806162e-08
by O 0 1.1027637691896075e-09
acetylcholine O 0 6.969078185647959e-07
or O 0 1.1534710210980847e-05
high O 0 6.416607902792748e-06
external O 0 0.0017666690982878208
K O 0 1.4282602023740765e-05
+ O 0 2.3978993795026327e-06
. O 0 5.138633696333272e-07

In O 0 4.259702635067697e-08
addition O 0 7.642851684863672e-09
, O 0 2.4097051021243487e-09
we O 0 1.5034288258775064e-09
observed O 0 2.3958737216389636e-09
that O 0 2.1645729653130275e-10
these O 0 1.972864316357459e-09
Ca2 O 0 1.7412624231383234e-07
+ O 0 9.02436241290161e-08
transients O 0 1.0486464816494845e-06
partially O 0 2.049634758805041e-06
result O 0 5.3809259270565235e-09
from O 0 2.3909149660106266e-10
an O 0 1.7708326471854718e-10
influx O 0 1.4174093898589035e-08
of O 0 7.573945359773404e-10
extracellular O 0 9.340691065062856e-08
Ca2 O 0 7.387784535239916e-07
+ O 0 7.993953232698914e-08
through O 0 3.6053140473057965e-09
the O 0 5.596900276572114e-09
l O 0 7.743543392280117e-06
- O 0 1.3381063581618946e-06
type O 0 2.464387762302067e-06
Ca2 O 0 7.366197223745985e-06
+ O 0 1.9863825855281902e-06
channel O 0 4.211857230984606e-06
. O 0 7.902589231889579e-07

Neither O 0 3.4545619200798683e-06
the O 0 1.2556928830065317e-08
content O 0 3.8430691517987725e-08
nor O 0 5.319537876857794e-08
the O 0 7.884645714106853e-10
activity O 0 6.8074887948910145e-09
of O 0 1.2518278635909041e-09
Na O 0 2.4517710244253976e-06
+ O 0 7.978801477293018e-07
/ O 0 6.10886331742222e-07
K O 0 1.0537521575315623e-06
+ O 0 8.617183766546077e-07
ATPase O 0 2.8375570764183067e-05
and O 0 1.0680781059591027e-07
sarcoplasmic O 0 1.7114245565608144e-05
reticulum O 0 3.4758362744469196e-05
Ca2 O 0 3.542395279509947e-05
+ O 0 1.746236375765875e-05
- O 0 6.645815574302105e-06
ATPase O 0 5.327680264599621e-05
are O 0 8.839690757156404e-09
affected O 0 2.947724198065771e-08
by O 0 8.183286048790706e-09
DMPK O 0 1.4228970030671917e-05
absence O 0 1.1657111826934852e-06
. O 0 4.6853560320414545e-07

In O 0 9.737582473690054e-08
conclusion O 0 2.3573811347432638e-08
, O 0 1.0627813074037817e-09
our O 0 8.16535283831854e-10
data O 0 1.47481404866312e-09
suggest O 0 1.198491639264887e-09
that O 0 1.177376529604146e-10
DMPK O 0 4.2296502300587235e-08
is O 0 1.144387154483617e-10
involved O 0 1.7796125684199637e-10
in O 0 7.977293825511822e-11
modulating O 0 8.910006066287224e-09
the O 0 3.642651180690848e-10
initial O 0 1.8872765572552908e-09
events O 0 7.879142893685298e-10
of O 0 1.1415857148477926e-10
excitation O 0 1.945738716813139e-07
- O 0 6.374833901645616e-06
contraction O 0 1.029356781145907e-06
coupling O 0 2.367797833358054e-07
in O 0 7.706939086915554e-09
skeletal O 0 3.7086249449203024e-06
muscle O 0 3.1314173156715697e-06
. O 0 4.751171900352347e-08
. O 0 1.2534464133295842e-07

Constitutional O 0 4.6735774958506227e-05
RB1 O 0 0.003060170914977789
- O 0 7.000329060247168e-05
gene O 0 3.5489849778969074e-06
mutations O 0 4.902438377030194e-06
in O 0 1.9142648355341407e-08
patients O 0 1.0130641925343298e-07
with O 0 5.7322289137573534e-09
isolated O 0 2.7915525606658775e-06
unilateral B-Disease 0 0.0002479323302395642
retinoblastoma I-Disease 0 0.0011610554065555334
. O 0 4.471092779567698e-06

In O 0 1.0544150796931717e-07
most O 0 2.1957287543727944e-08
patients O 0 8.589110933598931e-08
with O 0 3.4194116427244126e-09
isolated O 0 7.491776159440633e-07
unilateral B-Disease 0 6.187853614392225e-06
retinoblastoma I-Disease 0 4.067998816026375e-05
, O 0 2.810641319683782e-08
tumor B-Disease 0 6.725217644998338e-07
development O 0 4.357789684661384e-09
is O 0 8.379660854096471e-10
initiated O 0 5.32075272730026e-09
by O 0 4.599116643078105e-10
somatic O 0 8.318375677163203e-08
inactivation O 0 2.827118805726059e-07
of O 0 1.4855441876626685e-10
both O 0 1.427752027716167e-09
alleles O 0 3.998690800699478e-08
of O 0 1.894016499193185e-09
the O 0 3.892064981414478e-08
RB1 O 0 6.168212712509558e-05
gene O 0 2.528778622945538e-06
. O 0 7.046810992505925e-07

However O 0 1.3856245573151682e-07
, O 0 6.793670626059622e-10
some O 0 7.799830920030004e-11
of O 0 3.163322381816158e-11
these O 0 3.6443886797243863e-10
patients O 0 6.876090363761023e-09
can O 0 1.255955783818763e-09
transmit O 0 1.7012295927543164e-07
retinoblastoma B-Disease 0 2.8160800411569653e-06
predisposition O 0 1.3686920965483296e-06
to O 0 1.249910308587232e-08
their O 0 4.002597364660687e-08
offspring O 0 2.0071809103683336e-06
. O 0 6.84502765579964e-07

To O 0 2.0595786409671746e-08
determine O 0 1.6434023919487117e-08
the O 0 4.500270989193922e-10
frequency O 0 5.98662310835607e-08
and O 0 1.8013259772686752e-09
nature O 0 3.232263567909399e-09
of O 0 5.030191818633512e-10
constitutional O 0 6.811439590137525e-08
RB1 O 0 2.1353847841965035e-05
- O 0 2.12606011018579e-07
gene O 0 1.8850170135920052e-07
mutations O 0 2.2955001099944639e-07
in O 0 2.4659276842697864e-09
patients O 0 1.4330456821198823e-08
with O 0 4.221392957415304e-10
isolated O 0 1.6254655577085941e-07
unilateral B-Disease 0 1.051167600962799e-06
retinoblastoma I-Disease 0 3.400232117201085e-06
, O 0 7.132745061255719e-09
we O 0 2.394119569260056e-09
analyzed O 0 6.618766423827083e-09
DNA O 0 2.1193951482700868e-08
from O 0 4.806228193210416e-10
peripheral O 0 1.5622678972704307e-07
blood O 0 1.8702175452744996e-07
and O 0 7.390938971951755e-09
from O 0 1.4810388471175884e-08
tumor B-Disease 0 2.932280403911136e-05
tissue O 0 2.652780312928371e-05
. O 0 9.115136663240264e-07

The O 0 3.395729564203975e-08
analysis O 0 7.362956466749893e-08
of O 0 4.274921305835733e-09
tumors B-Disease 1 0.9999998807907104
from O 0 2.042618518771633e-09
54 O 0 6.975426458666334e-09
( O 0 5.336483477336174e-10
71 O 0 8.301729081949816e-09
% O 0 1.1939079724854196e-09
) O 0 5.547752257584193e-10
of O 0 1.6444605399623669e-10
76 O 0 9.233433573285765e-09
informative O 0 9.261710687269442e-08
patients O 0 2.1257538662666775e-07
showed O 0 8.737191592445015e-08
loss O 0 4.363289463071851e-08
of O 0 1.2854530773154238e-09
constitutional O 0 4.1144764395539823e-07
heterozygosity O 0 0.0001597279915586114
( O 0 9.749197715791524e-08
LOH O 1 0.9999940395355225
) O 0 6.203933367032732e-08
at O 0 3.8158972870405705e-08
intragenic O 0 4.161172910244204e-06
loci O 0 4.154138423473341e-06
. O 0 3.8997117712824547e-07

Three O 0 1.2461319442991226e-07
of O 0 7.027213033694579e-09
13 O 0 3.286361049958941e-08
uninformative O 0 1.7276195649174042e-05
patients O 0 2.614098775666207e-06
had O 0 7.029775872524624e-08
constitutional O 0 3.7386817552942375e-07
deletions O 0 2.004366433538962e-05
. O 0 2.1824589566676877e-06

For O 0 8.236232673652921e-08
39 O 0 1.4067390452510153e-07
randomly O 0 2.342116829368024e-07
selected O 0 3.835044140032551e-07
tumors B-Disease 1 1.0
, O 0 1.9683362495470647e-08
SSCP O 0 6.3243319345929194e-06
, O 0 1.8432706028193024e-08
hetero O 0 2.7154183044331148e-05
- O 0 5.759388272963406e-07
duplex O 0 1.6379468661398278e-06
analysis O 0 1.4284037952450035e-08
, O 0 1.7511603278563825e-10
sequencing O 0 1.5231366168322324e-09
, O 0 2.973652435400709e-10
and O 0 3.683678639898602e-10
Southern O 0 2.0450277027350694e-09
blot O 0 1.0598233757264097e-06
analysis O 0 5.08863440273899e-09
were O 0 3.746801202630934e-10
used O 0 6.406434494010682e-09
to O 0 6.779125705236311e-09
identify O 0 8.033201766011189e-07
mutations O 0 4.252220605849288e-06
. O 0 4.961112267665158e-07

Mutations O 0 2.275737642776221e-05
were O 0 6.800457441613617e-08
detected O 0 1.3804041998355387e-07
in O 0 3.4505582835464566e-09
21 O 0 2.556433509326439e-09
( O 0 3.1164321123711147e-10
91 O 0 5.177372752740439e-09
% O 0 1.3636651807757971e-09
) O 0 1.5780882156590792e-09
of O 0 3.385496993857373e-09
23 O 0 0.00012223891098983586
tumors B-Disease 1 1.0
with O 0 1.5846146197873168e-05
LOH O 1 0.9999998807907104
. O 0 5.658975624101004e-06

In O 0 1.7984059752507164e-07
6 O 0 4.3253230330719816e-08
( O 0 1.3888328265210248e-09
38 O 0 4.775481343699539e-09
% O 0 6.74741429396164e-10
) O 0 4.956827170943257e-10
of O 0 6.799089624642818e-10
16 O 0 4.273327704140684e-06
tumors B-Disease 1 1.0
without O 0 3.865413418679964e-06
LOH O 1 0.9999994039535522
, O 0 2.7771054345038237e-09
one O 0 8.686817931646829e-10
mutation O 0 2.0856498750276842e-08
was O 0 2.8863504919485194e-09
detected O 0 2.0319220084275003e-08
, O 0 2.6346355652684394e-10
and O 0 3.0072649925827477e-10
in O 0 2.512587082836859e-10
9 O 0 7.776587152008574e-10
( O 0 7.750994290844915e-11
56 O 0 9.813666546065747e-10
% O 0 2.2693878720669858e-10
) O 0 1.4168269335534944e-10
of O 0 1.2432159468556137e-10
the O 0 6.669267804682022e-07
tumors B-Disease 1 1.0
without O 0 3.395244129933417e-05
LOH O 1 0.9999995231628418
, O 0 1.4033932904666813e-09
both O 0 1.0820161433500175e-09
mutations O 0 1.0750004264536983e-07
were O 0 7.056560225038311e-09
found O 0 4.368652639641368e-08
. O 0 1.822091633130185e-07

Thus O 0 4.854926487496414e-07
, O 0 3.813727111889875e-09
a O 0 9.417265856015433e-10
total O 0 2.928248199474126e-10
of O 0 1.5086215610082832e-10
45 O 0 1.5361635297139742e-09
mutations O 0 3.2008291128704514e-08
were O 0 3.070734999610636e-09
identified O 0 7.989928718643569e-08
in O 0 1.5975294331838086e-07
tumors B-Disease 1 1.0
of O 0 6.606998059766056e-09
36 O 0 2.819737972004077e-07
patients O 0 1.4588475778509746e-06
. O 0 4.5703558271270595e-07

Thirty O 0 4.450406322575873e-06
- O 0 9.567283086653333e-06
nine O 0 1.161496765433867e-08
of O 0 1.9639427584206004e-10
the O 0 3.5266617404161593e-10
mutations O 0 5.152884341441677e-08
- O 0 3.7448046441568295e-08
including O 0 4.984311297029365e-10
34 O 0 1.7970672727685155e-09
small O 0 3.5083078664399636e-09
mutations O 0 6.421116438559693e-08
, O 0 9.5144359057997e-10
2 O 0 9.154760283180963e-10
large O 0 4.342795900669216e-09
structural O 0 8.18001281004399e-05
alterations O 0 1.0371431926614605e-06
, O 0 5.740113939722846e-10
and O 0 1.0828997698553167e-09
hypermethylation O 0 4.174780201537942e-07
in O 0 4.929384012086757e-09
3 O 0 6.80481733184024e-08
tumors O 1 1.0
- O 0 0.0005729789845645428
were O 0 2.9558020475661806e-09
not O 0 8.615140822954004e-10
detected O 0 1.2376171198980046e-08
in O 0 1.9852217092442004e-10
the O 0 6.158243914811123e-10
corresponding O 0 7.438772797740967e-08
peripheral O 0 2.8461408874136396e-06
blood O 0 4.878164077126712e-07
DNA O 0 3.1376080187328625e-06
. O 0 5.372867235564627e-07

In O 0 1.700937559689919e-07
6 O 0 2.8000572527275835e-08
( O 0 9.37087740737752e-10
17 O 0 1.2263750015506503e-09
% O 0 1.981964176112072e-10
) O 0 6.96276508671545e-11
of O 0 1.7865188495225226e-11
the O 0 7.067655349857205e-10
36 O 0 4.7424233429183005e-09
patients O 0 5.458225427190655e-09
, O 0 1.4236560541558418e-10
a O 0 4.997066649359283e-10
mutation O 0 6.315046618965425e-08
was O 0 2.2699182977703458e-08
detected O 0 2.2098287644212178e-08
in O 0 2.398259368874278e-10
constitutional O 0 6.660071938391354e-10
DNA O 0 1.901724111519343e-08
, O 0 1.393087728507325e-10
and O 0 2.2018578627047702e-10
1 O 0 2.000204307739395e-10
of O 0 1.5511956302782792e-11
these O 0 3.1359365104677295e-10
mutations O 0 1.0392184890406497e-08
is O 0 1.228087770366315e-10
known O 0 7.189437933874387e-10
to O 0 3.638429557639711e-10
be O 0 1.2724438169797736e-09
associated O 0 4.5998911346600835e-09
with O 0 3.6244123258200034e-09
reduced O 0 8.320198503497522e-07
expressivity O 0 0.000301271938951686
. O 0 1.3665609230884002e-06

The O 0 1.9501074532968232e-08
presence O 0 1.2418355233023703e-08
of O 0 1.5274181919266994e-10
a O 0 9.271228784690777e-10
constitutional O 0 1.2387223691234794e-08
mutation O 0 2.068950095690525e-07
was O 0 2.0064844008516047e-08
not O 0 1.2429676177205806e-09
associated O 0 7.163813431354527e-10
with O 0 9.122387567561674e-11
an O 0 2.959839595639835e-10
early O 0 5.1485617547086804e-08
age O 0 3.003060555784032e-08
at O 0 1.8229464160413045e-08
treatment O 0 2.3630988721379254e-07
. O 0 2.149341327140064e-07

In O 0 3.460123423337791e-07
1 O 0 1.4157375005652284e-07
patient O 0 3.6212949794389715e-07
, O 0 5.317770224166907e-09
somatic O 0 6.382690003192693e-07
mosaicism O 0 4.7228018956957385e-05
was O 0 2.7068219310422137e-07
demonstrated O 0 2.5144306192714794e-08
by O 0 6.580332945205214e-10
molecular O 0 3.396079151229969e-08
analysis O 0 1.957153905607356e-08
of O 0 5.46471201623433e-10
DNA O 0 2.440943092096859e-07
and O 0 1.1515129294537019e-08
RNA O 0 1.227604684572725e-07
from O 0 1.1585782999645744e-08
peripheral O 0 6.335566013149219e-06
blood O 0 1.1327199899824336e-05
. O 0 1.0516549764361116e-06

In O 0 2.404521239895985e-07
2 O 0 6.72435831461371e-08
patients O 0 7.635365761871071e-08
without O 0 3.755947552974703e-09
a O 0 5.337310593489519e-09
detectable O 0 5.992740170768229e-06
mutation O 0 9.969270422516274e-07
in O 0 7.943200763804725e-09
peripheral O 0 1.49957406847534e-06
blood O 0 4.931342232339375e-07
, O 0 1.271478256015257e-09
mosaicism O 0 8.015585422072036e-07
was O 0 9.851498283808269e-09
suggested O 0 2.947211141801631e-09
because O 0 8.648693983204225e-10
1 O 0 1.3654369301896452e-10
of O 0 1.1204640514017594e-11
the O 0 7.820839531547108e-10
patients O 0 5.641327760486092e-08
showed O 0 8.909211857144328e-08
multifocal O 1 0.967976450920105
tumors B-Disease 1 1.0
and O 0 1.5507838568851184e-08
the O 0 2.7450955397689825e-10
other O 0 5.245698320166525e-10
later O 0 1.8561088666047e-08
developed O 0 1.0284937701499075e-07
bilateral B-Disease 0 5.997761149956204e-07
retinoblastoma I-Disease 0 3.86675565096084e-05
. O 0 2.2140450255392352e-06

In O 0 2.4460160830130917e-07
conclusion O 0 1.0139920902929589e-07
, O 0 6.067040647650401e-09
our O 0 3.0584950128087485e-09
results O 0 1.9636028358860358e-09
emphasize O 0 6.793829943063656e-09
that O 0 2.631060092017634e-10
the O 0 2.971004831042734e-10
manifestation O 0 1.0669985783806624e-08
and O 0 1.3324926717572794e-09
transmissibility O 0 1.58175410547301e-07
of O 0 1.305533459117214e-10
retinoblastoma B-Disease 0 3.359851064033137e-08
depend O 0 7.5892199191685e-09
on O 0 5.894084664781474e-10
the O 0 2.2207236050064694e-10
nature O 0 1.026468354758947e-09
of O 0 2.470199392257122e-11
the O 0 9.03694133413957e-11
first O 0 7.554439296342252e-10
mutation O 0 5.459682927977383e-09
, O 0 7.663455287021392e-11
its O 0 7.930431311642394e-11
time O 0 1.6918536571708387e-09
in O 0 7.053807538071055e-11
development O 0 4.264126898800846e-11
, O 0 5.5698771983525575e-11
and O 0 5.644042178065689e-11
the O 0 2.2299457419494573e-11
number O 0 4.5466019837903104e-10
and O 0 6.876034186475977e-10
types O 0 3.0161355635272002e-09
of O 0 5.4507082875021595e-11
cells O 0 3.604832654602319e-09
that O 0 4.889061933077699e-10
are O 0 1.1239883468405765e-09
affected O 0 8.913882076910795e-09
. O 0 1.1469362348748291e-08
. O 0 1.5703341205153265e-07

Hereditary B-Disease 1 0.9999934434890747
deficiency I-Disease 1 0.9999721050262451
of I-Disease 0 2.4897230943565773e-09
the I-Disease 0 2.1139880956866364e-09
fifth I-Disease 0 1.8122305434076225e-08
component I-Disease 0 4.849355050851045e-08
of I-Disease 0 4.900228001147866e-10
complement I-Disease 0 3.139458470968748e-08
in O 0 1.7700443777357577e-08
man O 0 1.2160567166574765e-06
. O 0 6.743276799170417e-07

I O 0 0.0016537349438294768
. O 0 1.3488799595506862e-05

Clinical O 0 2.8526645110105164e-05
, O 0 2.9281618907361917e-08
immunochemical O 0 1.5379547448901576e-06
, O 0 1.0561275409770587e-08
and O 0 8.188626665628362e-09
family O 0 6.592939172378465e-08
studies O 0 5.901559916310362e-07
. O 0 5.029885414842283e-07

The O 0 3.1095360952804185e-08
first O 0 6.874333102757646e-09
recognized O 0 1.7513757555320808e-08
human O 0 8.507146098679641e-09
kindred O 0 8.349306312993576e-07
with O 0 6.445559819212576e-08
hereditary B-Disease 1 0.9999731779098511
deficiency I-Disease 1 0.9975696206092834
of I-Disease 0 4.2253001097947163e-10
the I-Disease 0 1.0375780234994636e-09
fifth I-Disease 0 3.241254020736051e-08
component I-Disease 0 2.1783449710710556e-07
of I-Disease 0 1.2099183877012365e-09
complement I-Disease 0 1.3941182430698973e-07
( O 0 6.6239946860946475e-09
C5 O 0 5.7853554835674e-07
) O 0 5.290071047880929e-09
is O 0 5.415377479778272e-09
described O 0 2.9117444455550867e-07
. O 0 4.196218696961296e-07

The O 0 3.7654391604746706e-08
proband O 0 9.310965651820879e-07
, O 0 1.9514982962931526e-09
a O 0 8.236318849164093e-10
20 O 0 1.7738793767207994e-09
- O 0 5.593317453644886e-08
year O 0 8.773542781170818e-09
- O 0 4.449653658866737e-07
old O 0 4.177113623882178e-07
black O 0 2.0421879298737622e-07
female O 0 1.4510354162666772e-07
with O 0 1.4648826152097172e-07
systemic B-Disease 1 1.0
lupus I-Disease 1 0.9998959302902222
erythematosus I-Disease 1 1.0
since O 0 2.600123252705089e-06
age O 0 5.240823597318922e-08
11 O 0 4.740722925333785e-09
, O 0 1.2460059650720723e-09
lacked O 0 4.7042635742400307e-07
serum O 0 1.2832142601837404e-06
hemolytic O 0 4.628161605069181e-06
complement O 0 2.0150062951529435e-08
activity O 0 2.223200823436855e-08
, O 0 1.2122328696406726e-09
even O 0 1.3264835452275747e-08
during O 0 9.40479836231134e-08
remission O 0 2.6633726974978345e-06
. O 0 2.9111834010109305e-07

C5 O 0 0.00027543166652321815
was O 0 5.640063136524986e-07
undetectable O 0 2.72314923677186e-06
in O 0 4.678455400863868e-09
her O 0 1.5241953477129755e-08
serum O 0 7.447346916933384e-08
by O 0 1.2650580583084547e-09
both O 0 7.71361552409644e-09
immunodiffusion O 0 9.16620047064498e-06
and O 0 2.2455991199876735e-07
hemolytic O 0 0.000221431371755898
assays O 0 9.989734826376662e-05
. O 0 1.238036020367872e-06

Other O 0 1.9609466050951596e-08
complement O 0 5.183462192803745e-08
components O 0 4.62447218296802e-08
were O 0 3.536835491146917e-09
normal O 0 1.175719432922051e-08
during O 0 5.854893903034508e-09
remission O 0 1.0451624632423773e-07
of O 0 5.746687015140139e-10
lupus O 0 6.1569612626044545e-06
, O 0 7.157339720897937e-10
but O 0 9.632985076279965e-09
C1 O 0 2.670285539352335e-06
, O 0 6.453820811103128e-10
C4 O 0 9.884816876137847e-08
, O 0 9.7585661773536e-10
C2 O 0 3.120057954220101e-07
, O 0 5.898155852612774e-10
and O 0 4.640364981156608e-09
C3 O 0 1.90994683180179e-06
levels O 0 7.008796387708571e-08
fell O 0 7.290511803148547e-07
during O 0 2.957885385512782e-07
exacerbations O 0 0.0006705141277052462
. O 0 1.8744686940408428e-06

A O 0 2.2457618342741625e-07
younger O 0 1.2946517813361424e-07
half O 0 1.4300721495885682e-08
- O 0 1.2099955881694768e-07
sister O 0 2.5348668941660435e-08
, O 0 7.129762336077761e-10
who O 0 6.425622700589884e-09
had O 0 9.888229612897703e-08
no O 0 5.348145748484967e-08
underlying O 0 0.00019595868070609868
disease O 0 7.574298024337622e-07
, O 0 9.80438730202593e-10
was O 0 7.833536841417299e-08
also O 0 2.480868177556772e-09
found O 0 5.712604167484869e-09
to O 0 5.996791951901059e-09
lack O 0 1.451144697739437e-07
immunochemically O 0 5.066355151939206e-05
detectable O 0 0.0002637988654896617
C5 O 0 2.7599704480962828e-05
. O 0 7.268469630616892e-07

By O 0 1.040858023770852e-06
hemolytic O 0 0.00016564660472795367
assay O 0 0.00012799537216778845
, O 0 3.71802286736056e-08
she O 0 7.470323737379658e-08
exhibited O 0 1.7106845717762553e-08
1 O 0 3.8579610617262006e-09
- O 0 5.012268289306121e-08
2 O 0 2.1477375433676116e-09
% O 0 2.460701642448271e-10
of O 0 4.6860414854021926e-11
the O 0 7.244153055196989e-10
normal O 0 6.489648285423755e-08
serum O 0 5.079769493931963e-07
C5 O 0 3.254607463532011e-07
level O 0 1.5271401920813332e-08
and O 0 1.4368081169280345e-09
normal O 0 3.870682885320775e-09
concentrations O 0 2.5531067038286892e-08
of O 0 1.4228959677176078e-10
other O 0 5.048261808582311e-10
complement O 0 4.8820972153862385e-08
components O 0 9.195498478220543e-07
. O 0 3.963405674767273e-07

C5 O 0 5.785620305687189e-05
levels O 0 4.257513808170188e-07
of O 0 2.322947806332465e-10
other O 0 1.548329103817636e-10
family O 0 4.638610884288852e-10
members O 0 6.203131758253377e-11
were O 0 1.6553393378249126e-10
either O 0 2.5274538018038584e-10
normal O 0 5.358923305109897e-10
or O 0 2.3284218997332573e-10
approximately O 0 1.6740184238805966e-10
half O 0 1.0707211117733095e-08
- O 0 2.963989345516893e-06
normal O 0 8.60645688049999e-09
, O 0 2.9484747976482595e-10
consistent O 0 4.158176469815089e-09
with O 0 1.598811305569825e-09
autosomal O 0 2.242295749965706e-06
codominant O 0 6.421098532882752e-07
inheritance O 0 7.988511896428463e-08
of O 0 7.464291962300251e-10
the O 0 1.024491425027918e-08
gene O 0 1.273449834116036e-05
determining O 0 0.09369045495986938
C5 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 5.100524958834285e-06

Normal O 0 0.00010965926776407287
hemolytic O 0 0.003175238147377968
titers O 0 0.00027982122264802456
were O 0 4.098946959629757e-08
restored O 0 8.164393960896632e-08
to O 0 2.228833784201356e-09
both O 0 3.513666868570908e-08
homozygous O 1 0.8702088594436646
C5 B-Disease 1 1.0
- I-Disease 1 0.9999995231628418
deficient I-Disease 1 1.0
( O 0 6.165406318814348e-08
C5D B-Disease 1 1.0
) O 0 8.477003099471858e-09
sera O 0 2.4141641574715322e-08
by O 0 1.6083287479595754e-10
addition O 0 1.8286601122241564e-09
of O 0 8.186389344189138e-10
highly O 0 7.792645106974305e-08
purified O 0 9.140912879956886e-07
human O 0 3.234581242850254e-07
C5 O 0 1.8030574210570194e-05
. O 0 5.962294267192192e-07

In O 0 3.6223832466930617e-07
specific O 0 2.4770830009401834e-07
C5 O 0 2.2639658254774986e-06
titrations O 0 6.57724149277783e-06
, O 0 3.1980327275249465e-09
however O 0 1.4299923467575582e-09
, O 0 3.4138969429164945e-10
it O 0 1.1348866291172044e-09
was O 0 7.574671556653811e-09
noted O 0 4.2699804803092434e-10
that O 0 7.365431875516748e-11
when O 0 5.650378498422981e-10
limited O 0 3.9608616386743734e-10
amounts O 0 8.697444986438541e-10
of O 0 1.12091134985004e-10
C5 O 0 2.151921130177925e-08
were O 0 2.3348034616788027e-10
assayed O 0 1.358434964515709e-08
in O 0 1.6503236277554123e-10
the O 0 1.3843810819924585e-10
presence O 0 1.4485301846889342e-09
of O 0 9.473433842943635e-11
low O 0 1.8607417828775397e-08
dilutions O 0 7.704905442551535e-07
of O 0 4.147932275433419e-10
either O 0 6.770664384703196e-08
C5D B-Disease 1 1.0
serum O 0 2.7278903758087836e-07
, O 0 1.8606938212428759e-10
curving O 0 4.234345762910152e-09
rather O 0 1.5263356134553874e-09
than O 0 2.529291220909613e-10
linear O 0 1.4080835164520522e-08
dose O 0 7.809397288838227e-07
- O 0 5.473845376968711e-08
response O 0 2.114859398716362e-09
plots O 0 9.189807137488515e-09
were O 0 8.950643559657578e-10
consistently O 0 4.440858791809887e-09
obtained O 0 2.660674569554544e-09
, O 0 2.9177335547636574e-10
suggesting O 0 7.2240258219835596e-09
some O 0 1.8537056334366753e-09
inhibitory O 0 3.2128212978932424e-07
effect O 0 8.095142334241245e-07
. O 0 3.0418581786761933e-07

Further O 0 5.335959940566681e-07
studies O 0 1.206448985158204e-07
suggested O 0 4.8661807028338444e-08
that O 0 2.109686203510819e-09
low O 0 8.773781701165717e-08
dilutions O 0 9.778295861906372e-06
of O 0 9.925848587499786e-09
C5D B-Disease 1 0.9999996423721313
serum O 0 3.0445980314652843e-07
contain O 0 5.591245244573884e-09
a O 0 9.231386211006054e-10
factor O 0 2.772516882743048e-09
( O 0 9.32453350643847e-11
or O 0 1.3360555994879064e-09
factors O 0 3.1957219093214917e-09
) O 0 2.2825846768270708e-10
interfering O 0 3.1255416033104666e-09
at O 0 3.77387676664398e-10
some O 0 2.1079023942993658e-11
step O 0 1.6474310804426295e-09
in O 0 7.352269904004061e-10
the O 0 2.5706521356028134e-09
hemolytic O 0 3.4173840504081454e-06
assay O 0 3.52614551957231e-06
of O 0 1.0317032783646596e-09
C5 O 0 9.247572307913288e-08
, O 0 1.2512424429900193e-10
rather O 0 5.036336347963299e-10
than O 0 8.579262300578705e-10
a O 0 3.218562971696315e-09
true O 0 1.4729486963460658e-07
C5 O 0 1.7382059240844683e-06
inhibitor O 0 4.071508215020003e-07
or O 0 6.364005145087503e-08
inactivator O 0 1.54792214743793e-05
. O 0 1.0579682339084684e-06

Of O 0 1.458452913993824e-08
clinical O 0 4.973595082446991e-07
interest O 0 1.1508807240545593e-08
are O 0 4.884476156874484e-10
( O 0 1.4747711385432183e-10
a O 0 2.1496708579871182e-10
) O 0 2.84215873058713e-10
the O 0 1.3260673115134125e-10
documentation O 0 3.041776608370128e-08
of O 0 2.977342816734563e-09
membranous O 1 0.9836736917495728
glomerulonephritis B-Disease 1 1.0
, O 0 5.958752353762975e-06
vasculitis B-Disease 1 1.0
, O 0 8.434106746335601e-08
and O 0 2.5087307221838273e-05
arthritis B-Disease 1 1.0
in O 0 3.1674856071362e-09
an O 0 1.1597428573040247e-09
individual O 0 3.4034325580023506e-08
lacking O 0 1.1085023743362399e-06
C5 O 0 4.2405758904351387e-07
( O 0 5.277823733607079e-10
and O 0 2.4650659291580723e-10
its O 0 1.5590417845601223e-10
biologic O 0 1.2463654996963669e-08
functions O 0 8.219934177766675e-10
) O 0 3.555671035382346e-10
, O 0 1.358340245838363e-10
and O 0 3.856870378626809e-10
( O 0 2.0425162949866404e-10
b O 0 1.2857258369081137e-08
) O 0 1.0079744677815583e-10
a O 0 1.6004884917375506e-10
remarkable O 0 6.007025987742054e-09
propensity O 0 1.1309925440627921e-07
to O 0 2.1132153804614973e-08
bacterial B-Disease 1 1.0
infections I-Disease 1 1.0
in O 0 1.2412950667339828e-09
the O 0 9.784112409150225e-11
proband O 0 4.811754550360092e-08
, O 0 6.799319440808915e-11
even O 0 1.183672188043161e-10
during O 0 1.0198891731150184e-10
periods O 0 2.4641502172073615e-09
of O 0 7.794610790146095e-11
low O 0 4.927280983224591e-08
- O 0 9.100087083879771e-08
dose O 0 7.67272396728913e-08
or O 0 1.2564278506488336e-09
alternate O 0 8.933302098057538e-09
- O 0 4.2962497559528856e-07
day O 0 5.297505367707345e-08
corticosteroid O 0 1.1929242646147031e-05
therapy O 0 4.064942459081067e-06
. O 0 3.0600139666603354e-07

Other O 0 4.014547982933436e-08
observations O 0 4.511017692720998e-08
indicate O 0 1.545406824732254e-08
that O 0 7.612150354496805e-10
the O 0 9.27545651396855e-10
C5D B-Disease 1 1.0
state O 0 4.055558555648986e-09
is O 0 8.26811397125482e-10
compatible O 0 4.183187130024635e-09
with O 0 2.62130261940996e-10
normal O 0 5.155103455223298e-09
coagulation O 0 1.0687135620912613e-08
function O 0 2.4478483684475805e-09
and O 0 5.278790182750015e-10
the O 0 3.0721278299061794e-10
capacity O 0 1.4908529966106698e-09
to O 0 7.196297446832034e-10
mount O 0 1.3204861204485496e-07
a O 0 1.1744445771455503e-07
neutrophilic O 0 0.0006979329045861959
leukocytosis O 0 0.00017415151523891836
during O 0 1.2500912589530344e-06
pyogenic B-Disease 0 0.2674916982650757
infection I-Disease 0 0.08642946928739548
. O 0 1.985023629913485e-07
. O 0 6.119924478298344e-07

Susceptibility O 0 0.00045891336048953235
to O 0 6.0417924032662995e-06
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
in O 0 1.0958648317682673e-06
twins O 0 6.603680731132044e-07
: O 0 1.674594130030016e-09
the O 0 1.5622865501274674e-10
role O 0 2.5020194804881157e-09
of O 0 9.608239898151183e-11
genes O 0 3.0127433880977605e-09
, O 0 6.478684255739608e-10
HLA O 0 5.4272611293981754e-08
, O 0 6.386459139307021e-10
and O 0 1.3665736320334076e-09
the O 0 7.992928097166896e-09
environment O 0 4.3311140984769736e-07
. O 0 2.663149132331455e-07

OBJECTIVE O 0 2.2708572942065075e-06
To O 0 4.518516227847158e-09
determine O 0 4.624610916437177e-09
the O 0 2.552383304710304e-10
relative O 0 7.475622787467273e-09
effects O 0 5.586344897778872e-08
of O 0 1.39644226737623e-10
genetic O 0 8.83966038145445e-08
and O 0 2.925971909206737e-09
environmental O 0 8.71821104198034e-09
factors O 0 5.301162175896934e-09
in O 0 1.076144173772775e-09
susceptibility O 0 1.3778397942587617e-06
to O 0 4.2217516238451935e-07
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
( O 0 3.5902032777812565e-06
AS B-Disease 1 0.9999954700469971
) O 0 1.609613917707975e-07
. O 0 3.940859301110322e-07

METHODS O 0 3.409798864595359e-06
Twins O 0 5.752504534939362e-07
with O 0 5.43193934277042e-09
AS B-Disease 1 0.9953867793083191
were O 0 1.2360170664749148e-09
identified O 0 3.9589003186790706e-09
from O 0 3.479052601562671e-10
the O 0 2.121849362879402e-09
Royal O 0 1.1142681159981294e-06
National O 0 2.0205327189160016e-08
Hospital O 0 2.591945644780935e-07
for O 0 3.870271214623244e-08
Rheumatic B-Disease 0 0.2875249981880188
Diseases I-Disease 0 8.235598943429068e-05
database O 0 3.9979267967282794e-06
. O 0 1.258452243746433e-06

Clinical O 0 4.656058445107192e-05
and O 0 7.262656964712733e-08
radiographic O 0 2.903668791987002e-05
examinations O 0 1.1682096783260931e-06
were O 0 9.9660424357495e-10
performed O 0 9.144185408871408e-10
to O 0 1.890193696008069e-10
establish O 0 7.949794600392579e-09
diagnoses O 0 2.367642991885077e-06
, O 0 2.1831161323149217e-09
and O 0 3.253976998962571e-08
disease O 0 5.689439603884239e-07
severity O 0 1.5517742895099218e-06
was O 0 1.2049905073752143e-08
assessed O 0 3.204724929872782e-09
using O 0 1.6377377232146273e-09
a O 0 8.340880208734802e-10
combination O 0 1.6201996189124657e-08
of O 0 3.325286712652087e-10
validated O 0 9.468153905345389e-08
scoring O 0 6.618869718977294e-08
systems O 0 1.0039931339633767e-06
. O 0 5.627603059110697e-07

HLA O 0 0.0005693757557310164
typing O 0 3.9232283597812057e-05
for O 0 1.3812984889227664e-07
HLA O 0 1.3383079021878075e-05
- O 0 4.2777478483913e-06
B27 O 0 1.4663042975371354e-06
, O 0 6.474068392492427e-09
HLA O 0 4.680831864334323e-07
- O 0 2.390430040577485e-07
B60 O 0 2.3636442847418948e-07
, O 0 1.172945851557472e-09
and O 0 4.413533538638603e-09
HLA O 0 8.742607064959884e-07
- O 0 6.349744580802508e-06
DR1 O 0 0.0565570667386055
was O 0 2.4175601964770976e-08
performed O 0 1.273162353321311e-09
by O 0 1.7090423520826903e-10
polymerase O 0 2.4286149979957372e-08
chain O 0 1.834145848533808e-07
reaction O 0 1.3768143958259316e-08
with O 0 1.690936557441347e-10
sequence O 0 4.419075771977532e-09
- O 0 2.3577317875833614e-08
specific O 0 1.1787725240353097e-09
primers O 0 1.5688834764659987e-07
, O 0 3.652419200417256e-10
and O 0 3.393466341261586e-10
zygosity O 0 9.454402771780224e-08
was O 0 4.507523687635739e-09
assessed O 0 1.0202754197052855e-08
using O 0 3.97721784395344e-08
microsatellite O 0 3.711167300934903e-05
markers O 0 1.4600901522499043e-05
. O 0 1.3932145748185576e-06

Genetic O 0 2.595158548501786e-05
and O 0 1.9821627006422204e-08
environmental O 0 8.58922177826571e-09
variance O 0 8.912470761401892e-09
components O 0 4.978444678727101e-08
were O 0 2.096449236432818e-09
assessed O 0 6.309999633913321e-09
with O 0 1.5561185673362843e-10
the O 0 3.5139982590415286e-10
program O 0 4.7860955199041655e-09
Mx O 0 2.3046002439741642e-08
, O 0 2.054863224021375e-11
using O 0 9.678944451474436e-11
data O 0 5.719949514038092e-10
from O 0 2.6266263469798545e-11
this O 0 4.3492327794769636e-11
and O 0 4.3368175717262147e-10
previous O 0 5.656311863333485e-09
studies O 0 2.4623649785837642e-09
of O 0 4.1537173006700456e-11
twins O 0 2.883798799757642e-08
with O 0 4.0498080444706375e-09
AS B-Disease 1 0.9999948740005493
. O 0 8.068443548836512e-07

RESULTS O 0 5.7924771681427956e-06
Six O 0 4.858724267364778e-08
of O 0 2.2095747453931835e-09
8 O 0 3.124702629975218e-08
monozygotic O 0 2.7205146579944994e-06
( O 0 1.7922623385402403e-08
MZ O 0 0.12740471959114075
) O 0 1.6816814607523156e-08
twin O 0 9.132408536061121e-07
pairs O 0 1.5643104234186467e-07
were O 0 3.634570475696819e-07
disease O 0 1.8387062539204635e-07
concordant O 0 1.170734122979411e-07
, O 0 7.390991707545425e-10
compared O 0 1.6150001336256992e-09
with O 0 2.3401044990656317e-10
4 O 0 9.35421629044697e-10
of O 0 1.8153838154955082e-10
15 O 0 4.595286817732358e-09
B27 O 0 2.621260932755831e-07
- O 0 4.165581799497886e-07
positive O 0 2.551860411870166e-08
dizygotic O 0 6.466598279075697e-07
( O 0 3.153301619818194e-09
DZ O 0 2.0810718979191734e-06
) O 0 1.9570520759515375e-09
twin O 0 7.176798533237161e-08
pairs O 0 1.8839507731627236e-08
( O 0 7.859150552569361e-10
27 O 0 2.374727525733533e-09
% O 0 2.4078200544508377e-10
) O 0 9.222229924166214e-11
and O 0 2.2302659719031226e-10
4 O 0 6.63231025654909e-10
of O 0 1.9990335775599277e-10
32 O 0 2.148640021459869e-08
DZ O 0 0.00016113565652631223
twin O 0 6.701746428916522e-07
pairs O 0 3.4582559038653926e-08
overall O 0 1.6451773277026405e-08
( O 0 3.941313386768286e-10
12 O 0 7.147353819902946e-10
. O 0 7.588549788550836e-10
5 O 0 3.3152822709325847e-09
% O 0 3.9975525112367905e-09
) O 0 2.013423561209038e-08
. O 0 2.6215960247100156e-07

Nonsignificant O 0 1.6751668226788752e-05
increases O 0 3.9691437336841773e-07
in O 0 9.946918844150332e-10
similarity O 0 6.262184548688765e-09
with O 0 1.8808145318960356e-10
regard O 0 2.5903692524309463e-09
to O 0 1.3333978365892563e-09
age O 0 1.2772736646127214e-08
at O 0 1.0954959606124248e-08
disease O 0 3.524641201124723e-08
onset O 0 3.822606586822985e-08
and O 0 5.120341928233074e-10
all O 0 8.402591122891323e-11
of O 0 4.419374935449305e-11
the O 0 5.058442109628913e-09
disease O 0 4.649843390325259e-07
severity O 0 4.215491742343147e-07
scores O 0 1.7004987640234503e-08
assessed O 0 1.2347029176851265e-08
were O 0 4.867698466526349e-10
noted O 0 1.808917904355667e-09
in O 0 1.0172519715467843e-08
disease O 0 7.982242095749825e-06
- O 0 7.763332541799173e-05
concordant O 0 0.001833163551054895
MZ O 1 0.8673710227012634
twins O 0 2.38688153331168e-06
compared O 0 8.968988396418354e-08
with O 0 2.15602948827609e-08
concordant O 0 9.863539162324741e-05
DZ O 0 0.07284022122621536
twins O 0 2.4945620680227876e-05
. O 0 1.430838210580987e-06

HLA O 0 0.0010843519121408463
- O 0 0.0001607710000826046
B27 O 0 4.972920123691438e-06
and O 0 1.4691378780185005e-08
B60 O 0 1.9171429244124738e-07
were O 0 2.2329698090572947e-09
associated O 0 1.7083034986598022e-09
with O 0 3.7522795981459467e-10
the O 0 5.483540732598158e-09
disease O 0 8.267585371868336e-08
in O 0 3.093601763648479e-10
probands O 0 1.1222243045949654e-07
, O 0 1.8906119725325965e-10
and O 0 1.5128949482079435e-10
the O 0 1.9690475638878269e-10
rate O 0 1.7665534812749684e-08
of O 0 3.713646612446553e-10
disease O 0 3.732553466306854e-08
concordance O 0 1.9985321841886616e-08
was O 0 9.759221875071944e-09
significantly O 0 1.2504324686801738e-08
increased O 0 4.035527467749489e-09
among O 0 3.2410234496182966e-09
DZ O 0 4.321663709561108e-06
twin O 0 1.7603318269721058e-07
pairs O 0 1.2423710060716076e-08
in O 0 9.902472175582488e-10
which O 0 1.7157124609923358e-09
the O 0 1.4081122934328505e-09
co O 0 6.7186033447796945e-06
- O 0 1.6886729099496733e-06
twin O 0 5.908169623580761e-05
was O 0 1.0714280129775489e-08
positive O 0 7.797603673864728e-10
for O 0 1.3289334910293604e-10
both O 0 3.338685106157868e-09
B27 O 0 1.1954087995036389e-06
and O 0 1.6571613059568335e-07
DR1 O 0 0.0003871489898301661
. O 0 8.818826131573587e-07

Additive O 0 5.545532076212112e-06
genetic O 0 1.553050424263347e-06
effects O 0 2.945994026504195e-07
were O 0 1.7322026035770932e-09
estimated O 0 5.209236375591786e-10
to O 0 2.088983847015058e-10
contribute O 0 3.061201570009331e-10
97 O 0 1.217632217276332e-09
% O 0 2.4303131729297434e-10
of O 0 4.499470587782106e-11
the O 0 2.575039514951527e-09
population O 0 2.524146758275947e-08
variance O 0 3.052310830753413e-07
. O 0 4.2987906567759637e-07

CONCLUSION O 0 1.3197512771512265e-06
Susceptibility O 0 1.907591240524198e-06
to O 0 1.371721491949529e-08
AS B-Disease 1 0.9993172883987427
is O 0 1.2838505814016798e-09
largely O 0 1.913606828551906e-09
genetically O 0 2.2044097658380224e-09
determined O 0 5.621357157536977e-09
, O 0 1.186282738707689e-10
and O 0 1.858033865653752e-10
the O 0 1.791703313491766e-10
environmental O 0 2.036872448485383e-09
trigger O 0 2.6063688096655824e-08
for O 0 6.295882704066003e-10
the O 0 8.624220448893993e-09
disease O 0 4.1279142237726774e-07
is O 0 8.564421172252423e-09
probably O 0 1.5351368176652613e-07
ubiquitous O 0 3.030876996490406e-06
. O 0 6.966971568544977e-07

HLA O 0 0.0005516301607713103
- O 0 1.1850109331135172e-05
B27 O 0 6.329674420157971e-07
accounts O 0 9.824028701643783e-09
for O 0 2.8539576257813337e-10
a O 0 1.0050453802534776e-09
minority O 0 7.170449833893144e-08
of O 0 1.856167164415723e-10
the O 0 2.0047696835945317e-09
overall O 0 5.77894212483443e-08
genetic O 0 2.3164467677361245e-07
susceptibility O 0 9.0389505658095e-07
to O 0 4.9078561659143816e-08
AS B-Disease 1 0.9999580383300781
. O 0 6.902346285642125e-07

Cell O 0 0.00015082390746101737
cycle O 0 3.664991891128011e-05
- O 0 1.873105065897107e-05
dependent O 0 1.2016256505376077e-06
colocalization O 0 2.383592345722718e-06
of O 0 3.011364491101176e-09
BARD1 O 0 2.503554014765541e-06
and O 0 1.3089531236687435e-08
BRCA1 O 0 5.709774200113316e-07
proteins O 0 8.579986499057668e-09
in O 0 1.0896126223514102e-09
discrete O 0 4.656939438518748e-07
nuclear O 0 9.282839528168552e-06
domains O 0 2.2822271148470463e-06
. O 0 4.773166892846348e-07

Germ O 0 0.0018839299445971847
- O 0 0.007831620052456856
line O 0 1.2399111710692523e-06
mutations O 0 4.1811867390606494e-07
of O 0 4.5981782270665406e-10
the O 0 1.8326477002617025e-09
BRCA1 O 0 4.6606092496404017e-07
gene O 0 4.384588336847628e-08
predispose O 0 7.000353008379534e-08
women O 0 1.3619938510345264e-09
to O 0 1.621579814869989e-10
early O 0 1.1663428445274349e-08
- O 0 7.978964276844636e-05
onset O 0 0.0016644621500745416
breast B-Disease 1 0.9999980926513672
and I-Disease 1 0.9999278783798218
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
by O 0 1.64528957125043e-09
compromising O 0 4.30562636211107e-07
the O 0 1.2694935103141347e-09
genes O 0 2.6234408423420064e-08
presumptive O 0 1.4193445849741693e-06
function O 0 3.512012014539323e-08
as O 0 7.354461484254671e-09
a O 0 3.268732129413365e-08
tumor B-Disease 0 1.018826606014045e-05
suppressor O 0 5.602296005235985e-05
. O 0 2.216187112935586e-06

Although O 0 7.278770794982847e-07
the O 0 8.585126387572473e-09
biochemical O 0 2.0505306963514158e-07
properties O 0 6.393656093450772e-08
of O 0 9.270592626897667e-10
BRCA1 O 0 1.7765458437679627e-07
polypeptides O 0 8.543068474864413e-08
are O 0 1.4106338319663791e-09
not O 0 1.7231374105364239e-09
understood O 0 1.6487460285929956e-08
, O 0 2.143950433852737e-10
their O 0 5.249001233664785e-10
expression O 0 1.0446180809253747e-08
pattern O 0 3.3957368827941536e-07
and O 0 7.410178692879299e-09
subcellular O 0 8.861121614245349e-07
localization O 0 1.302274768022471e-07
suggest O 0 3.3655719988701094e-08
a O 0 2.426474798866707e-09
role O 0 1.6870078667352573e-08
in O 0 4.534375985798533e-09
cell O 0 3.179083023496787e-06
- O 0 0.00013914615556132048
cycle O 0 1.909125558086089e-06
regulation O 0 9.500848818788654e-07
. O 0 5.249467562862264e-07

When O 0 1.139709183917148e-06
resting O 0 3.3125030540759326e-07
cells O 0 1.0010000295324062e-07
are O 0 1.3439941382031861e-09
induced O 0 1.9131332962274428e-08
to O 0 4.3836978491640366e-10
proliferate O 0 6.791928086613552e-08
, O 0 2.1570061015108166e-10
the O 0 1.350744516237512e-10
steady O 0 1.3176577162710146e-08
- O 0 4.4125759046664825e-08
state O 0 2.727139181146754e-09
levels O 0 2.1862121002413915e-09
of O 0 4.7340138753515504e-11
BRCA1 O 0 4.2001300215588344e-08
increase O 0 1.0883705048314596e-09
in O 0 1.7402985996728404e-10
late O 0 1.8148168523524078e-09
G1 O 0 8.468974499464821e-08
and O 0 4.1729764088671573e-10
reach O 0 5.775774303273806e-10
a O 0 3.9863121137351243e-10
maximum O 0 3.178021179550683e-09
during O 0 2.9195122763781e-08
S O 0 4.0278505366586614e-06
phase O 0 7.301561026906711e-07
. O 0 4.3219006329309195e-07

Moreover O 0 3.896547241311055e-06
, O 0 2.3299433493662036e-08
in O 0 9.05259778249956e-09
S O 0 4.939169684803346e-06
phase O 0 2.7220019660489925e-07
cells O 0 1.968302996147031e-07
, O 0 2.661395326342131e-09
BRCA1 O 0 2.306322386402826e-07
polypeptides O 0 1.1417484557796342e-07
are O 0 1.6212344799981793e-09
hyperphosphorylated O 0 1.8032558557479206e-07
and O 0 1.9747616875065432e-09
accumulate O 0 5.3651568521217996e-08
into O 0 7.231925724937582e-09
discrete O 0 1.170486825685657e-06
subnuclear O 0 8.995983807835728e-05
foci O 0 3.2572977943345904e-05
termed O 0 5.487400812853593e-06
" O 0 7.630676464032149e-07
BRCA1 O 0 4.4028303818777204e-05
nuclear O 0 8.389730282942764e-06
dots O 0 3.988680327893235e-05
. O 0 3.7693523609050317e-06

" O 0 1.8840407847164897e-06
BRCA1 O 0 1.681123649177607e-05
associates O 0 1.6494763031005277e-06
in O 0 7.129793200277845e-09
vivo O 0 1.7371918374919915e-06
with O 0 2.3678932148385456e-09
a O 0 3.822847460810408e-08
structurally O 0 5.9513013184187e-06
related O 0 3.0215329616112285e-07
protein O 0 1.0825698382177507e-06
termed O 0 6.351088813971728e-06
BARD1 O 0 0.00015767046716064215
. O 0 2.2270560293691233e-06

Here O 0 3.245315554067929e-07
we O 0 3.162796602396156e-08
show O 0 4.9376081001639704e-09
that O 0 8.87597217946734e-11
the O 0 7.213857289301018e-11
steady O 0 9.00482621801757e-09
- O 0 7.28277100847663e-08
state O 0 1.9169896781079387e-09
levels O 0 2.0018504631735823e-09
of O 0 3.503075260424815e-11
BARD1 O 0 3.531215853058711e-08
, O 0 4.0351305630181855e-11
unlike O 0 4.1912190384962855e-10
those O 0 9.82686640393915e-11
of O 0 3.947849339103193e-11
BRCA1 O 0 1.945518022239412e-07
, O 0 9.793564847981884e-10
remain O 0 3.296422912413277e-09
relatively O 0 2.860296888229641e-09
constant O 0 3.9051077038720905e-08
during O 0 5.084727305870729e-08
cell O 0 4.801478098670486e-06
cycle O 0 3.525358579281601e-06
progression O 0 3.623161092036753e-06
. O 0 8.360836432075303e-07

However O 0 3.466987550382328e-07
, O 0 1.3330220482998811e-08
immunostaining O 0 4.889682827524666e-07
revealed O 0 7.953801883786582e-08
that O 0 3.024938743934058e-09
BARD1 O 0 7.700960509282595e-07
resides O 0 4.24280450772585e-08
within O 0 2.8326190282257357e-09
BRCA1 O 0 3.2921525416895747e-07
nuclear O 0 7.08000840177192e-08
dots O 0 6.084680848061907e-08
during O 0 8.82388917489152e-09
S O 0 2.4385909114243987e-07
phase O 0 3.9595877687759184e-09
of O 0 3.5423542571466626e-11
the O 0 1.3294557121845685e-10
cell O 0 2.8533726492696587e-08
cycle O 0 1.1464266869154471e-08
, O 0 1.3372250529108953e-10
but O 0 2.79115508483585e-10
not O 0 2.179628422194213e-10
during O 0 6.780376260451249e-10
the O 0 2.0660027022501026e-09
G1 O 0 2.6674397304304875e-06
phase O 0 4.4786500552618236e-07
. O 0 2.696186811590451e-07

Nevertheless O 0 5.71990176467807e-06
, O 0 3.667138059881836e-08
BARD1 O 0 8.978536811810045e-07
polypeptides O 0 1.006638612466304e-07
are O 0 9.736905726143164e-10
found O 0 5.530637059436572e-10
exclusively O 0 1.3084432426424542e-09
in O 0 4.37519409590692e-10
the O 0 2.667482346119243e-10
nuclear O 0 6.850105815914276e-09
fractions O 0 1.892835665984194e-09
of O 0 4.745169188136167e-11
both O 0 1.0235827740956438e-09
G1 O 0 6.822594968980411e-07
- O 0 2.455514902521827e-07
and O 0 5.636667577135768e-09
S O 0 4.852130587096326e-06
- O 0 4.154921100507636e-07
phase O 0 2.84384356064038e-07
cells O 0 4.450340895800764e-07
. O 0 1.966723033319795e-07

Therefore O 0 6.270099106586713e-07
, O 0 1.0169628694711719e-08
progression O 0 5.791731183535376e-08
to O 0 5.539592340397803e-09
S O 0 3.156347702315543e-06
phase O 0 6.135398677997728e-08
is O 0 7.586393735437014e-10
accompanied O 0 8.38223379595604e-10
by O 0 1.8042169147580722e-10
the O 0 3.596479780654249e-10
aggregation O 0 1.0790942361893485e-08
of O 0 1.4469313525111716e-09
nuclear O 0 4.901064585283166e-07
BARD1 O 0 5.508964022737928e-07
polypeptides O 0 4.5545743887487333e-07
into O 0 3.1016284651741444e-08
BRCA1 O 0 1.0132811439689249e-05
nuclear O 0 3.0425769637076883e-06
dots O 0 1.4836727132205851e-05
. O 0 1.2443522336980095e-06

This O 0 3.038851446035551e-07
cell O 0 4.539186647889437e-06
cycle O 0 4.937158792017726e-06
- O 0 3.0986655019660247e-06
dependent O 0 3.019029861661693e-07
colocalization O 0 4.882218149759865e-07
of O 0 1.5199181913061466e-09
BARD1 O 0 1.506666876593954e-06
and O 0 6.917368899905796e-09
BRCA1 O 0 7.119508040887013e-07
indicates O 0 1.5179315582258823e-08
a O 0 1.1634672114624323e-09
role O 0 8.995522549071211e-09
for O 0 1.387948311837306e-09
BARD1 O 0 1.0205205853708321e-06
in O 0 2.17696332072137e-08
BRCA1 O 0 5.5827451433287933e-05
- O 0 2.875728750950657e-05
mediated O 0 1.7893995391204953e-05
tumor B-Disease 0 2.923934516729787e-05
suppression O 0 2.959763378385105e-06
. O 0 1.6858280105225276e-06

Ethnic O 0 1.5787874872330576e-05
differences O 0 9.189297998091206e-06
in O 0 9.646944221231024e-08
the O 0 7.20414519150836e-08
HFE O 0 0.0003290184249635786
codon O 0 1.7836699043982662e-05
282 O 0 1.718869953037938e-06
( O 0 1.7140591523912008e-07
Cys O 0 0.004850681871175766
/ O 0 1.325374159932835e-05
Tyr O 0 2.3681262973695993e-05
) O 0 1.1566555713216076e-07
polymorphism O 0 1.5504043403780088e-05
. O 0 1.229861027240986e-06

Recent O 0 1.008583240036387e-06
studies O 0 1.7124547468938545e-07
have O 0 9.722954885660329e-09
shown O 0 6.449175060652124e-08
that O 0 5.84640474698972e-07
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
( O 0 1.129665065491281e-06
HH B-Disease 1 0.8964412808418274
) O 0 7.043745586798877e-09
is O 0 9.723951643891837e-10
likely O 0 1.2689126416276508e-09
to O 0 2.950877042717792e-10
be O 0 1.2633220025648484e-09
caused O 0 8.136467610775355e-10
by O 0 8.136292334315343e-11
homozygosity O 0 1.934001936376717e-08
for O 0 1.6363693733367768e-10
a O 0 1.1199715599374827e-09
Cys282Tyr O 0 4.400666284709587e-07
mutation O 0 1.579179667032804e-07
in O 0 2.296604018070525e-09
the O 0 3.8237493171777714e-09
HFE O 0 7.1979357016971335e-06
gene O 0 2.8211528046995227e-07
located O 0 1.2071981814187893e-07
4 O 0 2.1949253437014704e-07
. O 0 6.477269494098437e-07

5 O 0 2.9020131933066295e-06
Mb O 0 1.7444403056288138e-05
telomeric O 0 4.72583451482933e-05
to O 0 9.822345248267084e-08
HLA O 0 1.8530601664679125e-05
- O 0 3.125930379610509e-05
A O 0 3.695300847539329e-07
. O 0 5.343782163436117e-07

Population O 0 1.1670226740534417e-06
studies O 0 1.5396791752664285e-07
of O 0 2.0812843115614044e-10
this O 0 2.6559476840049e-10
polymorphism O 0 5.995261886937442e-08
are O 0 2.2210286387824851e-10
facilitated O 0 7.641594024221376e-10
by O 0 9.156607416738183e-11
the O 0 8.869033285563432e-11
fact O 0 1.06109820929845e-09
that O 0 2.3036575425017247e-10
the O 0 1.0588601107031081e-09
Cys282Tyr O 0 9.982561550714308e-07
mutation O 0 2.9361322617660335e-07
creates O 0 6.151968534595653e-08
a O 0 1.2805911886459853e-08
Rsal O 0 1.650972876632295e-06
restriction O 0 3.1065252414919087e-07
site O 0 6.827438028267352e-07
. O 0 3.300464186395402e-07

We O 0 1.0018898137786891e-06
have O 0 1.1809200728407632e-08
studied O 0 2.8536938145862223e-08
the O 0 3.217709654279588e-09
codon O 0 7.894190616752894e-07
282 O 0 1.547188901440677e-07
( O 0 2.0149716561945752e-08
Cys O 0 0.00016032843268476427
/ O 0 8.719434845261276e-07
Tyr O 0 4.689907200372545e-07
) O 0 1.1202152538913879e-09
polymorphism O 0 4.962536337416168e-08
in O 0 7.441717797540548e-10
different O 0 2.5439423900763813e-09
ethnic O 0 5.04070420959124e-08
groups O 0 1.3652669395014527e-07
. O 0 6.699535219922836e-07

In O 0 5.573679473513948e-08
agreement O 0 2.3286995443072556e-08
with O 0 9.133691580842651e-10
previous O 0 4.25724744346212e-09
observations O 0 1.186820330900673e-08
the O 0 9.503262621279873e-10
Tyr O 0 1.6183503248612396e-07
allele O 0 4.601157144179524e-08
appeared O 0 3.831956085775801e-09
to O 0 1.4636850065308238e-10
be O 0 1.6480400377716364e-10
rare O 0 1.005896921313365e-09
or O 0 4.947355858320179e-09
absent O 0 3.184545960266405e-08
in O 0 1.9137820217451917e-09
Asiatic O 0 2.869587767406756e-08
( O 0 3.306754869925044e-10
Indian O 0 2.5828654770521098e-09
, O 0 3.1692967694674223e-10
Chinese O 0 7.793113376841632e-10
) O 0 3.5387315300283717e-09
populations O 0 1.1057217363941163e-07
. O 0 2.1241145020667318e-07

The O 0 1.3468411452777218e-07
highest O 0 3.349141195485572e-07
allele O 0 9.176697517432331e-07
frequency O 0 5.038339736529451e-07
( O 0 1.5998575797482317e-09
7 O 0 8.940542750579539e-10
. O 0 3.976007856287822e-10
5 O 0 4.994484270604005e-10
% O 0 3.681641380648415e-10
) O 0 5.447727824403614e-10
was O 0 1.2980808428153523e-08
found O 0 7.551792080562336e-09
in O 0 9.318107174749457e-09
Swedes O 0 5.1738479669438675e-05
. O 0 3.2956393170024967e-07

Saamis O 0 0.0001071612787200138
( O 0 8.923922933945505e-08
2 O 0 2.9245615706940953e-08
% O 0 4.202628467453451e-09
) O 0 1.2945788885332377e-09
and O 0 1.184840558998701e-09
Mordvinians O 0 6.610491709579946e-08
( O 0 1.1988636472448633e-10
1 O 0 3.418470784222194e-10
. O 0 1.9312575150198796e-10
8 O 0 2.9558452907529897e-10
% O 0 1.1694224755220972e-10
) O 0 2.2071684757651866e-10
had O 0 3.5229124062396977e-09
significantly O 0 9.07205954803203e-09
lower O 0 4.811266052229257e-09
frequencies O 0 1.8116223188258118e-08
of O 0 2.9408081525517105e-10
the O 0 7.879583208136864e-09
Tyr O 0 6.403226507245563e-06
allele O 0 6.624604793614708e-06
. O 0 4.421953576638771e-07

Comparisons O 0 3.363974769854394e-07
with O 0 5.680757197978892e-09
allele O 0 1.89654471682843e-07
frequencies O 0 1.119885055800296e-07
based O 0 2.565265866394384e-08
on O 0 1.0417210205559968e-08
prevalence O 0 6.072739324736176e-07
estimates O 0 2.08377279875549e-08
of O 0 9.719668403462833e-10
HH B-Disease 0 0.14525310695171356
showed O 0 6.65559483081779e-08
some O 0 1.581353659130258e-10
disagreements O 0 1.355766254818036e-08
with O 0 1.8992210581991742e-10
the O 0 1.8464214879276852e-10
RFLP O 0 1.0287330809433115e-07
data O 0 5.040720729709847e-09
, O 0 2.4682650368035297e-10
particularly O 0 3.685957317145494e-09
in O 0 8.620634872613664e-09
Finns O 0 4.161926881351974e-06
. O 0 2.49810170771525e-07

The O 0 3.6694055438601936e-07
newly O 0 4.047100219395361e-07
described O 0 9.502818443252181e-08
HFE O 0 5.817122655571438e-06
marker O 0 2.757651884621737e-07
provides O 0 5.4427662377065644e-09
a O 0 7.547526492679424e-10
new O 0 5.370485722799856e-10
approach O 0 4.039955481260904e-09
to O 0 2.0044588211476366e-10
the O 0 9.381906362904147e-11
screening O 0 5.6218825150722296e-09
of O 0 1.1347908029923914e-10
HH B-Disease 0 1.951333842953318e-06
as O 0 9.75240666001298e-10
well O 0 1.0061406152672703e-09
as O 0 6.308876754346215e-10
studies O 0 2.4998825232103172e-09
of O 0 1.80115245634882e-11
the O 0 3.312120300247301e-10
relationship O 0 1.3683609800807517e-08
between O 0 1.834623564178628e-09
the O 0 5.993156193540017e-09
HFE O 0 2.2282447389443405e-05
Tyr O 0 1.2343494972810731e-06
allele O 0 4.4479014604803524e-07
and O 0 6.286789755449718e-09
different O 0 6.046490597100274e-08
disorders O 0 5.906484875595197e-05
including O 0 5.578315835919057e-07
cancer B-Disease 0 0.0005508331814780831

Autosomal B-Disease 1 0.9995201826095581
dominant I-Disease 1 0.9984772801399231
neurohypophyseal I-Disease 1 0.9998977184295654
diabetes I-Disease 1 0.9999934434890747
insipidus I-Disease 1 0.9859837889671326
associated O 0 2.345248731216998e-06
with O 0 1.8682170477291038e-08
a O 0 7.006243407658985e-08
missense O 0 4.029669798910618e-05
mutation O 0 3.213294803572353e-06
encoding O 0 8.026685236472986e-07
Gly23 O 0 2.9248238206491806e-05
- O 0 0.00010413464769953862
- O 0 4.002092100563459e-05
> O 0 2.6340815111325355e-06
Val O 0 0.00013742486771661788
in O 0 8.403116424915424e-08
neurophysin O 0 2.9918270229245536e-05
II O 0 1.5143510609050281e-05
. O 0 7.374761139544717e-07

Autosomal B-Disease 1 0.9987331032752991
dominant I-Disease 1 0.9941719174385071
neurohypophyseal I-Disease 1 0.9995899796485901
diabetes I-Disease 1 0.999988317489624
insipidus I-Disease 1 0.7262173891067505
( O 0 1.2105103053272614e-07
ADNDI B-Disease 0 1.0366496098868083e-05
) O 0 8.949265328794809e-09
is O 0 6.6196879089375216e-09
an O 0 2.6122742724510317e-07
inherited B-Disease 1 1.0
disease I-Disease 1 1.0
caused O 0 2.507338876966969e-06
by O 0 3.993353647757658e-09
progressive O 0 7.269808293131064e-07
degeneration O 0 2.6849197638512123e-06
of O 0 4.856329227642675e-10
the O 0 1.8058118333996731e-09
magnocellular O 0 1.2645974720726372e-06
neurons O 0 5.0057238354384026e-08
of O 0 1.0166650854515069e-10
the O 0 1.6855332407583745e-10
hypothalamus O 0 1.4371954293324052e-08
leading O 0 4.9980797278692535e-09
to O 0 4.35723901404117e-10
decreased O 0 9.213729335044718e-09
ability O 0 3.6068066311401026e-09
to O 0 6.600193169781221e-10
produce O 0 7.536625545867537e-09
the O 0 5.33328092799934e-09
hormone O 0 2.515695314286859e-07
arginine O 0 1.687156725438399e-07
vasopressin O 0 4.3721453835132706e-07
( O 0 7.738785612332322e-09
AVP O 0 1.8582751408757758e-06
) O 0 4.2400053246183234e-08
. O 0 1.1217877471381144e-07

Affected O 0 5.140368557476904e-07
individuals O 0 9.294002900617215e-09
are O 0 6.789447892785461e-10
not O 0 1.1839731417495614e-09
symptomatic O 0 8.33077251627401e-09
at O 0 5.244577550023166e-10
birth O 0 1.735175447770132e-09
, O 0 3.146859162139748e-10
but O 0 6.673999575212974e-09
usually O 0 5.618466403234379e-08
develop O 0 5.054837970419612e-07
diabetes B-Disease 0 2.353582385694608e-05
insipidus I-Disease 0 1.1572481525945477e-05
at O 0 2.1484760637235922e-08
1 O 0 3.665893189008784e-08
- O 0 7.347001883317716e-06
6 O 0 1.0578497011692889e-07
yr O 0 1.170641462522326e-05
of O 0 7.0494974302448554e-09
age O 0 1.978088306486825e-07
. O 0 1.9873648682278144e-07

The O 0 1.5431689348588407e-07
genetic O 0 1.3900017847845447e-06
locus O 0 1.1909903605555883e-06
of O 0 4.078131166096455e-09
the O 0 1.8158289094571956e-08
disease O 0 9.687709052741411e-07
is O 0 2.724804604170572e-09
the O 0 2.494338513514549e-09
AVP O 0 6.437226602429291e-06
- O 0 5.895096819585888e-06
neurophysin O 0 7.172362984420033e-06
II O 0 2.214445373738272e-07
( O 0 1.0062057853588158e-09
NPII O 0 9.450130278310098e-08
) O 0 5.120058821361795e-10
gene O 0 3.4908660406784975e-09
, O 0 5.304092165481222e-10
and O 0 7.740789675914073e-10
mutations O 0 3.300948137052728e-08
that O 0 5.578544848283684e-10
cause O 0 2.147499733595737e-09
ADNDI B-Disease 0 1.8077155061746453e-07
have O 0 1.5441184997300184e-09
been O 0 1.2709495678109306e-09
found O 0 5.75545111569653e-10
in O 0 1.56908930293298e-10
both O 0 3.090405154004827e-10
the O 0 2.552573152847515e-10
signal O 0 5.793827639877236e-09
peptide O 0 4.3585046682892425e-09
of O 0 9.683911311730853e-11
the O 0 8.939808893160262e-10
prepro O 0 1.7031270544975996e-06
- O 0 6.756415018571715e-07
AVP O 0 2.957777041956433e-06
- O 0 3.2369729296988226e-07
NPII O 0 4.279312406652025e-07
precursor O 0 2.5973317718808175e-08
and O 0 4.155726429644346e-09
within O 0 5.699870353481629e-09
NPII O 0 4.8428287300339434e-06
itself O 0 6.344226903820527e-07
. O 0 3.3001904853335873e-07

An O 0 9.272952894434638e-08
affected O 0 1.2320427345002827e-07
girl O 0 7.059409199428046e-07
who O 0 7.215955832862164e-09
presented O 0 2.2214492467753644e-09
at O 0 9.665998002006404e-10
9 O 0 5.115568524338698e-10
months O 0 9.233728226476501e-10
of O 0 3.9048781569350766e-11
age O 0 2.3743560451094936e-09
and O 0 8.81180961531669e-10
her O 0 7.429311832396479e-09
similarly O 0 3.8822040693275994e-08
affected O 0 5.97407368019276e-09
younger O 0 1.652787906536446e-09
brother O 0 9.79367698050737e-10
and O 0 1.9506114778966577e-10
father O 0 6.101107952183327e-10
were O 0 1.6073749276035443e-10
all O 0 1.6142778086480902e-11
found O 0 1.7477166935897515e-10
to O 0 1.3719136937595522e-10
have O 0 1.3281385990993044e-09
a O 0 1.3039662682956532e-09
novel O 0 1.7178081179736182e-07
missense O 0 6.682945695501985e-06
mutation O 0 7.822575867066917e-07
( O 0 5.743292952331558e-09
G1758 O 0 8.030866069930198e-07
- O 0 4.698893008026062e-06
- O 0 3.054662784052198e-06
> O 0 2.953074158540403e-07
T O 0 9.99081862573803e-07
) O 0 6.674695796071717e-10
encoding O 0 2.503165230649529e-09
the O 0 6.083909487308858e-10
amino O 0 7.602085183577856e-09
acid O 0 1.1709682112837072e-08
substitution O 0 5.4095550261479275e-09
Gly23 O 0 4.3249846726212127e-07
- O 0 1.329479573541903e-06
- O 0 1.928463916556211e-06
> O 0 6.536506589327473e-07
Val O 0 1.0962025953631382e-05
within O 0 1.2476718325160618e-07
NPII O 0 5.565909668803215e-05
. O 0 1.7768995803635335e-06

The O 0 2.836016506080341e-07
mutation O 0 6.760933956684312e-06
was O 0 1.605774713198116e-07
confirmed O 0 3.866596998136629e-08
by O 0 2.0720130056162134e-09
restriction O 0 1.8871287466026843e-07
endonuclease O 0 7.103446932887891e-06
analysis O 0 2.2096805878391024e-06
. O 0 1.044023406393535e-06

A O 0 1.0457023336130078e-06
T1 O 0 3.4155506000388414e-05
- O 0 1.2964869711140636e-06
weighted O 0 1.4271665804699296e-07
magnetic O 0 4.863489877493521e-08
resonance O 0 6.794920750508027e-07
imaging O 0 2.1823068891535513e-05
of O 0 2.281741462439868e-09
the O 0 1.1957705048359912e-08
fathers O 0 6.405593921954278e-07
pituitary O 0 1.7376888763465104e-06
gland O 0 1.1115140523543232e-06
demonstrates O 0 1.74495454530188e-07
an O 0 1.5266682140691046e-08
attenuated O 0 9.109809070650954e-06
posterior O 0 0.00018450497009325773
pituitary O 0 0.000519252906087786
bright O 0 1.1525550689839292e-05
spot O 0 1.4080846995057072e-05
. O 0 1.6804651750135235e-06

This O 0 6.36336210391164e-08
mutation O 0 3.1706971981293464e-07
may O 0 1.1504900143677332e-08
be O 0 1.4804243941846096e-10
valuable O 0 5.485545906402933e-10
for O 0 9.316427490579926e-11
developing O 0 1.6748720188530797e-09
models O 0 1.0063157418471746e-08
of O 0 3.467776898968822e-10
dominantly B-Disease 0 2.5148221538984217e-05
inherited I-Disease 1 0.8177416324615479
neurodegeneration I-Disease 1 1.0
, O 0 9.671992096116355e-10
as O 0 9.958606855819951e-11
the O 0 6.283810971563497e-11
early O 0 3.766766010215861e-09
age O 0 1.7935815055381e-09
of O 0 6.352646186869038e-11
onset O 0 1.435245451375522e-07
of O 0 9.311475479556464e-10
symptoms O 0 2.4529941811124445e-07
suggests O 0 3.992972619215607e-09
that O 0 9.223830726989846e-11
this O 0 1.4661549752048586e-10
mutation O 0 2.4534914544460662e-08
may O 0 3.090347755474454e-09
be O 0 4.0314632188120925e-10
particularly O 0 2.2425690193728087e-09
deleterious O 0 1.0410440864916382e-07
to O 0 2.907063922918951e-09
the O 0 7.299122195547625e-09
magnocellular O 0 8.636339771328494e-06
neuron O 0 2.2945882847125176e-06
. O 0 1.3593736980510585e-07
. O 0 6.761919735254196e-07

Frequent O 0 0.00013807517825625837
inactivation O 0 0.00017055698845069855
of O 0 1.837048273500841e-07
PTEN O 0 0.0002081756538245827
/ O 0 2.270974437124096e-05
MMAC1 O 0 9.283237159252167e-05
in O 0 9.020427569339518e-07
primary O 1 0.9996685981750488
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 3.455234264038154e-06

Sporadic B-Disease 1 0.8130576014518738
prostate I-Disease 1 0.999974250793457
carcinoma I-Disease 1 1.0
is O 0 2.0879866724499152e-07
the O 0 6.35138885929365e-10
most O 0 1.0972038833045872e-09
common O 0 2.424172507176081e-08
male B-Disease 0 4.453440567431244e-07
cancer I-Disease 0 8.553748642725623e-08
in O 0 2.4274968146720255e-10
the O 0 1.410842970228643e-10
Western O 0 4.863228042495393e-09
world O 0 4.015955124003767e-09
, O 0 6.557776544013905e-11
yet O 0 2.1388041337999653e-10
many O 0 1.4893111049962826e-11
of O 0 4.6549318219457625e-12
the O 0 2.3041396915446377e-11
major O 0 2.5406632353508485e-10
genetic O 0 2.6302937605748866e-09
events O 0 1.971798696542848e-10
involved O 0 3.813696303200942e-10
in O 0 8.540906176746077e-11
the O 0 6.447185840752212e-11
progression O 0 1.3382872587897054e-09
of O 0 3.921851732258119e-11
this O 0 7.276279578860567e-10
often O 0 9.539762686472386e-07
fatal O 0 0.017941953614354134
cancer B-Disease 0 2.7870808025909355e-06
remain O 0 4.316164758932928e-09
to O 0 2.1396908689297334e-09
be O 0 9.304786274810795e-09
elucidated O 0 3.2174036732612876e-06
. O 0 2.966218346500682e-07

Numerous O 0 9.114658610087645e-07
cytogenetic O 0 6.736368231941015e-05
and O 0 5.817450343670316e-08
allelotype O 0 1.5064039189383038e-06
studies O 0 5.192179486357418e-08
have O 0 1.6961767546064266e-09
reported O 0 1.0843181463826568e-08
frequent O 0 1.0597298683023837e-07
loss O 0 2.737392037488462e-07
of O 0 1.3582036606507586e-09
heterozygosity O 0 2.0873685571132228e-05
on O 0 6.338058256005752e-08
chromosomal O 0 0.04428698495030403
arm O 0 0.00011933406494790688
10q O 0 6.355251116474392e-06
in O 0 1.5032696865091566e-07
sporadic B-Disease 1 0.9693398475646973
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 3.9874607864476275e-06

Deletion O 0 3.508332883939147e-05
mapping O 0 5.548261924559483e-06
studies O 0 7.753118893560895e-07
have O 0 1.0318533583131284e-08
unambiguously O 0 1.5253708340878802e-07
identified O 0 4.4468027482480466e-08
a O 0 2.4394959385887205e-09
region O 0 8.720306254872412e-09
of O 0 1.8530188494736421e-10
chromosome O 0 3.794602676521208e-08
10q23 O 0 3.299085093999565e-08
to O 0 2.3404661542159033e-10
be O 0 3.458173192250058e-10
the O 0 1.6191724350189673e-10
minimal O 0 1.4049688523698478e-08
area O 0 1.0975267805690692e-08
of O 0 2.7961386539487876e-09
loss O 0 2.1099867808516137e-06
. O 0 3.4396660453239747e-07

A O 0 1.1613237802521326e-06
new O 0 6.342654046420648e-07
tumor B-Disease 0 4.3638365241349675e-06
suppressor O 0 3.477946393104503e-06
gene O 0 1.7250707742277882e-06
, O 0 3.39031913654253e-08
PTEN O 0 1.8936232663691044e-05
/ O 0 2.555431592554669e-06
MMAC1 O 0 3.567693056538701e-05
, O 0 4.004772069521323e-09
was O 0 1.0330860611418302e-08
isolated O 0 6.630683913044777e-08
recently O 0 4.499872545693506e-07
at O 0 2.5574184991938864e-09
this O 0 4.516609308780062e-10
region O 0 9.06299746361583e-09
of O 0 1.8284707081761553e-10
chromosome O 0 8.57940136711477e-08
10q23 O 0 7.414493552460044e-08
and O 0 4.782379492418443e-10
found O 0 3.83698572914426e-10
to O 0 1.2809270311109344e-10
be O 0 3.210161858557825e-10
inactivated O 0 1.0839418251862298e-08
by O 0 1.652497028103994e-10
mutation O 0 5.218698717612824e-08
in O 0 7.45110906308355e-09
three O 0 5.519352271221578e-06
prostate B-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
cell O 0 2.3342916392721236e-05
lines O 0 4.5579192374134436e-05
. O 0 1.6660493429299095e-06

We O 0 2.2742142391507514e-06
screened O 0 6.000643679726636e-06
80 O 0 1.0848756346604205e-06
prostate B-Disease 0 0.11807172000408173
tumors I-Disease 1 1.0
by O 0 5.8088986953919175e-09
microsatellite O 0 9.379247785545886e-06
analysis O 0 2.400779521849472e-07
and O 0 9.235089137860086e-09
found O 0 7.499973087021772e-09
chromosome O 0 1.730744685346508e-07
10q23 O 0 1.3484542193964444e-07
to O 0 7.722621431227594e-10
be O 0 5.761756072253377e-10
deleted O 0 2.987430036682781e-08
in O 0 3.0569784481571105e-09
23 O 0 1.119551473749425e-08
cases O 0 9.148241275624969e-08
. O 0 2.822363853738352e-07

We O 0 3.4683631611187593e-07
then O 0 1.188689324749248e-08
proceeded O 0 1.0613922185598312e-08
with O 0 1.9349408186819517e-10
sequence O 0 3.770777468048436e-09
analysis O 0 7.616249853015233e-09
of O 0 2.339961557851211e-10
the O 0 2.921872743755216e-09
entire O 0 1.0148686158117926e-07
PTEN O 0 3.240452497266233e-05
/ O 0 6.453334435718716e-07
MMAC1 O 0 2.9442908271448687e-06
coding O 0 2.713163894441095e-06
region O 0 4.252202501220381e-08
and O 0 1.7738894797503235e-09
tested O 0 8.312756705208812e-09
for O 0 1.0481775863935283e-10
homozygous O 0 1.2036787566671592e-08
deletion O 0 1.6823102910734633e-08
with O 0 1.90727281190739e-10
new O 0 1.425091156193048e-09
intragenic O 0 5.6547829530018134e-08
markers O 0 3.336878862114645e-08
in O 0 4.3860309828502864e-10
these O 0 3.104471957282584e-10
23 O 0 6.786056161445231e-10
cases O 0 6.331962731920271e-10
with O 0 7.41281758198653e-10
10q23 O 0 8.989674711301632e-07
loss O 0 9.6584145126144e-08
of O 0 5.873394215427652e-09
heterozygosity O 0 5.075466106063686e-05
. O 0 1.026278027893568e-06

The O 0 2.2278788591734155e-08
identification O 0 1.6083056664228934e-08
of O 0 2.3158873430073612e-10
the O 0 3.8661948642548793e-10
second O 0 3.986017738100145e-09
mutational O 0 8.502816513100697e-07
event O 0 1.881049627172615e-08
in O 0 7.769589416284362e-10
10 O 0 4.702688793933874e-10
( O 0 2.6833982258445133e-10
43 O 0 7.473754948250644e-09
% O 0 1.197110144346425e-08
) O 0 1.4951515936445503e-07
tumors B-Disease 1 1.0
establishes O 0 1.1509265505083022e-06
PTEN O 0 1.1929162610613275e-05
/ O 0 3.317530001822888e-07
MMAC1 O 0 6.73123622618732e-07
as O 0 1.8468098161861235e-09
a O 0 7.836458149057535e-10
main O 0 1.1045683478982937e-08
inactivation O 0 8.364576729036344e-07
target O 0 2.9489109820701742e-08
of O 0 2.7441793282179106e-10
10q O 0 2.1697736940495815e-07
loss O 0 7.05833969050218e-08
in O 0 1.1165893099018831e-08
sporadic B-Disease 1 0.9956181049346924
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.1729021309747623e-07
. O 0 4.58357277466348e-07

Risk O 0 0.00022637350775767118
reversals O 0 5.312345820129849e-06
in O 0 2.6228056171362368e-08
predictive O 0 2.0310328636696795e-06
testing O 0 7.87401006618893e-07
for O 0 1.121528896419477e-07
Huntington B-Disease 1 0.9999996423721313
disease I-Disease 1 0.9999996423721313
. O 0 4.2221081457682885e-06

The O 0 1.9619005087179175e-08
first O 0 5.206695519177629e-09
predictive O 0 3.079264843108831e-07
testing O 0 1.0905430514185355e-07
for O 0 2.498739704037689e-08
Huntington B-Disease 1 0.9999998807907104
disease I-Disease 1 0.9999963045120239
( O 0 2.900633733204927e-09
HD B-Disease 0 1.2674599020101596e-05
) O 0 2.948313149175874e-09
was O 0 5.983869844072842e-09
based O 0 6.021431131486565e-10
on O 0 4.3642922609166135e-10
analysis O 0 5.3764948049206396e-09
of O 0 1.7631518467453589e-10
linked O 0 5.4546898553553547e-08
polymorphic O 0 7.250186939700143e-08
DNA O 0 2.955386158021156e-08
markers O 0 1.2079082623017712e-08
to O 0 1.997973869682923e-10
estimate O 0 2.0427237679143673e-09
the O 0 1.1550555650829963e-10
likelihood O 0 5.458995477880535e-09
of O 0 6.309488348454906e-11
inheriting O 0 3.817528337890508e-08
the O 0 2.6384388007727466e-09
mutation O 0 2.0028411995554052e-07
for O 0 1.2434140828077034e-08
HD B-Disease 0 3.3760334190446883e-05
. O 0 7.949992095745984e-07

Limits O 0 8.0245189337802e-07
to O 0 7.37096206293586e-09
accuracy O 0 4.662974006919285e-08
included O 0 1.3600286452586374e-09
recombination O 0 1.5750728721286578e-08
between O 0 8.804064144385393e-10
the O 0 3.9237094129340733e-10
DNA O 0 2.0002865142032533e-08
markers O 0 4.6358294980564096e-08
and O 0 1.0374218151198988e-09
the O 0 8.377023519301474e-10
mutation O 0 8.908735793511369e-08
, O 0 7.238421528832362e-10
pedigree O 0 9.431726510911176e-08
structure O 0 1.9453672450708837e-08
, O 0 3.252087488192501e-10
and O 0 1.5704605671462701e-10
whether O 0 5.149420334582544e-10
DNA O 0 4.838589084954492e-09
samples O 0 1.0646804549097055e-09
were O 0 2.057436859770334e-10
available O 0 1.1161969126760596e-09
from O 0 5.734018815317654e-10
family O 0 1.0113590853677579e-08
members O 0 1.1826872814424405e-08
. O 0 1.662147042225115e-07

With O 0 2.4809498455624635e-08
direct O 0 2.665384535305293e-08
tests O 0 3.140806015267117e-08
for O 0 1.526119369765766e-10
the O 0 1.7136775332105003e-10
HD B-Disease 0 4.265801010205905e-07
mutation O 0 1.7187071321700387e-08
, O 0 2.7175370287402245e-10
we O 0 4.163634714782205e-10
have O 0 6.584572470602623e-11
assessed O 0 4.3936923543874684e-10
the O 0 5.82167092311181e-11
accuracy O 0 2.1252123616477547e-08
of O 0 8.594358558156046e-11
results O 0 3.3068447979900384e-09
obtained O 0 1.14855347455034e-09
by O 0 1.2000075932938614e-10
linkage O 0 8.962315334315463e-09
approaches O 0 3.842026252698361e-09
when O 0 6.751134651317159e-10
requested O 0 2.344250071839582e-10
to O 0 7.228773829526247e-11
do O 0 8.736066869907688e-10
so O 0 8.187087813249505e-11
by O 0 9.744331730399125e-11
the O 0 1.1396436017108158e-09
test O 0 5.0963588904551216e-08
individuals O 0 1.1812083755557978e-08
. O 0 1.0543769235482614e-07

For O 0 1.5849515477839304e-08
six O 0 9.984344462310446e-10
such O 0 9.908739107000741e-11
individuals O 0 2.340783122889434e-10
, O 0 2.239913254875603e-10
there O 0 8.827925057630637e-10
was O 0 1.4007144777394842e-08
significant O 0 5.8484093123922776e-09
disparity O 0 2.8345338520807672e-08
between O 0 1.1097562868656041e-09
the O 0 5.603651320740255e-09
tests O 0 4.2961514168382564e-07
. O 0 1.1468754479437848e-07

Three O 0 4.908605077957873e-08
went O 0 2.3931166381885305e-08
from O 0 2.3696178352849984e-10
a O 0 6.527045015580768e-10
decreased O 0 9.53635392875185e-08
risk O 0 5.399012792395297e-08
to O 0 1.8752659147747153e-10
an O 0 1.0581570342171887e-10
increased O 0 3.613244592415299e-09
risk O 0 1.258870838682924e-07
, O 0 8.542437590630669e-11
while O 0 1.539483124313179e-10
in O 0 7.294703036064831e-11
another O 0 2.8031965637609346e-10
three O 0 4.101358974661906e-10
the O 0 6.253328077576725e-09
risk O 0 4.111100497539155e-05
was O 0 1.2652837710902531e-07
decreased O 0 6.597876449632167e-07
. O 0 2.10155519653199e-07

Knowledge O 0 2.769662330592837e-07
of O 0 1.629670398628491e-09
the O 0 8.609358781441756e-10
potential O 0 5.4919770953176794e-09
reasons O 0 5.995302032602012e-10
for O 0 2.0885727175512514e-11
these O 0 5.15557006808276e-11
changes O 0 5.531945457271092e-10
in O 0 3.198671605364467e-10
results O 0 1.115816505858902e-08
and O 0 1.3100064366611264e-09
impact O 0 3.8662042456394374e-09
of O 0 4.4226129702895633e-11
these O 0 8.149124708367594e-10
risk O 0 1.2509405955540842e-08
reversals O 0 9.063896300176566e-09
on O 0 2.765881690347527e-10
both O 0 6.467251734143531e-10
patients O 0 2.200053916823208e-09
and O 0 6.361460663795171e-11
the O 0 4.456407465269763e-11
counseling O 0 1.6966298366227761e-09
team O 0 8.216262392668483e-11
can O 0 4.3690374235128004e-11
assist O 0 4.875714762486716e-11
in O 0 6.029404059360033e-11
the O 0 4.3184827241971036e-11
development O 0 6.009335390411152e-11
of O 0 1.158759980329771e-11
strategies O 0 1.2134496740756617e-09
for O 0 4.2150269385921035e-11
the O 0 5.676494690964873e-11
prevention O 0 6.830089271936401e-10
and O 0 1.5816310761085361e-10
, O 0 3.312535662436389e-11
where O 0 1.848747405164275e-10
necessary O 0 9.722987970306463e-10
, O 0 2.4707050294558996e-10
management O 0 7.024181236658933e-10
of O 0 2.2156920395643986e-11
a O 0 1.7680492625515853e-09
risk O 0 6.731608692689406e-08
reversal O 0 1.597726750901529e-08
in O 0 2.3459589826302363e-10
any O 0 9.715905857632379e-10
predictive O 0 2.215121241988527e-07
testing O 0 3.135532722353673e-08
program O 0 1.686268014111647e-08
. O 0 6.605649804924951e-09
. O 0 8.15549228150303e-08

A O 0 1.4066803259993321e-06
novel O 0 1.3080443750368431e-06
common O 0 8.450037398688437e-07
missense O 0 3.8409230910474434e-05
mutation O 0 6.929144092282513e-06
G301C O 0 2.0034613044117577e-06
in O 0 1.2900393642212293e-08
the O 0 8.425114828014557e-09
N O 0 1.0494004527572542e-05
- O 0 4.465290203370387e-06
acetylgalactosamine O 0 6.860528810648248e-05
- O 0 6.48446712148143e-06
6 O 0 1.742413644478802e-07
- O 0 1.5933300119286287e-06
sulfate O 0 6.4283617575711105e-06
sulfatase O 0 2.259997017972637e-05
gene O 0 1.0582690492810798e-06
in O 0 1.088136940552431e-07
mucopolysaccharidosis B-Disease 0 2.286741255375091e-05
IVA I-Disease 0 0.0002040161198237911
. O 0 1.7159413800982293e-06

Mucopolysaccharidosis B-Disease 0 0.0012017653789371252
IVA I-Disease 0 0.004571760538965464
( O 0 1.542196400805551e-06
MPS B-Disease 1 0.9999978542327881
IVA I-Disease 1 0.9999998807907104
) O 0 1.3844643653726507e-08
is O 0 3.1490943186440745e-09
an O 0 9.738526429714511e-09
autosomal B-Disease 1 0.9998117089271545
recessive I-Disease 1 0.9994865655899048
lysosomal I-Disease 1 0.9996575117111206
storage I-Disease 1 0.9999310970306396
disorder I-Disease 1 0.9999955892562866
caused O 0 1.229523263646115e-06
by O 0 6.8739658409811e-09
a O 0 1.7551984683450428e-06
genetic B-Disease 1 1.0
defect I-Disease 1 1.0
in O 0 7.455946615664288e-08
N O 0 0.00015585211804136634
- O 0 1.0665116860764101e-05
acetylgalactosamine O 0 6.349184695864096e-05
- O 0 1.4246783393900841e-05
6 O 0 2.2156388013172545e-07
- O 0 3.630563014667132e-06
sulfate O 0 1.6761399820097722e-05
sulfatase O 0 2.96915095532313e-05
( O 0 1.920199999005945e-08
GALNS O 0 1.8587591057439568e-06
) O 0 3.5304477563613545e-08
. O 0 2.0652204568705201e-07

In O 0 6.26393088509758e-08
previous O 0 2.425328382571479e-08
studies O 0 2.163617551786956e-08
, O 0 6.253348949769588e-10
we O 0 1.3886420902053942e-09
have O 0 2.0774452991201287e-10
found O 0 3.36556255087217e-10
two O 0 1.493131729368713e-10
common O 0 4.560961830435417e-09
mutations O 0 4.149107368789373e-08
in O 0 5.09306985474467e-10
Caucasians O 0 4.471953118923011e-08
and O 0 3.3252249842519177e-09
Japanese O 0 2.1985155029824455e-08
, O 0 3.385606683892206e-09
respectively O 0 1.0320663079710357e-07
. O 0 3.167856164054683e-07

To O 0 9.97207791897381e-08
characterize O 0 7.455846002812905e-07
the O 0 6.026627641375626e-09
mutational O 0 1.4145529121378786e-06
spectrum O 0 6.157097942605105e-08
in O 0 1.1275700373403197e-09
various O 0 6.582528966347923e-10
ethnic O 0 1.2068329446890402e-08
groups O 0 5.675742986710475e-09
, O 0 1.0353146118191603e-09
mutations O 0 1.6217578391319876e-08
in O 0 2.7128915780494367e-10
the O 0 2.6745639036818147e-10
GALNS O 0 1.794267205923461e-07
gene O 0 1.7668432050754745e-08
in O 0 3.792213210118689e-09
Colombian O 0 5.580055812970386e-07
MPS B-Disease 1 0.999998927116394
IVA I-Disease 1 0.9999998807907104
patients O 0 2.438181638808601e-07
were O 0 5.428953397945691e-10
investigated O 0 1.07321973530361e-08
, O 0 3.3547503663911016e-10
and O 0 5.16474585321447e-10
genetic O 0 2.0707693337840283e-08
backgrounds O 0 1.6289314785922215e-08
were O 0 3.2907360170142397e-10
extensively O 0 3.220300914819063e-09
analyzed O 0 8.503252324487676e-09
to O 0 5.069837327731364e-10
identify O 0 7.024747450401492e-09
racial O 0 1.0167825692519727e-08
origin O 0 4.100805917062189e-09
, O 0 3.6008451775870753e-10
based O 0 2.093172968287149e-09
on O 0 1.5141543574515026e-09
mitochondrial O 0 7.454524109107297e-08
DNA O 0 5.408999186329311e-07
( O 0 7.620958086818064e-09
mtDNA O 0 3.9916653804539237e-07
) O 0 2.5556351701538915e-08
lineages O 0 8.756250053920667e-07
. O 0 5.714181270377594e-07

Three O 0 1.620293090809355e-07
novel O 0 6.210764240677236e-07
missense O 0 8.68182451085886e-06
mutations O 0 1.4424001619772753e-06
never O 0 2.538564274345845e-07
identified O 0 1.585855713415185e-08
previously O 0 7.48037187747741e-09
in O 0 1.6809838243592168e-10
other O 0 1.350870804106563e-10
populations O 0 2.04665484559996e-09
and O 0 8.833634934646284e-10
found O 0 1.2905357893444602e-09
in O 0 2.9716679117441913e-10
16 O 0 3.7701641808496333e-10
out O 0 1.936960591919501e-10
of O 0 1.4703668838045303e-10
19 O 0 8.957035113610345e-09
Colombian O 0 2.6935884989143233e-07
MPS B-Disease 1 0.9999942779541016
IVA I-Disease 1 0.9999916553497314
unrelated O 0 2.3748945920942788e-07
alleles O 0 2.357046753331815e-07
account O 0 4.672090625490455e-08
for O 0 9.861913063957672e-09
84 O 0 3.321711972148478e-07
. O 0 3.887977300109924e-07

2 O 0 3.389847904600174e-07
% O 0 1.0671837635811698e-08
of O 0 1.2496324808264347e-10
the O 0 6.581198919164422e-10
alleles O 0 5.843707029384859e-08
in O 0 4.610334780608127e-09
this O 0 8.540962603831304e-09
study O 0 1.2200534627027082e-07
. O 0 2.6072643777297344e-07

The O 0 1.75399406998622e-07
G301C O 0 2.2772267129766988e-06
and O 0 1.6892940379875654e-08
S162F O 0 5.248996899354097e-07
mutations O 0 1.5947848908126616e-07
account O 0 3.4310225771605474e-08
for O 0 8.773325177457991e-09
68 O 0 6.817443818363245e-07
. O 0 6.470644962064398e-07

4 O 0 2.5991314487328054e-06
% O 0 1.4152367100450647e-07
and O 0 5.007872516671341e-08
10 O 0 8.618452085329409e-08
. O 0 2.704855432966724e-07

5 O 0 6.306777322606649e-07
% O 0 2.845345647983777e-08
of O 0 5.021085214274024e-10
mutations O 0 7.940613500068139e-08
, O 0 5.311461825918684e-10
respectively O 0 8.845593590933731e-09
, O 0 3.5242009310820777e-10
whereas O 0 2.434708434861932e-09
the O 0 5.609497866210233e-10
remaining O 0 1.1085996121096287e-08
F69V O 0 2.849886413969216e-06
is O 0 5.019161197772348e-10
limited O 0 1.1400458355126375e-09
to O 0 4.3153888795721684e-10
a O 0 1.9105725890256053e-09
single O 0 1.5684018705997005e-07
allele O 0 6.310787739494117e-06
. O 0 5.283600330585614e-07

The O 0 1.978620360887362e-07
skewed O 0 2.610692945381743e-06
prevalence O 0 1.995696266021696e-06
of O 0 5.929004509575009e-10
G301C O 0 9.964777092363875e-08
in O 0 7.381101840842064e-10
only O 0 4.769507566670939e-10
Colombian O 0 2.7839057281653368e-08
patients O 0 2.9550029978508974e-08
and O 0 8.857744537849044e-10
haplotype O 0 9.558041824675456e-08
analysis O 0 8.425114828014557e-09
by O 0 4.3116452075331324e-10
restriction O 0 1.1870852745232696e-08
fragment O 0 4.299077360769843e-08
length O 0 2.1614191325625143e-08
polymorphisms O 0 3.7386209328360565e-07
in O 0 1.215163636381078e-09
the O 0 5.567150074270444e-10
GALNS O 0 3.100008143519517e-07
gene O 0 2.63150443657878e-08
suggest O 0 7.792285039442959e-09
that O 0 2.8254734663057945e-10
G301C O 0 2.1294239260782888e-08
originated O 0 5.775699918331156e-09
from O 0 5.792653579028695e-10
a O 0 2.9484537034107916e-09
common O 0 4.2597275040634486e-08
ancestor O 0 4.674287765737972e-07
. O 0 1.1417205314501189e-06

Investigation O 0 3.9283042951865355e-07
of O 0 2.16112949757985e-09
the O 0 1.5007499687413883e-09
genetic O 0 5.358938892641163e-08
background O 0 3.504611001403646e-08
by O 0 1.0960430341100391e-09
means O 0 1.5011316634172545e-08
of O 0 3.204478904450525e-10
mtDNA O 0 8.000771600791268e-08
lineages O 0 7.873558693916038e-09
indicate O 0 1.1707917302317128e-08
that O 0 4.4052470005162547e-10
all O 0 1.8986777428064983e-10
our O 0 9.931467870316624e-10
patients O 0 1.919052916576902e-09
are O 0 1.0734539646062302e-10
probably O 0 2.0876984585527225e-09
of O 0 2.2608291627701504e-10
native O 0 3.1750722939705156e-08
American O 0 9.733383876664448e-07
descent O 0 0.00015735416673123837

Low O 0 5.0941929657710716e-05
frequency O 0 8.120270649669692e-06
of O 0 8.398645690022022e-08
BRCA1 O 0 5.403179602581076e-05
germline O 0 1.696750223345589e-05
mutations O 0 1.7214914578289608e-06
in O 0 1.0369414660260645e-08
45 O 0 7.998757212135388e-08
German O 1 0.9268602728843689
breast B-Disease 1 0.9999996423721313
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 2.2408935365092475e-06
. O 0 1.2457212505978532e-06

In O 0 2.9925967481858606e-08
this O 0 1.0279770368271102e-09
study O 0 2.3901318702002072e-09
we O 0 1.393051118903088e-09
investigated O 0 2.3641081980940726e-08
45 O 0 1.4481303267643852e-08
German O 0 0.04422052949666977
breast B-Disease 1 0.9999899864196777
/ I-Disease 1 0.9999994039535522
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 3.13187484834998e-08
for O 0 3.615326482631076e-09
germline O 0 6.559188477694988e-06
mutations O 0 2.3965574200701667e-06
in O 0 1.3203294457753145e-08
the O 0 2.5622439281391962e-08
BRCA1 O 0 2.092606337100733e-05
gene O 0 5.901616077608196e-06
. O 0 1.4409661162062548e-06

We O 0 1.0752664820756763e-06
identified O 0 2.3429635120919556e-07
four O 0 1.542035477086756e-08
germline O 0 2.176541329390602e-06
mutations O 0 4.3201450239394035e-07
in O 0 4.774789452710593e-09
three O 0 3.27233777852598e-08
breast B-Disease 1 0.6402603983879089
cancer I-Disease 0 5.994775619910797e-06
families O 0 7.689344716510504e-10
and O 0 2.385089348244662e-10
in O 0 6.325492907244268e-10
one O 0 2.7214795409236103e-05
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 5.488971499545414e-09
. O 0 1.2989637143689947e-10
among O 0 3.7215151099667665e-11
these O 0 9.591760025129403e-11
were O 0 9.789736798992976e-10
one O 0 3.915009649801959e-09
frameshift O 0 1.4841270058241207e-05
mutation O 0 3.163448525356216e-07
, O 0 1.0739522604552576e-09
one O 0 3.5408851406515396e-09
nonsense O 0 4.820559524887358e-07
mutation O 0 2.503797418285103e-07
, O 0 9.44547218217906e-10
one O 0 7.362528364751597e-10
novel O 0 1.82189303643554e-08
splice O 0 1.4945969724067254e-06
site O 0 8.839273135663461e-08
mutation O 0 2.1744241962551314e-07
, O 0 1.1215235407036062e-09
and O 0 5.628137511592968e-09
one O 0 7.47012407487091e-08
missense O 0 0.0001766501081874594
mutation O 0 7.92406644904986e-05
. O 0 1.7251959434361197e-06

The O 0 4.903243393528101e-07
missense O 0 2.7678886908688582e-05
mutation O 0 1.419867476215586e-05
was O 0 4.953056418344204e-07
also O 0 1.7502603810726214e-08
found O 0 1.6860365548154732e-08
in O 0 1.749950051532778e-08
2 O 0 1.7998884516146063e-07
. O 0 5.941423069089069e-07

8 O 0 3.7594332980006584e-07
% O 0 9.991437011080961e-09
of O 0 2.0109881815333353e-10
the O 0 4.0680456225850037e-10
general O 0 5.575800376966811e-10
population O 0 6.723082646153955e-10
, O 0 9.270569728547784e-11
suggesting O 0 1.4447693041930165e-09
that O 0 1.2146786354527705e-10
it O 0 7.432554016695292e-10
is O 0 2.285953648595296e-09
not O 0 6.981565547903301e-08
disease O 0 3.024366890258534e-07
associated O 0 9.108595833140498e-08
. O 0 3.376084691808501e-07

The O 0 2.6496357108385382e-08
average O 0 1.4568036021955777e-07
age O 0 2.7847926631352493e-08
of O 0 1.232598689782094e-09
disease O 0 5.392008688431815e-07
onset O 0 4.481516668874974e-07
in O 0 3.614340382540604e-09
those O 0 6.9255801093959235e-09
families O 0 1.5668538466684367e-08
harbouring O 0 3.901920536009129e-06
causative O 0 2.2222433472052217e-05
mutations O 0 6.900937933096429e-06
was O 0 3.381807189839492e-08
between O 0 1.6691451776296162e-08
32 O 0 2.7329056706548727e-07
. O 0 4.471185945931211e-07

3 O 0 3.4803520065906923e-06
and O 0 2.745156564287754e-07
37 O 0 1.284693553316174e-06
. O 0 7.578329928037419e-07

4 O 0 5.362036858969077e-07
years O 0 3.9292551434755296e-08
, O 0 8.599052025992648e-10
whereas O 0 4.4924859388117966e-09
the O 0 5.353181786738048e-10
family O 0 5.9304552380012865e-09
harbouring O 0 3.18098898333119e-07
the O 0 1.1308826097788938e-09
missense O 0 7.35592948331032e-07
mutation O 0 2.3240853863626398e-07
had O 0 7.1967951598139734e-09
an O 0 2.168333429475311e-10
average O 0 1.4175933316096234e-08
age O 0 1.058854603996906e-08
of O 0 9.69158531205494e-10
onset O 0 6.425466381188016e-07
of O 0 7.569457949330172e-09
51 O 0 7.193758051471377e-07
. O 0 6.047229703654011e-07

2 O 0 8.429919944319408e-06
years O 0 2.078049192277831e-06
. O 0 1.1564432043087436e-06

These O 0 3.680107241166297e-08
findings O 0 3.7895397042575496e-08
show O 0 2.7455117290742237e-08
that O 0 1.6698767923983837e-09
BRCA1 O 0 2.6702983291215787e-07
is O 0 1.396973092759879e-09
implicated O 0 1.6409247294291163e-08
in O 0 2.1324944587952643e-10
a O 0 2.0635362862897466e-10
small O 0 1.0388573334907392e-09
fraction O 0 3.958577110552142e-08
of O 0 3.349095578641936e-08
breast B-Disease 1 0.9999998807907104
/ I-Disease 1 0.9999998807907104
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.0040324127658096e-08
suggesting O 0 2.9805775625391107e-08
the O 0 7.627017906131073e-10
involvement O 0 3.0274105000671625e-08
of O 0 8.036614151940569e-10
another O 0 1.72086540572991e-08
susceptibility O 0 1.2169605270173633e-06
gene O 0 2.4925859634095104e-06
( O 0 1.619533094299186e-07
s O 0 5.062800846644677e-05
) O 0 1.8087275748257525e-06

Paternal O 0 0.0005930995685048401
transmission O 0 0.03907725214958191
of O 0 1.4739669495611452e-05
congenital B-Disease 1 0.9999972581863403
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 0.9999997615814209
. O 0 0.00017948003369383514

We O 0 1.3443122952594422e-06
report O 0 2.9310507798641083e-08
a O 0 1.0838834274551346e-09
rare O 0 6.317839584824014e-09
case O 0 2.4112557284183822e-08
of O 0 1.0158152541350773e-08
paternally O 0 0.0009358288371004164
transmitted O 1 0.6825448274612427
congenital B-Disease 1 0.9999991655349731
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 3.507315705064684e-05
DM B-Disease 1 1.0
) O 0 2.1211842522461666e-06
. O 0 9.51469473875477e-07

The O 0 4.672955000728507e-08
proband O 0 1.4628179769715643e-06
is O 0 4.4255874520615635e-09
a O 0 1.0881630041481571e-09
23 O 0 1.3975700596802199e-09
year O 0 1.4307234286192738e-09
old O 0 1.4987547558575898e-07
, O 0 1.1418417322772711e-08
mentally B-Disease 1 0.9999994039535522
retarded I-Disease 1 0.9999821186065674
male O 0 4.984348834113916e-06
who O 0 1.7961450566872372e-06
suffers O 0 0.4412994980812073
severe O 0 0.021897457540035248
muscular B-Disease 0 0.01549539528787136
weakness I-Disease 0 0.44062963128089905
. O 0 3.9278497752093244e-06

He O 0 3.9338374335784465e-07
presented O 0 3.133308723590744e-08
with O 0 1.0514163761854434e-08
respiratory O 0 1.192421495943563e-05
and O 0 4.8407976294129185e-08
feeding O 0 9.070711826097977e-07
difficulties O 0 1.1016480129910633e-05
at O 0 1.0538481376443087e-07
birth O 0 8.246149150181736e-07
. O 0 9.248124115401879e-07

His O 0 3.6919828971804236e-07
two O 0 1.7543220565130468e-07
sibs O 0 0.023986153304576874
suffer O 0 0.0001294061803491786
from O 0 1.0172561815124936e-07
childhood O 0 6.816444511059672e-05
onset O 1 0.9006127715110779
DM B-Disease 1 1.0
. O 0 2.512683749955613e-05

Their O 0 7.708530347372289e-08
late O 0 5.5965621470477345e-08
father O 0 2.3107185498361105e-08
had O 0 5.484168230651676e-09
the O 0 4.3590925313807816e-10
adult O 0 1.4277473425750031e-08
type O 0 3.9641389548705774e-07
of O 0 2.4610691262694218e-09
DM B-Disease 1 1.0
, O 0 3.280165916663691e-09
with O 0 7.11536218833686e-10
onset O 0 1.3276635968395567e-07
around O 0 5.69897862234825e-09
30 O 0 1.711431885098591e-08
years O 0 6.776271277431078e-08
. O 0 2.0213775542288204e-07

Only O 0 1.654908565740243e-08
six O 0 1.730238063935019e-09
other O 0 3.489878941387303e-10
cases O 0 1.7799087759229337e-09
of O 0 1.4278929427735676e-10
paternal O 0 4.2516913367762754e-07
transmission O 0 0.006365726701915264
of O 0 3.093344957960653e-08
congenital B-Disease 1 0.9999998807907104
DM I-Disease 1 1.0
have O 0 3.502300614854903e-06
been O 0 1.0431251240561323e-07
reported O 0 2.2278369726791425e-07
recently O 0 5.660290867126605e-07
. O 0 2.0931882716013206e-07

We O 0 1.8703013893173193e-07
review O 0 1.2462039400418234e-08
the O 0 3.117413271969127e-10
sex O 0 7.40256433928721e-09
related O 0 4.900623018500028e-09
effects O 0 1.0111703829807084e-07
on O 0 6.479504044420992e-09
transmission O 0 9.393068467034027e-06
of O 0 1.361776753583399e-07
congenital B-Disease 1 0.9999986886978149
DM I-Disease 1 1.0
. O 0 8.450178029306699e-06

Decreased O 0 8.191758752218448e-06
fertility O 0 2.959289304271806e-06
of O 0 2.454833669673917e-09
males O 0 6.1565692988097e-08
with O 0 3.2154152673768976e-09
adult O 0 6.846686346761999e-07
onset O 0 0.0011784464586526155
DM B-Disease 1 1.0
and O 0 4.6029210665210485e-08
contraction O 0 3.954095006974967e-08
of O 0 6.146435443943332e-11
the O 0 1.617983802493228e-10
repeat O 0 4.023946686970703e-08
upon O 0 6.042692457519649e-10
male O 0 3.71714192759498e-09
transmission O 0 7.657646960979037e-09
contribute O 0 1.5751644433237288e-10
to O 0 4.6543484344407915e-11
the O 0 6.856622214446162e-11
almost O 0 5.576215045266508e-10
absent O 0 8.892417469041902e-09
occurrence O 0 4.4503750018520805e-08
of O 0 5.485734089205607e-10
paternal O 0 7.407369366774219e-07
transmission O 0 0.0017454030457884073
of O 0 2.2449289360793045e-07
congenital B-Disease 1 0.9999996423721313
DM I-Disease 1 1.0
. O 0 9.805358786252327e-06

Also O 0 1.515528111895037e-07
the O 0 9.704275161226406e-10
fathers O 0 1.0919163351275074e-08
of O 0 8.45806549798489e-11
the O 0 1.0297804831083113e-09
reported O 0 9.981821591509288e-08
congenitally O 0 3.8254191281339445e-07
affected O 0 7.45501882448707e-09
children O 0 1.6659034152155527e-09
showed O 0 2.2773327668090815e-09
, O 0 7.16171982828584e-11
on O 0 3.542038606862974e-10
average O 0 3.6953056170574428e-09
, O 0 5.683236659059787e-10
shorter O 0 5.35484190322677e-08
CTG O 0 5.206371156418754e-07
repeat O 0 8.890216918189253e-08
lengths O 0 1.114525858270099e-07
and O 0 9.208331319676688e-10
hence O 0 5.488269838593851e-09
less O 0 8.565924858316976e-09
severe O 0 5.5359209909511264e-06
clinical O 0 4.253246515872888e-06
symptoms O 0 8.450079747035488e-08
than O 0 1.9803128581408203e-10
the O 0 2.1393387061863223e-10
mothers O 0 6.727717050125648e-09
of O 0 1.5783101214861261e-10
children O 0 1.9773972681491614e-08
with O 0 1.2845472951994452e-07
congenital B-Disease 1 0.9999988079071045
DM I-Disease 1 1.0
. O 0 1.4862400348647498e-05

We O 0 2.9260496603455977e-07
conclude O 0 6.042041178488944e-08
that O 0 1.465814691847811e-09
paternal O 0 1.01296762977654e-07
transmission O 0 3.836741143459221e-06
of O 0 1.2280280792253961e-08
congenital B-Disease 1 0.9999998807907104
DM I-Disease 1 1.0
is O 0 6.187519119293938e-08
rare O 0 1.389246850891368e-08
and O 0 1.142348660110315e-09
preferentially O 0 2.7312946571100838e-08
occurs O 0 4.316057733433354e-09
with O 0 5.894388310778709e-10
onset O 0 1.0613420897698234e-07
of O 0 1.8518044875293072e-09
DM B-Disease 1 1.0
past O 0 2.6627626326103382e-08
30 O 0 1.5122927354838112e-09
years O 0 9.121000621448161e-10
in O 0 3.8973946292486517e-10
the O 0 1.198491639264887e-09
father O 0 2.3795392323222586e-08
. O 0 2.761946227280987e-08
. O 0 2.1817608342189487e-07

The O 0 1.011744075185561e-06
RB1 O 0 7.162505789892748e-05
gene O 0 1.4849898661850602e-06
mutation O 0 1.6958772448560921e-06
in O 0 1.802137816753202e-08
a O 0 5.319081708421436e-08
child O 0 4.1317443901789375e-06
with O 0 1.938871946549625e-06
ectopic B-Disease 1 0.9999969005584717
intracranial I-Disease 1 0.9999905824661255
retinoblastoma I-Disease 1 0.8992010354995728
. O 0 1.7482974726590328e-05

The O 0 1.1772237940022023e-06
RB1 O 0 9.65617218753323e-05
gene O 0 1.7414879494026536e-06
mutation O 0 2.144621021216153e-06
was O 0 2.0355100716074048e-08
investigated O 0 4.13786125363913e-08
in O 0 1.1143037603744688e-09
a O 0 5.861408247653799e-09
child O 0 9.525135737931123e-07
with O 0 1.7359053572363337e-07
ectopic B-Disease 1 0.9999794960021973
intracranial I-Disease 1 0.8623425364494324
retinoblastoma I-Disease 0 1.2102187838536338e-06
using O 0 1.4411756232846074e-08
DNA O 0 3.511676993639412e-08
obtained O 0 1.7268948493409653e-09
from O 0 8.472064022546633e-11
both O 0 3.9010314423215675e-10
the O 0 1.4560340710900732e-09
pineal B-Disease 0 1.3340314808374387e-06
and I-Disease 0 2.423165028631047e-07
retinal I-Disease 1 0.5329210758209229
tumours I-Disease 1 1.0
of O 0 5.444105610763472e-09
the O 0 4.6496079875169016e-08
patient O 0 1.9875005818903446e-06
. O 0 5.100565090288001e-07

A O 0 2.91340188596223e-06
nonsense O 0 1.0015163752541412e-05
mutation O 0 1.720258865134383e-06
in O 0 3.481990518139355e-08
exon O 0 1.580656203259423e-06
17 O 0 5.174729977852621e-08
( O 0 3.2146303396984877e-09
codon O 0 1.6264453961412073e-07
556 O 0 3.600910503109844e-08
) O 0 1.1959956358609247e-09
of O 0 2.084896005838388e-10
the O 0 1.5602236169698358e-09
RB1 O 0 7.213536150629807e-07
gene O 0 1.544976591105751e-08
was O 0 2.3088229106349445e-09
found O 0 3.2408981054388164e-10
to O 0 4.9886268727039607e-11
be O 0 1.3718037816801143e-10
present O 0 2.0063753436438958e-10
homozygously O 0 3.1943216072249925e-08
in O 0 1.4548730276064958e-10
both O 0 4.491901295367029e-10
the O 0 8.922637628749897e-10
retinal B-Disease 0 1.217782369167253e-06
and I-Disease 0 4.60091982290578e-08
the I-Disease 0 1.0994736499014834e-07
pineal I-Disease 0 0.001214755466207862
tumours I-Disease 1 1.0
. O 0 2.468478214723291e-06

The O 0 3.9613265556681654e-08
same O 0 2.1550263795688807e-08
mutation O 0 1.3592182313004741e-07
was O 0 9.198839023838445e-09
present O 0 1.0473927281040574e-09
heterozygously O 0 1.0322415278096742e-07
in O 0 3.9065936596749395e-10
the O 0 1.5494487637379706e-10
DNA O 0 1.558945328383743e-08
from O 0 2.1504294178686933e-10
the O 0 1.2581657937715818e-10
constitutional O 0 1.851560793575402e-09
cells O 0 2.2334469829132786e-09
of O 0 2.237533769378075e-11
the O 0 1.8842365168136865e-10
patient O 0 4.705975609198276e-09
, O 0 1.067934074505672e-10
proving O 0 5.254523038900061e-09
it O 0 3.418751393091668e-10
to O 0 2.2932543364273528e-10
be O 0 6.463947155310734e-10
of O 0 6.223102588798213e-10
germline O 0 1.3381611552176764e-06
origin O 0 2.896030935062299e-07
. O 0 4.620632694241067e-07

The O 0 1.3597394854514278e-07
initial O 0 1.9584390997806622e-07
mutation O 0 3.8054173501222976e-07
was O 0 5.153628190868176e-09
shown O 0 9.518029697730412e-10
to O 0 3.026541517403558e-10
have O 0 1.0631422409090874e-09
occurred O 0 5.581506368201872e-09
in O 0 1.0078673451374698e-09
the O 0 1.2102536750546733e-08
paternally O 0 7.57687985242228e-06
derived O 0 1.5358588143499219e-06
RB1 O 0 9.526526991976425e-05
allele O 0 1.811868787626736e-05
. O 0 1.4263584944274044e-06

The O 0 5.3277020128916774e-08
mutation O 0 2.2397988175271166e-07
is O 0 1.2842914509647585e-09
in O 0 3.944231052877001e-10
an O 0 1.52294399313746e-10
area O 0 6.972074473310386e-09
of O 0 1.5128717723023044e-10
the O 0 3.2908301084155767e-10
gene O 0 1.1387771614579378e-08
that O 0 5.460409346902395e-10
encodes O 0 1.891677037235695e-09
the O 0 1.7718496114760285e-10
protein O 0 7.025390491577355e-09
- O 0 6.325414148022901e-08
binding O 0 1.8073633256676658e-08
region O 0 3.606352771967636e-09
known O 0 2.7589228679403277e-09
as O 0 5.554528503814993e-10
the O 0 3.191870101559857e-10
pocket O 0 0.0022513745352625847
region O 0 7.129550994022793e-08
and O 0 1.445092401297643e-08
has O 0 5.957506044040883e-09
been O 0 2.512195562687225e-09
detected O 0 9.475394691094152e-09
in O 0 9.553016711016937e-11
other O 0 1.850800623870441e-10
cases O 0 2.4293274059061787e-09
of O 0 6.415920017488475e-10
retinoblastoma B-Disease 0 8.415624961344292e-07
. O 0 7.672592516883014e-08
. O 0 4.26476788106811e-07

Low O 0 0.00026514206547290087
levels O 0 6.178909757181827e-07
of O 0 5.226393762214343e-10
beta O 0 1.1655223453033159e-08
hexosaminidase O 0 1.5208968306978932e-07
A O 0 2.5471906806018296e-09
in O 0 6.38739727776283e-10
healthy O 0 2.586232339396588e-09
individuals O 0 4.668272990393518e-10
with O 0 2.074049154643376e-09
apparent O 0 0.007983370684087276
deficiency O 0 0.04583089426159859
of O 0 1.4826576633097943e-09
this O 0 9.18549680761771e-09
enzyme O 0 1.571124926158518e-06
. O 0 4.827612087865418e-07

Appreciable O 0 7.325909973587841e-05
beta O 0 4.499946498981444e-06
hexosaminidase O 0 1.3802406101603992e-05
A O 0 7.180947392271264e-08
( O 0 3.2751270584441272e-09
hex O 0 1.5229086613999243e-07
A O 0 2.1367136948668985e-09
) O 0 3.1579044934559874e-10
activity O 0 1.522033055145755e-09
has O 0 9.917668908343558e-10
been O 0 2.588255609836665e-09
detected O 0 2.504861740248998e-08
in O 0 1.37608124894939e-09
cultured O 0 3.681463169868948e-07
skin O 0 4.944744887325214e-06
fibroblasts O 0 2.7135109803566593e-07
and O 0 4.852500978813623e-08
melanoma B-Disease 0 0.00112871581222862
tissue O 0 1.2269434535028267e-07
from O 0 6.543810493475632e-10
healthy O 0 1.809366323435313e-09
individuals O 0 1.133038871059533e-10
previously O 0 1.988940789843241e-09
reported O 0 5.836686245430656e-09
as O 0 3.76964104376043e-09
having O 0 0.0004395119904074818
deficiency B-Disease 0 0.00039642647607252
of I-Disease 0 1.3628038975088685e-10
hex I-Disease 0 2.837282409018371e-07
A I-Disease 0 5.711228712179661e-10
activity O 0 1.226594825709526e-09
indistinguishable O 0 4.369858253028269e-09
from O 0 5.727403620814364e-11
that O 0 8.472015450289305e-11
of O 0 1.0654559179368306e-10
patients O 0 2.2179658998311425e-08
with O 0 1.5141066000978753e-07
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 0 0.013813475146889687
( O 0 5.886339238259097e-08
TSD B-Disease 0 4.254611485521309e-05
) O 0 1.48079095652065e-07
. O 0 2.95491105362089e-07

Identification O 0 3.785931312449975e-06
and O 0 8.386480487843073e-08
quantitation O 0 1.1903820450243074e-05
of O 0 6.623931625426849e-09
hex O 0 1.6386717334171408e-06
A O 0 5.936091174163494e-09
, O 0 9.198465877879869e-10
amounting O 0 9.101698061897423e-09
to O 0 3.78687881052997e-09
3 O 0 6.353842252337927e-08
. O 0 3.1789508625479357e-07

5 O 0 2.0390539248182904e-06
% O 0 3.680943336803466e-07
- O 0 3.5904213291360065e-05
6 O 0 8.296159421661287e-07
. O 0 4.986636668036226e-07

9 O 0 1.0101138059326331e-06
% O 0 4.484826021666777e-08
of O 0 7.664744949842373e-10
total O 0 1.718768460889919e-09
beta O 0 1.2954244787977132e-08
hexosaminidase O 0 1.0126894522954899e-07
activity O 0 1.4124518443736633e-08
, O 0 4.275775011830518e-10
has O 0 8.673490259347716e-10
been O 0 6.94308777138275e-10
obtained O 0 2.0627897168168374e-09
by O 0 1.7129070384314105e-09
cellulose O 0 2.471132575010415e-06
acetate O 0 1.3187486729293596e-06
gel O 0 5.0267819460714236e-05
electrophoresis O 0 3.4206902910227655e-06
, O 0 5.93624971401141e-09
DEAE O 0 9.658346016294672e-07
- O 0 1.237346225479996e-07
cellulose O 0 7.157495360843313e-07
ion O 0 2.696263834423007e-07
- O 0 2.87180341729254e-07
exchange O 0 5.0087898273432074e-08
chromatography O 0 2.5038809781108284e-07
, O 0 1.3393214315371438e-09
radial O 0 2.6439974476488715e-07
immunodiffusion O 0 1.4665811249869876e-06
, O 0 8.705565157640649e-09
and O 0 2.073654670198266e-08
radioimmunoassay O 0 8.541667739336845e-06
. O 0 5.988576390336675e-07

Previous O 0 6.60201237678848e-07
family O 0 3.0014916774234734e-08
studies O 0 1.5592069857461865e-08
suggested O 0 2.7572970573430666e-09
that O 0 6.19240977939306e-11
these O 0 5.941567376988033e-11
individuals O 0 1.96570038024646e-10
may O 0 1.5955272658629838e-09
be O 0 9.639831294316892e-11
compound O 0 1.842239805149859e-09
heterozygotes O 0 3.779707924422837e-08
for O 0 2.343825411532663e-10
the O 0 3.9071301749515897e-10
common O 0 1.0338824019129333e-08
mutant O 0 1.4569577899692376e-07
TSD B-Disease 0 8.863978564477293e-07
gene O 0 6.381204542549312e-08
and O 0 4.437640921395314e-09
a O 0 3.0975948472899972e-09
rare O 0 5.54938779373515e-08
( O 0 2.619345984555821e-08
allelic O 0 2.8475583349063527e-06
) O 0 5.2659835603208194e-08
mutant O 0 2.103782207996119e-06
gene O 0 6.602738721994683e-06
. O 0 1.6884571323316777e-06

Thus O 0 1.3017697710893117e-06
, O 0 1.2074591104749288e-08
the O 0 2.269553434075533e-09
postulated O 0 9.196175909664817e-08
rate O 0 3.3987557657155776e-08
mutant O 0 4.2913274711509075e-08
gene O 0 3.361677869406776e-08
appears O 0 9.80442926845626e-09
to O 0 1.1637153046750726e-10
code O 0 6.587440593008864e-10
for O 0 1.598624427279205e-10
the O 0 9.427882780022045e-11
expression O 0 1.0192401367348225e-09
of O 0 1.799299043092617e-10
low O 0 2.346560989963109e-08
amounts O 0 7.836268522964929e-09
of O 0 2.727139181146754e-09
hex O 0 3.825980456895195e-06
A O 0 1.654057228961392e-07
. O 0 3.8505643829012115e-07

Heterozygotes O 0 1.856431299529504e-05
for O 0 1.508720970377908e-08
the O 0 1.4805212611435081e-09
rare O 0 6.079759806709717e-09
mutant O 0 1.0276838224854146e-07
may O 0 1.1017025514092893e-08
be O 0 4.068665959700013e-10
indistinguishable O 0 1.0845333520137501e-08
from O 0 6.409315300714979e-10
heterozygotes O 0 7.787934919178952e-08
for O 0 6.068263669334328e-10
the O 0 3.2558626905654364e-09
common O 0 5.29136116256268e-07
TSD B-Disease 0 6.857912376290187e-05
mutant O 0 1.3544833564083092e-05
. O 0 1.0218333272860036e-06

However O 0 2.0856545290826034e-07
, O 0 1.9355581581947945e-09
direct O 0 7.978139038300469e-09
visualization O 0 1.6261260782357567e-07
and O 0 8.920395977440876e-09
quantitation O 0 3.7204499676590785e-06
of O 0 9.292881464340041e-10
hex O 0 9.676149375081877e-07
A O 0 1.1755461049034466e-09
by O 0 1.1764135499081618e-10
the O 0 7.670913210189312e-11
methods O 0 2.6229256988585803e-08
described O 0 1.1013222334099737e-08
may O 0 6.853516421045924e-09
prevent O 0 6.007484731895829e-09
false O 0 2.964023337881372e-08
- O 0 1.203468116273143e-07
positive O 0 1.3103445439810457e-08
prenatal O 0 2.0389586552482797e-06
diagnosis O 0 4.863258595833031e-07
of O 0 4.5761386346931943e-10
TSD B-Disease 0 8.367512691620504e-07
in O 0 1.7836708776641785e-09
fetuses O 0 1.6571249261687626e-07
having O 0 7.385894118527858e-09
the O 0 3.578729534936542e-10
incomplete O 0 2.843799329355079e-08
hex B-Disease 0 2.375849180680234e-05
A I-Disease 0 1.2423869577560254e-07
deficiency I-Disease 0 3.0331411835504696e-06
of O 0 4.748736820436861e-11
the O 0 3.932565106889996e-10
type O 0 3.5020059385715285e-07
described O 0 7.444702632142253e-09
in O 0 1.1696930091176228e-09
the O 0 3.5052243330113697e-09
four O 0 3.615438615156563e-08
healthy O 0 3.6479329423855233e-07
individuals O 0 2.9405006785054866e-07

The O 0 1.2862651601608377e-06
tumor B-Disease 0 1.1043228369089775e-05
suppressor O 0 5.6177973419835325e-06
gene O 0 1.800696963982773e-06
Smad4 O 0 8.107154826575425e-06
/ O 0 1.6257303059319383e-06
Dpc4 O 0 1.0316741736460244e-06
is O 0 2.256302700232027e-09
required O 0 1.1916261311029075e-09
for O 0 1.0294186336690103e-10
gastrulation O 0 1.9768391368302218e-08
and O 0 1.8192669593020128e-09
later O 0 9.165248116005387e-09
for O 0 8.247055816035243e-10
anterior O 0 1.0697840480133891e-06
development O 0 1.68592639848697e-09
of O 0 2.946906052514464e-10
the O 0 6.349889503098893e-09
mouse O 0 2.383337914579897e-06
embryo O 0 8.35255195852369e-06
. O 0 9.782743290998042e-07

Mutations O 0 0.0001258125266758725
in O 0 1.590621536706749e-07
the O 0 7.996805351240255e-08
SMAD4 O 0 0.00014686226495541632
/ O 0 1.1021335012628697e-05
DPC4 O 0 1.9409682863624766e-05
tumor B-Disease 0 1.6524347756785573e-06
suppressor O 0 2.9851065619368455e-07
gene O 0 1.7748118352756137e-07
, O 0 3.030945272541885e-09
a O 0 1.7835892762718686e-09
key O 0 2.9117156685742884e-08
signal O 0 6.901228033484585e-08
transducer O 0 2.019190787905245e-07
in O 0 4.905361672413733e-10
most O 0 6.81494249921144e-10
TGFbeta O 0 1.1466253226899425e-06
- O 0 1.548517332139454e-07
related O 0 3.145870675069773e-09
pathways O 0 1.6195716989741982e-09
, O 0 6.65776947461616e-11
are O 0 2.538569528198753e-11
involved O 0 4.246297757859452e-10
in O 0 5.293480098700343e-10
50 O 0 5.176612027923966e-09
% O 0 6.5541692073622926e-09
of O 0 2.2005629318755382e-08
pancreatic B-Disease 1 0.981278657913208
cancers I-Disease 1 0.9992411136627197
. O 0 1.5003494127086014e-06

Homozygous O 0 0.0005027760053053498
Smad4 O 0 0.00016816875722724944
mutant O 0 2.7693806259776466e-05
mice O 0 3.784191358136013e-05
die O 0 1.9426590370130725e-05
before O 0 3.584040797477428e-08
day O 0 3.3797888931985653e-08
7 O 0 8.716136079556236e-08
. O 0 2.2435293089984043e-07

5 O 0 2.341043227716e-06
of O 0 7.42479571158583e-08
embryogenesis O 0 2.7640691769192927e-05
. O 0 5.044160843681311e-06

Mutant O 0 1.7554095393279567e-05
embryos O 0 5.946615146967815e-06
have O 0 1.4103606815751846e-07
reduced O 0 4.929132657593982e-08
size O 0 6.11945765172095e-08
, O 0 8.433298503973674e-09
fail O 0 5.292880018714641e-07
to O 0 8.994351374802534e-10
gastrulate O 0 3.7560215560006327e-07
or O 0 1.0589172205754949e-08
express O 0 1.1861730264683956e-08
a O 0 1.2460368292721569e-09
mesodermal O 0 5.294566562952241e-07
marker O 0 1.0157367569263442e-06
, O 0 6.338660263338625e-09
and O 0 1.2333048360346766e-08
show O 0 5.659530302182247e-07
abnormal O 0 3.900804586010054e-06
visceral O 0 9.522860636934638e-06
endoderm O 0 0.0001174096978502348
development O 0 1.6982223769446136e-06
. O 0 7.133889425858797e-07

Growth B-Disease 1 0.9999997615814209
retardation I-Disease 1 0.9999961853027344
of O 0 6.1539964235635125e-09
the O 0 6.9483774289835765e-09
Smad4 O 0 6.14163582213223e-05
- O 0 4.9764959840103984e-05
deficient O 0 8.45294778173411e-07
embryos O 0 3.644761292775911e-08
results O 0 4.584658874762226e-09
from O 0 2.889709305176069e-10
reduced O 0 9.842803017079405e-09
cell O 0 1.2379410918583744e-07
proliferation O 0 6.585386103097335e-08
rather O 0 2.392220643798737e-09
than O 0 1.947749961317413e-09
increased O 0 1.7490922488150318e-08
apoptosis O 0 2.6239169415021024e-07
. O 0 5.597628387477016e-07

Aggregation O 0 8.865560630511027e-06
of O 0 6.630962445797195e-08
mutant O 0 4.9910413508769125e-06
Smad4 O 0 3.657335037132725e-05
ES O 0 7.612983949911722e-07
cells O 0 3.724609598521056e-08
with O 0 1.4089639455150405e-09
wild O 0 9.379307641665946e-08
- O 0 3.297839793958701e-05
type O 0 4.1007833715411834e-06
tetraploid O 0 2.5514438675600104e-05
morulae O 0 2.173399116145447e-05
rescues O 0 4.315518708608579e-06
the O 0 5.4921365233440156e-08
gastrulation B-Disease 0 2.2580603399546817e-05
defect I-Disease 0 5.9823825722560287e-05
. O 0 8.582402415413526e-07

These O 0 2.709314230742166e-07
results O 0 9.436008951979602e-08
indicate O 0 1.4861210040351125e-08
that O 0 4.878015213982678e-10
Smad4 O 0 6.716667400041842e-08
is O 0 4.017661481281465e-10
initially O 0 1.384466319365174e-09
required O 0 3.3903416185587787e-10
for O 0 4.421634239304417e-11
the O 0 6.225189114195118e-11
differentiation O 0 1.3247332120158717e-09
of O 0 4.389551916395007e-11
the O 0 1.9223049541050585e-10
visceral O 0 1.3521740171995589e-08
endoderm O 0 5.610038442682708e-07
and O 0 1.7901123916530537e-09
that O 0 2.6632523963954213e-10
the O 0 3.278294302688778e-10
gastrulation B-Disease 0 5.91802908900263e-08
defect I-Disease 0 5.799093472091954e-08
in O 0 2.7839136551577326e-10
the O 0 2.932831755231291e-10
epiblast O 0 3.1144037393460167e-07
is O 0 1.5458216928720958e-09
secondary O 0 8.168113296846968e-09
and O 0 2.3862600784241295e-09
non O 0 1.1357213480778228e-07
- O 0 2.592447572169476e-06
cell O 0 1.5496092373723513e-06
autonomous O 0 4.499349017805798e-07
. O 0 7.537828992099094e-07

Rescued O 0 2.11728474823758e-05
embryos O 0 6.082643722038483e-06
show O 0 4.437010375113459e-06
severe O 0 2.6811387215275317e-05
anterior O 0 4.567178257275373e-05
truncations O 0 4.097663804714102e-06
, O 0 6.168944466367066e-09
indicating O 0 1.0890127910556657e-08
a O 0 1.0021339313937005e-09
second O 0 1.6194852126005799e-09
important O 0 2.075450034055848e-09
role O 0 1.4005115289705827e-08
for O 0 2.120279729567187e-09
Smad4 O 0 1.2506135362855275e-06
in O 0 3.6104975009720874e-08
anterior O 0 3.1582225346937776e-05
patterning O 0 7.17728107701987e-05
during O 0 5.006669425711152e-07
embryogenesis O 0 1.5985009667929262e-05
. O 0 1.7563052097102627e-06

Prevalence O 0 0.001007179031148553
of O 0 1.4147119031804323e-07
p16 O 0 7.777499376970809e-06
and O 0 1.1145407086132764e-07
CDK4 O 0 1.7759761249180883e-05
germline O 0 1.3341025805857498e-05
mutations O 0 1.5674868336645886e-06
in O 0 1.263934912287823e-08
48 O 0 2.9540515811277146e-07
melanoma B-Disease 1 0.9994837045669556
- O 1 0.7303826212882996
prone O 0 0.0053554438054561615
families O 0 6.322616030729478e-08
in O 0 6.113029371590528e-08
France O 0 1.5123593584576156e-05
. O 0 8.336432983924169e-07

The O 0 1.735042701511702e-06
French O 0 9.040582517627627e-05
Familial B-Disease 0 0.0643775537610054
Melanoma I-Disease 1 0.9959166646003723
Study O 0 3.957169155910378e-06
Group O 0 2.1428709260362666e-06
. O 0 9.56028202381276e-07

Germline O 0 0.0006407464388757944
mutations O 0 2.8724833100568503e-05
in O 0 2.0393029487308922e-08
the O 0 2.6270299269270936e-09
p16 O 0 1.1604253558061828e-07
and O 0 2.8084212733148206e-09
CDK4 O 0 2.803980976295861e-07
genes O 0 1.4183939356371411e-08
have O 0 1.6808501257514763e-09
been O 0 2.329222370534012e-09
reported O 0 4.838469180867833e-09
in O 0 2.3126119075289608e-10
a O 0 4.4905310025988854e-10
subset O 0 1.3215943006628095e-08
of O 0 5.396844637850506e-10
melanoma B-Disease 0 3.450749318290036e-06
pedigrees O 0 6.043366340691136e-08
, O 0 8.429194009451635e-10
but O 0 1.3964244205411092e-09
their O 0 8.354158476109319e-10
prevalence O 0 1.7290894902544096e-06
is O 0 1.3721918046272208e-09
not O 0 1.806593874498219e-09
well O 0 2.597523529601631e-09
known O 0 7.101105126139373e-08
. O 0 3.26442744835731e-07

We O 0 1.865070089479559e-07
searched O 0 8.5668105498371e-08
for O 0 1.426774809409892e-09
such O 0 1.7936737650714463e-09
germline O 0 1.2364242820694926e-06
mutations O 0 3.0802283390585217e-07
in O 0 3.2591742638032883e-09
48 O 0 5.1382905041919e-08
French O 0 5.604088528343709e-06
melanoma B-Disease 1 0.9994674324989319
- O 0 0.08625631034374237
prone O 0 8.513141438015737e-06
families O 0 1.3329400916362033e-09
selected O 0 3.323042396807807e-10
according O 0 3.8265765556211306e-11
to O 0 2.2740576782753763e-11
two O 0 4.8744688840862693e-11
major O 0 1.3525679465331564e-09
criteria O 0 6.97271307359415e-09
families O 0 1.268519872477114e-10
with O 0 3.3790359399432646e-11
at O 0 4.758748950450808e-10
least O 0 1.5869978942095742e-10
three O 0 2.4759366779036895e-10
affected O 0 1.0203489164695156e-09
members O 0 1.304751862107878e-10
( O 0 1.0700850622269442e-10
n O 0 2.5565713102082555e-08
= O 0 4.202293979460592e-08
20 O 0 2.7211832787088497e-10
) O 0 8.383941457745792e-11
or O 0 2.4718127544787194e-10
families O 0 1.093517915107256e-10
with O 0 3.1229047126046794e-11
two O 0 5.03720065658797e-10
affected O 0 9.724303584590643e-10
members O 0 3.5963135247563116e-11
, O 0 2.0845171075367652e-11
one O 0 4.4309549085408406e-11
of O 0 5.23149492476227e-12
them O 0 7.313830791000342e-11
affected O 0 3.6053260377144625e-10
before O 0 3.4724365050031736e-10
the O 0 6.395098339773142e-11
age O 0 3.567457163011767e-10
of O 0 1.8964690928768846e-11
50 O 0 2.453175718120093e-10
( O 0 1.3569058376905474e-10
n O 0 4.95962169111408e-08
= O 0 9.111914778259234e-08
28 O 0 8.841523624347758e-10
) O 0 7.899528253751953e-11
, O 0 4.8008472197658136e-11
and O 0 1.368949537061681e-10
one O 0 8.745186796943472e-10
additional O 0 4.976068890272245e-09
minor O 0 1.7766373616723286e-07
criterion O 0 2.2855160750623327e-06
. O 0 3.9461619394387526e-07

Sixteen O 0 2.909817112595192e-06
different O 0 2.595203056898754e-07
p16 O 0 3.6272613215260208e-06
germline O 0 3.75924309992115e-06
mutations O 0 6.497915592262871e-07
were O 0 3.5080534033227195e-09
found O 0 2.4988147107052328e-09
in O 0 7.660418965826921e-10
21 O 0 1.245468950195061e-09
families O 0 2.62939447992494e-10
, O 0 7.832240411786984e-11
while O 0 7.489662778858985e-10
one O 0 2.7581599226778053e-09
germline O 0 4.458029820852971e-07
mutation O 0 1.1169156266532809e-07
, O 0 5.629970378784321e-10
Arg24His O 0 9.585683358181996e-08
, O 0 1.5074603787468277e-09
was O 0 5.908979971991357e-09
detected O 0 6.835373511648868e-08
in O 0 1.8757142505876345e-09
the O 0 8.067118528742867e-09
CDK4 O 0 8.09502580523258e-06
gene O 0 2.83939016298973e-06
. O 0 6.234835154828033e-07

The O 0 7.702210780280438e-08
frequency O 0 5.229480279922427e-07
of O 0 2.9804623213891546e-09
p16 O 0 3.7162547528168943e-07
gene O 0 1.7213388048276101e-07
mutation O 0 2.0760694496857468e-07
in O 0 2.6317690249300085e-09
our O 0 1.3528054232381237e-09
sample O 0 3.303667339693561e-09
( O 0 2.34404440302427e-10
44 O 0 4.744918347121541e-10
% O 0 2.736428028615734e-10
) O 0 1.2664964910147347e-10
is O 0 8.154998204501496e-11
among O 0 8.02051550174987e-11
the O 0 1.1370483027350886e-10
highest O 0 1.3393373521353169e-08
rates O 0 3.920077418229084e-08
yet O 0 5.575356620823868e-09
reported O 0 7.102823218474441e-09
and O 0 3.5815700405450457e-10
the O 0 3.9763639603229706e-10
CDK4 O 0 4.784017733072687e-07
mutation O 0 3.478963250813649e-08
is O 0 3.1046909487741914e-10
the O 0 2.2496539353600298e-10
second O 0 5.582677431448246e-09
mutation O 0 6.318733625221284e-08
detected O 0 3.365899559071295e-08
in O 0 4.5151279937094557e-10
this O 0 7.164606130594109e-10
gene O 0 1.923055634733828e-07
worldwide O 0 3.766405711758125e-07
. O 0 6.334173008326616e-07

In O 0 1.0060301036673991e-07
summary O 0 9.637104625426218e-08
, O 0 3.3610287886176593e-09
our O 0 3.337373710721181e-09
results O 0 8.679998941829581e-09
show O 0 9.026665637179576e-09
frequent O 0 1.2198365872961858e-08
involvement O 0 1.3128712339494086e-08
of O 0 3.4168803897394184e-10
the O 0 6.680988540175292e-10
p16 O 0 7.070453733604154e-08
gene O 0 3.1835316605111075e-08
in O 0 2.490976980240589e-09
familial B-Disease 0 1.761979001457803e-05
melanoma I-Disease 1 0.9603304266929626
and O 0 9.47575617971097e-09
confirm O 0 1.8132608303744746e-08
the O 0 1.2210200905915514e-10
role O 0 5.089595855878315e-09
of O 0 1.01502785343488e-10
the O 0 7.137885282837431e-10
CDK4 O 0 1.9846979171234125e-07
gene O 0 1.4647310919713163e-08
as O 0 1.8900143672340164e-09
a O 0 2.6368605077209395e-08
melanoma B-Disease 1 0.6542697548866272
- O 0 7.5698012551583815e-06
predisposing O 0 6.642463631578721e-06
gene O 0 1.4258594092098065e-06
. O 0 1.0074472811538726e-07
. O 0 3.77702775722355e-07

Progression O 0 3.2346328225685284e-05
of O 0 8.292664688269724e-08
somatic O 0 7.799180821166374e-06
CTG O 0 3.549739994923584e-05
repeat O 0 3.5321293125889497e-06
length O 0 1.5954861964928568e-07
heterogeneity O 0 9.671167617852916e-07
in O 0 1.0542216877240662e-08
the O 0 5.096346900046456e-09
blood O 0 1.92144980815101e-07
cells O 0 3.9202726043185976e-07
of O 0 5.98644049887298e-08
myotonic B-Disease 1 0.9999998807907104
dystrophy I-Disease 1 0.9999998807907104
patients O 0 0.0002645663043949753
. O 0 1.0646321015883586e-06

The O 0 1.4935410774796765e-07
genetic O 0 1.5032411511128885e-06
basis O 0 1.0111241266486104e-07
of O 0 3.3742942662229325e-08
myotonic B-Disease 1 0.9999994039535522
dystrophy I-Disease 1 0.9999984502792358
( O 0 4.0471542206432787e-07
DM B-Disease 1 1.0
) O 0 2.70388511580677e-08
is O 0 2.7856825179917166e-10
the O 0 4.3823996515035546e-11
expansion O 0 1.3040980517686762e-09
of O 0 1.1290091778137779e-10
an O 0 1.5025889421593774e-09
unstable O 0 2.3202551346912514e-06
CTG O 0 1.4030775901119341e-06
repeat O 0 4.46304511569906e-07
in O 0 1.8679595648052327e-09
the O 0 2.0919275200981247e-09
34 O 0 1.1808119815270857e-08
UTR O 0 3.300848163689807e-07
of O 0 1.5577614753681246e-09
the O 0 3.546679749888426e-08
DM B-Disease 1 0.9999979734420776
protein O 0 3.825393548595457e-07
kinase O 0 7.407389830405009e-07
gene O 0 5.457498559735541e-07
on O 0 7.66470833468702e-08
chromosome O 0 2.0373128791106865e-05
19 O 0 5.854070650457288e-07
. O 0 6.711097171319125e-07

One O 0 1.6043082951000542e-07
of O 0 8.294096520700123e-10
the O 0 4.589136015642481e-10
principal O 0 1.1635343355465011e-08
features O 0 6.275061803506787e-09
of O 0 2.8869659440822204e-10
the O 0 1.1514010189728197e-08
DM B-Disease 1 1.0
mutation O 0 1.262573164240166e-06
is O 0 1.3469119153342035e-09
an O 0 1.908226215929787e-10
extraordinarily O 0 3.370750079056961e-08
high O 0 3.082061184045415e-08
level O 0 5.225100352390655e-09
of O 0 7.292309811557374e-11
somatic O 0 3.051329500181055e-08
mosaicism O 0 6.329529469439876e-07
, O 0 7.019573811106739e-10
due O 0 6.148174191977773e-10
to O 0 1.3996422076889559e-10
an O 0 1.1275694961065952e-10
extremely O 0 2.874527726959286e-09
high O 0 5.253530943605256e-09
degree O 0 1.64526205992388e-08
of O 0 1.1978558422942598e-10
somatic O 0 8.30935178441905e-08
instability O 0 9.890739249840408e-08
both O 0 8.47795222913561e-10
within O 0 5.000117542230953e-10
and O 0 9.225648023303279e-10
between O 0 8.573127763256139e-10
different O 0 1.1566132052109879e-08
tissues O 0 1.4335344076243928e-06
. O 0 4.802745934284758e-07

This O 0 2.516729580293031e-07
instability O 0 8.381313136851531e-07
appears O 0 4.1353128921173266e-08
to O 0 1.4741755594016581e-09
be O 0 7.489762143819689e-10
biased O 0 3.576399620897064e-08
towards O 0 9.823573066114477e-10
further O 0 3.7736822000589143e-10
expansion O 0 1.214014555550591e-09
and O 0 3.481741284172557e-10
continuous O 0 6.366610572072773e-10
throughout O 0 7.938334989354701e-10
the O 0 1.9051640820499927e-10
life O 0 3.1145722112491114e-10
of O 0 7.330152977658155e-12
an O 0 1.324072535641152e-11
individual O 0 1.3314097047079088e-10
, O 0 2.2114613959511864e-11
features O 0 6.856364365148693e-10
that O 0 1.2063720022936764e-09
could O 0 3.150207206203959e-08
be O 0 5.183635187755442e-10
associated O 0 3.2070104905024266e-10
with O 0 4.884781121261561e-11
the O 0 3.8459102569277093e-10
progressive O 0 1.6275899739071065e-08
nature O 0 8.980470589392553e-09
of O 0 7.889730535559636e-10
the O 0 5.131170155436848e-08
disease O 0 4.703062131738989e-06
. O 0 3.5440299939182296e-07

Although O 0 4.0357380726163683e-07
increasing O 0 8.480839852609279e-08
measured O 0 2.4141047560988227e-07
allele O 0 7.957949605952308e-07
size O 0 1.2201849131088238e-07
between O 0 2.1015026163695438e-08
patients O 0 1.1707274438776949e-07
clearly O 0 4.518800444941462e-09
correlates O 0 3.212479171565974e-09
with O 0 1.679096445217354e-10
an O 0 3.0730301636694435e-10
increased O 0 6.1122462646778786e-09
severity O 0 4.310050769618101e-07
of O 0 3.594861353040102e-10
symptoms O 0 1.0536210481859598e-07
and O 0 3.3588737347045594e-10
an O 0 1.222889289831386e-10
earlier O 0 1.4636921008559511e-08
age O 0 2.709335200634655e-09
of O 0 4.961440286388452e-11
onset O 0 1.7838827304217375e-08
, O 0 1.3865215919839358e-10
this O 0 3.4396600151476164e-11
correlation O 0 9.24615761732639e-09
is O 0 3.590283625953816e-10
not O 0 1.6002627001299174e-10
precise O 0 3.7097120930695837e-09
and O 0 5.041939643568583e-10
measured O 0 8.104795945484966e-09
allele O 0 1.703985930134877e-08
length O 0 9.1558485237897e-09
cannot O 0 2.649372987661991e-08
be O 0 4.492138952483238e-11
used O 0 2.349178351845893e-10
as O 0 5.810267197925434e-11
an O 0 3.162194464612078e-11
accurate O 0 4.933685460173365e-08
predictor O 0 6.634174951614114e-07
of O 0 3.750905697152973e-10
age O 0 2.1309922715317953e-08
of O 0 5.133703240289833e-09
onset O 0 7.71865961723961e-06
. O 0 1.3864165566701558e-06

In O 0 1.0072320577592109e-07
order O 0 7.612836583348326e-09
to O 0 5.652663892519172e-10
further O 0 9.364676811784989e-10
characterize O 0 7.927448564259976e-08
the O 0 4.420357413437159e-09
dynamics O 0 6.166171715449309e-07
of O 0 1.2487117118098467e-08
DM B-Disease 1 1.0
CTG O 0 1.948674616869539e-05
repeat O 0 1.3543107115765451e-06
somatic O 0 2.6478178938305064e-07
instability O 0 1.2056599985044159e-07
, O 0 3.9588377021004817e-10
we O 0 4.5468273590643093e-10
have O 0 2.3427304540746263e-10
studied O 0 5.05267605532822e-09
repeat O 0 2.308137148077094e-08
length O 0 3.823107608269538e-09
changes O 0 1.564496865391618e-09
over O 0 4.4713349689473603e-10
time O 0 1.2465003473849379e-09
in O 0 2.6405633235526693e-09
111 O 0 4.6049146362747706e-07
myotonic B-Disease 1 0.9999991655349731
dystrophy I-Disease 1 0.9999961853027344
patients O 0 5.482151550495473e-07
with O 0 5.254249813013701e-10
varying O 0 4.727326086140238e-08
clinical O 0 5.239541678747628e-06
severity O 0 5.177023467695108e-06
and O 0 2.5408112946934125e-08
CTG O 0 7.634271810275095e-07
repeat O 0 1.8472763940735604e-07
size O 0 4.800696729034826e-09
over O 0 5.712928463630362e-10
time O 0 7.584816663630534e-10
intervals O 0 3.943804394168637e-09
of O 0 1.2056536324855927e-10
1 O 0 6.730579649172341e-09
- O 0 1.0583880794001743e-06
7 O 0 1.945467253960942e-08
years O 0 4.81626294401849e-08
. O 0 1.8493881270842394e-07

We O 0 1.2730703247143538e-06
have O 0 4.721763424697656e-09
found O 0 8.203035473108855e-10
a O 0 2.420205980069312e-10
direct O 0 2.4072979165623565e-09
progression O 0 2.1173708120159063e-08
of O 0 2.395767473295507e-10
the O 0 5.216673204522237e-10
size O 0 9.248397603300873e-09
heterogeneity O 0 4.7956383752989495e-08
over O 0 9.907913378626176e-10
time O 0 1.0643352865713496e-09
related O 0 1.1226728435786981e-09
to O 0 3.4231295575892773e-10
initial O 0 7.665274637247421e-09
CTG O 0 2.51223582381499e-07
repeat O 0 1.0207858736066555e-07
size O 0 4.84217999030534e-09
and O 0 2.6185742463269435e-10
the O 0 2.918132749329949e-11
time O 0 4.88273477206036e-10
interval O 0 3.3668030585687347e-09
and O 0 6.352685044674899e-10
always O 0 3.052992747498706e-09
biased O 0 2.124284215199168e-08
towards O 0 1.6297450056157459e-09
further O 0 4.002710163319989e-09
expansion O 0 1.7127682383488718e-07
. O 0 2.6718572598838364e-07

Attempts O 0 7.472545462405833e-07
to O 0 1.3029525902652495e-08
mathematically O 0 1.9842173060169443e-07
model O 0 5.535286007329887e-08
the O 0 1.3761546346913178e-09
dynamics O 0 9.815602908247456e-08
have O 0 4.084522498004617e-09
proved O 0 1.2480616540244682e-08
only O 0 3.091878975070017e-10
partially O 0 4.655811025600087e-08
successful O 0 2.9801665579753944e-09
suggesting O 0 3.280672844496735e-09
that O 0 5.957681570301077e-11
individual O 0 6.926154094699655e-11
specific O 0 4.4444747882010915e-10
genetic O 0 2.3385895886463004e-08
and O 0 3.0496871694651873e-09
/ O 0 2.827201228683407e-08
or O 0 8.691579012065631e-09
environmental O 0 5.688726822938861e-09
factors O 0 2.4173005819250193e-09
also O 0 6.737640445564352e-10
play O 0 1.4780806578684746e-09
a O 0 1.4078034293873998e-09
role O 0 5.237185973783198e-08
in O 0 1.0881344714164243e-08
somatic O 0 1.531704697299574e-06
mosaicism O 0 1.8993672711076215e-05
. O 0 1.4966222749990266e-07
. O 0 5.778941272183147e-07

Aspartylglucosaminuria B-Disease 1 0.9999936819076538
among O 0 6.204375040397281e-06
Palestinian O 0 9.042504825629294e-05
Arabs O 0 9.3605209258385e-05
. O 0 5.500719453266356e-06

Aspartylglucosaminuria B-Disease 1 0.9999988079071045
( O 0 4.894683570455527e-06
AGU B-Disease 1 0.9999992847442627
) O 0 4.556676813649574e-08
is O 0 2.9726672234886564e-09
a O 0 4.173790646433417e-09
rare O 0 7.373720336545375e-07
disorder B-Disease 0 0.0010445322841405869
of I-Disease 0 9.020241775736793e-10
glycoprotein I-Disease 0 2.6030656954389997e-06
metabolism I-Disease 0 1.0532396117923781e-05
caused O 0 9.398343081556959e-08
by O 0 1.214816025552068e-09
the O 0 2.0447558313207992e-08
deficiency B-Disease 0 0.0009191905846819282
of I-Disease 0 5.236451827705935e-10
the I-Disease 0 9.045797000339917e-09
lysosomal I-Disease 0 1.67249654623447e-05
enzyme I-Disease 0 4.655216798710171e-06
aspartylglucosaminidase I-Disease 0 5.459807198349154e-06
( O 0 2.172458657412335e-08
AGA O 0 6.996254455771123e-07
) O 0 3.894091804568234e-08
. O 0 2.0533467193217803e-07

AGU B-Disease 1 0.9999980926513672
is O 0 4.1698186237226764e-07
inherited O 0 1.7388060769008007e-06
as O 0 7.95539101261511e-09
an O 0 5.095608379690475e-09
autosomal O 0 0.12453801184892654
recessive O 0 0.305816650390625
trait O 0 0.0450424924492836
and O 0 1.245381753278707e-08
occurs O 0 4.465584346746709e-09
with O 0 2.650265007453356e-10
a O 0 8.793257233463692e-10
high O 0 8.958657815583138e-09
frequency O 0 3.0389239213945984e-07
in O 0 5.617927456569305e-09
Finland O 0 1.9323924789205194e-06
because O 0 4.9679225178067554e-09
of O 0 1.1190592896781482e-10
a O 0 2.817311051117599e-09
founder O 0 1.5196559388641617e-07
effect O 0 4.249915832588158e-07
. O 0 4.0359765307584894e-07

While O 0 3.345913341945561e-07
very O 0 1.121278181415164e-08
few O 0 9.887114238438244e-09
patients O 0 1.8602236195874866e-08
with O 0 1.1087767370909773e-09
AGU B-Disease 1 1.0
have O 0 6.9217502840501766e-09
been O 0 1.5708268019665184e-09
reported O 0 2.362835926916773e-09
from O 0 1.6858418827592203e-10
non O 0 5.5906085094648006e-08
- O 0 6.623655508519732e-07
Finnish O 0 4.929687236199243e-08
origin O 0 2.4511095375601144e-09
, O 0 3.241263091258162e-10
we O 0 4.903474515316475e-09
diagnosed O 0 1.9189829458809982e-07
the O 0 8.133348439187671e-10
disorder O 0 4.7625997012801236e-07
in O 0 4.2106496067617627e-10
8 O 0 8.27919177659453e-10
patients O 0 5.467735708641897e-10
originating O 0 4.229476768813356e-10
from O 0 1.4840093043311242e-10
3 O 0 2.7190197315896114e-10
unrelated O 0 2.96814040012805e-09
families O 0 9.24294307758089e-10
, O 0 1.790931153378139e-10
all O 0 1.9366945547272252e-10
Palestinian O 0 9.77383010081212e-08
Arabs O 0 1.1535117039329634e-07
from O 0 6.247042882989717e-10
the O 0 7.246544475592032e-10
region O 0 1.7094222926061775e-08
of O 0 3.157797578978716e-09
Jerusalem O 0 0.0005556158139370382
. O 0 1.1949585996262613e-06

The O 0 2.312636979695526e-07
clinical O 0 3.4898541798611404e-06
diagnosis O 0 3.089144956902601e-05
of O 0 1.0975519160183467e-08
AGU B-Disease 1 1.0
is O 0 2.817151667500184e-08
often O 0 2.8307031385566006e-08
difficult O 0 9.230337383314691e-08
, O 0 3.5079311677677083e-10
in O 0 8.307217413960899e-11
particular O 0 4.824036170525403e-10
early O 0 4.962514843498411e-09
in O 0 3.8115874345656664e-10
the O 0 3.0910771164904816e-10
course O 0 5.932630386951132e-08
of O 0 5.98162699927407e-11
the O 0 1.2892589218438388e-09
disease O 0 3.04345384449789e-08
, O 0 6.547302977555347e-11
and O 0 6.879703751128119e-11
most O 0 8.315904909128591e-11
of O 0 2.3800938650508918e-11
the O 0 2.9098418119488656e-10
patients O 0 9.347888685340422e-09
are O 0 4.687331078834234e-10
diagnosed O 0 9.4425082863836e-08
after O 0 5.794488222576888e-10
the O 0 2.4864996173157294e-10
age O 0 3.2942983896333544e-09
of O 0 2.443877322733101e-10
5 O 0 6.48741815822973e-09
years O 0 4.314372503699815e-08
. O 0 1.1456204873638853e-07

However O 0 3.733921118964645e-07
, O 0 4.7726040897089206e-09
since O 0 5.030501792901987e-09
these O 0 1.2838579088736424e-09
patients O 0 4.8694652754477374e-09
excrete O 0 5.04150943214654e-09
early O 0 4.736093184298795e-10
large O 0 3.087335664897495e-10
amounts O 0 1.3381621366548302e-09
of O 0 8.354808511690237e-11
aspartylglucosamine O 0 8.418469121806993e-08
in O 0 5.569232297553128e-10
urine O 0 7.650377220613791e-09
, O 0 2.26251170576397e-10
biochemical O 0 1.8170139171047595e-08
screening O 0 1.9300221865137246e-08
is O 0 1.6356649368276521e-09
easy O 0 1.4041651397178612e-08
by O 0 1.654144154983328e-09
urine O 0 6.441626965170144e-08
chromatography O 0 6.547443263116293e-07
. O 0 1.7546826214243083e-08
. O 0 1.5996791091765772e-07

Detection O 0 7.916575668787118e-06
of O 0 1.1479298400729476e-08
heterozygous O 0 7.978238727446296e-07
carriers O 0 2.776451140107383e-07
of O 0 2.411443045247097e-09
the O 0 1.785629706319014e-07
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 1.5688402754676645e-07
ATM O 0 1.5278021692211041e-06
) O 0 4.397081365681288e-09
gene O 0 3.0777023596328945e-08
by O 0 4.699884481595973e-09
G2 O 0 2.301162339790608e-06
phase O 0 3.5971629586128984e-07
chromosomal O 0 1.567223262100015e-05
radiosensitivity O 0 3.0986093406681903e-06
of O 0 1.3587952096827394e-08
peripheral O 0 3.982637281296775e-05
blood O 0 6.94578920956701e-05
lymphocytes O 0 0.00018256179464515299
. O 0 5.500860879692482e-06

In O 0 1.35617665364407e-05
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.001062391442246735
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 3.0887228774645337e-08
patients O 0 3.570537643327043e-08
, O 0 1.8729387485372229e-10
mutations O 0 1.25690062802164e-08
in O 0 2.655714537169729e-10
a O 0 2.6406626885133733e-10
single O 0 1.7984010947103002e-09
gene O 0 3.922993041527434e-09
, O 0 1.3047542213318053e-10
ATM O 0 2.053479164487726e-08
, O 0 1.5698377320294554e-10
result O 0 2.162717116505064e-09
in O 0 3.745245447106527e-09
an O 0 0.00011555921810213476
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
syndrome I-Disease 1 1.0
that O 0 1.076302780234073e-08
embraces O 0 2.2743645189393646e-08
a O 0 9.36810740093108e-10
variety O 0 1.683503447758028e-09
of O 0 1.232330210099164e-10
clinical O 0 7.93410421806584e-08
features O 0 2.446981639536716e-08
and O 0 5.890165688526849e-09
manifests O 0 4.106114559476737e-08
extreme O 0 3.269037662789742e-08
radiosensitivity O 0 5.102058935335663e-07
and O 0 2.0262937994175445e-09
a O 0 1.3606954452072273e-09
strong O 0 2.348522087913807e-08
pre O 0 1.0889745681197383e-05
- O 0 3.535020596245886e-06
disposition O 0 6.969124797251425e-07
to O 0 5.792162482975982e-08
malignancy B-Disease 0 0.00015890493523329496
. O 0 8.210632813643315e-07

Heterozygotes O 0 3.0390676329261623e-05
for O 0 2.3807512405937814e-08
the O 0 2.3932109627367026e-09
ATM O 0 1.6948347081324755e-07
gene O 0 6.899109195046549e-08
have O 0 8.246650473608952e-09
no O 0 3.893139588484473e-09
clinical O 0 1.8580321281547185e-08
expression O 0 2.4545623311666986e-09
of O 0 5.097131605680261e-10
A B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
but O 0 6.954545369808329e-06
may O 0 7.273691693399087e-08
be O 0 5.08700415124963e-09
cancer B-Disease 0 8.346346902499135e-08
prone O 0 3.972343165514758e-08
with O 0 2.979278490577997e-10
a O 0 1.862374143790646e-09
moderate O 0 1.2591061704370077e-07
increase O 0 4.691924715416462e-08
in O 0 7.260230194816586e-09
in O 0 1.9355850255919904e-08
vitro O 0 1.3805301932734437e-05
radiosensitivity O 0 2.4673772713867947e-05
. O 0 5.005495040677488e-07

We O 0 1.989459406104288e-06
performed O 0 1.7512996919322177e-07
a O 0 2.9547097213367124e-08
blind O 0 9.486733461017138e-07
chromosomal O 0 7.199356787168654e-06
analysis O 0 1.502249347140605e-07
on O 0 1.0160438712603082e-08
G2 O 0 1.935171667355462e-06
- O 0 1.2747493656206643e-06
phase O 0 1.2568820295655314e-07
lymphocytes O 0 1.7932765672412643e-07
from O 0 1.5536815167749296e-09
7 O 0 3.6331613273432595e-09
unrelated O 0 1.0683572071457093e-07
A B-Disease 1 0.9999997615814209
- I-Disease 1 0.9999995231628418
T I-Disease 1 1.0
patients O 0 3.990820687249652e-07
, O 0 5.255973989370943e-10
13 O 0 1.1022296408924603e-09
obligate O 0 1.21031177968689e-07
A B-Disease 1 0.9999985694885254
- I-Disease 1 0.9999881982803345
T I-Disease 1 0.9999998807907104
heterozygotes O 0 6.477417855421663e-07
( O 0 6.452084977404127e-10
parents O 0 1.1986425185739336e-09
of O 0 3.4216525446328916e-11
the O 0 2.9403426915486364e-10
patients O 0 7.895258669066152e-09
) O 0 2.6174803990919315e-10
, O 0 1.255947984502015e-10
and O 0 9.905003484078634e-10
14 O 0 1.0296233865503268e-09
normal O 0 2.6292954480311437e-09
controls O 0 2.7697012683347566e-08
following O 0 2.3704826990211814e-09
X O 0 1.4429116390601848e-07
- O 0 1.925018544568502e-08
irradiation O 0 4.078638937698997e-08
with O 0 1.1069510863492837e-09
1 O 0 4.071788684001376e-09
Gy O 0 5.048536877438892e-07
in O 0 1.5738491065953042e-10
order O 0 1.7418794184820285e-10
to O 0 8.475830454157673e-11
evaluate O 0 3.293550765448572e-09
this O 0 7.462295364968341e-11
cytogenetic O 0 3.0986363697138586e-08
method O 0 2.2001378496838697e-09
as O 0 2.3070167998184843e-10
a O 0 2.246875047129393e-10
tool O 0 3.7586868728567424e-08
for O 0 3.1267743949570104e-10
detection O 0 2.7698385807184422e-08
of O 0 3.5392717645521543e-09
ATM O 0 6.734274847985944e-06
carriers O 0 3.46678984897153e-06
. O 0 4.5846266516491596e-07

Both O 0 2.948196424767957e-06
A B-Disease 1 0.999942421913147
- I-Disease 1 0.9998577833175659
T I-Disease 1 0.9999995231628418
homozygotes O 0 3.3215364965144545e-05
and O 0 1.15375762277381e-08
heterozygotes O 0 8.587028332840418e-07
showed O 0 3.551357607989303e-08
significantly O 0 2.3833456097577255e-08
increased O 0 5.2576307751905915e-09
levels O 0 7.152103354002293e-09
of O 0 3.227776657066528e-10
radiation O 0 5.0411785196047276e-05
- O 0 2.003066947509069e-05
induced O 0 3.173587856508675e-06
chromatid O 0 0.0001878384209703654
damage O 0 2.455580670357449e-06
relative O 0 1.0111044446148298e-08
to O 0 2.0443637060996167e-10
that O 0 2.0319124161005675e-10
of O 0 2.5839727579857197e-10
normal O 0 7.844810312462869e-08
controls O 0 6.434937404264929e-06
. O 0 7.021153010100534e-07

These O 0 6.452054179817424e-08
results O 0 4.277435294852694e-08
show O 0 1.3017528388559185e-08
that O 0 7.635474474909643e-10
the O 0 6.616679981696905e-10
G2 O 0 1.0304470379196573e-06
- O 0 6.543329504893336e-07
phase O 0 7.84162423883572e-08
chromosomal O 0 6.909683065714489e-07
radiosensitivity O 0 5.6642928569772266e-08
assay O 0 9.146670265636203e-08
can O 0 9.168111270163593e-10
be O 0 4.1777449555358004e-11
used O 0 1.472845456707006e-10
for O 0 2.594728251703593e-11
the O 0 4.339554410259794e-11
detection O 0 1.915280201103542e-08
of O 0 1.664239301923942e-09
A B-Disease 1 1.0
- I-Disease 1 0.9999992847442627
T I-Disease 1 1.0
heterozygotes O 0 0.0003528124070726335
. O 0 1.2110892839700682e-06

In O 0 1.664975712856176e-07
combination O 0 3.982497958077147e-07
with O 0 3.201425791132806e-09
molecular O 0 1.1337063199334807e-07
genetic O 0 1.052713045623932e-07
analyses O 0 6.144369280036699e-08
, O 0 5.428031912835252e-10
this O 0 2.559437384253016e-10
test O 0 2.2756925233125003e-08
may O 0 1.2581881092543767e-09
be O 0 2.892840134105512e-11
of O 0 2.409375216699816e-12
value O 0 2.7275071090571146e-10
in O 0 1.6167035765679572e-10
studies O 0 3.144005056299193e-09
of O 0 1.0608386391552926e-10
familial B-Disease 0 4.112495446406683e-07
and I-Disease 0 2.3490775546974874e-08
sporadic I-Disease 0 2.4913076686061686e-06
cancers I-Disease 1 0.920951783657074
aimed O 0 7.256122103171947e-08
at O 0 2.3463850862270874e-09
determination O 0 3.6175613615796465e-09
of O 0 4.8532986657301436e-11
the O 0 1.7439272248509496e-10
potential O 0 3.5601723791245377e-09
involvement O 0 3.190283148768458e-09
of O 0 2.7362193066871043e-10
ATM O 0 7.377948350040242e-07
mutations O 0 4.342492161413247e-07
in O 0 6.596182267060158e-09
tumor B-Disease 0 8.478802556055598e-06
risk O 0 3.835804818663746e-06
or O 0 1.739616806162303e-08
development O 0 8.085095259957598e-09
. O 0 3.0010621543397065e-08
. O 0 3.083202386733319e-07

Ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
: O 0 1.996808691728802e-07
identification O 0 1.2750517441872944e-07
and O 0 3.2529330340480556e-09
detection O 0 2.3328025733349023e-08
of O 0 1.6434194283210246e-10
founder O 0 8.698697939735212e-08
- O 0 4.145302955294028e-05
effect O 0 3.238140209305129e-07
mutations O 0 6.481731418261916e-08
in O 0 3.202536014157431e-10
the O 0 3.861168607066645e-10
ATM O 0 1.1718020687112585e-07
gene O 0 7.302954685428631e-08
in O 0 7.512400479470216e-09
ethnic O 0 3.784397506478854e-07
populations O 0 4.820283720619045e-06
. O 0 6.652484785263368e-07

To O 0 4.7829590954506784e-08
facilitate O 0 2.0510405818185973e-08
the O 0 1.2358403189693945e-09
evaluation O 0 4.1983021503710916e-09
of O 0 2.1406448835747938e-10
ATM O 0 7.522583445052078e-08
heterozygotes O 0 9.677241763483835e-08
for O 0 2.3445453911641323e-10
susceptibility O 0 2.426068768102141e-08
to O 0 5.652717183224354e-10
other O 0 9.676217604948079e-10
diseases O 0 1.0992953747290812e-07
, O 0 2.364636784990548e-11
such O 0 6.129121515874303e-11
as O 0 2.827544864913989e-09
breast B-Disease 0 1.731961492623668e-05
cancer I-Disease 0 1.8705028992371808e-07
, O 0 1.4784153068436723e-10
we O 0 2.6688359855420174e-10
have O 0 4.967472266859119e-11
attempted O 0 1.730178555980899e-09
to O 0 6.22167595221157e-11
define O 0 3.5797145248039897e-09
the O 0 1.0946698408842437e-10
most O 0 3.576409723926588e-10
common O 0 2.5811663917352234e-09
mutations O 0 1.8509084043216717e-08
and O 0 1.9244694726694433e-10
their O 0 2.2997764803633913e-10
frequencies O 0 1.0201299005530018e-07
in O 0 1.7455671752486523e-07
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 8.134173549478874e-05
A B-Disease 1 1.0
- I-Disease 1 0.9999994039535522
T I-Disease 1 1.0
) O 0 2.0814688639347878e-08
homozygotes O 0 6.568325829903188e-07
from O 0 2.2563930723862313e-09
10 O 0 3.477183652123017e-09
ethnic O 0 1.4855831409477105e-07
populations O 0 1.8514753037379705e-06
. O 0 7.346878874159302e-07

Both O 0 2.070049447411293e-07
genomic O 0 3.5212860893807374e-06
mutations O 0 3.370102604094427e-06
and O 0 1.25103598591636e-08
their O 0 2.7507991440245405e-09
effects O 0 1.7402746266270697e-07
on O 0 2.2484925032983938e-09
cDNA O 0 1.0882428824743329e-07
were O 0 2.4474390514228617e-08
characterized O 0 7.084018989189644e-07
. O 0 1.0080370884679724e-06

Protein O 0 1.2847061952925287e-05
- O 0 1.0318677595932968e-05
truncation O 0 2.4133876195264747e-06
testing O 0 3.1524228916168795e-07
of O 0 4.89011608983958e-10
the O 0 6.940943375610686e-10
entire O 0 6.9128973656518156e-09
ATM O 0 1.3082933492114535e-07
cDNA O 0 1.1490650564383031e-07
detected O 0 2.394594105226133e-07
92 O 0 1.7967220600212386e-08
( O 0 1.3877815563390072e-09
66 O 0 1.3492448047713879e-08
% O 0 1.8986425764921933e-09
) O 0 1.6610521846871507e-09
truncating O 0 4.907724928671087e-07
mutations O 0 5.603867521131178e-07
in O 0 5.494145582929377e-09
140 O 0 2.0531462752160223e-08
mutant O 0 2.244114284621901e-06
alleles O 0 6.356094218062935e-06
screened O 0 1.1429808182583656e-05
. O 0 1.4119355000730138e-06

The O 0 7.381066779998946e-08
haplotyping O 0 1.3942420764578856e-06
of O 0 2.7536339874956184e-09
patients O 0 6.906666527584093e-08
with O 0 5.43370848316016e-10
identical O 0 7.274898905507143e-08
mutations O 0 3.697504382671468e-07
indicates O 0 3.2087573487160626e-08
that O 0 3.5202168957582103e-10
almost O 0 2.5345259224707206e-10
all O 0 3.480032928493415e-11
of O 0 8.662388514824038e-12
these O 0 8.627402958705233e-11
represent O 0 2.534903120743337e-10
common O 0 3.639805790101036e-09
ancestry O 0 7.814077207513037e-08
and O 0 2.0848811566054337e-09
that O 0 2.8789923223193625e-10
very O 0 1.2517419323287982e-09
few O 0 1.1593055404546249e-08
spontaneously O 0 9.370080533699365e-08
recurring O 0 1.8631194507179316e-06
ATM O 0 2.0493085685302503e-05
mutations O 0 9.763759408087935e-06
exist O 0 1.716037900223455e-06
. O 0 6.755983008588373e-07

Assays O 0 3.192266740370542e-05
requiring O 0 1.0686256928238436e-06
minimal O 0 5.794471462650108e-07
amounts O 0 4.581321988439413e-08
of O 0 9.833678316084615e-10
genomic O 0 1.500207673643672e-07
DNA O 0 1.2523615566806257e-07
were O 0 8.580440247207832e-10
designed O 0 1.3875354198944478e-09
to O 0 4.7433234423577275e-11
allow O 0 3.4971289752938617e-10
rapid O 0 1.6967010019186546e-09
screening O 0 1.0362969149468881e-08
for O 0 5.292490889985402e-10
common O 0 2.323278103233406e-08
ethnic O 0 7.727032880211482e-07
mutations O 0 3.0383720513782464e-05
. O 0 7.118320013432822e-07

These O 0 2.0422463364866417e-07
rapid O 0 5.646057843478047e-07
assays O 0 2.503415544197196e-06
detected O 0 6.77835146234429e-07
mutations O 0 3.454959767168475e-07
in O 0 3.4948168803339286e-09
76 O 0 1.2127585158339116e-08
% O 0 1.4814816040598089e-09
of O 0 3.0149491236919346e-10
Costa O 0 3.4253535119432854e-08
Rican O 0 5.815774883899394e-08
patients O 0 1.9739605505719737e-08
( O 0 7.815034730462855e-11
3 O 0 1.4471955578354567e-10
) O 0 8.41272676521676e-11
, O 0 5.976597688972518e-11
50 O 0 3.012282367986785e-10
% O 0 5.589899099156526e-10
of O 0 3.2997238275100926e-10
Norwegian O 0 0.03902179002761841
patients O 0 4.791615282329076e-08
( O 0 1.0835893987648504e-10
1 O 0 1.9407844775720662e-10
) O 0 9.763923003447417e-11
, O 0 5.47983360077442e-11
25 O 0 1.5103374106928413e-10
% O 0 1.6021806104049574e-10
of O 0 1.1453697712493494e-10
Polish O 0 5.2895575208822265e-06
patients O 0 1.374707281343035e-08
( O 0 5.932395547025848e-11
4 O 0 1.2239464997065852e-10
) O 0 7.967880522041781e-11
, O 0 4.4626424083871186e-11
and O 0 1.73457234686758e-10
14 O 0 2.553454669929067e-10
% O 0 1.033033866781885e-10
of O 0 7.841702981403742e-11
Italian O 0 1.1205703231098596e-05
patients O 0 1.215704426016373e-08
( O 0 5.8104885486409685e-11
1 O 0 1.8179305283361202e-10
) O 0 9.140169870969217e-11
, O 0 5.57938278911152e-11
as O 0 6.542309749502095e-11
well O 0 2.5794080760199734e-10
as O 0 3.678805593487766e-10
in O 0 9.968968983642412e-10
patients O 0 6.682622899489843e-09
of O 0 1.9024259945155109e-10
Amish O 0 2.5795540636863734e-07
/ O 0 1.6909066857806465e-07
Mennonite O 0 2.7212880127081007e-07
and O 0 4.85229705304846e-08
Irish O 0 7.881305350565526e-07
English O 0 5.965445097899646e-07
backgrounds O 0 2.7668504571920494e-06
. O 0 7.68443953802489e-07

Additional O 0 3.422970564770367e-07
mutations O 0 8.157590514201729e-07
were O 0 5.829109639421404e-09
observed O 0 6.382431916307496e-09
in O 0 5.586445750438429e-10
Japanese O 0 3.5061136216540945e-09
, O 0 1.1782773368107513e-10
Utah O 0 1.0535075034567853e-09
Mormon O 0 5.698261418274342e-09
, O 0 6.475818215001539e-10
and O 0 3.0001565676229802e-09
African O 0 1.673873306629048e-08
American O 0 3.0357549007931084e-07
patients O 0 6.184038738865638e-07
. O 0 2.2622987216891488e-07

These O 0 3.8867831619882054e-08
assays O 0 1.0279441085003782e-06
should O 0 5.900848254469793e-09
facilitate O 0 2.8315982891768954e-09
screening O 0 4.125048391756536e-08
for O 0 5.722528229057389e-09
A B-Disease 1 0.9999858140945435
- I-Disease 1 0.9999548196792603
T I-Disease 1 1.0
heterozygotes O 0 1.334074681835773e-06
in O 0 1.4393727321149186e-09
the O 0 6.226640869577693e-10
populations O 0 1.8199342477487335e-08
studied O 0 3.2106797220876615e-08
. O 0 8.969839981887162e-09
. O 0 9.540011092212808e-08

The O 0 4.937304765917361e-06
von B-Disease 1 0.9718643426895142
Hippel I-Disease 1 0.9976245760917664
- I-Disease 1 0.9975898265838623
Lindau I-Disease 1 0.9968822002410889
tumor I-Disease 0 4.409308894537389e-05
suppressor O 0 3.3025528409780236e-06
gene O 0 4.51634718956484e-07
is O 0 5.402460256931363e-09
required O 0 4.035189071771583e-09
for O 0 9.659216759771994e-10
cell O 0 4.2012840140159824e-07
cycle O 0 6.100701170907996e-07
exit O 0 3.504030416934256e-07
upon O 0 4.365703887287964e-08
serum O 0 4.731177796202246e-06
withdrawal O 0 4.260460627847351e-06
. O 0 6.807841259615088e-07

The O 0 2.6247030859849474e-07
inactivation O 0 7.482410637749126e-06
of O 0 7.915282651538291e-09
the O 0 4.9425484149878685e-08
von B-Disease 1 0.9979891777038574
Hippel I-Disease 1 0.9996569156646729
- I-Disease 1 0.9998117089271545
Lindau I-Disease 1 0.9998470544815063
( I-Disease 0 4.387014485018881e-07
VHL I-Disease 0 0.0002841503592208028
) I-Disease 0 1.419707160721373e-07
tumor I-Disease 0 1.349133754047216e-06
suppressor O 0 1.2136525811001775e-06
gene O 0 4.810369205188181e-07
predisposes O 0 1.5347899307016633e-06
affected O 0 1.7573587030028648e-08
individuals O 0 1.2354278711157463e-09
to O 0 7.412478408852508e-10
the O 0 7.729654249999385e-09
human O 0 9.268343887924857e-07
VHL B-Disease 1 0.9999831914901733
cancer I-Disease 1 0.9999964237213135
syndrome I-Disease 1 0.999950647354126
and O 0 4.195724212507912e-09
is O 0 3.2972213848125875e-09
associated O 0 4.442351908551245e-08
with O 0 4.870080516639064e-08
sporadic B-Disease 1 0.9999196529388428
renal I-Disease 1 0.9999998807907104
cell I-Disease 1 0.9999995231628418
carcinomas I-Disease 1 1.0
( O 0 1.4380282209458528e-06
RCC B-Disease 1 0.676645815372467
) O 0 1.1622982754033728e-07
and O 0 9.49625942325838e-08
brain B-Disease 0 5.999224231345579e-05
hemangioblastomas I-Disease 0 0.00011487660958664492
. O 0 1.2120136716475827e-06

VHL O 0 0.013336586765944958
- O 0 0.0583777017891407
negative O 0 5.206727655604482e-05
786 O 0 1.1997020919807255e-05
- O 0 8.532940410077572e-05
0 O 0 3.375511710146384e-07
RCC B-Disease 0 2.251718342449749e-06
cells O 0 7.356148046255839e-08
are O 0 2.1300403663104817e-09
tumorigenic O 0 3.6119067203799204e-07
in O 0 5.217581477978683e-09
nude O 0 1.9444662029854953e-05
mice O 0 1.4304398519016104e-06
which O 0 3.696821515575266e-09
is O 0 7.435163040803161e-10
suppressed O 0 6.868146940064435e-09
by O 0 2.591890313485834e-10
the O 0 1.3381595831418736e-09
reintroduction O 0 2.2268959298799018e-07
of O 0 1.56709294429902e-08
VHL B-Disease 0 8.549613994546235e-05
. O 0 7.636543841726962e-07

Remarkably O 0 4.28160046794801e-06
, O 0 2.1900572022559572e-08
this O 0 1.4018844973762157e-09
occurs O 0 2.9771896059571645e-09
without O 0 1.889870038240815e-09
affecting O 0 2.7451649842191728e-09
the O 0 4.41141845275439e-10
growth O 0 1.0308854214713392e-08
rate O 0 8.144684926492118e-09
and O 0 1.6035632821598256e-09
cell O 0 7.544252156321818e-08
cycle O 0 3.530319858668918e-08
profile O 0 1.0733941024909655e-07
of O 0 1.0041003445371288e-10
these O 0 9.442697734840522e-10
cells O 0 1.588725950796288e-08
in O 0 3.039478224664549e-09
culture O 0 3.262189807173854e-07
. O 0 3.307452800527244e-07

The O 0 2.7423908477430814e-07
786 O 0 6.206570560607361e-06
- O 0 3.0302412596938666e-06
0 O 0 5.1347537777246544e-08
cell O 0 1.0892686930219497e-07
line O 0 5.1009884316499665e-08
, O 0 3.20121679164842e-10
like O 0 7.597963369576632e-10
many O 0 1.4791184943518942e-09
cancer B-Disease 0 4.42523564458952e-08
cells O 0 4.428847510951073e-09
, O 0 5.605454989066061e-10
fails O 0 3.758041700052672e-08
to O 0 3.4820532568424767e-10
exit O 0 1.7904412175084872e-08
the O 0 1.067466226523095e-09
cell O 0 1.7944417152193637e-07
cycle O 0 9.067392880979241e-08
upon O 0 1.3092603445841178e-08
serum O 0 1.570705535414163e-06
withdrawal O 0 2.7478097308630822e-06
. O 0 8.051163717937015e-07

Here O 0 1.641971181243207e-07
, O 0 5.081030707287937e-09
it O 0 8.518718508376821e-10
is O 0 1.322409959314541e-10
shown O 0 4.926524188597625e-10
that O 0 5.848648648720811e-11
reintroduction O 0 2.1389032767160643e-09
of O 0 4.12841878738579e-11
the O 0 2.1250073922729484e-10
wild O 0 1.6288165483047123e-08
- O 0 6.120699708844768e-06
type O 0 1.4362437923409743e-06
VHL B-Disease 0 3.7675695239158813e-06
gene O 0 7.902735177367504e-08
restores O 0 8.377894289424148e-08
the O 0 8.11088529673043e-10
ability O 0 1.2580518848892552e-08
of O 0 2.8537521234994756e-09
VHL O 0 0.00014247559010982513
- O 0 0.0020740781910717487
negative O 0 6.244571704883128e-05
RCC B-Disease 0 0.00022871396504342556
cancer I-Disease 0 4.908324626740068e-07
cells O 0 6.250013395714404e-09
to O 0 2.920851616128317e-10
exit O 0 1.323577070166948e-08
the O 0 9.089098917947069e-10
cell O 0 1.3413678345841618e-07
cycle O 0 8.575703702717874e-08
and O 0 6.315514333721239e-09
enter O 0 5.468127284302682e-08
G0 O 0 1.2600035006471444e-05
/ O 0 4.2968068214577215e-07
quiescence O 0 1.8432498336551362e-06
in O 0 4.958203447813503e-08
low O 0 2.329287099200883e-06
serum O 0 1.3369619409786537e-05
. O 0 5.797577955490851e-07

Both O 0 1.9183898984920233e-06
VHL O 0 0.0001712962839519605
- O 0 0.00013174831110518426
positive O 0 3.1641573627894104e-07
and O 0 7.592712591986128e-08
VHL O 0 8.960222476162016e-05
- O 0 0.0003511268296279013
negative O 0 1.067041557689663e-05
RCC B-Disease 0 1.5353403796325438e-05
cells O 0 3.262559857830638e-07
exit O 0 2.701596883980528e-07
the O 0 3.694079264704442e-09
cell O 0 5.695427489627036e-07
cycle O 0 1.292315374712416e-07
by O 0 6.460191492863032e-09
contact O 0 4.0130018419404223e-07
inhibition O 0 4.100936166651081e-06
. O 0 6.93080835389992e-07

The O 0 1.078485070138413e-06
cyclin O 0 0.000702741788700223
- O 0 2.4876131647033617e-05
dependent O 0 1.532292003503244e-06
kinase O 0 3.840098088403465e-06
inhibitor O 0 1.6298969285344356e-06
, O 0 6.71734401436197e-09
p27 O 0 4.82459768136323e-07
, O 0 6.776717520473596e-10
accumulates O 0 4.733494929354265e-09
upon O 0 5.996240171057821e-10
serum O 0 2.2915251918220747e-08
withdrawal O 0 9.522628019453805e-09
, O 0 1.7191480183864627e-10
only O 0 9.765468989009207e-11
in O 0 1.183372011492878e-10
the O 0 2.770179086120095e-10
presence O 0 2.793750342178214e-09
of O 0 1.1384915232781623e-10
VHL B-Disease 0 2.385024231443822e-07
, O 0 2.893570105744203e-10
as O 0 2.3406224181066193e-10
a O 0 3.8860376028182486e-10
result O 0 3.1775302389291937e-09
of O 0 5.627810023556279e-11
the O 0 3.8232661481174546e-10
stabilization O 0 1.2689495676454499e-08
of O 0 2.673115340190435e-10
the O 0 4.736926850767986e-09
protein O 0 2.4558099198657146e-07
. O 0 2.499841400549485e-07

We O 0 1.7264123641780316e-07
propose O 0 9.563385816591108e-08
that O 0 1.1085081741413205e-09
the O 0 2.888519146093671e-10
loss O 0 4.325741542743344e-09
of O 0 1.418470896297208e-10
wild O 0 2.5169834216853815e-08
- O 0 7.971191371325403e-05
type O 0 6.432292593672173e-06
VHL B-Disease 0 3.934744654543465e-06
gene O 0 1.3066936332961632e-07
results O 0 2.370913243510131e-08
in O 0 2.691394607179376e-10
a O 0 3.35526245676121e-10
specific O 0 7.022765036168721e-09
cellular O 0 4.945566161040915e-07
defect O 0 3.985742864642816e-07
in O 0 9.094404673781753e-10
serum O 0 3.729579134414962e-07
- O 0 1.984752088901587e-06
dependent O 0 7.441198590640852e-07
growth O 0 6.461241497390802e-08
control O 0 7.807954460758992e-08
, O 0 6.138389796461752e-10
which O 0 3.4136249382754613e-09
may O 0 1.3804879017698113e-08
initiate O 0 8.317835664684026e-08
tumor B-Disease 0 1.7416506352674332e-06
formation O 0 2.1451148768392159e-07
. O 0 2.964767702451354e-07

This O 0 2.204283191531431e-07
is O 0 1.6366017874247518e-08
corrected O 0 9.829692260154843e-08
by O 0 2.0194634853254456e-10
the O 0 1.9759928415741257e-10
reintroduction O 0 1.2207652666518243e-08
of O 0 2.833617229747176e-10
wild O 0 2.845378155313938e-08
- O 0 0.000709633226506412
type O 0 0.0018161953194066882
VHL B-Disease 0 0.00013838254380971193
, O 0 6.5605227916876174e-09
implicating O 0 1.414741603866787e-07
VHL B-Disease 0 1.1656755987132783e-06
as O 0 1.2118838155217304e-09
the O 0 2.2925064624423896e-10
first O 0 2.8756461656342935e-09
tumor B-Disease 0 2.867158954700244e-08
suppressor O 0 3.5578118229295796e-08
involved O 0 4.796422370390019e-09
in O 0 4.152396759771193e-10
the O 0 2.5405955117463463e-10
regulation O 0 1.3659142705790828e-09
of O 0 5.6154685068587895e-11
cell O 0 2.6590678103843857e-08
cycle O 0 1.59203210614578e-08
exit O 0 5.2080789458841537e-08
, O 0 3.5449110313834353e-10
which O 0 1.0029370667297144e-09
is O 0 7.439588389779317e-10
consistent O 0 2.5583748453072985e-09
with O 0 1.2492941403596802e-10
its O 0 1.0392873228681765e-09
gatekeeper O 0 1.4285352278875507e-07
function O 0 1.0498313329776465e-08
in O 0 3.812927307222935e-09
the O 0 1.1672598887457752e-08
kidney O 0 1.4055391375222825e-06
. O 0 5.7167053313378347e-08
. O 0 2.831697827332391e-07

Piebaldism B-Disease 1 1.0
with O 0 0.002506326185539365
deafness B-Disease 1 1.0
: O 0 3.636684908769894e-08
molecular O 0 5.671222425007727e-08
evidence O 0 1.12306111077487e-08
for O 0 9.631290209810572e-10
an O 0 8.93066154361577e-09
expanded O 0 0.0046071987599134445
syndrome O 1 0.999897837638855
. O 0 1.1039174978577648e-06

In O 0 7.597579809726085e-08
a O 0 1.4384403890232988e-08
South O 0 1.3975760992934738e-08
African O 0 6.4913669994837164e-09
girl O 0 3.302648465819402e-08
of O 0 2.405602939070661e-10
Xhosa O 0 4.078873132584704e-07
stock O 0 2.0042588744217937e-07
with O 0 2.43899367369238e-09
severe O 0 2.6950092433253303e-06
piebaldism B-Disease 0 4.281821384211071e-05
and O 0 7.725810746705974e-08
profound O 0 2.881649152186583e-06
congenital O 1 0.9999706745147705
sensorineural B-Disease 1 0.9999372959136963
deafness I-Disease 1 1.0
we O 0 1.1931313565582968e-05
identified O 0 6.468380320256983e-08
a O 0 1.626139889410183e-09
novel O 0 2.3984538799481925e-08
missense O 0 3.561370078841719e-07
substitution O 0 1.4295676642461785e-08
at O 0 6.9737633445754454e-09
a O 0 1.2084445666360466e-09
highly O 0 3.059988706866079e-09
conserved O 0 8.81396555740821e-09
residue O 0 1.361195103299906e-07
in O 0 1.9656114513821876e-09
the O 0 1.1670588939693971e-09
intracellular O 0 9.477097506760401e-08
kinase O 0 1.0066251832085982e-07
domain O 0 2.1563831609228146e-08
of O 0 6.177089395542623e-10
the O 0 3.3906020213692045e-09
KIT O 0 2.6969782993546687e-06
proto O 0 1.6894100554054603e-05
- O 0 3.7921392959106015e-06
oncogene O 0 1.4421208106796257e-05
, O 0 4.8647798678302934e-08
R796G O 0 5.425043127615936e-06
. O 0 4.988173145648034e-07

Though O 0 1.6570585330555332e-06
auditory B-Disease 0 9.189272532239556e-06
anomalies I-Disease 0 5.666735887643881e-06
have O 0 1.24086483310748e-08
been O 0 3.242340618214712e-09
observed O 0 6.533288132715143e-09
in O 0 1.3041154822701628e-09
mice O 0 9.119808197510793e-08
with O 0 2.9508446797166243e-09
dominant O 0 1.9973673261119984e-05
white O 0 3.180035037075868e-06
spotting O 0 5.3082621889188886e-05
( O 0 5.303285810498437e-09
W O 0 0.1373671591281891
) O 0 3.4480318600316195e-09
due O 0 2.3819857197793226e-09
to O 0 2.4087492001001465e-09
KIT O 0 9.219354978995398e-06
mutations O 0 3.272112280683359e-06
, O 0 2.9035021498202696e-08
deafness B-Disease 1 1.0
is O 0 1.2559659978705895e-08
not O 0 3.3787364017712207e-09
typical O 0 1.8379063604356816e-08
in O 0 6.606657887431311e-09
human O 0 3.82561893275124e-08
piebaldism B-Disease 0 1.2502553545346018e-05
. O 0 4.671778697229456e-07

Thus O 0 2.7931451995755197e-07
, O 0 6.25130081033376e-09
the O 0 1.0919136705922483e-09
occurrence O 0 1.356343659608683e-07
of O 0 5.206725273154689e-09
sensorineural B-Disease 1 0.9990366697311401
deafness I-Disease 1 1.0
in O 0 1.338042068255163e-07
this O 0 4.366375705444625e-09
patient O 0 3.193706632487192e-08
extends O 0 7.491252063118736e-09
considerably O 0 8.026676212580242e-09
the O 0 4.192346192422036e-10
phenotypic O 0 9.623053642826562e-08
range O 0 5.6390763170099945e-09
of O 0 1.2319001374549998e-10
piebaldism B-Disease 0 4.210027668705152e-07
due O 0 7.546896441112949e-09
to O 0 1.1709698766182441e-09
KIT O 0 9.844420389981678e-08
gene O 0 2.7893538145917773e-08
mutation O 0 3.9614477032046125e-08
in O 0 2.4567156642341104e-10
humans O 0 1.6686636516993758e-09
and O 0 2.2436685842563975e-09
tightens O 0 3.6057331271877047e-06
the O 0 1.490159329264884e-09
clinical O 0 2.2374091912524818e-08
similarity O 0 7.896524323314225e-09
between O 0 6.098385130215433e-10
piebaldism B-Disease 0 2.072338816105912e-07
and O 0 7.304856164402906e-10
the O 0 1.0487815477189244e-10
various O 0 3.7679284692337944e-10
forms O 0 5.979958217494641e-08
of O 0 2.8384678785187134e-07
Waardenburg B-Disease 1 0.9999947547912598
syndrome I-Disease 1 0.9999434947967529
. O 0 1.4556940186594147e-07
. O 0 6.71789052830718e-07

Cycloheximide O 0 4.7755998821230605e-05
facilitates O 0 9.411821224603045e-07
the O 0 9.271304612923359e-09
identification O 0 4.0911906751261995e-08
of O 0 1.557250550732192e-09
aberrant O 0 1.5858836377447005e-07
transcripts O 0 1.5696018351718521e-07
resulting O 0 3.691883776468785e-08
from O 0 1.0214938894748116e-09
a O 0 1.0644997106012966e-09
novel O 0 3.34853353933795e-08
splice O 0 1.467831498302985e-05
- O 0 2.506499640730908e-06
site O 0 5.311295581122977e-08
mutation O 0 9.436836734266763e-08
in O 0 1.4103701539980307e-09
COL17A1 O 0 4.646057618629129e-07
in O 0 9.369339748488414e-10
a O 0 4.042291390504715e-09
patient O 0 2.0376356246742944e-07
with O 0 6.845315425607623e-08
generalized O 0 0.00013827979273628443
atrophic B-Disease 1 0.9991021156311035
benign I-Disease 1 0.9940978288650513
epidermolysis I-Disease 1 0.9936379790306091
bullosa I-Disease 1 0.9920342564582825
. O 0 8.159615390468389e-05

Patients O 0 7.925630052341148e-05
with O 0 7.355052957791486e-07
generalized O 0 0.0001781003811629489
atrophic B-Disease 1 0.9983762502670288
benign I-Disease 1 0.9270148873329163
epidermolysis I-Disease 1 0.9630522727966309
bullosa I-Disease 1 0.584197461605072
often O 0 7.0806681833346374e-06
show O 0 5.821201511935215e-07
decreased O 0 3.9727945022605127e-07
expression O 0 1.0261521765642101e-07
of O 0 4.8999124757642676e-09
type O 0 4.305652510083746e-06
XVII O 0 5.194455752643989e-06
collagen O 0 1.243252654603566e-06
, O 0 8.423780784028168e-09
a O 0 8.610709478773515e-09
transmembrane O 0 6.829208700764866e-07
hemidesmosomal O 0 8.081873943410756e-07
protein O 0 5.1564040148832646e-08
encoded O 0 3.793430281007204e-08
by O 0 3.472493048661818e-08
COL17A1 O 0 4.85290220240131e-05
. O 0 1.0036974344984628e-06

This O 0 3.229689582440187e-07
report O 0 6.35832790862878e-08
documents O 0 2.252214947873199e-08
a O 0 3.305684614929305e-09
novel O 0 3.8927034040625585e-08
splice O 0 8.095365956251044e-06
- O 0 6.157460120448377e-06
site O 0 1.7756988768269366e-07
mutation O 0 2.006963484291191e-07
in O 0 1.6866210650334779e-09
COL17A1 O 0 6.678585577901686e-07
in O 0 1.0999886557172545e-09
a O 0 2.476079563606959e-09
patient O 0 6.866014956585786e-08
with O 0 6.073095359937497e-09
generalized O 0 1.543514918012079e-05
atrophic B-Disease 1 0.9979119896888733
benign I-Disease 0 0.2837013900279999
epidermolysis I-Disease 0 0.02726076729595661
bullosa I-Disease 0 0.06622304022312164
, O 0 1.644299096881241e-08
and O 0 1.4304833984013499e-09
applies O 0 9.541554213399195e-09
a O 0 7.534696200295343e-10
new O 0 1.374575453461091e-09
methodology O 0 1.2700681395472202e-08
to O 0 3.657396607792407e-10
define O 0 1.546179362321709e-08
and O 0 2.256014486334834e-09
characterize O 0 1.1025606738712668e-07
the O 0 8.788616057131549e-09
resulting O 0 1.1234171637397594e-07
mRNA O 0 5.468397716867912e-07
splice O 0 1.6508329281350598e-05
variants O 0 9.078423317987472e-06
. O 0 1.743957682265318e-06

Mutational O 0 0.000406364822993055
analysis O 0 2.823989234457258e-06
of O 0 1.7185497469540678e-08
COL17A1 O 0 9.414196938450914e-06
identified O 0 4.0684770397092507e-07
a O 0 2.30985470750511e-08
maternally O 0 3.9330602703557815e-06
inherited O 0 2.680026227608323e-06
G O 0 2.3996126401470974e-06
- O 0 4.3548757844291686e-07
to O 0 8.557040409584715e-09
- O 0 1.0771016150101786e-06
T O 0 6.440066613322415e-07
transversion O 0 6.500128790776216e-08
at O 0 5.813795000975119e-10
the O 0 3.3136748900375324e-10
- O 0 4.2561943303098815e-08
1 O 0 1.7136521091032364e-09
position O 0 8.488830083308585e-09
of O 0 4.928084607058736e-10
exon O 0 5.096505333312962e-07
32 O 0 2.2181271219778864e-07
. O 0 3.00350222914858e-07

This O 0 1.6745860875744256e-07
acceptor O 0 1.2088357834727503e-06
splice O 0 2.0380592104629613e-05
- O 0 3.5723953715205425e-06
site O 0 9.423042257594716e-08
mutation O 0 8.883707636186955e-08
led O 0 2.1237402947349437e-09
to O 0 5.470593977818794e-10
the O 0 2.676523447320278e-10
formation O 0 9.913772025527123e-10
of O 0 8.811670143549222e-11
aberrant O 0 1.1096976670899039e-08
transcripts O 0 1.547565986470545e-08
present O 0 2.1696087149081222e-09
at O 0 8.989622379829143e-09
extremely O 0 6.705300847897888e-08
low O 0 2.140861170119024e-06
levels O 0 1.4235998833100894e-06
. O 0 6.45938087018294e-07

Based O 0 5.489863497132319e-07
on O 0 1.1910451291896607e-08
our O 0 4.1557739471898e-09
recent O 0 5.475200293147964e-09
finding O 0 9.236339693075024e-09
that O 0 2.199428861260344e-09
cycloheximide O 0 9.926209258992458e-07
stabilized O 0 2.6505058485781774e-06
mutant O 0 2.0344762674540107e-07
COL17A1 O 0 5.194626737647923e-07
transcripts O 0 6.385722173263275e-08
in O 0 2.5198834130435444e-09
keratinocytes O 0 1.4533884495904204e-07
homozygous O 0 1.921499261925419e-07
for O 0 1.2412002536876798e-09
a O 0 4.234556261195621e-09
frameshift O 0 6.30822432867717e-06
mutation O 0 5.032390504311479e-07
, O 0 1.4459685671042166e-09
the O 0 5.438975381188982e-10
effects O 0 3.7828678500773094e-07
of O 0 1.301542901233077e-10
the O 0 6.650589523538031e-10
splice O 0 5.210970630287193e-05
- O 0 2.6108650672540534e-06
site O 0 9.424748981246012e-08
mutation O 0 6.750740766392482e-08
on O 0 1.325274112673469e-09
splicing O 0 6.803454510873053e-08
of O 0 6.974198996090308e-10
COL17A1 O 0 1.663647282157399e-07
transcripts O 0 2.492475381643544e-08
were O 0 8.810464580122357e-10
determined O 0 3.2328431043282535e-09
using O 0 8.626523495536276e-09
reverse O 0 4.0062565176413045e-07
transcriptase O 0 2.4102730549202533e-06
polymerase O 0 4.919684215565212e-07
chain O 0 5.931125315328245e-07
reaction O 0 3.962747285868318e-08
of O 0 6.460963986043566e-10
total O 0 2.095613682584485e-09
RNA O 0 3.477231658166602e-08
from O 0 1.3753728156373768e-09
keratinocytes O 0 9.939227396671413e-08
incubated O 0 1.0062297661761477e-07
for O 0 3.5032792222722264e-09
2 O 0 4.6016921828595514e-08
. O 0 1.2386909986616956e-07

5 O 0 2.1971055730318767e-07
h O 0 3.7516466022680106e-07
in O 0 1.5487404692038353e-09
the O 0 4.323273128381544e-10
presence O 0 6.720548118011038e-09
or O 0 1.555591921942323e-08
absence O 0 9.455678906533649e-09
of O 0 8.461635836454207e-10
10 O 0 5.4762554491105675e-09
microg O 0 7.310060823328968e-07
cycloheximide O 0 2.0863612917310093e-06
per O 0 1.6635551958188444e-07
ml O 0 9.037011295731645e-06
. O 0 4.197887619739049e-07

Using O 0 9.552082502750636e-08
this O 0 3.758004130105519e-09
approach O 0 7.101240839801903e-08
, O 0 2.7970454841153014e-09
an O 0 1.4395484804197167e-09
abnormally O 0 1.0949804618576309e-07
spliced O 0 1.487178110437526e-06
transcript O 0 4.422819984029047e-06
was O 0 4.193358194015673e-08
identified O 0 6.1330562850514525e-09
that O 0 5.910642114637099e-11
contains O 0 4.3510580555183864e-11
an O 0 5.2016380786001903e-11
extra O 0 1.3571704871040424e-09
264 O 0 3.6239493628187347e-09
bases O 0 2.3769977097742867e-09
upstream O 0 5.527686752770933e-09
from O 0 3.1504565622952896e-10
exon O 0 4.563130673318483e-08
32 O 0 7.052510131444478e-09
, O 0 7.426630421747404e-10
resulting O 0 7.689495262752644e-09
in O 0 3.7800593766235124e-09
a O 0 2.907093055171117e-08
premature O 0 2.1274230732615251e-07
termination O 0 2.496917943517474e-07
codon O 0 4.995628160031629e-07
27 O 0 2.4670015363881248e-08
bp O 0 8.421600483643488e-08
downstream O 0 9.269271572520665e-09
from O 0 4.948910725666167e-10
the O 0 1.266385996068209e-09
cryptic O 0 6.012164135427156e-07
splice O 0 1.2247214726812672e-05
site O 0 3.0894473184162052e-06
. O 0 7.820457312845974e-07

Three O 0 9.28713035364126e-08
other O 0 3.1171769609983357e-09
splice O 0 2.235434664044078e-07
variants O 0 5.484881882011905e-08
, O 0 4.6517148466485025e-10
including O 0 5.977714850891047e-11
one O 0 1.0874341704880663e-10
derived O 0 9.243261156477445e-10
from O 0 6.20365217529617e-11
the O 0 3.5770355427677814e-11
skipping O 0 3.1281299772700777e-09
of O 0 8.49303197214546e-11
exon O 0 1.688018613776876e-08
32 O 0 2.4450161895117617e-09
, O 0 2.3749935351702334e-10
were O 0 1.8955741420967342e-09
also O 0 8.89224782696374e-09
identified O 0 1.89222703284031e-07
. O 0 2.3565657158997055e-07

These O 0 1.5253243645929615e-07
results O 0 1.0815941919872785e-07
indicate O 0 1.7389567119607818e-08
the O 0 4.755664195776887e-10
usefulness O 0 9.717021853816732e-09
of O 0 1.2951587025078481e-10
cycloheximide O 0 1.3569852796990745e-07
treatment O 0 1.6086646681401362e-08
in O 0 3.2331004540253616e-10
evaluating O 0 1.0003888384346737e-08
the O 0 4.447892332226644e-10
abnormal O 0 1.7466586399450534e-08
processing O 0 6.375812766634681e-09
of O 0 1.2091448675644045e-10
mRNA O 0 4.200592762515498e-09
due O 0 2.5878459375405782e-09
to O 0 5.55883172825844e-10
splice O 0 2.8319454941083677e-06
- O 0 6.515992936328985e-07
site O 0 3.4853922414868066e-08
mutations O 0 5.997046059746935e-08
, O 0 5.896367283320103e-10
because O 0 2.3772652735232214e-09
( O 0 5.426779026151962e-10
i O 0 7.650332811692806e-09
) O 0 3.5157951550068844e-10
aberrant O 0 8.24422929923685e-09
splicing O 0 8.912236637570459e-08
often O 0 2.7590767004426198e-08
generates O 0 3.302213968936485e-08
a O 0 1.946228245230941e-08
premature O 0 2.9600471407320583e-07
termination O 0 1.7964450194085657e-07
codon O 0 3.0078476243033947e-07
, O 0 1.7550533248922306e-09
( O 0 3.7444439215938985e-10
ii O 0 6.683630093817783e-09
) O 0 5.343113729239235e-10
transcripts O 0 1.4226640310255334e-08
with O 0 1.790617765173863e-09
premature O 0 3.5014103616504144e-08
termination O 0 1.0669557681808328e-08
codons O 0 2.1035718944517612e-08
can O 0 2.0935242428521406e-09
occur O 0 1.5361780736355968e-09
at O 0 1.4349814669856187e-09
low O 0 3.5436574563618706e-08
or O 0 2.9473813611957667e-08
undetectable O 0 4.805898697668454e-06
levels O 0 3.8807382196637263e-08
due O 0 3.2828573193199873e-09
to O 0 9.343338325251693e-10
nonsense O 0 2.7196742280466424e-07
- O 0 6.102742844404929e-08
mediated O 0 3.3891748074665884e-08
mRNA O 0 3.610936660791708e-09
decay O 0 5.7141407161509505e-09
, O 0 1.5487811033665366e-10
and O 0 1.0239863817984585e-10
( O 0 2.8091041645583736e-11
iii O 0 8.987560695672414e-10
) O 0 2.0227866603939049e-10
the O 0 1.3934808862359205e-10
levels O 0 8.654800209839664e-10
of O 0 3.4242754031604816e-12
these O 0 2.512868559068071e-11
transcripts O 0 6.885352288321656e-10
can O 0 2.564456147435834e-10
be O 0 1.099809826543563e-10
increased O 0 6.445701750124044e-10
by O 0 2.4352191374532595e-09
cycloheximide O 0 4.955469648848521e-06
. O 0 2.3473178600852407e-07

A O 0 6.49624951165606e-07
deletion O 0 4.447300398169318e-06
mutation O 0 1.3132890899214544e-06
in O 0 6.622958625968067e-09
COL17A1 O 0 6.77897219247825e-07
in O 0 4.247903806486875e-09
five O 0 5.323290697134553e-09
Austrian O 0 8.540313274352229e-07
families O 0 1.3984774227537855e-08
with O 0 9.467301609333845e-09
generalized O 0 4.400135367177427e-05
atrophic B-Disease 1 0.9995842576026917
benign I-Disease 1 0.977231502532959
epidermolysis I-Disease 1 0.9850330948829651
bullosa I-Disease 0 0.08519303798675537
represents O 0 2.675102734883694e-07
propagation O 0 1.876484816420998e-07
of O 0 2.5365198830229474e-09
an O 0 5.4718807263043345e-09
ancestral O 0 3.0864612199366093e-06
allele O 0 0.0001074396786862053
. O 0 3.538504870448378e-06

Patients O 0 8.329006959684193e-05
with O 0 4.396735846512456e-07
generalized O 0 0.00018391867342870682
atrophic B-Disease 1 0.9994450211524963
benign I-Disease 1 0.9873141646385193
epidermolysis I-Disease 1 0.9660912752151489
bullosa I-Disease 1 0.860488772392273
, O 0 7.760783660160087e-08
a O 0 7.0201129354074965e-09
usually O 0 1.648833958256546e-08
nonlethal O 0 6.184734502312494e-07
form O 0 1.3465817971791694e-07
of O 0 4.470384240562453e-08
junctional B-Disease 0 0.07030016928911209
epidermolysis I-Disease 1 0.6852502822875977
bullosa I-Disease 0 0.11460031569004059
, O 0 2.5487130628221166e-08
have O 0 4.974550105174558e-09
generalized O 0 1.0758639490404676e-07
blistering B-Disease 0 5.34017488007521e-07
, O 0 2.3747737998291996e-08
nail B-Disease 1 0.9431185126304626
dystrophy I-Disease 0 2.4508859496563673e-05
, O 0 5.418469228857248e-08
patchy B-Disease 0 0.00013843837950844318
alopecia I-Disease 1 0.9996036887168884
, O 0 1.0944980743943233e-07
and O 0 7.51326240333583e-07
dental B-Disease 1 0.999896764755249
abnormalities I-Disease 1 0.9997996687889099
. O 0 3.570555918486207e-06

Skin B-Disease 1 0.9983327984809875
fragility I-Disease 0 7.581035606563091e-05
in O 0 9.174605075656928e-09
most O 0 7.700455273429441e-10
cases O 0 3.0833062769630715e-09
is O 0 7.347895625287038e-10
due O 0 1.6851547934848554e-09
to O 0 4.4579481772721863e-10
mutations O 0 1.6995940654851438e-08
in O 0 2.6094301719403745e-10
the O 0 5.290048399331226e-10
gene O 0 6.23009199784974e-08
encoding O 0 5.00858959640027e-07
type O 0 2.3249609512276947e-05
XVII O 0 7.489421477657743e-06
collagen O 0 1.6232902453339193e-06
( O 0 1.882223088500723e-08
COL17A1 O 0 6.8696758717123885e-06
) O 0 7.711059879511595e-08
. O 0 1.9914249094199477e-07

Recently O 0 1.7482138900959399e-06
, O 0 1.0557992702331376e-08
we O 0 6.9628516286002196e-09
reported O 0 1.197649091011499e-08
five O 0 1.345137889963155e-09
Austrian O 0 2.445813436224853e-07
families O 0 6.303756627801249e-09
with O 0 4.121279317814697e-09
generalized O 0 1.1443518815212883e-05
atrophic B-Disease 1 0.9958562254905701
benign I-Disease 0 0.0704369843006134
epidermolysis I-Disease 0 0.02680431678891182
bullosa I-Disease 0 0.23063497245311737
who O 0 1.1330106417517527e-06
share O 0 1.0635042002604678e-07
the O 0 5.681071613139466e-09
same O 0 8.561877251622718e-08
COL17A1 O 0 5.751015123678371e-05
mutation O 0 1.4138179722067434e-05
. O 0 7.458490927092498e-07

Affected O 0 1.1586134860408492e-06
individuals O 0 1.6751092957179026e-08
in O 0 1.1056153770283572e-09
three O 0 3.86486037617928e-10
families O 0 5.119512036522167e-10
are O 0 1.453990816635553e-10
homozygous O 0 1.2636649060482341e-08
for O 0 2.895132467095607e-10
4003delTC O 0 2.4208594240349157e-08
, O 0 1.9408104290352668e-10
whereas O 0 1.0143683670804649e-09
those O 0 2.33732089238714e-10
in O 0 1.4635063994017372e-10
two O 0 2.729729220440902e-10
others O 0 4.400504405310812e-09
are O 0 1.4596460706783887e-09
compound O 0 2.533226961531909e-07
heterozygotes O 0 1.7007678252412006e-05
. O 0 9.041606290338677e-07

To O 0 3.814871618601501e-08
determine O 0 4.1969752118120596e-08
if O 0 4.212667992220531e-09
the O 0 1.9994453315241856e-10
occurrence O 0 8.961067443635784e-09
of O 0 7.584914640812457e-11
4003delTC O 0 9.445570725574726e-08
in O 0 3.2815097861238485e-10
these O 0 3.5172439960540203e-10
unrelated O 0 1.8455713401976936e-08
families O 0 1.0978570275099742e-09
signifies O 0 1.3024200606892578e-09
propagation O 0 1.545647720924137e-09
of O 0 4.46339978865673e-11
an O 0 1.25281368612562e-10
ancestral O 0 2.814707755760537e-08
allele O 0 6.327211963252921e-07
or O 0 3.1939865863250816e-08
a O 0 3.890036737175251e-09
mutational O 0 2.0644004052883247e-06
hot O 0 5.391612489802355e-07
spot O 0 7.574486176054052e-07
, O 0 1.8399256562773303e-09
haplotypes O 0 8.44027070456832e-08
were O 0 1.9608632495504708e-09
determined O 0 9.113823473683169e-09
for O 0 3.3658192899466144e-10
polymorphisms O 0 2.014407414208108e-07
both O 0 5.312579265392969e-09
within O 0 4.59658444640354e-09
and O 0 3.0922240767949916e-08
flanking O 0 3.256136187701486e-05
COL17A1 O 0 0.0020615316461771727
. O 0 1.7281220152653987e-06

Five O 0 3.7197577285041916e-07
intragenic O 0 2.2441786313720513e-06
polymorphisms O 0 2.6871816771745216e-06
were O 0 1.1879413897020186e-08
chosen O 0 1.2098797519399795e-08
based O 0 7.626818288031245e-09
on O 0 5.479724229928706e-09
their O 0 2.167740120739836e-08
informativeness O 0 1.4731351257069036e-05
. O 0 6.031747830093082e-07

One O 0 4.222089700078868e-08
of O 0 2.3253771130882228e-10
these O 0 2.0014179202831883e-10
, O 0 1.8623555475549836e-10
not O 0 4.859071478513499e-10
previously O 0 1.6719971185352733e-08
reported O 0 1.4639153889106638e-08
, O 0 4.2935580091274517e-10
was O 0 3.873917631125323e-09
2988 O 0 2.4953582311582068e-08
A O 0 1.820183226364236e-09
or O 0 8.449415389577553e-09
C O 0 3.8741561070310127e-08
that O 0 7.875532864742851e-11
introduces O 0 1.0597329680450684e-09
a O 0 4.664107988716637e-10
new O 0 8.562064945927261e-10
restriction O 0 2.8746480751351555e-09
site O 0 6.329297974616566e-09
for O 0 2.0304991021902197e-09
Eco0109 O 0 1.329998212895589e-06
I O 0 9.833383955992758e-07
. O 0 2.5009646265061747e-07

All O 0 6.480247805029649e-08
the O 0 8.773074711143636e-09
4003delTC O 0 4.219429285967635e-07
alleles O 0 2.3602116527854378e-07
showed O 0 2.137517718381332e-08
the O 0 1.7832617327240285e-10
same O 0 8.61474613866875e-10
haplotype O 0 1.479445757013309e-07
for O 0 3.994692077124995e-10
these O 0 1.0617521306599542e-09
five O 0 1.004105154578383e-08
polymorphic O 0 2.2767162590753287e-06
markers O 0 8.808203347143717e-06
. O 0 9.994821539294207e-07

Fourteen O 0 4.485032604861772e-06
microsatellite O 0 2.2205042114364915e-05
polymorphisms O 0 4.945140972267836e-06
were O 0 1.5180878776277495e-08
selected O 0 1.9618733304582747e-09
based O 0 1.772377800079994e-09
on O 0 1.7283908748666477e-09
their O 0 1.4566728934184425e-09
high O 0 4.2307636505256596e-08
heterozygosity O 0 1.0200516271652305e-06
and O 0 3.0437365960978013e-09
their O 0 8.642658810842363e-10
location O 0 2.8568525323180438e-08
within O 0 4.95345542361747e-09
10q23 O 0 1.522590423519432e-06
- O 0 4.73067711936892e-06
q25 O 0 3.653392241176334e-06
near O 0 2.915523396040953e-07
COL17A1 O 0 2.1892816221225075e-05
. O 0 6.87482724970323e-07

Three O 0 8.074740094343724e-07
families O 0 1.969966803017087e-07
shared O 0 1.128779274495173e-07
microsatellite O 0 7.546232609456638e-06
polymorphisms O 0 4.349606570031028e-06
covering O 0 2.1086580659357423e-07
at O 0 1.1961104995350524e-08
most O 0 7.565311710422407e-10
19 O 0 1.366417201609238e-09
cM O 0 7.765993181862996e-09
, O 0 4.670535624917704e-10
whereas O 0 2.866348047803058e-09
the O 0 4.600722303127469e-10
others O 0 1.568877583402184e-09
shared O 0 8.616948266038094e-10
smaller O 0 7.851663319513591e-09
regions O 0 1.7382104644525498e-08
consistent O 0 3.700936090922369e-08
with O 0 2.9854901884007745e-10
cross O 0 2.4880106863633955e-08
- O 0 2.1096316515922808e-07
over O 0 1.0832738039923129e-09
events O 0 1.1358394225169377e-09
during O 0 5.061557284413709e-10
passage O 0 7.794124234905553e-10
of O 0 5.4573037061578233e-11
this O 0 3.8868830376515007e-10
mutation O 0 7.98559796066911e-09
through O 0 7.988793515600889e-10
several O 0 3.017004424066272e-09
generations O 0 2.384883259765047e-07
. O 0 2.748519989381748e-07

These O 0 1.3017135813697678e-07
results O 0 9.073914952750783e-08
indicate O 0 4.03750810562542e-08
that O 0 1.1013678857807463e-09
4003delTC O 0 1.0504064817951075e-07
occurs O 0 2.796042508634855e-09
on O 0 5.688463589059722e-10
a O 0 1.8640586851859098e-09
single O 0 3.4594236808516143e-08
ancestral O 0 2.5490953703410923e-07
allele O 0 6.297927029663697e-06
. O 0 1.4191252262207854e-07
. O 0 4.3714450725929055e-07

The O 0 7.1259205469687e-07
haptoglobin O 0 8.640500163892284e-05
- O 0 8.395045369979925e-06
gene O 0 1.8127320799976587e-06
deletion O 0 2.360540975132608e-06
responsible O 0 3.1856521331974363e-07
for O 0 3.458070807482727e-08
anhaptoglobinemia B-Disease 0 3.843256854452193e-05
. O 0 1.6525260662092478e-06

We O 0 1.201868485622981e-06
have O 0 1.3979893687121603e-08
found O 0 2.3835080575906886e-09
an O 0 3.367642831264561e-10
allelic O 0 9.846542070590658e-08
deletion O 0 1.7272917318678083e-07
of O 0 4.6421158583775934e-10
the O 0 1.2823283546126163e-09
haptoglobin O 0 5.17582577685971e-07
( O 0 9.838743153522955e-10
Hp O 0 7.437209070815243e-09
) O 0 1.7430228094195144e-10
gene O 0 2.3968746987179657e-09
from O 0 2.5704402495385636e-10
an O 0 1.9943036111413903e-10
individual O 0 5.0626507430706624e-09
with O 0 8.489607239425823e-09
anhaptoglobinemia B-Disease 0 5.277367017697543e-05
. O 0 6.241569394660473e-07

The O 0 1.9928117467316042e-07
Hp O 0 7.432007009811059e-07
gene O 0 2.4451043145745643e-07
cluster O 0 1.7308569510987581e-07
consists O 0 5.233887989675168e-09
of O 0 5.493818178159415e-10
coding O 0 6.6511292970972136e-06
regions O 0 4.192382618839474e-08
of O 0 1.2393787107711773e-09
the O 0 2.155757128363689e-09
alpha O 0 1.3904504214679037e-08
chain O 0 3.9789333072803856e-07
and O 0 3.3115663544691643e-09
beta O 0 7.482998221064463e-09
chain O 0 4.483910842623118e-08
of O 0 2.2289689538546043e-10
the O 0 9.234978892713741e-10
haptoglobin O 0 1.5025042898741958e-07
gene O 0 7.270443358464718e-09
( O 0 2.4267790554866053e-10
Hp O 0 1.6790684398415578e-09
) O 0 1.4980638951556102e-10
and O 0 2.383497843538862e-10
of O 0 4.7419845827789686e-11
the O 0 3.5680766674595077e-10
alpha O 0 3.6071436948503788e-09
chain O 0 3.31897297201067e-07
and O 0 1.085588285931749e-09
beta O 0 3.1609794781672917e-09
chain O 0 1.5320297919174664e-08
of O 0 1.2964909701373983e-10
the O 0 9.435100478683012e-10
haptoglobin O 0 2.0329241579020163e-06
- O 0 1.533334312853185e-07
related O 0 1.5786248752647225e-08
gene O 0 5.011560944012672e-08
( O 0 7.215621988798659e-10
Hpr O 0 8.434815157443154e-08
) O 0 6.763842819168531e-10
, O 0 1.7777601613033767e-10
in O 0 1.634762741842266e-10
tandem O 0 2.053721992467672e-08
from O 0 7.915610389375161e-10
the O 0 2.806311627523428e-09
5 O 0 1.8370512222531943e-08
side O 0 1.3296038332555327e-06
. O 0 7.581604108963802e-07

Southern O 0 7.083950549713336e-06
blot O 0 3.2938951335381716e-05
and O 0 3.312471363869918e-08
PCR O 0 5.52499614059343e-07
analyses O 0 4.6005514064972886e-08
have O 0 1.3017942279702766e-09
indicated O 0 2.457804182398604e-09
that O 0 1.0072941092342802e-10
the O 0 2.8809959626285853e-11
individual O 0 1.401776889009554e-10
with O 0 1.5563857147515847e-10
anhaptoglobinemia B-Disease 0 1.2455224407403875e-07
was O 0 2.4287805100442483e-09
homozygous O 0 2.293899648009301e-08
for O 0 9.356084657019537e-11
the O 0 4.1641804587877473e-11
gene O 0 4.745499992964142e-09
deletion O 0 7.66114212069624e-08
and O 0 1.5213392767776668e-09
that O 0 1.0392234989220483e-10
the O 0 1.0575657710676367e-10
gene O 0 2.5435444861443557e-09
deletion O 0 5.310920769829863e-08
was O 0 1.6816679160314152e-09
included O 0 1.2320082454220227e-10
at O 0 3.086181865619153e-10
least O 0 5.5178004526590385e-11
from O 0 1.1159834861773632e-10
the O 0 3.8300249083356164e-10
promoter O 0 8.573528731403712e-08
region O 0 2.706284263354064e-08
of O 0 5.670340863517254e-10
Hp O 0 4.22148609402484e-08
to O 0 1.5572861888912826e-09
Hpr O 0 2.6404040909255855e-07
alpha O 0 4.608936787775519e-09
but O 0 4.9679131919333486e-09
not O 0 2.3319517428177505e-09
to O 0 4.195459979428051e-09
Hpr O 0 1.3721684126721811e-06
beta O 0 9.521342292373447e-08
( O 0 7.181971906078388e-09
Hpdel O 0 2.4265282263513654e-06
) O 0 9.745665607852061e-08
. O 0 3.031383641882712e-07

In O 0 2.334752302601828e-08
addition O 0 7.108976074476914e-09
, O 0 9.186140736971993e-10
we O 0 8.420645292162021e-10
found O 0 1.710881852856616e-10
seven O 0 8.197447581848039e-11
individuals O 0 3.548927818286529e-11
with O 0 2.6115897638900876e-11
hypohaptoglobinemia B-Disease 0 4.8232038807327626e-08
in O 0 2.1201573829898734e-10
three O 0 1.8022633385683662e-10
families O 0 1.83701068245945e-10
, O 0 4.4421924472182184e-11
and O 0 9.800717182262275e-11
the O 0 6.903153049186983e-11
genotypes O 0 1.0007630280028934e-08
of O 0 2.0735687472628328e-11
six O 0 1.2481317368528977e-10
of O 0 5.94692741232028e-12
the O 0 3.6826156707414626e-11
seven O 0 1.1875642136338627e-10
individuals O 0 9.673204598437124e-11
were O 0 1.7327470014372182e-10
found O 0 1.8912180155261638e-10
to O 0 2.8996141598902625e-10
be O 0 4.06603062330646e-09
Hp2 O 0 1.1082719311161782e-06
/ O 0 9.53477865550667e-07
Hpdel O 0 8.606682968093082e-06
. O 0 4.3470626565067505e-07

The O 0 1.559127298378371e-07
phenotypes O 0 1.0356438906455878e-06
and O 0 1.781669034528477e-08
genotypes O 0 1.7211880276590819e-07
in O 0 6.136727237482376e-10
one O 0 3.38393285614913e-10
of O 0 1.9686259566942255e-11
these O 0 1.6309038841644252e-10
three O 0 1.5461217028889251e-10
families O 0 3.6639880018896065e-10
showed O 0 2.3435717810826873e-09
the O 0 8.458807959632608e-11
father O 0 1.5770741379483866e-09
to O 0 2.812322041911841e-10
be O 0 7.378934685497995e-10
hypohaptoglobinemic B-Disease 0 6.868359037071059e-08
( O 0 2.794559028629351e-10
Hp2 O 0 2.639527352243931e-08
) O 0 3.761752853659317e-10
and O 0 4.902565020614702e-10
Hp2 O 0 9.951955348697084e-08
/ O 0 2.8846569577467562e-08
Hpdel O 0 1.204809478849711e-07
, O 0 4.298326694573973e-10
the O 0 1.6279763648263668e-10
mother O 0 3.803092951670806e-09
to O 0 1.5332209113427808e-10
be O 0 2.9055602368543987e-10
Hp2 O 0 3.898870915008956e-08
- O 0 3.6926021351746385e-08
1 O 0 8.906297921384976e-10
and O 0 3.4856881270250994e-10
Hp1 O 0 5.217564336135183e-08
/ O 0 4.908808470815984e-09
Hp2 O 0 1.265155269436491e-08
, O 0 6.292746185243558e-11
one O 0 4.170157968941268e-11
of O 0 4.38461289845038e-12
the O 0 1.5952943827057808e-11
two O 0 6.897652587989356e-11
children O 0 1.2045366093449417e-10
to O 0 8.061742245990544e-11
be O 0 3.866076903058513e-10
hypohaptoglobinemic B-Disease 0 1.9708004117546807e-08
( O 0 2.2178579806020338e-10
Hp2 O 0 1.9949103702288085e-08
) O 0 4.1988285071070663e-10
and O 0 5.17259290955252e-10
Hp2 O 0 4.466088654453415e-08
/ O 0 1.6911833711219515e-08
Hpdel O 0 7.451752281895097e-08
, O 0 2.8015931241576197e-10
and O 0 1.1882529682427645e-10
the O 0 3.620373792423415e-11
other O 0 7.929100431791625e-11
child O 0 7.996019957268174e-10
to O 0 5.918968093432397e-11
be O 0 3.276468818480538e-10
Hp1 O 0 1.8828227865697045e-08
and O 0 6.957882603408905e-10
Hp1 O 0 1.0059572019827101e-07
/ O 0 1.3800824483212182e-08
Hpdel O 0 5.226847221706521e-08
, O 0 2.3085000577793835e-10
showing O 0 7.769193288709175e-09
an O 0 3.561630712578534e-10
anomalous O 0 6.581229428093138e-08
inheritance O 0 2.042370965682494e-07
of O 0 9.643825737981615e-10
Hp O 0 1.2828395767883194e-07
phenotypes O 0 1.549980197523837e-07
in O 0 2.1593535848296597e-09
the O 0 3.119294378350901e-09
child O 0 1.0464471245086315e-07
with O 0 1.9537784723411278e-08
Hp1 O 0 1.7115144146373495e-05
. O 0 7.653363809367875e-07

The O 0 1.7781543704131764e-07
Hp2 O 0 5.824249910801882e-06
/ O 0 1.1551810530363582e-06
Hpdel O 0 8.640192845632555e-07
individuals O 0 7.245966937574622e-09
had O 0 2.40840130061315e-08
an O 0 1.1509020403366321e-09
extremely O 0 6.718294542906733e-08
low O 0 5.105454420117894e-06
level O 0 3.942279391822012e-08
of O 0 3.6142699944008427e-10
Hp O 0 2.4948249688350188e-08
( O 0 3.68926861282759e-10
mean O 0 1.0061449451370663e-08
+ O 0 9.693073366179306e-08
/ O 0 2.393151419255446e-07
- O 0 1.7642843204157543e-06
SD O 0 3.6837172956438735e-05
= O 0 7.227377523122414e-07
0 O 0 1.5894199734134418e-08
. O 0 4.932271036039992e-09
049 O 0 1.2149878330092179e-06
+ O 0 1.9946752161104087e-07
/ O 0 2.0822123758534872e-07
- O 0 3.376870267857157e-07
0 O 0 2.182401281913826e-08
. O 0 3.511259949462442e-09
043 O 0 6.691425937788154e-07
mg O 0 2.447596045840328e-07
/ O 0 1.1740548444549859e-07
ml O 0 3.922763482933078e-07
; O 0 4.453174273777449e-09
n O 0 1.111053506974713e-07
= O 0 6.46751772137577e-08
6 O 0 1.4416312588139135e-09
) O 0 1.8159414250096262e-10
, O 0 4.1626480040690694e-11
compared O 0 5.711000006236588e-10
with O 0 1.1296596297283301e-10
the O 0 1.9499577508241828e-09
level O 0 7.765015297422906e-09
( O 0 1.3156699341099198e-10
1 O 0 4.738315850794095e-10
. O 0 2.3882260058449845e-10
64 O 0 6.508422134565706e-10
+ O 0 1.216409462045931e-08
/ O 0 2.704359580718574e-08
- O 0 1.4910619938746095e-07
1 O 0 7.4216215395495055e-09
. O 0 1.559143703033783e-09
07 O 0 4.030098921248282e-08
mg O 0 7.491540543469455e-08
/ O 0 2.4064590320449497e-08
ml O 0 3.968329309600449e-08
) O 0 1.822655776306803e-10
obtained O 0 6.017194520424596e-10
from O 0 1.8354802400200043e-10
52 O 0 2.9737332596369015e-09
healthy O 0 3.800649128749001e-09
volunteers O 0 2.1655981452539663e-09
having O 0 8.863596967501053e-09
phenotype O 0 2.4528605990781216e-07
Hp2 O 0 1.8415947522498755e-07
, O 0 6.474398239753043e-10
whereas O 0 3.4524607617214542e-09
the O 0 4.926374308489301e-10
serum O 0 5.2888633916836625e-08
Hp O 0 2.1402264849257335e-08
level O 0 2.2061301674369815e-09
of O 0 3.0021856528561486e-11
an O 0 9.70136401767796e-11
individual O 0 9.720799720724926e-10
with O 0 1.3095743378599423e-09
Hp1 O 0 1.7558229501446476e-06
/ O 0 2.303080464116647e-07
Hpdel O 0 1.219564069288026e-06
was O 0 7.199077600716919e-08
0 O 0 7.741180496623201e-08
. O 0 1.0143769912929201e-07

50 O 0 2.4648156795592513e-06
mg O 0 3.866707629640587e-06
/ O 0 1.1844095979540725e-06
ml O 0 4.854769031226169e-06
, O 0 1.8186667727349004e-09
which O 0 2.6357915849928304e-10
was O 0 3.3943209354347914e-10
approximately O 0 1.0750460938124817e-10
half O 0 1.1745667771734247e-09
the O 0 2.2574724034551963e-10
level O 0 1.3416224797779819e-09
of O 0 6.469716429258199e-11
Hp O 0 1.3322011938043943e-08
in O 0 1.1148267864413697e-09
control O 0 1.2738824750613276e-07
sera O 0 6.629558413351333e-08
from O 0 2.78762762873086e-10
the O 0 6.980693245672853e-10
Hp1 O 0 7.87831424986507e-07
phenotype O 0 1.4212217536169192e-07
( O 0 2.2396527687984502e-10
1 O 0 5.544176784333388e-10
. O 0 5.250773704723599e-10
26 O 0 1.021567941350554e-09
+ O 0 1.079975486817375e-08
/ O 0 1.6733114449607456e-08
- O 0 4.454841828760436e-08
0 O 0 4.1802676875590805e-09
. O 0 7.159360326802755e-10
33 O 0 3.3560767498386213e-09
mg O 0 6.179062239652922e-08
/ O 0 2.945200883175403e-08
ml O 0 1.0601766575746296e-07
; O 0 2.133655252478661e-09
n O 0 8.989762534383772e-08
= O 0 1.249810708259247e-07
9 O 0 1.948597061485202e-09
) O 0 2.2356023976488615e-10
, O 0 8.461793071790069e-11
showing O 0 6.41636388465372e-09
a O 0 2.14805306875121e-09
gene O 0 1.572189205489849e-07
- O 0 3.847194875561399e-06
dosage O 0 3.286524588475004e-05
effect O 0 2.1117241431056755e-06
. O 0 4.059461957695021e-07

The O 0 6.572260957682374e-08
other O 0 7.702412929688762e-09
allele O 0 4.0681740642867226e-07
( O 0 3.1144431478224988e-09
Hp2 O 0 1.413874173294971e-07
) O 0 7.572183435833324e-10
of O 0 4.334012315698743e-11
individuals O 0 2.9879285157186075e-10
with O 0 2.3064536391892432e-10
Hp2 O 0 2.1728445176449895e-07
/ O 0 4.7311687012552284e-08
Hpdel O 0 1.9974504539277405e-07
was O 0 3.864339070958067e-09
found O 0 3.1491170782160793e-10
to O 0 7.571962501451424e-11
have O 0 2.4275753629510177e-10
, O 0 4.989987589798517e-11
in O 0 3.6736010067262015e-11
all O 0 4.646630996640866e-11
exons O 0 1.5572425127174938e-08
, O 0 5.823417303929546e-10
no O 0 2.8592932466153798e-09
mutation O 0 2.7915893596741626e-08
, O 0 4.775743134288746e-10
by O 0 1.0896998858811457e-09
DNA O 0 3.338184342283057e-07
sequencing O 0 1.3393779454418109e-06
. O 0 5.335328978617326e-07

On O 0 3.205313703347201e-08
the O 0 2.8497093573776056e-10
basis O 0 4.351027038662636e-10
of O 0 2.0348859749996784e-11
the O 0 7.222199921441685e-11
present O 0 2.6010621434480186e-10
study O 0 4.0711811699623013e-10
, O 0 3.8830574172754595e-11
the O 0 5.140105702183817e-11
mechanism O 0 4.826594679485652e-10
of O 0 2.53635289854115e-11
anhaptoglobinemia B-Disease 0 4.7700037697495645e-08
and O 0 7.460847495366352e-10
the O 0 1.229794183155164e-10
mechanism O 0 1.38861033782689e-09
of O 0 9.192971384130999e-11
anomalous O 0 3.743262055877494e-08
inheritance O 0 1.1259602672453184e-07
of O 0 9.839005166156767e-10
Hp O 0 1.72432919498533e-07
phenotypes O 0 3.566107693586673e-07
were O 0 1.4663132041903282e-08
well O 0 4.1475011869351874e-08
explained O 0 6.089883299864596e-07
. O 0 4.154112787091435e-07

However O 0 5.013698114453291e-07
, O 0 1.0702474462220835e-08
the O 0 2.8326729850647325e-09
mechanism O 0 7.265483503715586e-08
of O 0 1.0581984177804316e-08
hypohaptoglobinemia B-Disease 0 3.3775857446016744e-05
remains O 0 7.002822712820489e-06
unknown O 0 2.190869054174982e-05

ATM O 0 0.000197135959751904
mutations O 0 5.839625373482704e-05
and O 0 1.0736705036151761e-07
phenotypes O 0 1.140794120146893e-05
in O 0 6.54390362342383e-07
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
families O 0 2.4072223823168315e-06
in O 0 2.3149887340423447e-08
the O 0 1.2689301165380584e-08
British O 0 0.0009096685098484159
Isles O 0 5.630238888443273e-07
: O 0 4.01180338949203e-10
expression O 0 2.754867167720221e-10
of O 0 1.5002476691505784e-11
mutant O 0 3.1706588465851837e-09
ATM O 0 2.9158503167536765e-08
and O 0 6.434670574151369e-10
the O 0 1.4666312608824228e-09
risk O 0 2.1924734028289095e-07
of O 0 2.064974413684695e-09
leukemia B-Disease 0 0.16707396507263184
, O 0 1.483676214775187e-06
lymphoma B-Disease 1 1.0
, O 0 4.6878366077862665e-08
and O 0 1.596484594301728e-06
breast B-Disease 1 0.9964421391487122
cancer I-Disease 0 0.00040015229023993015
. O 0 9.87263319984777e-07

We O 0 1.8923943798654363e-06
report O 0 1.796584925273237e-08
the O 0 4.942863895962546e-10
spectrum O 0 9.448306137471718e-09
of O 0 4.002463915853127e-10
59 O 0 4.272217069001272e-08
ATM O 0 1.2513759202192887e-06
mutations O 0 7.168753768382885e-07
observed O 0 2.0181069260161166e-07
in O 0 2.0267978584342927e-07
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.003747625509276986
A B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
) O 0 3.6777990430891805e-08
patients O 0 2.218719075131048e-08
in O 0 8.235832571479307e-10
the O 0 1.1537444777331984e-08
British O 0 7.290979556273669e-05
Isles O 0 1.6308675185428e-05
. O 0 9.217580441145401e-07

Of O 0 2.2249024311804533e-07
51 O 0 1.5942298432491953e-06
ATM O 0 4.574229024001397e-06
mutations O 0 9.063983270607423e-07
identified O 0 4.4555555689385073e-08
in O 0 9.175108450776293e-10
families O 0 7.342866314985486e-10
native O 0 7.623963127478817e-10
to O 0 3.6688271864981914e-10
the O 0 1.1785252773677257e-09
British O 0 5.841221536684316e-06
Isles O 0 1.9499482561968762e-07
, O 0 3.6199201969289163e-10
11 O 0 3.7954964171582617e-10
were O 0 2.394451859011326e-10
founder O 0 1.7025620913102557e-09
mutations O 0 1.1791419396445235e-08
, O 0 1.5803465480690448e-10
and O 0 1.375791841562446e-10
2 O 0 1.1560518514697193e-10
of O 0 8.736442125290012e-12
these O 0 2.0877968798238555e-10
11 O 0 6.668143259780379e-10
conferred O 0 1.7902559434901377e-09
a O 0 8.079079072409456e-10
milder O 0 3.320384962535172e-07
clinical O 0 1.431165742360463e-06
phenotype O 0 1.5275283260507422e-07
with O 0 3.442411633525211e-10
respect O 0 1.2781259384198052e-09
to O 0 2.0892918506376645e-09
both O 0 1.782722769405609e-08
cerebellar B-Disease 0 2.941276216006372e-05
degeneration I-Disease 0 4.74923690489959e-05
and O 0 6.213229397644682e-08
cellular O 0 1.694899196991173e-06
features O 0 3.7214681469777133e-06
. O 0 3.1564650271320716e-06

We O 0 1.9258284282841487e-06
report O 0 2.6201254499369497e-08
, O 0 5.937809133271799e-10
in O 0 2.9369795484512906e-10
two O 0 2.6927118312869425e-08
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
families O 0 9.125685984656684e-09
, O 0 3.9482883629204935e-10
an O 0 4.210946868976606e-10
ATM O 0 7.15293083430879e-07
mutation O 0 1.534279192583199e-07
( O 0 9.813759804799815e-10
7271T O 0 8.248699856494568e-08
- O 0 1.672147647013844e-07
- O 0 5.774083433607302e-08
> O 0 7.161043757974994e-09
G O 0 3.386868030474943e-08
) O 0 1.099625251965719e-10
that O 0 4.815502510635561e-11
may O 0 1.6126576740660425e-09
be O 0 5.568337110850585e-11
associated O 0 5.964776589317822e-11
with O 0 2.1373595601725803e-11
an O 0 1.86373069754886e-10
increased O 0 2.38521007389636e-08
risk O 0 3.169968465499551e-07
of O 0 7.31779747908945e-10
breast B-Disease 0 0.022947898134589195
cancer I-Disease 0 7.105304575816263e-07
in O 0 3.0468599865329793e-10
both O 0 2.177506175371491e-09
homozygotes O 0 8.058900107243971e-07
and O 0 1.7953133424342127e-09
heterozygotes O 0 1.5989560608886677e-07
( O 0 5.446418871457581e-10
relative O 0 4.17301215804855e-08
risk O 0 2.5670531158539234e-06
12 O 0 1.1079607231678779e-09
. O 0 6.940268360011714e-10
7 O 0 1.306577845916479e-09
; O 0 3.3646654351571215e-09
P O 0 6.675376062048599e-05
= O 0 8.444006027730211e-08
. O 0 8.778711646506565e-10
0025 O 0 8.562857090055331e-08
) O 0 1.8674418955644256e-10
, O 0 5.306599257237643e-11
although O 0 2.9801822121200416e-10
there O 0 8.626382941301358e-11
is O 0 9.475783352419498e-11
a O 0 3.9010986108145573e-10
less O 0 2.3384915337487655e-08
severe O 1 0.7201123833656311
A B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
phenotype O 0 4.385008196550189e-06
in O 0 2.743143212580179e-10
terms O 0 5.535047975513407e-10
of O 0 2.302689983135764e-11
the O 0 4.1537276396219625e-10
degree O 0 6.239914540628888e-08
of O 0 4.7963584215438004e-09
cerebellar B-Disease 0 0.0010095098987221718
degeneration I-Disease 0 0.012841615825891495
. O 0 1.6513083664904116e-06

This O 0 5.552531661123794e-07
mutation O 0 2.3731156488793204e-06
( O 0 1.4125569158807139e-08
7271T O 0 7.758059155094088e-07
- O 0 9.500948294771661e-07
- O 0 7.552205261163181e-07
> O 0 5.0157499487113455e-08
G O 0 1.999917031980658e-07
) O 0 8.041750598763997e-10
also O 0 3.381984414740913e-10
allows O 0 3.453282382270828e-10
expression O 0 6.088924919822603e-10
of O 0 2.8366494916887142e-11
full O 0 1.4115838498085509e-09
- O 0 1.2074130140149464e-08
length O 0 5.581751061356499e-09
ATM O 0 4.8109747297075955e-08
protein O 0 2.4719835067799067e-09
at O 0 7.143469149539783e-10
a O 0 1.270910182649132e-10
level O 0 6.985781952906223e-10
comparable O 0 3.4350480238032333e-09
with O 0 2.1930018911930915e-10
that O 0 1.2101721846846658e-09
in O 0 3.6056302388232098e-09
unaffected O 0 7.170613685048011e-07
individuals O 0 5.440786665644737e-08
. O 0 2.0038002901401342e-07

In O 0 1.4351299704173925e-08
addition O 0 5.055220686500661e-09
, O 0 7.341885988054742e-10
we O 0 8.932122819160782e-10
have O 0 3.296678763309302e-10
studied O 0 3.8546680514173204e-08
18 O 0 1.1350690165556898e-08
A B-Disease 1 0.999998927116394
- I-Disease 1 0.9999996423721313
T I-Disease 1 1.0
patients O 0 3.3095321327891725e-07
, O 0 9.382908339183871e-11
in O 0 6.927951268220767e-11
15 O 0 1.2491488399213324e-10
families O 0 7.17264164729059e-11
, O 0 5.576042058641484e-11
who O 0 1.8472501306376898e-09
developed O 0 4.798159352503717e-06
leukemia B-Disease 1 0.7067142724990845
, O 0 1.117596980293456e-06
lymphoma B-Disease 1 1.0
, O 0 6.495131987804825e-09
preleukemic O 0 4.1908424464054406e-06
T O 0 0.00127218512352556
- O 0 8.155163300216373e-07
cell O 0 2.3630313705780281e-07
proliferation O 0 1.496712371817921e-07
, O 0 1.461916920852957e-09
or O 0 3.8474550478895253e-07
Hodgkin B-Disease 1 0.9999997615814209
lymphoma I-Disease 1 1.0
, O 0 4.502247907822721e-09
mostly O 0 7.04193148237664e-09
in O 0 2.8821711239856995e-08
childhood O 0 2.6350362531957217e-06
. O 0 7.659358516320935e-07

A O 0 4.685123542458314e-07
wide O 0 8.031105380723602e-08
variety O 0 2.8055424650119676e-08
of O 0 1.5958012689054613e-09
ATM O 0 1.435238914382353e-06
mutation O 0 3.5655909869092284e-07
types O 0 5.55433317117604e-08
, O 0 1.066176036346178e-09
including O 0 1.0246061776797433e-09
missense O 0 2.4407017917837948e-06
mutations O 0 1.5725490811746567e-06
and O 0 1.062506349569503e-08
in O 0 4.6858406044236744e-09
- O 0 3.080830595081352e-07
frame O 0 1.4165671018417925e-06
deletions O 0 1.5027850963633682e-07
, O 0 2.089933337501293e-09
were O 0 1.3654636310533874e-09
seen O 0 2.1834047458924033e-08
in O 0 3.1518465615221203e-09
these O 0 2.461201731307483e-08
patients O 0 4.7425797333744413e-07
. O 0 1.0489650748013446e-07

We O 0 2.3570602536437946e-07
also O 0 2.0303907444230163e-09
show O 0 3.5502856210456457e-09
that O 0 2.370798002360175e-10
25 O 0 1.1995018867061447e-10
% O 0 6.622497689123819e-11
of O 0 2.673317817114551e-11
all O 0 4.358299321438608e-08
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 6.900576181578799e-07
carried O 0 7.814134228567582e-09
in O 0 1.1932455024066257e-09
- O 0 8.588570210577018e-08
frame O 0 1.0215156862614094e-06
deletions O 0 2.9735599582636496e-07
or O 0 1.2147493677616694e-08
missense O 0 3.7440801747834485e-07
mutations O 0 2.955323985531777e-08
, O 0 9.401610739923072e-11
many O 0 6.58540166842414e-11
of O 0 1.7444851119208238e-11
which O 0 3.80820308620855e-09
were O 0 4.417165300196757e-08
also O 0 9.583266624701992e-09
associated O 0 3.3206553062825606e-09
with O 0 4.852496182650157e-10
expression O 0 7.783788724680107e-09
of O 0 1.1146927825222974e-09
mutant O 0 3.9450259237128193e-07
ATM O 0 3.0065853025007527e-06
protein O 0 1.5627640550519573e-06
. O 0 3.375151038653712e-07

The O 0 1.3693954770133132e-07
DMPK O 0 6.018743533786619e-06
gene O 0 7.40703001156362e-07
of O 0 3.407225790397206e-08
severely O 0 0.0005021459073759615
affected O 0 5.41017880095751e-06
myotonic B-Disease 1 0.9999998807907104
dystrophy I-Disease 1 0.9999998807907104
patients O 0 0.0009318325901404023
is O 0 1.3307460022815576e-08
hypermethylated O 0 4.938779056828935e-07
proximal O 0 2.3057066300680162e-07
to O 0 6.748575920312305e-09
the O 0 5.493820509627767e-09
largely O 0 1.3609303550765617e-07
expanded O 0 5.839996219947352e-07
CTG O 0 2.626565401442349e-05
repeat O 0 1.042526764649665e-05
. O 0 3.7407502873065823e-07

Using O 0 5.786105248262174e-07
methylation O 0 2.1723524241679115e-06
- O 0 6.258977919060271e-06
sensitive O 0 4.5842637064197334e-07
restriction O 0 1.0061718569431832e-08
enzymes O 0 1.491303081024853e-08
, O 0 5.297419169991713e-10
we O 0 6.120829398881256e-10
characterized O 0 1.3012034782988735e-09
the O 0 2.81308393246249e-10
methylation O 0 8.03035149488096e-09
pattern O 0 7.625977360703473e-08
on O 0 2.6684097154117126e-09
the O 0 3.4319225239443085e-10
5 O 0 6.136715580140617e-10
side O 0 3.450492336298794e-09
of O 0 4.7703424543854567e-11
the O 0 5.011298043200441e-10
CTG O 0 2.3093488721315225e-07
repeat O 0 5.860092144871487e-08
in O 0 1.4392677327723646e-10
the O 0 1.0489695917437203e-10
DMPK O 0 2.396272691385093e-08
gene O 0 1.8444442639875547e-09
of O 0 2.1355054877214563e-11
normal O 0 6.807939767483617e-10
individuals O 0 1.0341200812336027e-10
and O 0 1.0555767371300817e-10
of O 0 8.240495091849098e-11
patients O 0 2.1189022092471532e-08
affected O 0 4.50814274799427e-09
with O 0 6.006304342776048e-09
myotonic B-Disease 1 0.9999998807907104
dystrophy I-Disease 1 0.999996542930603
, O 0 3.928481540071971e-09
showing O 0 1.965590001873352e-08
expansions O 0 7.660367629114262e-08
of O 0 7.090677489607344e-10
the O 0 3.6569451911105944e-09
repetitive O 0 4.122447535337415e-06
sequence O 0 2.4875657800293993e-06
. O 0 1.072686472980422e-06

The O 0 1.6762894006205897e-07
gene O 0 7.023476769063564e-07
segment O 0 2.9007631496824615e-07
analyzed O 0 6.471108093819566e-08
corresponds O 0 1.8897630127412413e-08
to O 0 1.0031340202942829e-09
the O 0 1.3044887392510418e-09
genomic O 0 6.413301889551803e-07
SacI O 0 4.827534212381579e-06
- O 0 1.2907663631267496e-06
HindIII O 0 9.197173085340182e-07
fragment O 0 1.8292406878117617e-07
carrying O 0 1.2853654141053994e-08
exons O 0 4.989186663806322e-07
11 O 0 7.524018741378313e-08
- O 0 1.55912584887119e-06
15 O 0 1.7735393953444145e-07
. O 0 6.398365144377749e-07

There O 0 2.4805439124975237e-07
is O 0 9.514185883574555e-09
constitutive O 0 4.2965197621924744e-08
methylation O 0 7.434999105271345e-08
in O 0 2.4782715879467787e-09
intron O 0 1.2253559589225915e-06
12 O 0 9.398321232367834e-09
at O 0 4.5647621793598603e-10
restriction O 0 5.043074846611262e-10
sites O 0 2.0103831932516414e-09
of O 0 9.480446983012314e-11
SacII O 0 8.797508854740954e-08
and O 0 2.5037094619762e-09
HhaI O 0 1.4890129307332245e-07
, O 0 5.293046001497714e-10
localized O 0 1.1126648047365961e-08
1 O 0 1.8923627109757035e-09
, O 0 1.6888575260498584e-10
159 O 0 4.1648839932406645e-09
- O 0 9.153372104719892e-08
1 O 0 2.1711237252475257e-09
, O 0 1.8553140967991766e-10
232 O 0 1.3520804476030435e-09
bp O 0 2.0546153223222063e-08
upstream O 0 1.132516636026537e-09
of O 0 3.770845441453119e-11
the O 0 2.544144894756073e-10
CTG O 0 1.3059660375347448e-07
repeat O 0 5.375164491283613e-08
, O 0 3.561676648056178e-11
whereas O 0 1.496216345264756e-10
most O 0 4.131490982661745e-11
, O 0 3.996442760056951e-11
if O 0 3.070516618741692e-10
not O 0 1.383396452947494e-10
all O 0 1.749516850835242e-11
, O 0 1.1957915560523169e-11
of O 0 2.954613767189307e-12
the O 0 1.0586813543878026e-11
other O 0 4.2941209615898757e-11
sites O 0 6.452909873111423e-10
of O 0 3.948880805682009e-11
SacII O 0 4.0931421807499646e-08
, O 0 1.8315179928229952e-10
HhaI O 0 2.0358905672424044e-08
, O 0 7.418628211741662e-11
and O 0 8.723657907161453e-11
HpaII O 0 1.7338463109695113e-08
in O 0 1.399791671463646e-10
this O 0 2.3861676523573294e-10
region O 0 3.246827251501827e-09
are O 0 2.9796762279765687e-10
unmethylated O 0 8.239940996190853e-08
, O 0 6.363393145747409e-10
in O 0 1.85678694641922e-10
normal O 0 9.076071005864605e-10
individuals O 0 1.6595977370137405e-10
and O 0 1.6361507981788037e-10
most O 0 2.698452017391162e-10
of O 0 2.3985793906611264e-10
the O 0 1.322724063612668e-08
patients O 0 5.924047741245886e-07
. O 0 2.39558772818782e-07

In O 0 4.978929268872889e-08
a O 0 2.274103350075052e-09
number O 0 6.245815531435994e-10
of O 0 1.6220624843299447e-10
young O 0 1.010994488126471e-08
and O 0 8.381135785384686e-09
severely O 0 3.425555405556224e-05
affected O 0 2.0084373275608414e-08
patients O 0 2.8496360826579803e-08
, O 0 1.9071490220401444e-10
however O 0 9.61191126691574e-10
, O 0 1.0048819415464649e-10
complete O 0 1.476012090328993e-10
methylation O 0 2.0878696549431197e-09
of O 0 2.184263533933084e-11
these O 0 5.6120955105321e-11
restriction O 0 5.203069641801505e-10
sites O 0 4.8165547106293616e-09
was O 0 2.765234041746112e-09
found O 0 6.451666978435355e-10
in O 0 3.8762365539568577e-10
the O 0 2.6692599242039705e-09
mutated O 0 1.7807436734074145e-06
allele O 0 1.0566721357463393e-05
. O 0 4.746987087855814e-07

In O 0 3.5287243349557684e-08
most O 0 1.3709701152109233e-09
of O 0 9.485456864410935e-11
these O 0 6.599324975375964e-10
patients O 0 6.528442675346469e-09
, O 0 6.014230780060359e-11
the O 0 1.464159765651729e-10
onset O 0 3.8013254766156024e-08
of O 0 3.567130757442527e-10
the O 0 8.486567537602241e-08
disease O 0 0.0032841346692293882
was O 0 0.00013290930655784905
congenital O 1 0.9975392818450928
. O 0 1.9178976344846888e-06

Preliminary O 0 3.9224742067744955e-06
in O 0 1.4136193726699275e-07
vivo O 0 7.802112122590188e-06
footprinting O 0 2.5743966034497134e-05
data O 0 6.163030974448702e-08
gave O 0 4.25404955706199e-09
evidence O 0 3.1033664527058136e-09
for O 0 1.6002472957854508e-10
protein O 0 4.9229478271684e-09
- O 0 5.0683343744140075e-08
DNA O 0 8.291494424383927e-08
contact O 0 2.5182991691963252e-08
in O 0 2.5476327714102354e-09
normal O 0 2.102521001745572e-08
genes O 0 4.36002842718608e-08
at O 0 8.134593443287486e-09
an O 0 1.3161800538341595e-09
Sp1 O 0 1.4248423951812583e-07
consensus O 0 1.7858972078954594e-09
binding O 0 6.3090128676890345e-09
site O 0 3.0829767627693627e-09
upstream O 0 1.0998690846975023e-09
of O 0 3.234863071854832e-11
the O 0 2.0113602450244628e-10
CTG O 0 1.261228561588723e-07
repeat O 0 6.436394528464007e-08
and O 0 3.1328872829305965e-10
for O 0 3.967309120112006e-11
a O 0 8.05596284125798e-11
significant O 0 1.2738011756496803e-09
reduction O 0 2.216412831046455e-09
of O 0 1.857792045201201e-11
this O 0 1.0041423942341865e-10
interaction O 0 8.151799235633916e-10
in O 0 5.312749129515737e-10
cells O 0 6.820823461595182e-09
with O 0 8.763905157138652e-10
a O 0 1.3508154594887856e-08
hypermethylated O 0 3.576561084628338e-06
DMPK O 0 3.1868144105828833e-06
gene O 0 5.853366360497603e-07
. O 0 8.133014972599995e-08
. O 0 3.152726435473596e-07

The O 0 1.9794895251834532e-06
hemochromatosis B-Disease 1 0.9999200105667114
gene O 0 2.1470234514708864e-06
product O 0 1.9754263291815732e-07
complexes O 0 2.1919424852967495e-07
with O 0 2.8393047912800284e-09
the O 0 4.025026978382584e-09
transferrin O 0 1.127687710322789e-06
receptor O 0 2.1979417397233192e-07
and O 0 1.3389517050654831e-08
lowers O 0 5.220859407017997e-07
its O 0 9.459607541728587e-10
affinity O 0 1.9502525816506022e-08
for O 0 1.6576877648333266e-09
ligand O 0 1.5489901272758289e-07
binding O 0 1.0235675063086092e-06
. O 0 7.234921213239431e-07

We O 0 2.2887440991326002e-06
recently O 0 5.086046712676762e-07
reported O 0 3.159642858463485e-08
the O 0 3.4742517196484357e-10
positional O 0 2.6491406401873974e-08
cloning O 0 1.1614901040957193e-08
of O 0 2.547816124742752e-10
a O 0 1.350938472199914e-09
candidate O 0 5.776550793257229e-08
gene O 0 1.840746563175344e-06
for O 0 6.817900157329859e-06
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
called O 0 0.011525411158800125
HFE O 1 0.9935274720191956
. O 0 8.558172339689918e-06

The O 0 3.8820857639620954e-08
gene O 0 8.968337539272397e-08
product O 0 5.877655340214005e-08
, O 0 9.718055249408053e-10
a O 0 6.377195438389549e-10
member O 0 4.1858824739726685e-10
of O 0 4.15875944792532e-11
the O 0 6.149405429312083e-10
major O 0 2.215982775055636e-08
histocompatibility O 0 9.341080726699147e-07
complex O 0 1.2539007343548292e-07
class O 0 9.506189968533363e-08
I O 0 1.458781895280481e-07
- O 0 1.1929913057429076e-08
like O 0 1.1017650125566547e-09
family O 0 7.623163766901087e-10
, O 0 8.437714416054121e-11
was O 0 9.085944219222597e-10
found O 0 1.4650872182109254e-10
to O 0 7.337780383309678e-11
have O 0 1.2999283871550915e-09
a O 0 1.5571050004936637e-09
mutation O 0 1.4913236157099163e-07
, O 0 2.814003030593426e-09
Cys O 0 1.7509670215076767e-05
- O 0 4.382414715564664e-07
282 O 0 4.0350914787268266e-07
- O 0 2.32395564125909e-06
- O 0 1.0830902965608402e-06
> O 0 1.0496695068695772e-07
Tyr O 0 3.532833261488122e-07
( O 0 6.725673351581918e-10
C282Y O 0 2.2850873193647203e-08
) O 0 3.363136713563364e-10
, O 0 8.816848640069708e-11
in O 0 3.674857362856443e-10
85 O 0 4.130581210404216e-09
% O 0 1.9260237849039186e-09
of O 0 1.9979939924752443e-09
patient O 0 7.889705102570588e-07
chromosomes O 0 4.2904871406790335e-06
. O 0 7.491604492315673e-07

This O 0 1.508546176864911e-07
mutation O 0 1.7699045429253601e-06
eliminates O 0 1.1870239404743188e-06
the O 0 5.560997884401786e-09
ability O 0 2.4130731191007726e-08
of O 0 6.313294331761199e-10
HFE O 0 3.505705763018341e-06
to O 0 2.2797315146760866e-09
associate O 0 8.865744582919888e-09
with O 0 1.479313116448111e-09
beta2 O 0 3.613033641158836e-06
- O 0 1.972212203327217e-06
microglobulin O 0 2.3133989088819362e-06
( O 0 2.9042872551343635e-09
beta2m O 0 3.108451380740007e-07
) O 0 3.5848801704929656e-09
and O 0 2.7044613215565505e-09
prevents O 0 1.0568715680392415e-07
cell O 0 8.785460522631183e-06
- O 0 0.0005318641779012978
surface O 0 1.7918655430548824e-05
expression O 0 4.963074843544746e-06
. O 0 1.303730300605821e-06

A O 0 2.0210960371969122e-07
second O 0 3.133284920409096e-08
mutation O 0 7.182016048545847e-08
that O 0 8.917381277839809e-10
has O 0 3.0505600268071476e-09
no O 0 2.3908977020425937e-09
effect O 0 7.162614945599444e-09
on O 0 1.0969402053362387e-09
beta2m O 0 1.456632787721901e-07
association O 0 5.066357888772188e-10
, O 0 7.902210830135203e-11
H63D O 0 3.816203175688315e-08
, O 0 2.0149543145109305e-10
was O 0 7.224393860916223e-10
found O 0 2.1496708579871182e-10
in O 0 3.437089154956219e-11
eight O 0 1.3056231096264526e-10
out O 0 3.100915080267441e-10
of O 0 8.38734776076322e-11
nine O 0 3.872543619110047e-09
patients O 0 6.151261722209256e-09
heterozygous O 0 1.2418498229749275e-08
for O 0 3.613601085028506e-10
the O 0 3.542466098238606e-09
C282Y O 0 1.8179223388870014e-06
mutant O 0 2.9240177354949992e-06
. O 0 5.373646558837208e-07

In O 0 8.361084979924271e-08
this O 0 4.04435063217079e-09
report O 0 9.67985869237964e-09
, O 0 8.972847465038569e-10
we O 0 1.4560840311261813e-09
demonstrate O 0 3.7019085574740984e-09
in O 0 1.4314331941989167e-09
cultured O 0 2.225598620952951e-07
293 O 0 6.297689481016278e-08
cells O 0 5.153995275009038e-08
overexpressing O 0 8.747861670599377e-07
wild O 0 3.288185723704373e-08
- O 0 1.3371303566600545e-06
type O 0 1.152453137365228e-06
or O 0 2.710970115060718e-08
mutant O 0 2.7134851166010776e-07
HFE O 0 1.100364897865802e-06
proteins O 0 3.3889082651228364e-09
that O 0 1.4214690535752084e-10
both O 0 1.1340788724778506e-10
the O 0 1.404201199761701e-10
wild O 0 6.311251077306679e-09
- O 0 3.882614691974595e-06
type O 0 1.2675724065047689e-05
and O 0 2.7935334045992022e-08
H63D O 0 7.321947578020627e-06
HFE O 0 5.127441454533255e-06
proteins O 0 1.427812712506693e-08
form O 0 2.502068596754725e-08
stable O 0 2.2088933349095896e-08
complexes O 0 3.543136983807926e-08
with O 0 1.4167870210357592e-09
the O 0 1.3768774564937303e-08
transferrin O 0 6.806342298659729e-06
receptor O 0 1.6224080354731996e-06
( O 0 5.8798082847033584e-08
TfR O 0 2.5092022042372264e-05
) O 0 1.7182489386868838e-07
. O 0 5.633053206111072e-07

The O 0 2.37059282426344e-07
C282Y O 0 4.879150310443947e-06
mutation O 0 1.0315462759535876e-06
nearly O 0 3.678914239912956e-08
completely O 0 1.2079041766810406e-07
prevents O 0 4.3337376354202206e-08
the O 0 1.4896449629375752e-09
association O 0 1.4120820068797002e-09
of O 0 1.2109035996132889e-10
the O 0 2.6301583133658823e-09
mutant O 0 4.89373235268431e-07
HFE O 0 3.4222236990899546e-06
protein O 0 5.4979743424610206e-08
with O 0 3.4332532372616242e-09
the O 0 7.637434151774869e-08
TfR O 0 0.00030615695868618786
. O 0 9.871200745692477e-07

Studies O 0 2.4026126084208954e-06
on O 0 5.047150253290056e-08
cell O 0 1.52746406456572e-06
- O 0 2.157244580303086e-06
associated O 0 6.039702071802822e-08
transferrin O 0 3.62397258868441e-07
at O 0 4.542192399981104e-09
37 O 0 2.6085804627484777e-09
degrees O 0 3.0357892200072456e-08
C O 0 6.544091490923165e-08
suggest O 0 3.871598153182276e-09
that O 0 3.893167177526635e-10
the O 0 6.415675768423057e-10
overexpressed O 0 2.7958233772551466e-07
wild O 0 2.6717213330584855e-08
- O 0 1.9771048300754046e-06
type O 0 6.020449063726119e-07
HFE O 0 6.495266916317632e-06
protein O 0 5.0808299789650846e-08
decreases O 0 3.388237601598121e-08
the O 0 4.618588012039737e-10
affinity O 0 9.45605815871886e-09
of O 0 7.280652747354566e-10
the O 0 8.626226843944096e-09
TfR O 0 3.422452209633775e-06
for O 0 1.3919787988925236e-08
transferrin O 0 3.98801603296306e-06
. O 0 5.322034439814161e-07

The O 0 4.949170602230879e-07
overexpressed O 0 1.9003131455974653e-05
H63D O 0 3.0750643418286927e-06
protein O 0 5.379420642270816e-08
does O 0 8.357525338453797e-09
not O 0 7.943635749185773e-10
have O 0 1.1424831219963849e-10
this O 0 5.595934479685205e-11
effect O 0 1.9015273799993793e-09
, O 0 5.1724229066518745e-11
providing O 0 5.4453466041826104e-11
the O 0 2.4617334212773123e-11
first O 0 1.3190695757892001e-10
direct O 0 1.8657259071019894e-10
evidence O 0 2.5287423266462383e-09
for O 0 3.2574884456515463e-10
a O 0 2.071700588857084e-09
functional O 0 1.6671955904712377e-07
consequence O 0 4.890783245059538e-08
of O 0 4.6009857035400614e-10
the O 0 1.1053018056372821e-08
H63D O 0 5.320689160726033e-05
mutation O 0 6.963783562241588e-06
. O 0 3.675071695852239e-07

Addition O 0 2.3171450891368295e-07
of O 0 8.516935601221576e-09
soluble O 0 7.78463572714827e-07
wild O 0 1.2358697176750866e-07
- O 0 2.7160944227944128e-05
type O 0 3.315223511890508e-05
HFE O 0 0.026533758267760277
/ O 0 3.026330887223594e-06
beta2m O 0 1.191259570987313e-06
heterodimers O 0 3.7072601344334544e-07
to O 0 1.6185526252598947e-09
cultured O 0 5.821967974384279e-08
cells O 0 1.3999719605806149e-08
also O 0 1.4887444610423017e-09
decreased O 0 5.71822944550604e-09
the O 0 1.7630878701435648e-10
apparent O 0 3.933324776994596e-09
affinity O 0 5.593218777022457e-09
of O 0 7.130724483106476e-11
the O 0 5.836371386180872e-10
TfR O 0 9.46456069073065e-08
for O 0 3.690604072348336e-11
its O 0 4.48722344004171e-11
ligand O 0 1.4005507864567335e-09
under O 0 2.093155787585843e-10
steady O 0 7.683235381250597e-09
- O 0 7.708295157726752e-08
state O 0 3.163935113903449e-09
conditions O 0 1.1329579940877466e-08
, O 0 8.958205011122544e-11
both O 0 2.3226377765528383e-10
in O 0 6.175003841590865e-10
293 O 0 1.2275245708792681e-08
cells O 0 1.2680083649740936e-08
and O 0 4.440824596940729e-09
in O 0 9.592025840277074e-09
HeLa O 0 4.196368990960764e-06
cells O 0 1.1874406027345685e-06
. O 0 3.24577058563591e-07

Furthermore O 0 1.1738079592760187e-06
, O 0 5.706778161140846e-09
at O 0 1.3105413421143908e-09
4 O 0 8.755384195424654e-10
degrees O 0 3.710060525463632e-08
C O 0 8.752709845794016e-07
, O 0 6.436831068157289e-10
the O 0 1.0110441373001322e-09
added O 0 1.4284146310217238e-08
soluble O 0 1.1658830345595561e-07
complex O 0 1.832061435891319e-08
of O 0 1.4523894309448337e-09
HFE O 0 1.420529679307947e-05
/ O 0 2.8993554224143736e-07
beta2m O 0 3.402985555567284e-07
inhibited O 0 6.43100790398421e-08
binding O 0 1.6508794331571153e-08
of O 0 3.711224660918333e-10
transferrin O 0 1.5197906577668618e-07
to O 0 3.9512055849399985e-09
HeLa O 0 3.326857438423758e-07
cell O 0 1.5738048375624203e-07
TfR O 0 6.964819476706907e-07
in O 0 9.34084365411536e-10
a O 0 4.72903716186579e-09
concentration O 0 2.1813539206050336e-06
- O 0 3.726092018041527e-06
dependent O 0 1.2251607586222235e-06
manner O 0 1.1717031611624407e-06
. O 0 7.46824241559807e-07

Scatchard O 0 2.430332278891001e-05
plots O 0 1.3823977269566967e-06
of O 0 1.7059622603454727e-09
these O 0 1.090535772796386e-09
data O 0 4.723033519837827e-09
indicate O 0 6.349769154923024e-09
that O 0 3.5139982590415286e-10
the O 0 4.503439565706202e-10
added O 0 6.557858256428517e-09
heterodimer O 0 4.825771071637064e-08
substantially O 0 4.2514642473179265e-08
reduced O 0 6.235557847844575e-09
the O 0 2.8373220439803504e-10
affinity O 0 1.4557710592555395e-08
of O 0 9.899941977309368e-10
TfR O 0 2.0121563011343824e-06
for O 0 9.950756663101856e-09
transferrin O 0 7.815641765773762e-06
. O 0 5.689032605005195e-07

These O 0 4.784711222782789e-07
results O 0 3.289917742677062e-07
establish O 0 6.100834326616678e-08
a O 0 6.415372677537334e-09
molecular O 0 1.1230315521970624e-07
link O 0 6.881589342810912e-07
between O 0 2.308471636069953e-08
HFE O 0 0.012857863679528236
and O 0 3.286687189074655e-08
a O 0 1.738070354306842e-09
key O 0 5.065732278097812e-09
protein O 0 1.916675262947365e-09
involved O 0 1.5478249792977294e-09
in O 0 8.761816272517819e-10
iron O 0 2.789205791486893e-05
transport O 0 1.2045492603363073e-08
, O 0 1.6835155491889964e-10
the O 0 1.1819734080376065e-10
TfR O 0 1.5579799139686656e-07
, O 0 1.9400404893676892e-10
and O 0 1.4056374120219317e-10
raise O 0 2.9349916941256993e-10
the O 0 6.060973251065249e-11
possibility O 0 1.0928949967237145e-09
that O 0 1.8615244068431736e-10
alterations O 0 1.0960414797978046e-08
in O 0 2.7137919689224077e-10
this O 0 1.5275901377176382e-10
regulatory O 0 1.0031709685165424e-08
mechanism O 0 2.151242739500958e-09
may O 0 1.3579187774226398e-09
play O 0 2.080907252066666e-10
a O 0 9.892026781033181e-11
role O 0 3.3761402562504372e-09
in O 0 5.83151971156326e-10
the O 0 1.6532293312110369e-09
pathogenesis O 0 4.4635388007918664e-07
of O 0 1.126216915281475e-07
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 4.811387952941004e-06
. O 0 8.638709232400288e-07

Genomic O 0 5.565644460148178e-05
organization O 0 3.5934667153014743e-07
of O 0 8.142230889518487e-09
the O 0 3.6304545147913814e-08
UBE3A O 0 7.189358439063653e-05
/ O 0 7.507613645429956e-06
E6 O 0 7.736833140370436e-06
- O 0 5.0802016630768776e-05
AP O 0 1.8372042177361436e-05
gene O 0 1.5430276789629715e-07
and O 0 6.832920451671498e-09
related O 0 1.2241325464401598e-07
pseudogenes O 0 1.0547190868237521e-05
. O 0 1.7746302773957723e-06

The O 0 1.372099063701171e-06
UBE3A O 0 9.643951489124447e-05
gene O 0 3.3260816962865647e-06
encodes O 0 9.850672313405084e-07
the O 0 5.1705765002907356e-08
E6 O 0 5.575206159846857e-06
- O 0 6.221124203875661e-05
AP O 0 1.4381997061718721e-05
ubiquitin O 0 5.319112119650526e-07
- O 0 7.318167405401255e-08
protein O 0 3.766823741813141e-09
ligase O 0 5.1278994384063026e-09
and O 0 4.1437253628373583e-10
has O 0 2.4516974561628047e-10
recently O 0 2.1994663867985764e-09
been O 0 1.551379857911428e-10
shown O 0 1.0652283222167824e-10
to O 0 6.344193920204688e-11
be O 0 6.506746808021546e-10
mutated O 0 7.842205036467931e-07
in O 0 5.1929178880527616e-05
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 2.816010055539664e-05
who O 0 2.7685972625590693e-08
lack O 0 3.7770561789329804e-08
15q11 O 0 1.537497155368328e-06
- O 0 1.7864504116005264e-06
q13 O 0 1.3608113249574671e-06
deletions O 0 1.4463506659012637e-06
or O 0 3.5382649343773664e-07
chromosome O 0 7.012575952103361e-05
15 O 0 3.9076039115570893e-07
paternal O 0 1.8958780856337398e-05
uniparental B-Disease 0 0.014951354824006557
disomy I-Disease 0 0.0014447998255491257
. O 0 7.476126938854577e-06

Previous O 0 6.325574759102892e-06
UBE3A O 0 7.78082394390367e-05
cDNA O 0 2.9709312912018504e-06
analysis O 0 5.787633767795342e-07
has O 0 2.577192859121169e-08
shown O 0 1.790376202848165e-08
a O 0 6.228687343678985e-09
coding O 0 1.2579771464515943e-06
region O 0 5.821579307507818e-08
of O 0 8.870932322047054e-10
approximately O 0 1.4900237488291168e-08
2 O 0 1.4270318615672295e-07
. O 0 2.996652597175853e-07

6 O 0 2.059918642771663e-06
kb O 0 7.888374966569245e-06
and O 0 2.276543398238573e-08
a O 0 1.3461961323457672e-08
3 O 0 9.981649640167234e-08
- O 0 0.00035373371792957187
untranslated O 0 0.11219959706068039
region O 0 1.4068158407098963e-06
( O 0 5.007621872721302e-09
UTR O 0 2.7294777282804716e-07
) O 0 9.430854985836845e-10
of O 0 1.1023131019083365e-10
< O 0 1.8530172951614077e-08
50 O 0 1.3134916487800297e-09
bp O 0 6.645637284918848e-08
, O 0 2.0333157380036937e-10
whereas O 0 1.7771677462974367e-09
Northern O 0 4.498333705527102e-09
analysis O 0 6.78194709280433e-08
has O 0 1.1806385202817182e-08
indicated O 0 4.992134705616991e-09
mRNA O 0 3.7207310565889884e-09
sizes O 0 9.631515140995361e-09
of O 0 2.3440133167795807e-10
5 O 0 5.481710196875156e-09
- O 0 1.086537508854235e-06
8 O 0 8.836288856173269e-08
kb O 0 1.0050038326880895e-05
. O 0 3.990234347384103e-07

We O 0 4.975597107659269e-07
have O 0 7.007430635752598e-09
analyzed O 0 1.3470256909897671e-08
additional O 0 1.1229555063607677e-09
cDNA O 0 2.235382901005778e-08
clones O 0 2.770171292354462e-08
and O 0 9.0742358072049e-10
provide O 0 5.06757524831869e-10
evidence O 0 1.1624291529344077e-09
for O 0 1.8689635949975525e-10
an O 0 2.3361354517525967e-10
additional O 0 1.680232308842733e-08
0 O 0 1.3845730961747904e-07
. O 0 1.7637734117670334e-07

5 O 0 1.1765021099563455e-06
kb O 0 3.307961605969467e-06
of O 0 6.124429408060905e-09
5 O 0 4.841222178697535e-08
- O 0 1.0972044037771411e-06
UTR O 0 6.409580237232149e-06
and O 0 1.4545248561148583e-08
> O 0 3.6605758424457235e-08
2 O 0 5.0417399144464525e-09
kb O 0 2.3986075348148006e-07
of O 0 1.890122502956615e-09
3 O 0 1.6145548897839035e-07
- O 0 3.3703105145832524e-05
UTR O 0 0.00016753781528677791
. O 0 7.230424330373353e-07

We O 0 7.065989962029562e-07
have O 0 5.855284701539176e-09
established O 0 5.069733521878561e-09
the O 0 6.204767810658041e-10
genomic O 0 1.2442734487194684e-07
organization O 0 5.416306958494488e-09
of O 0 2.6907120975749876e-10
UBE3A O 0 4.796301595888508e-07
and O 0 1.3962112577203811e-09
the O 0 1.3297296597158947e-10
sequence O 0 3.074925425394781e-09
of O 0 1.1736575045162567e-09
intron O 0 1.4553009350493085e-05
- O 0 5.619597686745692e-06
exon O 0 6.094140189816244e-06
borders O 0 4.956953944201814e-06
. O 0 9.363020581076853e-07

We O 0 3.6923418633705296e-07
have O 0 4.341694559428788e-09
also O 0 5.652264767341819e-10
mapped O 0 4.1518223525827125e-08
two O 0 1.8508545807094379e-09
highly O 0 7.988736783204331e-09
homologous O 0 3.467899389875129e-08
processed O 0 1.8502836596212546e-08
pseudogenes O 0 1.2400053606143047e-07
, O 0 1.523822290572241e-09
UBE3AP1 O 0 1.284226414099976e-07
and O 0 8.044910848603593e-10
UBE3AP2 O 0 8.80692780924619e-08
, O 0 2.0822929491792763e-10
to O 0 8.030220932653265e-11
chromosomes O 0 2.1341231004612382e-09
2 O 0 8.013699703823818e-10
and O 0 3.196299336316599e-10
21 O 0 2.1233988178881447e-10
, O 0 3.203884380020838e-11
respectively O 0 1.7060923784839588e-09
, O 0 3.258333325373286e-10
and O 0 1.2316445641147311e-09
determined O 0 2.3355362088750553e-08
their O 0 2.8720119615854856e-09
genomic O 0 5.361812327464577e-07
organization O 0 1.7240957106423593e-07
. O 0 2.945280641597492e-07

These O 0 5.0675225793384016e-08
results O 0 4.888227778110377e-08
will O 0 4.276142218095913e-10
form O 0 3.321939390232842e-10
the O 0 5.190310334302062e-11
basis O 0 4.0160677561296154e-10
for O 0 2.21721918602924e-10
studies O 0 3.5848388701964495e-09
of O 0 8.254684435993198e-11
mutation O 0 5.5037975954519425e-08
and O 0 7.134717705525873e-09
imprinting O 0 1.4053260883883922e-06
of O 0 2.9387477340492296e-08
UBE3A O 0 0.00014918488159310073
. O 0 1.2760228855768219e-06

Mutation O 0 7.475007441826165e-05
spectrum O 0 4.912702479487052e-06
and O 0 4.235208450609207e-07
genotype O 0 0.039954978972673416
- O 0 0.1453588455915451
phenotype O 0 0.00012244938989169896
analyses O 0 1.1519631470946479e-06
in O 0 2.8924970862931332e-08
Cowden B-Disease 0 0.0012042461894452572
disease I-Disease 0 1.2752971997542772e-05
and O 0 4.201925207780732e-08
Bannayan B-Disease 1 0.7172769904136658
- I-Disease 1 0.9999785423278809
Zonana I-Disease 1 0.9999665021896362
syndrome I-Disease 1 0.9999912977218628
, O 0 1.8451981276257357e-08
two O 0 7.75664048546787e-08
hamartoma B-Disease 1 0.8576399683952332
syndromes I-Disease 1 0.6501363515853882
with O 0 3.356713023094926e-07
germline O 0 0.0013790545053780079
PTEN O 0 0.005228092428296804
mutation O 0 0.00042645575013011694
. O 0 5.483027052832767e-06

The O 0 1.111727124225581e-05
tumour B-Disease 1 0.9999982118606567
suppressor O 0 4.9625108658801764e-05
gene O 0 7.221566647785949e-06
PTEN O 0 4.9231712182518095e-05
, O 0 2.4169146684016596e-08
which O 0 4.158120958663858e-09
maps O 0 1.7975862931507436e-07
to O 0 5.150771542616894e-08
10q23 O 0 1.1713696039805654e-05
. O 0 1.0314911378372926e-06

3 O 0 9.007628136714629e-07
and O 0 2.0724012728123853e-08
encodes O 0 2.2449482628417172e-07
a O 0 3.3137158794716015e-08
403 O 0 1.315339375196345e-07
amino O 0 3.773945707052917e-07
acid O 0 9.80103550318745e-07
dual O 0 4.410011570143979e-06
specificity O 0 2.2406520656659268e-06
phosphatase O 0 0.0004915269673801959
( O 0 1.8491089548433592e-08
protein O 0 4.07332940710603e-08
tyrosine O 0 2.1621083590162016e-07
phosphatase O 0 4.350465133029502e-06
; O 0 4.922910079585563e-09
PTPase O 0 1.1355587758998809e-07
) O 0 7.766166598699442e-10
, O 0 1.0832752750378205e-10
was O 0 3.9959877073947325e-10
shown O 0 5.413411940935475e-10
recently O 0 3.5957408162090587e-09
to O 0 1.1692953549857776e-10
play O 0 9.68382485311281e-10
a O 0 4.509129736263162e-10
broad O 0 1.1087962548117503e-08
role O 0 9.451607496657743e-08
in O 0 1.844329133859901e-08
human O 0 1.0825125684732484e-07
malignancy B-Disease 0 0.0006289099110290408
. O 0 5.386766019910283e-07

Somatic O 0 0.00042209384264424443
PTEN O 0 0.0004026936658192426
deletions O 0 8.924005669541657e-06
and O 0 9.596348604645755e-08
mutations O 0 3.720616348346084e-07
were O 0 2.359629158732446e-09
observed O 0 7.3614225826190705e-09
in O 0 2.823540734553376e-09
sporadic B-Disease 0 1.9115388568025082e-05
breast I-Disease 1 0.9975224137306213
, I-Disease 0 2.4865732584089528e-08
brain I-Disease 0 4.1568942833691835e-05
, I-Disease 0 1.4489896393854451e-08
prostate I-Disease 0 0.0002809327270369977
and I-Disease 0 2.044577058768482e-07
kidney I-Disease 0 2.2695629013469443e-05
cancer I-Disease 0 2.0035795387229882e-06
cell O 0 2.532668759158696e-07
lines O 0 1.5552232071058825e-06
and O 0 2.0642458853359358e-09
in O 0 2.386768560569408e-10
several O 0 2.0448169824049955e-09
primary O 0 0.0008212880347855389
tumours B-Disease 1 1.0
such O 0 6.685517028870436e-09
as O 0 9.778565868145961e-08
endometrial B-Disease 1 0.9986770749092102
carcinomas I-Disease 1 1.0
, O 0 0.0062520988285541534
malignant B-Disease 1 1.0
melanoma I-Disease 1 1.0
and O 1 0.5838081240653992
thyroid B-Disease 1 0.9999991655349731
tumours I-Disease 1 1.0
. O 0 8.287292075692676e-06

In O 0 8.07486557619086e-08
addition O 0 3.680830573671301e-08
, O 0 3.3698932533354764e-09
PTEN O 0 2.0418676740519004e-06
was O 0 1.750794709209913e-08
identified O 0 7.2628201230884315e-09
as O 0 3.1664448840729165e-10
the O 0 3.116658042756626e-10
susceptibility O 0 4.3300033780724334e-08
gene O 0 3.9620520198013764e-08
for O 0 5.5843387691822954e-09
two O 0 3.7665529362129746e-07
hamartoma B-Disease 1 0.9998852014541626
syndromes I-Disease 1 0.999994158744812
Cowden B-Disease 1 0.9998878240585327
disease I-Disease 0 0.4711247980594635
( O 0 1.772033897395886e-08
CD B-Disease 0 5.904211661800218e-07
; O 0 7.129143142492467e-08
MIM O 0 3.523658597259782e-05
158350 O 0 7.66245648264885e-07
) O 0 3.9087271197502105e-09
and O 0 8.023844699778238e-09
Bannayan B-Disease 0 2.74099347734591e-05
- I-Disease 0 0.00022358258138410747
Zonana I-Disease 0 6.264289550017565e-05
( I-Disease 0 2.038027524520203e-08
BZS I-Disease 0 3.985863713751314e-06
) I-Disease 0 4.151543553376769e-09
or I-Disease 0 5.265930802522689e-09
Ruvalcaba I-Disease 0 6.776775535399793e-06
- I-Disease 0 1.4644882867287379e-05
Riley I-Disease 0 5.384096584748477e-05
- I-Disease 1 0.9873671531677246
Smith I-Disease 1 0.9273954629898071
syndrome I-Disease 1 0.9956216216087341
( O 0 4.920800833474459e-08
MIM O 0 3.503851985442452e-05
153480 O 0 4.384046405903064e-06
) O 0 9.422646485290898e-08
. O 0 3.4374559731986665e-07

Constitutive O 0 3.647825224106782e-06
DNA O 0 8.273301546068978e-07
from O 0 4.235573669575388e-09
37 O 0 6.687149056716635e-09
CD B-Disease 0 1.8770032639281453e-08
families O 0 2.377646080020668e-09
and O 0 1.1488952011973197e-09
seven O 0 3.181812147090568e-09
BZS B-Disease 0 1.8315533907298231e-06
families O 0 4.287897148458342e-09
was O 0 5.781133349813672e-09
screened O 0 2.2007502309406846e-07
for O 0 3.125638770029582e-08
germline O 0 3.446151822572574e-05
PTEN O 0 0.000322337553370744
mutations O 0 7.462451321771368e-05
. O 0 2.2623878521699226e-06

PTEN O 0 0.0003213590243831277
mutations O 0 1.2192245776532218e-05
were O 0 2.3294367323956067e-08
identified O 0 8.44841618885539e-09
in O 0 3.6115754831200775e-10
30 O 0 3.6689254412358707e-10
of O 0 7.578681432418577e-11
37 O 0 2.2813106959063134e-09
( O 0 4.1496733826917875e-10
81 O 0 4.8211870051773076e-09
% O 0 9.662201039262186e-10
) O 0 4.447400225870979e-10
CD B-Disease 0 1.6287916793089607e-08
families O 0 8.41594016698366e-10
, O 0 1.4729689690184955e-10
including O 0 3.636265177853204e-10
missense O 0 1.489386590947106e-06
and O 0 1.8041774296762014e-08
nonsense O 0 6.575621114279784e-07
point O 0 8.489529790267625e-08
mutations O 0 1.245402359018044e-07
, O 0 3.607286136464438e-10
deletions O 0 2.3218605704755646e-08
, O 0 3.958603445042286e-10
insertions O 0 7.902222165512285e-08
, O 0 2.14004192145012e-09
a O 0 3.4717229091540958e-09
deletion O 0 2.44863281295693e-06
/ O 0 5.810873631162394e-07
insertion O 0 8.818751098260691e-07
and O 0 1.0346344225808934e-07
splice O 0 3.64927327609621e-05
site O 0 6.2466888266499154e-06
mutations O 0 3.027251295861788e-05
. O 0 9.762164836502052e-07

These O 0 1.5620861404386233e-07
mutations O 0 5.434873742160562e-07
were O 0 3.6100826772411665e-09
scattered O 0 4.027960631702854e-09
over O 0 2.6348530024478123e-09
the O 0 9.873051265429922e-10
entire O 0 4.471567560671019e-09
length O 0 7.692194436970112e-09
of O 0 9.507573200950858e-11
PTEN O 0 2.30995226502273e-07
, O 0 1.4043725904411275e-10
with O 0 1.1877492045453408e-11
the O 0 3.00547399467721e-11
exception O 0 5.797914925942393e-10
of O 0 1.0914481991808334e-11
the O 0 1.2296511031628654e-10
first O 0 4.856905544414758e-09
, O 0 8.13905887131483e-10
fourth O 0 1.0118877291631634e-08
and O 0 5.303528283207015e-09
last O 0 2.9552507996299937e-08
exons O 0 1.8781529433908872e-06
. O 0 3.5214367244407185e-07

A O 0 1.1673309927573428e-06
hot O 0 1.9872352368111024e-06
spot O 0 9.413957968718023e-07
for O 0 1.1527633958507977e-08
PTEN O 0 8.826325029076543e-06
mutation O 0 5.045292823524505e-07
in O 0 2.610083482679215e-09
CD B-Disease 0 1.509277183231461e-07
was O 0 1.8397370737943675e-08
identified O 0 3.9937493312436345e-09
in O 0 3.5606120829534404e-10
exon O 0 1.7073173097514882e-08
5 O 0 9.462728378650809e-10
that O 0 8.75162303737298e-11
contains O 0 1.7529781792813282e-10
the O 0 3.361635969589827e-10
PTPase O 0 8.637426418545147e-08
core O 0 1.8801600276674435e-08
motif O 0 1.711079455901654e-08
, O 0 1.1205587152618435e-10
with O 0 4.0762376113390175e-11
13 O 0 1.053991408039856e-10
of O 0 1.6393582671914153e-11
30 O 0 3.559898764660119e-10
( O 0 1.1179648873316239e-10
43 O 0 1.7278106723139786e-09
% O 0 8.544283058853352e-10
) O 0 7.305162585957703e-10
CD B-Disease 0 4.817815835167494e-08
mutations O 0 4.9170381544172415e-08
identified O 0 9.793159172488686e-09
in O 0 9.543861256844366e-10
this O 0 3.3078164651811903e-09
exon O 0 3.643566287792055e-06
. O 0 1.0310466223018011e-06

Seven O 0 1.106793661165284e-07
of O 0 2.5800883651783124e-09
30 O 0 4.48264314556468e-09
( O 0 3.979269969089927e-10
23 O 0 1.0946390460730981e-09
% O 0 4.0419498303911894e-10
) O 0 5.271736380763059e-10
were O 0 6.892421078319444e-10
within O 0 1.4540407766716612e-10
the O 0 3.339307719230078e-10
core O 0 1.2315701347631602e-08
motif O 0 1.4649489621376688e-08
, O 0 1.5779851036956671e-10
the O 0 6.174719069385048e-11
majority O 0 1.4221966937455477e-09
( O 0 3.5688983018866693e-11
five O 0 4.522633309522739e-11
of O 0 1.1851716656685607e-11
seven O 0 1.4711665219380166e-10
) O 0 6.197821422748717e-11
of O 0 7.382446216841476e-12
which O 0 2.65236477225983e-09
were O 0 3.769561995881077e-09
missense O 0 2.5676726522760873e-07
mutations O 0 4.6906180273253995e-08
, O 0 3.1686561707822136e-10
possibly O 0 1.0868064226343677e-09
pointing O 0 5.4511923863742595e-09
to O 0 2.680078659000884e-10
the O 0 1.8317100614062554e-10
functional O 0 1.1662360854813869e-08
significance O 0 4.769273864724255e-09
of O 0 1.809506988692533e-10
this O 0 5.919787327002268e-09
region O 0 4.20219777197417e-07
. O 0 7.225502258734195e-07

Germline O 0 0.0017121514538303018
PTEN O 0 0.0003222877567168325
mutations O 0 1.0229302461084444e-05
were O 0 1.7495661808197838e-08
identified O 0 1.1571229308060538e-08
in O 0 2.8629806858582185e-10
four O 0 1.7505123739436357e-10
of O 0 5.27919999382398e-11
seven O 0 7.707493532294052e-10
( O 0 6.515936679107881e-10
57 O 0 1.3705027335220166e-08
% O 0 4.284030463708177e-09
) O 0 1.4611092780114632e-08
BZS B-Disease 0 9.720009984448552e-06
families O 0 2.1366821201240782e-08
studied O 0 5.220460934651783e-07
. O 0 4.272730507182132e-07

Interestingly O 0 3.3395517675671726e-06
, O 0 2.1632873270505115e-08
none O 0 5.44503020449838e-09
of O 0 6.446608524779407e-11
these O 0 5.693847615617642e-10
mutations O 0 1.0589540266892072e-07
was O 0 9.2856389244389e-09
observed O 0 6.9547687608917386e-09
in O 0 1.2156666784335357e-09
the O 0 4.369491879430143e-09
PTPase O 0 2.6327629711886402e-06
core O 0 1.0255813549520099e-06
motif O 0 7.3116548264806625e-06
. O 0 1.315146619162988e-06

It O 0 1.4736005482518522e-07
is O 0 4.393962527160511e-09
also O 0 1.1099976493511576e-09
worthy O 0 1.896771184561885e-09
of O 0 5.259090038456371e-11
note O 0 8.40550118397232e-09
that O 0 3.3145916567001166e-10
a O 0 5.760206756022512e-10
single O 0 3.279635762964972e-08
nonsense O 0 4.919384082313627e-07
point O 0 3.154151428930163e-08
mutation O 0 4.7935714064806234e-08
, O 0 3.859195740751886e-10
R233X O 0 2.1811985106978682e-08
, O 0 3.819024541051874e-10
was O 0 1.7675637620229168e-09
observed O 0 2.4278263843768855e-09
in O 0 3.152957339658258e-10
the O 0 4.889061933077699e-10
germline O 0 9.616942975299025e-08
DNA O 0 2.2980511715786633e-08
from O 0 2.4281773813861207e-10
two O 0 1.513544289899471e-10
unrelated O 0 9.325610506039084e-09
CD B-Disease 0 5.085697196705041e-08
families O 0 2.4529802633566078e-09
and O 0 2.1866832788930424e-09
one O 0 3.194486097868321e-08
BZS B-Disease 0 3.4610580769367516e-05
family O 0 3.160010919600609e-07
. O 0 3.8349710962393146e-07

Genotype O 1 0.882649838924408
- O 1 0.9270817041397095
phenotype O 0 3.3317490306217223e-05
studies O 0 1.757151864012485e-07
were O 0 1.8328433215586415e-09
not O 0 3.723860109161592e-10
performed O 0 1.078219291628102e-09
on O 0 3.889730482153908e-10
this O 0 4.314022472584611e-10
small O 0 1.3413979260690212e-08
group O 0 3.230878320437114e-08
of O 0 7.592840134407197e-09
BZS B-Disease 0 6.448904605349526e-05
families O 0 2.2892629658599617e-07
. O 0 1.7886189596083568e-07

However O 0 7.447701477758528e-07
, O 0 4.6456989366561174e-08
genotype O 0 2.9328399250516668e-05
- O 0 2.907206908275839e-05
phenotype O 0 6.9100656219234224e-06
analysis O 0 1.0049964771496889e-07
inthe O 0 1.0182164942307281e-06
group O 0 3.0152399688176956e-08
of O 0 2.249821162703114e-10
CD B-Disease 0 3.4105028134945314e-08
families O 0 1.5511586459737714e-09
revealed O 0 3.712706142522393e-09
two O 0 1.5300861966327517e-10
possible O 0 1.0935664596090078e-09
associations O 0 7.56793849809867e-10
worthy O 0 1.31531940894547e-09
of O 0 5.881425901854698e-11
follow O 0 2.913186136765944e-09
- O 0 3.506350196857966e-07
up O 0 7.490151610056728e-09
in O 0 3.672427695278202e-09
independent O 0 1.2191485154744441e-07
analyses O 0 1.4486491863863193e-06
. O 0 2.511507375402289e-07

The O 0 3.161831330089626e-08
first O 0 3.489522981681148e-08
was O 0 3.582660212941846e-08
an O 0 1.4842922724245255e-10
association O 0 4.918506157913782e-10
noted O 0 1.5798530261790233e-09
in O 0 2.6305832512285576e-10
the O 0 5.98682325936295e-10
group O 0 3.3104485819279716e-09
of O 0 6.390074580586713e-11
CD B-Disease 0 7.561250470189407e-08
families O 0 6.9990422346677406e-09
with O 0 2.353458938841868e-08
breast B-Disease 1 0.999496579170227
disease I-Disease 0 7.099549839040264e-05
. O 0 6.355078312481055e-07

A O 0 2.700880656902882e-07
correlation O 0 8.987514092950732e-07
was O 0 2.1726078713868446e-08
observed O 0 5.016340232089078e-09
between O 0 4.3783163206079223e-10
the O 0 4.98115604319338e-10
presence O 0 2.183850256187725e-08
/ O 0 1.7808034158406372e-07
absence O 0 5.448302697885765e-09
of O 0 1.306664498823551e-10
a O 0 2.094011408715346e-09
PTEN O 0 1.4002918078404036e-06
mutation O 0 1.1676990396836118e-07
and O 0 6.456775669683168e-10
the O 0 3.3929681286792857e-10
type O 0 8.245679339324852e-08
of O 0 2.6324769031305095e-09
breast O 0 0.00018046850163955241
involvement O 0 3.397278760530753e-07
( O 0 6.251515749511327e-09
unaffected O 0 1.1033217788281036e-06
versus O 0 2.074143367281067e-06
benign O 0 0.00017633660172577947
versus O 0 3.745431240531616e-05
malignant O 0 0.29276230931282043
) O 0 2.5540862225170713e-07
. O 0 8.311078545375494e-07

Specifically O 0 1.9434169473697693e-07
and O 0 3.6816432125164056e-09
more O 0 1.0987405429929709e-10
directly O 0 7.649293420897152e-10
, O 0 3.5522210173333235e-10
an O 0 1.199044474819999e-10
association O 0 5.765053989748026e-10
was O 0 1.1088094709066354e-07
also O 0 9.961195202023987e-10
observed O 0 1.1843005465195233e-09
between O 0 1.2844450503202154e-10
the O 0 1.3140247223653034e-10
presence O 0 1.0486299606426996e-09
of O 0 1.1523204612728932e-10
a O 0 7.1784524990903265e-09
PTEN O 0 6.581291381735355e-05
mutation O 0 7.241448656714056e-06
and O 0 3.769844738599204e-07
malignant B-Disease 1 0.9996743202209473
breast I-Disease 1 0.9999029636383057
disease I-Disease 0 0.028770802542567253
. O 0 2.4978637611638987e-06

Secondly O 0 1.1482754416647367e-05
, O 0 1.2946982153039244e-08
there O 0 2.367211315856821e-09
appeared O 0 6.0484843800168164e-09
to O 0 2.4309299018199226e-10
be O 0 1.2382752601070024e-09
an O 0 4.6498782602100164e-10
interdependent O 0 7.748986377009714e-07
association O 0 2.0820476454019854e-09
between O 0 5.7283672250108e-10
mutations O 0 2.149099209702854e-08
upstream O 0 5.09467534826058e-09
and O 0 5.436693872873377e-10
within O 0 1.5768267247473489e-10
the O 0 7.156357173521144e-10
PTPase O 0 1.5261535679655935e-07
core O 0 3.732639086706513e-08
motif O 0 5.112520895522721e-08
, O 0 7.434539095463322e-10
the O 0 2.847101721048517e-10
core O 0 1.4297421024878076e-08
motif O 0 8.879874613398897e-09
containing O 0 1.2941222538032093e-09
the O 0 5.958741833289594e-10
majority O 0 5.323006480040249e-09
of O 0 1.8665695378228264e-10
missense O 0 4.837668825530272e-07
mutations O 0 1.0510197512303421e-07
, O 0 2.9914981602985335e-10
and O 0 2.057322923132432e-10
the O 0 8.317491140275024e-11
involvement O 0 3.4632707812676244e-09
of O 0 3.597301276303533e-11
all O 0 1.7295738452549614e-10
major O 0 2.9675288892860863e-09
organ O 0 7.947007674147244e-08
systems O 0 3.3344042549288133e-07
( O 0 3.217192900972776e-10
central O 0 5.1982311788378865e-09
nervous O 0 2.2213798729353584e-06
system O 0 3.407980031511215e-08
, O 0 3.4084268740741663e-09
thyroid O 0 3.695363557199016e-05
, O 0 2.9483411267960946e-09
breast O 0 0.001324552926234901
, O 0 8.485628910648302e-08
skin O 1 0.9999088048934937
and O 0 0.003090467769652605
gastrointestinal O 1 0.9856658577919006
tract O 0 0.3066351115703583
) O 0 4.46319830871289e-07
. O 0 8.756659326536465e-07

However O 0 1.572993113541088e-07
, O 0 4.406247033905686e-10
these O 0 6.446780609348224e-11
observations O 0 1.3268978138469834e-09
would O 0 3.7006853137455664e-10
need O 0 1.423199891270599e-10
to O 0 4.4767769352693776e-11
be O 0 1.3119437480835217e-10
confirmed O 0 2.338524929257346e-10
by O 0 1.1964942057962613e-11
studying O 0 7.168638460619547e-10
a O 0 2.1218200807471277e-10
larger O 0 2.0574575376741677e-09
number O 0 1.8652679401043315e-09
of O 0 5.981983242087097e-10
CD B-Disease 0 6.56003066978883e-07
families O 0 7.767091858568165e-08
. O 0 1.8262913670241687e-07

Molecular O 0 0.003484043525531888
defects O 0 0.42691248655319214
leading O 0 1.2780733982253878e-07
to O 0 5.485234932933736e-09
human O 0 1.8247936495185968e-08
complement B-Disease 0 6.940902608221222e-07
component I-Disease 1 0.9816592335700989
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 2.993777226123484e-09
an O 0 6.293649490451969e-10
African O 0 6.584051970293103e-09
- O 0 6.357733468576043e-07
American O 0 9.927139643650662e-08
family O 0 7.354913122981088e-08
. O 0 1.7603485957806697e-07

Complement B-Disease 0 0.000986809958703816
component I-Disease 1 0.9993637204170227
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 5.300335814695245e-08
C6D B-Disease 0 2.7092028176411986e-06
) O 0 1.3138857113403901e-08
was O 0 2.1088229118504387e-07
diagnosed O 0 4.162847289990168e-06
in O 0 6.000244190396131e-10
a O 0 4.976598022565781e-10
16 O 0 1.1402784272362965e-09
- O 0 3.544083071460591e-08
year O 0 7.975597959841707e-09
- O 0 1.413263532867859e-07
old O 0 1.5916457130060735e-07
African O 0 2.716864511143058e-09
- O 0 2.1831672469829755e-08
American O 0 1.2323455145235584e-08
male O 0 8.33412912015774e-08
with O 0 5.531254387847184e-08
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 0.9999998807907104
. O 0 2.42579949372157e-06

The O 0 1.990167959320388e-07
patients O 0 3.8355122455868695e-07
father O 0 1.95613516495996e-08
and O 0 1.2931524739911993e-09
two O 0 3.9178388311356116e-10
brothers O 0 2.3653351277630463e-08
also O 0 1.7177491651310106e-09
had O 0 1.3766613404797567e-09
C6D B-Disease 0 1.0425583241158165e-07
, O 0 7.861065964842595e-11
but O 0 1.8155708880751575e-10
gave O 0 6.191845924874428e-10
no O 0 5.6708704399e-10
history O 0 1.721068065840825e-09
of O 0 1.1413403555593504e-09
meningitis B-Disease 1 0.9999879598617554
or O 0 3.37228698299441e-08
other O 0 1.3364615192301699e-08
neisserial B-Disease 0 0.0008318451000377536
infection I-Disease 0 0.0009313688497059047
. O 0 2.9316024097170157e-07

By O 0 1.99378060727895e-08
using O 0 4.973053790990889e-08
exon O 0 1.8698231087910244e-06
- O 0 9.359539490105817e-07
specific O 0 2.095818452119147e-08
polymerase O 0 3.2996271670526767e-07
chain O 0 6.200443181114679e-07
reaction O 0 8.821890418175826e-08
( O 0 1.3638004059401965e-09
PCR O 0 1.8642093380094593e-07
) O 0 1.903254664981091e-09
/ O 0 2.3976305385531305e-08
single O 0 3.902188794313588e-08
- O 0 5.330339831743913e-07
strand O 0 2.489405233063735e-06
conformation O 0 8.615099744702093e-08
polymorphism O 0 1.6518740153514955e-07
as O 0 1.0661842519965603e-09
a O 0 9.085389107710284e-10
screening O 0 1.5084504312312674e-08
step O 0 4.8299306776300455e-09
and O 0 1.7977760946585875e-10
nucleotide O 0 2.755131234266628e-09
sequencing O 0 1.5810045495001646e-09
of O 0 5.397470317913822e-11
target O 0 2.7608810793111616e-09
exons O 0 1.5228005523226784e-08
, O 0 5.086603915849253e-10
we O 0 4.143843879145237e-10
determined O 0 1.3146697064314594e-09
that O 0 1.292483758907892e-10
the O 0 1.0965547914132401e-10
proband O 0 9.490717900462187e-08
was O 0 5.7426574606722625e-09
a O 0 3.5294073219560573e-10
compound O 0 9.275284540422035e-09
heterozygote O 0 7.698081958551484e-07
for O 0 4.796989472310997e-09
two O 0 1.909655367171581e-08
C6 O 0 1.4158932572172489e-05
gene O 0 3.046810434170766e-06
mutations O 0 1.1056421499233693e-05
. O 0 7.872380365370191e-07

The O 0 5.1286459523680605e-08
first O 0 1.212141054196536e-08
, O 0 6.039074795793908e-10
1195delC O 0 2.940598164968833e-08
located O 0 3.6721545804141442e-09
in O 0 8.170260024087383e-10
exon O 0 1.2262614745850442e-07
7 O 0 7.926991507645198e-09
, O 0 5.32688337884224e-10
is O 0 3.132941128747291e-10
a O 0 3.0491389968467786e-10
novel O 0 5.561602733905602e-09
mutation O 0 2.4294907419175615e-08
, O 0 3.2385560899683696e-10
while O 0 2.784667774147209e-10
the O 0 8.645457266753809e-11
second O 0 1.6818924031269944e-09
, O 0 2.627028317103708e-10
1936delG O 0 8.731373846160295e-09
in O 0 1.2440533325719372e-10
exon O 0 1.180073372353263e-08
12 O 0 6.3341731859623e-10
, O 0 7.44838773991674e-11
has O 0 3.781463753238512e-10
been O 0 2.7249694167785776e-10
described O 0 6.767623683678892e-10
before O 0 9.033516157330723e-10
to O 0 1.8450344030362942e-10
cause O 0 2.0294073088678033e-09
C6D B-Disease 0 9.341617612790287e-08
in O 0 3.8521652534484474e-10
an O 0 2.443593105638797e-10
unrelated O 0 2.375906582585685e-08
African O 0 8.071920909458186e-09
- O 0 2.1746026845903543e-07
American O 0 2.9239092924626675e-08
individual O 0 5.96163474142486e-08
. O 0 2.6347848347541003e-07

Both O 0 3.4856057595789025e-07
mutations O 0 5.311373570293654e-06
result O 0 1.9705416320903169e-07
in O 0 2.7409598146732606e-08
premature O 0 7.691851919844339e-07
termination O 0 7.825948387107928e-07
codons O 0 3.850846951536369e-06
and O 0 2.118684392371506e-07
C6 O 0 9.878278069663793e-05
null O 0 5.089337355457246e-05
alleles O 0 2.6841011276701465e-05
. O 0 1.704953547232435e-06

Allele O 0 0.00015723163960501552
- O 0 7.1672548074275255e-06
specific O 0 4.3493471935107664e-08
PCR O 0 9.247303864867717e-07
indicated O 0 2.325964842952999e-08
that O 0 3.488049016286965e-10
the O 0 1.4430941164267352e-10
probands O 0 6.912530636782321e-08
two O 0 4.6455259083977296e-10
brothers O 0 2.7189395623850032e-08
also O 0 1.6774424071996918e-09
inherited O 0 8.523814187810785e-08
the O 0 7.745751817722635e-10
1195delC O 0 1.163397271852773e-07
mutation O 0 2.1389329418752823e-08
from O 0 1.5715811985117512e-10
their O 0 4.958765620344252e-10
heterozygous O 0 4.438473055756731e-08
mother O 0 1.9861515099250937e-08
and O 0 3.9504424731440224e-10
the O 0 5.541470615710864e-10
1936delG O 0 1.1097805696635987e-07
mutation O 0 3.87682455027516e-08
from O 0 4.178233037333001e-10
their O 0 1.717598507866569e-09
homozygous O 0 4.391761478927947e-07
father O 0 5.4286587669594155e-08
. O 0 2.4226377348668393e-08
. O 0 2.159066951890054e-07

PAX6 O 0 0.01704670861363411
mutations O 0 0.0008365613175556064
reviewed O 0 7.935748726595193e-05
. O 0 7.895871021901257e-06

Mutations O 0 5.305118975229561e-05
in O 0 4.560311595014355e-08
PAX6 O 0 3.809084091699333e-06
are O 0 3.758943378784352e-09
responsible O 0 3.316572350087199e-09
for O 0 2.633510354232982e-10
human O 0 8.397532669235375e-10
aniridia B-Disease 1 1.0
and O 0 2.8698108334168637e-09
have O 0 5.828373339511472e-10
also O 0 2.7066893171223683e-10
been O 0 4.853153434680735e-10
found O 0 3.646787871680601e-10
in O 0 3.5467101477948404e-10
patients O 0 5.2814113082888525e-09
with O 0 1.3393188780241871e-09
Peters B-Disease 1 1.0
anomaly I-Disease 1 1.0
, O 0 6.394738960580071e-09
with O 0 2.901619922113241e-08
congenital B-Disease 1 0.9999951124191284
cataracts I-Disease 1 0.9975704550743103
, O 0 9.37594091254823e-09
with O 0 1.5799924923953768e-08
autosomal B-Disease 1 0.9167395830154419
dominant I-Disease 1 0.6113481521606445
keratitis I-Disease 1 0.9973984956741333
, O 0 2.5296603922697614e-08
and O 0 9.272400625093269e-09
with O 0 4.476698478583785e-08
isolated B-Disease 0 0.048758432269096375
foveal I-Disease 1 1.0
hypoplasia I-Disease 1 1.0
. O 0 2.247923293907661e-05

No O 0 1.2468836985135567e-06
locus O 0 1.387445649925212e-06
other O 0 5.793054480562887e-09
than O 0 4.994248570255877e-09
chromosome O 0 4.317221282690298e-07
11p13 O 0 9.092120762943523e-07
has O 0 1.2594924214681669e-08
been O 0 3.6048601881333298e-09
implicated O 0 3.322246655557137e-08
in O 0 5.7505387118794715e-09
aniridia B-Disease 1 1.0
, O 0 2.825059741695668e-09
and O 0 1.423417828050333e-09
PAX6 O 0 4.4611851990339346e-07
is O 0 2.410261323859686e-09
clearly O 0 2.20031415310018e-09
the O 0 3.915976570789681e-11
major O 0 5.246448830931172e-10
, O 0 2.076716160148706e-10
if O 0 9.57140700030834e-10
not O 0 3.209433274697915e-10
only O 0 2.0394332056472564e-10
, O 0 7.005703239748584e-10
gene O 0 8.193050859972573e-08
responsible O 0 3.965046175835596e-07
. O 0 5.170142571842007e-07

Twenty O 0 1.8890982573793735e-06
- O 0 8.054596037254669e-06
eight O 0 3.724567321228278e-08
percent O 0 3.7463117052993766e-08
of O 0 2.6086538484904054e-10
identified O 0 5.798086633035382e-08
PAX6 O 0 2.5433432710997295e-06
mutations O 0 3.7744641190329276e-07
are O 0 5.627944332786683e-09
C O 0 1.8786886357702315e-06
- O 0 8.286140655400231e-05
T O 0 1.1501297194627114e-05
changes O 0 9.815711798921711e-09
at O 0 1.1313551206981742e-09
CpG O 0 3.056018016422968e-08
dinucleotides O 0 9.762800345924916e-08
, O 0 3.507683588033217e-10
20 O 0 2.6256458118822934e-10
% O 0 7.360530240863028e-11
are O 0 2.980470384383871e-11
splicing O 0 7.87319809347764e-09
errors O 0 1.0714975573478114e-08
, O 0 5.2275773987364715e-11
and O 0 2.630220867494426e-11
more O 0 1.4339347417791082e-11
than O 0 1.678286398743012e-10
30 O 0 3.8077288544435817e-10
% O 0 3.510688961760877e-10
are O 0 4.5098264012111144e-10
deletion O 0 9.648434939890649e-08
or O 0 1.3814283050805898e-08
insertion O 0 2.7504472654982237e-07
events O 0 3.8073119412729284e-07
. O 0 8.333237246915814e-07

There O 0 6.240563266146637e-07
is O 0 1.544829153488081e-08
a O 0 6.935349183834205e-09
noticeably O 0 1.7258922468954552e-07
elevated O 0 4.427912188020855e-07
level O 0 1.1464375226921675e-08
of O 0 1.1278813993875758e-10
mutation O 0 3.878991705619228e-08
in O 0 7.20141890564463e-10
the O 0 2.6982360790128723e-10
paired O 0 9.533550837659277e-09
domain O 0 3.2096554303251423e-09
compared O 0 2.5730855224281868e-09
with O 0 9.832753361527224e-11
the O 0 5.431138316858153e-10
rest O 0 2.2568924507027077e-09
of O 0 9.066619677255972e-11
the O 0 2.2390300724595136e-09
gene O 0 3.2891523460421013e-07
. O 0 2.0156755908828927e-07

Increased O 0 2.476946292517823e-06
mutation O 0 2.0483021216932684e-06
in O 0 4.788871521554938e-09
the O 0 9.52505740947629e-10
homeodomain O 0 3.8435311466855637e-07
is O 0 1.1864598192801168e-09
accounted O 0 6.788700268600678e-09
for O 0 2.1789425819207509e-10
by O 0 6.838132282638298e-10
the O 0 5.971726668718702e-09
hypermutable O 0 5.689304998668376e-06
CpG O 0 4.2484994082769845e-06
dinucleotide O 0 9.294745723309461e-06
in O 0 3.232012346643387e-08
codon O 0 1.294837375098723e-06
240 O 0 2.0010273260595568e-07
. O 0 2.4629702011225163e-07

Very O 0 1.7563677090493002e-07
nearly O 0 1.7444346411821243e-08
all O 0 7.095724008365778e-10
mutations O 0 1.5651812290684575e-08
appear O 0 7.226782283709099e-09
to O 0 1.5174299594633567e-09
cause O 0 1.3301749923755324e-08
loss O 0 1.1580767456109697e-08
of O 0 2.432709936273092e-11
function O 0 9.48786826882042e-10
of O 0 3.869003381562486e-11
the O 0 1.5910744943781197e-10
mutant O 0 2.031298151905503e-08
allele O 0 3.094844203133107e-08
, O 0 1.0833785257791106e-10
and O 0 5.4956386663640444e-11
more O 0 1.4406264375876887e-11
than O 0 8.744197727006409e-11
80 O 0 3.006267179639366e-10
% O 0 1.9283276364578938e-10
of O 0 8.582318883343376e-11
exonic O 0 1.5519739804403798e-07
substitutions O 0 5.472091757496855e-08
result O 0 6.43648121467777e-08
in O 0 1.7876327973453954e-08
nonsense O 0 4.005403297924204e-06
codons O 0 8.72040163812926e-06
. O 0 8.518367167198448e-07

In O 0 3.372814560975712e-08
a O 0 3.516460900243601e-09
gene O 0 1.4116007918119067e-08
with O 0 3.2225602741853265e-10
such O 0 4.385378449267563e-10
extraordinarily O 0 9.315480298255352e-08
high O 0 1.4693536165566456e-08
sequence O 0 5.336648900566843e-09
conservation O 0 6.441854272232206e-10
throughout O 0 2.773578589021497e-10
evolution O 0 3.7269015651375526e-10
, O 0 1.2973221108492083e-10
there O 0 4.032286171629096e-10
are O 0 6.833542065542986e-10
presumed O 0 2.7543612191038847e-07
undiscovered O 0 1.4855039580652374e-06
missense O 0 1.0778558134916238e-06
mutations O 0 1.582852604542495e-07
, O 0 5.262363877989173e-10
these O 0 1.6101088518016837e-10
are O 0 1.113772060690188e-10
hypothesized O 0 3.797258063542586e-09
to O 0 1.9287359209751997e-10
exist O 0 3.725133757015442e-09
in O 0 2.6783464335267126e-10
as O 0 2.9588027583571375e-09
- O 0 3.3909465855685994e-05
yet O 0 3.4116291658392583e-07
unidentified O 0 3.76202990537422e-07
phenotypes O 0 5.482664278133598e-07
. O 0 1.8520703193303234e-08
. O 0 1.6964274607289553e-07

Genetic O 0 0.00018615402223076671
heterogeneity O 0 4.25499674747698e-05
and O 0 2.580306954769185e-07
penetrance O 0 7.789442861394491e-06
analysis O 0 1.0610627043661225e-07
of O 0 1.0023518681734345e-09
the O 0 7.394322931730812e-09
BRCA1 O 0 2.108893750119023e-05
and O 0 1.1674318045606924e-07
BRCA2 O 0 1.165090361610055e-05
genes O 0 1.727304720589018e-06
in O 0 2.883180911794625e-07
breast B-Disease 1 0.9877837300300598
cancer I-Disease 0 0.0013266057940199971
families O 0 8.865610539032787e-07
. O 0 9.795794539968483e-07

The O 0 0.0001694386883173138
Breast B-Disease 1 1.0
Cancer I-Disease 1 0.9999998807907104
Linkage O 0 0.0014027366414666176
Consortium O 0 9.349128959001973e-05
. O 0 4.323312623455422e-06

The O 0 4.1709114384502755e-08
contribution O 0 3.368538870063276e-08
of O 0 1.0282142914874726e-09
BRCA1 O 0 8.28323265977815e-07
and O 0 1.5195798397371618e-08
BRCA2 O 0 2.028749258897733e-05
to O 0 1.0487684676263598e-06
inherited B-Disease 1 1.0
breast I-Disease 1 1.0
cancer I-Disease 1 1.0
was O 0 6.599185553568532e-07
assessed O 0 3.243845370093368e-08
by O 0 5.230861299665435e-10
linkage O 0 5.668626386068354e-07
and O 0 1.1312930148221767e-08
mutation O 0 4.017389798605109e-08
analysis O 0 3.3184011094533616e-09
in O 0 1.6100412669750597e-10
237 O 0 9.88627957276833e-10
families O 0 3.2891356305242425e-10
, O 0 2.2499831858757702e-11
each O 0 2.499341185402404e-11
with O 0 4.4371794433173406e-11
at O 0 7.083310604727444e-10
least O 0 1.0431794317256049e-10
four O 0 1.7944119801160952e-10
cases O 0 2.756739725384705e-09
of O 0 1.7010755026802826e-09
breast B-Disease 1 0.5274417400360107
cancer I-Disease 0 6.073769895920123e-07
, O 0 7.652558448034696e-11
collected O 0 3.62006508103363e-10
by O 0 1.3988394886865763e-09
the O 0 2.5611018372728722e-06
Breast B-Disease 1 1.0
Cancer I-Disease 1 0.9999998807907104
Linkage O 0 7.051657303236425e-05
Consortium O 0 4.8423116822959855e-06
. O 0 8.423526196565945e-07

Families O 0 5.228822033132019e-07
were O 0 5.377909673143222e-09
included O 0 3.276443838462484e-10
without O 0 5.636449640356034e-10
regard O 0 4.868571101823704e-10
to O 0 1.4894765976158908e-10
the O 0 2.167680063225319e-10
occurrence O 0 1.1658918452894795e-07
of O 0 4.473418524497674e-09
ovarian B-Disease 0 0.0015281467931345105
or I-Disease 0 6.206383318385633e-08
other I-Disease 0 7.67262164913518e-08
cancers I-Disease 1 0.7147658467292786
. O 0 5.261215392238228e-07

Overall O 0 0.00010677600948838517
, O 0 2.1247507220323314e-07
disease O 0 1.137316075983108e-06
was O 0 7.319504113922903e-09
linked O 0 3.961417149866975e-08
to O 0 7.359846621035615e-10
BRCA1 O 0 9.306742043690974e-08
in O 0 3.2660615878477017e-10
an O 0 7.229256082652569e-11
estimated O 0 5.880418929571363e-10
52 O 0 2.7180411255045556e-09
% O 0 3.013362614989745e-10
of O 0 2.757573162870397e-11
families O 0 2.018947509174751e-10
, O 0 9.272710377317139e-11
to O 0 1.741148752953947e-10
BRCA2 O 0 3.854190211427522e-08
in O 0 2.2419607836887678e-10
32 O 0 5.255211821264538e-10
% O 0 9.124354743983432e-11
of O 0 1.631282782466048e-11
families O 0 2.2418537859447696e-10
, O 0 1.0747590317716771e-10
and O 0 2.0928403454689715e-10
to O 0 2.734977522234061e-10
neither O 0 4.345049653409205e-09
gene O 0 6.15504092138508e-09
in O 0 6.208165648224906e-10
16 O 0 9.800498190770668e-10
% O 0 3.4091857115114976e-10
( O 0 2.0009789658548272e-10
95 O 0 4.487330507174647e-09
% O 0 6.086965154139534e-09
confidence O 0 9.902366571168386e-08
interval O 0 9.302394232690858e-08
[ O 0 3.5453069813229376e-08
CI O 0 2.222023027798059e-07
] O 0 8.887584890260314e-09
6 O 0 1.1767710139665155e-09
% O 0 8.686785180067602e-10
- O 0 4.420284085426829e-07
28 O 0 6.604251368003133e-09
% O 0 3.369904633121479e-10
) O 0 2.2073748384698888e-10
, O 0 2.1015285345260537e-10
suggesting O 0 1.607391908464706e-08
other O 0 7.652565692239932e-09
predisposition O 0 9.942922361005913e-07
genes O 0 1.2887380762549583e-06
. O 0 9.181600262309075e-07

The O 0 1.3017384503655194e-07
majority O 0 1.5970420008670771e-07
( O 0 2.2108521680053173e-09
81 O 0 5.9598130874860544e-09
% O 0 8.210423452226223e-10
) O 0 1.7650428341120517e-10
of O 0 1.9805811157791453e-10
the O 0 2.3658409986637707e-07
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 4.505357864559301e-09
were O 0 1.2927974246679241e-09
due O 0 1.5371541817188472e-09
to O 0 3.27774390962432e-10
BRCA1 O 0 6.661843343636065e-08
, O 0 7.470754570526594e-11
with O 0 5.945886838443215e-11
most O 0 3.915799351439375e-10
others O 0 2.2927393317218048e-09
( O 0 2.7956412185226043e-10
14 O 0 1.0355357682456656e-09
% O 0 9.744411944012654e-10
) O 0 1.3998271430892828e-09
due O 0 1.6710661299157437e-08
to O 0 2.1997529131567717e-08
BRCA2 O 0 5.1421713578747585e-05
. O 0 5.557914164455724e-07

Conversely O 0 4.314358193369117e-06
, O 0 1.587832088034702e-08
the O 0 1.0817313711442011e-09
majority O 0 4.579834289586415e-09
of O 0 1.2950747418916109e-10
families O 0 1.2973128127313771e-09
with O 0 5.692055715655897e-10
male B-Disease 0 2.0343948392564926e-07
and I-Disease 0 3.104031165435117e-08
female I-Disease 0 4.539994552033022e-05
breast I-Disease 0 0.42069748044013977
cancer I-Disease 0 8.111130227916874e-06
were O 0 2.8091231563109886e-09
due O 0 6.572558941542184e-09
to O 0 5.039654027427787e-09
BRCA2 O 0 1.8701618955674348e-06
( O 0 3.2210381029074142e-09
76 O 0 4.0888036068054134e-08
% O 0 1.2375108937590085e-08
) O 0 2.796140208261022e-08
. O 0 3.447744916229567e-07

The O 0 5.981213035965993e-08
largest O 0 1.0584249565681603e-07
proportion O 0 9.89747590551815e-08
( O 0 1.70289005119173e-09
67 O 0 8.436661147470659e-09
% O 0 6.673818164770751e-10
) O 0 2.2584285830351547e-10
of O 0 4.612625559285988e-11
families O 0 5.746303433085131e-10
due O 0 1.9775547865918952e-09
to O 0 8.052506578204444e-11
other O 0 7.812755303815422e-11
genes O 0 1.5920191831497732e-09
was O 0 1.0304785469372746e-08
found O 0 6.221833603881066e-10
in O 0 1.313631287080952e-10
families O 0 9.084258345559704e-11
with O 0 1.9762292496894318e-11
four O 0 1.5509213358022578e-10
or O 0 8.044758192937707e-10
five O 0 1.8267418133710578e-10
cases O 0 1.0734525490718738e-09
of O 0 5.92156823575607e-10
female O 0 7.97090251580812e-05
breast B-Disease 1 0.9033229947090149
cancer I-Disease 0 8.592044650868047e-06
only O 0 2.408043187074327e-08
. O 0 2.3488945544158923e-07

These O 0 3.1339183692580264e-08
estimates O 0 3.587440033925304e-08
were O 0 2.6459174851112266e-09
not O 0 8.582240473842262e-10
substantially O 0 8.069073409444627e-09
affected O 0 1.1136791489008147e-09
either O 0 4.707885192800632e-10
by O 0 1.9530313477567063e-10
changing O 0 1.664741589024743e-08
the O 0 1.5252238361185277e-09
assumed O 0 8.285787345130302e-08
penetrance O 0 3.388373954749113e-07
model O 0 3.7509234829258276e-08
for O 0 4.748494375483858e-10
BRCA1 O 0 8.392032668780303e-08
or O 0 8.169792620194016e-10
by O 0 9.39146677092495e-11
including O 0 3.9151271113979647e-10
or O 0 1.4802678194314467e-08
excluding O 0 4.966864253219683e-07
BRCA1 O 0 1.6908155885175802e-05
mutation O 0 2.597894990685745e-06
data O 0 9.026632028508175e-07
. O 0 6.550322950715781e-07

Among O 0 1.282120365431183e-07
those O 0 1.1601085425638757e-08
families O 0 6.602135727007408e-09
with O 0 6.199459168243493e-09
disease O 0 5.088700731903373e-07
due O 0 5.223117494068674e-09
to O 0 3.7725597645810183e-10
BRCA1 O 0 6.590939705120036e-08
that O 0 2.402833487735734e-10
were O 0 2.7478036512817994e-10
tested O 0 1.2399320459266505e-09
by O 0 1.7971202651012597e-11
one O 0 1.3592499348291653e-10
of O 0 1.8443826327319002e-11
the O 0 1.3172191115629062e-10
standard O 0 1.8411553170949446e-08
screening O 0 4.338234660394846e-09
methods O 0 7.969727988665909e-09
, O 0 3.0021585217809843e-10
mutations O 0 7.056224049506454e-09
were O 0 5.359230281776206e-10
detected O 0 1.6605808283998158e-08
in O 0 4.695984712199675e-10
the O 0 3.184973673686642e-10
coding O 0 1.3987261127113015e-07
sequence O 0 9.187282934419727e-09
or O 0 1.808003857739493e-09
splice O 0 5.060674368451146e-08
sites O 0 5.245170964229828e-09
in O 0 1.403917260223153e-10
an O 0 1.1351111717239348e-10
estimated O 0 1.074390687527682e-09
63 O 0 3.9944958452053925e-09
% O 0 3.88574145082643e-10
( O 0 1.4986469010214165e-10
95 O 0 3.538603188246725e-09
% O 0 3.1733873306905025e-09
CI O 0 8.47190506192419e-07
51 O 0 3.6584609119927336e-08
% O 0 1.2437390672914717e-08
- O 0 3.08451744785998e-05
77 O 0 7.960267112139263e-08
% O 0 1.0443789832947914e-08
) O 0 2.1266638228212287e-08
. O 0 2.0989894267131604e-07

The O 0 4.0429330994129486e-08
estimated O 0 8.022865038981308e-09
sensitivity O 0 5.872467312428853e-08
was O 0 3.977238538510619e-09
identical O 0 4.641462769683358e-09
for O 0 1.3578635438271647e-10
direct O 0 7.303629923072208e-10
sequencing O 0 9.451388116588078e-09
and O 0 1.5299148614644764e-09
other O 0 1.2498285739681592e-09
techniques O 0 1.016514829643711e-06
. O 0 8.071337447290716e-07

The O 0 4.6711105028407474e-07
penetrance O 0 1.565831007610541e-05
of O 0 1.635434720981266e-08
BRCA2 O 0 7.1651843427389394e-06
was O 0 1.80861867704607e-08
estimated O 0 1.6852383932786097e-09
by O 0 3.9515879457496794e-10
maximizing O 0 5.455054008507432e-08
the O 0 4.092148842005372e-09
LOD O 0 0.036188818514347076
score O 0 3.903692658013824e-08
in O 0 3.315914876012016e-09
BRCA2 O 0 5.131100351718487e-06
- O 0 8.668270083944662e-07
mutation O 0 1.0487448776075325e-07
families O 0 1.4514147661515153e-09
, O 0 1.0725024340851874e-10
over O 0 3.463070663567436e-10
all O 0 1.3479964922069598e-09
possible O 0 7.557833470173136e-08
penetrance O 0 5.434808826976223e-06
functions O 0 2.8528182838272187e-07
. O 0 5.891572527616518e-07

The O 0 3.537673975984035e-08
estimated O 0 3.2822015327838017e-08
cumulative O 0 2.721913574532664e-07
risk O 0 1.3981914435134968e-06
of O 0 2.582476232859676e-09
breast B-Disease 0 0.004198715556412935
cancer I-Disease 0 4.082600298715988e-06
reached O 0 1.0226484548070403e-08
28 O 0 3.977792317755302e-09
% O 0 5.629541277585304e-10
( O 0 1.8835896731239643e-10
95 O 0 1.9151624730540107e-09
% O 0 2.8618138969704887e-09
CI O 0 5.023969720241439e-07
9 O 0 4.008050336068436e-09
% O 0 1.0094409752525735e-09
- O 0 4.140790110795933e-08
44 O 0 1.4341742238244137e-09
% O 0 1.799710935834753e-10
) O 0 5.746498069059136e-11
by O 0 4.655324736813071e-11
age O 0 7.528059842165646e-10
50 O 0 1.4003204151791238e-10
years O 0 3.1040042758334607e-10
and O 0 4.917906082368972e-10
84 O 0 1.1536757105190532e-09
% O 0 1.7426637910489262e-10
( O 0 9.108843540550637e-11
95 O 0 1.5798530261790233e-09
% O 0 1.2712647601276217e-09
CI O 0 1.6315378559284e-07
43 O 0 3.762781197735876e-09
% O 0 1.2220341405466684e-09
- O 0 5.067541763992267e-08
95 O 0 4.285836574524637e-09
% O 0 6.542500430306575e-10
) O 0 1.4375337031857782e-10
by O 0 7.260628209770914e-10
age O 0 1.9660173933289116e-08
70 O 0 6.577525191175937e-09
years O 0 4.265703168471191e-08
. O 0 1.5118789065127203e-07

The O 0 1.423056914973131e-06
corresponding O 0 0.32188332080841064
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
risks O 0 0.3217942714691162
were O 0 7.179674099688782e-08
0 O 0 2.5352014176860393e-07
. O 0 4.553984069843864e-07

4 O 0 1.4620649153584964e-06
% O 0 4.9909182564533694e-08
( O 0 2.271978827295129e-09
95 O 0 1.0198785815873634e-08
% O 0 7.236437227220449e-09
CI O 0 1.1792496934504015e-06
0 O 0 8.76133565697046e-09
% O 0 2.1414057194135694e-09
- O 0 1.5937554564970924e-07
1 O 0 2.7841380312310093e-09
% O 0 2.96624863560524e-10
) O 0 6.000126784311277e-11
by O 0 5.7003426284785164e-11
age O 0 1.1216133577462983e-09
50 O 0 2.78172151979561e-10
years O 0 9.932037414728256e-10
and O 0 8.973326526273695e-10
27 O 0 1.6160168758716509e-09
% O 0 1.5040935164023495e-10
( O 0 7.822193587303516e-11
95 O 0 1.2829888262899658e-09
% O 0 9.42488420641041e-10
CI O 0 1.0971923103397785e-07
0 O 0 4.391984997909049e-09
% O 0 1.5885976978324834e-09
- O 0 1.0066769817740351e-07
47 O 0 1.0752152945769922e-08
% O 0 4.250098051272744e-10
) O 0 1.0310024362025771e-10
by O 0 2.541894472685158e-10
age O 0 1.521563675055404e-08
70 O 0 8.944572194025113e-09
years O 0 3.834436412830655e-08
. O 0 1.2972719787285314e-07

The O 0 9.855786942125633e-08
lifetime O 0 1.5326295397244394e-06
risk O 0 4.795414497493766e-06
of O 0 9.970362313538317e-09
breast B-Disease 1 0.8363616466522217
cancer I-Disease 0 1.78717564267572e-05
appears O 0 9.97820048809217e-09
similar O 0 1.1901269969527561e-09
to O 0 8.548879382175301e-10
the O 0 1.5600778446867025e-09
risk O 0 1.1125824528335215e-07
in O 0 3.9129621764999456e-10
BRCA1 O 0 9.843500947681605e-08
carriers O 0 1.3272098975392055e-08
, O 0 1.1258523974211343e-10
but O 0 4.957668719995922e-10
there O 0 1.563848633923115e-10
was O 0 4.612302484385822e-10
some O 0 2.962176337550915e-11
suggestion O 0 2.1309383146927985e-09
of O 0 5.962331323106085e-11
a O 0 6.901106797130296e-09
lower O 0 4.210387487546541e-06
risk O 0 1.7570991985849105e-06
in O 0 3.5592422342745067e-09
BRCA2 O 0 5.78725860123086e-07
carriers O 0 2.5653001500813843e-08
< O 0 2.4156149081022704e-08
50 O 0 8.379756888388101e-10
years O 0 2.3835944329420045e-09
of O 0 5.637761368859628e-10
age O 0 9.095158759464539e-08
. O 0 1.5637584738215082e-07

Eye B-Disease 1 0.9966380596160889
movement I-Disease 0 2.3236974811879918e-05
abnormalities I-Disease 0 0.0012207137187942863
correlate O 0 1.0551369769018493e-06
with O 0 3.883025812001506e-08
genotype O 0 8.208752115024254e-05
in O 0 2.727568073623843e-07
autosomal O 1 0.9942554831504822
dominant O 1 0.9569578170776367
cerebellar B-Disease 1 0.9761630296707153
ataxia I-Disease 1 0.99970942735672
type I-Disease 1 0.9999938011169434
I I-Disease 1 0.516053318977356
. O 0 1.7478338349974365e-06

We O 0 1.2570202443384915e-06
compared O 0 3.5778461437985243e-07
horizontal O 0 4.0963230276247486e-05
eye O 1 0.9444551467895508
movements O 0 4.937577614327893e-06
( O 0 1.98820586660986e-08
visually O 0 2.250077386634075e-07
guided O 0 7.84063729497575e-08
saccades O 0 4.7490880206169095e-06
, O 0 4.141420095749027e-09
antisaccades O 0 2.690653957415634e-07
, O 0 1.0141439910071881e-09
and O 0 5.577768247277959e-10
smooth O 0 1.344558953064734e-08
pursuit O 0 3.256286618125159e-08
) O 0 1.2541652161246475e-09
in O 0 3.943305959541732e-10
control O 0 1.629972778971478e-08
subjects O 0 1.782124492422099e-08
( O 0 1.8074615415475392e-10
n O 0 5.6258546266008125e-08
= O 0 8.361547543245251e-08
14 O 0 3.49483497696923e-10
) O 0 9.730476840941193e-11
and O 0 1.1101495417387142e-10
patients O 0 3.2311214814839673e-10
with O 0 7.805601651145189e-12
three O 0 1.2646690639162017e-10
forms O 0 7.273688762410302e-09
of O 0 5.033303995816141e-09
autosomal O 1 0.7275967001914978
dominant O 0 0.014136097393929958
cerebellar B-Disease 0 0.00017221533926203847
ataxias I-Disease 0 0.000359243800630793
type I-Disease 0 0.01734621822834015
I I-Disease 0 8.326263127855782e-07
spinocerebellar B-Disease 0 1.0975939403579105e-05
ataxias I-Disease 0 3.3798260119510815e-06
1 I-Disease 0 2.554114786335049e-08
and I-Disease 0 3.222144107084546e-09
2 I-Disease 0 2.5827324723337597e-09
( O 0 1.1350813622357236e-09
SCA1 B-Disease 0 4.703186959886807e-07
, O 0 1.530524929016508e-09
n O 0 1.7151317877051042e-07
= O 0 2.3183098107892874e-07
11 O 0 2.759606765323497e-09
; O 0 1.2677948690864582e-09
SCA2 B-Disease 0 2.3640816948500287e-07
, O 0 1.2452171516130761e-09
n O 0 9.087061414447817e-08
= O 0 1.3600507031696907e-07
10 O 0 2.0002588474454797e-09
) O 0 1.2622188849675808e-09
and O 0 7.639615162702285e-09
SCA3 B-Disease 1 1.0
/ O 0 6.327779260573152e-07
Machado B-Disease 0 7.759006734886498e-07
- I-Disease 0 1.7168858903460205e-06
Joseph I-Disease 0 2.6923480618279427e-06
disease I-Disease 0 2.1027451566624222e-06
( O 0 4.308359446980603e-09
MJD B-Disease 1 0.9999998807907104
) O 0 3.6461986763214327e-09
( O 0 6.720493050949017e-10
n O 0 5.216260774432158e-07
= O 0 1.5900103562671575e-06
16 O 0 2.4079053417835894e-08
) O 0 1.5813370168871188e-08
. O 0 9.028529035504107e-08

In O 0 2.691955103273358e-07
SCA1 B-Disease 0 5.512977168109501e-06
, O 0 9.391333044561634e-09
saccade O 0 1.2825854582843021e-06
amplitude O 0 8.379220872711812e-08
was O 0 2.573440305297936e-08
significantly O 0 2.9443809168583357e-08
increased O 0 5.604206876341777e-09
, O 0 1.073542588159171e-09
resulting O 0 1.6578340478190512e-08
in O 0 1.7773279736843506e-08
hypermetria B-Disease 0 1.95546199392993e-05
. O 0 4.811865323972597e-07

The O 0 1.7689684739252698e-07
smooth O 0 5.239543838797545e-07
pursuit O 0 1.2983193755644606e-06
gain O 0 1.9325480025145225e-05
was O 0 1.3335366020328365e-06
decreased O 0 4.734865797217935e-06
. O 0 1.3674174397237948e-06

In O 0 5.267330038805085e-07
SCA2 B-Disease 0 1.176321802631719e-05
, O 0 2.8211522007381973e-08
saccade O 0 6.523885076603619e-06
velocity O 0 2.4813673462631414e-06
was O 0 3.555845182745543e-07
markedly O 0 3.5919085803470807e-06
decreased O 0 6.613931418542052e-06
. O 0 1.20233858069696e-06

The O 0 3.083260580183378e-08
percentage O 0 1.2470627552829683e-07
of O 0 2.040079077891832e-10
errors O 0 1.0961753282856534e-08
in O 0 3.019841043894189e-10
antisaccades O 0 2.2454985071362898e-07
was O 0 3.506849477474816e-09
greatly O 0 7.47413575474809e-10
increased O 0 7.187024864130365e-10
and O 0 7.820108449685392e-10
was O 0 3.250935742826755e-09
significantly O 0 5.062110286502275e-09
correlated O 0 9.842032078211105e-09
with O 0 6.354466397517911e-10
age O 0 5.07210629052679e-08
at O 0 8.1864904188933e-08
disease O 0 2.0375396161398385e-06
onset O 0 1.3017552191740833e-05
. O 0 1.0480605396878673e-06

In O 0 8.196693102036079e-08
addition O 0 2.540113541726896e-08
, O 0 1.6387876611290153e-09
a O 0 7.131339962995753e-10
correlation O 0 2.4689125410759516e-08
between O 0 1.2706321550481903e-09
smooth O 0 1.9307952570102316e-08
pursuit O 0 6.404506791568565e-08
gain O 0 1.2983144870304386e-06
and O 0 2.8811912855530863e-09
the O 0 4.202033165867647e-10
number O 0 1.6131898039617454e-09
of O 0 2.242162677745796e-09
trinucleotide O 0 8.87725309439702e-06
repeats O 0 1.6921001133596292e-06
was O 0 1.043505264419764e-07
found O 0 1.2508813540534902e-07
. O 0 3.125943237591855e-07

In O 0 1.5790004681548453e-06
SCA3 B-Disease 1 0.9999985694885254
, O 0 1.1466872962273555e-07
gaze B-Disease 0 3.0164996132953092e-05
- I-Disease 0 7.396621185762342e-06
evoked I-Disease 0 8.004150231499807e-07
nystagmus I-Disease 0 5.482896995090414e-06
was O 0 2.1790320658965356e-08
often O 0 3.864825348642853e-09
present O 0 7.275058888644992e-10
as O 0 1.04575581527655e-09
was O 0 6.5572578478168e-09
saccade O 0 3.473129481790238e-07
hypometria O 0 2.687399671685853e-07
and O 0 3.0055402611139925e-09
smooth O 0 2.670437559970651e-08
pursuit O 0 1.296722871302336e-07
gain O 0 9.572388535161735e-07
was O 0 3.2148105333362764e-07
markedly O 0 2.1947255390841747e-06
decreased O 0 5.542054168472532e-06
. O 0 9.070668056665454e-07

Three O 0 2.5562721361893637e-07
major O 0 1.031790759498108e-07
criteria O 0 1.5350929061241914e-07
, O 0 2.39095254706001e-09
saccade O 0 6.976173381190165e-07
amplitude O 0 5.694114335597078e-08
, O 0 2.271008270327002e-09
saccade O 0 4.1418812202209665e-07
velocity O 0 1.1022095236512541e-07
, O 0 1.5443925027724958e-09
and O 0 1.2693724960044506e-09
presence O 0 4.377725293380763e-09
of O 0 6.427997578661859e-10
gaze B-Disease 0 3.171856587869115e-05
- I-Disease 0 2.6284503746865084e-06
evoked I-Disease 0 1.255305477343427e-07
nystagmus I-Disease 0 2.42170983710821e-07
, O 0 2.098600460076483e-10
permitted O 0 8.4231510655286e-10
the O 0 2.042002122948361e-10
correct O 0 1.4108686663405479e-08
assignment O 0 9.725366290069815e-09
of O 0 3.658846142728933e-11
90 O 0 2.655501929460513e-10
% O 0 1.2051593056838783e-10
of O 0 1.2997809425985274e-11
the O 0 1.7236888305571796e-10
SCA1 B-Disease 0 2.2994373694018577e-07
, O 0 2.1824905771516967e-10
90 O 0 2.0701750036433708e-10
% O 0 8.648723404114378e-11
of O 0 1.522885290095033e-11
the O 0 1.8649752575594647e-10
SCA2 B-Disease 0 1.4815904592069273e-07
, O 0 1.3386158848049945e-10
and O 0 1.210926775518928e-10
93 O 0 3.5620451033224754e-10
% O 0 9.380009963200209e-11
of O 0 7.540238398939803e-12
the O 0 2.701789347803185e-10
patients O 0 4.9531339030295385e-09
with O 0 3.68848729337401e-10
SCA3 B-Disease 1 1.0
to O 0 6.580997968796964e-10
their O 0 2.019151512655526e-10
genetically O 0 3.6556409011012647e-09
confirmed O 0 6.86872336785882e-09
patient O 0 7.471445684359423e-09
group O 0 9.715571680501967e-10
and O 0 5.663239321940239e-10
, O 0 2.2451829284619862e-10
therefore O 0 7.643518040723052e-10
, O 0 4.5648321234104117e-10
may O 0 3.6659193458632444e-09
help O 0 2.3106863089594754e-09
orient O 0 5.0371671278526264e-08
diagnoses O 0 1.5992458202163107e-07
of O 0 1.8646585664416904e-10
SCA1 B-Disease 0 2.0016265978028969e-07
, O 0 2.71893174641491e-10
SCA2 B-Disease 0 9.326272021326076e-08
, O 0 3.6894934329900764e-10
and O 0 1.9570520759515375e-09
SCA3 B-Disease 1 1.0
at O 0 2.2796882159781262e-09
early O 0 4.418064580846703e-09
clinical O 0 3.675456738960747e-08
stages O 0 9.813989620965913e-09
of O 0 3.259539582689541e-10
the O 0 1.7396201812402978e-08
diseases O 0 3.467176611593459e-06
. O 0 1.910336600019491e-08
. O 0 2.4479086846440623e-07

Genetic O 0 2.754914021352306e-05
basis O 0 3.6219512367097195e-07
and O 0 6.357636550546886e-08
molecular O 0 2.438268211335526e-06
mechanism O 0 1.2966604117536917e-05
for O 0 2.218783447460737e-05
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 0.9999947547912598
fibrillation I-Disease 1 1.0
. O 0 0.0001174812568933703

Ventricular B-Disease 0 0.004854378290474415
fibrillation I-Disease 0 0.00149816635530442
causes O 0 6.959295433262014e-07
more O 0 2.0541404133211927e-09
than O 0 1.0731864286128712e-09
300 O 0 1.8944501523066037e-09
, O 0 4.464355551903054e-10
000 O 0 3.268019854729687e-09
sudden O 0 6.5182277353414975e-09
deaths O 0 2.76670597543216e-09
each O 0 5.005432734961346e-10
year O 0 2.153315969977143e-09
in O 0 4.2363310082116357e-10
the O 0 1.7838444055229274e-09
USA O 0 6.441786695177143e-07
alone O 0 1.6392205282045325e-07
. O 0 1.592585618936937e-07

In O 0 7.079899688733349e-08
approximately O 0 1.0810471628985852e-08
5 O 0 5.092100963111079e-09
- O 0 1.270168041855868e-07
12 O 0 1.850346209586462e-09
% O 0 1.5926318597259126e-10
of O 0 4.770849514057485e-12
these O 0 5.034873559739417e-11
cases O 0 5.569316674503e-10
, O 0 6.477495623213869e-11
there O 0 9.67536398222002e-11
are O 0 1.7234060012416563e-10
no O 0 1.70075753480603e-09
demonstrable O 0 2.2136312054499285e-06
cardiac O 0 8.647033951092453e-07
or O 0 3.812550986026508e-08
non O 0 8.2812512118835e-05
- O 0 0.04422314837574959
cardiac O 0 2.2908973278390476e-06
causes O 0 2.096756990255244e-09
to O 0 8.382645966253932e-11
account O 0 3.465905618060816e-10
for O 0 2.9431970749449476e-11
the O 0 4.478006854213845e-11
episode O 0 4.498153405307903e-09
, O 0 8.442109511452855e-11
which O 0 1.4704062967219045e-10
is O 0 2.6894139693034447e-10
therefore O 0 1.5762171567956784e-09
classified O 0 6.948744157853071e-07
as O 0 5.6853124988265336e-05
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 0.9997077584266663
fibrillation I-Disease 1 1.0
( O 0 1.5035205933600082e-06
IVF B-Disease 1 0.9999998807907104
) O 0 7.220804718599538e-07
. O 0 7.39123777293571e-07

A O 0 3.165446003094985e-07
distinct O 0 1.256790937986807e-07
group O 0 4.075427284533362e-08
of O 0 1.2721235176371692e-09
IVF B-Disease 1 1.0
patients O 0 5.9921744650637265e-06
has O 0 3.746031485007961e-09
been O 0 8.29895430154437e-10
found O 0 3.0979710463618915e-10
to O 0 9.223460883944767e-11
present O 0 4.18397455570485e-10
with O 0 4.390475483173617e-10
a O 0 8.024181319399304e-09
characteristic O 0 1.0793836736411322e-05
electrocardiographic O 0 0.00012543627235572785
pattern O 0 0.00014509062748402357
. O 0 3.254056537116412e-06

Because O 0 2.7057842544309096e-07
of O 0 3.142522631005562e-10
the O 0 1.7913172334349525e-10
small O 0 1.0788056004074065e-09
size O 0 3.1705378322754996e-09
of O 0 3.2595877386132344e-11
most O 0 1.6356578591558701e-10
pedigrees O 0 1.5552002352592353e-08
and O 0 1.065080468265478e-09
the O 0 5.572292072208995e-10
high O 0 1.2830463447244256e-07
incidence O 0 2.4184508220059797e-05
of O 0 5.468601127489592e-10
sudden B-Disease 0 6.015284270688426e-08
death I-Disease 0 6.117622852741533e-09
, O 0 3.151646721377688e-10
however O 0 8.87414808303788e-10
, O 0 1.567563717719267e-10
molecular O 0 1.0123144100759873e-08
genetic O 0 2.6281638199066037e-08
studies O 0 3.715738383647249e-09
of O 0 1.20112045309817e-10
IVF B-Disease 1 0.9999995231628418
have O 0 1.2070953125942196e-08
not O 0 2.285352129760554e-09
yet O 0 7.742920082876026e-09
been O 0 7.0437722321514684e-09
done O 0 9.66480939723624e-08
. O 0 1.309378205860412e-07

Because O 0 3.9493024814873934e-05
IVF B-Disease 1 0.9999994039535522
causes O 0 2.618402140797116e-05
cardiac O 0 0.0025075103621929884
rhythm O 0 4.139395514357602e-06
disturbance O 0 5.828184157508076e-07
, O 0 3.4508873536509554e-09
we O 0 1.7010755026802826e-09
investigated O 0 1.2885442934873481e-08
whether O 0 5.242550393802503e-09
malfunction O 0 1.8197698636868154e-07
of O 0 5.937919600462749e-11
ion O 0 1.4536040815471551e-08
channels O 0 7.432631150550151e-07
could O 0 1.6287129938064027e-06
cause O 0 2.6619908055636188e-08
the O 0 3.2930984605883395e-09
disorder O 0 3.360671883001487e-07
by O 0 1.436725183268095e-10
studying O 0 7.795228462725845e-09
mutations O 0 1.618109592982364e-07
in O 0 2.830210288351509e-09
the O 0 1.588634823690427e-08
cardiac O 0 2.364262854825938e-06
sodium O 0 1.4040521136848838e-06
channel O 0 3.2303412353940075e-06
gene O 0 7.017168627498904e-06
SCN5A O 0 0.0001310907828155905
. O 0 1.2303830771998037e-06

We O 0 8.259553396783303e-07
have O 0 8.310299115521502e-09
now O 0 5.4065840693340306e-09
identified O 0 9.101785103382554e-09
a O 0 2.2517756548268153e-09
missense O 0 2.410613433312392e-06
mutation O 0 6.764408908566111e-07
, O 0 2.1289841001248533e-09
a O 0 3.473763054984147e-09
splice O 0 1.76025896507781e-05
- O 0 4.480526513361838e-06
donor O 0 8.052042232975509e-08
mutation O 0 3.845885316877684e-07
, O 0 9.072781970154153e-10
and O 0 1.3054145542312767e-09
a O 0 5.122875013086059e-09
frameshift O 0 1.0628056770656258e-05
mutation O 0 4.013928105450759e-07
in O 0 1.4710016538188597e-09
the O 0 9.883829310552983e-10
coding O 0 2.6596719635563204e-06
region O 0 2.587704095446952e-08
of O 0 8.198358658617622e-10
SCN5A O 0 7.718563210801221e-07
in O 0 3.3713656311107343e-09
three O 0 1.7755931835949923e-08
IVF B-Disease 1 0.9999978542327881
families O 0 2.12087570616859e-07
. O 0 2.0896081309729198e-07

We O 0 6.175787916617992e-07
show O 0 5.91530913141014e-08
that O 0 1.3448147040406866e-09
sodium O 0 1.0475191380976412e-08
channels O 0 1.733763710376479e-08
with O 0 5.590687912615522e-10
the O 0 2.2086394935172393e-09
missense O 0 2.5507811187708285e-06
mutation O 0 3.6028279737365665e-07
recover O 0 1.4859175223591592e-07
from O 0 5.793228119443938e-10
inactivation O 0 9.563622427322116e-08
more O 0 9.545694790169534e-11
rapidly O 0 1.826718332154087e-09
than O 0 2.6066096503463143e-10
normal O 0 1.341164512780324e-09
and O 0 1.0167277020300958e-09
that O 0 6.144246778028162e-10
the O 0 4.40445102611875e-09
frameshift O 0 1.0315037798136473e-05
mutation O 0 3.197552871370135e-07
causes O 0 7.690287517903016e-09
the O 0 4.801509190244246e-10
sodium O 0 7.655690303920437e-09
channel O 0 2.067663373850337e-08
to O 0 5.63150637233889e-10
be O 0 1.6490533383262118e-09
non O 0 4.953013998942879e-08
- O 0 1.5894675016170368e-06
functional O 0 3.02649823424872e-06
. O 0 6.165013246572926e-07

Our O 0 1.7469506019551773e-06
results O 0 4.575497598580114e-07
indicate O 0 3.3085122197462624e-08
that O 0 2.307625202035979e-09
mutations O 0 1.0750476064913528e-07
in O 0 2.651727504243695e-09
cardiac O 0 3.91300034152664e-07
ion O 0 4.435578659922612e-07
- O 0 3.279531483713072e-06
channel O 0 1.8025235704044462e-07
genes O 0 1.867440424518918e-08
contribute O 0 7.496379628157968e-10
to O 0 1.449375064410674e-10
the O 0 6.686737830108314e-10
risk O 0 3.038888607420631e-08
of O 0 3.2721969578375365e-10
developing O 0 6.533714014267389e-08
IVF B-Disease 1 0.9999891519546509
. O 0 6.849703737543678e-08
. O 0 1.7351175074509229e-07

Molecular O 0 1.5768871890031733e-05
heterogeneity O 0 1.3756060070591047e-05
in O 0 7.345870756125805e-08
mucopolysaccharidosis B-Disease 0 4.605626600096002e-06
IVA I-Disease 0 5.188509476283798e-06
in O 0 4.843768941498183e-09
Australia O 0 5.475158548762238e-09
and O 0 1.308410824130135e-09
Northern O 0 1.245814118533417e-08
Ireland O 0 9.241999521236721e-08
: O 0 5.814460579678382e-10
nine O 0 6.499477622767813e-10
novel O 0 7.525766676508283e-09
mutations O 0 8.098460568817245e-09
including O 0 1.0087880530917914e-10
T312S O 0 3.074704224559355e-08
, O 0 2.0341536788315295e-10
a O 0 2.0362692088049528e-10
common O 0 6.855138234840297e-09
allele O 0 3.320603525480692e-07
that O 0 4.7481072407151714e-09
confers O 0 2.1646192749358306e-07
a O 0 1.4288144711827044e-07
mild O 0 2.446146208967548e-05
phenotype O 0 0.00022437763982452452
. O 0 1.7070166222765693e-06

Mucopolysaccharidosis B-Disease 0 0.002814307576045394
IVA I-Disease 0 0.01069971825927496
( O 0 2.6514487672102405e-06
MPS B-Disease 1 0.9999977350234985
IVA I-Disease 1 0.9999997615814209
) O 0 2.7527637058710752e-08
is O 0 4.697948696730236e-09
an O 0 1.704720631323653e-08
autosomal B-Disease 1 0.9999170303344727
recessive I-Disease 1 0.9999500513076782
lysosomal I-Disease 1 0.9999297857284546
storage I-Disease 1 0.9999392032623291
disorder I-Disease 1 0.9999974966049194
caused O 0 2.895337274821941e-06
by O 0 1.1781888353823433e-08
a O 0 1.638693674976821e-06
genetic B-Disease 1 1.0
defect I-Disease 1 1.0
in O 0 3.629021350093353e-08
N O 0 8.319514017784968e-05
- O 0 4.81162669530022e-06
acetylgalactosamine O 0 4.977339995093644e-05
- O 0 5.22682057635393e-06
6 O 0 8.370754756015231e-08
- O 0 2.0369898265926167e-06
sulfate O 0 7.933829692774452e-06
sulfatase O 0 1.344774955214234e-05
( O 0 1.0329816113596735e-08
GALNS O 0 1.7003324046527268e-06
) O 0 5.4812844041407516e-08
. O 0 2.0776856501925067e-07

Previous O 0 6.182364131745999e-07
studies O 0 9.072582685121233e-08
of O 0 4.1834000152896067e-10
patients O 0 8.535686824018285e-09
from O 0 1.9952699215064484e-10
a O 0 1.8378704114141442e-09
British O 0 2.955526952064247e-06
- O 0 6.549512818310177e-06
Irish O 0 1.3343759519557352e-07
population O 0 1.2659029380301945e-09
showed O 0 2.185532421705716e-09
that O 0 2.7473306615788395e-11
the O 0 5.4962888407228405e-11
I113F O 0 1.4129853731503772e-08
mutation O 0 9.329489181197914e-09
is O 0 1.505517099875675e-10
the O 0 2.6651009524258917e-11
most O 0 1.777004099423607e-10
common O 0 2.9010318591815576e-09
single O 0 3.7105632344491823e-08
mutation O 0 8.821148185234051e-07
among O 0 7.397853352131278e-08
MPS B-Disease 1 0.9999988079071045
IVA I-Disease 1 1.0
patients O 0 1.805392912501702e-06
and O 0 3.3745370942028785e-09
produces O 0 5.977985750860171e-08
a O 0 1.3252927999474196e-07
severe O 0 0.002511709462851286
clinical O 0 0.0005451137549243867
phenotype O 0 0.0005638180300593376
. O 0 4.628982878784882e-06

We O 0 1.0386002031737007e-06
studied O 0 4.0013424040807877e-07
mutations O 0 3.9470052115575527e-07
in O 0 2.2314117220645358e-09
the O 0 1.4071699361295487e-09
GALNS O 0 1.8696503900628159e-07
gene O 0 2.289729650328809e-08
from O 0 1.0311327347523047e-09
23 O 0 4.311730084083365e-09
additional O 0 2.838742929611726e-08
MPS B-Disease 1 0.9999994039535522
IVA I-Disease 1 0.9999998807907104
patients O 0 3.4435387874509615e-07
( O 0 2.995620695944723e-10
15 O 0 1.2879580735258855e-10
from O 0 6.269348928888974e-11
Australia O 0 3.5329769665359834e-10
, O 0 3.416201002637287e-11
8 O 0 5.3706570440903434e-11
from O 0 2.7562480076070983e-11
Northern O 0 2.1298900421129474e-09
Ireland O 0 2.012360056369289e-08
) O 0 1.0183245219286263e-10
, O 0 1.4932876116202642e-11
with O 0 1.1601421212592555e-11
various O 0 6.162732546499683e-10
clinical O 0 6.333200417429907e-07
phenotypes O 0 2.607075373362022e-07
( O 0 3.667324666167815e-09
severe O 0 3.4754464195430046e-06
, O 0 1.0820595530702803e-09
16 O 0 7.563349391226382e-10
cases O 0 1.6252129642069235e-09
; O 0 1.1781859932114003e-09
intermediate O 0 5.625958809929443e-09
, O 0 3.350472677077221e-10
4 O 0 8.999619938165893e-10
cases O 0 4.6345447479723134e-09
; O 0 9.8301384809929e-09
mild O 0 3.2912922165451164e-07
, O 0 1.335912935829242e-09
3 O 0 4.280003906842467e-09
cases O 0 2.112167507561935e-08
) O 0 2.4803963327713063e-08
. O 0 1.7648838479544793e-07

We O 0 5.165815650798322e-07
found O 0 9.026631886399628e-09
two O 0 5.336910913200654e-10
common O 0 2.636708185121961e-09
mutations O 0 1.4701384998261346e-08
that O 0 5.3189817134091655e-11
together O 0 8.804093565295545e-11
accounted O 0 9.105548537391428e-10
for O 0 1.2161299745017118e-10
32 O 0 9.289177760329892e-10
% O 0 1.9364655712283962e-10
of O 0 1.796904465500848e-11
the O 0 1.1568134228312488e-09
44 O 0 2.6704616296058248e-09
unrelated O 0 2.43896707274871e-08
alleles O 0 9.603196104990275e-08
in O 0 3.4656493230755814e-09
these O 0 2.163638157526293e-08
patients O 0 4.974515377398347e-07
. O 0 1.923778398804643e-07

One O 0 7.219428255211824e-08
is O 0 3.0171483089702633e-09
the O 0 1.1478219485994146e-09
T312S O 0 4.559406932003185e-07
mutation O 0 2.0776936082711472e-07
, O 0 7.219311815021001e-10
a O 0 7.686544178930887e-10
novel O 0 4.3965972196247094e-08
mutation O 0 1.2161362406004628e-07
found O 0 3.341564802639141e-09
exclusively O 0 9.832276326449119e-09
in O 0 1.2470503740757977e-08
milder O 0 7.66996708989609e-06
patients O 0 8.789356797933578e-06
. O 0 7.763402436467004e-07

The O 0 1.2850345676440611e-08
other O 0 2.6834765520789006e-09
is O 0 6.899036897323185e-10
the O 0 1.6148329895493418e-10
previously O 0 5.974563510591224e-09
described O 0 3.5068694614892593e-09
I113F O 0 3.978340501475941e-08
that O 0 4.429250299864407e-10
produces O 0 1.108417801987116e-08
a O 0 5.7701203814986e-08
severe O 0 0.00025464294594712555
phenotype O 0 0.0008571999496780336
. O 0 2.0570523702190258e-06

The O 0 2.2284574185960082e-07
I113F O 0 1.891140414045367e-06
and O 0 1.1838743319003697e-08
T312S O 0 2.571944150986383e-07
mutations O 0 6.446985878483247e-08
accounted O 0 1.4438884754497394e-08
for O 0 9.742961992742494e-10
8 O 0 1.8284089797759862e-09
( O 0 1.9367611681087027e-10
18 O 0 3.7033898170335533e-10
% O 0 2.0879163675768808e-10
) O 0 1.6137921554637558e-10
and O 0 2.624444273013893e-10
6 O 0 5.637320610318852e-10
( O 0 9.205832623981891e-11
14 O 0 3.1144892220780207e-10
% O 0 1.6876305908297695e-10
) O 0 6.289781889767809e-11
of O 0 6.695616977525631e-11
44 O 0 3.191962916204716e-09
unrelated O 0 4.8588354673029244e-08
alleles O 0 3.431393338360067e-07
, O 0 1.1260404164659121e-08
respectively O 0 3.3497988738417916e-07
. O 0 3.477411780750117e-07

The O 0 9.182767257698288e-08
relatively O 0 4.5007048754541756e-08
high O 0 7.745050112362151e-08
residual O 0 1.3271853731566807e-06
GALNS O 0 1.1103263659606455e-06
activity O 0 3.840313667069495e-08
seen O 0 7.247089683914965e-08
when O 0 6.460290080667619e-09
the O 0 4.5041184670857604e-10
T312S O 0 4.901691141867559e-08
mutant O 0 2.666320142452605e-08
cDNA O 0 2.7829768711740144e-08
is O 0 2.23028839840822e-09
overexpressed O 0 2.7484941256261664e-07
in O 0 1.164386254082217e-09
mutant O 0 5.430502270087345e-08
cells O 0 1.3009461063973049e-08
provides O 0 4.5113060509471836e-10
an O 0 3.489358108010876e-11
explanation O 0 6.842332811451968e-10
for O 0 1.2162412743599305e-10
the O 0 1.7055131751320118e-09
mild O 0 9.231426361111517e-07
phenotype O 0 7.532528798037674e-06
in O 0 6.6886545191380264e-09
patients O 0 3.302856299569612e-08
with O 0 8.108178572996394e-10
this O 0 1.016553685673216e-08
mutation O 0 5.049065293860622e-06
. O 0 4.543061038475571e-07

The O 0 2.2573843239115376e-08
distribution O 0 2.7767891097596475e-08
and O 0 2.7395472557145695e-09
relative O 0 4.733016201186047e-09
frequencies O 0 9.45914280237048e-09
of O 0 1.358762546921355e-10
the O 0 4.562246691541816e-10
I113F O 0 9.605009410051935e-08
and O 0 1.273546157420924e-09
T312S O 0 3.75784097172982e-08
mutations O 0 1.2191317289023118e-08
in O 0 2.8733804224856385e-10
Australia O 0 9.439703879676742e-11
corresponded O 0 2.1321203136359657e-10
to O 0 4.377746082306899e-11
those O 0 9.015060226102989e-11
observed O 0 7.223581177662197e-10
in O 0 2.124987130702749e-10
Northern O 0 4.490361860121084e-09
Ireland O 0 2.0362990937883296e-07
and O 0 4.939282871596617e-10
are O 0 4.2174153058738284e-11
unique O 0 2.1193648225281692e-10
to O 0 7.191354456370647e-11
these O 0 5.46586664817994e-11
two O 0 6.310354322414113e-11
populations O 0 1.375813574178153e-09
, O 0 1.064911422932191e-10
suggesting O 0 1.2025813678206987e-09
that O 0 5.029518121424381e-11
both O 0 1.1563296847816318e-10
mutations O 0 2.002423116209684e-09
were O 0 1.081017220183611e-10
probably O 0 1.247531938863844e-10
introduced O 0 2.584909508662747e-10
to O 0 1.188101006466269e-10
Australia O 0 3.69768687891181e-10
by O 0 1.877996924637415e-10
Irish O 0 1.1922224096849732e-08
migrants O 0 4.633298633649474e-09
during O 0 1.3999765791083973e-09
the O 0 6.671145302838966e-10
19th O 0 1.2292120743495616e-07
century O 0 9.964775244952762e-07
. O 0 5.179978757041681e-07

Haplotype O 0 0.0001717230916256085
analysis O 0 4.995061431145587e-07
using O 0 1.3260894604627538e-07
6 O 0 2.4379531282647804e-08
RFLPs O 0 1.2427767615008634e-07
provides O 0 1.2330666487869735e-09
additional O 0 6.110424388694469e-10
data O 0 8.797371719992952e-09
that O 0 5.19424447897876e-10
the O 0 9.461880168259995e-10
I113F O 0 1.9690500607794093e-07
mutation O 0 4.111749518642682e-08
originated O 0 9.519196098040084e-09
from O 0 7.41092354150652e-10
a O 0 3.367747414273481e-09
common O 0 9.651195398419077e-08
ancestor O 0 1.4676976434202516e-06
. O 0 1.4176981721902848e-06

The O 0 4.859447244598414e-08
other O 0 5.083046872300656e-09
9 O 0 4.51978321436286e-09
novel O 0 1.0626806101754482e-08
mutations O 0 3.685924099272597e-08
identified O 0 1.5585825963171374e-08
in O 0 1.4235040923793463e-10
these O 0 1.7389184536753532e-10
23 O 0 4.2409395439868547e-10
patients O 0 3.9634390214260407e-10
were O 0 3.653922650559416e-11
each O 0 3.188807551346429e-11
limited O 0 1.178900754794654e-09
to O 0 4.581771628764386e-10
a O 0 3.2619791312527013e-09
single O 0 1.9478034118947107e-07
family O 0 2.1988263654293405e-07
. O 0 2.870535809051944e-07

These O 0 2.8876296909174926e-08
data O 0 2.3776383528684164e-08
provide O 0 2.5919804080842823e-09
further O 0 4.165628675334432e-10
evidence O 0 1.9011503482602166e-09
for O 0 3.034234807852698e-10
extensive O 0 2.1950922857172372e-08
allelic O 0 9.404365073351073e-07
heterogeneity O 0 2.5530614493618486e-06
in O 0 4.412525527186517e-07
MPS B-Disease 1 0.9999985694885254
IVA I-Disease 1 0.9999998807907104
in O 0 5.378990053372945e-08
British O 0 8.993920346256346e-06
- O 0 7.460322649421869e-06
Irish O 0 1.383081809080977e-07
patients O 0 5.90612936335333e-09
and O 0 8.387811972765391e-11
provide O 0 9.36715496835383e-11
evidence O 0 2.0332538430700708e-10
for O 0 1.762306967023619e-11
their O 0 4.4458884490561346e-11
transmission O 0 5.54585088963222e-09
to O 0 4.232874328824465e-10
Australia O 0 8.594953082585732e-10
by O 0 2.8124186313149835e-10
British O 0 2.6124116629944183e-06
- O 0 1.5598041045450373e-06
Irish O 0 1.2432379037363717e-07
migrants O 0 3.37558176966013e-08
. O 0 1.1724364590293135e-08
. O 0 8.031473441860726e-08

Identification O 0 3.0028543278604047e-06
of O 0 1.8126868894796644e-08
constitutional O 0 2.862703354367113e-07
WT1 O 0 1.6573190805502236e-05
mutations O 0 1.8400235148874344e-06
, O 0 3.959360839189685e-09
in O 0 2.093300421890376e-09
patients O 0 4.342823345382385e-08
with O 0 3.3045308711621146e-09
isolated O 0 1.688395241217222e-05
diffuse B-Disease 1 0.8591189980506897
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
, O 0 7.265175128168266e-09
and O 0 9.193887873237827e-10
analysis O 0 7.949490843373042e-09
of O 0 1.279462424896849e-09
genotype O 0 0.01077516470104456
/ O 0 1.4156191355141345e-05
phenotype O 0 1.5454000958925462e-06
correlations O 0 1.122115094176479e-07
by O 0 2.231065887592365e-10
use O 0 3.751150945419113e-09
of O 0 3.431948614185387e-10
a O 0 8.723915811970073e-09
computerized O 0 1.6749239875935018e-05
mutation O 0 8.704556421434972e-06
database O 0 3.3675742088234983e-06
. O 0 1.0902472240559291e-06

Constitutional O 0 2.261507688672282e-06
mutations O 0 1.95439747585624e-06
of O 0 3.948583682245044e-09
the O 0 4.226938354889853e-09
WT1 O 0 2.8706720058835344e-06
gene O 0 8.461611855636875e-08
, O 0 1.0373684133924144e-09
encoding O 0 1.9283074692566515e-08
a O 0 9.11121578184293e-09
zinc O 0 0.0004572337493300438
- O 0 7.995109854164184e-07
finger O 0 4.129126409679884e-07
transcription O 0 4.749785631474879e-08
factor O 0 3.5872140813353326e-08
involved O 0 9.026872582751366e-09
in O 0 1.5955341936546574e-08
renal O 0 0.0046147252433001995
and O 0 1.576413488635353e-08
gonadal O 0 0.006716608069837093
development O 0 2.9979425608672727e-09
, O 0 1.8737963958237458e-10
are O 0 4.643636516976635e-11
found O 0 3.187033692508834e-10
in O 0 7.692538966930229e-11
most O 0 6.353811921044894e-10
patients O 0 9.926113264668857e-09
with O 0 6.224222026673942e-09
Denys B-Disease 1 0.9999991655349731
- I-Disease 1 0.9999996423721313
Drash I-Disease 1 0.9999974966049194
syndrome I-Disease 1 0.999998927116394
( O 0 2.203868554317978e-08
DDS B-Disease 1 1.0
) O 0 1.306685692981091e-08
, O 0 1.534579241457834e-09
or O 0 1.752546125999288e-07
diffuse B-Disease 1 0.9832034111022949
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
( O 0 1.759190553229928e-07
DMS B-Disease 0 0.1499384045600891
) O 0 3.85565135374577e-09
associated O 0 8.145616625654384e-09
with O 0 4.571901079941654e-09
pseudohermaphroditism B-Disease 1 1.0
and O 0 8.203783750104776e-07
/ O 0 9.845940439845435e-06
or O 0 2.7991447950626025e-06
Wilms B-Disease 1 0.9412566423416138
tumor I-Disease 0 0.002309537725523114
( O 0 1.7942021202088654e-07
WT B-Disease 1 0.9999998807907104
) O 0 2.4307476564899844e-07
. O 0 4.2981349679394043e-07

Most O 0 8.794771702014259e-07
mutations O 0 1.173194050352322e-05
in O 0 3.5895621408599254e-07
DDS B-Disease 1 1.0
patients O 0 0.0005083946161903441
lie O 0 5.979639468023379e-07
in O 0 3.829625061513298e-09
exon O 0 2.4168323875528586e-07
8 O 0 5.109057621410784e-09
or O 0 2.0364294694985574e-09
exon O 0 1.5433219857641234e-07
9 O 0 5.443057116139016e-09
, O 0 4.964179067812324e-10
encoding O 0 5.175845174676397e-08
zinc O 0 0.00017775039304979146
finger O 0 1.4304466276371386e-05
2 O 0 2.6391145269144545e-08
or O 0 2.0504772990648235e-08
zinc O 0 0.00010070228745462373
finger O 0 1.9713137589860708e-05
3 O 0 4.8722523793287564e-09
, O 0 2.1873831912433417e-10
respectively O 0 1.5895130767162868e-09
, O 0 1.0009222617402003e-10
with O 0 1.20341819842551e-10
a O 0 1.912898950351405e-09
hot O 0 5.462174499371031e-07
spot O 0 4.169259682385018e-06
( O 0 1.138166449976552e-09
R394W O 0 5.430253580129829e-08
) O 0 9.823311053480666e-10
in O 0 2.1924466686584765e-09
exon O 0 1.1796221315307776e-06
9 O 0 1.6970018634765438e-07
. O 0 1.7373363903061545e-07

We O 0 1.4809801029969094e-07
analyzed O 0 3.8503106480902716e-08
a O 0 9.81821624002066e-10
series O 0 2.21398344102397e-09
of O 0 2.1746081324547362e-10
24 O 0 3.4322251707408213e-09
patients O 0 6.012322195658726e-09
, O 0 2.2915971897852216e-10
10 O 0 3.0677185791638806e-10
with O 0 8.673142759541008e-10
isolated B-Disease 0 6.587247298739385e-06
DMS I-Disease 1 0.9503311514854431
( O 0 3.4346023802811487e-09
IDMS B-Disease 0 9.555994438414928e-06
) O 0 1.353827605576896e-09
, O 0 2.0478917173161193e-10
10 O 0 2.2234912522289818e-10
with O 0 1.0610354816975587e-09
DDS B-Disease 1 1.0
, O 0 9.184883076329697e-09
and O 0 2.8715463340489578e-09
4 O 0 4.215054971723475e-09
with O 0 5.789983159587564e-09
urogenital B-Disease 0 0.0387127585709095
abnormalities I-Disease 1 0.9998341798782349
and O 0 1.4442376823353698e-06
/ O 0 0.00032119941897690296
or O 0 0.0009798438986763358
WT B-Disease 1 1.0
. O 0 3.360702066856902e-06

We O 0 9.08153106138343e-06
report O 0 1.6444579387098202e-06
WT1 O 0 3.8342255720635876e-05
heterozygous O 0 3.828667104244232e-06
mutations O 0 1.1356371487636352e-06
in O 0 6.478169556345392e-09
16 O 0 1.0330546196257728e-08
patients O 0 3.480795029986439e-08
, O 0 3.2107805303382975e-10
4 O 0 7.452811701114115e-10
of O 0 2.616287742007728e-10
whom O 0 7.588687367388047e-08
presented O 0 1.087956462697548e-07
with O 0 1.206674369313987e-07
IDMS B-Disease 1 0.7667528390884399
. O 0 1.4218996966519626e-06

One O 0 4.862080231760046e-07
male O 0 5.153130473445344e-07
and O 0 1.0335393874072452e-08
two O 0 2.054705561249648e-08
female O 0 3.4771837817970663e-06
IDMS B-Disease 1 0.8359817862510681
patients O 0 2.131144128725282e-06
with O 0 3.56938016921049e-08
WT1 O 0 0.00027869653422385454
mutations O 0 7.087596895871684e-05
underwent O 0 8.01394253358012e-06
normal O 0 8.505561709171161e-06
puberty O 0 6.210691935848445e-05
. O 0 3.7751367472083075e-06

Two O 0 6.385076858350658e-07
mutations O 0 8.610008080722764e-06
associated O 0 1.4276879767294304e-07
with O 0 8.566512832430817e-09
IDMS B-Disease 0 5.047880404163152e-05
are O 0 8.280707786134656e-10
different O 0 4.296581146423506e-10
from O 0 5.350140330762088e-10
those O 0 2.264693099718329e-09
described O 0 1.5708373268807918e-07
in O 0 6.256026949813531e-07
DDS B-Disease 1 1.0
patients O 0 6.244202813832089e-05
. O 0 5.762981345469598e-07

No O 0 2.4532073439331725e-06
WT1 O 0 2.6602490834193304e-05
mutations O 0 2.0338936792541062e-06
were O 0 6.072712999127816e-09
detected O 0 3.387617297789802e-08
in O 0 3.0065594458505984e-10
the O 0 2.4562471501177185e-10
six O 0 1.8372464660743049e-09
other O 0 2.594542802825117e-09
IDMS B-Disease 0 0.004077746998518705
patients O 0 7.912357347095167e-08
, O 0 3.626492439678941e-10
suggesting O 0 2.1462724930643162e-08
genetic O 0 2.8264528850741044e-07
heterogeneity O 0 3.4331083043070976e-07
of O 0 3.5236917828029846e-09
this O 0 1.3101389129133167e-07
disease O 0 1.941725713550113e-05
. O 0 9.781268772712792e-07

We O 0 1.944792302310816e-06
analyzed O 0 4.434302809386281e-06
genotype O 0 4.182745033176616e-05
/ O 0 7.870145054766908e-06
phenotype O 0 1.4463769275607774e-06
correlations O 0 1.0529696510275244e-06
, O 0 2.069970639340113e-09
on O 0 3.8368977439695584e-10
the O 0 8.719848454408208e-11
basis O 0 6.302779409494974e-10
of O 0 6.696587728782788e-11
the O 0 5.437046368683696e-10
constitution O 0 5.728731267140574e-09
of O 0 1.925372777877854e-10
a O 0 3.5479974513918933e-09
WT1 O 0 1.83028214451042e-06
mutation O 0 5.254465662574148e-08
database O 0 8.188798084063365e-09
of O 0 3.5167205258979095e-10
84 O 0 9.332406847306629e-09
germ O 0 1.0502745681151282e-05
- O 0 7.2281395659956615e-06
line O 0 3.8148428416207025e-07
mutations O 0 5.866377250640653e-08
, O 0 8.159043579647474e-11
to O 0 2.0307604556291103e-11
compare O 0 1.390781267929242e-09
the O 0 2.45531841386315e-11
distribution O 0 4.196410718915189e-10
and O 0 8.481866320408926e-10
type O 0 2.5992992647161373e-08
of O 0 4.646382931183801e-11
mutations O 0 2.5084236909833635e-08
, O 0 1.0623127377762387e-10
according O 0 5.670932473611501e-11
to O 0 9.867869021906728e-11
the O 0 1.045099784491299e-09
different O 0 5.3780969011540947e-08
symptoms O 0 4.3772620301751886e-06
. O 0 2.4515370000699477e-07

This O 0 7.19858306297283e-08
demonstrated O 0 5.866567320822469e-08
( O 0 7.506265609080742e-10
1 O 0 1.0825054186369698e-09
) O 0 5.582461715114562e-10
the O 0 5.151797877189779e-10
association O 0 8.969031628502933e-10
between O 0 8.033074205826551e-10
mutations O 0 3.6653826640531406e-08
in O 0 4.179875057186422e-10
exons O 0 6.822035913955915e-08
8 O 0 2.944536614535309e-09
and O 0 1.8147338076701658e-09
9 O 0 2.664412468433852e-09
and O 0 4.392311847567498e-09
DMS B-Disease 0 2.42179048655089e-05
; O 0 1.1050819148650248e-09
( O 0 1.0239532138855978e-10
2 O 0 6.032592758664634e-10
) O 0 3.4668773407631193e-10
among O 0 7.486748998530857e-10
patients O 0 3.3009528443983527e-09
with O 0 2.318057135131113e-10
DMS B-Disease 0 0.0005985872121527791
, O 0 3.5388444952211273e-10
a O 0 1.6510415257187105e-10
higher O 0 2.6607354097762936e-09
frequency O 0 1.522417214516736e-08
of O 0 3.625828248754459e-10
exon O 0 8.475906554394896e-08
8 O 0 6.951704545343773e-09
mutations O 0 3.215876986928379e-08
among O 0 1.9389871930286517e-09
46 O 0 9.96496307692496e-09
, O 0 4.2402299449406655e-09
XY O 0 4.877048013440799e-06
patients O 0 3.361953559988251e-08
with O 0 5.183694029575747e-10
female O 0 3.6154730764792475e-08
phenotype O 0 8.108108318083396e-08
than O 0 9.354037544540006e-10
among O 0 1.2464266285761028e-09
46 O 0 2.1105970304802213e-08
, O 0 8.901768211444505e-09
XY O 0 2.1524567273445427e-05
patients O 0 4.3956493556152054e-08
with O 0 3.42808226250213e-10
sexual O 0 3.039717455521895e-08
ambiguity O 0 3.039176021957246e-07
or O 0 1.6822983184283657e-07
male O 0 7.257975767060998e-07
phenotype O 0 5.758882366535545e-07
; O 0 4.119558028037318e-09
and O 0 1.8246673061383945e-09
( O 0 2.5141402848483096e-10
3 O 0 3.581372143290906e-10
) O 0 1.714050013035262e-10
statistically O 0 3.2972213848125875e-09
significant O 0 1.2338619015395125e-09
evidence O 0 6.284128772904296e-09
that O 0 9.624476771108448e-10
mutations O 0 1.014655293118949e-08
in O 0 2.9573116178127634e-10
exons O 0 3.620020549988112e-08
8 O 0 2.717139402363955e-09
and O 0 1.4889830479702937e-09
9 O 0 2.504951357451546e-09
preferentially O 0 3.8162468740665645e-08
affect O 0 1.0389965332535667e-08
amino O 0 5.416100012922698e-09
acids O 0 1.609722799500446e-09
with O 0 6.62424073927248e-11
different O 0 1.0374178183170102e-09
functions O 0 1.1464965865570775e-08
. O 0 4.112165186143102e-08
. O 0 3.1467129701923113e-07

The O 0 3.4855824537771696e-07
185delAG O 0 1.7384649254381657e-05
BRCA1 O 0 1.0909733646258246e-05
mutation O 0 3.9100120829971274e-07
originated O 0 2.244679997431831e-08
before O 0 2.8856570466473386e-09
the O 0 2.097307882920063e-10
dispersion O 0 2.5714873785886994e-08
of O 0 4.264647315843639e-11
Jews O 0 3.5616802840365835e-09
in O 0 1.8002362101032787e-10
the O 0 1.5765649896692935e-10
diaspora O 0 4.140133125218881e-09
and O 0 7.516265942975053e-10
is O 0 2.7453991857662174e-10
not O 0 6.014199693815669e-10
limited O 0 3.310776763854051e-09
to O 0 5.2327098210014356e-09
Ashkenazim O 0 3.073507514272933e-06
. O 0 2.2003325739206048e-07

The O 0 2.290446587949191e-07
185delAG O 0 4.3528139030968305e-06
mutation O 0 8.422955488640582e-07
in O 0 4.8372137406715865e-09
BRCA1 O 0 5.350161131900677e-07
is O 0 2.0927655164371117e-09
detected O 0 2.8271365692944528e-08
in O 0 9.567847625291392e-10
Ashkenazi O 0 1.2140121441461815e-07
Jews O 0 4.2375614128786765e-09
both O 0 5.806723990531282e-10
in O 0 2.3578565766513293e-09
familial B-Disease 0 0.1721441149711609
breast I-Disease 1 0.9999972581863403
and I-Disease 1 0.9999780654907227
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 6.521709838835932e-09
in O 0 9.326264205355983e-10
the O 0 1.215103351270841e-09
general O 0 8.937034223777118e-09
population O 0 6.050598244655703e-08
. O 0 2.6018966536867083e-07

All O 0 3.8366096077879774e-07
tested O 0 1.74538865849172e-06
Ashkenazi O 0 3.7170950690779136e-06
mutation O 0 3.7174066847001086e-07
carriers O 0 1.4011264681812463e-07
share O 0 3.2084759737927016e-08
the O 0 9.640497289353789e-10
same O 0 9.358788410906982e-09
allelic O 0 1.3896743666919065e-06
pattern O 0 1.1209786862309556e-05
at O 0 9.856783833583904e-08
the O 0 7.384051770031874e-08
BRCA1 O 0 9.351241169497371e-05
locus O 0 7.702790026087314e-05
. O 0 3.5377086078369757e-06

Our O 0 4.507083417593094e-07
previous O 0 4.168199652099247e-08
study O 0 1.2415040551161383e-08
showed O 0 6.9513865774695205e-09
that O 0 2.1699676777675592e-10
this O 0 6.624105153285598e-10
Ashkenazi O 0 1.0069850304716965e-06
mutation O 0 1.008666217217069e-07
also O 0 2.1379609194127625e-09
occurs O 0 1.9766988046399092e-09
in O 0 6.668626206796091e-10
Iraqi O 0 8.736871670578239e-09
Jews O 0 1.0452877674538286e-08
with O 0 3.7616523784755884e-10
a O 0 3.798924286257943e-09
similar O 0 1.3822854327827372e-07
allelic O 0 1.123922447732184e-05
pattern O 0 6.338005914585665e-05
. O 0 1.481630192756711e-06

We O 0 3.7287222198756353e-07
extended O 0 2.1316425957706997e-08
our O 0 3.2199198862770118e-09
analysis O 0 2.3425930084641777e-09
to O 0 2.460199544085384e-10
other O 0 4.817783394450714e-10
non O 0 4.7864268992725556e-08
- O 0 2.2255179032981687e-07
Ashkenazi O 0 3.52163823436058e-07
subsets O 0 1.636539437299689e-08
354 O 0 9.41095024131755e-09
of O 0 3.7714659173460063e-10
Moroccan O 0 8.837722020871297e-08
origin O 0 1.068750155042153e-08
, O 0 5.248280698921803e-10
200 O 0 9.416493140790294e-10
Yemenites O 0 9.426690184000108e-08
and O 0 1.598299048666263e-09
150 O 0 2.0988417670508852e-09
Iranian O 0 8.112996852105425e-08
Jews O 0 1.5195021774161432e-07
. O 0 1.335863117901681e-07

Heteroduplex O 0 3.773808202822693e-05
analysis O 0 5.171163479644747e-07
complemented O 0 1.0508053094326897e-07
by O 0 2.176584468216447e-09
direct O 0 1.200904087284016e-08
DNA O 0 8.308465027084821e-08
sequencing O 0 6.204832914136205e-08
of O 0 1.1278410427806307e-09
abnormally O 0 7.672797153190913e-08
migrating O 0 1.869493004846845e-08
bands O 0 8.191207001573275e-08
were O 0 2.2410779010328952e-08
employed O 0 1.0542698873905465e-06
. O 0 5.038493782194564e-07

Four O 0 1.62619727461788e-07
of O 0 4.3775170155413434e-09
Moroccan O 0 3.97514781980135e-07
origin O 0 1.230842094912532e-08
( O 0 2.689203582040278e-10
1 O 0 3.192381359262697e-10
. O 0 1.2160394913252048e-10
1 O 0 4.690166033327614e-10
% O 0 1.422027773312351e-10
) O 0 1.2975250041069586e-10
and O 0 3.17963239071517e-10
none O 0 8.151597175043435e-10
of O 0 8.824919961458733e-12
the O 0 6.89281201560199e-11
Yemenites O 0 1.1185674608782392e-08
or O 0 6.910508276725125e-10
Iranians O 0 2.9384941147014842e-09
was O 0 9.141796764033927e-10
a O 0 2.2295471024946778e-10
carrier O 0 1.1251579223880981e-08
of O 0 1.7526037565662733e-10
the O 0 4.184774748949849e-09
185delAG O 0 2.609348939586198e-06
mutation O 0 3.4955367027578177e-06
. O 0 3.3648407793407387e-07

BRCA1 O 0 0.00020202250743750483
allelic O 0 1.0197937626799103e-05
patterns O 0 9.357397061648953e-07
were O 0 5.433514083108548e-09
determined O 0 6.44168629548858e-09
for O 0 1.0105481729194565e-10
four O 0 7.530109868980617e-11
of O 0 5.262428513785888e-12
these O 0 2.895986922490934e-11
individuals O 0 3.409118820574264e-11
and O 0 9.529904643201803e-11
for O 0 5.518053028397141e-11
12 O 0 2.84488682611439e-10
additional O 0 1.3334207071835635e-09
non O 0 1.4563605077455577e-07
- O 0 1.7394894484823453e-06
Ashkenazi O 0 7.612468380102655e-07
185delAG O 0 1.847938904120383e-07
mutation O 0 6.071650204830803e-08
carriers O 0 2.5072662168668103e-08
who O 0 2.2806199595493126e-08
had O 0 6.982336913097242e-07
breast B-Disease 1 0.9999793767929077
/ I-Disease 1 0.9999984502792358
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.9913212529208977e-06

Six O 0 2.7835797027364606e-06
non O 0 1.6884241631487384e-05
- O 0 0.0001227900938829407
Ashkenazi O 0 1.822578633436933e-05
individuals O 0 7.658991663106463e-09
shared O 0 7.10010050752885e-09
the O 0 1.692347484372192e-09
common O 0 4.301816858287566e-08
Ashkenazi O 0 1.5092281273609842e-06
haplotype O 0 4.91348998821195e-07
, O 0 8.679034158021182e-10
four O 0 1.1491143592223807e-09
had O 0 1.0970245156727287e-08
a O 0 3.653715385798506e-10
closely O 0 6.314694989129066e-09
related O 0 7.895033071747548e-09
pattern O 0 1.195443019241793e-06
, O 0 1.802047733256984e-09
and O 0 9.033671033442658e-10
the O 0 8.403284734725958e-10
rest O 0 3.368318957086558e-09
( O 0 6.381077333195151e-10
n O 0 1.313553070758644e-07
= O 0 3.737031306627614e-07
6 O 0 5.205275321884528e-09
) O 0 6.841941457835787e-10
displayed O 0 1.276623340373817e-08
a O 0 1.090324186492353e-08
distinct O 0 7.312745538001764e-07
BRCA1 O 0 7.794086559442803e-05
allelic O 0 3.599451156333089e-05
pattern O 0 0.00011415416520321742
. O 0 5.88565899306559e-06

We O 0 5.890584020562528e-07
conclude O 0 9.695735769810199e-08
that O 0 9.600550354704751e-10
the O 0 1.2153374973067343e-09
185delAG O 0 5.437616437120596e-07
BRCA1 O 0 1.3548274182539899e-06
mutation O 0 8.712978427638518e-08
occurs O 0 2.1153030438370024e-09
in O 0 1.4322189267890195e-10
some O 0 2.9308969140551255e-10
non O 0 1.4177804530390858e-07
- O 0 1.1876095413754229e-05
Ashkenazi O 0 1.2353751117188949e-05
populations O 0 1.612643174553341e-08
at O 0 1.511024083633572e-09
rates O 0 2.2455524106845814e-09
comparable O 0 2.258360831675077e-09
with O 0 1.3661584363777735e-10
that O 0 8.9940432879132e-10
of O 0 2.425651013382435e-09
Ashkenazim O 0 7.640560397703666e-06
. O 0 2.906583915773808e-07

The O 0 1.354456315993957e-07
majority O 0 7.727991402362022e-08
of O 0 9.241991616448786e-10
Jewish O 0 7.282840641664734e-08
185delAG O 0 3.016597815985733e-07
mutation O 0 1.8640066912212205e-07
carriers O 0 7.453670747281649e-08
have O 0 3.779893731348238e-09
a O 0 1.3833655332362582e-09
common O 0 1.8824781733428608e-08
allelic O 0 4.4150178268864693e-07
pattern O 0 2.203080157414661e-06
, O 0 4.785383644900776e-09
supporting O 0 1.0023944341241986e-08
the O 0 6.776303962396923e-10
founder O 0 1.176051434015335e-08
effect O 0 7.960567316445122e-09
notion O 0 6.395665774761028e-09
, O 0 2.931176135145819e-10
but O 0 3.915351098893183e-10
dating O 0 5.331785679629775e-09
the O 0 2.4183599567351166e-10
mutations O 0 4.289557598013971e-09
origin O 0 8.838573206659817e-10
to O 0 1.0907016262384772e-10
an O 0 5.109150255644401e-11
earlier O 0 1.838799557063453e-09
date O 0 7.999791939994338e-09
than O 0 1.1945366917842648e-09
currently O 0 1.3875784077299613e-08
estimated O 0 3.7975929956246546e-08
. O 0 1.7025637077949796e-07

However O 0 3.0941276918383664e-07
, O 0 4.438605927248318e-09
the O 0 3.497095391047367e-10
different O 0 2.501198803628313e-09
allelic O 0 2.7487300258144387e-07
pattern O 0 2.1273610855132574e-06
at O 0 1.6383259193730737e-08
the O 0 2.3932977821772283e-09
BRCA1 O 0 3.168182445278944e-07
locus O 0 1.0880996370588036e-07
even O 0 4.275565679279225e-09
in O 0 1.3369344520341997e-10
some O 0 1.204038119206885e-10
Jewish O 0 9.63412460919244e-09
mutation O 0 2.0718044169143468e-08
carriers O 0 9.662169730972892e-09
, O 0 3.160423311943106e-10
might O 0 1.163691365491104e-09
suggest O 0 2.991174419264553e-09
that O 0 3.872290543771584e-10
the O 0 1.0331091537807424e-09
mutation O 0 6.665516849579944e-08
arose O 0 2.8063505297382108e-08
independently O 0 3.957158156708829e-08
. O 0 2.0493864383297478e-08
. O 0 1.5714157086677005e-07

Crystal O 0 0.00010523451783228666
structure O 0 6.852120577605092e-07
of O 0 7.252852984862557e-09
the O 0 4.150049193185623e-08
hemochromatosis B-Disease 1 0.9999997615814209
protein O 0 8.85976135123201e-07
HFE O 0 9.518599108560011e-05
and O 0 7.638275789645377e-09
characterization O 0 1.0935674055190248e-07
of O 0 7.877159480251805e-10
its O 0 4.335016789980273e-09
interaction O 0 2.8369623095159113e-08
with O 0 1.1275125721965651e-08
transferrin O 0 1.029391114570899e-05
receptor O 0 4.119531695323531e-06
. O 0 6.311031484074192e-07

HFE O 0 0.004174433182924986
is O 0 6.64185392906802e-07
an O 0 3.259206948769133e-08
MHC O 0 1.111869187297998e-05
- O 0 4.049007316098141e-07
related O 0 6.940920282971774e-09
protein O 0 3.896705624839569e-09
that O 0 1.253358666852833e-10
is O 0 1.1501202074049033e-10
mutated O 0 1.1670772792626849e-08
in O 0 6.097129467974582e-10
the O 0 3.829303985014576e-09
iron B-Disease 1 0.9967652559280396
- I-Disease 1 0.9999945163726807
overload I-Disease 1 0.9994530081748962
disease I-Disease 1 0.9997727274894714
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 0.00017395996837876737

HFE O 0 0.0016283354489132762
binds O 0 1.935550790221896e-05
to O 0 2.52643530984642e-07
transferrin O 0 1.1784935850300826e-05
receptor O 0 1.372807219013339e-06
( O 0 9.193734662460429e-09
TfR O 0 1.4083515225138399e-06
) O 0 4.050387136800282e-09
and O 0 2.4574291490608857e-09
reduces O 0 3.572540663299151e-08
its O 0 6.299690213928955e-10
affinity O 0 1.3276478583179596e-08
for O 0 1.476108568709833e-09
iron O 0 0.00014553983055520803
- O 0 9.932497960107867e-06
loaded O 0 1.448636481882204e-07
transferrin O 0 7.393394412247289e-07
, O 0 5.888885379334852e-09
implicating O 0 6.254541631278698e-07
HFE O 0 5.0083701353287324e-05
in O 0 5.2561198060629977e-08
iron O 0 0.00011940007243538275
metabolism O 0 2.528683762648143e-05
. O 0 6.190819021867355e-07

The O 0 1.135354636971897e-06
2 O 0 1.6450854900540435e-06
. O 0 1.5330871292462689e-06

6 O 0 7.5232956078252755e-06
A O 0 1.4839660877896677e-07
crystal O 0 1.232698923558928e-05
structure O 0 5.823422384310106e-07
of O 0 2.167701795841026e-09
HFE O 0 1.3257888895168435e-05
reveals O 0 6.333949897907587e-08
the O 0 3.656538682950128e-10
locations O 0 2.1456013854503908e-08
of O 0 4.146984977637658e-09
hemochromatosis B-Disease 1 1.0
mutations O 0 0.0006883527967147529
and O 0 2.0528291955201894e-08
a O 0 4.479865367557068e-09
patch O 0 3.0076464554440463e-06
of O 0 1.1513471426249922e-10
histidines O 0 1.0918063253484434e-07
that O 0 3.7940631192334706e-10
could O 0 2.1816008999309133e-09
be O 0 2.5241297940681306e-10
involved O 0 8.136529228153222e-10
in O 0 2.7433590954473175e-09
pH O 0 1.8885687040892662e-06
- O 0 3.2922605441854103e-06
dependent O 0 1.0489244459677138e-06
interactions O 0 4.219626248413988e-07
. O 0 2.6724967483460205e-07

We O 0 8.159005915331363e-07
also O 0 8.376372484519834e-09
demonstrate O 0 2.983665936540092e-08
that O 0 5.6263345094009765e-09
soluble O 0 7.614436299263616e-07
TfR O 0 3.5797618238575524e-06
and O 0 7.16816384027652e-09
HFE O 0 1.8584948975330917e-06
bind O 0 1.697761149443977e-07
tightly O 0 1.2675688765284576e-07
at O 0 6.1693330444256844e-09
the O 0 3.6267897018937845e-10
basic O 0 5.173285799742189e-09
pH O 0 1.531121185394113e-08
of O 0 3.1915702719542693e-11
the O 0 3.3570035640195783e-10
cell O 0 1.9234666126521915e-07
surface O 0 4.089068625034997e-06
, O 0 8.720251742921903e-10
but O 0 2.5825255267619696e-09
not O 0 1.2486968126168563e-09
at O 0 1.9758354952159607e-09
the O 0 3.077343047053205e-09
acidic O 0 3.905335574927449e-07
pH O 0 4.3248033421150467e-07
of O 0 1.1511770203753713e-08
intracellular O 0 7.669206752325408e-06
vesicles O 0 1.5682278899475932e-05
. O 0 1.3111516636854503e-06

TfR O 0 0.02953021414577961
HFE O 0 0.0014026405988261104
stoichiometry O 0 2.4992765247588977e-05
( O 0 1.282124060253409e-07
2 O 0 2.987589553526959e-08
1 O 0 8.704635234835223e-09
) O 0 2.436613133482979e-09
differs O 0 2.362264694966143e-08
from O 0 5.54925794205019e-09
TfR O 0 1.8632563296705484e-06
transferrin O 0 4.583428392379574e-07
stoichiometry O 0 1.395485611510594e-07
( O 0 7.38389016596841e-10
2 O 0 5.699313243567872e-10
2 O 0 5.339629294276449e-10
) O 0 1.8027480896964931e-10
, O 0 5.634985186797614e-11
implying O 0 1.4325967079287238e-09
a O 0 8.143154206496916e-11
different O 0 1.442551911257084e-10
mode O 0 3.2318689946464474e-09
of O 0 3.9967782555772047e-11
binding O 0 9.326606154047568e-09
for O 0 1.2302359131410867e-09
HFE O 0 1.611418269931164e-06
and O 0 2.0570141145981324e-09
transferrin O 0 7.595956930117609e-08
to O 0 8.635178128102439e-10
TfR O 0 3.176532743509597e-07
, O 0 3.21264265190635e-10
consistent O 0 9.120270094697958e-10
with O 0 1.0712593312423024e-10
our O 0 9.32348864779442e-10
demonstration O 0 2.6241753214861774e-09
that O 0 4.923630947395452e-10
HFE O 0 3.464594442448288e-07
, O 0 3.951844407268368e-10
transferrin O 0 5.6851177987482515e-08
, O 0 9.220545438282102e-10
and O 0 4.791896213163227e-09
TfR O 0 1.3712775626117946e-06
form O 0 2.53201601907449e-08
a O 0 1.7211510439096855e-08
ternary O 0 2.1852185909665423e-06
complex O 0 4.316143986216048e-06
. O 0 1.9781082301051356e-06

Identification O 0 5.87604063184699e-07
of O 0 2.1389237048197174e-09
three O 0 1.0417006146568042e-09
novel O 0 1.4015002491873929e-08
mutations O 0 7.360541331991044e-08
and O 0 1.1931430288214528e-09
a O 0 4.6174783441266243e-10
high O 0 3.3218143791202692e-09
frequency O 0 2.8208400948415147e-08
of O 0 1.1031123930971276e-10
the O 0 1.0254176396884418e-09
Arg778Leu O 0 1.978332647922798e-06
mutation O 0 3.927423506411287e-07
in O 0 3.1164753000467726e-09
Korean O 0 1.6730471941173164e-07
patients O 0 5.932562530119867e-08
with O 0 6.04477090604405e-09
Wilson B-Disease 0 3.695128498293343e-06
disease I-Disease 0 3.440427917666966e-06
. O 0 5.350426022232568e-07

Four O 0 4.788655019183352e-07
mutations O 0 3.7649440400855383e-06
- O 0 1.0968217793561053e-05
- O 0 5.0661246859817766e-06
R778L O 0 6.005745376569394e-07
, O 0 1.4869084852264791e-09
A874V O 0 3.8010352199080444e-08
, O 0 3.0577232412731803e-10
L1083F O 0 2.108424190794267e-08
, O 0 2.801069654001509e-10
and O 0 3.5567565559446734e-10
2304delC O 0 7.408697655364449e-08
- O 0 2.0013403911889327e-07
- O 0 1.4088443833770725e-07
in O 0 1.0716073584049468e-09
the O 0 3.2395572335808254e-10
copper O 0 3.586670516142476e-07
- O 0 7.037677818289012e-08
transporting O 0 1.93340063958658e-08
enzyme O 0 3.951425853188084e-08
, O 0 1.0466079114479498e-09
P O 0 2.8767176445398945e-06
- O 0 2.464533110924094e-07
type O 0 8.649310530017829e-07
ATPase O 0 4.106344476895174e-06
( O 0 9.482223894963226e-10
ATP7B O 0 1.0479490697434812e-07
) O 0 2.886018923842215e-10
, O 0 7.061574935907089e-11
were O 0 3.679851146021207e-10
identified O 0 1.1084854811826972e-08
in O 0 1.9018466801412615e-09
Korean O 0 1.9162435194175487e-07
Patients O 0 3.717994800922497e-08
with O 0 7.900757381662515e-09
Wilson B-Disease 0 8.33730518934317e-06
disease I-Disease 0 5.655446784658125e-06
. O 0 5.43030466815253e-07

Arg778Leu O 0 1.460198745917296e-05
, O 0 1.1333145089054142e-08
the O 0 4.958775057239961e-10
most O 0 4.50203957447215e-10
frequently O 0 1.4941559101089297e-08
reported O 0 1.9253782568284805e-08
mutation O 0 2.4752354832457968e-08
of O 0 6.351325021469734e-11
this O 0 6.48921819057513e-11
enzyme O 0 1.9817536500710276e-09
, O 0 8.975632737051598e-11
was O 0 9.998886163486986e-10
found O 0 2.550543942714256e-10
in O 0 8.437023302221291e-11
six O 0 3.3692684753283686e-10
of O 0 4.4207911636950925e-11
eight O 0 1.0432714692143463e-09
unrelated O 0 1.7585826128652116e-08
patients O 0 9.211339246917305e-09
studied O 0 5.159106919450096e-09
, O 0 2.55071408439278e-10
an O 0 3.773776013904495e-10
allele O 0 1.450674318448364e-07
frequency O 0 3.048721168852353e-07
of O 0 1.0765923263988952e-08
37 O 0 6.66503353841108e-07
. O 0 5.779228331448394e-07

5 O 0 2.2684992018184857e-07
% O 0 1.9930505246179564e-08
, O 0 7.906149623870817e-10
which O 0 4.836307465616585e-10
is O 0 1.5292138388911525e-10
considerably O 0 1.305061059220236e-09
higher O 0 6.280770348254805e-10
than O 0 3.1044052745121675e-11
those O 0 1.0302239616954978e-10
in O 0 1.5720010015929375e-10
other O 0 1.3489971362190545e-09
Asian O 0 7.67648629107498e-08
populations O 0 3.5071462889391114e-07
. O 0 2.9748022711828526e-07

The O 0 6.901714755258581e-08
novel O 0 8.910792104188658e-08
single O 0 3.056776165522024e-08
nucleotide O 0 3.420079508487106e-07
deletion O 0 2.965675491850561e-07
, O 0 1.6290518933814724e-09
2304delC O 0 1.5016891552477318e-07
, O 0 1.3211148841563158e-09
was O 0 3.6174785389420094e-09
found O 0 1.3546515020834704e-09
in O 0 1.4326294595079503e-09
one O 0 1.7853871270290256e-08
patient O 0 8.431514970652643e-07
. O 0 3.407411952593975e-07

Since O 0 3.4729250728560146e-06
a O 0 1.0989012366735551e-07
mutation O 0 1.1519588269948144e-06
at O 0 2.3416605543502556e-08
cDNA O 0 9.32814600673737e-07
nucleotide O 0 3.3668611649773084e-06
2302 O 0 1.713374695100356e-05
( O 0 4.271905051922431e-09
2302insC O 0 5.649866707813089e-08
) O 0 9.186630900437365e-10
had O 0 3.190490094340248e-09
been O 0 1.6947635517183812e-09
previously O 0 2.5608306586377694e-09
described O 0 2.109235675007426e-09
, O 0 1.1217712175826122e-10
this O 0 1.34999511569589e-10
region O 0 1.1323222359749252e-09
of O 0 6.092581300576327e-11
the O 0 1.0978528086624806e-09
ATP7B O 0 4.7628856236769934e-07
gene O 0 3.294708506018651e-08
may O 0 7.787293476724244e-09
be O 0 5.768045485687878e-10
susceptible O 0 2.7926649437404194e-08
to O 0 1.7241467142881106e-09
gene O 0 4.6674367126797733e-07
rearrangements O 0 6.076405043131672e-06
causing O 0 2.8681706680799834e-06
Wilson B-Disease 0 1.2338397027633619e-05
disease I-Disease 0 2.6484582122066058e-05
. O 0 8.525209977960913e-07

Disruption O 0 8.636191523692105e-06
of O 0 1.176421537962824e-08
splicing O 0 5.091307571092329e-07
regulated O 0 1.9621330693553318e-07
by O 0 2.436947754702601e-09
a O 0 8.254787076111825e-09
CUG O 0 8.366343536181375e-06
- O 0 8.356029184142244e-07
binding O 0 2.7507621780387126e-07
protein O 0 6.230513918126235e-07
in O 0 1.8535091328431008e-07
myotonic B-Disease 1 0.9999986886978149
dystrophy I-Disease 1 0.9999966621398926
. O 0 1.0438040590088349e-05

Myotonic B-Disease 1 0.9999984502792358
dystrophy I-Disease 1 0.9999992847442627
( O 0 2.268995922349859e-05
DM B-Disease 1 1.0
) O 0 1.123378069678438e-06
is O 0 1.5332165759218697e-08
caused O 0 1.470951893622896e-08
by O 0 3.8624944909138037e-10
a O 0 2.2182229386658037e-09
CTG O 0 3.832155925920233e-07
expansion O 0 1.3773213680678964e-08
in O 0 1.4077202736828553e-09
the O 0 1.2678262883980551e-09
3 O 0 5.194009222719842e-09
untranslated O 0 1.1363154044374824e-06
region O 0 4.306069101289722e-08
of O 0 2.335726723146081e-09
the O 0 8.947647245349799e-08
DM B-Disease 1 0.9999998807907104
gene O 0 8.539240297977813e-06
. O 0 1.0331983730793581e-06

One O 0 8.633743391328608e-07
model O 0 1.7350922689729487e-06
of O 0 4.3717029996059864e-08
DM B-Disease 1 0.9999998807907104
pathogenesis O 0 2.506229748178157e-06
suggests O 0 1.4365791400905437e-07
that O 0 7.693173875722437e-10
RNAs O 0 2.7389162937652145e-08
from O 0 1.2786909031614613e-10
the O 0 8.16047507345985e-11
expanded O 0 1.9723112032465906e-09
allele O 0 2.1905250946474553e-08
create O 0 2.3064063991995454e-09
a O 0 8.818971664048547e-10
gain O 0 6.451193002021682e-08
- O 0 7.236744181682297e-08
of O 0 6.186108847394678e-10
- O 0 2.316296701110332e-07
function O 0 1.4574156992352982e-08
mutation O 0 1.2744409971787718e-08
by O 0 2.156072542724985e-10
the O 0 1.9062616762877127e-10
inappropriate O 0 9.121475130768886e-09
binding O 0 3.570025386423481e-09
of O 0 4.385886445690268e-11
proteins O 0 1.3196893577926971e-09
to O 0 1.0765445201954549e-09
the O 0 4.558517563424402e-09
CUG O 0 5.973693532723701e-06
repeats O 0 3.85352541343309e-06
. O 0 3.8337933006005187e-07

Data O 0 5.816285124637943e-07
presented O 0 3.077632015902054e-08
here O 0 2.6801825203648377e-09
indicate O 0 4.376030648955975e-09
that O 0 2.86910328828327e-10
the O 0 5.316144746636553e-10
conserved O 0 2.9765210740606562e-08
heterogeneous O 0 2.437428463508695e-07
nuclear O 0 8.55460200455127e-07
ribonucleoprotein O 0 1.1643289781204658e-06
, O 0 3.436378293031339e-09
CUG O 0 1.3334221193872509e-06
- O 0 2.3664819082114263e-07
binding O 0 4.156219901574332e-08
protein O 0 3.2333382193883153e-08
( O 0 1.3447044588943413e-09
CUG O 0 6.887288463985897e-07
- O 0 4.3883116518372844e-07
BP O 0 6.813758659518498e-07
) O 0 6.156587462058383e-10
, O 0 3.0422608876534696e-10
may O 0 2.1581183506924617e-09
mediate O 0 1.103557512038833e-08
the O 0 9.827322289268636e-10
trans O 0 1.339946180678453e-07
- O 0 3.8654400213999907e-07
dominant O 0 1.3966601954962243e-06
effect O 0 4.089669403128937e-08
of O 0 3.1445251957862297e-10
the O 0 4.92158669374021e-09
RNA O 0 4.835777644984773e-07
. O 0 1.9889537838935212e-07

CUG O 0 0.0005070328479632735
- O 0 0.013450408354401588
BP O 0 3.4443248296156526e-05
was O 0 1.1391051657483331e-08
found O 0 3.786328195420907e-10
to O 0 6.422504195136014e-11
bind O 0 3.754715649506579e-09
to O 0 3.1200186878521663e-10
the O 0 1.3976393375969565e-09
human O 0 4.737200853810464e-08
cardiac O 0 2.49672552854463e-06
troponin O 0 9.336466064269189e-06
T O 0 2.0389702513057273e-06
( O 0 2.9305964321935107e-09
cTNT O 0 5.2237680847611045e-08
) O 0 3.1896505436890266e-09
pre O 0 7.064480769258807e-07
- O 0 3.9292334008678154e-07
messenger O 0 3.77509721261049e-08
RNA O 0 2.193137937922529e-08
and O 0 1.3514178665019472e-09
regulate O 0 2.27295089416657e-08
its O 0 1.1049539061502855e-08
alternative O 0 1.5076787462930952e-07
splicing O 0 7.896654096839484e-06
. O 0 1.357100813947909e-06

Splicing O 0 9.18659134185873e-06
of O 0 2.2767647323007623e-08
cTNT O 0 2.257342885059188e-06
was O 0 1.9294411401915568e-07
disrupted O 0 2.561575684012496e-06
in O 0 9.715154192235786e-08
DM B-Disease 1 1.0
striated O 0 8.332256402354687e-05
muscle O 0 1.2932496247231029e-05
and O 0 3.7446472589408586e-08
in O 0 8.874423862437197e-09
normal O 0 1.277371524111004e-07
cells O 0 1.3630942419240455e-07
expressing O 0 1.2264668391992473e-08
transcripts O 0 5.085008325522722e-08
that O 0 5.412041925723088e-09
contain O 0 1.25400248407459e-07
CUG O 0 8.93034757609712e-06
repeats O 0 1.1162559530930594e-05
. O 0 7.460184292540362e-07

Altered O 0 1.9587767383200116e-05
expression O 0 4.6680912646479555e-07
of O 0 6.326581925009123e-09
genes O 0 8.001870099860753e-08
regulated O 0 1.041383796973605e-07
posttranscriptionally O 0 3.0853675525577273e-07
by O 0 3.411685378651441e-09
CUG O 0 4.479616563912714e-06
- O 0 2.0235197553120088e-06
BP O 0 1.0264473075949354e-06
therefore O 0 7.07892500173557e-09
may O 0 5.529584790053832e-09
contribute O 0 5.5594915338019746e-09
to O 0 1.2235181756636848e-08
DM B-Disease 1 0.9999983310699463
pathogenesis O 0 1.2803490108126425e-06
. O 0 4.9558583015141267e-08
. O 0 2.53294899721368e-07

Identification O 0 8.682069960741501e-07
of O 0 4.451892188228612e-09
a O 0 7.171637506075967e-09
novel O 0 1.5552127763385215e-07
nonsense O 0 1.0525138804950984e-06
mutation O 0 4.1192544131263276e-07
and O 0 3.2668605598473732e-09
a O 0 1.4217789168213812e-09
missense O 0 1.2696158080416353e-07
substitution O 0 5.8273421643662004e-09
in O 0 1.5628267568956744e-09
the O 0 1.248546710463927e-09
vasopressin O 0 3.056551918234618e-07
- O 0 4.3298547325321124e-07
neurophysin O 0 6.686360620733467e-07
II O 0 2.4610374182998385e-08
gene O 0 8.046358246360796e-09
in O 0 4.306705547740819e-10
two O 0 1.1831740032164362e-09
Spanish O 0 8.907172599492696e-08
kindreds O 0 2.5576794087101007e-06
with O 0 2.3892624767540838e-08
familial B-Disease 1 0.9831938743591309
neurohypophyseal I-Disease 1 0.9996973276138306
diabetes I-Disease 1 0.999822199344635
insipidus I-Disease 1 0.9436501264572144
. O 0 7.793782970111351e-06

Familial B-Disease 1 0.9999270439147949
neurohypophyseal I-Disease 1 0.999713122844696
diabetes I-Disease 1 0.9999951124191284
insipidus I-Disease 1 0.9982419013977051
( O 0 3.0233077268349007e-06
FNDI B-Disease 1 0.9999998807907104
) O 0 2.1934683402946575e-08
is O 0 3.538940696046211e-09
an O 0 7.492652720486603e-09
autosomal B-Disease 1 0.9998646974563599
dominant I-Disease 1 0.9999971389770508
disease I-Disease 1 0.9991819262504578
caused O 0 8.960273589764256e-07
by O 0 3.3861830672776705e-08
deficiency O 0 0.07898521423339844
in O 0 3.640291845741217e-09
the O 0 6.205208791243422e-09
antidiuretic O 0 1.900193456094712e-05
hormone O 0 1.9499907466524746e-06
arginine O 0 3.267638817305851e-07
vasopressin O 0 5.338260393727978e-07
( O 0 4.629544303469402e-09
AVP O 0 1.0183511278683e-07
) O 0 3.722752384138772e-10
encoded O 0 1.2006354799254382e-09
by O 0 3.8664968449175774e-10
the O 0 2.1404866767937847e-09
AVP O 0 2.0617051177396206e-06
- O 0 6.169124162624939e-07
neurophysin O 0 4.597113729687408e-06
II O 0 4.443352281668922e-07
( O 0 6.477279601568853e-09
AVP O 0 1.896524508993025e-06
- O 0 9.158626426142291e-07
NPII O 0 2.298309254911146e-06
) O 0 3.4597318343543293e-09
gene O 0 5.40341140720102e-08
on O 0 2.9071594909169107e-08
chromosome O 0 1.7467607904109173e-05
20p13 O 0 2.082159335259348e-05
. O 0 7.876683980612142e-07

In O 0 4.4089919271073086e-08
this O 0 1.0959824159328946e-09
study O 0 2.080348560085099e-09
, O 0 2.5144664128617933e-10
we O 0 2.6446195233731373e-10
analyzed O 0 2.5333382058789766e-09
two O 0 1.9945507745422475e-10
families O 0 3.884940980025675e-10
with O 0 2.5763449706950325e-10
FNDI B-Disease 1 0.9999605417251587
using O 0 4.9061594786792284e-09
direct O 0 3.806837511888261e-09
automated O 0 1.274925267580329e-07
fluorescent O 0 1.8065125573230034e-07
, O 0 1.33957689385511e-09
solid O 0 1.9775708182123708e-08
phase O 0 2.067698900987125e-08
, O 0 8.2030510162312e-10
single O 0 2.3481861788354763e-08
- O 0 6.45298996460042e-07
stranded O 0 1.509210179051479e-08
DNA O 0 1.0873730360572154e-08
sequencing O 0 6.407485209081187e-09
of O 0 5.277944192805251e-10
PCR O 0 2.2799038106313674e-06
- O 0 8.473431876154791e-07
amplified O 0 2.504308667994337e-06
AVP O 0 9.675959518062882e-06
- O 0 3.361484232300427e-06
NPII O 0 1.4913714039721526e-05
DNA O 0 4.7766006900928915e-06
. O 0 7.359691380770528e-07

In O 0 3.4972725160287155e-08
one O 0 1.835141594241918e-09
of O 0 7.629138293330229e-11
the O 0 2.4781193763701026e-10
families O 0 8.825231656572896e-10
, O 0 2.897745376984062e-10
affected O 0 1.6679955194831564e-09
individuals O 0 2.220168771049913e-10
presented O 0 1.169267016543074e-09
a O 0 9.041135062837213e-10
novel O 0 4.843900924811351e-08
nonsense O 0 1.3792278252822143e-07
mutation O 0 3.287389205297586e-08
in O 0 3.795727898658896e-10
exon O 0 2.3954410011128857e-08
3 O 0 1.5492367388958428e-09
of O 0 3.350700619741964e-11
the O 0 1.1964719492940645e-10
gene O 0 3.790361802202824e-09
, O 0 8.857908850856688e-11
consisting O 0 1.5206277903523358e-10
in O 0 5.910791855967545e-10
a O 0 3.053458819124444e-09
G O 0 3.9387853689731855e-07
to O 0 7.693720327495157e-09
T O 0 7.243081654451089e-07
transition O 0 2.07478603186928e-08
at O 0 2.1259245475135913e-09
nucleotide O 0 7.09531065012925e-08
2101 O 0 2.50953235081397e-07
, O 0 6.530693763551199e-10
which O 0 3.8837999483121166e-10
produces O 0 1.4756919020086912e-09
a O 0 8.642246918100227e-10
stop O 0 3.016977245806629e-08
signal O 0 1.205931283720929e-07
in O 0 6.380666661698342e-09
codon O 0 4.464079665922327e-07
82 O 0 6.468516744462249e-08
( O 0 6.305475697132579e-09
Glu O 0 1.6567597640460008e-06
) O 0 3.3361644558027592e-09
of O 0 3.885676669312943e-09
NPII O 0 3.052425745408982e-05
. O 0 6.461697239501518e-07

The O 0 5.371981615098775e-07
premature O 0 2.212738309026463e-06
termination O 0 4.836062998947455e-07
eliminates O 0 5.535031846193306e-07
part O 0 1.070100541511465e-08
of O 0 2.970778067989954e-10
the O 0 1.593629339602387e-09
C O 0 1.0149281024496304e-06
- O 0 2.316941731805855e-07
terminal O 0 4.284866150783273e-08
domain O 0 3.500747913776081e-09
of O 0 5.0776546162145664e-11
NPII O 0 9.569242109819243e-08
, O 0 5.146197357142057e-11
including O 0 3.003434306814157e-11
a O 0 6.220536585832548e-11
cysteine O 0 1.5866595814983953e-09
residue O 0 2.2260818965946783e-08
in O 0 3.439543649896848e-10
position O 0 1.2261907933464045e-08
85 O 0 2.78772366302249e-10
, O 0 2.1724969045955334e-11
which O 0 8.123080680322303e-11
could O 0 1.0672951411550002e-09
be O 0 2.12958831125043e-10
involved O 0 4.258285113412086e-10
in O 0 2.0411299039846398e-10
the O 0 8.558407316172634e-10
correct O 0 6.576084956577688e-07
folding O 0 3.717349841281248e-07
of O 0 2.510768037922162e-09
the O 0 2.662315701229545e-08
prohormone O 0 6.614928133785725e-05
. O 0 8.647413665130443e-07

In O 0 9.850844406855686e-08
the O 0 4.606054204714383e-09
second O 0 1.2797853443657914e-08
family O 0 5.268381730871852e-09
, O 0 3.3415886724341703e-10
a O 0 3.3931493725880557e-10
G279A O 0 1.0382913195883248e-08
substitution O 0 1.6896574139835252e-09
at O 0 9.42229627654001e-10
position O 0 3.2049101150732895e-08
- O 0 5.1967173675393497e-08
1 O 0 8.767884196458908e-10
of O 0 3.25149039637207e-11
the O 0 7.614557595569948e-11
signal O 0 2.5536457393116052e-09
peptide O 0 1.9904282666516337e-09
was O 0 8.172831855723928e-10
observed O 0 7.285598235817758e-10
in O 0 9.030187708702897e-11
all O 0 2.7572377714335516e-10
affected O 0 6.947357356068551e-09
individuals O 0 8.774714288506402e-09
. O 0 8.227957692952259e-08

This O 0 4.457506861399452e-07
missense O 0 2.6723268092609942e-05
mutation O 0 4.875801550952019e-06
, O 0 2.329023729430446e-08
which O 0 1.6757324416971642e-08
replaces O 0 4.3282571482450294e-07
Ala O 0 1.4552331606410007e-07
with O 0 1.0036680375691276e-09
Thr O 0 3.2465306958329165e-06
, O 0 1.016919770613356e-09
is O 0 5.428684168862219e-10
frequent O 0 2.9502498222200302e-08
among O 0 1.4211831711463674e-08
FNDI B-Disease 1 1.0
patients O 0 6.054131063137902e-07
and O 0 5.220067156308517e-10
is O 0 2.201589188732811e-10
thought O 0 2.8760136494554445e-09
to O 0 3.61859486819327e-10
reduce O 0 8.092300163298205e-09
the O 0 4.5378253932248924e-10
efficiency O 0 6.47352527138878e-09
of O 0 1.9237428316998262e-10
cleavage O 0 1.931471729221812e-07
by O 0 4.093092975665513e-09
signal O 0 4.6639172524010064e-07
peptidases O 0 2.1385592390288366e-06
. O 0 7.895216924680426e-08
. O 0 3.3777399721657275e-07

Genetic O 0 6.291829777183011e-05
heterogeneity O 0 1.533268550701905e-05
of O 0 6.254916939951727e-08
Saethre B-Disease 0 0.3325071930885315
- I-Disease 1 0.9999011754989624
Chotzen I-Disease 1 0.9999603033065796
syndrome I-Disease 1 0.9999988079071045
, O 0 7.3102537356817265e-09
due O 0 5.592386553843198e-09
to O 0 2.662075448967016e-09
TWIST O 0 9.559895261190832e-06
and O 0 1.218451046725022e-07
FGFR O 0 5.7524684962118044e-05
mutations O 0 1.819739190977998e-05
. O 0 9.725274594529765e-07

Thirty O 0 5.546780812437646e-06
- O 0 8.428899309365079e-05
two O 0 7.4406423244965936e-09
unrelated O 0 7.073177954453058e-08
patients O 0 3.0670840089896956e-08
with O 0 7.5764845786086e-11
features O 0 3.732836706404896e-09
of O 0 1.2180944031214835e-09
Saethre B-Disease 1 0.5740734338760376
- I-Disease 1 0.9998258948326111
Chotzen I-Disease 1 0.9998341798782349
syndrome I-Disease 1 0.9999393224716187
, O 0 9.506363474187651e-10
a O 0 1.3804714038556654e-09
common O 0 3.1945691603141313e-07
autosomal B-Disease 1 0.9776180386543274
dominant I-Disease 1 0.9982252717018127
condition I-Disease 0 0.005130760837346315
of O 0 4.4362704620937166e-09
craniosynostosis B-Disease 1 0.8007858991622925
and O 0 1.1785342479697647e-07
limb B-Disease 0 0.0002188133803429082
anomalies I-Disease 0 2.9744904168182984e-05
, O 0 4.2973349878572265e-10
were O 0 4.663841535190727e-10
screened O 0 3.0955291663303797e-08
for O 0 3.8025393944707275e-10
mutations O 0 3.542947624168846e-08
in O 0 7.201377827392719e-10
TWIST O 0 8.861105129653879e-07
, O 0 1.4524337288435163e-09
FGFR2 O 0 3.865664837121585e-07
, O 0 2.1771906499878924e-09
and O 0 1.1252374143566612e-08
FGFR3 O 0 1.2755465832015034e-05
. O 0 7.333942448894959e-07

Nine O 0 3.171425930759142e-07
novel O 0 1.7443622368773504e-07
and O 0 1.517245529214506e-08
three O 0 7.569500581894317e-09
recurrent O 0 7.84098756412277e-06
TWIST O 0 3.7211080780252814e-05
mutations O 0 2.7780877189798048e-06
were O 0 5.014809900671935e-09
found O 0 4.077369109012352e-09
in O 0 4.151131438590028e-09
12 O 0 2.153292477657942e-08
families O 0 9.258302213766001e-08
. O 0 3.768090834910254e-07

Seven O 0 1.1951871670135006e-07
families O 0 2.173797497562191e-08
were O 0 1.2493852619144263e-09
found O 0 8.298574605269948e-10
to O 0 5.870132158136698e-10
have O 0 1.1434690971867667e-09
the O 0 6.129521334941046e-10
FGFR3 O 0 3.197147293576563e-07
P250R O 0 3.849275032052901e-08
mutation O 0 1.4594798258826813e-08
, O 0 1.1052436743597127e-10
and O 0 6.435502131196813e-11
one O 0 1.2471371158007116e-10
individual O 0 4.0447414861866093e-10
was O 0 7.705763138687871e-09
found O 0 2.4518143071361465e-10
to O 0 2.3351776068381014e-10
have O 0 1.3725529601771314e-09
an O 0 6.133345498149367e-10
FGFR2 O 0 1.874458007478097e-06
VV269 O 0 1.1847902214867645e-06
- O 0 1.0175351690122625e-06
270 O 0 3.787589264447888e-07
deletion O 0 9.752498954185285e-06
. O 0 8.388525429836591e-07

To O 0 4.0216292518380214e-08
date O 0 7.214335084881895e-08
, O 0 1.486066381062301e-09
our O 0 1.1382966791373406e-09
detection O 0 1.8250092992389e-08
rate O 0 6.584881084847893e-09
for O 0 2.8484323233435305e-10
TWIST O 0 1.9327229949794855e-07
or O 0 1.1084663853466736e-08
FGFR O 0 4.438900873537932e-07
mutations O 0 9.649888710328014e-08
is O 0 1.1513389130968221e-09
68 O 0 3.2455518272911377e-09
% O 0 5.049263229750522e-10
in O 0 5.28717347680896e-10
our O 0 1.3614256388905233e-08
Saethre B-Disease 0 0.024083683267235756
- I-Disease 1 0.9784430265426636
Chotzen I-Disease 1 0.9982566237449646
syndrome I-Disease 1 0.997978150844574
patients O 0 1.1120011578213962e-07
, O 0 1.2057915776964023e-10
including O 0 1.5756031201963339e-10
our O 0 1.3031506984617636e-09
five O 0 1.6252624801538218e-09
patients O 0 1.1820286971442329e-08
elsewhere O 0 2.976509883012568e-08
reported O 0 5.909771871870362e-08
with O 0 9.146353008304686e-09
TWIST O 0 0.0009222434018738568
mutations O 0 9.090262756217271e-05
. O 0 1.5952381318129483e-06

More O 0 1.6352165843613875e-08
than O 0 3.5274978493760045e-09
35 O 0 4.437497480580532e-09
different O 0 2.0224519836631316e-09
TWIST O 0 7.196090905381425e-07
mutations O 0 2.2391088805306936e-07
are O 0 7.54047546625003e-10
now O 0 2.2438140234726234e-09
known O 0 2.24176521790298e-09
in O 0 1.0027572105997251e-09
the O 0 2.025996259646945e-09
literature O 0 9.434280912046233e-08
. O 0 2.503659004560177e-07

The O 0 3.6539560710480146e-08
most O 0 5.4846700514588065e-09
common O 0 5.71864378073883e-09
phenotypic O 0 1.3107825225233682e-07
features O 0 3.630849221281096e-08
, O 0 2.939585797001598e-10
present O 0 1.3048065405918408e-10
in O 0 4.446694054638378e-11
more O 0 1.6494826338142587e-11
than O 0 1.1945110178768203e-10
a O 0 5.00250285639936e-10
third O 0 1.256725656872959e-08
of O 0 1.277301459046143e-10
our O 0 4.9916586419840314e-09
patients O 0 2.644615859637156e-09
with O 0 1.6714310491217077e-10
TWIST O 0 2.1697003376175417e-06
mutations O 0 3.2780135938992316e-07
, O 0 4.451388979642701e-10
are O 0 3.755071531497123e-10
coronal B-Disease 0 2.67787726215829e-07
synostosis I-Disease 0 4.2879645434368285e-07
, O 0 9.93984450303742e-10
brachycephaly B-Disease 0 3.3385344977432396e-07
, O 0 8.769728054858206e-09
low B-Disease 0 0.00020330150437075645
frontal I-Disease 1 0.9999977350234985
hairline I-Disease 1 0.9999998807907104
, O 0 4.267754434295057e-07
facial B-Disease 1 0.9880397915840149
asymmetry I-Disease 0 7.980273221619427e-05
, O 0 6.028124488466347e-08
ptosis B-Disease 0 0.0440949909389019
, O 0 1.490529655256978e-08
hypertelorism B-Disease 0 8.789374078332912e-06
, O 0 6.56712062507836e-09
broad B-Disease 0 6.009344133417471e-08
great I-Disease 0 7.345436614514256e-08
toes I-Disease 0 2.1199679395067506e-05
, O 0 6.9731918017623684e-09
and O 0 2.2621081896545547e-08
clinodactyly B-Disease 0 8.784044439380523e-06
. O 0 6.87870283400116e-07

Significant O 0 4.44295119450544e-06
intra O 0 1.2406999303493649e-05
- O 0 0.00013102905359119177
and O 0 5.745366848941558e-08
interfamilial O 0 1.8649078583621304e-06
phenotypic O 0 2.563928774179658e-06
variability O 0 1.3850130926584825e-06
is O 0 4.0236223242118285e-09
present O 0 1.7829531184787584e-09
for O 0 6.814110387054484e-10
either O 0 3.0702327791232165e-08
TWIST O 0 4.9211335863219574e-05
mutations O 0 1.034117849485483e-05
or O 0 3.639676435795991e-07
FGFR O 0 6.803579890402034e-05
mutations O 0 1.8563638150226325e-05
. O 0 1.6865822090039728e-06

The O 0 7.690979941799014e-08
overlap O 0 3.650379767350387e-07
in O 0 6.305463706723913e-09
clinical O 0 8.888284241947986e-08
features O 0 1.5207859860311146e-08
and O 0 3.1743256911909157e-09
the O 0 4.3294701157492455e-10
presence O 0 2.616508565367326e-09
, O 0 3.95872445935197e-10
in O 0 1.5063644775992202e-10
the O 0 5.6963433969769994e-11
same O 0 3.0052293986670975e-10
genes O 0 1.8490232678303187e-09
, O 0 7.80768991126557e-11
of O 0 7.225530503779387e-12
mutations O 0 1.2533521998037145e-09
for O 0 1.4585119570420524e-11
more O 0 8.265014540820292e-12
than O 0 9.707712411710645e-11
one O 0 1.6117013279526304e-09
craniosynostotic B-Disease 0 4.072924184583826e-06
condition I-Disease 0 1.8211675012480555e-07
- O 0 1.0103969216856967e-08
such O 0 3.811492788052817e-10
as O 0 1.704414054337633e-09
Saethre B-Disease 0 3.2449224818265066e-07
- I-Disease 0 1.3305078994108044e-07
Chotzen I-Disease 0 1.98379339622079e-07
, I-Disease 0 8.842299115130459e-10
Crouzon I-Disease 0 5.665340907512473e-08
, I-Disease 0 8.009742313852541e-10
and I-Disease 0 5.540543135396092e-09
Pfeiffer I-Disease 0 6.772141205146909e-05
syndromes I-Disease 0 4.7393961722264066e-05
- O 0 2.4016819111238874e-07
support O 0 2.2708437352747524e-09
the O 0 2.7320004591935287e-10
hypothesis O 0 6.962785459307952e-09
that O 0 1.8448127747650034e-10
TWIST O 0 4.0340211171496776e-08
and O 0 4.416419452368814e-10
FGFRs O 0 1.646357539186738e-08
are O 0 1.362122914461139e-10
components O 0 2.1933210803126713e-09
of O 0 2.0364158276331423e-11
the O 0 9.110355525532299e-11
same O 0 6.739825364476815e-10
molecular O 0 6.945370056854472e-09
pathway O 0 2.6086250937140676e-09
involved O 0 1.27391297510826e-09
in O 0 2.130071674599776e-10
the O 0 2.1240552372514543e-10
modulation O 0 7.061773743544109e-08
of O 0 8.379948956971361e-10
craniofacial O 0 0.0021957512944936752
and O 0 5.031578709235873e-08
limb O 0 1.1680375791911501e-05
development O 0 3.1107327824742015e-09
in O 0 1.3997042414004568e-09
humans O 0 1.1985242132084295e-08
. O 0 1.5669824549036093e-08
. O 0 1.5366074990197376e-07

Mutation O 0 6.933797703823075e-05
analysis O 0 2.848359372364939e-06
of O 0 2.2585197712032823e-07
UBE3A O 0 0.11562205106019974
in O 0 0.05470222234725952
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 0.0835350975394249
. O 0 3.965053110732697e-06

Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 5.351693744160002e-06
AS B-Disease 1 0.9999995231628418
) O 0 7.420067760222082e-08
is O 0 1.907478441864896e-08
caused O 0 4.8835310906270024e-08
by O 0 2.8954321162899532e-09
chromosome O 0 3.99850659960066e-06
15q11 O 0 2.3481111384171527e-06
- O 0 6.993893180151645e-07
q13 O 0 1.9728847178157594e-07
deletions O 0 8.629275782823242e-08
of O 0 7.535371771005828e-10
maternal O 0 3.854182750728796e-08
origin O 0 2.6418391030347266e-08
, O 0 1.3899007500484117e-09
by O 0 3.18291681900007e-09
paternal O 0 2.554137836341397e-06
uniparental B-Disease 0 0.006035026628524065
disomy I-Disease 0 0.00033172834082506597
( O 0 1.0868343736092356e-07
UPD B-Disease 1 0.9999998807907104
) O 0 3.235287238112505e-08
15 O 0 1.7909832505935697e-09
, O 0 2.0708186554418972e-10
by O 0 7.020966585891131e-10
imprinting O 0 0.003218607045710087
defects O 1 0.999248206615448
, O 0 1.8937167389765364e-09
and O 0 7.640806320985405e-10
by O 0 8.669702733499207e-10
mutations O 0 2.649353518791031e-07
in O 0 4.536019559964188e-09
the O 0 1.8390563738535093e-08
UBE3A O 0 1.7368010958307423e-05
gene O 0 1.654822312957549e-06
. O 0 3.034631674836419e-07

UBE3A O 0 0.0010666009038686752
encodes O 0 9.492520803178195e-06
a O 0 3.598817102101748e-07
ubiquitin O 0 2.7026842417399166e-06
- O 0 1.336326022283174e-06
protein O 0 1.0205950928821039e-07
ligase O 0 8.564196463112239e-08
and O 0 8.426818354223542e-09
shows O 0 2.1145906714536977e-07
brain O 0 1.2239672287250869e-05
- O 0 3.4613949537742883e-06
specific O 0 4.899275154457428e-07
imprinting O 0 9.786190639715642e-05
. O 0 2.494888121873373e-06

Here O 0 9.350554819320678e-07
we O 0 1.8646592536697426e-07
describe O 0 6.99725603681145e-07
UBE3A O 0 4.902384171145968e-05
coding O 0 0.00032192262005992234
- O 0 0.0005586524493992329
region O 0 1.0231419764750171e-06
mutations O 0 8.525307180207164e-07
detected O 0 1.1040695824249269e-07
by O 0 9.477016948977735e-10
SSCP O 0 2.0777768838797783e-07
analysis O 0 9.29769061741581e-09
in O 0 8.524261296827262e-10
13 O 0 2.1270845085297196e-09
AS B-Disease 1 0.9749768376350403
individuals O 0 3.760147748721465e-09
or O 0 4.0292228220550896e-08
families O 0 5.59925261711669e-08
. O 0 1.596971799244784e-07

Two O 0 6.410763830899668e-07
identical O 0 2.3937980131449876e-06
de O 0 1.407557988386543e-06
novo O 0 1.42981514272833e-06
5 O 0 5.66365550014325e-08
- O 0 4.905670607513457e-07
bp O 0 6.502410201392195e-07
duplications O 0 6.090864417274133e-07
in O 0 4.485978699619864e-09
exon O 0 2.2380349662398658e-07
16 O 0 1.3829125400377507e-08
were O 0 4.928340846532819e-09
found O 0 6.849037248457535e-08
. O 0 3.1333212291428936e-07

Among O 0 1.0816766859989002e-07
the O 0 1.4212420129666725e-09
other O 0 1.2603784682596597e-09
11 O 0 1.956055761809239e-09
unique O 0 3.6155884952648876e-09
mutations O 0 6.99497419986983e-08
, O 0 5.61908186647031e-10
8 O 0 9.344497398089402e-10
were O 0 2.9373772858498626e-10
small O 0 1.0469153322034686e-09
deletions O 0 5.810031922237613e-08
or O 0 1.1049581694067001e-08
insertions O 0 1.98410376128777e-07
predicted O 0 1.3494872064256924e-07
to O 0 1.2288897677237287e-09
cause O 0 6.662780993593742e-09
frameshifts O 0 3.695258783409372e-07
, O 0 1.091659651564214e-09
1 O 0 1.8588111050377165e-09
was O 0 5.74900305139181e-09
a O 0 3.194714492948947e-10
mutation O 0 8.29487589726341e-09
to O 0 2.854583514011466e-10
a O 0 7.841856053403262e-10
stop O 0 1.3119249686610601e-08
codon O 0 4.936546815770271e-08
, O 0 6.832838739256886e-10
1 O 0 1.54627588511147e-09
was O 0 2.743531846149949e-09
a O 0 9.119800470358541e-10
missense O 0 3.872727063480852e-07
mutation O 0 7.52390363345512e-08
, O 0 3.398797632225836e-10
and O 0 5.325227481201011e-10
1 O 0 2.9461884043513464e-09
was O 0 2.6630926797110988e-08
predicted O 0 8.683062269199127e-09
to O 0 3.1729499583299514e-10
cause O 0 7.193388107396004e-10
insertion O 0 8.864813771936042e-09
of O 0 2.578050550816613e-10
an O 0 6.544771946614958e-10
isoleucine O 0 4.21284948970424e-06
in O 0 1.6344205988616523e-09
the O 0 5.388010038132052e-10
hect O 0 9.681801316219207e-08
domain O 0 1.500919744046314e-08
of O 0 2.5630184086189445e-10
the O 0 1.0064860056502312e-09
UBE3A O 0 2.7111104827781674e-07
protein O 0 9.801119915664458e-09
, O 0 4.842889422818075e-10
which O 0 3.204491116903796e-10
functions O 0 9.70286739843118e-10
in O 0 1.3565311096641608e-09
E2 O 0 9.39013631295893e-08
binding O 0 3.0226448899384195e-08
and O 0 2.8749442826381255e-09
ubiquitin O 0 1.2302440666189796e-07
transfer O 0 1.9397805317566963e-07
. O 0 5.511844278771605e-07

Eight O 0 1.0517577209157025e-07
of O 0 1.0174261433348875e-09
the O 0 5.237930089663223e-10
cases O 0 5.562058369434908e-09
were O 0 1.7378217753716285e-09
familial O 0 7.747486847620166e-07
, O 0 1.4811653015200932e-09
and O 0 1.2601549803648027e-09
five O 0 2.6660798013722342e-09
were O 0 1.5699351152420604e-08
sporadic O 0 3.068868181799189e-06
. O 0 2.179815055569634e-06

In O 0 1.8583764926916047e-07
two O 0 1.1687390610859438e-08
familial O 0 2.433782128719031e-06
cases O 0 7.014828895535175e-08
and O 0 4.226188288214416e-09
one O 0 1.5228868166516918e-09
sporadic O 0 6.369628380298309e-08
case O 0 6.530313356734041e-08
, O 0 2.678618438167746e-09
mosaicism O 0 1.2091758208043757e-06
for O 0 2.460688763861185e-09
UBE3A O 0 9.56972371568554e-07
mutations O 0 1.8556281133896846e-07
was O 0 6.001827035362339e-09
detected O 0 1.2582487052270608e-08
in O 0 2.924770703405244e-10
the O 0 2.414065058964354e-10
mother O 0 7.634022303193433e-09
of O 0 3.016466243455085e-11
three O 0 1.4993767338822295e-09
AS B-Disease 1 0.9999996423721313
sons O 0 4.1568540609659976e-08
, O 0 2.058535841786835e-10
in O 0 1.0640911068948711e-10
the O 0 1.7408000041463367e-10
maternal O 0 3.144202898042181e-09
grandfather O 0 2.9860671713066722e-09
of O 0 1.6490893720022548e-11
two O 0 4.735407066469577e-10
AS B-Disease 1 0.9999984502792358
first O 0 6.433320542953425e-10
cousins O 0 7.73698527467559e-09
, O 0 1.3785236840924142e-10
and O 0 2.184906422453281e-10
in O 0 2.107256313887973e-10
the O 0 6.244314509906701e-10
mother O 0 6.823259468546894e-08
of O 0 1.1118532483589405e-10
an O 0 4.946714149411946e-09
AS B-Disease 1 1.0
daughter O 0 3.713553087436594e-05
. O 0 3.094974374562298e-07

The O 0 1.982072106443411e-08
frequencies O 0 5.722770879401651e-08
with O 0 1.735764754151603e-09
which O 0 2.3292980877442915e-09
we O 0 1.6906019917328763e-09
detected O 0 4.890948979152654e-09
mutations O 0 5.302517092076187e-09
were O 0 1.8844233118375797e-10
5 O 0 7.435670135169659e-11
( O 0 4.561974756289722e-11
14 O 0 1.4827700178798864e-10
% O 0 8.964887859841397e-11
) O 0 4.068368905651987e-11
of O 0 1.4626851813082098e-11
35 O 0 5.39276012734291e-10
in O 0 1.777749891740399e-10
sporadic O 0 1.9580498999971496e-08
cases O 0 4.2380648324069625e-08
and O 0 2.79795253632642e-09
8 O 0 4.700034805793507e-10
( O 0 4.7499865152289544e-11
80 O 0 7.60303417446373e-11
% O 0 1.1950283818062957e-10
) O 0 6.951830777701673e-11
of O 0 4.6471805570380553e-11
10 O 0 5.646154654925795e-10
in O 0 1.1868718230445552e-09
familial O 0 4.625937435775995e-06
cases O 0 5.065832056061481e-07
. O 0 1.0020678331557065e-07
. O 0 3.6827972849096113e-07

The O 0 5.652190338878427e-06
hemochromatosis B-Disease 1 0.9999938011169434
845 O 0 2.3431459339917637e-05
G O 0 1.8198275938630104e-05
- O 0 1.0532646228966769e-05
- O 0 1.781412834134244e-06
> O 0 7.599405904556988e-08
A O 0 3.365217438044965e-09
and O 0 8.996272615746648e-10
187 O 0 7.557670933522331e-09
C O 0 1.0169418374061934e-07
- O 0 1.766173625128431e-07
- O 0 3.614570402987738e-07
> O 0 7.010321212419512e-08
G O 0 5.484191092364199e-07
mutations O 0 1.049001028263774e-07
: O 0 2.0068164907627306e-09
prevalence O 0 1.2541424609935348e-07
in O 0 5.271155956165785e-09
non O 0 6.08491973252967e-07
- O 0 1.705617796687875e-05
Caucasian O 0 1.8865035599446855e-05
populations O 0 1.4812642348260852e-06
. O 0 5.039743200541125e-07

Hemochromatosis B-Disease 0 0.01224355399608612
, O 0 1.0862453336812905e-06
the O 0 1.7941557644007844e-06
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
of I-Disease 0 4.999090474910872e-09
iron I-Disease 0 0.002031921874731779
metabolism I-Disease 0 2.2082924715505214e-06
, O 0 8.48851877677248e-10
leads O 0 3.018650662767186e-09
, O 0 7.302571325418228e-10
if O 0 7.50157624906933e-09
untreated O 0 1.0464690802791665e-07
, O 0 3.212232146942995e-10
to O 0 7.539497914876847e-10
progressive O 0 1.4022867844687426e-07
iron B-Disease 1 0.9224384427070618
overload I-Disease 0 0.0037264146376401186
and O 0 1.8619067532199551e-07
premature B-Disease 0 1.1353188256180147e-06
death I-Disease 0 1.4162777972615004e-07
. O 0 4.0382789734394464e-07

The O 0 2.0939121441188036e-06
hemochromatosis B-Disease 1 0.999972939491272
gene O 0 5.761196916864719e-06
, O 0 3.5177773582972804e-08
HFE O 0 7.238010766741354e-06
, O 0 4.9714201644235345e-09
recently O 0 5.0061537137935375e-08
has O 0 2.481914007645969e-09
been O 0 1.1959568890773653e-09
identified O 0 4.648009532814967e-09
, O 0 1.285925671501431e-10
and O 0 2.0539235590089078e-10
characterization O 0 1.381241165887559e-08
of O 0 7.405437374430335e-11
this O 0 1.1864774440706327e-10
gene O 0 4.333710279524894e-09
has O 0 1.9873935830361233e-09
shown O 0 1.1725074244850475e-09
that O 0 5.935156532910213e-11
it O 0 6.621827391972701e-11
contains O 0 5.3207879074923525e-11
two O 0 2.297470547141245e-10
mutations O 0 1.7808433838695237e-08
that O 0 6.264033181047068e-10
result O 0 5.4641415836442775e-09
in O 0 9.592185934437225e-10
amino O 0 1.4512604451510924e-08
acid O 0 2.8998496048870948e-08
substitutions O 0 3.436425899394635e-08
- O 0 6.500636828832285e-08
cDNA O 0 1.6177854433863104e-07
nucleotides O 0 9.784294263681659e-08
845 O 0 1.9637637649339013e-07
G O 0 3.1320425364356197e-07
- O 0 2.3439311291895137e-07
- O 0 2.536908993988618e-07
> O 0 1.895951129426976e-08
A O 0 1.8464964002262718e-09
( O 0 2.2766191709600037e-10
C282Y O 0 1.018642059591457e-08
) O 0 1.2917812652890603e-10
and O 0 1.452967884896239e-10
187 O 0 3.348883170772865e-09
C O 0 5.744018949371821e-08
- O 0 2.615979042275285e-07
- O 0 3.5831081390824693e-07
> O 0 7.484870678808875e-08
G O 0 3.559909771411185e-07
( O 0 2.4906967599491736e-09
H63D O 0 1.2843688637076411e-06
) O 0 2.352996730792256e-08
. O 0 6.070966662719002e-08

Although O 0 7.871188245189842e-06
hemochromatosis B-Disease 1 0.9999998807907104
is O 0 1.897018790941729e-07
common O 0 5.8718732987017574e-08
in O 0 4.917542373306105e-09
Caucasians O 0 4.0928929934125335e-07
, O 0 2.6274959985528312e-09
affecting O 0 1.439983154938318e-08
> O 0 1.640711921879756e-08
= O 0 3.601089204607888e-08
1 O 0 1.7983805555843446e-09
/ O 0 6.5985852337746564e-09
300 O 0 1.148649231286214e-10
individuals O 0 4.290895069813949e-11
of O 0 8.424299452469697e-12
northern O 0 1.8059161277506064e-08
European O 0 1.1290684831521958e-08
origin O 0 2.030836165900496e-09
, O 0 1.4128087588716198e-10
it O 0 2.9463048667466296e-10
has O 0 6.336892122149607e-10
not O 0 1.5567390432291717e-10
been O 0 3.8536718260928637e-10
recognized O 0 9.047690929797625e-10
in O 0 3.7399469632326543e-10
other O 0 2.366281393051395e-09
populations O 0 2.2718204206739756e-07
. O 0 1.6530511004475557e-07

The O 0 2.993498782188908e-08
present O 0 4.190733537967617e-09
study O 0 1.446018083051115e-09
used O 0 1.627247669944154e-09
PCR O 0 3.2532327054468624e-07
and O 0 1.522758918959255e-09
restriction O 0 9.542027612496895e-09
- O 0 2.8498101656282415e-08
enzyme O 0 6.837509669566089e-09
digestion O 0 6.616835079853445e-09
to O 0 1.1713043035488369e-10
analyze O 0 3.61488528000109e-09
the O 0 1.5394449603967075e-10
frequency O 0 7.929774170634118e-09
of O 0 8.54579462750138e-11
the O 0 5.918778800406699e-10
845 O 0 2.69533746433126e-08
G O 0 1.6099269828373508e-07
- O 0 1.0554453666600239e-07
- O 0 9.150579671768355e-08
> O 0 6.31992458366426e-09
A O 0 8.217928004761177e-10
and O 0 2.853130232072232e-10
187 O 0 3.337927489965864e-09
C O 0 4.6345032700401134e-08
- O 0 9.243674270464908e-08
- O 0 3.083131900893932e-07
> O 0 9.740295325855186e-08
G O 0 3.369253249729809e-07
mutations O 0 6.111129380315106e-08
in O 0 6.926924034367232e-10
HLA O 0 7.012420866203684e-08
- O 0 2.7827008253211716e-08
typed O 0 2.238916074759345e-08
samples O 0 3.68742014700274e-09
from O 0 3.8229161503089415e-10
non O 0 2.7286599646458853e-08
- O 0 1.3010235022647976e-07
Caucasian O 0 3.9866779388830764e-07
populations O 0 1.6943765501764574e-08
, O 0 2.3524696080023944e-10
comprising O 0 3.87350179709145e-10
Australian O 0 6.964206544779472e-09
Aboriginal O 0 4.578716517045223e-09
, O 0 1.601279386864718e-10
Chinese O 0 1.369032942566406e-10
, O 0 2.7999053076044333e-10
and O 0 1.965296592132404e-09
Pacific O 0 3.912077772838529e-08
Islanders O 0 9.060137813321489e-07
. O 0 2.508921852495405e-07

Results O 0 6.532700808747904e-06
showed O 0 8.767190706748806e-08
that O 0 7.103103660810461e-10
the O 0 6.651109107913555e-10
845 O 0 4.283436183527556e-08
G O 0 5.745327484873997e-07
- O 0 8.019890174182365e-07
- O 0 2.1476245137819205e-07
> O 0 1.4684289340038958e-08
A O 0 2.0237251874277717e-09
mutation O 0 2.4923139108068426e-08
was O 0 1.0036182995776244e-09
present O 0 9.235501946536218e-11
in O 0 7.400467044726966e-11
these O 0 2.7796956403314255e-10
populations O 0 3.0833651187833766e-09
( O 0 1.0513531711886515e-10
allele O 0 5.045703410644364e-09
frequency O 0 9.469070860745887e-09
0 O 0 1.7898905690927336e-09
. O 0 2.484067951336044e-10
32 O 0 5.145905368486581e-10
% O 0 1.2778229863119606e-10
) O 0 6.064905522240593e-11
, O 0 7.683506608735513e-11
and O 0 3.0981486820458315e-10
, O 0 1.1239793124007136e-10
furthermore O 0 1.0772799319269666e-09
, O 0 1.0779432207952411e-10
it O 0 7.083283959374853e-10
was O 0 3.0928376304473204e-08
always O 0 1.0480386336553238e-08
seen O 0 4.061898817298015e-09
in O 0 2.444376090426914e-10
conjunction O 0 4.857980684391805e-09
with O 0 3.0545888041189073e-09
HLA O 0 3.688132892420981e-07
haplotypes O 0 2.803315055643907e-07
common O 0 1.5928158347833232e-08
in O 0 1.5035894751491696e-09
Caucasians O 0 1.2742640365104307e-07
, O 0 8.327114553452475e-10
suggesting O 0 3.58539975486849e-09
that O 0 5.557496129959816e-10
845 O 0 1.4396947634054413e-08
G O 0 1.5924732110761397e-07
- O 0 2.0696209901416296e-07
- O 0 1.0638836300813637e-07
> O 0 1.6155892623714863e-08
A O 0 1.7848312827695167e-09
may O 0 2.2352539819081585e-09
have O 0 1.1421214668461133e-10
been O 0 1.0301080127783635e-10
introduced O 0 3.4550412530975905e-10
into O 0 2.898519479987982e-10
these O 0 9.483598351067712e-10
populations O 0 1.656095705016014e-08
by O 0 1.0753034906940684e-08
Caucasian O 0 7.122671377146617e-06
admixture O 0 2.948943802039139e-05
. O 0 1.6462624898849754e-06

187 O 0 8.647415597806685e-06
C O 0 7.048195129755186e-06
- O 0 2.4948358259280212e-06
- O 0 8.342763635482697e-07
> O 0 8.329854495059408e-08
G O 0 3.853789962704468e-07
was O 0 5.852404338924089e-09
present O 0 3.470761178459014e-10
at O 0 7.264368551140876e-10
an O 0 1.994295978358096e-10
allele O 0 4.6063814096442e-08
frequency O 0 1.9647995941340923e-07
of O 0 3.932147496499283e-09
2 O 0 1.0144234607878388e-07
. O 0 3.484502428818814e-07

68 O 0 2.6945517674903385e-06
% O 0 5.800464819571971e-08
in O 0 9.44057276797139e-10
the O 0 2.0418501611718654e-10
two O 0 5.800736002647966e-10
populations O 0 7.257682455019676e-09
analyzed O 0 2.618362060502477e-08
( O 0 6.635612614935837e-10
Australian O 0 8.824731168033395e-09
Aboriginal O 0 1.8430384329803928e-08
and O 0 3.2476012989945957e-09
Chinese O 0 2.537768217791836e-09
) O 0 1.3220683214854034e-08
. O 0 8.900040171511137e-08

In O 0 7.139620805673985e-08
the O 0 5.996688923204374e-09
Australian O 0 1.8438155890976304e-08
Aboriginal O 0 1.1523193954587896e-08
samples O 0 4.823155208555363e-09
, O 0 2.0701394765065828e-10
187 O 0 2.8779179039872815e-09
C O 0 4.2901159957864365e-08
- O 0 9.498559450094035e-08
- O 0 1.188211555813723e-07
> O 0 1.4078901600100835e-08
G O 0 8.97033984870177e-08
was O 0 9.609454343362245e-10
found O 0 3.067607556861418e-10
to O 0 2.6938032360313e-10
be O 0 7.391710576953869e-10
associated O 0 3.180434582361613e-09
with O 0 2.6287740872987797e-09
HLA O 0 6.175446287670638e-07
haplotypes O 0 3.018390657416603e-07
common O 0 2.00759462387623e-08
in O 0 7.290532622050705e-10
Caucasians O 0 6.053980428077921e-08
, O 0 4.5387085756409817e-10
suggesting O 0 3.2604925426227283e-09
that O 0 1.88808219059311e-10
it O 0 7.238007415644176e-10
was O 0 1.8031651727312692e-09
introduced O 0 1.8190240425042248e-09
by O 0 1.0900927938095606e-09
recent O 0 2.5629043420849484e-07
admixture O 0 1.6928483091760427e-05
. O 0 1.1898505363205913e-06

In O 0 5.7647081774803155e-08
the O 0 1.480329192560248e-09
Chinese O 0 5.62719038033066e-10
samples O 0 2.3607906740608087e-09
analyzed O 0 4.1792871385837316e-09
, O 0 9.251564098144982e-11
187 O 0 2.081980143842088e-09
C O 0 2.1125423188550485e-08
- O 0 3.822686878152126e-08
- O 0 5.1232877495976936e-08
> O 0 1.7751935033061272e-08
G O 0 2.531446909870283e-07
was O 0 4.946223430835062e-09
present O 0 2.1830652563448183e-10
in O 0 2.5749202769986823e-10
association O 0 1.6829794502459805e-10
with O 0 4.6737592962475816e-11
a O 0 3.7894493098988846e-10
wide O 0 3.249385871484378e-09
variety O 0 7.056546902362015e-09
of O 0 4.2530740040902515e-10
HLA O 0 8.820881447491047e-08
haplotypes O 0 1.0590974142132836e-07
, O 0 5.145405213013987e-10
showing O 0 1.945440475381588e-09
this O 0 1.1583384945668129e-10
mutation O 0 2.7101725308398272e-09
to O 0 9.396698696928496e-11
be O 0 1.4424227090525932e-10
widespread O 0 4.783921037088135e-10
and O 0 8.472197943198978e-10
likely O 0 2.752331695887733e-09
to O 0 1.5515722040504443e-10
predate O 0 1.3020136080399425e-08
the O 0 1.4201873010932786e-10
more O 0 1.746137262559344e-10
genetically O 0 6.921697881523414e-09
restricted O 0 5.3671089794704585e-09
845 O 0 5.3590820670024186e-08
G O 0 3.237047110360436e-07
- O 0 5.420525326371717e-07
- O 0 9.420594437870022e-07
> O 0 2.1137661576631217e-07
A O 0 7.922006517446789e-08
mutation O 0 2.222979674115777e-06
. O 0 4.4756399120160495e-07

Genotype O 1 0.9439355731010437
- O 1 0.9639373421669006
phenotype O 0 0.0011920405086129904
correlations O 0 0.0001409642572980374
in O 0 8.417699973506387e-06
attenuated B-Disease 1 0.998672604560852
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 0.999998927116394
coli I-Disease 1 0.9999998807907104
. O 0 0.00010957104677800089

Germ O 0 0.004517972934991121
- O 0 0.1354600340127945
line O 0 3.0046046504139667e-06
mutations O 0 4.830992565985071e-07
of O 0 8.576120924530528e-10
the O 0 4.8028949706235835e-09
tumor B-Disease 0 1.9042215626541292e-06
suppressor O 0 1.7833574474934721e-06
APC O 0 2.697078969049471e-07
are O 0 8.988078725735704e-09
implicated O 0 1.099622068068129e-06
in O 0 8.365589110326255e-07
attenuated B-Disease 1 0.999954342842102
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
( O 0 5.456173767015571e-06
AAPC B-Disease 1 0.9999998807907104
) O 0 6.036142963239399e-08
, O 0 1.7191454926290817e-09
a O 0 1.1524820209274367e-08
variant O 0 0.0005992041551508009
of O 0 6.5006697695935145e-06
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 5.058718306827359e-05
FAP B-Disease 0 0.0005942164571024477
) O 0 1.3161591141397366e-06
. O 0 1.3039827990724007e-06

AAPC B-Disease 1 0.9999992847442627
is O 0 2.3781333879924205e-07
recognized O 0 2.9127432910058815e-08
by O 0 8.347803559516365e-10
the O 0 1.0189602495103145e-09
occurrence O 0 8.077206814505189e-08
of O 0 6.965611420994833e-10
< O 0 5.995936902536414e-08
100 O 0 3.085294686400175e-09
colonic B-Disease 0 4.0585251781521947e-07
adenomas I-Disease 0 2.1478570033650612e-06
and O 0 9.986154125840585e-10
a O 0 7.839732751868667e-10
later O 0 2.327185200101667e-08
onset O 0 2.451981572448858e-06
of O 0 1.3803182810079306e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 7.3745196615959685e-09
age O 0 1.9752937063799436e-08
> O 0 2.8477019853312413e-08
40 O 0 5.531314961615408e-09
years O 0 3.5405630427476353e-08
) O 0 2.447509039882334e-08
. O 0 2.2373478714143857e-07

The O 0 4.9547242753078535e-08
aim O 0 4.9621199593730125e-08
of O 0 8.74716687970789e-11
this O 0 8.695301423333746e-11
study O 0 9.293094072049257e-10
was O 0 8.072917889734299e-10
to O 0 1.1266305666168819e-09
assess O 0 2.744528444509342e-07
genotype O 0 2.5119457859545946e-05
- O 0 3.2327301596524194e-05
phenotype O 0 1.4730493603565264e-05
correlations O 0 6.832376129750628e-06
in O 0 4.868929295298585e-07
AAPC B-Disease 1 0.9999969005584717
families O 0 1.5460974509551306e-06
. O 0 8.914172440199764e-07

By O 0 1.9923670890875655e-07
protein O 0 1.3574917829828337e-06
- O 0 2.006195245485287e-06
truncation O 0 3.0134690405247966e-06
test O 0 4.4367382656673726e-07
( O 0 2.8075322067167008e-09
PTT O 0 7.980059280043861e-08
) O 0 4.1068384803999436e-10
assay O 0 2.339914928484177e-08
, O 0 1.347443268073789e-10
the O 0 1.084188919198148e-10
entire O 0 6.368229055198071e-09
coding O 0 5.028594387113117e-06
region O 0 2.3866618903412018e-08
of O 0 3.8660177836824516e-10
the O 0 8.417256891490865e-10
APC B-Disease 0 2.063428183873839e-08
gene O 0 1.4722767893715627e-08
was O 0 1.0193223154431053e-08
screened O 0 6.536020435987666e-08
in O 0 7.874966234666658e-10
affected O 0 4.7843342620979e-09
individuals O 0 7.11099346073496e-10
from O 0 1.877439315123297e-09
11 O 0 3.0818910090602e-08
AAPC B-Disease 1 0.9999988079071045
kindreds O 0 1.2382814020384103e-05
, O 0 2.560488709946185e-09
and O 0 1.8214438846086978e-09
their O 0 2.348699901233431e-09
phenotypic O 0 1.762202487043396e-06
differences O 0 1.0719291822169907e-05
were O 0 1.1122916987460485e-07
examined O 0 3.871050466841552e-06
. O 0 7.90269496064866e-07

Five O 0 2.6695801125242724e-07
novel O 0 6.671659775747685e-07
germ O 0 7.449404074577615e-05
- O 0 6.717418000334874e-05
line O 0 1.1657956520139123e-06
APC B-Disease 0 3.276025779541669e-07
mutations O 0 1.6971297611689806e-07
were O 0 1.87618653946231e-09
identified O 0 1.346481148800649e-08
in O 0 5.578824069374377e-09
seven O 0 8.19242629290784e-08
kindreds O 0 0.00015656081086490303
. O 0 1.534359626020887e-06

Mutations O 0 1.1409050785005093e-05
were O 0 2.6370415184828744e-08
located O 0 6.262709906224018e-09
in O 0 8.171912035948026e-10
three O 0 2.810606192227283e-10
different O 0 7.849532690507033e-10
regions O 0 3.3882943117902187e-09
of O 0 2.3566412710174234e-10
the O 0 5.226682420200746e-10
APC B-Disease 0 7.81005127237222e-09
gene O 0 3.353530120264736e-09
( O 0 1.0075342643522944e-10
1 O 0 2.6005758657632327e-10
) O 0 1.0060326183225499e-10
at O 0 2.407893606726219e-10
the O 0 1.7866731705229455e-10
5 O 0 4.895127081461226e-10
end O 0 1.1550849166042099e-09
spanning O 0 2.984512637027592e-09
exons O 0 5.165361827152992e-08
4 O 0 1.5580408074811203e-09
and O 0 4.792250485330385e-10
5 O 0 3.182757390973734e-10
, O 0 1.2295268969619855e-10
( O 0 5.913483591690749e-11
2 O 0 1.9941248652344257e-10
) O 0 7.364574922119616e-11
within O 0 8.697606523888624e-11
exon O 0 1.4710304974130395e-08
9 O 0 1.5417377374760122e-09
, O 0 9.654606281106481e-11
and O 0 1.8503490406551748e-10
( O 0 7.317905309500716e-11
3 O 0 2.621237671363019e-10
) O 0 1.5280067489076288e-10
at O 0 4.894399330268584e-10
the O 0 2.6197430336161176e-10
3 O 0 7.720029060465095e-10
distal O 0 2.4691669153753537e-08
end O 0 1.0886123646969281e-07
of O 0 4.698349487242126e-10
the O 0 6.082299996990059e-09
gene O 0 9.572205499353004e-07
. O 0 4.31167052283854e-07

Variability O 0 2.4889966880436987e-05
in O 0 1.3917398788976243e-08
the O 0 1.4789097724232647e-09
number O 0 1.1373487929233761e-08
of O 0 1.2114458058931632e-07
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
was O 0 6.828572077210993e-05
most O 0 2.728148595920743e-09
apparent O 0 2.3133246429551946e-08
in O 0 3.3669297905269957e-10
individuals O 0 2.8253333006489356e-10
with O 0 2.4439097967565715e-10
mutations O 0 9.796376332360524e-08
in O 0 1.5429701960556486e-09
region O 0 1.183906039869953e-08
1 O 0 8.865490563891854e-09
, O 0 9.932907829579563e-10
and O 0 1.885054423667043e-08
upper O 0 0.017818404361605644
- O 1 0.9977898597717285
gastrointestinal O 0 0.0011810772120952606
manifestations O 0 1.1451966486220044e-07
were O 0 2.5683390969533093e-09
more O 0 5.045200923703419e-10
severe O 0 2.6095827365679725e-07
in O 0 2.5131923209187335e-09
them O 0 8.767085724059598e-09
. O 0 1.9986394761417614e-07

In O 0 5.99609677465196e-08
individuals O 0 7.500287502182346e-09
with O 0 1.7734937962643471e-09
mutations O 0 1.0575814002322659e-07
in O 0 1.731043419717082e-09
either O 0 9.895225971945365e-09
region O 0 2.0010498147371436e-08
2 O 0 3.853122265695674e-09
or O 0 1.7470219049187108e-08
region O 0 8.07883626663397e-09
3 O 0 1.1192626825362595e-09
, O 0 8.995273276246607e-11
the O 0 5.392366414502803e-11
average O 0 1.6127499335993889e-09
number O 0 1.3414683253110127e-10
of O 0 5.224018786997853e-11
adenomas B-Disease 0 5.8305023031834935e-08
tended O 0 6.1082952029778426e-09
to O 0 1.4115050794849537e-10
be O 0 7.969126747386923e-11
lower O 0 2.446139124590019e-10
than O 0 5.12274250796807e-11
those O 0 9.304564757561806e-11
in O 0 6.594452067743006e-11
individuals O 0 8.571210408092611e-11
with O 0 9.379669263509527e-11
mutations O 0 1.778677649610927e-08
in O 0 3.585548247198034e-10
region O 0 3.910322732281202e-09
1 O 0 2.346582039791656e-09
, O 0 2.0886969931410704e-10
although O 0 3.378691326716421e-09
age O 0 5.1453095117892644e-09
at O 0 3.088156175223844e-09
diagnosis O 0 8.25741892640508e-07
was O 0 2.622585526523835e-08
similar O 0 1.8013550118212152e-07
. O 0 5.405534579949745e-07

In O 0 5.351304253053968e-07
all O 0 1.919867145261378e-07
AAPC B-Disease 1 0.9999955892562866
kindreds O 0 5.244476051302627e-05
, O 0 9.202137718489212e-09
a O 0 2.911092034096896e-09
predominance O 0 1.9860347322264715e-07
of O 0 2.232365181598084e-09
right O 0 0.004180177114903927
- O 1 0.9999970197677612
sided O 1 1.0
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and O 0 1.016380156215746e-05
rectal B-Disease 1 0.9990200996398926
polyp I-Disease 0 0.001063631847500801
sparing O 0 2.3190957563201664e-06
was O 0 1.4553302207787056e-07
observed O 0 4.978777496944531e-07
. O 0 4.771132466885319e-07

No O 0 7.738154636172112e-06
desmoid B-Disease 0 0.01073905173689127
tumors I-Disease 1 1.0
were O 0 8.686561159265693e-08
found O 0 2.119092101793285e-08
in O 0 1.005745886573095e-08
these O 0 6.705032262743771e-08
kindreds O 0 9.308332664659247e-05
. O 0 1.3864298580301693e-06

Our O 0 2.6452687507116934e-07
data O 0 2.7579403649724554e-08
suggest O 0 8.190828459930799e-09
that O 0 3.5812355858588774e-10
, O 0 3.580941931868864e-10
in O 0 2.085318584477136e-09
AAPC B-Disease 1 1.0
families O 0 2.525132547503972e-09
, O 0 8.705672988051916e-11
the O 0 4.032730052672129e-11
location O 0 6.583939171633801e-09
of O 0 1.2390118098171143e-10
the O 0 3.2902105484566846e-09
APC B-Disease 0 3.7127585983398603e-07
mutation O 0 1.0343942449253518e-06
may O 0 8.19011347630294e-08
partially O 0 2.8816577923862496e-07
predict O 0 1.0898984470486539e-07
specific O 0 3.2674666528009766e-08
phenotypic O 0 3.3057763175747823e-06
expression O 0 2.024488821916748e-06
. O 0 1.0591594445941155e-06

This O 0 4.9082117925536295e-08
should O 0 8.830203235277168e-09
help O 0 2.254151976188723e-09
in O 0 1.6606965802523632e-10
the O 0 1.456933462762322e-10
design O 0 1.0393259941565702e-07
of O 0 2.6702820510315917e-10
tailored O 0 3.093333873493975e-07
clinical O 0 3.806400627581752e-06
- O 0 1.9028001361220959e-06
management O 0 8.321466182792392e-09
protocols O 0 2.767244433599103e-09
in O 0 1.800590093692378e-10
this O 0 2.887659833472611e-10
subset O 0 2.4839613033122987e-08
of O 0 2.6770761163419365e-09
FAP B-Disease 0 2.1301445940480335e-06
patients O 0 1.3414573629688675e-07
. O 0 1.7089787363033793e-08
. O 0 1.4475786258572043e-07

Wilms B-Disease 0 0.04080573841929436
' I-Disease 0 1.0556729648669716e-05
tumor I-Disease 0 4.486906163947424e-06
1 O 0 4.033974576600485e-08
and O 0 5.605019559595803e-09
Dax O 0 7.08880033926107e-05
- O 0 8.493294103573135e-07
1 O 0 1.0177410025846712e-08
modulate O 0 1.0341708645000836e-07
the O 0 3.4232028323089025e-09
orphan O 0 3.115297886324697e-07
nuclear O 0 3.751654276129557e-07
receptor O 0 2.1800366312163533e-07
SF O 0 5.015204442315735e-05
- O 0 2.604299709219049e-07
1 O 0 2.716434410743318e-09
in O 0 5.840647410160216e-10
sex O 0 2.109152319462737e-08
- O 0 6.631240268006877e-08
specific O 0 2.0039944814698174e-08
gene O 0 2.2415829903366102e-07
expression O 0 3.7849608247597644e-07
. O 0 4.690112973548821e-07

Products O 0 2.4877747364371317e-06
of O 0 1.1603342287003215e-08
steroidogenic O 0 4.607911250786856e-06
factor O 0 1.8830748160780786e-07
1 O 0 9.4378771464676e-09
( O 0 2.741141535977931e-09
SF O 0 0.32923224568367004
- O 0 8.226471436501015e-06
1 O 0 1.3173285573486737e-08
) O 0 2.1077555256709957e-09
and O 0 6.891701875844092e-09
Wilms B-Disease 0 1.8821006960934028e-05
tumor I-Disease 0 8.101119419734459e-07
1 O 0 6.773684280148018e-09
( O 0 6.88556212047331e-10
WT1 O 0 1.9941788309552066e-07
) O 0 4.610560822015941e-10
genes O 0 1.7762697979151199e-09
are O 0 1.1134618921326833e-10
essential O 0 8.304433252170895e-10
for O 0 1.7162975207707376e-10
mammalian O 0 2.682648947427424e-08
gonadogenesis O 0 2.2661033938220498e-07
prior O 0 1.9158317599021757e-08
to O 0 6.035208777177559e-09
sexual O 0 1.706302299453455e-07
differentiation O 0 1.212777988257585e-06
. O 0 9.195647407977958e-07

In O 0 3.101675929428893e-07
males O 0 3.748542383164022e-07
, O 0 1.92963920397915e-08
SF O 0 0.18161574006080627
- O 0 5.471681561175501e-06
1 O 0 1.3310150315248848e-08
participates O 0 5.819544846019653e-09
in O 0 6.325118762084969e-10
sexual O 0 5.32572785871821e-09
development O 0 3.5317643254373365e-10
by O 0 8.726686734350508e-11
regulating O 0 5.8172364703068524e-09
expression O 0 2.870500503959761e-09
of O 0 1.2173785590707809e-10
the O 0 1.7661786477773944e-09
polypeptide O 0 2.3499076178268297e-06
hormone O 0 1.894405841085245e-06
Mullerian O 0 5.822850653203204e-06
inhibiting O 0 8.003562470548786e-07
substance O 0 5.992095566398348e-07
( O 0 1.4071519061076287e-08
MIS O 0 1.8030745195574127e-05
) O 0 8.824397923490324e-08
. O 0 3.641266346221528e-07

Here O 0 1.282750332620708e-07
, O 0 9.487511221095701e-09
we O 0 7.266561574681418e-09
show O 0 3.986080443496576e-08
that O 0 1.5671766107061558e-08
WT1 O 0 2.67438681476051e-05
- O 0 3.671544391181669e-06
KTS O 0 1.5257552149705589e-05
isoforms O 0 1.824026725216754e-07
associate O 0 9.653773247464414e-08
and O 0 2.1148029993867112e-09
synergize O 0 6.600941446777142e-07
with O 0 1.0310820641734608e-08
SF O 0 0.4473351240158081
- O 0 2.970914238176192e-06
1 O 0 2.746580207713123e-08
to O 0 4.833718314500857e-09
promote O 0 7.72183312847119e-08
MIS O 0 2.0307526938267983e-05
expression O 0 1.269238396162109e-06
. O 0 5.792294359707739e-07

In O 0 5.375952696340391e-07
contrast O 0 1.8407712332191295e-06
, O 0 9.18411586781076e-08
WT1 O 0 4.096686461707577e-05
missense O 0 4.450268534128554e-05
mutations O 0 5.689956196874846e-06
, O 0 5.0198818435376324e-09
associated O 0 1.9457049305060536e-08
with O 0 4.640311690451426e-09
male B-Disease 0 7.694222404097673e-06
pseudohermaphroditism I-Disease 1 1.0
in O 0 1.6390487189710257e-07
Denys B-Disease 1 0.9999959468841553
- I-Disease 1 0.9999963045120239
Drash I-Disease 1 0.9999741315841675
syndrome I-Disease 1 0.9999991655349731
, O 0 8.533375783770225e-09
fail O 0 5.092861101729795e-07
to O 0 1.5285497312333973e-09
synergize O 0 8.253553005488357e-07
with O 0 1.5731423275155976e-08
SF O 1 0.9874020218849182
- O 0 0.00019884271023329347
1 O 0 4.1116246052297356e-07
. O 0 4.488121021495317e-07

Additionally O 0 1.8343328065384412e-06
, O 0 1.0675848649555064e-08
the O 0 2.433194978834763e-09
X O 0 1.8752105461317115e-05
- O 0 3.941470822610427e-06
linked O 0 1.5861028259678278e-06
, O 0 6.867252877462704e-10
candidate O 0 1.6500736776947633e-08
dosage O 0 1.529641963315953e-06
- O 0 2.953541695660533e-07
sensitive O 0 3.308897760234686e-07
sex O 0 1.614893818668861e-07
- O 0 6.261506513283166e-08
reversal O 0 3.73152850841052e-08
gene O 0 1.4758586353025294e-08
, O 0 5.662947888396275e-10
Dax O 0 1.5765313037263695e-06
- O 0 1.023993689841518e-07
1 O 0 4.671410813728016e-09
, O 0 1.472686084191821e-09
antagonizes O 0 4.23589938236546e-07
synergy O 0 4.175886658686068e-08
between O 0 2.3517123803884488e-09
SF O 0 0.0627598688006401
- O 0 2.254593255202053e-06
1 O 0 6.268470631454193e-09
and O 0 1.2473898580722675e-09
WT1 O 0 1.3780551455511159e-07
, O 0 1.867701965307944e-10
most O 0 1.378029496068578e-10
likely O 0 8.136203377695495e-10
through O 0 1.9099302694947085e-10
a O 0 4.316327295583733e-10
direct O 0 3.338602505564836e-09
interaction O 0 1.701086027594556e-08
with O 0 1.1058014948162054e-08
SF O 1 0.9979546070098877
- O 0 4.242205977789126e-05
1 O 0 2.352687715756474e-07
. O 0 3.9731506262796756e-07

We O 0 1.0710193691920722e-06
propose O 0 4.84263978250965e-07
that O 0 8.374887450202095e-09
WT1 O 0 1.424164793206728e-06
and O 0 9.083228391659759e-09
Dax O 0 2.064955697278492e-05
- O 0 3.281369629348774e-07
1 O 0 3.837383300009378e-09
functionally O 0 1.2929140424944308e-08
oppose O 0 4.8171058253387855e-09
each O 0 5.29512600433435e-10
other O 0 3.940636705834777e-10
in O 0 8.947622087696061e-10
testis O 0 4.5034875029159593e-07
development O 0 1.5211971682305148e-09
by O 0 1.2783843983399379e-09
modulating O 0 1.562683678457688e-06
SF O 1 0.9615875482559204
- O 0 3.0202501875464804e-05
1 O 0 2.298060621797049e-07
- O 0 1.5389582586067263e-06
mediated O 0 3.967076736444142e-06
transactivation O 0 2.8440401365514845e-05
. O 0 1.9626646974302275e-07
. O 0 2.9354714570217766e-07

A O 0 6.627396373914962e-07
mouse O 0 6.322414265014231e-06
model O 0 3.930311777367024e-06
for O 0 8.371039825760818e-07
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 0.9999998807907104
imprinting O 0 0.36888471245765686
- O 1 0.9693530797958374
centre O 0 1.432157114322763e-05
mutations O 0 3.7190253351582214e-05
. O 0 1.9835788407362998e-06

Imprinting O 0 7.452737190760672e-05
in O 0 8.767742798454492e-08
the O 0 1.1848051428842155e-08
15q11 O 0 1.3855336646884098e-06
- O 0 9.186040301756293e-07
q13 O 0 5.848306159350614e-07
region O 0 1.821837436466467e-08
involves O 0 6.177776068483354e-09
an O 0 8.445898425080145e-10
imprinting O 0 6.808113539591432e-07
centre O 0 5.225212973414273e-08
( O 0 5.279263137758505e-10
IC O 0 6.759360360319988e-08
) O 0 4.269418429903027e-10
, O 0 4.7811095360561495e-11
mapping O 0 4.328779112938719e-09
in O 0 4.143654308563782e-10
part O 0 5.361172061846275e-10
to O 0 1.2186260334168253e-10
the O 0 9.066136036350869e-11
promoter O 0 1.0646972192773774e-08
and O 0 9.16975495535155e-10
first O 0 2.0577517467756934e-09
exon O 0 1.375450011664725e-07
of O 0 4.9214361474980706e-09
SNRPN O 0 2.573470919742249e-05
. O 0 4.5332930653785297e-07

Deletion O 0 1.6724086890462786e-05
of O 0 2.5869738351502747e-08
this O 0 2.075609373264342e-08
IC O 0 6.510888397315284e-06
abolishes O 0 1.696325284683553e-06
local O 0 3.811693005673078e-08
paternally O 0 6.352381660690298e-07
derived O 0 2.1267124949986282e-08
gene O 0 3.2902370605825126e-08
expression O 0 1.769237556459302e-08
and O 0 4.966662192629201e-09
results O 0 9.824611879594158e-08
in O 0 6.165730610518949e-07
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 3.1744657462695614e-06
PWS B-Disease 1 0.9999998807907104
) O 0 7.927295087029052e-07
. O 0 7.79743061229965e-07

We O 0 4.7010973958094837e-07
have O 0 5.315518691872967e-09
created O 0 4.529336461445155e-09
two O 0 2.1129240579398356e-09
deletion O 0 4.940239364259469e-07
mutations O 0 3.4309647389818565e-07
in O 0 1.841533592283895e-09
mice O 0 1.2786610170678614e-07
to O 0 2.6220339233162804e-09
understand O 0 1.934991331609126e-07
PWS B-Disease 1 0.9999998807907104
and O 0 3.827719474713831e-09
the O 0 3.706399909209068e-10
mechanism O 0 3.224480238372962e-09
of O 0 3.1373362241460256e-10
this O 0 1.0081080858981295e-08
IC O 0 2.0406923795235343e-05
. O 0 4.095641941148642e-07

Mice O 0 0.0006420595454983413
harbouring O 0 9.309958113590255e-05
an O 0 5.3604924943329024e-08
intragenic O 0 3.7398194763227366e-06
deletion O 0 2.14153897104552e-06
in O 0 1.1140535605136392e-08
Snrpn O 0 7.59673127959104e-07
are O 0 2.6408504272268374e-09
phenotypically O 0 1.8600610474095447e-07
normal O 0 2.9281562063943056e-08
, O 0 4.953755738945631e-10
suggesting O 0 1.0123240024029201e-08
that O 0 7.924099709732957e-10
mutations O 0 1.5361672822677974e-08
of O 0 7.686012937213604e-11
SNRPN O 0 2.298428967151267e-07
are O 0 6.801786911481145e-10
not O 0 1.3986527491738343e-09
sufficient O 0 9.130648237487549e-09
to O 0 1.182276854194697e-08
induce O 0 3.0249486826505745e-06
PWS B-Disease 1 0.9999939203262329
. O 0 4.3337645365681965e-06

Mice O 0 5.786640758742578e-05
with O 0 3.888347421820981e-08
a O 0 1.306653363286614e-08
larger O 0 3.963057437772477e-08
deletion O 0 3.316005177111947e-07
involving O 0 9.764323571914701e-09
both O 0 1.6713680439650602e-09
Snrpn O 0 3.708798601564922e-07
and O 0 1.9531105621695133e-09
the O 0 3.899248479655171e-09
putative O 0 3.755971556529403e-05
PWS O 1 1.0
- O 1 0.7593500018119812
IC O 0 0.0004138201184105128
lack O 0 3.977892859552412e-08
expression O 0 1.0672386530075073e-08
of O 0 5.76701131294044e-10
the O 0 3.837016926411252e-09
imprinted O 0 8.873392403074831e-07
genes O 0 1.4260305647439964e-07
Zfp127 O 0 5.60504304303322e-07
( O 0 2.0982093840160587e-09
mouse O 0 9.88159385428844e-08
homologue O 0 2.5147360815935826e-07
of O 0 1.2638714519397354e-09
ZNF127 O 0 8.480998872073542e-07
) O 0 2.577388080737819e-09
, O 0 1.0667253746987626e-09
Ndn O 0 5.521819730347488e-07
and O 0 6.436761346151343e-09
Ipw O 0 7.245776032505091e-07
, O 0 1.861990561735638e-09
and O 0 1.6443044703606802e-09
manifest O 0 1.1900913143847447e-08
several O 0 2.206584692743263e-09
phenotypes O 0 4.957380497216946e-07
common O 0 2.5177328666359244e-07
to O 0 1.0358355666539865e-06
PWS B-Disease 1 1.0
infants O 0 0.018305636942386627
. O 0 1.3021075346841826e-06

These O 0 2.2874857563692785e-08
data O 0 2.2254324605341935e-08
demonstrate O 0 5.805553815463327e-09
that O 0 1.217914935569553e-10
both O 0 1.337620569863418e-10
the O 0 3.8580919015096526e-10
position O 0 2.7987849193777947e-07
of O 0 8.948863178259714e-11
the O 0 7.111183308872171e-10
IC O 0 5.93868662690511e-07
and O 0 8.742284673957101e-10
its O 0 3.944238546882417e-10
role O 0 1.0428541585838502e-08
in O 0 6.820807252339023e-10
the O 0 2.3325510967175944e-10
coordinate O 0 6.775609406872718e-09
expression O 0 6.480048053703058e-09
of O 0 2.2644414121586465e-10
genes O 0 5.05975439324402e-09
is O 0 1.6230744526168905e-10
conserved O 0 8.950267749163743e-10
between O 0 2.020831418869662e-10
mouse O 0 2.2300767454908055e-08
and O 0 1.0634465530401371e-09
human O 0 2.909375518278523e-10
, O 0 1.4100683121132107e-10
and O 0 1.6180948247956906e-10
indicate O 0 1.733164389783326e-09
that O 0 1.0919214837867841e-10
the O 0 7.855235906184532e-11
mouse O 0 1.9737948164788577e-08
is O 0 9.805976031174168e-10
a O 0 3.881156229734728e-10
suitable O 0 1.725720188971991e-08
model O 0 9.502945630401882e-08
system O 0 2.0047581372750756e-09
in O 0 2.5160881711450145e-10
which O 0 2.5456109442600905e-10
to O 0 1.6326905105668033e-10
investigate O 0 1.9748709334521664e-09
the O 0 1.2214766698104285e-10
molecular O 0 4.677473963710099e-09
mechanisms O 0 1.4012776494709556e-09
of O 0 3.187622041322946e-11
imprinting O 0 3.2835853147616945e-08
in O 0 7.461331552605088e-10
this O 0 5.883987186372508e-10
region O 0 3.678274129725878e-09
of O 0 1.0238887515612305e-10
the O 0 7.047289418693481e-10
genome O 0 1.5350542170722292e-08
. O 0 1.148352435365041e-08
. O 0 9.416681479024192e-08

Mutations O 0 1.2280570445000194e-05
of O 0 6.03073280203148e-09
the O 0 4.279848919708229e-09
ATM O 0 6.299347319327353e-07
gene O 0 1.9638217452211393e-07
detected O 0 5.099295776744839e-07
in O 0 1.3648785213149495e-08
Japanese O 0 1.1237080798309762e-05
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 0 0.49785658717155457
: O 0 3.3044993408282153e-09
possible O 0 5.033006456045541e-09
preponderance O 0 8.80531558777875e-08
of O 0 1.8127610523777093e-10
the O 0 6.296675403305585e-10
two O 0 1.894431944649e-09
founder O 0 1.0176811571227518e-07
mutations O 0 5.284638859848201e-07
4612del165 O 0 3.498213914099324e-07
and O 0 1.8773040011410558e-08
7883del5 O 0 5.670774044119753e-06
. O 0 6.508664114335261e-07

The O 0 7.547058089585335e-08
ATM O 0 4.057684236613568e-06
( O 0 7.230438825445162e-08
A O 1 0.9999994039535522
- O 1 0.9999995231628418
T O 1 1.0
, O 0 6.212954151152417e-09
mutated O 0 5.108699951961171e-08
) O 0 1.637868951576138e-09
gene O 0 2.6961911814282757e-08
on O 0 8.678509466619744e-09
human O 0 9.477603413188262e-08
chromosome O 0 1.689716191322077e-05
11q22 O 0 2.086273889290169e-05
. O 0 1.055777033798222e-06

3 O 0 6.898588367221237e-07
has O 0 2.738399196289265e-08
recently O 0 3.4250923874878936e-08
been O 0 1.9164925202375116e-09
identified O 0 2.101629981154929e-09
as O 0 1.1388975873494189e-10
the O 0 4.950031703976343e-11
gene O 0 1.4099128531341876e-09
responsible O 0 6.721877499060724e-10
for O 0 1.191734627647989e-10
the O 0 9.356250219028084e-10
human O 0 8.318866662193614e-08
recessive B-Disease 1 0.9999972581863403
disease I-Disease 1 0.9999352693557739
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.004754714667797089
A B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
) O 0 4.4211230942892144e-07
. O 0 3.922841926851106e-07

In O 0 5.097069077919514e-08
order O 0 3.724387687142894e-09
to O 0 6.491251425266853e-10
define O 0 1.0887115209357034e-08
the O 0 2.6909482975234766e-10
types O 0 1.3238246054925185e-08
of O 0 1.4060753672495707e-09
disease O 0 4.128270120418165e-06
- O 0 3.1011375540401787e-05
causing O 0 8.06155426857913e-08
ATM O 0 5.31704813511169e-07
mutations O 0 1.0244781378787593e-07
in O 0 1.4124915681534844e-09
Japanese O 0 1.3912376743974164e-06
A B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999995231628418
T I-Disease 1 1.0
patients O 0 1.2528285253665672e-07
as O 0 2.368849838507714e-10
well O 0 1.4933453085230752e-10
as O 0 7.766547821530523e-11
to O 0 6.406769559319514e-11
look O 0 1.5595066349405329e-09
for O 0 1.0296523356156939e-10
possible O 0 2.1759825052924953e-09
mutational O 0 2.7174394290341297e-07
hotspots O 0 1.151700175228143e-07
, O 0 2.086070427509412e-09
reverse O 0 7.832511528249597e-07
- O 0 2.9990829375492467e-07
transcribed O 0 4.457807989410867e-08
RNA O 0 8.385037553182428e-09
derived O 0 1.1662689702873763e-09
from O 0 1.1498679786114963e-10
ten O 0 4.807126363637337e-10
patients O 0 8.293400410863683e-10
belonging O 0 3.883222077227799e-10
to O 0 8.798939354903723e-11
eight O 0 2.683470112785358e-10
unrelated O 0 1.2876941291040112e-08
Japanese O 0 1.4076491652303957e-06
A B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999980926513672
T I-Disease 1 1.0
families O 0 5.538493219603424e-09
was O 0 1.310143882271575e-09
analyzed O 0 3.953912308674035e-09
for O 0 9.293213421024404e-11
mutations O 0 3.899969680531967e-09
by O 0 9.030479836136251e-11
the O 0 3.5697170219783914e-10
restriction O 0 1.8806657564596208e-08
endonuclease O 0 7.17629859536828e-07
fingerprinting O 0 4.957390160598152e-07
method O 0 6.422072260647838e-07
. O 0 5.517113663700002e-07

As O 0 8.702183151854115e-08
has O 0 1.1932302257378069e-08
been O 0 4.045916934813931e-09
reported O 0 1.48994905302402e-09
by O 0 5.8178298983913024e-11
others O 0 1.505793600919958e-09
, O 0 1.3305212487324525e-10
mutations O 0 1.0548492745954263e-08
that O 0 3.490158717589509e-10
lead O 0 7.640791888086085e-10
to O 0 1.6490273035962844e-10
exon O 0 5.374539213676144e-08
skipping O 0 1.0683164219926766e-07
or O 0 6.046329303899256e-08
premature O 0 3.9415500197037545e-08
protein O 0 3.739713427819424e-09
truncation O 0 9.769301101414385e-08
were O 0 7.918438349463486e-09
also O 0 2.7255582235596876e-09
predominant O 0 2.892172688007122e-07
in O 0 1.1806587707496874e-08
our O 0 6.335762492426511e-08
mutants O 0 1.8782336610456696e-06
. O 0 2.048511760222027e-07

Six O 0 3.9935235918164835e-07
different O 0 1.8750890617980076e-08
mutations O 0 1.0901187863510131e-07
were O 0 1.6488582721407852e-09
identified O 0 4.4473091875829596e-09
on O 0 6.24314766550782e-10
12 O 0 1.3075326377176566e-09
of O 0 1.0455777910145514e-10
the O 0 2.9840230286737324e-09
16 O 0 2.7471566355075083e-08
alleles O 0 3.833778805528709e-07
examined O 0 2.0421111912583e-06
. O 0 4.218419462631573e-07

Four O 0 5.238884170921665e-08
were O 0 1.9429153841343805e-09
deletions O 0 3.108699786480429e-08
involving O 0 5.083395926419598e-09
a O 0 2.477524851940416e-09
loss O 0 1.9007378782021078e-08
of O 0 7.600076817881884e-11
a O 0 1.1360495877354992e-09
single O 0 1.3209592530927239e-08
exon O 0 3.9317558275797637e-07
exon O 0 2.9400857215478027e-07
7 O 0 5.507396760862093e-09
, O 0 4.0336939344243206e-10
exon O 0 8.193536160661097e-08
16 O 0 5.5447508806594215e-09
, O 0 6.944624320048831e-10
exon O 0 1.462711765043423e-07
33 O 0 2.0297838076999142e-08
or O 0 2.0301362368968512e-08
exon O 0 2.24025870920741e-06
35 O 0 5.637218123411003e-07
. O 0 8.246432798841852e-07

The O 0 4.020701283025119e-08
others O 0 1.592970733099719e-08
were O 0 1.2515462000095567e-09
minute O 0 5.235025746230804e-09
deletions O 0 4.025090305503909e-08
, O 0 1.2711848240698487e-09
4649delA O 0 5.0637257942298675e-08
in O 0 1.0335270417272113e-09
exon O 0 8.913885807260158e-08
33 O 0 6.493211746061434e-09
and O 0 1.4918315471845744e-09
7883del5 O 0 1.4843709550405038e-07
in O 0 6.005479669113356e-09
exon O 0 1.5812623814781546e-06
55 O 0 5.488847705237276e-07
. O 0 4.221325013986643e-07

The O 0 2.688050528831809e-07
mutations O 0 2.11799260796397e-06
4612del165 O 0 6.638427976213279e-07
and O 0 4.381659923780035e-09
7883del5 O 0 7.253727574152435e-08
were O 0 1.4129872827339796e-09
found O 0 4.566242661763198e-10
in O 0 3.75259996687749e-11
more O 0 1.378091737946896e-11
than O 0 6.977401989516352e-11
two O 0 2.391754017061487e-10
unrelated O 0 5.322904783611193e-09
families O 0 5.286820980998641e-10
; O 0 2.9840555026972027e-10
44 O 0 2.1765583779753683e-10
% O 0 1.2378308100746693e-10
( O 0 3.20264439968021e-11
7 O 0 1.4888489052733433e-10
of O 0 3.3337693716717354e-11
16 O 0 3.056189745720417e-10
) O 0 6.074943326161986e-11
of O 0 5.5752099985262316e-12
the O 0 8.925066935505654e-11
mutant O 0 1.4739429232690782e-08
alleles O 0 1.922776426965811e-08
had O 0 5.216397092056013e-09
one O 0 3.916187651942238e-10
of O 0 5.212990455971678e-11
the O 0 1.0700285102416274e-09
two O 0 1.392143467171536e-08
mutations O 0 5.953741947450908e-06
. O 0 5.657317956320185e-07

The O 0 1.0479191558943057e-07
4612del165 O 0 8.069512773545284e-07
mutations O 0 1.2975020524663705e-07
in O 0 4.6311496304518585e-10
three O 0 6.928849854981323e-11
different O 0 2.3230009582597688e-10
families O 0 4.485583016133887e-10
were O 0 1.9767769365852672e-10
all O 0 2.0384754648161696e-11
ascribed O 0 6.771213034717505e-10
to O 0 1.7228275750458266e-10
the O 0 1.8965207182475297e-10
same O 0 5.244710443719214e-09
T O 0 5.213563326833537e-06
- O 0 2.549263342643826e-07
- O 0 6.596750523613082e-08
> O 0 5.642336375899504e-09
A O 0 4.0840142379039435e-10
substitution O 0 3.0741513779020124e-09
at O 0 1.2936829385523652e-09
the O 0 4.265918451817896e-10
splice O 0 3.7879073033764143e-07
donor O 0 3.167571804851832e-08
site O 0 4.1931901506586655e-08
in O 0 7.042697536263631e-09
intron O 0 1.829621396609582e-05
33 O 0 9.748024467626237e-07
. O 0 7.137088005038095e-07

Microsatellite O 0 0.0001822377962525934
genotyping O 0 3.463286702753976e-05
around O 0 7.458235984358907e-08
the O 0 3.784669466710966e-09
ATM O 0 3.609072791732615e-07
locus O 0 5.106746812089114e-07
also O 0 1.0678536277453077e-08
indicated O 0 8.883890068034361e-09
that O 0 5.319369944523089e-10
a O 0 6.155683740516338e-10
common O 0 9.281849955300459e-09
haplotype O 0 1.4308367326520965e-06
was O 0 3.3162958601451464e-08
shared O 0 1.0725765831054446e-09
by O 0 1.4143725080018044e-10
the O 0 3.6351416321522834e-10
mutant O 0 1.1881594019769182e-07
alleles O 0 7.940341362200343e-08
in O 0 5.355277998830843e-09
both O 0 3.1403807554397645e-08
mutations O 0 6.305775968939997e-06
. O 0 5.371858264879847e-07

This O 0 7.099981047531401e-08
suggests O 0 4.8568804089654805e-08
that O 0 3.1346686357736075e-10
these O 0 1.2499924706421695e-10
two O 0 1.778682617858962e-10
founder O 0 1.737504540244572e-08
mutations O 0 1.353642886670059e-07
may O 0 1.4102632839296803e-08
be O 0 1.4389005542625455e-09
predominant O 0 1.2198078991332295e-07
among O 0 4.684830745560475e-09
Japanese O 0 5.756808008072767e-08
ATM O 0 2.5702424863993656e-06
mutant O 0 5.485035671881633e-06
alleles O 0 1.6412604963988997e-05
. O 0 2.1411467514553806e-06

W474C O 0 0.00014674858539365232
amino O 0 8.093249562080018e-06
acid O 0 1.4798720258113462e-06
substitution O 0 1.0811238837504789e-07
affects O 0 6.119375939306337e-08
early O 0 3.7218599313604273e-09
processing O 0 9.4356815694141e-09
of O 0 2.6481375425824183e-10
the O 0 2.9035268633847977e-10
alpha O 0 3.2747713429870373e-09
- O 0 4.610589687814581e-09
subunit O 0 4.8853170397933354e-09
of O 0 8.669070322708805e-11
beta O 0 1.09115632085377e-08
- O 0 4.289756461162142e-08
hexosaminidase O 0 1.721299440760049e-07
A O 0 1.6046586281959208e-09
and O 0 6.424173415453538e-10
is O 0 3.5727415470532264e-10
associated O 0 2.3936677084890334e-09
with O 0 3.1935343258737703e-09
subacute O 0 3.277151336078532e-05
G B-Disease 0 1.3434801985567901e-05
( I-Disease 0 9.952768387222477e-09
M2 I-Disease 0 9.762260560819414e-06
) I-Disease 0 1.4672117742975388e-07
gangliosidosis I-Disease 0 1.5760979295009747e-05
. O 0 9.284568704970297e-07

Mutations O 0 6.835817475803196e-05
in O 0 1.1432629776209069e-07
the O 0 3.0972064024581414e-08
HEXA O 0 1.7966529412660748e-05
gene O 0 3.1474843353862525e-07
, O 0 1.6272941882888858e-09
encoding O 0 9.519940391555792e-09
the O 0 8.14736889065415e-10
alpha O 0 3.891973854308617e-09
- O 0 8.591007016889307e-09
subunit O 0 1.1604138983045686e-08
of O 0 2.3061061393825355e-10
beta O 0 2.2879744321357975e-08
- O 0 1.3684737609764852e-07
hexosaminidase O 0 6.802181928833306e-07
A O 0 2.366150608779094e-09
( O 0 2.1369570002427452e-10
Hex O 0 2.159630696496606e-08
A O 0 4.5784173674512374e-10
) O 0 1.6733800456414372e-10
, O 0 4.3103028091184825e-11
that O 0 1.2213274835914945e-10
abolish O 0 4.593151459175715e-08
Hex O 0 1.4548973581440805e-07
A O 0 2.3115944713936187e-09
enzyme O 0 4.53035831071702e-08
activity O 0 1.6815603487430053e-07
cause O 0 3.049507358809933e-05
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 0 0.0005811636801809072
( O 0 2.85975132463534e-09
TSD B-Disease 0 1.0165488220081897e-06
) O 0 1.898367463226691e-09
, O 0 3.9924680228509146e-10
the O 0 2.8269895313570714e-09
fatal O 0 0.00038246868643909693
infantile B-Disease 0 7.107236683623341e-07
form I-Disease 0 2.4592214487029196e-08
of I-Disease 0 1.1805456612279386e-09
G I-Disease 0 6.124163292042795e-07
( I-Disease 0 1.4273980886159165e-09
M2 I-Disease 0 8.727129738872463e-07
) I-Disease 0 9.283160018469516e-09
gangliosidosis I-Disease 0 5.728077780986496e-07
, I-Disease 0 9.204296880227503e-09
Type I-Disease 0 4.940521876051207e-07
1 I-Disease 0 1.2839201701808634e-07
. O 0 2.3694424555742444e-07

Less O 0 3.566261284504435e-06
severe O 0 0.00012379408872220665
, O 0 5.2240171299899885e-08
subacute O 0 3.594518420868553e-05
( O 0 3.305308027279352e-08
juvenile O 0 0.00012984697241336107
- O 1 0.579829752445221
onset O 0 0.018801357597112656
) O 0 4.052422184486204e-07
and O 0 2.8613762879103888e-06
chronic O 0 0.021678892895579338
( O 0 1.3358618655701093e-09
adult O 0 8.026876798794547e-07
- O 0 0.004227360710501671
onset O 0 6.113378276495496e-06
) O 0 1.365961121990722e-09
variants O 0 8.827592878901669e-09
are O 0 3.9598269108154227e-10
characterized O 0 1.429948603970388e-09
by O 0 1.6503111377463853e-10
a O 0 5.645778289320447e-10
broad O 0 3.945444415620614e-09
spectrum O 0 6.150792764003654e-09
of O 0 1.4451957686123507e-10
clinical O 0 2.6630216254375227e-08
manifestations O 0 1.7689609776994075e-08
and O 0 1.1580738590311057e-09
are O 0 3.09097109019163e-10
associated O 0 2.5323285690603825e-09
with O 0 6.980426792146943e-10
residual O 0 0.003781959880143404
levels O 0 1.7997169265981938e-07
of O 0 1.079939915271666e-09
Hex O 0 8.106282507469587e-07
A O 0 2.0881811835238295e-08
enzyme O 0 2.316177187822177e-07
activity O 0 3.8873469065947575e-07
. O 0 6.066719606678816e-07

We O 0 1.6978369785647374e-06
identified O 0 2.976306063828815e-07
a O 0 5.279369119648436e-08
1422 O 0 4.844760042033158e-06
G O 0 4.612457360053668e-06
- O 0 4.5711717575613875e-06
- O 0 3.4321924431424122e-06
> O 0 3.937557266908698e-07
C O 0 2.3570422058583063e-07
( O 0 8.699220233054916e-10
amino O 0 3.985667795802783e-09
acid O 0 4.393426511484222e-09
W474C O 0 7.717412486840658e-09
) O 0 3.891524602561702e-11
substitution O 0 8.639736842619428e-11
in O 0 4.239239168035702e-11
the O 0 4.548846022078834e-11
first O 0 5.667842861711847e-10
position O 0 4.443078349680718e-09
of O 0 4.28405887153982e-11
exon O 0 1.6219805942796484e-08
13 O 0 7.660974077339233e-10
of O 0 9.935915284975394e-11
HEXA O 0 5.245773877504689e-07
of O 0 1.1428973045735091e-10
a O 0 1.4552261617950535e-09
non O 0 7.198994467216835e-08
- O 0 2.726623904436565e-07
Jewish O 0 1.1818127632068354e-07
proband O 0 7.912355499684054e-07
who O 0 8.501695347717941e-09
manifested O 0 3.569278206327908e-08
a O 0 5.311839856858569e-09
subacute O 0 1.577647253725445e-06
variant O 0 2.598197170300409e-06
of O 0 5.271749259350145e-09
G B-Disease 0 5.006945684726816e-06
( I-Disease 0 8.358625791515806e-09
M2 I-Disease 0 1.4902737348165829e-05
) I-Disease 0 1.0780207304605938e-07
gangliosidosis I-Disease 0 1.3349782420846168e-05
. O 0 1.3715548448089976e-06

On O 0 8.162385967125374e-08
the O 0 5.596185292944256e-09
second O 0 3.843618756604883e-08
maternally O 0 1.671590894147812e-06
inherited O 0 7.723783710389398e-07
allele O 0 6.062803663553495e-07
, O 0 4.8863326718162625e-09
we O 0 2.9050573058242435e-09
identified O 0 5.5874926907506506e-09
the O 0 1.5715519996462035e-09
common O 0 1.7861897276816308e-06
infantile O 0 0.13402776420116425
disease O 0 0.021693876013159752
- O 0 0.00015987519873306155
causing O 0 1.4602087503590155e-06
4 O 0 3.3176370095588936e-08
- O 0 6.510774710477563e-07
bp O 0 9.330806278740056e-07
insertion O 0 1.5022722266166966e-07
, O 0 3.947830951034348e-09
+ O 0 6.714016365094722e-08
TATC O 0 4.982121026841924e-07
1278 O 0 2.57916553891846e-07
, O 0 1.1140742772752787e-09
in O 0 2.0234474096270105e-09
exon O 0 1.2218609981573536e-06
11 O 0 9.952696444770481e-08
. O 0 1.840435999156398e-07

Pulse O 0 0.0007322887540794909
- O 0 0.00020136708917561918
chase O 0 5.503694865183206e-06
analysis O 0 7.080818420490687e-08
using O 0 5.272104175446657e-08
proband O 0 1.230162411047786e-06
fibroblasts O 0 3.412804119307111e-07
revealed O 0 1.4970520112456143e-07
that O 0 1.5528164309941417e-09
the O 0 6.338535807337564e-10
W474C O 0 1.7701835020034196e-07
- O 0 2.2511713382300513e-08
containing O 0 2.5780175771927816e-09
alpha O 0 6.920456652181883e-09
- O 0 6.310842515233617e-09
subunit O 0 8.13620726347608e-09
precursor O 0 3.5369165374277145e-09
was O 0 6.641056593537087e-10
normally O 0 2.387100794809527e-10
synthesized O 0 2.373377938624799e-09
, O 0 8.9856698470836e-11
but O 0 1.8407390889318975e-10
not O 0 5.145049317145656e-11
phosphorylated O 0 8.599118084262614e-10
or O 0 3.556478445077005e-10
secreted O 0 3.28176819053283e-09
, O 0 4.747842674568403e-10
and O 0 7.519047606763252e-10
the O 0 1.6978534134182155e-09
mature O 0 2.2182494063827107e-08
lysosomal O 0 2.9989828931320517e-07
alpha O 0 1.770783875088e-08
- O 0 2.6410329923010067e-08
subunit O 0 5.1944880397059023e-08
was O 0 3.067002296575083e-08
not O 0 1.445335051641905e-08
detected O 0 6.361032660606725e-07
. O 0 2.078002694361203e-07

When O 0 1.6017138477764092e-06
the O 0 2.5492916222447093e-08
W474C O 0 5.924612764829362e-07
- O 0 1.072291127002245e-07
containing O 0 7.85184273155437e-09
alpha O 0 2.0452432636375306e-08
- O 0 3.216705124486907e-08
subunit O 0 6.234966321017055e-08
was O 0 1.6012565495771014e-08
transiently O 0 2.1308383679752296e-07
co O 0 5.841522465743765e-07
- O 0 9.333264472388692e-08
expressed O 0 4.059116653909456e-10
with O 0 1.0345304474190797e-10
the O 0 1.3132005205473973e-10
beta O 0 3.7615035530791374e-09
- O 0 5.471671560286495e-09
subunit O 0 7.551244962655801e-09
to O 0 4.4240661134509196e-10
produce O 0 1.9166861431330062e-09
Hex O 0 1.1662766752351672e-07
A O 0 1.4857943764212678e-09
( O 0 4.79170203515622e-10
alphabeta O 0 2.2355022721853857e-08
) O 0 3.530329917289521e-10
in O 0 5.53698087379928e-10
COS O 0 2.0330468032625504e-05
- O 0 6.673753318864328e-07
7 O 0 5.602283081884707e-09
cells O 0 9.146038593144112e-09
, O 0 2.7444671535370446e-10
the O 0 3.7855774071005044e-10
mature O 0 3.634699874410785e-09
alpha O 0 1.2913237146250367e-09
- O 0 2.3687829475704802e-09
subunit O 0 3.6656115920408183e-09
was O 0 1.8418497838013081e-09
present O 0 8.978303517315211e-11
, O 0 9.952302870708252e-11
but O 0 2.2350311879026918e-10
its O 0 1.8711464322418436e-10
level O 0 1.292679074893499e-09
was O 0 4.860221114455499e-10
much O 0 4.5863684378089076e-11
lower O 0 5.459242502503514e-10
than O 0 7.516807315477436e-11
that O 0 9.776390114124567e-11
from O 0 1.2446893515871693e-10
normal O 0 1.2807614968579628e-09
alpha O 0 9.90519222199282e-10
- O 0 3.3386662323664495e-09
subunit O 0 4.741283810005825e-09
transfections O 0 2.7138879588051168e-08
, O 0 1.621245915295333e-10
although O 0 2.649390706821464e-10
higher O 0 4.161848088379827e-10
than O 0 2.509809027273491e-10
in O 0 5.47079215262869e-10
those O 0 1.3687361244407725e-09
cells O 0 7.144822067317591e-09
transfected O 0 8.897426084786275e-08
with O 0 3.0300534303862037e-10
an O 0 2.1058900456782936e-10
alpha O 0 9.705185988195808e-09
- O 0 8.424380126825781e-08
subunit O 0 1.2577105223954277e-07
associated O 0 1.228057868729593e-07
with O 0 7.817909164486991e-08
infantile O 0 0.00025220669340342283
TSD B-Disease 0 0.0012332092737779021
. O 0 2.07898483495228e-06

Furthermore O 0 3.471431455182028e-06
, O 0 2.1997362154024813e-08
the O 0 1.2724147291365284e-09
precursor O 0 3.6764102873121374e-08
level O 0 1.0264121108605195e-08
of O 0 1.375736746744849e-10
the O 0 2.5544336090810305e-10
W474C O 0 1.868737342647364e-08
alpha O 0 8.331975664965796e-10
- O 0 2.0692640934072415e-09
subunit O 0 5.2391815330565805e-09
was O 0 1.4148211491260554e-09
found O 0 2.017865735615132e-10
to O 0 4.923928972888625e-11
accumulate O 0 1.1070291350279149e-09
in O 0 2.302557970679242e-11
comparison O 0 5.618546183860929e-10
to O 0 2.306884822056432e-10
the O 0 5.193254160040794e-10
normal O 0 8.967735887210893e-09
alpha O 0 1.5672124931143117e-08
- O 0 5.0211287572210495e-08
subunit O 0 2.3149097216901282e-07
precursor O 0 4.080012843132863e-07
levels O 0 4.794467827196058e-07
. O 0 1.5229086613999243e-07

We O 0 1.2823945780837676e-06
conclude O 0 2.077554910329127e-07
that O 0 6.573599442560862e-09
the O 0 4.836023581589188e-09
1422 O 0 1.3872988802177133e-06
G O 0 1.0756460824268288e-06
- O 0 6.227787139323482e-07
- O 0 3.638201349076553e-07
> O 0 6.616269843107148e-08
C O 0 1.4316172780581837e-07
mutation O 0 3.8378388467208424e-08
is O 0 5.857940243991777e-10
the O 0 3.1531857680455744e-10
cause O 0 3.702487649803743e-09
of O 0 2.2675834820962137e-10
Hex B-Disease 0 8.916488877730444e-05
A I-Disease 0 3.1202562240650877e-06
enzyme I-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 4.8871440228026586e-09
the O 0 7.4439925334957024e-09
proband O 0 7.979487236298155e-06
. O 0 2.2724249504335603e-07

The O 0 2.597481056909601e-07
resulting O 0 2.439041963953059e-07
W474C O 0 1.5033169802336488e-06
substitution O 0 7.984109373637693e-08
clearly O 0 6.664969731673409e-08
interferes O 0 1.4504890089028777e-07
with O 0 6.497470339539291e-10
alpha O 0 7.399515222772379e-09
- O 0 1.0540769146416551e-08
subunit O 0 9.934391087540462e-09
processing O 0 9.451748717026476e-09
, O 0 5.382360668271247e-10
but O 0 6.445652345199449e-10
because O 0 2.935092446865184e-10
the O 0 2.984611863210418e-11
base O 0 3.5607136683601937e-10
substitution O 0 1.2924818992843257e-09
falls O 0 9.285961510840934e-08
at O 0 4.0949574287019175e-10
the O 0 7.641560995086394e-11
first O 0 6.134445174055259e-10
position O 0 5.6006377313622124e-09
of O 0 7.864064954787864e-11
exon O 0 3.011613003423008e-08
13 O 0 9.754006491391465e-10
, O 0 1.148377504200937e-10
aberrant O 0 6.94733071071596e-09
splicing O 0 9.283943569471376e-08
may O 0 1.4015750338103317e-08
also O 0 4.492235472497441e-10
contribute O 0 7.225138265454234e-10
to O 0 7.116841560517173e-10
Hex B-Disease 0 1.9910366972908378e-06
A I-Disease 0 6.213916492470162e-08
deficiency I-Disease 0 5.551607046072604e-06
in O 0 5.142824499593246e-10
this O 0 1.4036584117249618e-09
proband O 0 7.688397545280168e-07
. O 0 3.178756458055432e-08
. O 0 2.0405563816439098e-07

Two O 0 5.365427000469936e-07
frequent O 0 8.070774129009806e-06
missense O 0 0.0004032629367429763
mutations O 0 0.00181989383418113
in O 0 3.624710734584369e-05
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 1.889630948426202e-05

Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 3.119765324299806e-06
an O 0 0.00011657134746201336
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 0 4.265718598617241e-05
by O 0 8.650682303823487e-08
early O 0 1.4462554645433556e-05
childhood O 1 0.9976797699928284
deafness B-Disease 1 1.0
and O 0 0.21024101972579956
goiter B-Disease 1 1.0
. O 0 1.195803633891046e-05

A O 0 3.53903118366361e-07
century O 0 8.427015529832715e-08
after O 0 1.2609009836239693e-08
its O 0 5.590347074146962e-10
recognition O 0 1.236229962842117e-08
as O 0 1.4805164205711208e-08
a O 0 1.5457096935733716e-07
syndrome O 0 0.017597932368516922
by O 0 9.359569785871713e-10
Vaughan O 0 4.1685414231551476e-08
Pendred O 0 1.4560492900272948e-07
, O 0 1.2951519856585492e-09
the O 0 6.053770373881662e-09
disease O 0 2.1664324378889432e-07
gene O 0 7.013370861841395e-08
( O 0 2.654591879647228e-09
PDS O 0 3.1007087386569765e-07
) O 0 2.147520383743995e-09
was O 0 2.3012782790488018e-09
mapped O 0 2.8694819320662646e-07
to O 0 2.0324685934269837e-08
chromosome O 0 8.299068213091232e-06
7q22 O 0 9.762493391463067e-06
- O 0 1.314929704676615e-05
q31 O 0 1.3659843716595788e-05
. O 0 9.459810712542094e-07

1 O 0 7.336979024330503e-07
and O 0 7.92678012118131e-09
, O 0 1.9308017407126954e-09
recently O 0 2.344668281750728e-08
, O 0 3.9194456014080004e-10
found O 0 7.020591330508807e-10
to O 0 2.8000546326012454e-10
encode O 0 1.801863014350147e-08
a O 0 1.763927315323599e-08
putative O 0 6.3584889176127035e-06
sulfate O 0 9.977396985050291e-05
transporter O 0 0.00012932058598380536
. O 0 1.385116206620296e-06

We O 0 1.3336460824575624e-06
performed O 0 6.305249655724765e-08
mutation O 0 9.286209490255715e-08
analysis O 0 1.236739333165815e-08
of O 0 1.7010551300877808e-10
the O 0 9.020981739382705e-10
PDS B-Disease 0 2.4520585384379956e-07
gene O 0 7.097882814832701e-08
in O 0 3.5554221788913765e-09
patients O 0 1.1898915630581541e-08
from O 0 2.4668247999848347e-10
14 O 0 5.372247646739936e-10
Pendred B-Disease 0 2.4073633753118884e-08
families O 0 1.6799198143679916e-10
originating O 0 6.74870104244718e-10
from O 0 1.7506592009386424e-10
seven O 0 5.298288474619994e-10
countries O 0 3.2535021898816296e-10
and O 0 1.054591192151122e-09
identified O 0 1.4879192100636374e-08
all O 0 6.370451721693371e-09
mutations O 0 1.347234729109914e-06
. O 0 2.559838776505785e-07

The O 0 1.1266757127259552e-07
mutations O 0 2.613846845633816e-07
include O 0 2.977973201367945e-09
three O 0 8.075120017103643e-10
single O 0 1.168362473435991e-08
base O 0 1.063617371954706e-08
deletions O 0 1.4377305035395693e-07
, O 0 3.6649263623900197e-09
one O 0 2.0933086375407584e-09
splice O 0 1.760663735694834e-06
site O 0 2.0166407921351492e-07
mutation O 0 1.2192222129669972e-06
and O 0 7.016059555553511e-08
10 O 0 1.04101630427067e-07
missense O 0 6.691806629532948e-05
mutations O 0 8.931449701776728e-05
. O 0 4.631393949239282e-06

One O 0 2.6847480967262527e-06
missense O 0 6.984718493185937e-05
mutation O 0 7.731087862339336e-06
( O 0 2.1378847137043522e-08
L236P O 0 2.3144770011640503e-07
) O 0 5.7257598662374676e-09
was O 0 5.223725008107749e-09
found O 0 9.117191446250672e-10
in O 0 1.2893984491224586e-10
a O 0 2.395041109881646e-10
homozygous O 0 2.28159908743919e-08
state O 0 6.015106190915276e-10
in O 0 3.4876165844188733e-10
two O 0 3.371646850602872e-10
consanguineous O 0 1.1015391265800645e-07
families O 0 8.212960311837492e-10
and O 0 2.7983246275731233e-10
in O 0 1.1640238078980403e-10
a O 0 3.6885647314299774e-10
heterozygous O 0 7.822544390023722e-09
state O 0 3.8431383075909764e-10
in O 0 2.847367619462915e-10
five O 0 7.47581829774191e-10
additional O 0 4.3345376177228445e-09
non O 0 5.319477054399613e-07
- O 0 7.736375664535444e-06
consanguineous O 0 4.810938116861507e-05
families O 0 7.100156835804228e-07
. O 0 3.3894988860083686e-07

Another O 0 6.756067705282476e-06
missense O 0 0.00013032328570261598
mutation O 0 1.272668032470392e-05
( O 0 2.691412781530289e-08
T416P O 0 3.262140069182351e-07
) O 0 9.551150093045635e-09
was O 0 4.879729953444212e-09
found O 0 1.1843164227087755e-09
in O 0 1.8826198933119542e-10
a O 0 2.80914846939595e-10
homozygous O 0 1.9120971472830206e-08
state O 0 1.068961696937265e-09
in O 0 2.8707289323470775e-10
one O 0 2.9703928206004093e-10
family O 0 6.477115510605813e-10
and O 0 3.078621246821456e-10
in O 0 1.3395481945899235e-10
a O 0 3.6598948871535697e-10
heterozygous O 0 2.620465444636011e-08
state O 0 1.7146689623714906e-09
in O 0 1.4137259141122627e-09
four O 0 6.175290057086613e-09
families O 0 3.934729875254561e-08
. O 0 1.613994555782483e-07

Pendred B-Disease 0 8.482413250021636e-05
patients O 0 6.296048013609834e-06
in O 0 3.593430220050209e-09
three O 0 2.7386017897867987e-09
non O 0 1.7243407057776494e-07
- O 0 3.2146112971531693e-07
consanguineous O 0 1.2389466519380221e-06
families O 0 5.532000635355416e-09
were O 0 5.869482677667293e-10
shown O 0 5.419828474906296e-10
to O 0 1.312178976586864e-10
be O 0 4.352637417159855e-10
compound O 0 4.8651762618590055e-09
heterozygotes O 0 1.1582693559830659e-07
for O 0 1.551410111488849e-09
L236P O 0 3.7350679349401616e-07
and O 0 2.5242814061243735e-08
T416P O 0 4.3229824768786784e-06
. O 0 5.971615451016987e-07

In O 0 3.4569499263170655e-08
total O 0 2.2962580725760517e-09
, O 0 2.412094968207157e-10
one O 0 2.696095846577151e-10
or O 0 1.1862922866257009e-09
both O 0 1.4538603654301596e-10
of O 0 1.0841801414973595e-11
these O 0 1.5938961261952045e-10
mutations O 0 3.4700680107135895e-09
were O 0 2.715563052202441e-10
found O 0 2.760948136781849e-10
in O 0 1.7045302669327356e-10
nine O 0 4.675696496647674e-10
of O 0 4.398116940085295e-11
the O 0 1.4056060759770617e-09
14 O 0 4.9257278256220616e-09
families O 0 4.227712402382622e-09
analyzed O 0 2.824232296916307e-07
. O 0 1.4047282093088143e-07

The O 0 8.173162591162964e-09
identification O 0 1.1789441423104563e-08
of O 0 1.7014378794755203e-10
two O 0 9.804554945702648e-10
frequent O 0 1.4944815518447285e-07
PDS B-Disease 0 9.263966603612062e-06
mutations O 0 7.296034141290875e-07
will O 0 6.269041397111152e-10
facilitate O 0 2.2598130033912867e-09
the O 0 1.81041936997417e-09
molecular O 0 1.0887001735682134e-06
diagnosis O 0 0.0006733249174430966
of O 0 6.795581271035189e-07
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 9.31412614590954e-06

Insertional O 0 0.00019278330728411674
mutation O 0 6.97482937539462e-06
by O 0 1.3567906798073182e-08
transposable O 0 4.974390321876854e-06
element O 0 6.056914685359516e-07
, O 0 1.006563365990587e-08
L1 O 0 1.8562027435109485e-06
, O 0 1.3841678914161548e-09
in O 0 1.0486299606426996e-09
the O 0 7.659751055655306e-09
DMD B-Disease 1 0.9999998807907104
gene O 0 1.0078476861963281e-06
results O 0 1.388225001619503e-07
in O 0 2.0926629318296364e-08
X B-Disease 1 0.9999629259109497
- I-Disease 1 0.9999927282333374
linked I-Disease 1 0.9999953508377075
dilated I-Disease 1 0.9998681545257568
cardiomyopathy I-Disease 1 0.9999998807907104
. O 0 1.5396719390992075e-05

X B-Disease 1 0.9999902248382568
- I-Disease 1 0.999998927116394
linked I-Disease 1 0.9999746084213257
dilated I-Disease 1 0.9998798370361328
cardiomyopathy I-Disease 1 0.9999998807907104
( O 0 6.775198357900081e-08
XLDCM B-Disease 0 8.872699254425243e-06
) O 0 6.3780265513457834e-09
is O 0 1.382336911603943e-09
a O 0 2.7055191420544134e-09
clinical O 0 2.9994117767273565e-07
phenotype O 0 1.6919454992603278e-07
of O 0 1.8537613111213602e-10
dystrophinopathy B-Disease 0 1.7077965139833395e-06
which O 0 4.018943400296848e-09
is O 0 3.0878360979258446e-10
characterized O 0 3.2856888321219913e-09
by O 0 1.1021854540160803e-09
preferential O 0 1.0581720744085032e-06
myocardial B-Disease 0 0.00018163895583711565
involvement I-Disease 0 1.0078777989974697e-07
without O 0 7.939429558234679e-09
any O 0 4.673968767576753e-09
overt O 0 4.5943960458316724e-07
clinical O 0 2.6778031951835146e-06
signs O 0 4.980477115168469e-07
of O 0 9.356185870501577e-08
skeletal B-Disease 1 1.0
myopathy I-Disease 1 1.0
. O 0 6.0658516304101795e-05

To O 0 5.4965379803206815e-08
date O 0 4.847931123208582e-08
, O 0 6.574286115501593e-10
several O 0 8.908405124685714e-10
mutations O 0 4.009244847225091e-08
in O 0 1.0052121357517763e-09
the O 0 1.2962796169802004e-08
Duchenne B-Disease 0 0.00013326997577678412
muscular I-Disease 0 2.5896156330418307e-06
dystrophy I-Disease 0 2.3655979930481408e-06
gene O 0 4.3737304622482043e-07
, O 0 1.4337619091975284e-08
DMD O 1 1.0
, O 0 4.1481635904006e-09
have O 0 1.2731915521868586e-09
been O 0 2.368001572605749e-09
identified O 0 1.0610441414371508e-08
in O 0 7.741586816045753e-10
patients O 0 3.546962057399128e-09
with O 0 6.286999393312342e-11
XLDCM B-Disease 0 5.513126666301105e-07
, O 0 2.1489697521470674e-10
but O 0 3.6315242479822984e-10
a O 0 1.8368601084617353e-10
pathogenic O 0 6.945873209929232e-09
correlation O 0 6.222750315032499e-09
of O 0 4.559391059144602e-11
these O 0 4.457446911576568e-10
cardiospecific O 0 3.4953791328007355e-07
mutations O 0 1.574673973436802e-07
in O 0 3.0450955090799425e-09
DMD O 1 0.9999998807907104
with O 0 2.5400201941749856e-09
the O 0 4.991477453586413e-09
XLDCM B-Disease 0 0.0003692696336656809
phenotype O 0 2.250445686513558e-05
has O 0 1.7601967883251746e-08
remained O 0 9.651818011491287e-09
to O 0 1.8001068413653343e-09
be O 0 1.1359460927451437e-08
elucidated O 0 2.4954854325187625e-06
. O 0 3.300596063127159e-07

We O 0 1.2974047649549902e-06
report O 0 1.4284637472883333e-08
here O 0 2.70948374847535e-10
the O 0 1.0001017375360632e-10
identification O 0 2.5326329922137347e-09
of O 0 2.7610322361759643e-10
a O 0 8.337893930843165e-09
unique O 0 1.4337541642817087e-07
de O 0 6.931945222277136e-07
novo O 0 8.569667784286139e-07
L1 O 0 7.162985866671079e-07
insertion O 0 5.521830814814166e-08
in O 0 1.1726505322329217e-09
the O 0 5.815425363486781e-10
muscle O 0 4.860735813849715e-08
exon O 0 1.436701069224e-07
1 O 0 9.318480209685731e-09
in O 0 5.677518899460665e-09
DMD O 1 1.0
in O 0 3.544169180358381e-09
three O 0 1.7915948724578357e-09
XLDCM B-Disease 0 2.664566636667587e-06
patients O 0 2.2390782561387823e-08
from O 0 1.609979788375071e-10
two O 0 4.668166408983154e-10
unrelated O 0 9.27787127125157e-08
Japanese O 0 2.1401167771273322e-07
families O 0 8.870703993579809e-08
. O 0 1.9838540765704238e-07

The O 0 4.193742242364351e-08
insertion O 0 3.809229554008198e-07
was O 0 3.619350863459658e-08
a O 0 1.9370502979398907e-09
5 O 0 2.2526305265557767e-09
- O 0 3.113726165793196e-08
truncated O 0 1.1035979241569294e-07
form O 0 1.524907666805575e-08
of O 0 5.275518910607957e-10
human O 0 3.970606510250718e-09
L1 O 0 3.013435048160318e-07
inversely O 0 4.402773257083936e-08
integrated O 0 2.4372005213990633e-07
in O 0 1.3045234892317126e-09
the O 0 5.98757710079667e-10
5 O 0 2.9679931845549845e-09
- O 0 7.385826705785803e-08
untranslated O 0 1.4503107195196208e-06
region O 0 1.1885011197421136e-08
in O 0 4.765625116753824e-10
the O 0 3.685449168067123e-10
muscle O 0 9.131536415907249e-09
exon O 0 2.19629843201119e-08
1 O 0 2.2560875390098545e-09
, O 0 1.1196827492954142e-10
which O 0 3.0962873931450474e-10
affected O 0 3.173034612835579e-10
the O 0 2.2665187435211287e-11
transcription O 0 1.0815972562028264e-09
or O 0 3.12533887658617e-09
the O 0 3.3524222287084626e-10
stability O 0 2.9356204134245445e-09
of O 0 4.1247429083401954e-11
the O 0 5.909213673938041e-10
muscle O 0 1.4076029231091525e-08
form O 0 1.906415469932199e-09
of O 0 7.056822487472303e-11
dystrophin O 0 1.728797371924884e-08
transcripts O 0 8.871546164357369e-09
but O 0 8.221126557295122e-10
not O 0 1.6273367375863046e-10
that O 0 2.5533656786147496e-11
of O 0 1.5025156466230705e-11
the O 0 4.5287207317556977e-10
brain O 0 1.5058812152801693e-07
or O 0 5.159677574084753e-09
Purkinje O 0 4.841249960918503e-07
cell O 0 2.0514481491318293e-07
form O 0 2.6188516244474158e-08
, O 0 2.072831017940757e-09
probably O 0 2.678487120988393e-08
due O 0 1.7233511284686642e-09
to O 0 2.0976601011746254e-10
its O 0 3.5889968774682757e-10
unique O 0 2.5541864179245977e-09
site O 0 2.0829503455388476e-08
of O 0 9.193782957162e-10
integration O 0 1.8181445682330377e-07
. O 0 2.055266605793804e-07

We O 0 3.1640124120713153e-07
speculate O 0 9.551681756647667e-08
that O 0 3.235944290302939e-10
this O 0 7.073330116069698e-11
insertion O 0 5.073419462320317e-09
of O 0 1.6741014130516874e-10
an O 0 6.72586597527669e-10
L1 O 0 7.027442734397482e-07
sequence O 0 2.917703056937171e-08
in O 0 1.8944508184404185e-08
DMD O 1 1.0
is O 0 3.0032307751781673e-09
responsible O 0 9.63544244392267e-10
for O 0 3.2146025424895086e-11
some O 0 8.191285323644326e-12
of O 0 6.348039715414755e-12
the O 0 1.366601554142477e-10
population O 0 5.468402952679696e-10
of O 0 7.913266569792299e-11
Japanese O 0 6.122399298646997e-08
patients O 0 9.244464749258441e-09
with O 0 1.0600927913273495e-09
XLDCM B-Disease 0 2.167651018680772e-06
. O 0 3.0154236441148896e-08
. O 0 1.1438802971497353e-07

Severe O 0 0.002069103065878153
early O 0 1.1366111721144989e-05
- O 1 0.9837831854820251
onset O 1 0.995859682559967
obesity B-Disease 1 1.0
, O 0 1.7338186353299534e-06
adrenal B-Disease 1 0.9999995231628418
insufficiency I-Disease 1 1.0
and O 0 2.3362451884167967e-07
red O 0 1.0113368261954747e-05
hair O 1 0.9999945163726807
pigmentation O 1 0.99000084400177
caused O 0 1.518695285085414e-06
by O 0 1.8109208355099327e-08
POMC O 0 9.833496005740017e-05
mutations O 0 5.15856709171203e-06
in O 0 2.3203286403372658e-08
humans O 0 3.090055145094084e-07
. O 0 4.56004187299186e-07

Sequential O 0 9.137861525232438e-06
cleavage O 0 3.3011467166943476e-05
of O 0 7.74885933196856e-09
the O 0 2.4380446550509305e-09
precursor O 0 4.69916976442164e-08
protein O 0 3.6575400486071885e-08
pre O 0 1.3881564200346475e-06
- O 0 1.809887180570513e-06
pro O 0 6.755454933227156e-07
- O 0 3.895087047567358e-06
opiomelanocortin O 0 2.5970600745495176e-06
( O 0 9.687783020240204e-09
POMC O 0 1.975246505026007e-06
) O 0 3.408511251024038e-09
generates O 0 5.888750376215057e-09
the O 0 3.987218999412789e-09
melanocortin O 0 3.00258511742868e-06
peptides O 0 4.61514076732783e-07
adrenocorticotrophin O 0 1.3724536529480247e-06
( O 0 7.57103180148988e-09
ACTH O 0 1.617410475773795e-06
) O 0 2.1020065688048817e-09
, O 0 2.1014734397084567e-09
melanocyte O 0 5.84762574362685e-06
- O 0 1.9675965177157195e-06
stimulating O 0 1.2667582041103742e-06
hormones O 0 3.9612328350813186e-07
( O 0 1.5811312259472743e-09
MSH O 0 6.323749062175921e-07
) O 0 3.8273667568589076e-10
alpha O 0 9.27094623293101e-10
, O 0 7.468844986924239e-11
beta O 0 8.995140743373042e-10
and O 0 7.56181645078513e-11
gamma O 0 8.735150935912372e-10
as O 0 1.3811080057379854e-10
well O 0 2.986002833882395e-10
as O 0 1.8800326573309434e-10
the O 0 5.227520083472825e-10
opioid O 0 1.537583784738672e-07
- O 0 2.0659295785208087e-07
receptor O 0 1.9144954421790317e-07
ligand O 0 1.281202486325128e-07
beta O 0 5.961680358268495e-07
- O 0 5.780270839750301e-06
endorphin O 0 0.00026078446535393596
. O 0 1.2117327514715726e-06

While O 0 1.8738774087978527e-07
a O 0 6.960833687230661e-09
few O 0 9.42765865374895e-09
cases O 0 1.2976352437021887e-08
of O 0 4.919888052512533e-09
isolated O 0 0.0018342582043260336
ACTH B-Disease 1 0.9998478889465332
deficiency I-Disease 1 0.7415816783905029
have O 0 1.2180392694460807e-08
been O 0 9.90901316555437e-09
reported O 0 4.400791908665269e-08
( O 0 2.135039256501159e-09
OMIM O 0 4.070842805958819e-06
201400 O 0 1.163961016459325e-07
) O 0 1.1412205624949934e-09
, O 0 6.803357877060989e-10
an O 0 1.9907016035602965e-09
inherited O 0 0.0010208728490397334
POMC O 0 0.0043578241020441055
defect O 0 0.0005263623897917569
has O 0 1.9792009808838884e-08
not O 0 1.787952563780948e-09
been O 0 1.3473950843945204e-09
described O 0 4.717154666877832e-09
so O 0 7.829664916414458e-09
far O 0 3.4045104513324986e-08
. O 0 1.4885911525652773e-07

Recent O 0 1.9332680949446512e-06
studies O 0 3.094933163083624e-07
in O 0 2.231011597686461e-09
animal O 0 1.0316171916713301e-08
models O 0 1.1847603786918626e-07
elucidated O 0 2.7914435918319214e-07
a O 0 1.5725595270410508e-09
central O 0 2.0810311252006386e-09
role O 0 8.862515166185858e-09
of O 0 2.5540536352508525e-10
alpha O 0 1.065095300845087e-08
- O 0 7.544424818206608e-08
MSH O 0 1.916376731969649e-06
in O 0 2.354493822132042e-10
the O 0 6.739153679546916e-11
regulation O 0 7.839478510796027e-10
of O 0 4.495396069281732e-11
food O 0 9.838780901105793e-10
intake O 0 2.6001902853067804e-09
by O 0 8.709791221583885e-11
activation O 0 2.0833028635536266e-09
of O 0 2.612009497582335e-10
the O 0 4.315703794333103e-09
brain O 0 8.711380701242888e-07
melanocortin O 0 3.1936992854753044e-06
- O 0 9.136467724601971e-07
4 O 0 2.95203967937141e-08
- O 0 3.181841350397008e-07
receptor O 0 1.58523349114148e-07
( O 0 5.991944274086336e-09
MC4 O 0 8.68766255734954e-06
- O 0 3.37961552077104e-07
R O 0 2.4379608021263266e-07
; O 0 1.3335885729048869e-09
refs O 0 4.2216388607130284e-08
3 O 0 1.6420541593120674e-09
- O 0 1.4777628898343664e-08
5 O 0 3.0445249099564364e-10
) O 0 5.3967292440448844e-11
and O 0 4.783344206837903e-11
the O 0 1.4364237577169092e-10
linkage O 0 8.493433512057891e-08
of O 0 6.874303348780586e-10
human O 0 1.2273958738262536e-08
obesity B-Disease 1 0.9999767541885376
to O 0 7.916758359982623e-10
chromosome O 0 2.814020660935057e-08
2 O 0 9.740992457096809e-10
in O 0 1.8179339977830722e-10
close O 0 1.953054606929072e-09
proximity O 0 1.2864176390792181e-08
to O 0 1.6562592408675414e-09
the O 0 1.6047566608889952e-09
POMC O 0 8.14989220998541e-07
locus O 0 5.4081958467122604e-08
, O 0 3.070944332161929e-10
led O 0 1.7554005471431822e-10
to O 0 5.712315342965013e-11
the O 0 5.901810290476206e-11
proposal O 0 2.9525675238062377e-09
of O 0 5.4490655043704095e-11
an O 0 3.294592099134519e-10
association O 0 7.577558025495534e-10
of O 0 3.185204600075764e-10
POMC O 0 2.682309059309773e-06
with O 0 9.634197439822856e-09
human O 0 3.7829687471457873e-07
obesity B-Disease 1 0.9999964237213135
. O 0 1.55537452428689e-06

The O 0 1.1143558253934316e-07
dual O 0 3.2123880373546854e-06
role O 0 1.9775450255110627e-07
of O 0 1.7211632119540354e-09
alpha O 0 1.29173386653747e-07
- O 0 9.193490768666379e-07
MSH O 0 7.284372259164229e-06
in O 0 1.0467257061108626e-09
regulating O 0 2.0079239604342547e-08
food O 0 1.2028022133847571e-08
intake O 0 4.792163466049715e-08
and O 0 3.3471783122962506e-09
influencing O 0 3.154961234486109e-07
hair O 0 0.1428314447402954
pigmentation O 0 2.0012264940305613e-05
predicts O 0 2.1577145048468083e-07
that O 0 5.350905829537567e-10
the O 0 5.1215243157543e-10
phenotype O 0 4.295995665870578e-07
associated O 0 7.338011531743405e-09
with O 0 6.759547921397768e-10
a O 0 1.202210331285869e-08
defect O 0 6.60190107737435e-06
in O 0 4.7067834074709936e-09
POMC O 0 1.7841025510278996e-06
function O 0 2.5688693838787913e-08
would O 0 3.270033577251752e-09
include O 0 8.533879380934195e-09
obesity B-Disease 1 0.9999951124191284
, O 0 3.804311532462634e-09
alteration O 0 8.303385357066873e-07
in O 0 5.08496000861669e-08
pigmentation O 0 0.08129154145717621
and O 0 0.000310970819555223
ACTH B-Disease 1 0.9981247782707214
deficiency I-Disease 1 0.6574257612228394
. O 0 6.687834002150339e-07

The O 0 4.380300211437316e-08
observation O 0 1.3773744456102577e-07
of O 0 6.537809738027534e-10
these O 0 7.331394602516639e-09
symptoms O 0 1.8000841350840346e-07
in O 0 3.731610298540744e-10
two O 0 5.489607102227012e-10
probands O 0 1.5352100035670446e-07
prompted O 0 5.079490161818967e-09
us O 0 1.2857521713982578e-09
to O 0 4.8205384128863216e-11
search O 0 1.0550539331077857e-09
for O 0 6.000621666224504e-10
mutations O 0 4.477304926808756e-08
within O 0 3.83186815611225e-09
their O 0 3.0477409040940984e-08
POMC O 0 3.499971717246808e-05
genes O 0 1.301347765547689e-06
. O 0 3.1241995657182997e-07

Patient O 0 0.00010416006989544258
1 O 0 2.9038798743385996e-07
was O 0 6.4172942515483555e-09
found O 0 5.517529766407847e-10
to O 0 1.68513786258373e-10
be O 0 2.1413062989417142e-10
a O 0 9.15067119300339e-11
compound O 0 2.4477924132071394e-09
heterozygote O 0 1.0371279302034964e-07
for O 0 2.8595262269170973e-10
two O 0 7.265642532061634e-10
mutations O 0 4.978349466000509e-08
in O 0 7.990333394936044e-10
exon O 0 5.2132275385474713e-08
3 O 0 2.7734952112723477e-09
( O 0 2.4282978405842925e-10
G7013T O 0 1.4646527546346988e-08
, O 0 3.238234957958497e-10
C7133delta O 0 3.023440342531103e-08
) O 0 3.1264940636432925e-10
which O 0 2.7367152988233556e-10
interfere O 0 2.6071329539689714e-09
with O 0 1.7057076584503506e-10
appropriate O 0 1.9300172571234953e-09
synthesis O 0 6.75587807918987e-09
of O 0 9.24676946123526e-10
ACTH O 0 1.9071966335104662e-06
and O 0 5.210013753753628e-09
alpha O 0 8.831975861767205e-08
- O 0 3.814365982179879e-06
MSH O 0 0.0001469558192184195
. O 0 2.8220006242918316e-07

Patient O 0 1.8136528524337336e-05
2 O 0 8.660406081162364e-08
was O 0 7.60988960735176e-09
homozygous O 0 7.310480043543066e-08
for O 0 1.4745551446537775e-09
a O 0 2.3752573241608843e-09
mutation O 0 2.1821270479449595e-07
in O 0 5.439061645517995e-09
exon O 0 4.944471925227845e-07
2 O 0 3.006872262290017e-08
( O 0 4.16996304153372e-09
C3804A O 0 5.974742975922709e-07
) O 0 1.4749469201547072e-08
which O 0 3.004372572945613e-08
abolishes O 0 8.150411304086447e-06
POMC O 0 8.493332279613242e-05
translation O 0 1.625637310098682e-06
. O 0 8.795174721853982e-07

These O 0 5.0740801782467315e-08
findings O 0 9.859411953527797e-09
represent O 0 4.555160693087146e-10
the O 0 9.129141886887737e-11
first O 0 2.4093912975864384e-10
examples O 0 1.8514089150656332e-09
of O 0 1.6150361603628482e-10
a O 0 1.1078222428295703e-07
genetic B-Disease 1 1.0
defect I-Disease 1 0.9999998807907104
within O 0 9.282876689553632e-09
the O 0 1.502365343242218e-09
POMC O 0 7.57792520289513e-07
gene O 0 2.1627016622005613e-08
and O 0 1.1348844086711551e-09
define O 0 1.716508890581281e-08
a O 0 3.4788287806009066e-09
new O 0 1.4340660925427073e-07
monogenic B-Disease 1 0.7019472718238831
endocrine I-Disease 0 0.4706660807132721
disorder I-Disease 0 0.00048508739564567804
resulting O 0 3.326133324321745e-08
in O 0 3.280115956627583e-09
early O 0 3.381443320904509e-07
- O 1 0.8169089555740356
onset O 1 0.9857686161994934
obesity B-Disease 1 1.0
, O 0 7.295192290257546e-07
adrenal B-Disease 1 0.9999991655349731
insufficiency I-Disease 1 1.0
and O 0 5.546635293285362e-07
red O 0 3.956437012675451e-06
hair O 1 0.9989668130874634
pigmentation O 0 0.004472403787076473
. O 0 2.416571760477382e-07
. O 0 3.740989313882892e-07

A O 0 1.9664432784338715e-06
European O 0 9.317387821283774e-07
multicenter O 0 2.9744618586846627e-05
study O 0 2.7781089784184587e-07
of O 0 7.883915742468162e-08
phenylalanine B-Disease 1 1.0
hydroxylase I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 2.010568245225386e-08
classification O 0 2.112538233234318e-08
of O 0 1.6057906393474042e-10
105 O 0 1.9086492386577447e-09
mutations O 0 8.567676701431992e-08
and O 0 1.1151329859515613e-09
a O 0 2.8745206215319286e-10
general O 0 2.3205476429311034e-10
system O 0 2.3875894594738156e-09
for O 0 4.0656875088807e-10
genotype O 0 8.981122618934023e-07
- O 0 3.068798832828179e-07
based O 0 3.628003852895745e-08
prediction O 0 1.6174830363979709e-07
of O 0 7.505196464308028e-09
metabolic O 0 0.00013772658712696284
phenotype O 0 0.00013736657274421304
. O 0 1.3324116707735811e-06

Phenylketonuria B-Disease 0 0.007367066573351622
( O 0 1.6174412849068176e-06
PKU B-Disease 0 2.6120376787730493e-05
) O 0 5.039550643459734e-08
and O 0 5.323333951423592e-08
mild B-Disease 0 5.138210326549597e-05
hyperphenylalaninemia I-Disease 1 1.0
( O 0 8.532286415174895e-07
MHP B-Disease 1 1.0
) O 0 8.929865202844667e-08
are O 0 3.762617950542335e-08
allelic B-Disease 0 0.0671876072883606
disorders I-Disease 1 0.9990922212600708
caused O 0 1.0300446007249775e-07
by O 0 1.0374059389306467e-09
mutations O 0 2.821637110628217e-07
in O 0 2.0518102772371094e-09
the O 0 3.7109717521133234e-09
gene O 0 1.0613962331262883e-06
encoding O 0 4.887015620624879e-06
phenylalanine O 0 0.0002735270536504686
hydroxylase O 0 0.005329320207238197
( O 0 2.965969656543166e-07
PAH O 0 7.36875444999896e-05
) O 0 1.8087018816004274e-07
. O 0 4.776741207024315e-07

Previous O 0 4.913204634249269e-07
studies O 0 4.982149448551354e-08
have O 0 8.867498402231888e-10
suggested O 0 2.0090797914207315e-09
that O 0 9.053486432764046e-11
the O 0 1.8755126618419382e-10
highly O 0 1.5798116592691258e-08
variable O 0 3.5014622881135438e-06
metabolic O 0 0.0003054252010770142
phenotypes O 0 2.8861219107056968e-05
of O 0 1.561666067573242e-07
PAH B-Disease 1 0.9991263747215271
deficiency I-Disease 1 0.974665641784668
correlate O 0 8.76621106726816e-06
with O 0 7.773166998958914e-07
PAH O 0 0.012101217173039913
genotypes O 0 0.00046636880142614245
. O 0 1.9428625819273293e-06

We O 0 7.586168067064136e-07
identified O 0 9.602243977724356e-08
both O 0 6.943290387084744e-09
causative O 0 2.8310757897997973e-06
mutations O 0 1.293031914428866e-06
in O 0 6.6852363644898105e-09
686 O 0 1.5245099405092333e-07
patients O 0 7.092916121109738e-08
from O 0 7.245024025159807e-10
seven O 0 5.399287683616194e-09
European O 0 1.5093375793640007e-07
centers O 0 1.7090904691485775e-07
. O 0 2.3772012980316504e-07

On O 0 5.121871282653956e-08
the O 0 1.309371944202553e-09
basis O 0 2.1881603196050037e-09
of O 0 1.0639125691547235e-10
the O 0 6.157573895215762e-10
phenotypic O 0 2.9227197728687315e-07
characteristics O 0 4.1621856183837735e-08
of O 0 9.088110264343641e-10
297 O 0 3.678135485074563e-08
functionally O 0 2.0391750865655922e-07
hemizygous O 0 6.405300609912956e-07
patients O 0 8.289628539159821e-08
, O 0 1.3305974377875174e-10
105 O 0 1.636300678287128e-10
of O 0 1.987065546826816e-11
the O 0 1.4703445405661597e-10
mutations O 0 7.787694045191529e-09
were O 0 1.1294615243073736e-10
assigned O 0 4.0716785498773334e-10
to O 0 3.798000455801365e-11
one O 0 8.18754022913204e-11
of O 0 2.836027419850229e-11
four O 0 1.0111889103825433e-09
arbitrary O 0 2.3188138698060357e-07
phenotype O 0 0.0002325757232028991
categories O 0 4.058520062244497e-06
. O 0 7.488696951440943e-07

We O 0 3.874592948704958e-07
proposed O 0 4.810112130826383e-08
and O 0 5.0811470586609175e-09
tested O 0 1.8725692996213184e-08
a O 0 5.781725653797309e-10
simple O 0 3.8577181449284126e-09
model O 0 1.959002737805804e-08
for O 0 6.497916094083678e-10
correlation O 0 6.10381363230772e-08
between O 0 1.4447313567700348e-08
genotype O 0 4.712602731160587e-06
and O 0 4.0436503923046985e-08
phenotypic O 0 1.4619514331570826e-05
outcome O 0 6.450617547670845e-06
. O 0 2.071921016977285e-06

The O 0 1.790784978084048e-07
observed O 0 3.711844840381673e-07
phenotype O 0 1.8059560034089372e-06
matched O 0 2.1262445670799934e-07
the O 0 4.959903154855283e-09
predicted O 0 9.559318669971617e-08
phenotype O 0 1.6409536840455985e-07
in O 0 9.99213711772029e-10
79 O 0 4.350821480869627e-09
% O 0 2.597997927900053e-10
of O 0 1.3406848548003225e-11
the O 0 1.1284752993168112e-10
cases O 0 3.940661130741319e-09
, O 0 3.455851993461323e-10
and O 0 2.4786961372313954e-10
in O 0 6.099220434263586e-11
only O 0 1.0140584899565042e-10
5 O 0 3.541888310421015e-11
of O 0 7.618562898603631e-12
184 O 0 4.975829193121228e-10
patients O 0 5.264113145386773e-09
was O 0 8.499762005342859e-10
the O 0 1.477569594454664e-10
observed O 0 5.276890036043369e-09
phenotype O 0 8.308603582918295e-09
more O 0 3.23916622690934e-11
than O 0 3.729374101202332e-11
one O 0 1.437139018900524e-10
category O 0 3.3059242010580192e-09
away O 0 2.1653752124706216e-09
from O 0 1.710842717494998e-10
that O 0 8.115434990685344e-10
expected O 0 1.5410446252417387e-08
. O 0 1.5344328119226702e-07

Among O 0 1.1488349116461904e-07
the O 0 3.955194394222872e-09
seven O 0 9.600441552848338e-10
contributing O 0 1.938743166007839e-09
centers O 0 1.6614037923190494e-09
, O 0 2.318968211900696e-10
the O 0 2.70289235437815e-10
proportion O 0 1.2659084447363966e-08
of O 0 1.1026600466035319e-10
patients O 0 3.1486797613666795e-09
for O 0 6.981355771262798e-11
whom O 0 2.3568136331419964e-09
the O 0 1.6616312492612195e-10
observed O 0 5.325849983250919e-09
phenotype O 0 4.671974451753158e-08
did O 0 2.89173995859926e-09
not O 0 8.888038083298966e-10
match O 0 4.602040970524968e-09
the O 0 5.898876387355756e-10
predicted O 0 3.290889694085308e-08
phenotype O 0 1.980742325713436e-07
was O 0 8.372714965787509e-09
4 O 0 1.4398038317153805e-09
% O 0 2.134408205733962e-09
- O 0 6.676910970782046e-07
23 O 0 9.983074811259485e-09
% O 0 1.304772290211531e-09
( O 0 1.1368298524772058e-09
P O 0 6.907258921273751e-06
< O 0 2.3882009259068582e-08
. O 0 7.561575254833031e-10
0001 O 0 2.7330143481663072e-08
) O 0 1.0763551161474538e-10
, O 0 3.857302324772327e-11
suggesting O 0 1.1881583494854908e-09
that O 0 8.009738011738321e-11
differences O 0 7.948425806425519e-10
in O 0 1.8870658508030047e-11
methods O 0 5.893781573895751e-10
used O 0 6.798882012937213e-10
for O 0 2.4105542562047333e-10
mutation O 0 3.008610605093054e-08
detection O 0 1.0785925042000599e-07
or O 0 4.535519693149581e-08
phenotype O 0 2.1362559436965967e-06
classification O 0 1.5660538110751077e-07
may O 0 4.5009600491141555e-09
account O 0 6.272701247311829e-10
for O 0 5.842728384441997e-11
a O 0 3.528841940880767e-10
considerable O 0 4.988774726655265e-09
proportion O 0 1.1081751694064224e-07
of O 0 6.669723884300538e-09
genotype O 0 0.27191293239593506
- O 1 0.5930366516113281
phenotype O 0 0.0006446700426749885
inconsistencies O 0 1.8680244465940632e-05
. O 0 1.1387334097889834e-06

Our O 0 4.769140105054248e-07
data O 0 1.297267004929381e-07
indicate O 0 3.816290572444814e-08
that O 0 2.170954083169363e-09
the O 0 3.804732529033572e-09
PAH O 0 7.888517757237423e-06
- O 0 9.303030878982099e-07
mutation O 0 3.220026485450944e-07
genotype O 0 6.932342557774973e-07
is O 0 1.0911974657190626e-09
the O 0 1.6589649098897041e-10
main O 0 5.941913183704628e-09
determinant O 0 2.0623191687718645e-07
of O 0 1.735751320453005e-09
metabolic O 0 1.4599188034480903e-05
phenotype O 0 2.8046010811522137e-06
in O 0 2.430152301613475e-09
most O 0 1.0188208499073426e-08
patients O 0 8.950067922341987e-07
with O 0 3.360482878633775e-07
PAH B-Disease 1 0.9718946218490601
deficiency I-Disease 1 0.9953576922416687
. O 0 1.313999405283539e-06

In O 0 4.671858633287229e-08
the O 0 1.3202482440632934e-09
present O 0 1.066818855477436e-09
study O 0 7.511207211763349e-10
, O 0 9.630091862833368e-11
the O 0 2.0350811313907258e-10
classification O 0 1.2067523869063734e-08
of O 0 2.395059151005796e-10
105 O 0 1.0844795284015163e-08
PAH O 0 1.232472186529776e-06
mutations O 0 1.4878148135721858e-07
may O 0 1.598704502114856e-09
allow O 0 2.1693054297333703e-10
the O 0 9.22483339715896e-11
prediction O 0 4.539654430146811e-09
of O 0 6.59111931700096e-11
the O 0 8.263888462423097e-10
biochemical O 0 2.0226593733241316e-06
phenotype O 0 5.016993895878841e-07
in O 0 1.846781616521298e-09
> O 0 6.995839019197092e-09
10 O 0 5.348670950588996e-10
, O 0 2.0241179565783085e-10
000 O 0 1.3246623797869006e-09
genotypes O 0 6.406290253835323e-08
, O 0 2.6154342580575474e-10
which O 0 4.4343559379989017e-10
may O 0 1.326675214130546e-09
be O 0 3.0283303642519854e-11
useful O 0 1.6593097729167283e-10
for O 0 5.341877981623888e-11
the O 0 3.139084270298298e-10
management O 0 7.940035295916914e-09
of O 0 9.381070364966604e-10
hyperphenylalaninemia B-Disease 1 0.9999996423721313
in O 0 2.2823003575922485e-07
newborns O 0 1.6288111510220915e-05
. O 0 2.6699109412220423e-07

Somatic O 0 0.0002504984731785953
instability O 0 2.3569333279738203e-05
of O 0 1.7825835030294e-08
the O 0 1.2784362013462669e-08
CTG O 0 2.152583647330175e-06
repeat O 0 3.291873156285874e-07
in O 0 1.4036770634717755e-09
mice O 0 3.900566625247848e-08
transgenic O 0 2.128075848872868e-08
for O 0 4.115095486589837e-10
the O 0 3.5692220290428622e-09
myotonic B-Disease 1 0.9999985694885254
dystrophy I-Disease 1 0.9999938011169434
region O 0 8.880892892193515e-07
is O 0 8.797908179758451e-09
age O 0 7.1435413140363835e-09
dependent O 0 9.978809778488085e-09
but O 0 9.432491454575143e-10
not O 0 3.791213176729258e-10
correlated O 0 2.1246355785820015e-09
to O 0 1.70774547281205e-10
the O 0 3.393421377229089e-10
relative O 0 2.484416228298869e-08
intertissue O 0 3.923429687802127e-07
transcription O 0 2.269996883796921e-07
levels O 0 3.173958589286485e-07
and O 0 6.870442348372308e-08
proliferative O 0 0.0002233584236819297
capacities O 0 1.2393612450978253e-05
. O 0 7.258446999003354e-07

A O 0 1.2024715942970943e-06
( O 0 6.932270224524473e-08
CTG O 0 3.230599986636662e-06
) O 0 6.408413799618984e-09
nexpansion O 0 2.8414416419764166e-07
in O 0 1.219726541989985e-09
the O 0 1.7052985690213518e-09
3 O 0 5.847006789849729e-08
- O 0 7.975609332788736e-05
untranslated O 0 0.00708717480301857
region O 0 2.888754409013927e-07
( O 0 2.8903335280716647e-09
UTR O 0 4.2082052686964744e-07
) O 0 1.6546458647681561e-09
of O 0 2.3892918199486246e-10
the O 0 1.3446614488543673e-08
DM O 1 0.9999998807907104
protein O 0 7.019459502544123e-08
kinase O 0 2.4064297576842364e-07
gene O 0 6.009412345520104e-08
( O 0 1.2318278619360967e-09
DMPK O 0 1.700074818700159e-07
) O 0 7.032062709910747e-10
is O 0 2.917499852816974e-10
responsible O 0 5.88515725041816e-09
for O 0 1.1234424057704473e-08
causing O 0 1.7202512026415206e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 1.1449500561866444e-05
DM B-Disease 1 1.0
) O 0 1.384149527439149e-06
. O 0 9.13979647521046e-07

Major O 0 4.335409812483704e-06
instability O 0 4.34631419921061e-06
, O 0 7.810840862987334e-09
with O 0 2.969429979682303e-10
very O 0 6.405917463148114e-10
large O 0 9.085648899898047e-10
expansions O 0 4.4412168165308685e-08
between O 0 7.916168831556547e-10
generations O 0 4.286261567898464e-09
and O 0 2.517399844137458e-09
high O 0 7.784635158714082e-09
levels O 0 3.556738015220162e-09
of O 0 1.0061458610710616e-10
somatic O 0 3.995930697442418e-08
mosaicism O 0 8.657315788695996e-07
, O 0 6.629944371283614e-10
is O 0 4.6561085542684566e-10
observed O 0 1.3291859168873543e-08
in O 0 1.2956542505548896e-08
patients O 0 7.909722512522421e-07
. O 0 3.7064683056087233e-07

There O 0 1.6756341381096718e-07
is O 0 4.379370643903258e-09
a O 0 1.5197963998403452e-09
good O 0 1.1039111846855576e-08
correlation O 0 1.8316212546665156e-08
between O 0 7.204702390239959e-10
repeat O 0 2.957092988253862e-07
size O 0 1.88438207260333e-08
( O 0 3.7628722360238953e-10
at O 0 4.609707893177273e-10
least O 0 1.7330908930190958e-10
in O 0 2.99319319330138e-10
leucocytes O 0 1.204131621079796e-07
) O 0 8.843868415375766e-10
, O 0 3.182381025368386e-10
clinical O 0 4.336408565563943e-08
severity O 0 1.7599121804323659e-07
and O 0 6.319490708506237e-09
age O 0 2.3941300497654083e-08
of O 0 4.912826589986707e-09
onset O 0 6.020206910761772e-06
. O 0 8.603142873653269e-07

The O 0 5.91595210153173e-07
trinucleotide O 0 0.00027298566419631243
repeat O 0 4.510124563239515e-05
instability O 0 1.109185518544109e-06
mechanisms O 0 3.5347600402246826e-08
involved O 0 1.1348569195490654e-08
in O 0 1.2714060915186565e-08
DM B-Disease 1 1.0
and O 0 2.4817816690614336e-09
other O 0 8.306745846731189e-10
human O 0 6.074453295923377e-08
genetic B-Disease 1 1.0
diseases I-Disease 1 1.0
are O 0 2.4034086720803316e-08
unknown O 0 1.0364788067818154e-06
. O 0 4.414840759636718e-07

We O 0 1.6168168031072128e-06
studied O 0 7.682269824726973e-07
somatic O 0 1.343881535831315e-06
instability O 0 6.623301942454418e-07
by O 0 2.394480391743059e-09
measuring O 0 3.139153648135107e-07
the O 0 4.447691104303431e-09
CTG O 0 1.3933514537711744e-06
repeat O 0 2.7650597189676773e-07
length O 0 1.1859536463987297e-08
at O 0 1.0667660088614639e-09
several O 0 3.179274621345485e-10
ages O 0 6.023961329759686e-09
in O 0 3.28183535902582e-10
various O 0 9.119591748429912e-10
tissues O 0 2.5763378985743657e-08
of O 0 3.0139832296605107e-10
transgenic O 0 6.8513891449129e-08
mice O 0 7.701402893189879e-08
carrying O 0 2.5788438051677076e-09
a O 0 1.4720344942986685e-09
( O 0 7.245369859631978e-10
CTG O 0 1.786628018862757e-07
) O 0 9.043584214829536e-10
55expansion O 0 6.598877178021212e-08
surrounded O 0 4.889316507217245e-09
by O 0 6.748173686510484e-10
45 O 0 1.0858222099230375e-09
kb O 0 6.787382034190159e-08
of O 0 1.1413419515049483e-10
the O 0 2.5591653241008316e-09
human O 0 1.044688247020531e-07
DM B-Disease 1 1.0
region O 0 1.3143926480552182e-07
, O 0 3.280308247255448e-10
using O 0 4.094334649096254e-09
small O 0 5.921743451153816e-08
- O 0 1.0072020813822746e-05
pool O 0 2.0161382963124197e-06
PCR O 0 1.7439711882616393e-05
. O 0 6.497575668618083e-07

These O 0 1.003498582008433e-07
mice O 0 4.929227088723565e-07
have O 0 4.86833240387341e-09
been O 0 8.417770924751267e-10
shown O 0 1.0089156177173209e-09
to O 0 2.188793868374006e-10
reproduce O 0 3.420770511297633e-08
the O 0 5.038373052101974e-10
intergenerational O 0 4.624798677355102e-08
and O 0 1.300508700730063e-09
somatic O 0 6.418397902052675e-08
instability O 0 3.2658466153634436e-08
of O 0 1.4256341940299677e-10
the O 0 1.3164890289019127e-09
55 O 0 1.0184653120859366e-08
CTG O 0 4.526363568402303e-07
repeat O 0 1.1225839813278071e-07
suggesting O 0 8.703174181334816e-09
that O 0 8.227098863278215e-11
surrounding O 0 4.708441969647481e-10
sequences O 0 3.0403481954266454e-09
and O 0 1.3865407710866862e-09
the O 0 2.713232971629509e-10
chromatin O 0 2.3450038355576908e-08
environment O 0 1.2032633556202654e-08
are O 0 3.2566060959027254e-10
involved O 0 3.1506321995777853e-09
in O 0 1.2030131557594359e-08
instability O 0 1.7470938473707065e-06
mechanisms O 0 1.3105741345498245e-06
. O 0 6.300128916336689e-07

As O 0 3.533061487814848e-08
observed O 0 2.36020643029633e-08
in O 0 7.111685129679302e-10
some O 0 1.1122605614310999e-10
of O 0 6.737945618118246e-11
the O 0 5.194046304168864e-10
tissues O 0 5.582020179417668e-08
of O 0 1.9499504233522202e-09
DM B-Disease 1 1.0
patients O 0 4.222571533318842e-06
, O 0 1.8235112031472767e-10
there O 0 2.4271401555253647e-10
is O 0 3.2167019048401357e-10
a O 0 3.6434227856929624e-10
tendency O 0 1.866685295226489e-08
for O 0 3.7538971930928255e-10
repeat O 0 9.119234789523034e-08
length O 0 8.662334849418585e-09
and O 0 7.012013192309041e-10
somatic O 0 1.4656197144802263e-08
mosaicism O 0 9.627073893625493e-08
to O 0 5.432806982064164e-10
increase O 0 7.131421564388063e-10
with O 0 1.553345924110161e-10
the O 0 8.011973307020526e-10
age O 0 5.436022743054991e-09
of O 0 1.559410656160054e-10
the O 0 6.88886325761473e-09
mouse O 0 2.7418807349022245e-06
. O 0 8.333404366567265e-07

Furthermore O 0 1.9552771846065298e-06
, O 0 2.3738000010098403e-08
we O 0 6.002570884788838e-09
observed O 0 3.904643719465639e-09
no O 0 8.684001850944867e-10
correlation O 0 5.733431507337627e-09
between O 0 2.678882948803363e-10
the O 0 7.288405989847035e-10
somatic O 0 1.8730983697423653e-07
mutation O 0 5.225173254075344e-07
rate O 0 1.9760462066642503e-07
and O 0 2.081806371734274e-08
tissue O 0 1.7609206679480849e-06
proliferation O 0 7.687828656344209e-06
capacity O 0 4.283419912098907e-07
. O 0 3.089648430432135e-07

The O 0 7.420888437081885e-08
somatic O 0 2.2262108814175008e-06
mutation O 0 9.877595630314318e-07
rates O 0 7.245984079418122e-08
in O 0 2.649521990694126e-10
different O 0 2.7020780057895877e-10
tissues O 0 4.460348979051787e-09
were O 0 4.905221229201118e-10
also O 0 3.1783894960391024e-10
not O 0 2.157944378744503e-10
correlated O 0 2.1997854648958537e-09
to O 0 1.3537597431945159e-10
the O 0 1.4392731451096097e-10
relative O 0 9.146248203251162e-09
inter O 0 8.4014011747513e-08
- O 0 1.0528842722123954e-06
tissue O 0 2.821273881181696e-07
difference O 0 1.9727108835354557e-08
in O 0 1.4777556955891669e-10
transcriptional O 0 1.1948950273676928e-08
levels O 0 4.383423846121559e-09
of O 0 3.371760856629713e-11
the O 0 1.153039330681338e-10
three O 0 4.5654677260920096e-10
genes O 0 1.0566292729663473e-08
( O 0 7.377217725590413e-10
DMAHP O 0 1.348316516214254e-07
, O 0 5.953368353850408e-10
DMPK O 0 3.496119234114303e-07
and O 0 2.97646263192064e-09
59 O 0 4.887926952079624e-09
) O 0 5.194739638447743e-10
surrounding O 0 4.747736426224947e-09
the O 0 5.559396054621857e-09
repeat O 0 6.435606337618083e-06
. O 0 3.8482106390347326e-08
. O 0 2.0585424920227524e-07

A O 0 8.842136480780027e-07
novel O 0 1.5327070741477655e-06
missense O 0 2.5904164431267418e-05
mutation O 0 5.015380793338409e-06
in O 0 1.546798777951608e-08
patients O 0 8.161997300248913e-08
from O 0 5.500203070774035e-10
a O 0 3.2370697233830015e-09
retinoblastoma B-Disease 0 1.402846123710333e-06
pedigree O 0 1.6706599126337096e-05
showing O 0 1.2209559372422518e-06
only O 0 1.9037710075053837e-08
mild O 0 2.0331671635176463e-07
expression O 0 2.6574756617492312e-08
of O 0 1.4295968853161867e-09
the O 0 4.8906713345786557e-08
tumor B-Disease 0 4.5959794078953564e-05
phenotype O 0 8.573494415031746e-05
. O 0 1.1649799489532597e-06

We O 0 2.919574626503163e-07
have O 0 3.838554363255753e-09
used O 0 6.842232114223634e-09
single O 0 1.1768412022661323e-08
strand O 0 3.217607797978417e-07
conformation O 0 9.345449569764241e-08
polymorphism O 0 1.2944296656769438e-07
analysis O 0 1.138803185085635e-08
to O 0 4.693737065686321e-10
study O 0 1.4621176491758092e-09
the O 0 2.5906943257325565e-10
27 O 0 1.0727116972475415e-09
exons O 0 1.4799177883162429e-08
of O 0 2.328763848424842e-10
the O 0 7.283263991908484e-10
RB1 O 0 7.919262543509831e-07
gene O 0 8.10590972122327e-09
in O 0 1.6502356425807108e-10
individuals O 0 1.7328857793152963e-10
from O 0 1.0794307114814217e-10
a O 0 8.562326403449561e-10
family O 0 1.1724096360410385e-08
showing O 0 1.269583435714594e-06
mild O 0 8.170094361048541e-07
expression O 0 2.6787374096670646e-08
of O 0 1.6215930820351332e-09
the O 0 3.092011979788367e-08
retinoblastoma B-Disease 0 0.00010316309635527432
phenotype O 0 0.0002730398264247924
. O 0 2.3002628495305544e-06

In O 0 7.128789292210058e-08
this O 0 2.117111375099512e-09
family O 0 8.992983246969288e-09
affected O 0 5.68985525362109e-09
individuals O 0 6.655550555123568e-10
developed O 0 5.791024548784662e-08
unilateral B-Disease 1 0.5986369252204895
tumors I-Disease 1 1.0
and O 0 1.060975307609624e-08
, O 0 1.6558131255006714e-10
as O 0 3.837827555752682e-10
a O 0 4.77970718559817e-10
result O 0 3.806198911604497e-09
of O 0 8.743547552647613e-11
linkage O 0 9.882612062028784e-08
analysis O 0 3.103427204109721e-08
, O 0 9.009082369004773e-10
unaffected O 0 3.456185382333388e-08
mutation O 0 5.092423904784482e-08
carriers O 0 3.783754465302991e-08
were O 0 4.092601368910209e-09
also O 0 3.3213394257103346e-09
identified O 0 1.0695598184895516e-08
within O 0 1.3304940482683492e-09
the O 0 9.426039504489836e-09
pedigree O 0 2.7591235266299918e-05
. O 0 8.626063845440513e-07

A O 0 3.9209905366988096e-07
single O 0 7.204186402987034e-08
band O 0 3.809381965425018e-08
shift O 0 4.765539074469416e-08
using O 0 1.822174588994585e-08
SSCP O 0 1.7997613213083241e-06
was O 0 1.054539477962635e-08
identified O 0 2.828758782769114e-09
in O 0 2.288731704158664e-10
exon O 0 4.92481930791655e-08
21 O 0 4.121837537951478e-09
which O 0 6.081496417564836e-10
resulted O 0 3.62679131171717e-09
in O 0 1.121414516802588e-09
a O 0 6.20201401346776e-09
missense O 0 2.675332325452473e-06
mutation O 0 2.4624139882689633e-07
converting O 0 5.606284148029772e-08
a O 0 1.0727060129056554e-08
cys O 0 8.48057825351134e-05
- O 0 1.6787687400210416e-06
- O 0 4.446294212812063e-07
> O 0 1.0748814815997321e-07
arg O 0 2.1871272792850505e-07
at O 0 1.397495452692965e-09
nucleotide O 0 3.6356585297880883e-08
position O 0 9.21348686233614e-08
28 O 0 4.796258057382374e-09
in O 0 5.255262336412159e-10
the O 0 5.41902478445877e-09
exon O 0 4.372614512249129e-06
. O 0 8.914325917430688e-07

The O 0 2.796612932343123e-07
mutation O 0 3.3117116799985524e-06
destroyed O 0 1.1456329502834706e-06
an O 0 1.1825157741895964e-08
NdeI O 0 2.3384884570987197e-06
restriction O 0 3.335482574584603e-07
enzyme O 0 1.1574516065593343e-06
site O 0 5.667469622494536e-07
. O 0 3.5865716085936583e-07

Analysis O 0 4.955097665515495e-07
of O 0 2.3749719968435556e-09
all O 0 9.98567784016302e-10
family O 0 1.8948005386931754e-09
members O 0 2.288539635575404e-10
demonstrated O 0 2.752672978445503e-09
that O 0 2.7891489118303525e-10
the O 0 8.743435420122125e-10
missense O 0 1.8789627347359783e-06
mutation O 0 1.68280007528665e-06
co O 0 1.9040163579120417e-06
- O 0 6.036282229615608e-07
segregated O 0 1.040968697907374e-07
with O 0 1.2889220801781676e-09
patients O 0 2.3456703246438337e-08
with O 0 1.6304445571435622e-09
tumors B-Disease 1 1.0
or O 0 1.4184242047576845e-07
who O 0 1.3441461277352573e-08
, O 0 1.5625188642953702e-10
as O 0 2.743729132781425e-10
a O 0 3.9618064384683294e-10
result O 0 1.5309014056441583e-09
of O 0 2.0418998089577478e-11
linkage O 0 1.2426316864377895e-08
analysis O 0 9.33450827744764e-09
had O 0 9.876747419923504e-09
been O 0 1.9453849642303567e-09
predicted O 0 1.930897441937418e-09
to O 0 1.844344815760124e-10
carry O 0 5.744015929565194e-09
the O 0 6.148305864428494e-09
predisposing O 0 3.1969111660146154e-06
mutation O 0 7.25777954357909e-06
. O 0 7.14012401203945e-07

These O 0 1.5925607499411853e-08
observations O 0 2.3864297205022922e-08
point O 0 8.346964008865143e-09
to O 0 2.7769292421098157e-10
another O 0 5.835102401263725e-10
region O 0 7.3045671733495965e-09
of O 0 2.067921528459138e-10
the O 0 3.4454024078200973e-09
RB1 O 0 1.2069695003447123e-06
gene O 0 1.8754716890612144e-08
where O 0 3.2802409677401556e-09
mutations O 0 9.861650163145441e-09
only O 0 2.651559249944313e-10
modify O 0 1.1802129940008399e-08
the O 0 1.2619438827243812e-10
function O 0 4.5804085524459026e-10
of O 0 1.75041457023406e-11
the O 0 5.96557317433799e-11
gene O 0 1.5223610150272293e-09
and O 0 2.434112633675767e-10
raise O 0 1.8416768110540715e-10
important O 0 8.475393303841727e-11
questions O 0 5.859728258172936e-10
for O 0 3.7066669178464906e-11
genetic O 0 3.5157030620069918e-09
counseling O 0 4.281514254245167e-09
in O 0 2.461593706648557e-10
families O 0 4.0588532534968635e-10
with O 0 2.189933928642418e-10
these O 0 5.3232702690309e-09
distinctive O 0 1.786554321370204e-06
phenotypes O 0 2.912451691372553e-06
. O 0 5.339319386621355e-08
. O 0 4.678007030634035e-07

Maternal B-Disease 0 0.0008372630691155791
disomy I-Disease 0 0.007926099002361298
and O 0 0.006523299030959606
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
consistent O 0 5.627645691674843e-07
with O 0 5.058094831866811e-09
gamete O 0 9.451424602957559e-07
complementation O 0 5.415010491560679e-06
in O 0 4.451476076638983e-09
a O 0 2.214697092384199e-09
case O 0 8.385132588273336e-09
of O 0 7.013029601488086e-10
familial O 0 2.142014864148223e-06
translocation O 0 6.283999027800746e-07
( O 0 5.250044843307933e-09
3 O 0 3.6899105992915793e-09
; O 0 2.859064096583097e-09
15 O 0 1.5609825654294696e-09
) O 0 7.15332681977543e-10
( O 0 5.436383010426482e-10
p25 O 0 5.3856524573348e-08
; O 0 3.0279287965839785e-09
q11 O 0 9.409302492713323e-08
. O 0 2.846462399119787e-09
2 O 0 1.0235421399329425e-08
) O 0 1.7069069713215868e-08
. O 0 1.9745299084661383e-07

Maternal B-Disease 0 0.0017282662447541952
uniparental I-Disease 0 0.011562823317945004
disomy I-Disease 0 0.0014125016750767827
( I-Disease 0 9.618233889341354e-07
UPD I-Disease 1 0.9999983310699463
) I-Disease 0 3.453826025179296e-08
for I-Disease 0 6.901945126536191e-10
chromosome I-Disease 0 1.7859908041373274e-07
15 I-Disease 0 3.0446654086802027e-09
is O 0 2.7633714760888495e-10
responsible O 0 5.853819096124369e-10
for O 0 7.053162220937992e-11
an O 0 4.476589585133972e-11
estimated O 0 3.58517882048659e-10
30 O 0 4.238109307941329e-10
% O 0 9.46765305043229e-11
of O 0 3.5591911362597983e-11
cases O 0 1.2765210222198675e-08
of O 0 1.568624838910182e-07
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 3.7038571463199332e-06
PWS B-Disease 1 0.9999998807907104
) O 0 1.1422183661125018e-06
. O 0 7.686916774218844e-07

We O 0 3.675713287520921e-06
report O 0 1.7880521951951778e-08
on O 0 5.927059398835866e-10
an O 0 1.5858601931650895e-10
unusual O 0 3.365602463389905e-09
case O 0 3.730957320868811e-09
of O 0 1.7631518467453589e-10
maternal B-Disease 0 1.5333979419551724e-08
disomy I-Disease 0 4.735886136586487e-07
15 I-Disease 0 3.2445985898021945e-09
in O 0 2.09414730001356e-09
PWS B-Disease 1 1.0
that O 0 1.4814477422575578e-09
is O 0 2.966356049682872e-10
most O 0 2.1740440003803485e-10
consistent O 0 1.7579848687887534e-09
with O 0 1.3644294027947979e-10
adjacent O 0 2.2463845894549195e-08
- O 0 1.6073372535174713e-06
1 O 0 4.2045367187881766e-09
segregation O 0 1.9837589348981055e-08
of O 0 7.832449966382882e-11
a O 0 1.1332079719039712e-09
paternal O 0 7.576495875127875e-08
t O 0 2.166244428281061e-07
( O 0 2.577922875168781e-10
3 O 0 6.601577617892929e-10
; O 0 6.067430446954347e-10
15 O 0 7.394390100223802e-10
) O 0 3.054488328935179e-10
( O 0 1.126064935741411e-10
p25 O 0 1.2527337389656168e-08
; O 0 3.464299680455696e-10
q11 O 0 1.6956146708935194e-08
. O 0 5.351364906758249e-10
2 O 0 4.535913311620732e-10
) O 0 2.202395626982323e-10
with O 0 2.2512765263105194e-10
simultaneous O 0 1.6241018840901233e-07
maternal O 0 9.303234378421621e-07
meiotic O 0 5.6948797464428935e-06
nondisjunction O 0 7.687403922318481e-06
for O 0 1.747335076629497e-08
chromosome O 0 5.9049430092272814e-06
15 O 0 1.391801447425678e-07
. O 0 3.1441450687452743e-07

The O 0 2.3676217608681327e-07
patient O 0 6.598430104531872e-07
( O 0 4.802867437092573e-09
J O 0 1.3752522818322177e-06
. O 0 4.359402616671559e-09
B O 0 1.0472398059846455e-07
. O 0 2.0365099884234183e-10
) O 0 1.0170685821320191e-10
, O 0 3.7214158837839406e-11
a O 0 1.408662214652523e-10
17 O 0 9.433750447485068e-10
- O 0 5.2468944744532564e-08
year O 0 1.614526645710157e-08
- O 0 1.7946725847650669e-06
old O 0 1.801269900170155e-05
white O 0 1.2824663997434982e-07
male O 0 1.6948289882634526e-08
with O 0 9.709736348284537e-10
PWS B-Disease 1 1.0
, O 0 1.0993824739458091e-09
was O 0 9.28129684218959e-10
found O 0 1.3682446842189222e-10
to O 0 1.2561085505069514e-10
have O 0 4.853162316464932e-10
47 O 0 9.60304169517201e-10
chromosomes O 0 3.4100198220698985e-09
with O 0 4.438739376055878e-10
a O 0 2.1160375673900944e-09
supernumerary O 0 2.2441633973357966e-06
, O 0 1.748644562482582e-09
paternal O 0 6.093368654092046e-08
der O 0 1.6206204236368649e-06
( O 0 2.8962809928145816e-10
15 O 0 2.79409551051657e-10
) O 0 3.72365228928917e-11
consisting O 0 2.3787414746290203e-11
of O 0 2.8821226655262322e-11
the O 0 1.0363102598276441e-09
short O 0 3.95130155084189e-06
arm O 0 0.0009466282790526748
and O 0 1.3745572458034871e-09
the O 0 2.623012917979395e-10
proximal O 0 1.6099208721698233e-07
long O 0 7.941404328448698e-05
arm O 0 0.00011488931340863928
of O 0 4.1195166722296506e-10
chromosome O 0 5.093424988444895e-07
15 O 0 2.570220924980049e-09
, O 0 8.500782855414002e-10
and O 0 9.309118809142092e-09
distal O 0 4.717706542578526e-05
chromosome O 1 0.9745432138442993
arm O 1 0.9078088998794556
3p O 0 0.0005793024902231991
. O 0 2.6796683414431754e-06

The O 0 3.3661697784737044e-07
t O 0 2.0226573269610526e-06
( O 0 2.1898971525047273e-09
3 O 0 1.0882377221577144e-09
; O 0 5.550483406224771e-10
15 O 0 2.8180355271523183e-10
) O 0 1.717125885924986e-10
was O 0 1.1867540283816425e-09
present O 0 1.2871181898077566e-10
in O 0 1.9753634838970413e-10
the O 0 1.4029642725343905e-10
balanced O 0 3.2719242870626886e-09
state O 0 6.780699335351414e-10
in O 0 3.3522751241577e-10
the O 0 1.0617480228347631e-09
patients O 0 2.206472160537487e-08
father O 0 4.075705106743044e-09
and O 0 2.303904622635855e-09
a O 0 1.1467130356379585e-08
sister O 0 6.488400686066598e-06
. O 0 5.636352398141753e-07

Fluorescent O 0 3.432023004279472e-05
in O 0 6.145705100379928e-08
situ O 0 4.926914698444307e-07
hybridization O 0 1.702580050277902e-07
analysis O 0 4.626421912234946e-08
demonstrated O 0 1.7423262832494402e-08
that O 0 1.777581415396412e-09
the O 0 1.4047812690876071e-08
PWS B-Disease 1 0.9999997615814209
critical O 0 4.081884981133044e-07
region O 0 5.0107772153751284e-08
resided O 0 1.171974091107586e-07
on O 0 3.021674910286265e-09
the O 0 8.920664207323625e-10
derivative O 0 1.1711361480593041e-07
chromosome O 0 9.175694515306532e-08
3 O 0 2.227643847163563e-09
and O 0 2.892593387038289e-10
that O 0 1.5654065543824203e-10
there O 0 3.457869823808579e-10
was O 0 8.139606322288273e-09
no O 0 5.243407374955211e-10
deletion O 0 1.383379366615145e-08
of O 0 2.153733719145734e-10
the O 0 4.3765897572711765e-09
PWS B-Disease 1 1.0
region O 0 1.610455342415662e-07
on O 0 2.2800012988710705e-09
the O 0 1.2216566647182958e-09
normal O 0 1.0369870295789951e-08
pair O 0 1.59581112768592e-08
of O 0 7.356842912642492e-10
15s O 0 9.087459318379842e-08
present O 0 1.0228317748328664e-08
in O 0 3.928326108848523e-08
J O 0 0.00019545969553291798
. O 0 6.698347192468646e-07

B O 0 0.011627902276813984
. O 0 3.441370063228533e-05

Methylation O 0 7.898273906903341e-06
analysis O 0 5.231830186858133e-07
at O 0 1.0999493760266432e-08
exon O 0 1.0191205745968546e-07
alpha O 0 1.0063618383071571e-08
of O 0 2.4189597547241704e-10
the O 0 1.0255936100378449e-09
small O 0 3.863485886768103e-08
nuclear O 0 9.343893907498568e-06
ribonucleoprotein O 0 9.207386938214768e-06
- O 0 9.058746854861965e-07
associated O 0 7.91385161846847e-08
polypeptide O 0 1.0501386213945807e-06
N O 0 6.605903877243691e-07
( O 0 1.6278871584063381e-09
SNRPN O 0 1.2028347384784865e-07
) O 0 4.661831476404643e-10
gene O 0 1.4199206255227637e-08
showed O 0 2.2436356772459476e-08
a O 0 6.251082984576328e-10
pattern O 0 1.090520171942444e-07
characteristic O 0 7.83589797492823e-08
of O 0 3.741502385690154e-10
only O 0 1.849227881933757e-09
the O 0 2.159950884816908e-09
maternal O 0 1.3662334197306336e-07
chromosome O 0 1.9012148868569057e-06
15 O 0 2.4578802992891724e-08
in O 0 1.868968979579222e-08
J O 0 0.002845345064997673
. O 0 1.1394765806471696e-06

B O 0 0.014293055050075054
. O 0 2.295723788847681e-05

Maternal B-Disease 0 0.0005745301023125648
disomy I-Disease 0 0.0017920287791639566
was O 0 1.6960228776952135e-06
confirmed O 0 5.846181494462144e-08
by O 0 1.4855789931544905e-09
polymerase O 0 1.2473600463636103e-07
chain O 0 4.6982515300442174e-07
reaction O 0 2.5821428550898418e-08
analysis O 0 1.731797105719579e-08
of O 0 7.715259542351305e-10
microsatellite O 0 1.8523140852266806e-06
repeats O 0 2.96618452466646e-07
at O 0 2.657722708576671e-09
the O 0 9.244900400773304e-10
gamma O 0 2.6376082473689166e-07
- O 0 3.8053769912949065e-06
aminobutyric O 0 9.558163583278656e-06
acid O 0 5.284759367896186e-07
receptor O 0 2.0515184928626695e-07
beta3 O 0 7.872080800552794e-07
subunit O 0 3.034110989119654e-07
( O 0 1.8328023543290328e-08
GABRB3 O 0 3.6828294014412677e-06
) O 0 5.628323052064843e-08
locus O 0 8.659175364300609e-06
. O 0 1.253486288987915e-06

A O 0 8.542381806364574e-07
niece O 0 2.281606839460437e-06
( O 0 1.3473314908196699e-08
B O 0 2.2680448807932407e-07
. O 0 1.911950375799165e-09
B O 0 1.850163755534595e-08
. O 0 1.4776598000754149e-10
) O 0 5.066316810520277e-11
with O 0 2.2237827898563545e-11
45 O 0 1.1317689146972398e-10
chromosomes O 0 1.4472680831545404e-09
and O 0 4.671693587532388e-10
the O 0 1.3057177561393019e-10
derivative O 0 6.782361339219278e-08
3 O 0 9.501015529878032e-10
but O 0 9.44714750872322e-10
without O 0 5.277883685650409e-10
the O 0 2.6136193209680414e-10
der O 0 5.457040970213711e-07
( O 0 1.1378206710155325e-10
15 O 0 1.291441398265647e-10
) O 0 1.1063656935039745e-10
demonstrated O 0 1.6678555203597512e-09
a O 0 9.99732185924529e-10
phenotype O 0 9.329687600256875e-08
consistent O 0 4.113802631877661e-09
with O 0 1.7202467228472074e-10
that O 0 6.930465645815787e-10
reported O 0 4.9179740280180795e-09
for O 0 3.141414073315474e-10
haploinsufficiency O 0 1.3701087198114692e-07
of O 0 7.573714433384282e-10
distal O 0 1.5482058870475157e-06
3 O 0 5.822323032589338e-07
p O 0 0.0008687587105669081
. O 0 7.734626592537097e-07

Uniparental B-Disease 1 0.9999932050704956
disomy I-Disease 1 0.9999942779541016
associated O 0 6.1572895901917946e-06
with O 0 6.08473911256624e-08
unbalanced O 0 4.218542471789988e-06
segregation O 0 5.491125421031029e-07
of O 0 1.5292875854555632e-09
non O 0 6.662136087243198e-08
- O 0 1.0192469090952727e-07
Robertsonian O 0 1.19433494205623e-07
translocations O 0 3.5998021985506057e-07
has O 0 6.560009868650241e-09
been O 0 1.545913175249325e-09
reported O 0 9.911522713679233e-10
previously O 0 2.144851407592796e-09
but O 0 2.3202610943684476e-09
has O 0 5.807012648517684e-10
not O 0 2.586596214992909e-10
, O 0 3.604588502681416e-11
to O 0 3.1988835191842924e-11
our O 0 6.57146143057119e-11
knowledge O 0 2.0139936940388736e-10
, O 0 3.3793644965696146e-11
been O 0 3.0646013504664893e-10
observed O 0 1.1292380364125165e-09
in O 0 1.3006222487899066e-10
a O 0 8.90792883900815e-10
case O 0 9.781886944892904e-08
of O 0 5.7686232679543537e-08
PWS B-Disease 1 0.9999997615814209
. O 0 2.741546040851972e-06

Furthermore O 0 2.804756149998866e-06
, O 0 3.1552282564462075e-08
our O 0 7.531538948057914e-09
findings O 0 6.05564176581197e-09
are O 0 2.4719587488064576e-10
best O 0 2.6547435361123917e-09
interpreted O 0 7.4353225798518e-09
as O 0 1.9434451825617316e-09
true O 0 2.9998833639410805e-08
gamete O 0 1.6464147165606846e-06
complementation O 0 1.1342225661792327e-05
resulting O 0 8.187011530935706e-07
in O 0 1.8247001776217076e-07
maternal B-Disease 0 0.0004940815852023661
UPD I-Disease 1 1.0
15 I-Disease 0 8.095203156699426e-06
and O 0 1.0868186109291855e-05
PWS B-Disease 1 0.9999994039535522

Schwartz B-Disease 1 0.9981504082679749
- I-Disease 1 0.9999849796295166
Jampel I-Disease 1 0.9998948574066162
syndrome I-Disease 1 0.999987006187439
type I-Disease 0 6.4132736952160485e-06
2 I-Disease 0 4.792236651951498e-08
and O 0 4.3675445482449504e-08
Stuve B-Disease 1 0.9986950755119324
- I-Disease 1 0.9999994039535522
Wiedemann I-Disease 1 0.9999998807907104
syndrome I-Disease 1 0.9999947547912598
: O 0 2.8434126164711415e-09
a O 0 6.314775924387561e-10
case O 0 6.911236472006976e-09
for O 0 8.121257000226478e-10
" O 0 1.785240755225459e-08
lumping O 0 6.514936785606551e-07
" O 0 1.4692869854115997e-07
. O 0 2.6633244942786405e-07

Recent O 0 8.813016734166013e-07
studies O 0 1.8815669022842485e-07
demonstrated O 0 1.3149513478083463e-08
the O 0 1.6813302139428998e-10
existence O 0 1.8228585307866751e-09
of O 0 5.17154444268364e-11
a O 0 3.863555586569589e-10
genetically O 0 2.793276054902094e-09
distinct O 0 3.3404943255987973e-09
, O 0 2.0181351034764816e-10
usually O 0 3.069035303671086e-10
lethal O 0 2.829244394320085e-09
form O 0 5.521098023208992e-10
of O 0 8.430475761933565e-11
the O 0 5.297664529280155e-09
Schwartz B-Disease 1 0.9965841770172119
- I-Disease 1 0.9998669624328613
Jampel I-Disease 1 0.9999399185180664
syndrome I-Disease 1 0.9999706745147705
( O 0 5.2308767095610165e-08
SJS B-Disease 1 0.9602049589157104
) O 0 5.3732343019419204e-09
of O 0 1.8748556041003894e-09
myotonia B-Disease 1 0.9396817684173584
and O 0 2.3459661235847307e-07
skeletal B-Disease 0 0.004024595487862825
dysplasia I-Disease 1 0.9756057858467102
, O 0 1.6162458038593286e-08
which O 0 1.4349820887105125e-08
we O 0 2.9240929677598615e-08
called O 0 2.0353050445010012e-07
SJS B-Disease 1 0.9681498408317566
type I-Disease 0 9.95198297459865e-06
2 I-Disease 0 3.196010425199347e-07
. O 0 6.251839863580244e-07

This O 0 6.251660806810833e-07
disorder O 0 0.0001735246041789651
is O 0 3.640819645767124e-09
reminiscent O 0 2.339562144015872e-08
of O 0 2.2036393543256594e-10
another O 0 2.932363463159504e-09
rare O 0 5.653877011013719e-08
condition O 0 4.4881122107653937e-07
, O 0 4.682783050213857e-10
the O 0 5.019776594394898e-09
Stuve B-Disease 1 0.9910485744476318
- I-Disease 1 0.9999957084655762
Wiedemann I-Disease 1 0.9999984502792358
syndrome I-Disease 1 0.9999784231185913
( O 0 8.781864124784988e-09
SWS B-Disease 0 1.027739290293539e-05
) O 0 1.965607676623904e-09
, O 0 1.2352575906593444e-10
which O 0 2.1657417526022016e-10
comprises O 0 3.39783839953256e-10
campomelia B-Disease 0 3.3120738862635335e-07
at O 0 4.823394572639472e-09
birth O 0 1.498488266804543e-08
with O 0 3.0461293487604735e-09
skeletal B-Disease 0 0.002947139320895076
dysplasia I-Disease 1 0.9782773852348328
, O 0 2.0996756333602207e-08
contractures B-Disease 0 2.4318647774634883e-05
, O 0 7.075847019422099e-09
and O 0 3.178002971893079e-09
early B-Disease 0 1.1009510103576758e-07
death I-Disease 0 2.961413656521472e-07
. O 0 4.121879726426414e-07

To O 0 2.359936424056741e-08
test O 0 1.1509047048718912e-08
for O 0 1.6475529274195821e-10
possible O 0 2.7172586403167998e-09
nosologic O 0 2.3805611704119656e-07
identity O 0 4.077526583046165e-08
between O 0 1.212249078896832e-09
these O 0 2.2381678732585897e-09
disorders O 0 1.316034854426107e-06
, O 0 2.510029406543879e-10
we O 0 2.802298670889769e-10
reviewed O 0 5.817211157221891e-10
the O 0 2.7752017697779685e-11
literature O 0 3.737451181873297e-10
and O 0 1.126475301926888e-10
obtained O 0 9.52127932052349e-10
a O 0 1.074131963929581e-10
follow O 0 8.471906509655014e-10
- O 0 1.5726143942629278e-08
up O 0 6.258181195484269e-10
of O 0 1.0754331453144417e-11
the O 0 9.931008793095941e-11
only O 0 1.7926159168180078e-10
two O 0 3.465211451114669e-10
surviving O 0 7.052822326159003e-08
patients O 0 1.4015215654694657e-08
, O 0 7.312701139072786e-11
one O 0 2.1197206490075615e-10
with O 0 1.1125835808201145e-09
SJS B-Disease 0 0.006697508972138166
type I-Disease 0 4.894870642146998e-08
2 I-Disease 0 8.533940221155945e-10
at O 0 9.36880351076752e-10
age O 0 4.5889436695034647e-10
10 O 0 5.838951544490101e-11
years O 0 2.763108075676257e-10
and O 0 1.3097833928554792e-10
another O 0 5.312262851830951e-10
with O 0 1.9737562695354427e-09
SWS B-Disease 0 0.0001044495147652924
at O 0 1.0221609336724669e-08
age O 0 6.1044866939141684e-09
7 O 0 7.787842370987619e-09
years O 0 4.9141974045596726e-08
. O 0 1.478894233741812e-07

Patients O 0 8.601335866842419e-05
reported O 0 5.057297585153719e-07
as O 0 4.948403464766216e-09
having O 0 1.0419579865583728e-07
either O 0 9.521321544525563e-07
neonatal O 1 0.9998972415924072
SJS B-Disease 1 0.9999991655349731
or O 0 1.3465756865116418e-06
SWS B-Disease 0 0.00020798757032025605
presented O 0 5.543270731322991e-09
a O 0 6.931126783626951e-10
combination O 0 1.0425757146492742e-08
of O 0 1.5322912383375353e-10
a O 0 4.7635646538424226e-09
severe O 0 5.758267320743471e-07
, O 0 6.107514494146926e-09
prenatal O 0 0.17534057796001434
- O 1 0.8761286735534668
onset O 0 0.19567722082138062
neuromuscular B-Disease 1 0.999923825263977
disorder I-Disease 1 0.9996868371963501
( O 0 1.4203701326209739e-08
with O 0 2.2815337175075e-08
congenital B-Disease 1 0.9999852180480957
joint I-Disease 0 4.2198247683700174e-05
contractures I-Disease 1 0.9986221790313721
, O 0 2.4286296707032307e-07
respiratory O 0 0.0003530420071911067
and O 0 1.1169130509358638e-08
feeding O 0 1.2039444641231967e-07
difficulties O 0 5.848707473887771e-07
, O 0 8.211973878680112e-10
tendency O 0 2.3201517151960616e-08
to O 0 1.4775309864489827e-09
hyperthermia B-Disease 0 5.913041718486056e-07
, O 0 9.942802137175022e-10
and O 0 5.600870323085871e-10
frequent O 0 2.2361632545653265e-08
death O 0 2.4654021046899288e-08
in O 0 4.257604935276049e-09
infancy O 0 3.5861268088410725e-07
) O 0 6.369634819591852e-10
with O 0 1.0767493147101348e-10
a O 0 3.5190241831628555e-09
distinct O 0 4.6518968588316056e-07
campomelic B-Disease 0 0.16529420018196106
- I-Disease 0 0.2793385982513428
metaphyseal I-Disease 0 0.010782795958220959
skeletal I-Disease 0 0.12664201855659485
dysplasia I-Disease 1 0.9053198099136353
. O 0 7.294222541531781e-06

The O 0 3.1248340803813335e-08
similarity O 0 1.0945920081439908e-07
of O 0 5.160905036660779e-10
the O 0 6.725904833082552e-10
clinical O 0 1.0059208221946392e-07
and O 0 1.7587729050916323e-09
radiographic O 0 0.0005331401480361819
findings O 0 2.6495499128031952e-08
is O 0 7.696021042669088e-10
so O 0 2.7605162600252697e-10
extensive O 0 1.5456713686745616e-09
that O 0 7.646580035824968e-10
these O 0 1.4597518749326355e-09
disorders O 0 9.637840747700466e-08
appear O 0 1.7780188432681143e-09
to O 0 2.306471263979759e-10
be O 0 1.0077866319235795e-09
a O 0 2.2635961993699993e-09
single O 0 1.1979670944128884e-07
entity O 0 2.5725263185449876e-05
. O 0 1.622750119167904e-06

The O 0 2.1621078261091498e-08
follow O 0 2.0223216878889616e-08
- O 0 1.5261217356510315e-07
up O 0 2.7750350906075028e-09
observation O 0 5.873326713867755e-09
of O 0 2.6836886879433308e-11
an O 0 5.5856437530810155e-11
identical O 0 3.103048484831561e-08
and O 0 1.9795172168102226e-09
unique O 0 7.317075390034233e-09
pattern O 0 1.6360891095246188e-06
of O 0 2.3341768518037043e-09
progressive O 0 1.028932842928043e-06
bone B-Disease 1 0.9169305562973022
dysplasia I-Disease 1 0.9902294278144836
in O 0 7.921006961453259e-09
the O 0 1.040822761311233e-09
two O 0 4.564555844410734e-09
patients O 0 3.202545073577312e-08
( O 0 1.8418276626075425e-10
one O 0 1.0351447476963926e-09
with O 0 5.163881322545194e-09
SJS B-Disease 1 0.9220873117446899
type I-Disease 0 1.3142613397576497e-06
2 I-Disease 0 3.0657372196429833e-09
, O 0 3.4000682824775197e-10
one O 0 9.871318207288482e-10
with O 0 3.819900840085211e-09
SWS B-Disease 0 6.068675429560244e-05
) O 0 2.0094017560978727e-09
surviving O 0 4.553410448693285e-08
beyond O 0 9.750663387819714e-09
infancy O 0 1.5217935356304224e-07
adds O 0 1.9436685150253652e-08
to O 0 1.0662691563023685e-10
the O 0 6.544581543366235e-11
evidence O 0 1.825440132385836e-09
in O 0 3.8441647087772424e-10
favor O 0 6.203729085996201e-09
of O 0 1.0814426021354961e-09
identity O 0 2.811649665090954e-06
. O 0 5.688750661647646e-07

The O 0 1.8921332411991898e-07
hypothesis O 0 1.6531771507288795e-06
that O 0 4.1132711459113125e-08
SWS B-Disease 0 3.4263070119777694e-05
and O 0 5.177375683729224e-08
SJS B-Disease 1 0.658458411693573
type I-Disease 0 3.948556468458264e-07
2 I-Disease 0 1.938151639180319e-09
are O 0 1.492937995450916e-10
the O 0 1.8741681817591171e-10
same O 0 3.3224115014718336e-08
disorder O 0 3.327521881146822e-06
should O 0 9.289816138569051e-10
be O 0 2.1357876578420587e-10
testable O 0 6.456828405276838e-09
by O 0 3.1040575665386427e-10
molecular O 0 2.291127465525733e-08
methods O 0 1.4798395397974673e-07
. O 0 3.5620214333675904e-08
. O 0 2.0210073614634894e-07

A O 0 4.623013012405863e-07
mouse O 0 1.8914381598733598e-06
model O 0 7.19833508355805e-07
of O 0 4.702720701743601e-08
severe O 1 0.9995443224906921
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
: O 0 0.011909049935638905
defects O 1 0.9999649524688721
in O 0 6.936634235898964e-07
hemostasis O 1 0.9976848363876343
and O 0 2.4243623556685634e-05
thrombosis B-Disease 1 0.6757054924964905
. O 0 2.492291287126136e-06

von B-Disease 1 0.7575467228889465
Willebrand I-Disease 0 0.21614453196525574
factor I-Disease 0 8.605257607996464e-05
( I-Disease 0 5.202495003686636e-07
vWf I-Disease 0 0.010744377970695496
) I-Disease 0 0.0009760448592714965
deficiency I-Disease 1 0.9999072551727295
causes O 0 0.014940928667783737
severe O 1 0.9999980926513672
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
in O 0 6.299047186075768e-07
humans O 0 3.083230694755912e-06
. O 0 1.5216091924230568e-06

We O 0 2.3700820861449756e-07
generated O 0 1.1635654217911906e-08
a O 0 1.134468852193038e-09
mouse O 0 5.091035149007439e-08
model O 0 5.953555870519267e-08
for O 0 9.998580852155214e-10
this O 0 3.2013771633643273e-09
disease O 0 2.176622793115257e-08
by O 0 2.5972546335850666e-10
using O 0 1.511119940289518e-08
gene O 0 4.841799068344699e-07
targeting O 0 5.182116183277685e-06
. O 0 9.994211040975642e-07

vWf B-Disease 1 0.7954626083374023
- I-Disease 1 0.9999239444732666
deficient I-Disease 0 0.30847054719924927
mice O 0 1.3879054677090608e-05
appeared O 0 8.538881957065314e-08
normal O 0 2.29496315284905e-08
at O 0 1.3043841562421221e-09
birth O 0 2.0828738733769114e-09
; O 0 4.598143255041265e-10
they O 0 1.0599835453817263e-09
were O 0 1.8518645505949394e-09
viable O 0 1.2268737918930128e-06
and O 0 3.9267526119601825e-08
fertile O 0 1.2291269513298175e-06
. O 0 9.860955287877005e-07

Neither O 0 0.00018784721032716334
vWf O 0 0.0022402117028832436
nor O 0 9.100601891987026e-05
vWf O 0 0.0007085194811224937
propolypeptide O 0 0.0002755695313680917
( O 0 2.132809413524228e-06
von B-Disease 0 0.009908733889460564
Willebrand I-Disease 0 0.08504287153482437
antigen O 0 0.0008680326864123344
II O 0 1.752816569933202e-05
) O 0 1.1342682348924882e-08
were O 0 2.1128474525511365e-09
detectable O 0 3.432623714161309e-07
in O 0 9.356161401186114e-10
plasma O 0 1.1554913470490646e-07
, O 0 1.7660607420921792e-09
platelets O 0 8.56752961908569e-08
, O 0 1.286102890851737e-09
or O 0 7.397483070548105e-09
endothelial O 0 1.732461285541831e-08
cells O 0 1.508611546796601e-08
of O 0 5.295610616684598e-10
the O 0 6.547384856503413e-09
homozygous O 0 5.582064204645576e-06
mutant O 0 9.092987056646962e-06
mice O 0 1.228700148203643e-05
. O 0 7.985264574017492e-07

The O 0 3.5483179772199946e-07
mutant O 0 1.1865793567267247e-05
mice O 0 1.7244212358491495e-05
exhibited O 0 6.186154223541962e-06
defects O 0 0.23370271921157837
in O 0 1.2381648595294337e-08
hemostasis O 0 9.150732694251928e-06
with O 0 4.144754761625791e-09
a O 0 1.2759198142475725e-08
highly O 0 2.8247927730262745e-07
prolonged O 0 7.279141573235393e-05
bleeding O 0 0.02048458345234394
time O 0 3.154548622319453e-08
and O 0 3.0931783800980384e-09
spontaneous O 0 3.8302623295294325e-08
bleeding O 0 1.295980041504663e-06
events O 0 4.506431672268718e-09
in O 0 5.354182652794748e-10
approximately O 0 1.892517698109941e-09
10 O 0 3.5473071147151813e-09
% O 0 2.9284732416812176e-09
of O 0 4.45257963832546e-09
neonates O 0 4.267488475306891e-05
. O 0 4.7179671014419e-07

As O 0 5.072550735008008e-08
in O 0 3.2044866760116975e-09
the O 0 1.396935900288554e-09
human O 0 4.96897412105568e-09
disease O 0 6.680522801616462e-08
, O 0 1.9301638065627458e-10
the O 0 2.639897189737894e-10
factor O 0 1.8306431925907418e-08
VIII O 0 5.840352059749421e-07
level O 0 1.1442900849090165e-08
in O 0 2.6144617026879757e-10
these O 0 3.153817484946586e-10
mice O 0 3.462294984046821e-08
was O 0 5.762198718173295e-09
reduced O 0 1.0968900232555256e-09
strongly O 0 8.636858450650209e-10
as O 0 3.7773406624808104e-10
a O 0 2.786841035717913e-10
result O 0 3.4470719612045286e-09
of O 0 3.748521978930164e-11
the O 0 7.773531818244805e-10
lack O 0 2.645019314684305e-09
of O 0 7.289042286418024e-11
protection O 0 2.0166353031925155e-09
provided O 0 2.500564422192042e-09
by O 0 1.191399512379121e-08
vWf O 0 1.8329725207877345e-05
. O 0 1.1633301255642436e-06

Defective O 0 0.03031209483742714
thrombosis B-Disease 0 0.019373107701539993
in O 0 2.587526459763012e-08
mutant O 0 4.0067800455290126e-07
mice O 0 2.3535949367214926e-06
was O 0 3.695307526641045e-08
also O 0 1.2517323844107864e-09
evident O 0 5.921062751212958e-09
in O 0 2.251057396041034e-10
an O 0 1.4414050508726461e-10
in O 0 1.1855820769568481e-09
vivo O 0 5.524811399482132e-07
model O 0 9.285572133421738e-08
of O 0 6.5248948466489765e-09
vascular B-Disease 0 0.08238686621189117
injury I-Disease 0 0.061844371259212494
. O 0 8.266582653959631e-07

In O 0 1.1552885581522787e-07
this O 0 2.6395610142060377e-09
model O 0 5.176378081728217e-08
, O 0 8.141217144874702e-10
the O 0 1.0767827740565394e-09
exteriorized O 0 8.976310255093267e-07
mesentery O 0 3.04340119328117e-06
was O 0 1.2234784740883242e-08
superfused O 0 9.877730633434112e-08
with O 0 4.890955418446197e-10
ferric O 0 2.2497684426525666e-07
chloride O 0 1.7612352110063512e-07
and O 0 1.9245511850840558e-09
the O 0 8.158129172208817e-10
accumulation O 0 1.57923025767559e-08
of O 0 8.650162808265804e-10
fluorescently O 0 7.30655938241398e-06
labeled O 0 1.0441636959512834e-06
platelets O 0 2.1432347239169758e-06
was O 0 1.1920768372419843e-08
observed O 0 1.8657917877362706e-08
by O 0 3.996172726061786e-09
intravital O 0 2.200014705522335e-06
microscopy O 0 3.6520023058983497e-06
. O 0 8.559360367144109e-07

We O 0 8.448844823760737e-07
conclude O 0 9.17373412789857e-08
that O 0 1.0316029142032335e-09
these O 0 8.842400700537212e-10
mice O 0 3.7908193917246535e-08
very O 0 1.260707871431066e-09
closely O 0 1.896540524626289e-08
mimic O 0 8.682321094966028e-06
severe O 0 0.0003497690486256033
human O 0 2.3975082967808703e-06
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
and O 0 2.5579387511243112e-05
will O 0 4.793458963092689e-09
be O 0 3.6363620448121026e-10
very O 0 8.865769229871034e-11
useful O 0 4.6544926246561147e-10
for O 0 4.403883854808832e-11
investigating O 0 7.305329674522909e-10
the O 0 1.0753455070844353e-10
role O 0 1.7931333085030587e-09
of O 0 1.3027424972111845e-10
vWf O 0 1.5330886071751593e-07
in O 0 3.2423033147210845e-09
normal O 0 3.6928273772218745e-08
physiology O 0 7.274829982861775e-08
and O 0 8.807578666392146e-09
in O 0 2.076678740081661e-08
disease O 0 2.866372312837484e-07
models O 0 2.6052461521430814e-07
. O 0 3.1051559545858254e-08
. O 0 2.1580727604941785e-07

Oral O 0 3.837568328890484e-06
contraceptives O 0 6.60701043670997e-05
and O 0 1.9358397551627604e-08
the O 0 7.0123111761688506e-09
risk O 0 6.623114586545853e-06
of O 0 1.4452336927206488e-07
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 3.435368853388354e-06

Hereditary B-Disease 1 0.999998927116394
Ovarian I-Disease 1 0.9999998807907104
Cancer I-Disease 1 0.9980339407920837
Clinical O 0 0.0001996836217585951
Study O 0 5.707880518457387e-06
Group O 0 3.86776628147345e-06
. O 0 2.525038553358172e-06

BACKGROUND O 0 0.00017239460430573672
Women O 0 3.8840488514324534e-07
with O 0 2.221728800932965e-09
mutations O 0 6.459713119966182e-08
in O 0 4.804669440083842e-10
either O 0 1.5376614426187984e-09
the O 0 1.069394017783054e-09
BRCA1 O 0 8.017022423700837e-07
or O 0 7.742978702651726e-09
the O 0 6.176782973987827e-10
BRCA2 O 0 1.671580065476519e-07
gene O 0 6.9508563349529595e-09
have O 0 1.7030135079920683e-09
a O 0 1.2433137852596587e-09
high O 0 9.891115837490361e-08
lifetime O 0 2.1350174392864574e-06
risk O 0 0.001091398997232318
of O 0 2.279821046613506e-06
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 0 2.4301155008288333e-06

Oral O 0 1.572841028973926e-05
contraceptives O 0 0.0003276345960330218
protect O 0 1.5664016245864332e-05
against O 0 0.007982646115124226
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 8.522749173067723e-10
general O 0 2.407085364364292e-10
, O 0 1.7974742527737675e-10
but O 0 1.1067884386761762e-09
it O 0 2.523778408480837e-10
is O 0 6.027862931023975e-11
not O 0 5.721256454704893e-11
known O 0 1.2919045000447937e-10
whether O 0 2.7611798958382394e-10
they O 0 5.447696738158925e-10
also O 0 4.37365893501962e-10
protect O 0 2.19741203011381e-09
against O 0 3.391882996695017e-09
hereditary B-Disease 0 2.204074007750023e-06
forms I-Disease 0 2.145107828255277e-06
of I-Disease 0 0.0012869633501395583
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 0 1.3512376426660921e-06

METHODS O 0 1.5049507737785461e-06
We O 0 7.32746912035509e-08
enrolled O 0 7.825427417174069e-08
207 O 0 7.045817085327144e-08
women O 0 7.859787842789956e-08
with O 0 7.345842334416375e-08
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 4.56439019913546e-09
161 O 0 2.677602140011004e-09
of O 0 1.7535065066631716e-10
their O 0 6.868065005605217e-10
sisters O 0 2.167053736457092e-08
as O 0 6.594254031710989e-10
controls O 0 1.6707895156287123e-07
in O 0 1.0336650424491722e-09
a O 0 1.2435391605336577e-09
case O 0 7.691039627388818e-08
- O 0 1.0666215530363843e-05
control O 0 1.3370118949751486e-06
study O 0 2.847740745437477e-07
. O 0 3.261682763877616e-07

All O 0 1.9898523717643002e-08
the O 0 3.5291263245085247e-09
patients O 0 1.8660445633145173e-08
carried O 0 4.064681480286936e-09
a O 0 2.3363770917939064e-09
pathogenic O 0 1.1664234733643752e-07
mutation O 0 1.2217020639582188e-07
in O 0 1.3075102112125592e-09
either O 0 7.609541441411238e-09
BRCA1 O 0 9.067148312169593e-07
( O 0 1.2378573721605335e-09
179 O 0 8.146424868016311e-09
women O 0 4.926714591846348e-09
) O 0 1.1553911161144015e-09
or O 0 1.1208291184061636e-08
BRCA2 O 0 2.236254204035504e-06
( O 0 3.7739575908801726e-09
28 O 0 2.4103222528992774e-08
women O 0 6.140479769101148e-08
) O 0 2.4580163682230705e-08
. O 0 2.9982021487739985e-07

The O 0 4.4295084933310136e-08
control O 0 3.1204152151076414e-07
women O 0 1.3298375733938883e-08
were O 0 2.8385777062212014e-10
enrolled O 0 1.7149862641119284e-09
regardless O 0 7.177873850849892e-10
of O 0 1.109740337817966e-11
whether O 0 2.464149162495488e-10
or O 0 5.075633247031419e-10
not O 0 5.448528295204369e-10
they O 0 1.3305270218921805e-09
had O 0 8.660699712947917e-09
either O 0 3.360869982316217e-08
mutation O 0 2.7797307211585576e-06
. O 0 4.191327320768323e-07

Lifetime O 0 5.243270607024897e-06
histories O 0 7.285764240805293e-07
of O 0 1.7168451105220583e-09
oral O 0 1.4371080681030435e-07
- O 0 4.367544761407771e-07
contraceptive O 0 1.7241135310541722e-06
use O 0 5.230354815921601e-09
were O 0 4.969682998456904e-10
obtained O 0 1.3140881716111608e-09
by O 0 2.359969997201006e-10
interview O 0 3.199644993401307e-08
or O 0 3.440921714226164e-10
by O 0 2.055517735188861e-11
written O 0 3.1724176063896437e-10
questionnaire O 0 3.1029403491089624e-09
and O 0 1.7388654405259274e-10
were O 0 1.434400515032408e-10
compared O 0 4.392996799662541e-10
between O 0 2.939361531950624e-10
patients O 0 1.068528021619386e-08
and O 0 6.663298801612427e-10
control O 0 1.6768873933870054e-07
women O 0 6.9807502001140165e-09
, O 0 6.43535433275666e-11
after O 0 2.220939543384759e-10
adjustment O 0 1.8716683758412955e-09
for O 0 5.340686226595892e-11
year O 0 2.6866400770764187e-10
of O 0 8.115167565714287e-11
birth O 0 1.579757480385524e-08
and O 0 1.4849536711381006e-08
parity O 0 1.0689304872357752e-06
. O 0 2.857027823210956e-07

RESULTS O 0 2.3259663066710345e-06
The O 0 9.51908774027288e-09
adjusted O 0 1.4004922377353068e-06
odds O 0 2.179322655138094e-05
ratio O 0 6.66544001433067e-05
for O 0 0.008110396564006805
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
associated O 0 9.92639748176316e-09
with O 0 1.2435313889724853e-10
any O 0 7.866514106780187e-10
past O 0 1.6998268348444867e-09
use O 0 2.3000670257289357e-09
of O 0 1.628342738424493e-10
oral O 0 4.595254310402197e-08
contraceptives O 0 3.410632416489534e-05
was O 0 7.550312375315116e-08
0 O 0 7.048908656770436e-08
. O 0 1.43501551974623e-07

5 O 0 3.3341277116960555e-07
( O 0 5.649001710850143e-09
95 O 0 1.5435215772185984e-08
percent O 0 1.6248392853412952e-07
confidence O 0 1.7735420243525368e-08
interval O 0 1.562007945210553e-08
, O 0 1.6173511141470698e-10
0 O 0 2.901163198565371e-10
. O 0 1.4553558358443297e-10
3 O 0 1.9239262960546455e-10
to O 0 1.9556481434257478e-10
0 O 0 1.5476242509748772e-09
. O 0 1.1372658370589761e-09
8 O 0 3.5991030156168335e-09
) O 0 1.3586240577012632e-08
. O 0 1.791287047581136e-07

The O 0 5.652948971146543e-07
risk O 0 6.014761311234906e-06
decreased O 0 6.463756108132657e-08
with O 0 4.709151402160217e-10
increasing O 0 2.51641574244843e-09
duration O 0 1.4603903863985579e-08
of O 0 6.823600712246858e-11
use O 0 5.787179180316571e-09
( O 0 4.998896852015378e-10
P O 0 8.036841450120846e-07
for O 0 1.9284084051829353e-10
trend O 0 3.0164017061906634e-08
, O 0 6.023108123365262e-10
< O 0 1.0057189747669781e-08
0 O 0 1.5802720243485169e-09
. O 0 2.1129230309835378e-10
001 O 0 4.400798392367733e-09
) O 0 4.202431458377731e-11
; O 0 8.944251589371177e-12
use O 0 6.851562373011433e-11
for O 0 1.7759292300634222e-11
six O 0 3.679708968085116e-11
or O 0 1.132101357104176e-10
more O 0 1.1935448289424055e-11
years O 0 6.520814110899664e-09
was O 0 4.095998651365562e-09
associated O 0 1.9252294203297993e-10
with O 0 2.8296625459445224e-11
a O 0 4.638840700454949e-10
60 O 0 2.4489086314360975e-09
percent O 0 2.6061648839004192e-08
reduction O 0 3.990203367720824e-08
in O 0 4.055622682130888e-08
risk O 0 5.290071840136079e-06
. O 0 3.7079033177178644e-07

Oral O 0 1.3192065125622321e-05
- O 0 8.250827704614494e-06
contraceptive O 0 1.3508843949239235e-05
use O 0 9.076563856069697e-08
protected O 0 1.7840072814578889e-06
against O 0 0.026266101747751236
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999964237213135
both O 0 9.086359997745319e-10
for O 0 3.3207359084741483e-10
carriers O 0 7.426847137281811e-09
of O 0 1.583300157648182e-10
the O 0 2.860919057212641e-09
BRCA1 O 0 4.033224286104087e-06
mutation O 0 2.1595488419734465e-07
( O 0 1.354165779510197e-09
odds O 0 4.2503862118792313e-07
ratio O 0 3.418820071487971e-08
, O 0 3.763805378476093e-10
0 O 0 7.040840133143433e-10
. O 0 1.6696498350565747e-10
5 O 0 1.900380547370517e-10
; O 0 2.063870879753793e-10
95 O 0 1.0773908432071266e-09
percent O 0 6.563028165373908e-08
confidence O 0 6.712400413277919e-09
interval O 0 4.315201973525973e-09
, O 0 5.7498745348327773e-11
0 O 0 1.2232183321803092e-10
. O 0 6.025380194785157e-11
3 O 0 8.111190191728568e-11
to O 0 4.518502932926438e-11
0 O 0 3.0136615425391255e-10
. O 0 9.140972007104509e-11
9 O 0 8.539847301536341e-11
) O 0 1.6232501454105375e-11
and O 0 3.282835114859495e-11
for O 0 2.299863077759312e-11
carriers O 0 1.221281520358275e-09
of O 0 3.37776681624824e-11
the O 0 2.146951061376967e-09
BRCA2 O 0 2.928321009676438e-06
mutation O 0 6.517894490798426e-08
( O 0 5.859862040047403e-10
odds O 0 5.171128805159242e-07
ratio O 0 4.9508887656202205e-08
, O 0 2.462495485300309e-10
0 O 0 4.823391686059608e-10
. O 0 1.0342463691026538e-10
4 O 0 1.189690707059654e-10
; O 0 1.3920277430745642e-10
95 O 0 8.747705337874834e-10
percent O 0 8.1438500387776e-08
confidence O 0 7.854374040050516e-09
interval O 0 6.7237788670126974e-09
, O 0 1.1340204469911797e-10
0 O 0 3.980150653504211e-10
. O 0 1.4110043689008478e-10
2 O 0 1.8317800054568067e-10
to O 0 1.5229180416742594e-10
1 O 0 9.073647944113361e-10
. O 0 1.0703244956999924e-09
1 O 0 4.272288300910532e-09
) O 0 6.777250760592324e-09
. O 0 1.2022819362300652e-07

CONCLUSIONS O 0 2.3012744350126013e-06
Oral O 0 8.712095223017968e-07
- O 0 9.580087407812243e-07
contraceptive O 0 1.4509290622299886e-06
use O 0 1.7385819006676684e-08
may O 0 1.0470256661676558e-08
reduce O 0 5.811724879123403e-09
the O 0 1.229647161871128e-09
risk O 0 3.6609292237699265e-06
of O 0 3.018588756731333e-08
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
in O 0 3.136643833556718e-09
women O 0 1.0686666662707012e-08
with O 0 1.064203392076024e-09
pathogenic O 0 1.2747636901622172e-07
mutations O 0 1.4748295029676228e-07
in O 0 2.174123769904668e-09
the O 0 7.176836902544892e-09
BRCA1 O 0 2.9042199457762763e-05
or O 0 9.799877034311066e-07
BRCA2 O 0 0.00024519130238331854
gene O 0 0.00015936045383568853

A O 0 6.266703280743968e-07
Japanese O 0 1.4847503848613997e-07
family O 0 1.6356283438767605e-08
with O 0 4.13113276920285e-09
adrenoleukodystrophy B-Disease 1 0.9999991655349731
with O 0 1.4189079244886216e-08
a O 0 2.298529011568462e-08
codon O 0 1.2156218645031913e-06
291 O 0 5.410124970239849e-08
deletion O 0 2.254149364944169e-07
: O 0 1.4562534511597391e-09
a O 0 6.502379745754183e-10
clinical O 0 6.91315094059064e-08
, O 0 6.64233668068448e-10
biochemical O 0 1.3490523542714072e-07
, O 0 1.1212369921409504e-09
pathological O 0 1.0220345814104803e-07
, O 0 4.018560151308748e-09
and O 0 1.4759037547662501e-08
genetic O 0 1.0279627531417646e-05
report O 0 1.5281518699339358e-06
. O 0 3.659941114619869e-07

We O 0 1.4527277016895823e-06
report O 0 4.771578332452009e-08
a O 0 1.6826047222195939e-09
Japanese O 0 1.5278654785788603e-08
family O 0 9.281690083184913e-09
with O 0 7.492110043472167e-09
adrenoleukodystrophy B-Disease 1 1.0
( O 0 8.034783149923896e-08
ALD B-Disease 1 1.0
) O 0 7.227250353736281e-09
with O 0 4.1736289424498807e-10
a O 0 9.451004423510767e-10
three O 0 8.665454465095479e-10
base O 0 1.1311247938294855e-08
pair O 0 6.771064420263428e-08
deletion O 0 1.3889257388655096e-06
( O 0 3.0219229341099663e-09
delGAG O 0 1.248138374876362e-07
291 O 0 2.951887800861641e-08
) O 0 3.1126969890493683e-09
in O 0 3.975023865621097e-09
the O 0 8.839458587317495e-08
ALD B-Disease 1 0.9999996423721313
gene O 0 6.682780167466262e-06
. O 0 1.281543745790259e-06

A O 0 1.6089018117781961e-07
variety O 0 3.2367257318810516e-08
of O 0 1.3402439158483048e-09
phenotypes O 0 2.2371580143953906e-07
were O 0 2.646472596623539e-09
observed O 0 1.0162241714795073e-08
within O 0 2.9785640620616505e-09
this O 0 5.6317457364229995e-09
family O 0 1.7700519094887568e-07
. O 0 4.5372200929705286e-07

While O 0 2.807724683862034e-07
the O 0 9.03017927100791e-09
proband O 0 6.044335805199808e-07
( O 0 2.330795778604511e-09
patient O 0 1.370670066336288e-08
1 O 0 1.134754512577274e-09
) O 0 3.496715417217189e-10
was O 0 5.352018273008241e-10
classified O 0 2.4793449515669863e-09
as O 0 2.6336910430302396e-10
having O 0 8.50101045113405e-10
a O 0 9.453704485906655e-11
rare O 0 2.099206142247567e-09
intermediate O 0 8.90246365514713e-09
type O 0 9.560594804725042e-08
of O 0 5.127075985988938e-10
adult O 0 6.137213404144859e-07
cerebral O 0 4.6041390305617824e-05
and O 0 1.5609566972329958e-08
cerebello O 0 0.05260360240936279
- O 0 0.11920711398124695
brain O 0 2.082347964460496e-05
stem O 0 7.240955568477148e-08
forms O 0 1.8873064888680346e-08
, O 0 1.343086974969765e-09
his O 0 1.1962718593494515e-09
younger O 0 1.2139109273334725e-08
brother O 0 7.726102424499004e-09
( O 0 6.386495776666834e-10
patient O 0 1.1625760798494866e-08
2 O 0 1.4362463440775741e-09
) O 0 7.957921543955138e-10
and O 0 2.492626327565972e-09
nephew O 0 4.537700348805629e-08
( O 0 1.114023207016146e-09
patient O 0 1.380266745343306e-08
3 O 0 2.1071606681744015e-09
) O 0 2.278862210047805e-09
had O 0 3.158582373430363e-08
a O 0 6.377761252451819e-08
childhood O 0 0.0006430742796510458
ALD B-Disease 1 1.0
type O 0 0.1233290359377861
. O 0 1.8109196844307007e-06

Another O 0 6.147570275061298e-07
nephew O 0 7.891014774941141e-07
( O 0 9.518651644668807e-09
patient O 0 7.545000357822573e-08
4 O 0 1.846873320943132e-09
) O 0 5.134326852562765e-10
of O 0 1.2544755512156058e-10
patient O 0 3.7455830437238546e-08
1 O 0 5.876408248894904e-09
was O 0 3.0606774892305566e-09
classified O 0 8.956881458743737e-09
as O 0 1.4970135131520124e-09
having O 0 1.807459959479729e-08
an O 0 2.3564898921080157e-09
adolescent O 0 8.850489621181623e-07
form O 0 2.9338036711124005e-07
. O 0 6.514141546176688e-07

The O 0 1.3949801314083743e-07
tau O 0 1.4702877138006443e-07
level O 0 7.938554347219906e-08
in O 0 2.13043027663673e-09
the O 0 7.284462810730474e-09
cerebrospinal O 0 5.2637966291513294e-05
fluid O 0 9.344118439003068e-07
( O 0 8.832376607870174e-09
CSF O 0 8.266516488220077e-06
) O 0 4.589784108333106e-10
in O 0 2.4717183855216263e-10
patient O 0 7.835072146633593e-09
1 O 0 3.297202511021169e-09
was O 0 1.4829694805484905e-08
as O 0 2.2520364739708754e-10
high O 0 5.671887404190556e-10
as O 0 7.960194309264423e-11
that O 0 6.717311429316197e-11
of O 0 9.028981728942398e-11
patients O 0 2.4262121200990805e-08
with O 0 1.509953051481716e-08
Alzheimers B-Disease 1 0.981105387210846
disease I-Disease 0 1.2660947504627984e-05
( O 0 1.1268202371184088e-08
AD B-Disease 0 4.716383955383208e-06
) O 0 1.1086021345363406e-07
. O 0 3.2077267064778425e-07

His O 0 7.54259644963895e-07
brain O 0 1.2671879630943295e-05
magnetic O 0 6.177131126605673e-07
resonance O 0 3.2184470910578966e-06
image O 0 4.754762358061271e-06
( O 0 9.309224502374036e-09
MRI O 0 4.498693670029752e-06
) O 0 1.2722503051065814e-08
showed O 0 2.7909698019357165e-07
abnormalities B-Disease 0 8.946920570451766e-05
in I-Disease 0 1.4302050654890763e-09
the I-Disease 0 1.2234427915203128e-09
bilateral I-Disease 0 3.679293314462484e-08
cerebellar I-Disease 0 2.3464858713850845e-06
hemispheres I-Disease 0 4.813210398424417e-05
and O 0 3.532515790993784e-08
brain O 0 1.9876415535691194e-07
stem O 0 9.168395820324804e-09
, O 0 2.3393548209682535e-10
but O 0 7.068100549290079e-10
not O 0 2.891495654022691e-10
in O 0 1.3935075315885115e-10
the O 0 8.989686217653059e-10
cerebral O 0 1.1699254400809878e-06
white O 0 7.257823853024092e-08
matter O 0 7.970772930576686e-10
, O 0 7.933487200517675e-11
where O 0 2.1192517185575355e-10
marked O 0 1.0404059835877888e-09
reductions O 0 1.9486723346062718e-08
of O 0 6.634596344534671e-11
the O 0 1.273628758013956e-09
cerebral O 0 1.117294345931441e-06
blood O 0 5.460414698177374e-08
flow O 0 2.6898527849539278e-08
and O 0 7.300096083184826e-09
oxygen O 0 8.157339692616006e-09
metabolism O 0 6.011863007415741e-09
were O 0 3.840617546213565e-10
clearly O 0 1.3932530684712674e-09
demonstrated O 0 1.032474883366774e-09
by O 0 2.9299915271785437e-10
positron O 0 3.4713613672465726e-07
emission O 0 1.675697944847343e-07
tomography O 0 2.020257170443074e-06
( O 0 3.420131022835449e-08
PET O 0 9.979096375900554e-07
) O 0 9.391479949272252e-08
. O 0 2.851512590495986e-07

In O 0 2.4939598119999573e-07
patients O 0 5.875581337022595e-07
2 O 0 5.703349792440804e-09
and O 0 1.3794239084319315e-09
3 O 0 2.210009064640417e-09
, O 0 3.1663119348657176e-10
the O 0 5.676898395812202e-10
autopsy O 0 4.924378345094738e-07
findings O 0 2.0107945530867255e-08
showed O 0 3.537228820960081e-08
massive O 0 4.787084151303134e-08
demyelination B-Disease 1 0.9999997615814209
of I-Disease 0 2.5672126646725246e-09
the I-Disease 0 1.3590336855884289e-08
cerebral I-Disease 0 7.264517626026645e-05
white I-Disease 0 1.1266293853395837e-07
matter I-Disease 0 1.3364507278623705e-09
with O 0 8.779426491356546e-11
sparing O 0 2.0640253950432452e-09
of O 0 9.436284392760896e-11
the O 0 7.995623607648383e-10
U O 0 2.4345529254787834e-06
- O 0 1.0919642591034062e-05
fibers O 0 7.152438229240943e-06
, O 0 2.097368112519149e-10
compatible O 0 1.1580032488467396e-09
with O 0 1.720017184236866e-10
the O 0 8.228719372560533e-10
findings O 0 3.620655775193882e-08
of O 0 6.14135586829434e-09
childhood O 0 1.6420759493485093e-05
ALD B-Disease 1 0.9999996423721313
. O 0 1.6065741874626838e-06

Oleic O 0 0.01765521429479122
and O 0 3.223653720851871e-06
erucic O 0 0.00017870614829007536
acids O 0 9.998491350415861e-07
( O 0 3.49205819816234e-09
Lorenzos O 0 1.4607391563004057e-07
Oil O 0 2.7720211903670133e-08
) O 0 3.2117114523444457e-10
were O 0 1.7755506787064945e-10
administered O 0 8.403140405732756e-10
to O 0 4.446026324878005e-10
patients O 0 2.3663264681061946e-09
1 O 0 2.4575827484163426e-10
and O 0 2.0567149372485716e-10
4 O 0 3.8484343489741946e-10
, O 0 1.8762497111524112e-10
but O 0 1.1530575383389419e-09
sufficient O 0 3.8686089887107755e-09
effectiveness O 0 3.501838108377342e-08
was O 0 6.500175953050302e-09
not O 0 3.0694113917206778e-09
obtained O 0 3.839845064135261e-08
. O 0 1.3837124868132378e-07

The O 0 6.598940416324695e-08
findings O 0 2.68813966641801e-08
in O 0 9.493243968705656e-10
this O 0 1.8846857408050255e-10
family O 0 5.254229828999257e-10
suggest O 0 2.5944437709313206e-09
that O 0 7.918717070953818e-11
delGAG291 O 0 1.1267944799442375e-08
is O 0 1.1120737664072067e-10
part O 0 1.0861013477470038e-10
of O 0 4.60277371772122e-11
the O 0 6.013534670223919e-10
cause O 0 7.141007341004979e-09
of O 0 6.346241865351487e-10
Japanese O 0 1.472363237553509e-06
ALD B-Disease 1 0.9999998807907104
with O 0 1.6592988316688206e-08
phenotypic O 0 1.014295412460342e-05
variations O 0 7.708375960646663e-06
. O 0 1.9268277355877217e-06

Moreover O 0 2.7139221856486984e-06
, O 0 1.2883722533274522e-08
although O 0 2.6972133415625876e-09
the O 0 2.0313969950613853e-10
scale O 0 2.074576421762231e-08
of O 0 6.115154910224518e-11
the O 0 2.6088228799459046e-10
study O 0 5.434506178403353e-10
is O 0 8.632999870528124e-11
limited O 0 4.478965809351365e-10
, O 0 7.089794723524889e-11
there O 0 1.1341545758103422e-10
is O 0 9.889442736943366e-11
a O 0 1.0814420192684082e-10
possibility O 0 2.4165953682597774e-09
that O 0 1.7814737185428697e-10
PET O 0 4.293126298904326e-09
can O 0 1.8532956280736812e-09
detect O 0 4.720077697584202e-07
an O 0 7.224904008396038e-10
insidious B-Disease 0 3.213111085642595e-06
lesion I-Disease 1 0.7859289646148682
which O 0 1.5200667391468414e-08
is O 0 3.0303670683906603e-09
undetectable O 0 4.2295376090351056e-08
by O 0 1.0847722026197104e-10
computed O 0 2.0682982437847386e-08
tomogram O 0 1.603766719426858e-07
( O 0 5.29556065664849e-10
CT O 0 0.0011241328902542591
) O 0 9.030071135285311e-10
or O 0 9.991298899336698e-10
MRI O 0 2.838998511833779e-07
analysis O 0 2.5970678940723246e-09
, O 0 5.465241106894503e-11
and O 0 1.1861199522567034e-10
that O 0 1.2741674382255042e-10
the O 0 2.93047197619245e-10
higher O 0 2.0755935636884715e-08
level O 0 4.024289790294233e-09
of O 0 4.191177266354984e-11
tau O 0 9.507395981600553e-10
reflects O 0 8.014677810308513e-10
the O 0 5.799128885430882e-11
process O 0 1.3678983501463904e-09
of O 0 5.934571167820479e-10
neuronal B-Disease 0 8.037064276322781e-07
degeneration I-Disease 0 4.8165620682993904e-05
in O 0 7.460063216058188e-07
ALD B-Disease 1 1.0
. O 0 2.643447942318744e-06

Lorenzos O 0 2.5319533961010166e-05
Oil O 0 1.7653059103395208e-06
should O 0 7.481028241329568e-09
be O 0 3.190354647131244e-10
given O 0 2.4439844592549775e-10
in O 0 1.4219382615809906e-10
the O 0 5.49081169420873e-10
early O 0 5.4367411905786867e-08
stage O 0 7.598310389766993e-07
. O 0 3.229947864724636e-08
. O 0 1.6782024658823502e-07

Nonsense O 0 0.00010658679821062833
mutation O 0 8.04330557002686e-06
in O 0 1.8692933423380964e-08
exon O 0 6.713926268275827e-07
4 O 0 3.370454138007517e-08
of O 0 1.20584287000014e-09
human O 0 7.85320608542861e-09
complement O 0 5.233970767903884e-08
C9 O 0 5.288803208713944e-07
gene O 0 5.7851622159432736e-08
is O 0 2.4509974050346273e-09
the O 0 6.436266519749267e-10
major O 0 1.684422912262562e-08
cause O 0 2.156547651566143e-08
of O 0 1.6175958350572728e-09
Japanese O 0 6.263859404498362e-07
complement B-Disease 0 6.1706514316028915e-06
C9 I-Disease 0 0.042399901896715164
deficiency I-Disease 0 0.1793091744184494
. O 0 7.980544296515291e-07

Deficiency B-Disease 1 0.9554385542869568
of I-Disease 0 3.2582607722986268e-09
the I-Disease 0 1.973903263063903e-09
ninth I-Disease 0 1.4225066458095625e-08
component I-Disease 0 4.168350642430596e-08
of I-Disease 0 3.8515993172616447e-10
human I-Disease 0 1.5310795964396107e-09
complement I-Disease 0 1.004815963767669e-08
( O 0 2.9204619278466737e-10
C9 O 0 5.609172148979269e-08
) O 0 1.9678235430031776e-10
is O 0 2.9247750055194643e-11
the O 0 2.9106619892083074e-11
most O 0 1.4624551569752953e-09
common O 0 6.304539965640288e-07
complement B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 1.4358546573944864e-09
Japan O 0 5.747884390672198e-09
but O 0 1.9788601868242495e-09
is O 0 2.0200298378458825e-10
rare O 0 7.011544678192649e-10
in O 0 4.6065529168970443e-10
other O 0 1.1325813620288727e-09
countries O 0 1.295063789541473e-08
. O 0 1.6333905250576208e-07

We O 0 3.867748148422834e-07
studied O 0 5.643727263304754e-08
the O 0 1.0228664582001556e-09
molecular O 0 1.7454063083732763e-08
basis O 0 7.591709483278919e-09
of O 0 7.09598468873196e-09
C9 B-Disease 0 0.2724793255329132
deficiency I-Disease 0 0.02976345084607601
in O 0 9.930938293933878e-10
four O 0 1.937405125218561e-09
Japanese O 0 7.674084656628111e-08
C9 B-Disease 0 0.00022651467588730156
- I-Disease 0 5.960970156593248e-05
deficient I-Disease 0 2.760135203061509e-06
patients O 0 1.946287753185061e-08
who O 0 5.067422925719711e-09
had O 0 9.39355828677435e-08
suffered O 0 0.0009141101618297398
from O 0 3.78423152369578e-07
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 1.0
. O 0 5.906046681047883e-06

Direct O 0 2.3215832243295154e-06
sequencing O 0 2.6595298550091684e-06
of O 0 5.5126861298049334e-08
amplified O 0 3.4615006825333694e-06
C9 O 0 1.0266361641697586e-05
cDNA O 0 1.0673454653442604e-06
and O 0 4.0506286325125984e-08
DNA O 0 2.949212500880094e-07
revealed O 0 9.061237449259352e-08
a O 0 4.843140999355455e-09
nonsense O 0 1.565799863101347e-07
substitution O 0 2.4163524514619894e-08
( O 0 3.468975995346568e-09
CGA O 0 5.046514957030013e-07
- O 0 1.8436804793964257e-06
- O 0 9.18315038234141e-07
> O 0 9.506824483196397e-08
TGA O 0 1.1430802260292694e-06
) O 0 2.3236048640740137e-09
at O 0 8.346625612887237e-10
codon O 0 1.734699850430843e-08
95 O 0 8.964448072745768e-10
in O 0 1.9446604049289107e-10
exon O 0 1.6419548387602845e-08
4 O 0 2.555000211401648e-09
in O 0 5.488455245838963e-10
the O 0 1.3850711688689898e-09
four O 0 3.23553450698455e-08
C9 B-Disease 0 0.0030226903036236763
- I-Disease 0 0.0008630138472653925
deficient I-Disease 0 4.716680996352807e-05
individuals O 0 1.1312320680190169e-07
. O 0 2.0950596990587655e-07

An O 0 5.254485699879297e-07
allele O 0 2.03389809030341e-05
- O 0 2.999654498125892e-06
specific O 0 7.04450044963778e-08
polymerase O 0 4.531671606855525e-07
chain O 0 1.3364127653403557e-06
reaction O 0 4.38306635430763e-08
system O 0 5.9852962586148806e-09
designed O 0 9.849732585109905e-09
to O 0 2.4041396651242053e-10
detect O 0 1.4386160707147155e-08
exclusively O 0 4.840007838957661e-10
only O 0 9.083166857548619e-11
one O 0 5.94800805830964e-11
of O 0 1.0515913660691378e-11
the O 0 1.233649571386053e-10
normal O 0 2.308131685779813e-09
and O 0 7.227026754819121e-10
mutant O 0 1.298499352486715e-08
alleles O 0 1.0054006516213576e-08
indicated O 0 2.8114548467073064e-09
that O 0 1.0110706716304207e-10
all O 0 2.9890156322265327e-11
the O 0 4.1286234847559555e-11
four O 0 3.015748761825421e-10
patients O 0 1.1119895004796376e-09
were O 0 4.904105940783943e-11
homozygous O 0 3.1181521809031665e-09
for O 0 4.5658136993420584e-11
the O 0 1.131419263833422e-10
mutation O 0 7.05949521062621e-09
in O 0 1.2073587962735388e-10
exon O 0 1.4512105295239053e-08
4 O 0 1.1479291961435933e-09
and O 0 8.123519079639152e-10
that O 0 2.831634648980952e-10
the O 0 3.0989286137206307e-10
parents O 0 3.0347977464373344e-09
of O 0 1.951050571102897e-10
patient O 0 2.990850944684098e-08
2 O 0 7.93661314446581e-09
were O 0 1.584739983684358e-08
heterozygous O 0 2.179640659960569e-06
. O 0 4.006443816706451e-07

The O 0 2.108187544536122e-07
common O 0 2.0637614284169103e-07
mutation O 0 5.939831453360966e-07
at O 0 1.2022264961331075e-08
codon O 0 1.2438984242635343e-07
95 O 0 3.291459327314783e-09
in O 0 2.336402737945775e-10
exon O 0 1.9229855041658084e-08
4 O 0 2.8955702280342166e-09
might O 0 3.92125754089534e-09
be O 0 2.4257332253974084e-10
responsible O 0 5.159467852955402e-10
for O 0 1.4858191066391413e-10
most O 0 5.648269407743101e-09
Japanese O 0 2.5229924176528584e-06
C9 B-Disease 0 0.017887506633996964
deficiency I-Disease 0 0.0008800030336715281
. O 0 3.0574465625932135e-08
. O 0 1.6669204683239514e-07

BRCA1 O 0 0.0001503479143138975
required O 0 2.140982360288035e-07
for O 0 7.371988353099823e-09
transcription O 0 4.350326605617738e-07
- O 0 0.0007287375046871603
coupled O 0 7.003130122029688e-06
repair O 0 3.718301741173491e-05
of O 0 8.970096665450455e-09
oxidative O 0 3.4819588563550496e-06
DNA O 0 1.6578504073549993e-05
damage O 0 0.00016280515410471708
. O 0 1.5253809806381469e-06

The O 0 2.85967121271824e-06
breast B-Disease 1 0.9998012185096741
and I-Disease 1 0.9998519420623779
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
susceptibility O 0 0.00016057076572906226
gene O 0 1.929214886331465e-05
BRCA1 O 0 6.907004717504606e-05
encodes O 0 2.7631508601189125e-06
a O 0 3.802427954724408e-07
zinc O 0 0.0009680995135568082
finger O 0 1.439563675376121e-05
protein O 0 4.789458785126044e-07
of O 0 7.353647912822225e-09
unknown O 0 6.687802169835777e-07
function O 0 1.2188618256914197e-06
. O 0 1.509069761596038e-06

Association O 0 9.08712763703079e-07
of O 0 9.695361846695505e-09
the O 0 1.055016163320488e-08
BRCA1 O 0 1.2843419199271011e-06
protein O 0 2.7924839329784845e-08
with O 0 1.6933418001130462e-09
the O 0 3.2651663595117952e-09
DNA O 0 6.655137667621602e-07
repair O 0 1.4532196246364038e-06
protein O 0 4.7397492153322673e-08
Rad51 O 0 8.250837595369376e-07
and O 0 3.1618720974790904e-09
changes O 0 3.5550422605723497e-09
in O 0 1.1585615800058235e-10
the O 0 3.837774542603256e-11
phosphorylation O 0 2.155066347597767e-09
and O 0 1.2769635349130226e-09
cellular O 0 2.0841026682205666e-08
localization O 0 1.0898751234833526e-08
of O 0 9.165239400754643e-11
the O 0 1.4975667927963343e-10
protein O 0 2.2871093907639306e-09
after O 0 2.0337900252798136e-09
exposure O 0 5.99533080958281e-08
to O 0 3.253849412132581e-10
DNA O 0 1.2631413426333893e-07
- O 0 1.930131361405074e-07
damaging O 0 5.404029934652499e-08
agents O 0 7.266685919660176e-09
are O 0 2.2850067671331686e-10
consistent O 0 1.326578957794311e-09
with O 0 8.809166590628692e-11
a O 0 9.026575598092279e-10
role O 0 1.7508414273947892e-08
for O 0 3.2186611154116918e-09
BRCA1 O 0 1.8475932392902905e-06
in O 0 2.3010688465774365e-08
DNA O 0 6.043221674190136e-06
repair O 0 0.00017939826648216695
. O 0 6.504208727164951e-07

Here O 0 1.7301917409895395e-07
, O 0 3.314928331832334e-09
it O 0 6.794254048259063e-10
is O 0 3.0934479977595686e-10
shown O 0 2.6774233941040393e-09
that O 0 1.0752393420077055e-09
mouse O 0 1.7370281568673818e-07
embryonic O 0 2.7325148721502046e-07
stem O 0 5.252562118585047e-07
cells O 0 4.2435857494638185e-07
deficient B-Disease 0 1.1355754168107524e-06
in I-Disease 0 1.4644230272864434e-09
BRCA1 I-Disease 0 1.7675957053597813e-07
are O 0 5.082385623467189e-10
defective O 0 2.305989710293943e-08
in O 0 2.708496760206458e-10
the O 0 5.89599341571656e-11
ability O 0 1.6899603938469454e-09
to O 0 1.3608116022911787e-10
carry O 0 1.1196683580294575e-09
out O 0 2.8938459961658225e-10
transcription O 0 3.203443199595313e-08
- O 0 5.398311486715102e-07
coupled O 0 2.9425345360323263e-07
repair O 0 1.239782250195276e-06
of O 0 2.700346890538441e-10
oxidative O 0 8.588931166286784e-08
DNA O 0 2.8332050305834855e-07
damage O 0 1.7794601490095374e-06
, O 0 3.2088273704822257e-10
and O 0 2.976018598221941e-10
are O 0 3.5247249563497007e-10
hypersensitive O 0 1.0436426123305864e-07
to O 0 2.9805189427634105e-09
ionizing O 0 8.185692763618135e-07
radiation O 0 1.774763973116933e-06
and O 0 1.9949066398794457e-08
hydrogen O 0 4.506786979163735e-07
peroxide O 0 4.0583508962299675e-05
. O 0 7.900825949036516e-07

These O 0 8.531035433634315e-08
results O 0 1.0049178200688402e-07
suggest O 0 1.9009407381531673e-08
that O 0 1.2893646150757831e-09
BRCA1 O 0 1.7518108563763235e-07
participates O 0 6.445250111397627e-09
, O 0 1.9908601156526373e-10
directly O 0 6.55527909732001e-10
or O 0 1.618249978463382e-09
indirectly O 0 1.4873887010935505e-08
, O 0 5.238439682031526e-10
in O 0 3.0126384720219335e-10
transcription O 0 6.010420605662148e-08
- O 0 0.001057756133377552
coupled O 0 2.906713461925392e-06
repair O 0 8.111950592137873e-06
of O 0 1.8005084090333412e-09
oxidative O 0 7.084870503604179e-07
DNA O 0 3.470978072073194e-06
damage O 0 5.605028945865342e-06
. O 0 5.279198234120486e-08
. O 0 1.9252466643138177e-07

Truncation O 0 0.00011561112478375435
mutations O 0 1.6349897123291157e-05
in O 0 4.131961972575482e-08
the O 0 8.163675069283727e-09
transactivation O 0 5.724239599658176e-06
region O 0 2.2910538177711715e-07
of O 0 2.768960172261359e-09
PAX6 O 0 4.086019998794654e-06
result O 0 8.49304484518143e-08
in O 0 3.851666985354996e-09
dominant O 0 6.708801811328158e-05
- O 0 0.002960133831948042
negative O 0 6.052645858289907e-06
mutants O 0 7.848162567825057e-06
. O 0 3.659983178749826e-07

PAX6 O 0 0.0004051284631714225
is O 0 2.1205804046076082e-07
a O 0 9.518923427265236e-09
transcription O 0 4.3247371905863474e-08
factor O 0 4.587600344052589e-08
with O 0 7.902471454990234e-10
two O 0 1.2133015703241767e-09
DNA O 0 9.337784945273597e-07
- O 0 2.4970422600745223e-06
binding O 0 1.1273753131035846e-07
domains O 0 1.2794843939900602e-07
( O 0 1.2093230861154325e-09
paired O 0 5.576082884317657e-08
box O 0 1.4892911792685481e-07
and O 0 5.953745940701083e-09
homeobox O 0 4.085826219579758e-07
) O 0 1.550206296663248e-09
and O 0 5.590133911326234e-10
a O 0 1.0991958454553696e-09
proline O 0 3.8627129583801434e-07
- O 0 2.0119000510021579e-07
serine O 0 1.2392798680593842e-06
- O 0 5.831519729326828e-07
threonine O 0 8.4522946508514e-07
( O 0 2.2086268369747586e-09
PST O 0 3.8709438854311884e-07
) O 0 7.544693758632093e-09
- O 0 3.3979557656493853e-07
rich O 0 3.9612140767530946e-07
transactivation O 0 2.616084020701237e-05
domain O 0 3.089898200414609e-06
. O 0 9.983932613977231e-07

PAX6 O 0 0.0008021245594136417
regulates O 0 4.607802111422643e-05
eye O 0 0.12091180682182312
development O 0 3.4726120645700576e-08
in O 0 1.731135790272731e-09
animals O 0 8.530897654956959e-10
ranging O 0 1.6224006582632455e-09
from O 0 5.300673788788401e-10
jellyfish O 0 1.1613217054673441e-08
to O 0 4.924833318931121e-10
Drosophila O 0 6.298360055723151e-09
to O 0 2.433250712030599e-09
humans O 0 5.3667534416490525e-08
. O 0 1.747232545312727e-07

Heterozygous O 0 0.00023711808898951858
mutations O 0 3.597086470108479e-05
in O 0 3.86790226514222e-08
the O 0 7.319476136302683e-09
human O 0 2.052226300008897e-08
PAX6 O 0 1.96517794393003e-06
gene O 0 1.7917055572524987e-07
result O 0 1.2837874763249602e-08
in O 0 2.664476972391583e-10
various O 0 4.956250410081964e-10
phenotypes O 0 8.323041100766204e-08
, O 0 4.111094520364844e-10
including O 0 1.987681574888711e-09
aniridia B-Disease 1 1.0
, O 0 1.8293209791409026e-07
Peters B-Disease 1 0.9999998807907104
anomaly I-Disease 1 0.9999998807907104
, O 0 1.2102563573535008e-07
autosomal B-Disease 0 0.01736617274582386
dominant I-Disease 0 0.021817483007907867
keratitis I-Disease 1 0.9874159693717957
, O 0 1.9606405032845942e-07
and O 0 4.253232646078686e-07
familial B-Disease 1 0.9863727688789368
foveal I-Disease 1 0.989956259727478
dysplasia I-Disease 1 0.9996926784515381
. O 0 2.4469069103361107e-05

It O 0 7.322732642478513e-08
is O 0 2.0057793204131258e-09
believed O 0 2.203703441949756e-09
that O 0 1.7662282747465952e-10
the O 0 2.1234353164700792e-10
mutated O 0 1.1187214710162152e-07
allele O 0 2.5998204478128173e-07
of O 0 1.036583152647097e-09
PAX6 O 0 1.1573048368518357e-06
produces O 0 9.501781583765023e-09
an O 0 2.2162890966903603e-10
inactive O 0 7.368150978237509e-09
protein O 0 4.148765331279947e-09
and O 0 2.430458057034457e-09
aniridia B-Disease 1 1.0
is O 0 1.366264683611007e-07
caused O 0 7.406352153793705e-08
due O 0 1.854399656053829e-08
to O 0 9.86793491364324e-09
genetic O 0 1.7936869198820204e-06
haploinsufficiency O 0 1.8255306713399477e-05
. O 0 5.312288635650475e-07

However O 0 2.8291117359913187e-07
, O 0 2.7135813596146363e-09
several O 0 1.2774239444013347e-09
truncation O 0 2.692052589736704e-07
mutations O 0 5.491926344802778e-07
have O 0 4.95387109111789e-09
been O 0 1.8511264743281686e-09
found O 0 6.027038312872435e-10
to O 0 2.1248776349569454e-10
occur O 0 7.896986953248586e-10
in O 0 1.565239327039336e-10
the O 0 6.895458648514818e-10
C O 0 8.638552912998421e-07
- O 0 1.958543691671366e-07
terminal O 0 2.2613281203121005e-07
half O 0 3.1148590373675233e-09
of O 0 2.3056136166932362e-10
PAX6 O 0 5.788610906165559e-07
in O 0 2.548575794847352e-09
patients O 0 1.519869741173352e-08
with O 0 2.1647061920759825e-09
Aniridia B-Disease 1 1.0
resulting O 0 8.980816801340552e-08
in O 0 1.6686191317560883e-09
mutant O 0 2.5423576133221104e-08
proteins O 0 2.4691608757620997e-09
that O 0 4.5941980775232594e-10
retain O 0 1.3736955573051546e-08
the O 0 4.95944674216986e-10
DNA O 0 1.080528093666544e-07
- O 0 4.721739088608956e-08
binding O 0 7.354573394735553e-09
domains O 0 7.1960544190119435e-09
but O 0 3.849104146524951e-09
have O 0 8.59954440990407e-10
lost O 0 8.461688238980969e-09
most O 0 2.467563653407723e-10
of O 0 2.700392964793963e-10
the O 0 5.972524252939593e-09
transactivation O 0 1.6794441762613133e-05
domain O 0 4.303838068153709e-06
. O 0 6.57152668281924e-07

It O 0 8.322565037133245e-08
is O 0 1.9407151441441783e-09
not O 0 5.428238969429344e-10
clear O 0 5.223792509667646e-10
whether O 0 1.977410457598694e-10
such O 0 1.5367136729782516e-10
mutants O 0 6.43723012672126e-08
really O 0 1.9007414309157866e-08
behave O 0 2.4241710860906096e-09
as O 0 3.839980000641674e-10
loss O 0 5.146457926485937e-09
- O 0 5.550806392307095e-08
of O 0 4.426716493366456e-10
- O 0 1.8878123455579043e-06
function O 0 2.0927386046309948e-08
mutants O 0 1.0997504773513356e-07
as O 0 2.294414880310569e-09
predicted O 0 3.8887996822722926e-08
by O 0 7.436159243923157e-09
haploinsufficiency O 0 5.874186626897426e-06
. O 0 4.559524597880227e-07

Contrary O 0 5.884105007680773e-07
to O 0 4.267580955286121e-09
this O 0 1.837690555284155e-10
theory O 0 6.709171551655402e-10
, O 0 1.6766769916909396e-10
our O 0 1.3708256751954195e-10
data O 0 8.962516839794432e-10
showed O 0 8.425400377376491e-10
that O 0 2.9011838070802654e-11
these O 0 4.436062628343507e-11
mutants O 0 5.6726365826875735e-09
are O 0 2.1903222291452806e-10
dominant O 0 4.360103673661797e-07
- O 0 1.9484794393065386e-05
negative O 0 4.040501551116904e-07
in O 0 7.891807207727197e-10
transient O 0 2.248738084631441e-08
transfection O 0 4.113013005735411e-07
assays O 0 2.6830383603737573e-07
when O 0 3.953617877527904e-09
they O 0 6.903078109132821e-10
are O 0 1.4032025541510507e-10
coexpressed O 0 3.588685260069724e-08
with O 0 1.2396955684224054e-09
wild O 0 5.235668254499615e-08
- O 0 6.709608715027571e-05
type O 0 5.024639540351927e-05
PAX6 O 0 0.0003234648611396551
. O 0 1.5745044947834685e-06

We O 0 3.2106834169098875e-07
found O 0 4.6263313180361365e-09
that O 0 1.5127188390806623e-10
the O 0 1.7167361976433426e-10
dominant O 0 5.19062552939431e-07
- O 0 0.0001577229704707861
negative O 0 1.6812356989248656e-05
effects O 0 4.8579922804492526e-06
result O 0 7.803528490057943e-09
from O 0 9.495104702494928e-11
the O 0 1.3311812763205921e-10
enhanced O 0 6.833024812635813e-09
DNA O 0 2.0050345383992862e-08
binding O 0 6.8640741979209e-09
ability O 0 3.941037274302062e-09
of O 0 2.0946334944316192e-10
these O 0 3.380180357837048e-09
mutants O 0 1.0279510433974792e-06
. O 0 2.2249831488352356e-07

Kinetic O 0 4.156135673838435e-06
studies O 0 4.41392302263921e-07
of O 0 1.2000105353848767e-09
binding O 0 8.962472719531434e-08
and O 0 8.83931949857697e-09
dissociation O 0 2.4589760982962616e-07
revealed O 0 4.645069751063602e-08
that O 0 5.487963417039055e-10
various O 0 5.727897600671383e-10
truncation O 0 1.1514706699244925e-07
mutants O 0 1.2340522914655594e-07
have O 0 2.057649828302033e-09
3 O 0 1.2243837055336826e-09
- O 0 3.967920747527387e-08
5 O 0 7.787471112408184e-09
- O 0 6.577715794264805e-08
fold O 0 6.92640185206983e-08
higher O 0 3.4699885187450263e-09
affinity O 0 1.8397257051105953e-09
to O 0 6.60472301849957e-11
various O 0 9.952322299611183e-11
DNA O 0 1.4650858304321446e-08
- O 0 3.381599222862519e-09
binding O 0 8.029489850791549e-10
sites O 0 1.7013902509077639e-09
when O 0 1.1925083143182746e-09
compared O 0 3.433900108706922e-10
with O 0 3.122845038117106e-11
the O 0 3.250611446681262e-10
wild O 0 3.0299581510462303e-08
- O 0 4.87517609144561e-05
type O 0 1.0950469913950656e-05
PAX6 O 0 0.0001152564727817662
. O 0 6.142378197182552e-07

These O 0 6.449015899079313e-08
results O 0 4.1173372267166997e-08
provide O 0 3.098735268380892e-09
a O 0 8.738650358885991e-10
new O 0 1.5203646119843484e-09
insight O 0 4.936949071776553e-09
into O 0 3.845954110737182e-10
the O 0 2.5209012655125207e-10
role O 0 8.915072235993193e-09
of O 0 1.0786430637566014e-09
mutant O 0 4.2954550849572115e-07
PAX6 O 0 6.863304406579118e-06
in O 0 2.6666304719924483e-08
causing O 0 7.424307568726363e-07
aniridia B-Disease 1 0.9999992847442627
. O 0 4.4311900637694634e-07
. O 0 7.304304858735122e-07

Reversal O 0 7.744639879092574e-05
of O 0 4.4906209950568154e-07
severe O 0 0.031955089420080185
hypertrophic B-Disease 1 0.9839194416999817
cardiomyopathy I-Disease 1 1.0
and O 0 3.2495523782927194e-07
excellent O 0 3.5623961025521567e-07
neuropsychologic O 0 4.133068614464719e-06
outcome O 0 1.0806063954760248e-07
in O 0 2.9965363523842825e-09
very B-Disease 0 2.1820765638835837e-08
- I-Disease 0 3.081606701016426e-05
long I-Disease 0 2.295216290804092e-06
- I-Disease 0 3.6712326618726365e-06
chain I-Disease 0 7.294994702533586e-06
acyl I-Disease 0 7.322520559682744e-06
- I-Disease 0 5.426637017080793e-06
coenzyme I-Disease 0 6.022888555889949e-06
A I-Disease 0 1.5806954252184369e-06
dehydrogenase I-Disease 0 0.0010824373457580805
deficiency I-Disease 0 0.005362963303923607
. O 0 1.0236124126095092e-06

Very B-Disease 0 5.204571607464459e-06
- I-Disease 0 0.0005295398295857012
long I-Disease 0 3.6438339066080516e-06
- I-Disease 0 7.63715070206672e-06
chain I-Disease 0 4.760365300171543e-06
acyl I-Disease 0 6.733176633133553e-06
- I-Disease 0 2.570585820649285e-06
coenzyme I-Disease 0 4.5434683215717087e-07
A I-Disease 0 1.785196523940158e-08
dehydrogenase I-Disease 0 8.59709018641297e-07
( I-Disease 0 5.531019198201648e-09
VLCAD I-Disease 0 2.680297029655776e-06
) I-Disease 0 5.333049557521008e-08
deficiency I-Disease 0 1.420468652213458e-05
is O 0 3.9707654941878445e-09
a O 0 2.5743631226760044e-08
disorder O 0 0.00011704673670465127
of O 0 1.2855291275926106e-09
fatty O 0 6.12639496466727e-07
acid O 0 9.647256860034759e-08
beta O 0 8.438769683039027e-09
oxidation O 0 5.90467585936949e-09
that O 0 7.55683182696032e-10
reportedly O 0 4.089131167006599e-08
has O 0 2.773484775175916e-09
high O 0 8.53700576897154e-09
rates O 0 5.841109995685656e-08
of O 0 1.1099827723626277e-09
morbidity O 0 2.3022552340989932e-05
and O 0 8.430825459981861e-08
mortality O 0 4.218144113110611e-06
. O 0 4.3344903133402113e-07

We O 0 2.3935828608045995e-07
describe O 0 8.221071823300008e-08
the O 0 1.3864560610699073e-09
outcome O 0 6.3041407649677694e-09
of O 0 5.0041606275419426e-11
a O 0 3.6439579131908317e-10
5 O 0 1.0569229935697422e-09
- O 0 9.406520717902822e-08
year O 0 1.0533252492450629e-08
- O 0 1.8189576849181321e-06
old O 0 2.942028231700533e-06
girl O 0 2.804355574426154e-07
with O 0 6.864374846315968e-09
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
who O 0 5.771768396556354e-09
was O 0 5.006215442193707e-10
first O 0 1.6212954589978068e-10
seen O 0 3.649023083696079e-09
at O 0 2.490301298507802e-10
5 O 0 7.995161477314383e-11
months O 0 4.873904613234004e-10
of O 0 3.9337633844782616e-11
age O 0 8.241289428667642e-09
with O 0 1.927858761519019e-08
severe O 1 0.8911974430084229
hypertrophic B-Disease 1 0.9992707371711731
cardiomyopathy I-Disease 1 1.0
, O 0 1.971888877960737e-06
hepatomegaly B-Disease 1 1.0
, O 0 1.4166127471071377e-07
encephalopathy B-Disease 0 9.172732097795233e-05
, O 0 2.759487394143889e-08
and O 0 1.0416261631007728e-07
hypotonia B-Disease 0 0.00015623286890331656
. O 0 3.449841187830316e-06

Biochemical O 0 0.0005176192498765886
studies O 0 0.0001330274681095034
indicated O 0 0.1995309293270111
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
caused O 0 6.354205197567353e-07
by O 0 2.5083699561889716e-09
a O 0 1.686309758497373e-08
stable O 0 6.801974450354464e-07
yet O 0 3.11399389829603e-07
inactive O 0 1.873936071206117e-06
enzyme O 0 3.250455847592093e-06
. O 0 3.6427459804144746e-07

Molecular O 0 2.1136536815902218e-05
genetic O 0 7.938680937513709e-06
analysis O 0 2.2787770603827084e-07
of O 0 3.106670920516308e-09
her O 0 1.3539565202336235e-07
VLCAD O 0 8.687182344147004e-06
gene O 0 6.686213964712806e-07
revealed O 0 4.800118063030823e-07
a O 0 1.4589260466379983e-08
T1372C O 0 7.898234457570652e-07
( O 0 5.565550242891959e-09
F458L O 0 5.415125770014129e-07
) O 0 1.5473711201252627e-08
missense O 0 5.687606972060166e-06
mutation O 0 4.631809133570641e-06
and O 0 7.555627945521337e-08
a O 0 6.178863145578362e-07
1668 O 0 0.1668653041124344
ACAG O 0 0.002877953462302685
1669 O 0 2.526574462535791e-05
splice O 0 6.150444824015722e-05
site O 0 4.838821951125283e-06
mutation O 0 6.201228825375438e-05
. O 0 4.226737473800313e-06

After O 0 4.1409967366234923e-07
initial O 0 8.917133698105317e-08
treatment O 0 1.9297166531373477e-08
with O 0 3.487330424434276e-10
intravenous O 0 3.841317308683756e-08
glucose O 0 1.4895811091264477e-06
and O 0 2.8894904247067643e-09
carnitine O 0 5.522578021555091e-07
, O 0 1.3077546823225816e-09
the O 0 2.8035709864759895e-10
patient O 0 1.5427062294293137e-08
has O 0 1.559084195079663e-09
thrived O 0 3.457596520206607e-08
on O 0 1.2622382028482093e-09
a O 0 3.2488778334283097e-09
low O 0 2.722357521633967e-07
- O 0 1.6998542662349791e-07
fat O 0 5.600010410944378e-08
diet O 0 1.0843926645520696e-08
supplemented O 0 3.607714793574246e-09
with O 0 8.450603550258506e-10
medium O 0 1.793451019693748e-06
- O 0 3.984682450663968e-07
chain O 0 1.6378811551476247e-06
triglyceride O 0 1.7564207155373879e-06
oil O 0 2.755348873506591e-07
and O 0 2.734285242667056e-09
carnitine O 0 2.8039542598889966e-07
and O 0 2.6250013274164985e-09
avoidance O 0 7.054934769712418e-08
of O 0 5.0462807266171694e-09
fasting O 0 2.321029569429811e-06
. O 0 5.924217134634091e-07

Her O 0 4.304264803067781e-05
ventricular O 0 3.776188168558292e-05
hypertrophy O 0 1.9855526261380874e-05
resolved O 0 6.147681688162265e-07
significantly O 0 7.041894178883013e-08
over O 0 1.7077070868509736e-09
1 O 0 2.1680284234548708e-09
year O 0 1.1085926621134945e-09
, O 0 1.0249594922795424e-10
and O 0 2.1290724738776134e-10
cognitively O 0 3.2823141538074196e-08
, O 0 2.9087762754009816e-10
she O 0 3.590616159954152e-08
is O 0 9.861132743704815e-11
in O 0 1.1615553657806643e-10
the O 0 1.9394671979533484e-10
superior O 0 1.3403878007522962e-08
range O 0 1.0043120113323312e-08
for O 0 3.852431262885148e-09
age O 0 1.3351511540804495e-07
. O 0 2.2466767291007272e-07

Clinical O 0 3.2969339372357354e-05
recognition O 0 7.452120485140767e-07
of O 0 1.3583967017893883e-07
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
is O 0 2.4867286008145584e-09
important O 0 4.2964007351820044e-10
because O 0 2.3204338450710793e-09
it O 0 2.52490972574293e-10
is O 0 3.608454507419978e-11
one O 0 5.837827443677668e-11
of O 0 1.1159064124133256e-11
the O 0 7.231724941103579e-11
few O 0 4.263138730919991e-09
directly O 0 3.386118407888716e-08
treatable O 0 0.05525444075465202
causes O 0 1.6543404868230027e-08
of O 0 2.1182826603904914e-09
cardiomyopathy B-Disease 1 0.9999996423721313
in O 0 2.984861424693008e-08
children O 0 5.953010884240939e-08
. O 0 2.4203883342011068e-08
. O 0 4.206451933441713e-07

Cloning O 0 1.2406989071678254e-06
of O 0 6.759319326476998e-09
a O 0 4.483429627555324e-09
novel O 0 1.9096116687933318e-08
member O 0 9.29906929236779e-10
of O 0 1.256257042836495e-10
the O 0 3.3410358923902095e-09
low O 0 0.0002049386821454391
- O 0 0.015809085220098495
density O 0 2.9414165965135908e-06
lipoprotein O 0 0.00013368947838898748
receptor O 0 1.5969299056450836e-05
family O 0 1.995633283513598e-06
. O 0 1.2838680731874774e-06

A O 0 7.713823606536607e-07
gene O 0 1.5839156048969016e-06
encoding O 0 6.980479270168871e-07
a O 0 5.253633972301941e-08
novel O 0 2.5385014623680036e-07
transmembrane O 0 1.3261643516671029e-06
protein O 0 3.8063828355916485e-07
was O 0 4.5153392136398907e-08
identified O 0 1.335261412549471e-08
by O 0 2.976960900014092e-10
DNA O 0 2.6368100591867005e-08
sequence O 0 8.493235448270298e-09
analysis O 0 3.930107794758442e-09
within O 0 5.316631579432851e-10
the O 0 3.0635394221434353e-09
insulin B-Disease 1 0.9537627696990967
- I-Disease 1 0.9999470710754395
dependent I-Disease 1 0.9999678134918213
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
( O 0 1.3220940786595747e-07
IDDM B-Disease 0 2.3044805857352912e-05
) O 0 3.902307810221828e-08
locus O 0 4.9285499699180946e-06
IDDM4 O 0 2.1156220100237988e-05
on O 0 1.086341114842071e-07
chromosome O 0 3.279142765677534e-05
11q13 O 0 3.461569576757029e-05
. O 0 1.5851865100557916e-06

Based O 0 9.533414413454011e-07
on O 0 1.6722394136081675e-08
its O 0 6.5936034410185584e-09
chromosomal O 0 0.0001597971422597766
position O 0 2.451178261253517e-05
, O 0 5.4480292499548e-10
this O 0 1.0254327248437889e-10
gene O 0 5.2213247059285095e-09
is O 0 4.908272122072788e-10
a O 0 5.543817627184922e-10
candidate O 0 8.411338292546588e-09
for O 0 6.158701881808781e-10
conferring O 0 1.3644235252741055e-07
susceptibility O 0 8.8600581875653e-06
to O 0 1.2338152828306193e-06
diabetes B-Disease 0 0.158430814743042
. O 0 2.0013071662106086e-06

The O 0 4.45104539892327e-08
gene O 0 2.2940776034374721e-07
, O 0 7.249146616317148e-09
termed O 0 2.074604878998798e-07
low O 0 1.2019937457807828e-05
- O 0 0.00010448576358612627
density O 0 6.200064603945066e-07
lipoprotein O 0 2.2898444512975402e-05
receptor O 0 1.0865976491913898e-06
related O 0 9.011531432179254e-08
protein O 0 5.7529110364384906e-08
5 O 0 3.324711173036121e-09
( O 0 5.149332071852086e-10
LRP5 O 0 4.759716318858409e-07
) O 0 9.040824755501831e-10
, O 0 1.524118053986001e-10
encodes O 0 3.1103291053824478e-09
a O 0 1.2859460163383574e-09
protein O 0 1.485302014714307e-08
of O 0 5.209355169455421e-10
1615 O 0 1.5900997141216067e-07
amino O 0 1.1608920935657352e-08
acids O 0 5.329498176109837e-09
that O 0 5.044794096353833e-11
contains O 0 4.7439021461093134e-11
conserved O 0 4.003479214809147e-10
modules O 0 2.8358302373021615e-09
which O 0 2.862271253345483e-10
are O 0 4.0960724395633363e-11
characteristic O 0 1.858073805927063e-09
of O 0 6.830997573148423e-11
the O 0 1.312409847464835e-09
low O 0 0.00043864332837983966
- O 0 0.0011057177325710654
density O 0 2.673195240276982e-06
lipoprotein O 0 0.0013588821748271585
( O 0 1.019243001110226e-07
LDL O 0 8.600786532042548e-05
) O 0 4.865029978873281e-08
receptor O 0 7.26835196473985e-07
family O 0 2.0573159531522833e-07
. O 0 3.294564692168933e-07

These O 0 8.429120867958773e-08
modules O 0 1.3206373239427194e-07
include O 0 9.662242561603307e-09
a O 0 4.287463717389528e-09
putative O 0 1.4613969767651724e-07
signal O 0 3.461680719851756e-08
peptide O 0 2.8355286119108314e-08
for O 0 2.4348650873307065e-10
protein O 0 1.6180402573340302e-09
export O 0 3.7040488454209708e-09
, O 0 3.27230936791878e-10
four O 0 1.0097644942419493e-09
epidermal O 0 3.2552875950386806e-07
growth O 0 1.948776855442702e-07
factor O 0 6.002333208243726e-08
( O 0 3.498725087425214e-09
EGF O 0 1.7834084928836091e-06
) O 0 4.4347898686680765e-09
repeats O 0 8.200650114531527e-08
with O 0 1.8127205292373105e-09
associated O 0 2.9455492267516092e-08
spacer O 0 1.1699455626512645e-06
domains O 0 2.0153565571945364e-07
, O 0 3.2125464510812662e-09
three O 0 7.03775571153642e-09
LDL O 0 2.540866807976272e-05
- O 0 1.862314775280538e-06
receptor O 0 1.6162712768164056e-07
( O 0 1.3624900097042314e-09
LDLR O 0 1.6604724351054756e-07
) O 0 5.775267486463065e-10
repeats O 0 1.7554826925447742e-08
, O 0 4.400905195822702e-10
a O 0 7.949214064773003e-10
single O 0 1.2190015219459838e-08
transmembrane O 0 4.335656100806773e-08
spanning O 0 1.3010503785437777e-08
domain O 0 4.2097703101262596e-08
, O 0 1.8218748731868573e-09
and O 0 3.669039072562441e-09
a O 0 1.4587089758322236e-08
cytoplasmic O 0 7.062338227115106e-06
domain O 0 4.974077910446795e-06
. O 0 1.412094320585311e-06

The O 0 2.8383208672266846e-08
encoded O 0 5.449344797625599e-08
protein O 0 7.992230877107431e-08
has O 0 5.392094326595043e-09
a O 0 8.300062859234458e-10
unique O 0 6.03822547518007e-09
organization O 0 3.0150544283458203e-09
of O 0 3.5954098032142667e-10
EGF O 0 2.375987151026493e-06
and O 0 6.03212457761515e-09
LDLR O 0 5.223897687756107e-07
repeats O 0 3.6026694516522184e-08
; O 0 1.4619837562790394e-09
therefore O 0 7.268387558490019e-10
, O 0 2.7932053892065767e-10
LRP5 O 0 2.2878158745243127e-07
likely O 0 4.433174272122642e-09
represents O 0 6.42086606106318e-10
a O 0 3.351373623061704e-10
new O 0 1.5364536309903087e-09
category O 0 1.1755176387850952e-08
of O 0 2.376919494562202e-10
the O 0 5.53838752637148e-09
LDLR O 0 4.767464270116761e-05
family O 0 1.6846550465743348e-07
. O 0 2.7508198741088563e-07

Both O 0 1.8854288441616518e-07
human O 0 2.842448942885767e-08
and O 0 5.458704155358873e-09
mouse O 0 1.6727058493870572e-07
LRP5 O 0 8.511943860867177e-07
cDNAs O 0 1.692858973001421e-07
have O 0 6.138931585297769e-09
been O 0 3.6579219653276596e-09
isolated O 0 3.215840038706119e-08
and O 0 6.481786773981923e-10
the O 0 1.3017092959088927e-10
encoded O 0 2.4136517229322862e-09
mature O 0 1.4127286007692419e-09
proteins O 0 1.4955572891217628e-10
are O 0 6.475704694697271e-11
95 O 0 3.552823868435695e-10
% O 0 1.367130852969467e-10
identical O 0 6.513306338717939e-09
, O 0 7.613137342765697e-10
indicating O 0 8.654342131819703e-09
a O 0 2.6692548171780572e-09
high O 0 4.3477712097228505e-08
degree O 0 3.278334759215795e-08
of O 0 3.7642863826015116e-10
evolutionary O 0 2.696329914897433e-08
conservation O 0 2.79226011201672e-08
. O 0 3.755863176024832e-08
. O 0 2.584010871942155e-07

The O 0 2.4186030600503727e-07
APC B-Disease 0 1.0599659390209126e-06
variants O 0 2.712758089273848e-07
I1307K O 0 4.221019196393172e-07
and O 0 2.2702721924616753e-09
E1317Q O 0 7.328880968771045e-08
are O 0 7.776631005818047e-10
associated O 0 3.466166731413978e-08
with O 0 0.31220099329948425
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 8.154836450557923e-07
but O 0 8.903385406711095e-08
not O 0 6.880235936534973e-09
always O 0 4.8917323525188294e-09
with O 0 2.746357585792225e-10
a O 0 7.0286074738135085e-09
family O 0 5.764641741734522e-08
history O 0 3.9680537611275213e-07
. O 0 4.656130840885453e-07

Classical O 1 0.7764346599578857
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 8.853554390952922e-06
FAP B-Disease 0 1.0505289537832141e-05
) O 0 1.7158114928861323e-08
is O 0 1.153871553860597e-09
a O 0 5.392834623307863e-09
high O 0 0.0001155436912085861
- O 1 0.9998704195022583
penetrance O 1 0.9999549388885498
autosomal B-Disease 1 0.9999771118164062
dominant I-Disease 1 0.9915823340415955
disease I-Disease 0 1.7658632714301348e-05
that O 0 5.434973027185208e-10
predisposes O 0 1.6758475496203573e-08
to O 0 1.2362617873851178e-10
hundreds O 0 1.518459941118877e-10
or O 0 6.088448634145038e-10
thousands O 0 2.705689450266391e-09
of O 0 4.705592004938808e-08
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.525340735912323
carcinoma I-Disease 1 1.0
and O 0 3.0159102948346117e-07
that O 0 2.8427402654074285e-09
results O 0 7.0703158883134165e-09
from O 0 9.224574437638466e-10
truncating O 0 4.516179217262106e-07
mutations O 0 8.821165238259709e-07
in O 0 2.863364656491285e-09
the O 0 7.243756261487988e-09
APC B-Disease 0 7.440531248903426e-07
gene O 0 2.7560845410334878e-06
. O 0 7.319129622374021e-07

A O 0 7.068025524858967e-07
variant O 0 7.945710422063712e-06
of O 0 4.0106140630769005e-08
FAP B-Disease 0 3.589301559259184e-05
is O 0 7.743837500129302e-07
attenuated B-Disease 1 0.7815907001495361
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 0.9999978542327881
coli I-Disease 1 1.0
, O 0 1.0943227124471377e-07
which O 0 5.146585380089164e-09
results O 0 8.351422664532038e-09
from O 0 6.180471689987144e-10
germ O 0 1.734270085762546e-06
- O 0 1.4712824167872895e-06
line O 0 1.9788164706824318e-07
mutations O 0 3.0225180580600863e-08
in O 0 3.126637004857713e-10
the O 0 1.7118480244437961e-10
5 O 0 4.950053145158506e-10
and O 0 6.582968614665674e-10
3 O 0 6.328026991297975e-10
regions O 0 1.5680100551307419e-09
of O 0 3.883651733538329e-10
the O 0 1.1481881223573964e-08
APC B-Disease 0 6.291440399763815e-07
gene O 0 1.1237199259994668e-06
. O 0 5.272456178317952e-07

Attenuated B-Disease 1 0.999923586845398
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 0.9999998807907104
coli I-Disease 1 1.0
patients O 1 0.9997302889823914
have O 0 2.3735111653877539e-07
" O 0 2.5128963798692894e-08
multiple O 0 3.468298018560745e-06
" O 1 0.9695820808410645
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
( O 0 3.7452814183325245e-09
typically O 0 1.8567453130557965e-09
fewer O 0 6.935940710661725e-10
than O 0 1.6006319880634834e-10
100 O 0 2.7985114225970165e-10
) O 0 2.0916153531391757e-10
without O 0 1.0641180159254304e-09
the O 0 2.2613262373738507e-09
florid O 0 1.0998383004334755e-05
phenotype O 0 3.990670847997535e-06
of O 0 4.837140465951961e-09
classical O 0 1.1214715414098464e-06
FAP B-Disease 0 1.580751995788887e-05
. O 0 3.796941712153057e-07

Another O 0 3.0665901817883423e-07
group O 0 4.5441705509574604e-08
of O 0 5.301745709118677e-10
patients O 0 1.3625375494541458e-08
with O 0 2.938329857204991e-10
multiple O 0 1.0213272361170311e-07
adenomas B-Disease 1 0.6702407598495483
has O 0 8.276734888568171e-07
no O 0 9.227482777873774e-09
mutations O 0 6.025124577035967e-08
in O 0 4.552129506674163e-10
the O 0 3.412282123527177e-10
APC B-Disease 0 6.718727796339863e-09
gene O 0 4.5687889027590245e-09
, O 0 2.4570390166900324e-10
and O 0 3.391454339585209e-10
their O 0 1.1217053952350398e-09
phenotype O 0 4.084938041160058e-07
probably O 0 1.8417383174096358e-08
results O 0 2.725865089203694e-09
from O 0 6.051593948175338e-11
variation O 0 4.524475016864926e-09
at O 0 3.245607560486974e-09
a O 0 1.0540843753403806e-09
locus O 0 3.3236861440855137e-07
, O 0 1.2052840947518462e-09
or O 0 1.567322382989289e-09
loci O 0 1.2730707155128584e-08
, O 0 4.5080719712764505e-10
elsewhere O 0 8.988764399475713e-09
in O 0 1.1423531010024135e-09
the O 0 7.120415812522651e-09
genome O 0 5.391078161665064e-07
. O 0 3.853624548355583e-07

Recently O 0 9.32509374251822e-06
, O 0 1.4368882972348729e-08
however O 0 3.41182193608347e-09
, O 0 4.4992581882397076e-10
a O 0 1.8198778040101615e-09
missense O 0 1.2102002528990852e-06
variant O 0 2.1701039258914534e-06
of O 0 3.2256983750755808e-09
APC B-Disease 0 7.289803249932447e-08
( O 0 4.720320245787946e-10
I1307K O 0 4.576693157787304e-08
) O 0 1.1401044552883377e-09
was O 0 1.8719112926390835e-09
described O 0 9.03241370586727e-10
that O 0 9.115273813531388e-11
confers O 0 1.1312730752166544e-09
an O 0 7.723942319071142e-11
increased O 0 1.1568602964473484e-08
risk O 0 9.916105045704171e-05
of O 0 5.223655989539111e-06
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 1.09026183636729e-08
including O 0 1.4386646318698126e-09
multiple O 0 4.35616357208346e-07
adenomas B-Disease 0 0.008298973552882671
, O 0 1.711529762360442e-08
in O 0 4.962971900113189e-08
Ashkenazim O 0 5.17748630954884e-05
. O 0 8.342493629243108e-07

We O 0 3.373484105395619e-07
have O 0 3.0528297667586912e-09
studied O 0 5.56379875504831e-09
a O 0 2.2547572142705974e-10
set O 0 6.741895375306228e-10
of O 0 1.0174140002705556e-10
164 O 0 1.729176446474412e-08
patients O 0 1.4814315996147798e-08
with O 0 5.383389733992772e-09
multiple O 1 0.9999508857727051
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 0 9.001665603136644e-05
/ I-Disease 0 0.00920383632183075
or I-Disease 0 0.013109654188156128
carcinoma I-Disease 1 1.0
and O 0 4.0343604723602766e-07
analyzed O 0 1.035987679642858e-06
codons O 0 4.2179149204457644e-06
1263 O 0 7.179233307397226e-06
- O 0 1.3453421843223623e-06
1377 O 0 1.3668606015926343e-06
( O 0 4.174984802318704e-09
exon O 0 2.317931802053863e-07
15G O 0 5.394791173785052e-07
) O 0 1.5320552604336513e-09
of O 0 6.377788575040455e-11
the O 0 5.788058921041284e-10
APC B-Disease 0 1.4492163025181526e-08
gene O 0 1.3673565391059128e-08
for O 0 1.5465442260165219e-09
germ O 0 1.3622157894133125e-05
- O 0 9.52471327764215e-06
line O 0 2.296854290761985e-06
variants O 0 4.04914908358478e-06
. O 0 1.0996326409440371e-06

Three O 0 2.9718930250055564e-07
patients O 0 3.307216047687689e-07
with O 0 1.0329831434674475e-09
the O 0 1.5145125153992467e-09
I1307K O 0 2.1574409458935406e-07
allele O 0 2.2320219272842223e-07
were O 0 3.5385629981732336e-09
detected O 0 1.5659814778246073e-08
, O 0 3.3105604368977026e-10
each O 0 9.460526806392977e-10
of O 0 8.246603400152708e-09
Ashkenazi O 0 0.0002832774771377444
descent O 0 2.5375202312716283e-05
. O 0 1.3762362414126983e-06

Four O 0 4.7554513571412826e-07
patients O 0 1.1933357200177852e-06
had O 0 1.5937517972020032e-08
a O 0 4.40705605342373e-09
germ O 0 8.37065017549321e-05
- O 0 5.3957228374201804e-05
line O 0 1.894550337055989e-06
E1317Q O 0 7.659182870156656e-07
missense O 0 1.0705537079047645e-06
variant O 0 2.390753763847897e-07
of O 0 2.7415636427718937e-10
APC O 0 9.278946500046459e-09
that O 0 4.431768563240013e-10
was O 0 1.9898513947680385e-09
not O 0 1.3171136403755668e-10
present O 0 5.633996047471612e-11
in O 0 7.968489063037154e-11
controls O 0 2.113130648240258e-08
; O 0 5.596449415001814e-10
one O 0 6.682374098510024e-11
of O 0 3.895622106148133e-12
these O 0 5.064606373172964e-11
individuals O 0 1.0130145333686613e-10
had O 0 1.3596914705260588e-09
an O 0 4.410482395966753e-11
unusually O 0 2.443477642444236e-09
large O 0 1.921580228270159e-09
number O 0 3.1592677363079247e-09
of O 0 8.620220093291664e-10
metaplastic B-Disease 0 1.5404531268359278e-06
polyps I-Disease 0 1.484766130488424e-06
of I-Disease 0 7.409906022104451e-10
the I-Disease 0 1.3133420573296917e-08
colorectum I-Disease 0 9.340348697151057e-06
. O 0 4.807241680282459e-07

There O 0 1.2214107414365571e-07
is O 0 5.910197220515556e-09
increasing O 0 3.0281830376566177e-09
evidence O 0 7.3021295676767295e-09
that O 0 8.235062076700217e-10
there O 0 2.989490321958499e-10
exist O 0 6.512685502002569e-09
germ O 0 8.736073482396023e-07
- O 0 2.107532139916657e-07
line O 0 2.4201254333888755e-08
variants O 0 1.0974724240497835e-08
of O 0 1.3577626523098019e-10
the O 0 3.725110497843076e-10
APC B-Disease 0 3.6959468818764663e-09
gene O 0 1.0745976330994722e-09
that O 0 6.626187099012526e-11
predispose O 0 1.4548847682149812e-09
to O 0 2.4923622193862016e-11
the O 0 2.54582327441355e-11
development O 0 1.6944168290677908e-10
of O 0 5.478488218635391e-10
multiple O 1 0.9999344348907471
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 0 0.06860824674367905
carcinoma I-Disease 1 1.0
, O 0 9.128193312335497e-09
but O 0 3.5654457164469022e-09
without O 0 1.4267338421802833e-09
the O 0 2.532322684878352e-10
florid O 0 1.379087279929081e-06
phenotype O 0 5.269058078738453e-07
of O 0 1.0306799164139235e-10
classical O 0 9.27073795509159e-09
FAP B-Disease 0 3.961356753734435e-08
, O 0 1.229245455425243e-10
and O 0 4.641564563256928e-11
possibly O 0 2.8945140728708907e-10
with O 0 4.233405292985992e-11
importance O 0 4.843787149155787e-09
for O 0 0.002365326974540949
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
risk O 0 0.0014043221017345786
in O 0 7.194101425689325e-10
the O 0 5.004106018446919e-10
general O 0 2.0336385908592547e-09
population O 0 1.5913672157807923e-08
. O 0 1.9395061556792825e-08
. O 0 1.9017990382508287e-07

Genomic O 0 1.8561975593911484e-05
structure O 0 6.033387194293027e-07
of O 0 2.382094743680341e-09
the O 0 1.3604108062281739e-08
human O 0 9.495622634858591e-07
congenital B-Disease 1 0.9999977350234985
chloride I-Disease 1 0.9999786615371704
diarrhea I-Disease 1 1.0
( O 0 1.2506732218753314e-06
CLD B-Disease 0 0.14636297523975372
) O 0 1.8405168589197274e-07
gene O 0 6.035422757122433e-06
. O 0 2.266696583319572e-06

Congenital B-Disease 1 0.9999990463256836
chloride I-Disease 1 0.9999825954437256
diarrhea I-Disease 1 1.0
( O 0 5.119711204315536e-06
CLD B-Disease 1 0.8249123692512512
) O 0 5.809732215311669e-07
is O 0 2.2974289137778214e-08
caused O 0 1.8583795835525052e-08
by O 0 1.5980674561433261e-09
mutations O 0 3.5808059806186066e-07
in O 0 1.6631287458324095e-09
a O 0 1.9428745279270743e-09
gene O 0 7.272069524333347e-08
which O 0 9.237766995795482e-09
encodes O 0 2.705180577322608e-07
an O 0 8.360574810239996e-08
intestinal O 0 0.00023190253705251962
anion O 0 0.00020136650709901005
transporter O 0 0.00029315557912923396
. O 0 3.014402864209842e-06

We O 0 2.975328925458598e-06
report O 0 2.554845757174462e-08
here O 0 1.0183657250806277e-09
the O 0 2.634555074099154e-10
complete O 0 1.6855148388117414e-09
genomic O 0 1.1097065311105325e-07
organization O 0 3.612121268758983e-09
of O 0 2.0371160314169856e-10
the O 0 2.4299853240705716e-09
human O 0 1.5307913159290365e-08
CLD B-Disease 0 2.3656928078708006e-06
gene O 0 3.166532636100783e-08
which O 0 1.153858342206604e-09
spans O 0 1.3338155469000412e-08
approximately O 0 1.4812896464988512e-09
39kb O 0 6.132287353466381e-07
, O 0 1.575066077563747e-09
and O 0 3.346507959633982e-09
comprises O 0 1.7883317937616994e-08
21 O 0 7.714222505228463e-08
exons O 0 5.5135551519924775e-06
. O 0 7.981259955158748e-07

All O 0 4.618399316314026e-07
exon O 0 1.1968806575168855e-05
/ O 0 2.2163560515764402e-06
intron O 0 1.199758207803825e-05
boundaries O 0 4.4071470028939075e-07
conform O 0 4.5062623144076497e-07
to O 0 6.817337805387069e-09
the O 0 8.108383298122135e-09
GT O 0 3.113678303634515e-06
/ O 0 5.548124136112165e-06
AG O 1 0.9925180673599243
rule O 0 1.767541334629641e-06
. O 0 7.276757969520986e-07

An O 0 3.5736309911271746e-08
analysis O 0 3.3776942132135446e-08
of O 0 4.50632670068174e-10
the O 0 1.2741098176505261e-09
putative O 0 1.6205711972361314e-07
promoter O 0 4.785664486917085e-07
region O 0 7.24362152482172e-08
sequence O 0 5.74095224692428e-08
shows O 0 1.526747581692689e-07
a O 0 1.8169306059689916e-08
putative O 0 2.1234998257568805e-06
TATA O 0 2.8857668439741246e-05
box O 0 3.194919315774314e-07
and O 0 9.722639582321335e-09
predicts O 0 1.0765557334480036e-07
multiple O 0 4.424822108717308e-08
transcription O 0 1.1956159085002582e-07
factor O 0 1.6114539391764993e-07
binding O 0 2.3261031856236514e-07
sites O 0 1.6684695083313272e-06
. O 0 8.08541301466903e-07

The O 0 7.182851646803101e-08
genomic O 0 1.4884820984661928e-06
structure O 0 2.6979924427905644e-07
was O 0 1.0683751661133556e-08
determined O 0 2.9115085897757353e-09
using O 0 1.3302985379937127e-09
DNA O 0 1.4064837294824883e-08
from O 0 9.9906069528366e-11
several O 0 8.31814131463382e-11
sources O 0 4.080992765942426e-10
including O 0 1.259592152802469e-10
multiple O 0 8.05925992608536e-09
large O 0 1.2430599838353373e-07
- O 0 4.802554758498445e-05
insert O 0 8.34919433145842e-07
libaries O 0 6.180949299050553e-07
and O 0 1.9045036658837944e-09
genomic O 0 9.282384638709118e-08
DNA O 0 1.6792479584637476e-07
from O 0 1.0258759175485466e-08
Finnish O 0 2.893347073040786e-06
CLD B-Disease 0 0.00028024730272591114
patients O 0 9.25625045056222e-07
and O 0 2.3912868130082643e-08
controls O 0 6.668118203378981e-06
. O 0 1.2435846201697132e-06

Exon O 0 4.663951403927058e-05
- O 0 6.694280727970181e-06
specific O 0 2.7794172297035402e-08
primers O 0 5.051807079325954e-07
developed O 0 1.3406868504262093e-08
in O 0 2.549600253143325e-10
this O 0 9.579218668287481e-11
study O 0 4.051876334454363e-10
will O 0 6.673419455927032e-11
facilitate O 0 2.392137321560739e-10
mutation O 0 1.02975157290075e-08
screening O 0 8.277206475781895e-09
studies O 0 1.9572237164311446e-09
of O 0 8.248388777554183e-11
patients O 0 7.006294655553802e-09
with O 0 8.085091485199314e-10
the O 0 5.867238783707762e-08
disease O 0 1.2268700629647356e-05
. O 0 5.435962293631746e-07

Genomic O 0 2.3646061890758574e-05
sequencing O 0 1.556024244564469e-06
of O 0 1.5935208708128812e-08
a O 0 6.841086275244379e-08
BAC O 0 1.3408308404905256e-05
clone O 0 6.403605311788851e-06
H O 1 0.9999996423721313
_ O 0 4.7764135757688564e-08
RG364P16 O 0 1.567712502037466e-07
revealed O 0 1.765799062525275e-08
the O 0 1.834087465235612e-10
presence O 0 6.750349168527237e-10
of O 0 3.535658224529392e-11
another O 0 9.181813642733516e-10
, O 0 4.2309852843480655e-10
highly O 0 1.2776091296018421e-09
homologous O 0 3.945422211160121e-09
gene O 0 7.253337042101293e-09
3 O 0 6.465574742264835e-10
of O 0 5.945387931971524e-11
the O 0 7.172782368058961e-10
CLD B-Disease 0 1.1443290759416413e-06
gene O 0 1.5256670593544186e-08
, O 0 3.9815475916249454e-10
with O 0 1.7407268682045896e-10
a O 0 7.316512951049958e-10
similar O 0 6.2689364810353254e-09
genomic O 0 2.703328902953217e-07
structure O 0 2.259189813003104e-07
, O 0 9.238519393939271e-10
recently O 0 8.468001411188197e-09
identified O 0 9.950110957390734e-09
as O 0 3.289658101479631e-09
the O 0 1.2369077921903227e-06
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
gene O 0 1.915819211717462e-06
( O 0 1.2714012953551901e-08
PDS B-Disease 0 9.560263833918725e-07
) O 0 9.248203092226959e-09
. O 0 2.360188489092252e-08
. O 0 4.012397596397932e-07

The O 0 2.477900409303402e-07
APCI1307K O 0 1.811996662581805e-05
allele O 0 1.5000450730440207e-05
and O 0 1.3590500884674839e-06
cancer B-Disease 0 0.002963527338579297
risk O 0 5.04556055602734e-06
in O 0 1.1667339316900893e-09
a O 0 2.447559044327363e-09
community O 0 7.332037643692502e-09
- O 0 6.396492153726285e-07
based O 0 2.3695887918506742e-08
study O 0 1.0204759703924537e-08
of O 0 2.1064736621667635e-09
Ashkenazi O 0 3.5966527320852038e-06
Jews O 0 3.779438486617437e-07
. O 0 3.696210342241102e-07

Mutations O 0 8.366755355382338e-05
in O 0 1.0996015475939203e-07
APC O 0 1.2190408824608312e-06
are O 0 2.5095099331906567e-08
classically O 0 0.00014471355825662613
associated O 0 4.738045845442684e-06
with O 0 7.81561029725708e-05
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 6.742750429111766e-06
FAP B-Disease 0 8.17022464616457e-06
) O 0 5.954302384481025e-09
, O 0 5.552092119387453e-10
a O 0 5.854726481402395e-09
highly O 0 2.6944158889818937e-05
penetrant O 1 0.999998927116394
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 0 2.20998208533274e-06
by O 0 7.600837292898177e-09
multiple O 0 2.1791083781863563e-06
intestinal O 0 0.00308393407613039
polyps B-Disease 0 0.00021934352116659284
and O 0 2.1988582066256868e-09
, O 0 2.2776183716821663e-10
without O 0 1.2540624094725672e-09
surgical O 0 1.306584067606309e-07
intervention O 0 8.460058431580819e-09
, O 0 1.8943045743124998e-10
the O 0 3.5036049061965e-10
development O 0 1.2051744491259342e-08
of O 0 4.5808923459844664e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 2.805028742614013e-08
CRC B-Disease 0 1.127911446019425e-06
) O 0 5.112013923280756e-08
. O 0 1.7053945100542478e-07

APC B-Disease 0 5.636344576487318e-05
is O 0 6.578392799383437e-07
a O 0 5.630678856505256e-07
tumour O 1 1.0
- O 0 1.153973880718695e-05
suppressor O 0 1.8479737491361448e-06
gene O 0 3.0542472018169065e-07
, O 0 3.223010747177568e-09
and O 0 1.6676138248072903e-09
somatic O 0 5.771357791672926e-07
loss O 0 6.908332466082356e-07
occurs O 0 1.6984979822609603e-07
in O 0 4.5571508167085995e-07
tumours B-Disease 1 1.0
. O 0 2.6095929115399485e-06

The O 0 6.649503916378308e-07
germline O 0 1.7937651136890054e-05
T O 0 1.1319704753987025e-05
- O 0 5.807987122352642e-07
to O 0 3.2892504275849888e-09
- O 0 7.524592859908807e-08
A O 0 2.8610172009280177e-09
transversion O 0 1.0645473480508372e-07
responsible O 0 4.265603426034659e-09
for O 0 2.2338249305864366e-10
the O 0 5.63351532090195e-10
APC O 0 3.268993964411493e-08
I1307K O 0 2.8332799217878346e-08
allele O 0 1.831320695089289e-08
converts O 0 6.77942324500691e-09
the O 0 1.2757968292920197e-10
wild O 0 2.628322892661572e-09
- O 0 3.832286665783613e-08
type O 0 1.345018052489877e-08
sequence O 0 3.8357801379618195e-09
to O 0 6.517851258713847e-10
a O 0 1.4019245764274046e-09
homopolymer O 0 4.4113194235251285e-06
tract O 0 5.5115365285018925e-06
( O 0 2.885128802532222e-09
A8 O 0 1.669078869781515e-06
) O 0 7.759474174307002e-10
that O 0 1.167655139244772e-10
is O 0 1.3514488417243342e-09
genetically O 0 5.806309388844966e-08
unstable O 0 1.0867730452446267e-05
and O 0 3.010722693375101e-08
prone O 0 8.52777986892761e-07
to O 0 1.0398668592870308e-08
somatic O 0 4.067688223585719e-06
mutation O 0 1.563589830766432e-05
. O 0 8.910475344237057e-07

The O 0 2.403950247753528e-07
I1307K O 0 4.685522071667947e-06
allele O 0 4.656215878640069e-06
was O 0 1.0454476040422378e-07
found O 0 1.350328648896948e-08
in O 0 9.265788136758601e-09
6 O 0 1.4682672144772368e-07
. O 0 4.7393334057233005e-07

1 O 0 2.2802255443821196e-06
% O 0 7.081506936401638e-08
of O 0 2.254904485354814e-09
unselected O 0 1.5293491742340848e-05
Ashkenazi O 0 8.950734809332062e-06
Jews O 0 1.7393024620560027e-07
and O 0 5.710664829905454e-09
higher O 0 1.4188971775297432e-08
proportions O 0 2.5106189127654943e-07
of O 0 4.3134962268709387e-10
Ashkenazim O 0 9.538689482724294e-07
with O 0 1.0964570362759218e-09
family O 0 8.530641082415968e-09
or O 0 8.44385716902707e-09
personal O 0 2.7649665668150192e-08
histories O 0 1.1705689217933468e-07
of O 0 1.7370099802960226e-09
CRC B-Disease 0 5.442166184366215e-07
( O 0 2.3431023787878758e-09
ref O 0 2.2731519493390806e-06
. O 0 2.9861524364349634e-09
2 O 0 8.215894631291576e-09
) O 0 9.533259515137615e-09
. O 0 1.1538527644461283e-07

To O 0 1.259127913044722e-07
evaluate O 0 1.7817038155953924e-07
the O 0 7.460391748814743e-10
role O 0 6.187221401887655e-09
of O 0 2.3867322007653513e-10
I1307K O 0 9.821221169659111e-08
in O 0 4.371550677007008e-09
cancer B-Disease 0 1.147146733160298e-07
, O 0 6.985088618627344e-10
we O 0 2.2550508127494595e-09
genotyped O 0 7.005348834354663e-08
5 O 0 2.6435365008126155e-09
, O 0 1.9731767331165884e-09
081 O 0 1.2959417290403508e-06
Ashkenazi O 0 7.681054512431729e-07
volunteers O 0 8.998354061873215e-09
in O 0 1.3278700361496476e-09
a O 0 4.669023834225072e-09
community O 0 5.570363725837524e-08
survey O 0 1.1410619435991975e-06
. O 0 4.4694084522234334e-07

Risk O 0 0.0011684144847095013
of O 0 3.9200028112418295e-08
developing O 0 5.1353886192373466e-06
colorectal B-Disease 1 1.0
, I-Disease 0 1.6333594032857945e-07
breast I-Disease 0 0.0008315891027450562
and I-Disease 0 1.6601850560959974e-08
other I-Disease 0 5.4900812784808295e-09
cancers I-Disease 0 0.0004057168844155967
were O 0 2.059141523957919e-09
compared O 0 1.4767363998302585e-09
between O 0 4.4211814764771873e-10
genotyped O 0 9.991803295861246e-08
I1307K O 0 6.035521948888345e-08
carriers O 0 9.695213520899415e-09
and O 0 4.783693441368086e-10
non O 0 8.766868120346771e-09
- O 0 1.5041042900065804e-07
carriers O 0 1.1084833495544899e-08
and O 0 1.8470695806183102e-10
their O 0 1.573909197416512e-10
first O 0 4.797355845909124e-09
- O 0 7.172330356297607e-07
degree O 0 2.9152536740184587e-07
relatives O 0 1.7784546457733086e-07
. O 0 1.661522617268929e-07

Sperm O 0 1.3619455785374157e-05
DNA O 0 1.4976732245486346e-06
analysis O 0 2.642011338593875e-07
in O 0 1.572536412197678e-08
a O 0 1.0755192647593503e-07
Friedreich B-Disease 0 0.00021822249982506037
ataxia I-Disease 0 0.0009379305993206799
premutation O 0 0.0013971691951155663
carrier O 0 2.3967511879163794e-05
suggests O 0 3.4017202210634423e-07
both O 0 7.918438349463486e-09
meiotic O 0 1.374153612232476e-06
and O 0 8.748310520445557e-09
mitotic O 0 2.926384468082688e-07
expansion O 0 1.5173301903814718e-07
in O 0 1.4638428247337743e-08
the O 0 1.876527200295186e-08
FRDA B-Disease 0 1.1670977983158082e-05
gene O 0 5.075428816780914e-06
. O 0 9.178930326925183e-07

Friedreich B-Disease 0 0.0288702379912138
ataxia I-Disease 1 0.8667736053466797
is O 0 7.74373529566219e-06
usually O 0 1.0332101965104812e-06
caused O 0 3.016747029960243e-08
by O 0 3.189356834187862e-10
an O 0 1.416021744304885e-10
expansion O 0 9.244552678921991e-09
of O 0 6.080394521212895e-10
a O 0 1.4008106674623377e-08
GAA O 0 7.762299674141104e-07
trinucleotide O 0 3.892617314704694e-06
repeat O 0 3.511775048536947e-07
in O 0 9.348026797084685e-10
intron O 0 4.0447349647365627e-07
1 O 0 5.443711259545125e-09
of O 0 4.776827267072292e-10
the O 0 7.819053848834301e-09
FRDA B-Disease 0 6.737048352079e-06
gene O 0 2.219558609795058e-06
. O 0 6.402949566108873e-07

Occasionally O 0 9.024704013427254e-06
, O 0 3.034023521308882e-08
a O 0 4.283180921049734e-09
fully O 0 1.3900367967778493e-08
expanded O 0 3.5230736106228733e-09
allele O 0 1.0095708802282388e-07
has O 0 3.2027207552687287e-09
been O 0 9.170331716212843e-10
found O 0 1.9360224534636927e-10
to O 0 8.924760930284492e-11
arise O 0 7.592342865514468e-10
from O 0 2.5670191666771203e-11
a O 0 1.1400234228853279e-10
premutation O 0 2.4431900058630163e-08
of O 0 6.896046927939992e-11
100 O 0 4.121701591142113e-10
or O 0 6.708253508236339e-09
less O 0 2.264983578470492e-08
triplet O 0 3.497816214803606e-05
repeats O 0 2.9374781661317684e-05
. O 0 8.599853345003794e-07

We O 0 1.6715143829060253e-06
have O 0 1.6422930571025063e-08
examined O 0 2.8280101815880698e-08
the O 0 6.908425498330928e-10
sperm O 0 2.2919492081996395e-08
DNA O 0 3.739750908948736e-08
of O 0 7.473950347502978e-10
a O 0 1.793907244973525e-08
premutation O 0 1.9321831132401712e-05
carrier O 0 1.2680402505793609e-05
. O 0 6.036190143277054e-07

This O 0 3.2221768719864485e-07
mans O 0 1.744543283166422e-06
leucocyte O 0 3.219561449441244e-06
DNA O 0 5.853556785950786e-07
showed O 0 4.092361649554732e-08
one O 0 1.345263678231845e-09
normal O 0 9.515820131866803e-09
allele O 0 1.695764382247944e-07
and O 0 3.4423872641298203e-09
one O 0 2.5983857288025547e-09
allele O 0 5.039291295361181e-08
of O 0 6.716622813485174e-10
approximately O 0 1.086749001899534e-08
100 O 0 3.888354882519707e-08
repeats O 0 5.713615337299416e-06
. O 0 1.0948630233542644e-06

His O 0 1.145313532902037e-07
sperm O 0 3.796195926497603e-07
showed O 0 2.0939205924719317e-08
an O 0 9.24930479428987e-11
expanded O 0 2.625912598475111e-09
allele O 0 6.824183884646118e-08
in O 0 2.0630177566260954e-09
a O 0 2.7055140350285e-09
tight O 0 3.7714695366730666e-08
range O 0 2.8857727318865045e-09
centering O 0 3.494436962014902e-09
on O 0 1.3014590516391422e-09
a O 0 8.055567324305457e-10
size O 0 8.455299571608066e-09
of O 0 6.273371266907191e-10
approximately O 0 2.4402000420309378e-08
320 O 0 3.1912955478219374e-07
trinucleotide O 0 4.931163493893109e-05
repeats O 0 1.7389938875567168e-05
. O 0 1.0517693453948596e-06

His O 0 3.3903006624314003e-07
affected O 0 3.56047337390919e-07
son O 0 1.9560052066935896e-07
has O 0 1.334153942877947e-08
repeat O 0 1.2386945513753744e-07
sizes O 0 1.0371832814826121e-07
of O 0 1.5043926104851835e-09
1040 O 0 6.038521860318724e-07
and O 0 3.060136322119433e-08
540 O 0 5.629390216199681e-07
. O 0 3.531744994234032e-07

These O 0 2.3144499650129546e-08
data O 0 1.777016223059036e-08
suggest O 0 9.322319804994095e-09
that O 0 1.5261251984366453e-10
expansion O 0 1.3973514567666712e-09
occurs O 0 7.214356334550587e-10
in O 0 7.028304327416635e-11
two O 0 1.1592755921885356e-10
stages O 0 7.2243016013828765e-09
, O 0 1.0077533946217798e-10
the O 0 5.1568090075893025e-11
first O 0 3.9153735809094314e-10
during O 0 3.791307268130595e-10
meiosis O 0 5.7389017982245605e-09
followed O 0 8.035326293232004e-10
by O 0 2.938184417988765e-10
a O 0 2.4446102919739587e-09
second O 0 2.625678519052599e-08
mitotic O 0 1.1654487934720237e-06
expansion O 0 1.8248616697746911e-06
. O 0 9.829313967202324e-07

We O 0 7.983353498275392e-07
also O 0 3.4165301698863004e-09
show O 0 4.981063561615429e-09
that O 0 1.6282371284592756e-10
in O 0 5.107250039548816e-11
all O 0 4.707308501328278e-11
informative O 0 3.603567888532666e-09
carrier O 0 1.2463227783143793e-08
father O 0 1.4371177581296024e-09
to O 0 2.8014007780186034e-10
affected O 0 1.2779064473278368e-09
child O 0 2.5219413224419895e-09
transmissions O 0 4.5589025887693424e-08
, O 0 1.645668462613159e-10
with O 0 5.0342018748095185e-11
the O 0 7.824148273716247e-11
notable O 0 1.6606181985068247e-09
exception O 0 3.752488986208391e-09
of O 0 3.5598701070282956e-11
the O 0 1.8064758022795502e-10
premutation O 0 1.358453545208249e-07
carrier O 0 2.3677726446180714e-08
, O 0 6.385177109269335e-11
the O 0 8.818462626791757e-11
expansion O 0 1.3085463379525208e-08
size O 0 8.107644333676944e-08
decreases O 0 2.499026265923021e-07
. O 0 1.733029719730439e-08
. O 0 1.3448159563722584e-07

The O 0 1.4424260541545664e-07
R496H O 0 1.6786823380243732e-06
mutation O 0 3.329295168441604e-07
of O 0 5.471866848516527e-10
arylsulfatase O 0 4.901345391772338e-07
A O 0 1.1094288154822607e-08
does O 0 1.126839990206463e-07
not O 0 1.4222439403965836e-07
cause O 0 3.034052497241646e-06
metachromatic B-Disease 1 0.9999998807907104
leukodystrophy I-Disease 1 0.9999998807907104
. O 0 7.688158802920952e-06

Deficiency B-Disease 1 0.9994544386863708
of I-Disease 0 3.057394337702135e-08
arylsulfatase I-Disease 0 1.8243681552121416e-05
A I-Disease 0 2.5045520146704803e-07
( O 0 4.349720583718408e-08
ARSA O 0 7.330669177463278e-05
) O 0 3.040547014165895e-08
enzyme O 0 5.156999236533011e-07
activity O 0 8.493366863149276e-07
causes O 0 1.3239933650766034e-05
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 3.5947048218076816e-06
MLD B-Disease 1 0.999998927116394
) O 0 6.065278626010695e-07
. O 0 6.014761879669095e-07

A O 0 5.689857403012866e-07
number O 0 6.799419338676671e-08
of O 0 1.0933605132379398e-08
ARSA O 0 7.811647810740396e-05
gene O 0 1.3929901570008951e-06
mutations O 0 1.570823997099069e-06
responsible O 0 1.0099022063059238e-07
for O 0 7.792526446337433e-08
MLD B-Disease 1 0.9999998807907104
have O 0 4.2447962300684594e-07
been O 0 8.941948692609003e-08
identified O 0 4.429305988651322e-07
. O 0 3.3043755820472143e-07

Recently O 0 3.809400141108199e-06
, O 0 1.1840415758967993e-08
the O 0 2.2835178192792682e-09
R496H O 0 3.0990682375886536e-07
mutation O 0 9.246918608596388e-08
of O 0 5.499101174422094e-10
ARSA O 0 9.57773590926081e-06
was O 0 2.56932874975746e-09
proposed O 0 5.086623899863696e-10
to O 0 2.0866383620976592e-10
be O 0 1.0300870156854103e-09
a O 0 1.4378882529086923e-09
cause O 0 1.753454803576915e-08
of O 0 5.595256702406459e-09
MLD B-Disease 1 0.9999997615814209
( O 0 7.985842209734528e-09
Draghia O 0 8.242501507993438e-07
et O 0 3.289337371370493e-07
al O 0 8.723201858629182e-07
. O 0 1.1505163044489564e-08
, O 0 3.6314706797213603e-09
1997 O 0 3.8555945991447516e-08
) O 0 2.062814274950142e-08
. O 0 1.8216921660041407e-07

We O 0 5.657468591380166e-07
have O 0 5.943953773623889e-09
investigated O 0 1.9241484849885637e-08
the O 0 4.501000683276857e-10
R496H O 0 8.831317899193891e-08
mutation O 0 2.8529644424679645e-08
and O 0 4.204245840355725e-10
found O 0 9.759124619534987e-10
this O 0 2.957999678532275e-10
mutation O 0 1.877626409907407e-08
at O 0 1.0024263641383868e-09
a O 0 2.473213300824284e-10
relatively O 0 1.6711290129478584e-09
high O 0 3.354131417054873e-09
frequency O 0 6.150302311880296e-08
in O 0 1.2757001011109992e-09
an O 0 4.6220161031840235e-10
African O 0 1.8244445953996546e-09
American O 0 2.9766444864520736e-09
population O 0 9.052213423288435e-10
( O 0 4.383078622272052e-10
f O 0 1.7432704169095814e-08
= O 0 1.5202582304141288e-08
0 O 0 2.7386697354359057e-09
. O 0 1.203379840220009e-09
09 O 0 2.0262056921183103e-08
, O 0 9.404126366518994e-10
n O 0 2.364487698969242e-07
= O 0 4.797605583917175e-07
61 O 0 3.790226443811662e-08
subjects O 0 2.399554830390116e-07
) O 0 4.230021488638158e-08
. O 0 2.3255375936059863e-07

The O 0 5.394996946961328e-07
ARSA O 0 7.329320214921609e-05
enzyme O 0 4.5267174186847114e-07
activity O 0 5.380703171908863e-08
in O 0 9.935617883982673e-10
subjects O 0 9.023292335541555e-09
with O 0 3.307190077350697e-10
and O 0 1.3641907603556547e-09
without O 0 9.527655331353913e-10
the O 0 1.9882646917768199e-10
R496H O 0 5.300658756368648e-08
mutation O 0 2.5588787977426364e-08
was O 0 4.322393110101075e-09
determined O 0 1.1020661716543145e-08
and O 0 3.841027773621164e-10
found O 0 4.1712097664792225e-10
to O 0 4.964585964550849e-10
be O 0 3.777306023522442e-09
normal O 0 1.5095822902821965e-07
. O 0 2.641406524617196e-07

It O 0 2.346604048852896e-07
is O 0 6.5939054216812565e-09
therefore O 0 1.838143748322807e-09
concluded O 0 4.509604689673097e-09
that O 0 1.4833130557168062e-10
the O 0 3.203690368547285e-10
R496H O 0 9.447156656960942e-08
mutation O 0 2.9449257255009798e-08
of O 0 3.512564406005225e-10
ARSA O 0 4.248365712555824e-06
does O 0 2.116115460637502e-08
not O 0 1.2581352626384046e-09
negatively O 0 1.3777331497877299e-09
influence O 0 1.053686471408355e-09
the O 0 2.1011357931310926e-10
activity O 0 3.795121994443207e-09
of O 0 2.0871400441269117e-10
ARSA O 0 2.252229933219496e-05
and O 0 2.686641575877502e-09
is O 0 1.0240807091221882e-09
not O 0 4.404115294676103e-09
a O 0 1.104490365833044e-08
cause O 0 3.3391140163985256e-07
of O 0 7.050205681480293e-07
MLD B-Disease 1 0.9999979734420776

Down O 0 1.305660407524556e-05
- O 0 5.310218512022402e-06
regulation O 0 2.2697737733778922e-07
of O 0 5.805321112717365e-09
transmembrane O 0 2.077314093185123e-06
carbonic O 0 1.9776402041316032e-05
anhydrases O 0 3.289795131422579e-05
in O 0 8.48310264700558e-07
renal B-Disease 1 0.99977046251297
cell I-Disease 1 0.9999594688415527
carcinoma I-Disease 1 1.0
cell O 0 0.42356348037719727
lines O 0 2.550396629885654e-06
by O 0 5.32359534233251e-09
wild O 0 4.03022625050653e-07
- O 1 0.7037774920463562
type O 1 0.8585333228111267
von B-Disease 1 0.9996918439865112
Hippel I-Disease 1 0.9960293769836426
- I-Disease 0 0.4641413688659668
Lindau I-Disease 0 0.15560659766197205
transgenes O 0 0.0009334409260191023
. O 0 5.935532954026712e-06

To O 0 1.9831163911021576e-07
discover O 0 1.0722865226853173e-06
genes O 0 3.277523035194463e-07
involved O 0 7.189814255070814e-08
in O 0 8.181401511819786e-08
von B-Disease 1 0.9994039535522461
Hippel I-Disease 1 0.9999226331710815
- I-Disease 1 0.9998443126678467
Lindau I-Disease 1 0.9997709393501282
( O 0 1.9033051046335459e-07
VHL B-Disease 0 2.2057958631194197e-05
) O 0 3.791209834957954e-08
- O 0 1.0765839988380321e-06
mediated O 0 4.108198936592089e-07
carcinogenesis O 0 2.6545835680735763e-06
, O 0 3.741033260951099e-09
we O 0 6.0943303736848975e-09
used O 0 4.806599918083521e-07
renal B-Disease 1 0.6578816175460815
cell I-Disease 1 0.9996300935745239
carcinoma I-Disease 1 1.0
cell O 1 0.9751469492912292
lines O 0 0.0006043737521395087
stably O 0 1.3906638741900679e-05
transfected O 0 3.844821549137123e-06
with O 0 8.638510351488549e-09
wild O 0 1.565352079069271e-07
- O 0 0.001144290086813271
type O 0 0.008226782083511353
VHL O 0 0.013518673367798328
- O 0 3.022310193045996e-05
expressing O 0 3.039134753635153e-06
transgenes O 0 8.389757567783818e-05
. O 0 2.6754958071251167e-06

Large O 0 4.138866643188521e-06
- O 0 4.06983817811124e-05
scale O 0 1.966210675163893e-06
RNA O 0 2.2110182840151538e-07
differential O 0 1.5996027968867566e-07
display O 0 2.5447590701332956e-08
technology O 0 3.9331091272742924e-08
applied O 0 8.25248847036164e-09
to O 0 3.201021392396086e-10
these O 0 4.761572802713943e-10
cell O 0 4.001154607635726e-08
lines O 0 2.5698648187244544e-07
identified O 0 2.4757314420753573e-08
several O 0 1.4300141071288408e-09
differentially O 0 1.3030773970967857e-07
expressed O 0 1.7166323917905402e-09
genes O 0 7.385189348951826e-09
, O 0 2.4846363855246523e-10
including O 0 3.2521307868904614e-10
an O 0 1.01507868777162e-09
alpha O 0 1.0972404140829894e-07
carbonic O 0 4.2286928874091245e-06
anhydrase O 0 4.456517672224436e-06
gene O 0 8.095311727629451e-07
, O 0 3.254703173638518e-08
termed O 0 1.4824117897660471e-06
CA12 O 0 7.764184556435794e-05
. O 0 1.1676850135700079e-06

The O 0 1.1825343193549998e-07
deduced O 0 2.590917347333743e-07
protein O 0 1.8433444992638215e-08
sequence O 0 1.3066109083581523e-08
was O 0 3.816769122977348e-09
classified O 0 5.746919828908403e-09
as O 0 5.934299718290958e-10
a O 0 5.564846361494347e-10
one O 0 6.089682536014607e-09
- O 0 1.4486932968793553e-06
pass O 0 5.679026671145948e-08
transmembrane O 0 3.463325981556409e-07
CA O 0 2.0574984205268265e-07
possessing O 0 8.108275828533351e-09
an O 0 1.187489884202364e-09
apparently O 0 8.24116668241004e-08
intact O 0 4.570787481839034e-08
catalytic O 0 2.9512854382574005e-08
domain O 0 2.199345949804865e-08
in O 0 2.776734620013599e-09
the O 0 8.354067659865905e-09
extracellular O 0 3.271772129664896e-06
CA O 0 0.00028705570730380714
module O 0 3.4549902920844033e-06
. O 0 4.3854959130840143e-07

Reintroduced O 0 2.437567491142545e-05
wild O 0 3.817441211140249e-06
- O 0 0.00011581017315620556
type O 0 1.6600906747044064e-05
VHL B-Disease 0 3.115651270491071e-05
strongly O 0 6.388511764043869e-08
inhibited O 0 7.365287757465921e-08
the O 0 7.754354935940455e-10
overexpression O 0 1.309105446267722e-08
of O 0 1.2587082764969892e-10
the O 0 8.311817900619189e-10
CA12 O 0 2.690718190478947e-07
gene O 0 3.381974877925131e-08
in O 0 1.6611186870463257e-09
the O 0 2.052359349136168e-08
parental O 0 0.0109694954007864
renal B-Disease 1 0.9998630285263062
cell I-Disease 1 0.999987006187439
carcinoma I-Disease 1 1.0
cell O 1 0.993516206741333
lines O 0 0.21652409434318542
. O 0 7.736110092082527e-06

Similar O 0 1.1946282256758423e-06
results O 0 1.9596834022195253e-07
were O 0 4.0141476809196774e-09
obtained O 0 1.1305510305703592e-08
with O 0 3.5595204561644778e-09
CA9 O 0 7.190160249592736e-05
, O 0 1.1159330126631062e-09
encoding O 0 3.825334360385568e-08
another O 0 3.006430659979742e-08
transmembrane O 0 1.6875388610060327e-05
CA O 0 0.002263477537781
with O 0 2.360763584619008e-09
an O 0 3.945504811753153e-09
intact O 0 1.4739478046976728e-06
catalytic O 0 2.5276453925471287e-06
domain O 0 6.369000402628444e-06
. O 0 1.4910832533132634e-06

Although O 0 6.24927679382381e-07
both O 0 1.1207157868398099e-08
domains O 0 7.644982957799584e-08
of O 0 1.095392998529121e-09
the O 0 2.759206862990027e-09
VHL B-Disease 0 1.0253123718939605e-06
protein O 0 7.562876547240194e-09
contribute O 0 7.912954180788745e-10
to O 0 2.7289279169728786e-10
regulation O 0 2.818703270790479e-09
of O 0 1.5506136652465585e-10
CA12 O 0 1.9112664517706435e-07
expression O 0 7.577503957634235e-09
, O 0 5.928970647772758e-10
the O 0 4.997219305025169e-10
elongin O 0 1.5023752553133818e-07
binding O 0 2.8795117401614334e-08
domain O 0 6.522383699802958e-08
alone O 0 4.6271456000113176e-08
could O 0 2.7893538145917773e-08
effectively O 0 2.7014783654522034e-07
regulate O 0 3.150501242998871e-06
CA9 O 0 0.00024089722137432545
expression O 0 2.8364484023768455e-06
. O 0 1.1858766129080323e-06

We O 0 2.7273672458250076e-06
mapped O 0 1.0490012755326461e-05
CA12 O 0 3.679107248899527e-05
and O 0 2.1491426593911456e-07
CA9 O 0 5.2235725888749585e-05
loci O 0 1.4526750646837172e-06
to O 0 1.9115466542984905e-08
chromosome O 0 1.1665474630717654e-06
bands O 0 5.31883301846392e-07
15q22 O 0 5.666384822688997e-06
and O 0 1.487982359549278e-07
17q21 O 0 1.6065700037870556e-05
. O 0 1.2550245855891262e-06

2 O 0 5.021018978368375e-07
respectively O 0 6.002252916914586e-08
, O 0 2.9926181532857754e-09
regions O 0 2.004132149124871e-08
prone O 0 7.042565357551211e-07
to O 0 1.8574005666849303e-09
amplification O 0 1.1482784856298167e-07
in O 0 1.7333098289995519e-09
some O 0 2.269393117870777e-09
human O 0 2.5162952965729346e-07
cancers B-Disease 0 0.016362646594643593
. O 0 4.848023422709957e-07

Additional O 0 1.922149976962828e-07
experiments O 0 1.0092956159724054e-07
are O 0 1.7662897811021594e-09
needed O 0 2.5635231715170903e-09
to O 0 1.7298774912521964e-10
define O 0 8.115810246067667e-09
the O 0 8.293574160767037e-10
role O 0 1.552526995851622e-08
of O 0 1.3504696250166148e-09
CA O 0 9.694894288259093e-06
IX O 0 2.021674561092368e-07
and O 0 1.383767411766712e-08
CA O 0 2.984958484830713e-07
XII O 0 3.210538679354613e-08
enzymes O 0 3.6243434919924766e-09
in O 0 2.2789306552972732e-10
the O 0 1.9006488050088421e-10
regulation O 0 2.3635842172353705e-09
of O 0 1.1378988029608905e-10
pH O 0 2.180645353178079e-08
in O 0 3.666665582269246e-10
the O 0 2.7082489029162105e-10
extracellular O 0 1.4333955355994021e-08
microenvironment O 0 1.194959367012416e-07
and O 0 1.5737298131313082e-09
its O 0 1.6696506399682676e-09
potential O 0 3.946492554973702e-08
impact O 0 5.5370705354107486e-08
on O 0 4.286631849481637e-08
cancer B-Disease 0 1.0125096423507784e-06
cell O 0 8.277634151454549e-07
growth O 0 6.63866842387506e-07
. O 0 1.941168363828183e-07

A O 0 4.927699706058775e-07
gene O 0 7.95013647802989e-07
encoding O 0 3.9669527041041874e-07
a O 0 2.9727084793762515e-08
transmembrane O 0 6.959135703255015e-07
protein O 0 5.128802271769928e-08
is O 0 1.1263340260470045e-09
mutated O 0 1.272389056339307e-07
in O 0 6.946429653709174e-09
patients O 0 4.85714963360806e-07
with O 0 1.4609080380978412e-06
diabetes B-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 0 0.0003424683818593621
optic B-Disease 1 0.9999988079071045
atrophy I-Disease 1 0.9997832179069519
( O 0 0.0008409394067712128
Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
) O 0 1.2410280305630295e-06
. O 0 8.34905165447708e-07

Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 1.1051067303924356e-05
WFS B-Disease 0 0.2070869505405426
; O 0 3.1381716780742863e-07
OMIM O 0 8.922510460251942e-05
222300 O 0 8.44396367938316e-07
) O 0 4.751866899965762e-09
is O 0 1.929550075274733e-09
an O 0 1.4338275455827443e-08
autosomal B-Disease 1 0.999980092048645
recessive I-Disease 1 0.9999938011169434
neurodegenerative I-Disease 1 0.9998553991317749
disorder I-Disease 1 0.9837902188301086
defined O 0 2.0681629564478499e-07
by O 0 9.316667437531123e-09
young O 0 2.1948898165646824e-07
- O 0 4.679780249716714e-05
onset O 0 0.00038418459007516503
non O 0 0.0001170647083199583
- O 0 0.004637613892555237
immune O 0 0.00012881522707175463
insulin B-Disease 1 0.8963027000427246
- I-Disease 1 0.9309906959533691
dependent I-Disease 1 0.9006083011627197
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 0 1.1768589729399537e-06
progressive O 0 1.0944612768071238e-05
optic B-Disease 1 0.9997424483299255
atrophy I-Disease 0 0.03838484361767769
. O 0 6.6548345785122365e-06

Linkage O 0 2.249244244012516e-05
to O 0 6.96774336006456e-08
markers O 0 1.0470455436006887e-06
on O 0 6.675389130350595e-08
chromosome O 0 9.562566447129939e-06
4p O 0 0.010709710419178009
was O 0 8.560617175135121e-07
confirmed O 0 7.555080827614802e-08
in O 0 4.663069486099403e-09
five O 0 2.4809972742900754e-08
families O 0 1.3418284083854815e-07
. O 0 4.580474524118472e-07

On O 0 4.0376853860379924e-08
the O 0 1.4400647341261674e-09
basis O 0 2.2881958550158288e-09
of O 0 3.092610612043245e-10
meiotic O 0 8.335208576681907e-07
recombinants O 0 5.6973400205606595e-05
and O 0 3.0304903475553147e-07
disease O 0 8.001296009751968e-06
- O 0 3.937691417377209e-06
associated O 0 4.813250953361603e-08
haplotypes O 0 1.249588308382954e-06
, O 0 1.8557928527229706e-09
the O 0 1.0182996668106625e-09
WFS B-Disease 0 2.9840468869224424e-06
gene O 0 4.812480014493303e-08
was O 0 4.4901820039910945e-09
localized O 0 3.2063407928717425e-08
to O 0 3.5001535003686968e-09
a O 0 2.006151511579901e-08
BAC O 0 4.410928340803366e-06
/ O 0 2.4878903559510945e-07
P1 O 0 9.745207307787496e-07
contig O 0 1.68694910485101e-07
of O 0 2.0640007758476742e-10
less O 0 1.0137746198068953e-09
than O 0 2.0442749715243735e-09
250 O 0 2.1502307490095518e-08
kb O 0 1.2442557817848865e-05
. O 0 8.293809514725581e-07

Mutations O 0 0.00021595558791887015
in O 0 1.0777823433727463e-07
a O 0 2.7652829359681164e-08
novel O 0 1.5483254856007989e-07
gene O 0 5.153110578248743e-07
( O 0 1.6902868438251062e-08
WFS1 O 0 1.565573029438383e-06
) O 0 2.6754325421762815e-09
encoding O 0 1.8651192590368737e-08
a O 0 3.581558383203287e-09
putative O 0 1.1235136554432756e-07
transmembrane O 0 6.114942152635194e-08
protein O 0 8.913236371199673e-09
were O 0 7.771145393853374e-10
found O 0 4.928206731591445e-10
in O 0 1.4929323055579147e-10
all O 0 1.7510132233056197e-10
affected O 0 7.498767717883936e-10
individuals O 0 3.099850653942582e-10
in O 0 5.109581646678407e-10
six O 0 3.3790263920252528e-09
WFS B-Disease 0 1.4439498272622586e-06
families O 0 6.629527482537867e-10
, O 0 6.420103337845262e-11
and O 0 5.091988983241258e-11
these O 0 1.6521252421686228e-10
mutations O 0 1.2431461193784799e-08
were O 0 3.6728461938473345e-10
associated O 0 7.383327282894925e-10
with O 0 9.319294225207386e-10
the O 0 1.2263936355338956e-07
disease O 0 4.342840475146659e-05
phenotype O 0 0.00010123163519892842
. O 0 9.940059726432082e-07

WFS1 O 0 0.00013221333210822195
appears O 0 6.02303373398172e-07
to O 0 5.452159168584103e-09
function O 0 1.9646378746074333e-08
in O 0 9.977781267878072e-09
survival O 0 9.139448593487032e-07
of O 0 1.3975274271160743e-09
islet O 0 3.508341023916728e-06
beta O 0 4.772497845806356e-07
- O 0 3.3869180242618313e-06
cells O 0 1.4503561374112905e-07
and O 0 1.0489866753005117e-08
neurons O 0 1.2024665352328157e-07
. O 0 2.087086414803707e-08
. O 0 2.212058092254665e-07

Stable O 0 4.5947467697260436e-06
interaction O 0 4.869114889061166e-08
between O 0 3.059597908361411e-09
the O 0 2.7190250051489784e-10
products O 0 4.524958630014453e-09
of O 0 8.943949053596967e-11
the O 0 2.2132022881038438e-09
BRCA1 O 0 1.3979666618979536e-05
and O 0 5.902494493170707e-08
BRCA2 O 0 2.3912694814498536e-05
tumor B-Disease 0 2.1773428215965396e-06
suppressor O 0 1.5114377447389415e-06
genes O 0 4.1281657559011364e-07
in O 0 1.1534363686394045e-08
mitotic O 0 3.1443419175047893e-06
and O 0 1.8795797984694218e-07
meiotic O 0 4.187793820165098e-05
cells O 0 1.8838140022126026e-05
. O 0 1.669231664891413e-06

BRCA1 O 0 0.00029058000654913485
and O 0 2.090560968781574e-07
BRCA2 O 0 1.9850058379233815e-06
account O 0 1.4174364793007044e-08
for O 0 2.5880519949339487e-10
most O 0 2.6734212066337193e-10
cases O 0 1.6403386426944166e-09
of O 0 1.1567002911050395e-10
familial O 0 3.6299190924182767e-06
, O 0 2.085004169316562e-09
early O 0 3.672723636327646e-08
onset O 0 3.2992666092468426e-06
breast B-Disease 0 0.13625499606132507
and I-Disease 0 8.934786706049636e-07
/ I-Disease 0 0.22844280302524567
or I-Disease 1 0.9998270869255066
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
and O 0 3.0321925525989e-10
encode O 0 3.785477709072893e-09
products O 0 1.7434766519386358e-08
that O 0 3.9791486772244866e-10
each O 0 4.2841097336321354e-10
interact O 0 5.867985652940888e-09
with O 0 7.849102701129596e-09
hRAD51 O 0 8.644249646749813e-06
. O 0 5.394976483330538e-07

Results O 0 1.4807643538006232e-06
presented O 0 2.9013541791300668e-08
here O 0 3.496023692761696e-09
show O 0 1.9363788794635184e-08
that O 0 2.2056421133953563e-09
BRCA1 O 0 8.335534857906168e-07
and O 0 9.246122978368021e-09
BRCA2 O 0 1.7085621948353946e-06
coexist O 0 2.685795834622695e-07
in O 0 2.131609111444277e-09
a O 0 3.853688035349023e-09
biochemical O 0 3.583388377137453e-07
complex O 0 3.932974124154498e-08
and O 0 4.00113764342791e-09
colocalize O 0 3.471278375855036e-07
in O 0 3.084765110017429e-09
subnuclear O 0 4.902672685602738e-07
foci O 0 2.513536969672714e-07
in O 0 9.761116359641164e-10
somatic O 0 3.3191241755048395e-08
cells O 0 2.3908899748903423e-08
and O 0 5.772206046472661e-10
on O 0 2.630914652801408e-10
the O 0 1.6539254688030525e-10
axial O 0 1.8760870190703827e-08
elements O 0 1.9565939979315772e-08
of O 0 1.8522778866270073e-09
developing O 0 1.659169583945186e-07
synaptonemal O 0 5.991483249090379e-06
complexes O 0 3.615363766584778e-06
. O 0 6.075137548577914e-07

Like O 0 9.321242941950914e-06
BRCA1 O 0 0.00013069836131762713
and O 0 7.068335889925947e-07
RAD51 O 0 9.174814476864412e-05
, O 0 5.6590444330595346e-08
BRCA2 O 0 9.43765917327255e-06
relocates O 0 1.2456428066798253e-06
to O 0 3.241365220674197e-08
PCNA O 0 8.102285391942132e-06
+ O 0 1.1964142743181583e-07
replication O 0 2.847886726442539e-08
sites O 0 8.8565839106991e-09
following O 0 6.155651099959414e-09
exposure O 0 8.358181275980314e-07
of O 0 1.0575380571253845e-09
S O 0 1.336145146524359e-06
phase O 0 4.1521630578245095e-08
cells O 0 2.672134158387962e-08
to O 0 2.591916237193459e-09
hydroxyurea O 0 1.3375398566495278e-06
or O 0 7.409177982253823e-08
UV O 0 1.3028655303060077e-05
irradiation O 0 1.0455454685143195e-05
. O 0 9.779701031220611e-07

Thus O 0 1.0486894552741433e-06
, O 0 2.997589731990047e-08
BRCA1 O 0 1.4828600569671835e-06
and O 0 7.732411155814134e-09
BRCA2 O 0 2.612301841509179e-07
participate O 0 2.046455893633947e-09
, O 0 2.392338271928196e-10
together O 0 3.3607833183069147e-10
, O 0 3.5253033825455304e-10
in O 0 6.147036213377532e-10
a O 0 2.3283208694380164e-09
pathway O 0 3.164093698160286e-08
( O 0 1.5888643734029984e-09
s O 0 2.629678874654928e-07
) O 0 1.1780713071729565e-09
associated O 0 2.068344828742852e-09
with O 0 1.4620668564724326e-10
the O 0 2.850829294853696e-10
activation O 0 1.6777880196272577e-09
of O 0 1.4956770544305442e-10
double O 0 2.1048487042207853e-07
- O 0 9.393535037816036e-06
strand O 0 0.007609983440488577
break O 0 2.2796104531153105e-05
repair O 0 1.2021529983030632e-05
and O 0 9.516799792663733e-09
/ O 0 9.763508046489733e-08
or O 0 2.2603874327842277e-08
homologous O 0 2.8411047878762474e-06
recombination O 0 7.7847789725638e-06
. O 0 8.095389034679101e-07

Dysfunction O 0 0.00024260587815660983
of O 0 6.299441412949136e-09
this O 0 1.394305781943217e-09
pathway O 0 2.1453763210388388e-08
may O 0 1.7664726570387757e-08
be O 0 2.370684759611663e-10
a O 0 5.346536408046276e-11
general O 0 8.841941068205017e-11
phenomenon O 0 5.170464945081221e-09
in O 0 1.6521693735338516e-10
the O 0 1.8212727159738762e-10
majority O 0 2.9766558107269248e-09
of O 0 7.924760847544121e-11
cases O 0 6.36308072898828e-09
of O 0 9.698057912288505e-10
hereditary B-Disease 1 0.9735418558120728
breast I-Disease 1 0.9987296462059021
and I-Disease 0 1.9769446225836873e-05
/ I-Disease 1 0.8714181184768677
or I-Disease 1 0.999970555305481
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 9.75557838955865e-08
. O 0 2.735001771725365e-07

A O 0 1.1357033145031892e-06
novel O 0 7.671720254620595e-07
Arg362Ser O 0 4.205985078442609e-06
mutation O 0 1.501325641584117e-06
in O 0 9.124432764906487e-09
the O 0 1.0556160390251534e-08
sterol O 0 2.25539188249968e-05
27 O 0 2.3117064529287745e-07
- O 0 7.66217851833062e-07
hydroxylase O 0 6.883283276692964e-06
gene O 0 2.900118829529674e-07
( O 0 3.0361988478944113e-09
CYP27 O 0 5.804227498629189e-07
) O 0 1.6663483926038225e-09
: O 0 1.903841806427664e-10
its O 0 4.619927218563191e-10
effects O 0 3.4097718071279814e-07
on O 0 5.355655918748425e-09
pre O 0 1.1466834166640183e-06
- O 0 1.0284858831255406e-07
mRNA O 0 3.4849271912662516e-08
splicing O 0 2.3217259581542748e-07
and O 0 5.548294712554025e-09
enzyme O 0 1.2893831069504813e-07
activity O 0 1.506771809545171e-07
. O 0 2.0403501821419923e-07

A O 0 2.3398040127631248e-07
novel O 0 1.619860370283277e-07
C O 0 2.0212928575347178e-07
to O 0 1.3968080025961171e-09
A O 0 2.7443063377319277e-09
mutation O 0 7.940887059021406e-08
in O 0 1.7186766454457825e-09
the O 0 4.430215749806621e-09
sterol O 0 3.395761814317666e-05
27 O 0 1.1171223235351135e-07
- O 0 3.6683837834061706e-07
hydroxylase O 0 2.697500576687162e-06
gene O 0 2.0291224700486055e-07
( O 0 2.267610543782439e-09
CYP27 O 0 6.190665544636431e-07
) O 0 2.7325179896564578e-09
was O 0 3.7572087663306775e-09
identified O 0 3.1973375058669262e-09
by O 0 1.937917742944606e-10
sequencing O 0 1.3961001243956161e-08
amplified O 0 6.709048960829023e-08
CYP27 O 0 1.7332355639609887e-07
gene O 0 1.365451307577814e-08
products O 0 5.796547242198358e-09
from O 0 1.692259388175188e-10
a O 0 1.5537644504348691e-09
patient O 0 1.77477460283626e-07
with O 0 5.382089085514963e-08
cerebrotendinous B-Disease 1 1.0
xanthomatosis I-Disease 1 0.9999998807907104
( O 0 1.8888553654505813e-07
CTX B-Disease 0 0.001046523335389793
) O 0 2.8849825639554183e-07
. O 0 7.146350640141463e-07

The O 0 2.0427781066700845e-07
mutation O 0 1.2922702126161312e-06
changed O 0 1.235636375440663e-07
the O 0 5.352164045291374e-09
adrenodoxin O 0 9.562069180901744e-07
cofactor O 0 3.821418772531615e-07
binding O 0 1.7311705846623227e-07
residue O 0 5.277718742036086e-07
362Arg O 0 4.329326372953801e-07
to O 0 7.225142262257123e-09
362Ser O 0 4.40084676256447e-07
( O 0 3.869169429293606e-09
CGT O 0 3.7877626368754136e-07
362Arg O 0 2.360153104064011e-07
to O 0 3.907579593231958e-09
AGT O 0 9.035288144332299e-07
362Ser O 0 7.641120447487992e-08
) O 0 4.5484754851443654e-10
, O 0 1.2936847426647802e-10
and O 0 3.623705779887132e-10
was O 0 7.954587211145281e-09
responsible O 0 1.4924156133133692e-08
for O 0 2.6325688295969485e-08
deficiency O 0 3.3641936170170084e-05
in O 0 1.044183295384471e-09
the O 0 1.0655905047229908e-09
sterol O 0 5.440705535875168e-06
27 O 0 2.7016271886282084e-08
- O 0 4.241655560122126e-08
hydroxylase O 0 2.111382713110288e-07
activity O 0 1.0475150524769106e-08
, O 0 3.573048246163779e-10
as O 0 4.6600351355508e-10
confirmed O 0 1.8258963230266545e-09
by O 0 7.955792968861175e-11
expression O 0 1.7803297724938716e-09
of O 0 2.0558912905421778e-10
mutant O 0 1.7299452537145044e-08
cDNA O 0 3.334562848067435e-08
into O 0 1.1754547557529804e-08
COS O 0 1.4270552128436975e-05
- O 0 1.365286834698054e-06
1 O 0 6.660751239451201e-08
cells O 0 3.9261280448954494e-07
. O 0 2.581838316473295e-07

Quantitative O 0 5.1304346015967894e-06
analysis O 0 3.974514868332335e-07
showed O 0 5.839940797613963e-08
that O 0 1.000804439321712e-09
the O 0 4.822821586536463e-10
expression O 0 1.186320108814698e-08
of O 0 7.669512247510113e-10
CYP27 O 0 4.6741450887566316e-07
gene O 0 6.905191440864655e-08
mRNA O 0 3.695645744983267e-08
in O 0 2.5148658711060534e-09
the O 0 2.7402424773725897e-09
patient O 0 1.2282171724109503e-07
represented O 0 5.9356299431101434e-08
52 O 0 2.7368989208298444e-07
. O 0 4.81985637179605e-07

5 O 0 7.628915454915841e-07
% O 0 2.3605037924312455e-08
of O 0 7.938092960735332e-10
the O 0 7.592462658578825e-09
normal O 0 5.599401333711285e-07
level O 0 1.4374496686286875e-06
. O 0 8.023478130780859e-07

As O 0 1.8843770988041797e-07
the O 0 6.7302323714102386e-09
mutation O 0 1.6147026826729416e-07
occurred O 0 2.378001262570706e-08
at O 0 1.9964205844047456e-09
the O 0 6.828200227460002e-10
penultimate O 0 3.997821096390908e-08
nucleotide O 0 7.473558838455574e-08
of O 0 4.721229518445114e-10
exon O 0 5.6968733730400345e-08
6 O 0 2.9743458807018897e-09
( O 0 5.672536884659962e-10
- O 0 4.51378916466183e-08
2 O 0 1.8029072679226488e-09
position O 0 5.91359139434644e-09
of O 0 1.3666172360426998e-10
exon O 0 8.947987595320228e-08
6 O 0 1.2203646981845395e-08
- O 0 8.837030662789402e-08
intron O 0 1.538657443234115e-06
6 O 0 6.161877230681512e-09
splice O 0 1.3197836778999772e-07
site O 0 1.3777023077921058e-08
) O 0 3.126464365177384e-10
of O 0 3.341332072137604e-11
the O 0 9.253893484828524e-11
gene O 0 3.692360639462322e-09
, O 0 4.978325529592098e-10
we O 0 4.70959160558948e-10
hypothesized O 0 1.5818943932544016e-09
that O 0 1.5123265140193354e-10
the O 0 4.705730805021346e-10
mutation O 0 1.9048412980282592e-07
may O 0 6.23006854993946e-08
partially O 0 2.2757453166377672e-07
affect O 0 7.785436295648651e-09
the O 0 3.696241368533748e-10
normal O 0 3.3004554644833206e-09
splicing O 0 5.292345051088887e-08
efficiency O 0 1.0731971755717495e-08
in O 0 4.319275492825625e-10
exon O 0 6.371450922415534e-08
6 O 0 8.618761704326516e-09
and O 0 1.8529774381548236e-09
cause O 0 1.313221198451231e-09
alternative O 0 1.5753424120745763e-09
splicing O 0 4.183260671197786e-08
elsewhere O 0 4.343552362229275e-08
, O 0 3.8858524731288924e-10
which O 0 7.041538463425923e-10
resulted O 0 4.756754989898582e-09
in O 0 2.158060841139786e-09
decreased O 0 4.142156839748168e-08
transcript O 0 1.3071473858872196e-07
in O 0 5.633851163366899e-09
the O 0 1.4841891271544227e-08
patient O 0 1.020802869788895e-06
. O 0 1.9898340042345808e-07

Transfection O 0 0.00012259191134944558
of O 0 2.5377211443355918e-08
constructed O 0 3.991185906215833e-07
minigenes O 0 1.6807440488264547e-06
, O 0 1.3170741164358901e-09
with O 0 2.8947513830424043e-10
or O 0 7.607408036847119e-09
without O 0 9.014828883380233e-09
the O 0 7.17861270427278e-10
mutation O 0 6.016706777245417e-08
, O 0 4.4931525167157815e-10
into O 0 1.2826585349401398e-09
COS O 0 2.062708153971471e-05
- O 0 2.8784307914975216e-07
1 O 0 5.115415202538998e-09
cells O 0 9.745234841318506e-09
confirmed O 0 2.584082503531704e-09
that O 0 6.751427195084148e-11
the O 0 1.0841474940015416e-10
mutant O 0 7.793370393471832e-09
minigene O 0 6.703869104285332e-08
was O 0 5.836841676654103e-09
responsible O 0 1.1694185619859354e-09
for O 0 2.633620543868176e-10
a O 0 7.617902419987388e-10
mRNA O 0 8.999160527878303e-09
species O 0 1.4012829785414738e-09
alternatively O 0 1.7358649628818057e-08
spliced O 0 5.35060507900198e-07
at O 0 1.1526446463960838e-08
an O 0 9.19550158240412e-10
activated O 0 7.580383964977955e-08
cryptic O 0 8.762626180214284e-08
5 O 0 3.2199507504770963e-09
splice O 0 2.731149493229168e-07
site O 0 5.199017749646373e-08
88 O 0 9.428018366008928e-09
bp O 0 5.049913553989427e-08
upstream O 0 3.6684091320182688e-09
from O 0 1.7262419271801832e-10
the O 0 4.283276511252154e-10
3 O 0 1.6110313083572692e-09
end O 0 6.29898488924141e-09
of O 0 1.3897629713710558e-09
exon O 0 5.811610890305019e-07
6 O 0 1.4360585964823258e-07
. O 0 1.9611528045970772e-07

Our O 0 2.2883700978582056e-07
data O 0 3.703944528865577e-08
suggest O 0 1.0111564918702243e-08
that O 0 2.4951840593701036e-10
the O 0 4.670909770077003e-10
C O 0 3.389827796240752e-08
to O 0 3.20686366350742e-10
A O 0 9.72729119474991e-10
mutation O 0 1.2543452498903207e-08
at O 0 5.514320666755168e-10
the O 0 3.182878682839174e-10
penultimate O 0 1.9883728441527637e-08
nucleotide O 0 1.396547588683461e-08
of O 0 9.992837113337316e-11
exon O 0 3.1228079677703136e-08
6 O 0 1.4296213102227284e-09
of O 0 4.76221492795581e-11
the O 0 3.2309796504925714e-10
CYP27 O 0 1.5027650590582198e-07
gene O 0 1.0534337846479502e-08
not O 0 1.739649091447859e-09
only O 0 7.590518769085008e-10
causes O 0 1.2904972201965847e-08
the O 0 1.654331072131754e-08
deficiency B-Disease 0 0.0004300412838347256
in I-Disease 0 1.2581856667637226e-09
the I-Disease 0 2.3541986138297943e-09
sterol I-Disease 0 5.68345876672538e-06
27 I-Disease 0 1.497765467206591e-08
- I-Disease 0 2.168691182191651e-08
hydroxylase I-Disease 0 1.9991048816336843e-07
activity I-Disease 0 4.7753085929969075e-09
, O 0 2.2356579088000927e-10
but O 0 1.6313217443553185e-09
also O 0 1.7006926977813919e-09
partially O 0 4.172519041389933e-08
leads O 0 1.3112013697025304e-09
to O 0 2.851579805618343e-10
alternative O 0 1.0553321772022173e-08
pre O 0 2.5897489308590593e-07
- O 0 4.6714042412077106e-08
mRNA O 0 1.5861825630736348e-08
splicing O 0 5.630309729554028e-08
of O 0 5.112944512219997e-10
the O 0 4.23609858302143e-09
gene O 0 6.293678893598553e-07
. O 0 4.598204839112441e-07

To O 0 1.2163590668023971e-07
our O 0 8.144793284259322e-09
knowledge O 0 3.2336449073966378e-09
, O 0 1.6730608565218574e-10
this O 0 4.619951296525038e-11
is O 0 1.3300137380323207e-10
the O 0 1.2083840872367801e-10
first O 0 5.996082741432929e-09
report O 0 5.357648547033023e-09
regarding O 0 3.018230332330063e-09
effects O 0 3.4501521639640487e-08
on O 0 1.4073255893976011e-09
pre O 0 1.3662830156135897e-07
- O 0 1.1238711294936365e-08
mRNA O 0 2.6903745897755016e-09
splicing O 0 5.709946293563917e-09
of O 0 5.5926690362140263e-11
a O 0 3.763360456598974e-10
mutation O 0 9.497487241105773e-09
at O 0 7.632387499789672e-10
the O 0 4.5556469707719316e-10
- O 0 7.775250310260162e-07
2 O 0 1.0955691465142081e-08
position O 0 3.791290055232821e-07
of O 0 3.169859097429395e-10
a O 0 5.515217615936763e-09
5 O 0 1.429894869175996e-08
splice O 0 3.951862709072884e-06
site O 0 1.1301930271656602e-06
. O 0 5.019788886784227e-07

ATM O 0 0.0008038476225920022
germline O 0 0.00038280009175650775
mutations O 0 5.14528073836118e-05
in O 0 1.5505641215440846e-07
classical O 0 7.826709043001756e-05
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 1 0.963888943195343
in O 0 2.5093569888667844e-08
the O 0 1.1773440888873665e-08
Dutch O 0 2.3172799046733417e-05
population O 0 2.0941806155860831e-07
. O 0 4.1788229054873227e-07

Germline O 0 0.000457391346571967
mutations O 0 1.7263153495150618e-05
in O 0 1.1582557135625393e-08
the O 0 1.1834808688604426e-09
ATM O 0 7.409093427668267e-08
gene O 0 7.012925795635283e-09
are O 0 1.4814866000634197e-10
responsible O 0 1.0927136973037932e-09
for O 0 1.5130889874370723e-09
the O 0 1.5314801203203388e-05
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.4686606526374817
A B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
) O 0 5.746352371716057e-07
. O 0 3.816858793470601e-07

In O 0 1.4899447364769003e-07
our O 0 9.952104029764541e-09
study O 0 1.3326655334822135e-09
, O 0 1.5701641375986952e-10
we O 0 4.027559119545998e-10
have O 0 2.369324181294985e-10
determined O 0 2.8174025334948283e-09
the O 0 1.684125755518906e-10
ATM O 0 8.432144227299432e-08
mutation O 0 1.4803610781655152e-08
spectrum O 0 7.092304077360723e-09
in O 0 5.946729220163149e-10
19 O 0 1.0593086408050567e-09
classical O 0 1.4162696970743127e-07
A B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
patients O 0 1.4754118637938518e-07
, O 0 3.385415905943212e-11
including O 0 1.9149886537617178e-11
some O 0 6.053487572321714e-11
immigrant O 0 1.6612652586900367e-08
populations O 0 5.261834523651032e-09
, O 0 1.187328568796886e-10
as O 0 8.812089946630408e-11
well O 0 4.235749251346732e-10
as O 0 5.039872408296731e-10
12 O 0 5.786436330090794e-10
of O 0 2.6887317372548125e-10
Dutch O 0 4.269266355549917e-06
ethnic O 0 1.3745373905749148e-07
origin O 0 1.4065313962419168e-06
. O 0 5.150457695890509e-07

Both O 0 6.497327120769114e-08
the O 0 3.134813519878321e-09
protein O 0 1.4844155238336043e-08
truncation O 0 6.778797683182347e-07
test O 0 2.1950363304767961e-07
( O 0 6.435493249412616e-10
PTT O 0 1.4089491173763236e-07
) O 0 3.941674209251289e-10
and O 0 1.3437832790952342e-10
the O 0 1.6182584439139447e-10
restriction O 0 3.5329181802268295e-09
endonuclease O 0 2.4050510205597675e-07
fingerprinting O 0 1.6407000202889321e-07
( O 0 8.058995137893987e-10
REF O 0 6.750856584858411e-08
) O 0 4.906678535698816e-11
method O 0 4.261860309107135e-10
were O 0 6.471666952334587e-11
used O 0 4.840607914502471e-10
and O 0 1.0212634904416262e-10
compared O 0 4.0633926778887997e-10
for O 0 1.7584189312969123e-11
their O 0 7.72630084910908e-11
detection O 0 9.859130400968752e-09
efficiency O 0 1.938092575315409e-09
, O 0 4.2151154094893784e-11
identifying O 0 2.304295865229733e-09
76 O 0 2.4515116603396336e-09
% O 0 4.1068545786338007e-10
and O 0 4.4011655431219765e-10
60 O 0 6.451014722408388e-10
% O 0 2.3467464083104517e-10
of O 0 4.961544369797011e-11
the O 0 1.741970012680838e-09
mutations O 0 5.84244730816863e-07
, O 0 7.161713000414238e-09
respectively O 0 2.7618759190772835e-07
. O 0 4.2556101220725395e-07

Most O 0 2.760175163984968e-07
patients O 0 4.72612242674586e-07
were O 0 2.0173434034376214e-09
found O 0 1.87512028126946e-09
to O 0 1.68806613132233e-09
be O 0 8.540930629408194e-09
compound O 0 3.282486886746483e-07
heterozygote O 0 8.286946831503883e-05
. O 0 1.468543246119225e-06

Seventeen O 0 3.6043509226146853e-06
mutations O 0 1.962417172762798e-06
were O 0 1.0796500582443969e-08
distinct O 0 1.1113496789505461e-08
, O 0 8.500621317963919e-10
of O 0 3.841832060813566e-11
which O 0 5.700737104596953e-10
10 O 0 2.427621714762296e-10
were O 0 7.300426929646164e-10
not O 0 4.433884814858402e-09
reported O 0 6.168887978219573e-08
previously O 0 2.1196262878220296e-07
. O 0 2.343989393693846e-07

Mutations O 0 9.130895341513678e-05
are O 0 6.21541005330073e-08
small O 0 3.4762436484925274e-08
deletions O 0 5.902055022488639e-07
or O 0 2.4587086500105215e-07
point O 0 5.468397716867912e-07
mutations O 0 4.531850663624937e-06
frequently O 0 6.881103900013841e-07
affecting O 0 4.315747332839237e-07
splice O 0 1.6056403183029033e-05
sites O 0 5.5851578508736566e-06
. O 0 2.24018185690511e-06

Moreover O 0 1.3403258890321013e-05
, O 0 1.1355437123938827e-07
a O 0 1.184690248123843e-07
16 O 0 2.75790171144763e-07
. O 0 6.015806093273568e-07

7 O 0 5.454373877000762e-06
- O 0 5.536824119189987e-06
kb O 0 2.68558801508334e-06
genomic O 0 5.712976758331934e-07
deletion O 0 4.72317594812921e-07
of O 0 3.9278125196773317e-10
the O 0 5.141314596279756e-10
3 O 0 1.2672218829834492e-09
end O 0 1.8395009959704112e-09
of O 0 2.481869224024713e-11
the O 0 6.433231725111455e-11
gene O 0 1.589312903504947e-09
, O 0 1.2211179289955965e-10
most O 0 1.802809984630116e-10
likely O 0 2.6898976379641226e-09
a O 0 5.201025721213171e-10
result O 0 2.033545554169791e-09
of O 0 3.350688129732937e-11
recombination O 0 4.2026444546650055e-09
between O 0 9.126343014642657e-10
two O 0 1.4777621348827097e-09
LINE O 0 4.886116471425339e-07
elements O 0 7.39956078632531e-08
, O 0 7.854958461450678e-09
was O 0 4.6351132709787635e-08
identified O 0 2.3638338575437956e-07
. O 0 1.5164475541951106e-07

The O 0 3.8370629340533924e-08
most O 0 1.4382373514365554e-08
frequently O 0 8.055990008415392e-08
found O 0 1.4158072048076065e-08
mutation O 0 8.077206814505189e-08
, O 0 4.2266784516797884e-10
identified O 0 6.498886317984898e-09
in O 0 5.426272209341221e-10
three O 0 1.1107643693719638e-09
unrelated O 0 1.4289983596427192e-07
Turkish O 0 0.006734149530529976
A B-Disease 1 1.0
- I-Disease 1 0.9999957084655762
T I-Disease 1 1.0
individuals O 0 2.2386927867046325e-09
, O 0 2.2919730002790573e-10
was O 0 2.8167417287505714e-09
previously O 0 2.128164089398865e-09
described O 0 6.403462204929156e-10
to O 0 1.477761385482168e-10
be O 0 5.355183518851447e-10
a O 0 1.389717896316256e-09
Turkish O 0 8.039570275286678e-06
A B-Disease 1 0.9999997615814209
- I-Disease 1 0.9999822378158569
T I-Disease 1 0.9999998807907104
founder O 0 3.4082252113876166e-06
mutation O 0 9.420537026016973e-06
. O 0 7.423761871905299e-07

The O 0 7.85666998126544e-08
presence O 0 4.812305220980306e-08
of O 0 8.009466978542434e-10
a O 0 2.550885724872387e-09
founder O 0 3.4587834818466945e-08
mutation O 0 4.8182844381017276e-08
among O 0 9.569580683432832e-10
relatively O 0 1.8311275828963858e-09
small O 0 4.12201028865411e-09
ethnic O 0 2.143184119063335e-08
population O 0 7.21990733865141e-09
groups O 0 6.33346042278049e-10
in O 0 3.871079568007474e-10
Western O 0 4.417878951556986e-09
Europe O 0 5.46961906877641e-08
could O 0 2.051755654264298e-09
indicate O 0 1.0237622971587257e-09
a O 0 3.567933726245087e-10
high O 0 4.874111336761189e-09
carrier O 0 1.9203024947955782e-08
frequency O 0 1.5944937814538207e-08
in O 0 7.524685874393811e-10
such O 0 6.4930016918651745e-09
communities O 0 1.702937169056895e-07
. O 0 2.04501375833388e-07

In O 0 2.5413402227059123e-07
patients O 0 4.639447297449806e-07
of O 0 9.547156398781453e-10
Dutch O 0 8.419113328272942e-06
ethnic O 0 1.6911187117329973e-08
origin O 0 4.7662570779039015e-08
, O 0 7.275572366793881e-10
however O 0 2.0809638456853463e-09
, O 0 3.9028325016232657e-10
no O 0 8.958158104199754e-10
significant O 0 1.1568023206010025e-09
founder O 0 7.398442747330591e-09
effect O 0 3.6286891713643854e-08
could O 0 1.7164499155342128e-08
be O 0 5.99649485621967e-09
identified O 0 1.3591663616807637e-07
. O 0 2.094847815214962e-07

The O 0 1.0208715650605882e-07
observed O 0 1.510555875938735e-07
genetic O 0 1.4289997807281907e-07
heterogeneity O 0 1.6285345338928892e-07
including O 0 9.453438032380745e-10
the O 0 1.1006413558334316e-09
relative O 0 6.930471840860264e-08
high O 0 9.00072620879655e-08
percentage O 0 1.6526601598343404e-07
of O 0 4.29948299185412e-10
splice O 0 2.3722021069261245e-05
- O 0 3.4741208310151706e-06
site O 0 5.2368065439623024e-08
mutations O 0 3.4643167623471527e-07
had O 0 2.1733123745093508e-08
no O 0 2.8131819096444133e-09
reflection O 0 1.3643631113779975e-08
on O 0 4.4225161310862404e-09
the O 0 2.7696431814661082e-08
phenotype O 0 2.054950709862169e-05
. O 0 1.0371887810833869e-06

All O 0 5.161550689081196e-07
patients O 0 7.628653406754893e-07
manifested O 0 2.119658546462233e-07
classical O 0 1.6008664260880323e-06
A B-Disease 1 0.9999958276748657
- I-Disease 1 0.999972939491272
T I-Disease 1 1.0
and O 0 3.726791319991207e-08
increased O 0 4.8909324590340475e-08
cellular O 0 6.909399417054374e-07
radioresistant O 0 2.2488018203148386e-06
DNA O 0 1.4615631016567932e-06
synthesis O 0 1.413359427715477e-06
. O 0 9.094549113797257e-07

Determination O 0 2.037061676674057e-06
of O 0 2.958723710477784e-09
the O 0 9.829121960791554e-10
genomic O 0 1.1817136424951968e-07
structure O 0 2.0155212610006856e-08
of O 0 1.85562218368851e-10
the O 0 3.6467528996553256e-10
COL4A4 O 0 1.5678111253691895e-07
gene O 0 6.556144516167706e-09
and O 0 4.602372372097818e-10
of O 0 2.1813503781054067e-10
novel O 0 1.6656617845001165e-06
mutations O 0 0.011464262381196022
causing O 0 0.00021693381131626666
autosomal B-Disease 1 0.9999988079071045
recessive I-Disease 1 0.9999998807907104
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 3.360864502610639e-05

Autosomal B-Disease 1 0.9999986886978149
recessive I-Disease 1 0.9999998807907104
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 1.4194596360539435e-06
a O 0 6.996915544732474e-07
progressive O 0 2.8482661946327426e-05
hematuric B-Disease 1 0.9981306195259094
glomerulonephritis I-Disease 1 1.0
characterized O 0 3.853518137475476e-05
by O 0 2.58533191299648e-07
glomerular B-Disease 1 0.914253830909729
basement I-Disease 1 0.9984532594680786
membrane I-Disease 1 0.8719178438186646
abnormalities I-Disease 1 0.9999983310699463
and O 0 1.8775654808678155e-08
associated O 0 1.0677395856362182e-08
with O 0 5.191807539439708e-10
mutations O 0 6.746132896751078e-08
in O 0 5.37325184346571e-10
either O 0 2.8421871522965603e-09
the O 0 8.246882621243401e-10
COL4A3 O 0 1.2080670330760768e-06
or O 0 4.737306547042408e-09
the O 0 4.371732142960383e-10
COL4A4 O 0 1.3329234604952944e-07
gene O 0 7.2806565221128494e-09
, O 0 1.3270565202283535e-10
which O 0 9.295269415288132e-11
encode O 0 1.7579714350901554e-09
the O 0 4.6208170623174283e-10
alpha3 O 0 2.434473458379216e-07
and O 0 7.350674735562279e-09
alpha4 O 0 2.0259758457541466e-06
type O 0 1.0707603905757423e-05
IV O 0 1.0205595799561706e-06
collagen O 0 7.281075795617653e-07
chains O 0 4.290941433282569e-06
, O 0 1.296198082201272e-08
respectively O 0 3.4320510167162865e-07
. O 0 4.4454372982727364e-07

To O 0 3.630828615541759e-08
date O 0 5.2921329540822626e-08
, O 0 1.3289900291368895e-09
mutation O 0 1.5289616683844542e-08
screening O 0 2.3695932327427727e-08
in O 0 2.9074614937840693e-10
the O 0 7.831822690373968e-11
two O 0 1.0790458110365719e-10
genes O 0 4.3441135133548414e-09
has O 0 1.6944767367021996e-08
been O 0 1.3262559050986056e-08
hampered O 0 3.528091951920942e-08
by O 0 4.170971346084684e-10
the O 0 1.144138894737523e-09
lack O 0 4.159279143323147e-09
of O 0 3.3316352454626497e-10
genomic O 0 2.7777011268881324e-07
structure O 0 2.380615740094072e-07
information O 0 1.2793819337275636e-07
. O 0 3.5201711057197826e-07

We O 0 1.3908477285440313e-06
report O 0 2.6971479272219767e-08
here O 0 3.5509881146644773e-10
the O 0 9.613445456357894e-11
complete O 0 8.609194468434112e-10
characterization O 0 2.5560934702184568e-08
of O 0 2.513862173980641e-10
the O 0 5.893107113408291e-10
48 O 0 1.9501067427540875e-09
exons O 0 1.1020577339593274e-08
of O 0 1.0468070160696286e-10
the O 0 3.625226507875112e-10
COL4A4 O 0 8.312744625982305e-08
gene O 0 9.410393353448399e-09
, O 0 3.353861077748377e-10
a O 0 1.7753407077769623e-10
comprehensive O 0 3.5433851408583905e-09
gene O 0 1.0987436738219003e-08
screen O 0 8.520419214619324e-06
, O 0 7.835173065906531e-10
and O 0 2.6472690706214053e-10
the O 0 1.1009473194212305e-10
subsequent O 0 2.1646937575781067e-09
detection O 0 1.4190000285907445e-08
of O 0 4.95673016520648e-11
10 O 0 2.1250114168314127e-10
novel O 0 3.6893055277431586e-09
mutations O 0 3.303593487657963e-08
in O 0 5.810746328549499e-10
eight O 0 9.642102227758187e-09
patients O 0 7.223208058348973e-07
diagnosed O 0 0.0001183188142022118
with O 0 3.6257978308640304e-07
autosomal B-Disease 1 0.9999996423721313
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 2.7449956178315915e-05

Furthermore O 0 2.2552555947186192e-06
, O 0 2.385642261515386e-08
we O 0 5.348143261585392e-09
identified O 0 3.76966990955907e-09
a O 0 4.5870535148040403e-10
glycine O 0 1.3363417039613523e-08
to O 0 3.70990849152264e-10
alanine O 0 4.9296499327056154e-08
substitution O 0 7.962191794774753e-09
in O 0 9.988516680436987e-10
the O 0 4.861296365454848e-10
collagenous O 0 2.8648472039094486e-07
domain O 0 1.5699500366395114e-08
that O 0 4.358934879711285e-10
is O 0 5.254610635496704e-10
apparently O 0 7.72409869398416e-09
silent O 0 1.5542603648555087e-08
in O 0 2.53568638308721e-10
the O 0 3.3030925217225615e-10
heterozygous O 0 5.355730436917838e-08
carriers O 0 2.1821181306336257e-08
, O 0 9.73870761811213e-10
in O 0 3.867339781749024e-09
11 O 0 5.55467174478963e-08
. O 0 1.5288195243101654e-07

5 O 0 1.7460732237850607e-07
% O 0 5.999857943805864e-09
of O 0 6.808663355339917e-11
all O 0 2.0600363082046158e-10
control O 0 5.039307637844104e-09
individuals O 0 2.110264879506829e-10
, O 0 1.282760703213981e-10
and O 0 4.0206818430199576e-10
in O 0 3.391512348738246e-10
one O 0 1.7188307444016004e-09
control O 0 2.03180974267525e-08
individual O 0 2.8354840697630834e-09
homozygous O 0 5.124988788907103e-08
for O 0 6.008398223400491e-10
this O 0 1.1606656746820931e-09
glycine O 0 2.1954046758310142e-07
substitution O 0 3.683092586470593e-07
. O 0 6.593555212930369e-07

There O 0 1.025709934765473e-07
has O 0 9.825770419524815e-09
been O 0 2.700327517146661e-09
no O 0 6.689314657748469e-10
previous O 0 2.901900941765234e-09
finding O 0 1.5534562525232332e-09
of O 0 1.4487497139448191e-11
a O 0 6.261342139213255e-11
glycine O 0 2.9209363816562472e-09
substitution O 0 1.1994727433517482e-09
that O 0 3.5008460019803067e-10
is O 0 1.9570885190223208e-10
not O 0 2.886162142612392e-10
associated O 0 4.5239981205646984e-10
with O 0 6.967467575114128e-11
any O 0 3.7611092018607906e-09
obvious O 0 2.0000697986688465e-07
phenotype O 0 5.314644795362256e-07
in O 0 4.762992222850926e-09
homozygous O 0 6.58418628063373e-07
individuals O 0 6.644103223152342e-08
. O 0 2.2217919593003899e-07

Founder O 0 2.842172034434043e-05
BRCA1 O 0 0.0002017776423599571
and O 0 3.597502882257686e-07
BRCA2 O 0 1.856388735177461e-05
mutations O 0 1.065912215381104e-06
in O 0 1.791893033953329e-08
French O 0 2.5168187676172238e-06
Canadian O 0 6.324229161691619e-06
breast B-Disease 1 0.9999849796295166
and I-Disease 1 0.999923825263977
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 7.852412977626955e-07
. O 0 9.994887477660086e-07

We O 0 3.2371272595810296e-07
have O 0 5.191255425529562e-09
identified O 0 6.309734956744251e-09
four O 0 4.635806738484405e-10
mutations O 0 5.892884846758761e-09
in O 0 8.663747497195118e-11
each O 0 1.1184980025502611e-10
of O 0 2.032284479591695e-10
the O 0 8.905202264486434e-08
breast B-Disease 1 0.9999626874923706
cancer I-Disease 0 0.2799175977706909
- O 0 6.224115622899262e-06
susceptibility O 0 1.9988026451756014e-06
genes O 0 1.6840510852489388e-07
, O 0 2.943076893302532e-09
BRCA1 O 0 4.796013399754884e-07
and O 0 3.82757336936379e-09
BRCA2 O 0 4.2719483417386073e-07
, O 0 6.499601967746571e-10
in O 0 1.2389391734757282e-09
French O 0 6.073920530980104e-07
Canadian O 0 9.644677447795402e-07
breast B-Disease 0 0.19603154063224792
cancer I-Disease 0 0.0006470764637924731
and O 0 3.7799968595209066e-06
breast B-Disease 1 0.9999990463256836
/ I-Disease 1 0.9999998807907104
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 9.639513365300445e-08
from O 0 2.9579576121818718e-08
Quebec O 0 2.599850404294557e-06
. O 0 9.106647667067591e-07

To O 0 1.8756905717509653e-07
identify O 0 4.4208866256667534e-07
founder O 0 9.825642877103746e-08
effects O 0 6.461241355282255e-07
, O 0 3.5484848392997037e-09
we O 0 2.640427432254455e-09
examined O 0 2.055285541757712e-08
independently O 0 3.661315872705018e-08
ascertained O 0 5.7824314581012e-07
French O 0 1.9025192443677952e-07
Canadian O 0 3.9690181807827685e-08
cancer B-Disease 0 7.037154148292757e-08
families O 0 3.2552774364980053e-10
for O 0 4.2675033645744875e-11
the O 0 4.463476463434368e-11
distribution O 0 7.80406128608746e-10
of O 0 1.4600658182484239e-10
these O 0 3.3926399467532065e-09
eight O 0 2.5228086286688267e-08
mutations O 0 2.6904458536591846e-06
. O 0 4.43665356897327e-07

Mutations O 0 2.271736775583122e-05
were O 0 5.782625223105242e-08
found O 0 1.3763181705428451e-08
in O 0 2.329151316260436e-09
41 O 0 1.333810484283049e-08
of O 0 1.418431039290624e-09
97 O 0 1.3295273504354554e-07
families O 0 1.401190559136012e-07
. O 0 3.835907307347952e-07

Six O 0 7.125880330249856e-08
of O 0 1.3362798645388807e-09
eight O 0 4.003488651704856e-09
mutations O 0 7.549621017233221e-08
were O 0 1.9176185084290864e-09
observed O 0 8.43138447947922e-09
at O 0 4.435745548647674e-09
least O 0 7.608758068045063e-09
twice O 0 5.05382615756389e-07
. O 0 4.801386239705607e-07

The O 0 5.168333245819667e-07
BRCA1 O 0 1.9818504370050505e-05
C4446T O 0 3.988448952441104e-06
mutation O 0 1.5019456895970507e-06
was O 0 2.4570882217744838e-08
the O 0 2.659323872222785e-10
most O 0 8.47691750127666e-10
common O 0 1.2413927663601498e-08
mutation O 0 9.413448509576483e-08
found O 0 3.454226238375213e-09
, O 0 2.2074927996662552e-10
followed O 0 1.516602399220801e-09
by O 0 1.4207054421788712e-09
the O 0 3.684511540313906e-08
BRCA2 O 0 7.050830754451454e-05
8765delAG O 0 1.2829186744056642e-05
mutation O 0 1.8378526874585077e-05
. O 0 7.819607503734005e-07

Together O 0 1.4882405707794533e-07
, O 0 2.395238674068878e-09
these O 0 3.1055261140444657e-10
mutations O 0 9.817734181183368e-09
were O 0 7.860229689349296e-10
found O 0 8.924407879362661e-10
in O 0 3.7936506713798224e-10
28 O 0 5.622716181541421e-10
of O 0 2.5710173573445516e-11
41 O 0 9.049864746479841e-10
families O 0 1.4639614520639554e-10
identified O 0 3.997437936220649e-09
to O 0 5.479794396023863e-10
have O 0 7.940807122963633e-09
a O 0 2.164372858715069e-08
mutation O 0 7.574061783088837e-06
. O 0 7.54937559577229e-07

The O 0 8.51737809171027e-08
odds O 0 1.0744259952844004e-06
of O 0 2.690173084296532e-10
detection O 0 1.2531304882656968e-08
of O 0 9.842904963308641e-11
any O 0 8.404407170203854e-10
of O 0 9.66096230792246e-11
the O 0 1.079919265123408e-09
four O 0 1.560328577454584e-08
BRCA1 O 0 6.073212716728449e-06
mutations O 0 2.1141302113392157e-06
was O 0 1.6418334780610166e-07
18 O 0 3.701133977074278e-08
. O 0 1.7002969343593577e-07

7x O 0 4.160681419307366e-05
greater O 0 1.2919383607368218e-07
if O 0 1.3918540098245558e-08
one O 0 2.6663121710512883e-10
or O 0 3.4209884924862877e-10
more O 0 4.244481502380104e-11
cases O 0 9.91706716746421e-09
of O 0 1.4774450107779558e-07
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
were O 0 1.316441888832287e-08
also O 0 1.1743495065275056e-09
present O 0 1.4301341222378028e-09
in O 0 2.9377655863527252e-09
the O 0 1.2263919657584665e-08
family O 0 1.906376922988784e-07
. O 0 4.6646289320051437e-07

The O 0 5.5111929242457336e-08
odds O 0 1.0840824415936368e-06
of O 0 2.5574561912655724e-10
detection O 0 1.8632064779922075e-08
of O 0 8.168837828392839e-11
any O 0 8.404230644742938e-10
of O 0 9.231046482760519e-11
the O 0 1.2109480085342739e-09
four O 0 1.6230234933800602e-08
BRCA2 O 0 1.2431338291207794e-05
mutations O 0 7.93841593349498e-07
was O 0 1.3022946632190724e-07
5 O 0 4.3975028063414356e-08
. O 0 1.9867015055297088e-07

3x O 0 2.475258406775538e-05
greater O 0 8.268026618907243e-08
if O 0 2.4873701320871078e-08
there O 0 4.3190204190857173e-10
were O 0 1.6227277854774513e-10
at O 0 1.2100770385714554e-10
least O 0 5.983714912449756e-11
five O 0 2.219872341502338e-10
cases O 0 2.3546657956785566e-09
of O 0 1.5930093910654364e-09
breast B-Disease 1 0.8047594428062439
cancer I-Disease 0 8.223921759054065e-05
in O 0 4.710914769390229e-09
the O 0 1.502391988594809e-08
family O 0 3.24673010254628e-07
. O 0 4.721018456166348e-07

Interestingly O 0 3.02911439575837e-06
, O 0 1.181181374931839e-08
the O 0 6.635473281946247e-10
presence O 0 4.362346928132865e-09
of O 0 3.527469150110818e-10
a O 0 1.798604465363951e-08
breast B-Disease 0 0.0008802416850812733
cancer I-Disease 0 5.362078354664845e-07
case O 0 4.686189214453407e-09
< O 0 7.2840178333422045e-09
36 O 0 5.440563000114196e-10
years O 0 3.982823515435996e-10
of O 0 1.2818843209139175e-11
age O 0 1.6162264859787001e-09
was O 0 1.2143041017154133e-09
strongly O 0 4.121190610995029e-10
predictive O 0 1.180834452441104e-08
of O 0 1.530619728185023e-11
the O 0 7.516491595804808e-11
presence O 0 2.425094847158249e-10
of O 0 1.62422263139117e-11
any O 0 2.602838777843175e-10
of O 0 5.316689796752705e-11
the O 0 1.1332685900811157e-09
eight O 0 2.024861522897936e-08
mutations O 0 7.971827358232986e-07
screened O 0 1.9326064375491114e-06
. O 0 2.9665889655916544e-07

Carriers O 0 1.8221870732304524e-06
of O 0 1.071245647743524e-09
the O 0 3.370778933753371e-10
same O 0 1.3092321671237528e-09
mutation O 0 2.5450406226923405e-08
, O 0 1.8406232094037023e-10
from O 0 7.630113207923728e-11
different O 0 5.41694411548832e-10
families O 0 8.307206034174897e-10
, O 0 1.2505957380781751e-10
shared O 0 4.5041184670857604e-10
similar O 0 9.293129599186045e-10
haplotypes O 0 7.566516302404125e-08
, O 0 1.8156330605645365e-10
indicating O 0 1.6993503271223176e-09
that O 0 7.253385392314016e-11
the O 0 3.7395458257760694e-11
mutant O 0 3.3606246674366957e-09
alleles O 0 4.566933498040271e-09
were O 0 7.266751644863234e-10
likely O 0 6.016299680666748e-10
to O 0 5.458802507241067e-11
be O 0 6.944700370326018e-11
identical O 0 9.884526530612447e-10
by O 0 1.165825769255946e-10
descent O 0 5.0048647892708686e-08
for O 0 5.974617467430221e-10
a O 0 1.532794779990354e-09
mutation O 0 1.0576701470199623e-07
in O 0 1.476621047658e-09
the O 0 1.309284569650515e-09
founder O 0 1.307892887325579e-07
population O 0 1.1704773328347073e-07
. O 0 3.866165911858843e-07

The O 0 2.5455648255956476e-08
identification O 0 4.981047041496822e-08
of O 0 9.726288663358673e-10
common O 0 5.5850556179848354e-08
BRCA1 O 0 1.5113241715880577e-05
and O 0 3.959166505751455e-08
BRCA2 O 0 3.184514525855775e-06
mutations O 0 1.5204342673769133e-07
will O 0 5.069170638805076e-10
facilitate O 0 2.381803865247889e-09
carrier O 0 3.4129108428260224e-08
detection O 0 4.8631005000743244e-08
in O 0 3.3529223841810563e-09
French O 0 7.726303010713309e-07
Canadian O 0 3.4827749573196343e-07
breast B-Disease 0 0.031401220709085464
cancer I-Disease 0 4.394147254060954e-05
and O 0 2.2937392714084126e-06
breast B-Disease 1 0.9999992847442627
/ I-Disease 1 0.9999998807907104
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.5668292689952068e-06
. O 0 8.938894779930706e-07

Are O 0 4.6556246502404974e-07
Dp71 O 0 1.6106401744764298e-05
and O 0 2.4676583620930614e-07
Dp140 O 0 1.452255037293071e-05
brain O 0 5.5374789553752635e-06
dystrophin O 0 3.846438630716875e-06
isoforms O 0 4.892276024293096e-07
related O 0 8.118136207713178e-08
to O 0 1.841471330976674e-08
cognitive B-Disease 0 4.228426860208856e-06
impairment I-Disease 0 8.58521343616303e-06
in O 0 1.9218622071548452e-07
Duchenne B-Disease 0 0.004757768474519253
muscular I-Disease 0 0.0014054718194529414
dystrophy I-Disease 0 0.004056163597851992
? O 0 0.00011355746391927823

Molecular O 0 7.514268418162828e-06
study O 0 1.6777352129793144e-07
and O 0 9.516545773635698e-09
neuropsychological O 0 6.547686837166111e-08
analysis O 0 3.994869324230876e-09
were O 0 2.3240558089110408e-10
performed O 0 4.5301201678782377e-10
concurrently O 0 1.1568663804695234e-09
on O 0 3.1263942545933787e-09
49 O 0 4.613353965510214e-08
patients O 0 5.0908504078961414e-08
with O 0 8.619156055544863e-09
Duchenne B-Disease 0 0.00024063805176410824
muscular I-Disease 0 9.271603630622849e-06
dystrophy I-Disease 0 1.627100573386997e-05
( O 0 3.213871835328064e-08
DMD B-Disease 1 1.0
) O 0 2.2269823318765702e-08
in O 0 2.099197066174341e-10
order O 0 6.951118014519864e-10
to O 0 2.6500221461667195e-10
find O 0 1.988698095090058e-09
a O 0 1.3654342934099617e-10
molecular O 0 5.167901218072757e-09
explanation O 0 1.3190148973052374e-09
for O 0 1.8890330966137014e-10
the O 0 1.964022500189344e-09
cognitive B-Disease 0 3.5073034609922615e-07
impairment I-Disease 0 1.878708815183927e-07
observed O 0 2.0612842988043667e-08
in O 0 5.401419755912684e-09
most O 0 2.9367902243393473e-07
DMD B-Disease 1 1.0
patients O 0 6.341251719277352e-05
. O 0 4.801152613254089e-07

Complete O 0 4.569371014895296e-07
analysis O 0 1.2794295400908595e-07
of O 0 6.022453091780733e-10
the O 0 3.5749705973309176e-10
dystrophin O 0 1.4305337003861496e-07
gene O 0 6.65336088445656e-08
was O 0 9.606014650387351e-09
performed O 0 2.182096281444501e-09
to O 0 3.0106622750381007e-10
define O 0 1.2054939269035003e-08
the O 0 3.3840424906728117e-10
localization O 0 4.3369605684517865e-09
of O 0 5.145539896944662e-11
deletions O 0 1.8751139307937592e-08
and O 0 1.363152923872235e-09
duplications O 0 9.437341219609152e-08
in O 0 8.919370797499937e-10
relation O 0 5.460526253386888e-09
to O 0 1.017375628187267e-09
the O 0 3.2644191794162225e-09
different O 0 1.825716680059486e-07
DMD B-Disease 1 0.9999995231628418
promoters O 0 1.652981518418528e-05
. O 0 1.9931474071199773e-06

Qualitative O 0 9.557169505569618e-06
analysis O 0 1.881688973526252e-07
of O 0 9.59893942109602e-10
the O 0 6.05258954067267e-10
Dp71 O 0 1.1294393686966941e-07
transcript O 0 3.733436315656036e-08
and O 0 5.911490741361547e-10
testing O 0 1.6155669024797703e-09
for O 0 2.2521299061772915e-11
the O 0 2.1413952208670928e-11
specific O 0 2.5500671019251797e-10
first O 0 2.624819528396216e-10
exon O 0 4.383574392363698e-09
of O 0 5.7334584996349136e-11
Dp140 O 0 3.297034112392794e-08
were O 0 8.904497694750546e-10
also O 0 1.1930839649565428e-09
carried O 0 2.575276702998508e-08
out O 0 3.56313591964863e-08
. O 0 1.6257662593943678e-07

Neuropsychological O 0 0.00030272454023361206
analysis O 0 1.9766634977713693e-06
assessed O 0 9.191666663355136e-07
verbal O 0 1.4417826150747715e-06
and O 0 2.4076939553197008e-08
visuospatial O 0 3.1396825761476066e-06
intelligence O 0 9.741908115756814e-07
, O 0 3.777255397352519e-09
verbal O 0 1.1267594857145014e-07
memory O 0 4.3177809061489825e-07
, O 0 2.1979651432246783e-09
and O 0 5.131529423607617e-09
reading O 0 1.4226617395252106e-07
skills O 0 1.5728850257801241e-06
. O 0 3.4933597703457053e-07

Comparison O 0 1.1107204045401886e-06
of O 0 5.026511651351484e-09
molecular O 0 3.018995471393282e-07
and O 0 1.7134896168613523e-08
psychometric O 0 2.880819238271215e-06
findings O 0 4.9307971039525e-08
demonstrated O 0 8.171916476840124e-09
that O 0 1.793481196887825e-10
deletions O 0 2.5076920096012145e-08
and O 0 9.431214698096824e-10
duplications O 0 3.157401806674898e-08
that O 0 6.044018063811052e-10
were O 0 5.26986676518959e-10
localized O 0 9.019953672861902e-09
in O 0 8.174234622515542e-10
the O 0 1.883704581207013e-10
distal O 0 1.5076365045274542e-08
part O 0 4.06931999208382e-09
of O 0 6.325127921424922e-11
the O 0 9.881485907303755e-11
gene O 0 3.769188072766383e-09
seemed O 0 3.1903075736749997e-09
to O 0 1.169498387021406e-10
be O 0 2.818761057898911e-10
preferentially O 0 1.2659229220446377e-08
associated O 0 6.680316300133882e-09
with O 0 9.822116453506169e-09
cognitive B-Disease 0 1.1786485629272647e-05
impairment I-Disease 0 1.509232879470801e-05
. O 0 4.0667157463758485e-07

Two O 0 2.0547885526411847e-07
altered O 0 1.7959463320948998e-06
Dp71 O 0 1.4287628573583788e-06
transcripts O 0 1.7153870146557892e-07
and O 0 3.4469798126934847e-09
two O 0 6.329897717094468e-10
deleted O 0 5.6631584754995856e-08
Dp140 O 0 2.729857229155641e-08
DNA O 0 6.551169384749755e-09
sequences O 0 3.010698357286401e-09
were O 0 1.878394523258109e-10
found O 0 2.194675691180592e-10
in O 0 1.0910720937840068e-10
four O 0 1.441339714247647e-09
patients O 0 4.4072770322145516e-08
with O 0 3.785205393569413e-08
severe O 1 0.9931734204292297
cerebral B-Disease 1 0.9997172951698303
dysfunction I-Disease 0 0.48262345790863037
. O 0 5.904306817683391e-06

These O 0 1.4920135527063394e-07
findings O 0 1.3578241464529128e-07
suggest O 0 2.0686890422894066e-08
that O 0 2.061970455491391e-10
some O 0 4.5226503098128035e-11
sequences O 0 1.0325537092015225e-09
located O 0 1.1994658599689956e-09
in O 0 3.728095887556293e-10
the O 0 1.195112619978289e-10
distal O 0 1.6239710021181963e-08
part O 0 8.45825098849673e-09
of O 0 4.26550149368321e-11
the O 0 6.989429868209385e-11
gene O 0 2.7664843749164447e-09
and O 0 9.29406940297639e-10
, O 0 1.0588919324705515e-10
in O 0 8.082697011690954e-11
particular O 0 4.5713491325649613e-10
, O 0 3.487383715139458e-10
some O 0 6.139818098382932e-10
DMD B-Disease 1 0.9999904632568359
isoforms O 0 3.1588598403686774e-08
expressed O 0 5.344438780419125e-10
in O 0 2.782581109972426e-10
the O 0 7.244222444136028e-10
brain O 0 2.046398094535107e-06
may O 0 2.7871878138796546e-09
be O 0 5.198206795564708e-11
related O 0 2.660896503137167e-10
to O 0 2.705264900981774e-10
the O 0 2.817418742750988e-09
cognitive B-Disease 0 1.3548158221965423e-06
impairment I-Disease 0 6.317853831205866e-07
associated O 0 5.675063974308614e-08
with O 0 7.419133396524558e-08
DMD B-Disease 1 1.0
. O 0 5.236137212705216e-07
. O 0 6.318950340755691e-07

I1307K O 0 0.00017529905016999692
APC O 0 7.937810551084112e-06
and O 0 5.132599056878462e-08
hMLH1 O 0 6.542169330714387e-07
mutations O 0 2.311291922296732e-07
in O 0 1.379597547312983e-09
a O 0 2.7394635448985127e-09
non O 0 2.2654550946299423e-07
- O 0 2.6612221972754924e-06
Jewish O 0 1.0169884490096592e-07
family O 0 6.5581708952322515e-09
with O 0 4.920835738886353e-09
hereditary B-Disease 1 0.9928637146949768
non I-Disease 1 0.9995526671409607
- I-Disease 1 0.9999998807907104
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.3532542652683333e-05

We O 0 4.380283940008667e-07
describe O 0 1.5220518889691448e-07
a O 0 1.4900122913275027e-08
French O 0 7.118965186236892e-07
Canadian O 0 6.97769053203956e-07
hereditary B-Disease 1 0.7876860499382019
non I-Disease 1 0.9997956156730652
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 8.046128527894325e-07
HNPCC B-Disease 0 0.1568266898393631
) O 0 5.081140130869244e-08
kindred O 0 1.0706701232265914e-06
which O 0 7.281768077405104e-09
carries O 0 2.3609178612105097e-08
a O 0 6.240959748993191e-09
novel O 0 1.355976309014295e-07
truncating O 0 3.3963306123041548e-06
mutation O 0 5.53795416635694e-06
in O 0 7.824442604942305e-08
hMLH1 O 0 1.992476245504804e-05
. O 0 8.996484552881157e-07

Interestingly O 0 4.215642547933385e-06
, O 0 2.2535253663136245e-08
the O 0 3.4020812833546188e-09
I1307K O 0 2.508400314127357e-07
APC O 0 7.343545149751662e-08
polymorphism O 0 2.2538486632583954e-07
, O 0 9.893825758666708e-10
associated O 0 6.1991484168189e-10
with O 0 8.938798312652096e-11
an O 0 3.0211028123616757e-10
increased O 0 9.505500742079676e-08
risk O 0 0.001559091848321259
of O 0 4.073279455951706e-07
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 9.249156107671297e-09
is O 0 1.8265337020650918e-09
also O 0 1.5885037729646e-09
present O 0 6.345915459782248e-10
in O 0 1.4610889165211915e-09
this O 0 4.96592367227322e-09
family O 0 1.4865001674024825e-07
. O 0 2.166872405950926e-07

The O 0 1.227766261990837e-07
I1307K O 0 8.878691346581036e-07
polymorphism O 0 9.045469937518646e-07
has O 0 1.1085509399322291e-08
previously O 0 3.670137971312215e-09
only O 0 2.2882079564467972e-10
been O 0 5.456827212313442e-10
identified O 0 1.105159963543656e-09
in O 0 1.227895701783055e-10
individuals O 0 2.0212054252510825e-10
of O 0 2.7974389471552286e-10
self O 0 0.00024752484750933945
- O 1 0.5382629632949829
reported O 0 0.00011890469613717869
Ashkenazi O 0 1.1856564924528357e-05
Jewish O 0 3.0352194357874396e-07
origins O 0 1.6157562185981078e-06
. O 0 7.164748012655764e-07

In O 0 4.072381187825158e-08
addition O 0 9.854768556749605e-09
, O 0 9.040272974658592e-10
in O 0 4.339076598025571e-10
this O 0 1.9504106663070786e-10
family O 0 1.320625941936271e-09
, O 0 1.4409487492095252e-10
there O 0 1.620899664489528e-10
appears O 0 1.5181537138531098e-09
to O 0 3.128945991193177e-10
be O 0 3.2364830815367895e-09
no O 0 1.2917178437987786e-09
relationship O 0 2.1559214413713335e-09
between O 0 1.6318436879547704e-10
the O 0 2.4687407673695816e-10
I1307K O 0 1.8068153195827108e-08
polymorphism O 0 3.435128093087769e-08
and O 0 4.916076989935902e-10
the O 0 1.2432065099599043e-10
presence O 0 1.8980705895899064e-09
or O 0 4.349842708251117e-09
absence O 0 9.29499499591202e-09
of O 0 1.5985276435870333e-09
cancer B-Disease 0 7.307747296181333e-07
. O 0 2.4982107049709157e-08
. O 0 2.350005701146074e-07

Identification O 0 5.872673796147865e-07
of O 0 3.994671260443283e-09
a O 0 7.47382600252422e-09
novel O 0 7.818997715958176e-08
mutation O 0 1.5740825176635553e-07
of O 0 4.890778337873769e-10
the O 0 2.407651633618002e-09
CPO O 0 4.2737210037557816e-07
gene O 0 7.548152325398405e-08
in O 0 5.155830873349032e-09
a O 0 1.849151409771821e-08
Japanese O 0 1.219647856487427e-06
hereditary B-Disease 0 0.012761685997247696
coproporphyria I-Disease 0 0.0012758370721712708
family O 0 2.0639479316741927e-06
. O 0 8.416299124291982e-07

Hereditary B-Disease 1 0.9846845269203186
coproporphyria I-Disease 0 0.0009651588625274599
( O 0 1.268374063556621e-07
HCP B-Disease 0 7.770485353830736e-06
) O 0 9.599182781983018e-09
is O 0 1.8186564476607714e-09
an O 0 9.363930963957046e-09
autosomal B-Disease 1 0.9999096393585205
dominant I-Disease 1 0.9999953508377075
disease I-Disease 0 0.13604943454265594
characterized O 0 2.2157783519105578e-07
by O 0 5.101919775540864e-09
a O 0 1.9416792440551944e-07
deficiency B-Disease 0 0.008898586966097355
of I-Disease 0 6.33486207934908e-10
coproporphyrinogen I-Disease 0 1.7658985598245636e-06
oxidase I-Disease 0 4.0714579085943114e-07
( O 0 2.8350837233404036e-09
CPO O 0 3.2462966714774666e-07
) O 0 2.814115829252728e-09
caused O 0 3.1981668424663212e-09
by O 0 2.7409152725255126e-10
a O 0 2.9133473411491195e-09
mutation O 0 1.824943751671526e-07
in O 0 2.4370963025432957e-09
the O 0 7.440443816619791e-09
CPO O 0 4.09765243603033e-06
gene O 0 1.5804467921043397e-06
. O 0 6.020569571774104e-07

Only O 0 1.635569759628197e-07
11 O 0 3.1098384312144844e-08
mutations O 0 3.0068491696511046e-08
of O 0 7.512277605536966e-11
the O 0 1.46023290681363e-10
gene O 0 8.803296758230772e-09
have O 0 4.2450283288530954e-09
been O 0 2.270658683301008e-08
reported O 0 1.254178272347417e-07
in O 0 3.410522353419765e-08
HCP B-Disease 0 0.0007139371591620147
patients O 0 3.6945787087461213e-06
. O 0 5.393993660618435e-07

We O 0 1.0771950655907858e-06
report O 0 4.986598867162684e-08
another O 0 4.5209729293560486e-09
mutation O 0 8.11621703178389e-08
in O 0 3.8591312367941555e-09
a O 0 1.5771922434737462e-08
Japanese O 0 3.6760602029062284e-07
family O 0 4.327419276251021e-07
. O 0 7.118217695278872e-07

Polymerase O 0 8.268743840744719e-05
chain O 0 3.5572025808505714e-05
reaction O 0 4.063322649017209e-06
- O 0 7.89767818787368e-06
single O 0 2.674434256277891e-07
strand O 0 2.2155425085657043e-06
conformational O 0 1.7602714308395662e-07
polymorphism O 0 4.785660507877765e-07
and O 0 2.315716063350237e-09
direct O 0 5.031135064115233e-09
sequence O 0 2.4794456265908593e-08
analyses O 0 5.8703950145400086e-08
demonstrated O 0 1.4754364840996459e-08
a O 0 1.7311952982268508e-09
C O 0 2.152951594780461e-08
to O 0 4.925622132390117e-10
T O 0 1.8773935295257616e-08
substitution O 0 7.932658974141304e-10
in O 0 1.7680754083038153e-10
exon O 0 1.0032436215112739e-08
1 O 0 9.672250778081093e-10
of O 0 4.3272555677598135e-11
the O 0 2.2836864344011332e-10
CPO O 0 4.531533548401967e-08
gene O 0 6.492518078715648e-09
at O 0 3.9740288837464277e-10
nucleotide O 0 7.1755499320147464e-09
position O 0 2.5893138300148166e-08
85 O 0 9.665076516895965e-10
, O 0 1.1257644122464328e-10
which O 0 5.882102027676694e-10
lies O 0 5.0278639029954775e-09
in O 0 5.516477274980502e-10
the O 0 3.9622219394352953e-10
putative O 0 3.655329194884871e-08
presequence O 0 7.952375824515912e-08
for O 0 3.801712833428894e-10
targeting O 0 3.325987663060914e-08
to O 0 8.874897261534898e-09
mitochondria O 0 1.7604253343961318e-06
. O 0 6.476652174569608e-07

This O 0 8.943023033225472e-08
mutation O 0 3.5090096162093687e-07
changes O 0 8.265736539669888e-09
the O 0 6.935769181204421e-10
codon O 0 2.0195964012259537e-08
for O 0 8.882695273770835e-11
glutamine O 0 1.0794729554675087e-08
to O 0 5.356726173744164e-10
a O 0 1.2001502014413745e-09
termination O 0 1.4161697947656648e-07
codon O 0 3.1868310657046095e-07
at O 0 8.201568313381813e-09
amino O 0 5.673656744420441e-08
acid O 0 2.7086784371022077e-07
position O 0 6.116458735050401e-07
29 O 0 3.26785993820522e-07
. O 0 2.617608743094024e-07

MaeI O 0 3.392738653928973e-05
restriction O 0 6.15969440787012e-07
analysis O 0 1.582852604542495e-07
showed O 0 2.1129574534484163e-08
two O 0 4.4545828137287913e-10
other O 0 4.62291538383397e-10
carriers O 0 2.3138630567132168e-08
in O 0 2.536684418075197e-09
the O 0 7.585109429442127e-09
family O 0 1.7782376460218074e-07
. O 0 3.3943410926440265e-07

The O 0 8.47845967655303e-07
C O 0 0.0004549011355265975
- O 0 0.0028957659378647804
T O 0 0.0003645955875981599
mutation O 0 1.8443471105911158e-07
is O 0 9.458525074279578e-10
located O 0 1.0112795045813527e-09
within O 0 3.705071527360104e-10
a O 0 1.4348171539779742e-09
recently O 0 2.4243572482873788e-08
proposed O 0 6.771978977582194e-09
putative O 0 7.519901146224583e-08
alternative O 0 1.8364765708156483e-08
translation O 0 1.244410618994607e-08
initiation O 0 1.2932963144862697e-08
codon O 0 2.873175901640934e-07
( O 0 2.486581385241493e-09
TIC O 0 3.425334682560788e-07
- O 0 8.611188917484469e-08
1 O 0 3.747425036948471e-09
) O 0 4.0508332799227276e-10
, O 0 1.5042196654935225e-10
supporting O 0 2.329320070160179e-09
that O 0 1.2915527536350169e-09
TIC O 0 2.9754519914604316e-07
- O 0 1.1078750361548373e-07
1 O 0 2.7517912393193456e-09
is O 0 3.003475801399702e-10
the O 0 3.286495520171684e-10
real O 0 2.9495915043753484e-08
TIC O 0 1.1125336385475748e-07
rather O 0 1.409283800768435e-09
than O 0 9.40961752959879e-10
TIC O 0 5.900502060285362e-07
- O 0 2.187302499123689e-07
2 O 0 9.593673411245618e-09
. O 0 7.4387411785892255e-09
. O 0 1.5807316344762512e-07

Human B-Disease 0 1.482256266172044e-06
complement I-Disease 0 8.062304914346896e-06
factor I-Disease 0 0.001869861502200365
H I-Disease 1 1.0
deficiency I-Disease 1 0.9999277591705322
associated O 0 1.3580778613686562e-05
with O 0 5.384024916565977e-05
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 1.6798558135633357e-05

This O 0 1.9873718670737617e-08
study O 0 5.1692321534346775e-09
reports O 0 1.4376770884894086e-09
on O 0 2.754551864381227e-10
six O 0 7.054820616581026e-10
cases O 0 3.4956169070454735e-09
of O 0 1.2458372111723293e-09
deficiency B-Disease 0 0.0009297042270191014
in I-Disease 0 1.0385878823626626e-09
the I-Disease 0 6.281656861339968e-10
human I-Disease 0 2.0724832960894446e-09
complement I-Disease 0 1.1185461445961664e-08
regulatory I-Disease 0 3.387132707644014e-08
protein I-Disease 0 4.8791740425713215e-08
Factor I-Disease 0 6.980233280273751e-08
H I-Disease 1 0.9999951124191284
( O 0 2.301484558486777e-09
FH O 0 4.301688022678718e-06
) O 0 2.965405698773793e-10
in O 0 4.273188400349959e-11
the O 0 3.574184698207361e-11
context O 0 2.1654495974132715e-09
of O 0 3.6755792853782054e-10
an O 0 3.5026405953431095e-07
acute B-Disease 1 0.9999754428863525
renal I-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 6.219457645784132e-06

Five O 0 2.0720928972650654e-08
of O 0 2.585668901211591e-10
the O 0 1.725122822371361e-10
cases O 0 4.4133624532705085e-10
were O 0 1.5523063390254777e-10
observed O 0 1.2716553365876848e-09
in O 0 4.052974067469961e-10
children O 0 2.935295562167539e-09
presenting O 0 4.559563393513599e-08
with O 0 9.016178523779672e-07
idiopathic O 1 0.9999992847442627
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 1.6858597518876195e-05
HUS B-Disease 1 0.9999362230300903
) O 0 3.635728944573202e-06
. O 0 2.9256943889777176e-06

Two O 0 2.1862424759433452e-08
of O 0 3.782278934494343e-10
the O 0 1.0308770503897335e-09
children O 0 5.352878584830023e-09
exhibited O 0 6.594863322106903e-08
a O 0 4.583612067676768e-08
homozygous O 0 0.010252965614199638
deficiency O 0 0.003109921934083104
characterized O 0 1.1820604051138162e-08
by O 0 7.751781994080886e-10
the O 0 9.586991200905004e-10
absence O 0 3.437001128148154e-09
of O 0 3.9999354523034825e-11
the O 0 7.52993709052241e-11
150 O 0 3.5580388635381155e-10
- O 0 1.0828714813726492e-08
kD O 0 6.081362613485908e-08
form O 0 7.159743353746251e-10
of O 0 8.045796667799365e-11
Factor O 0 3.034440254623405e-08
H O 1 1.0
and O 0 3.290084871210297e-09
the O 0 2.7075566788603567e-10
presence O 0 1.3484927618989673e-09
, O 0 4.451531157578792e-11
upon O 0 8.89332427145284e-11
immunoblotting O 0 2.3723154995991536e-08
, O 0 1.13687489977643e-10
of O 0 2.0757489477274405e-11
the O 0 1.4786070978711763e-10
42 O 0 4.319739232983011e-09
- O 0 7.962378134607206e-08
kD O 0 1.8339111420573317e-06
Factor O 0 2.281706201756606e-07
H O 1 0.9999995231628418
- O 0 2.3983560026863415e-07
like O 0 3.0088038727171806e-09
protein O 0 4.951972165656571e-09
1 O 0 9.298750658359722e-10
( O 0 3.12776443633922e-10
FHL O 0 7.76859451434575e-07
- O 0 6.512650685408516e-08
1 O 0 1.7825078080235812e-09
) O 0 1.6271753389140997e-10
and O 0 2.7704433191999556e-10
other O 0 2.3619617373071833e-09
FH O 0 0.08244524896144867
- O 0 1.7160054710529948e-07
related O 0 2.504059359864641e-08
protein O 0 3.0158265218460656e-08
( O 0 2.0441150994088275e-09
FHR O 0 4.944839702147874e-07
) O 0 3.508508594762816e-09
bands O 0 2.1051938858818176e-07
. O 0 2.5078313115045603e-07

Southern O 0 8.247146070061717e-06
blot O 0 4.266263931640424e-05
and O 0 3.457451214217144e-08
PCR O 0 2.9362274744926253e-07
analysis O 0 3.665618475423571e-09
of O 0 6.164609794856446e-11
DNA O 0 4.901997030515304e-09
of O 0 5.252573723191212e-11
one O 0 1.0324079369183892e-09
patient O 0 1.0719513277024362e-08
with O 0 1.194885301813997e-09
homozygous O 0 2.6075600544572808e-05
deficiency O 0 0.00016472770948894322
ruled O 0 3.262602987774699e-08
out O 0 8.09783906596806e-10
the O 0 8.470835838325641e-11
presence O 0 7.343132768511396e-10
of O 0 1.562488333162193e-11
a O 0 1.1729990589959272e-10
large O 0 1.150820883033532e-09
deletion O 0 6.457852919083962e-08
of O 0 1.1604348731930614e-10
the O 0 1.013792050308382e-09
FH O 0 3.0463454550044844e-06
gene O 0 9.214889296060846e-09
as O 0 9.061161265755402e-10
the O 0 6.529223828266595e-10
underlying O 0 1.2845963226482127e-07
defect O 0 2.951218789348786e-07
for O 0 5.69563152197361e-09
the O 0 1.4330434794374014e-07
deficiency O 0 0.01413779053837061
. O 0 4.584049406730628e-07

The O 0 1.4861948116617896e-08
other O 0 1.5966049593529874e-09
four O 0 1.0356898672014836e-09
children O 0 1.4714955920425155e-09
presented O 0 3.0469080591899456e-09
with O 0 6.78288936128979e-09
heterozygous O 0 0.004213138949126005
deficiency O 0 0.01085363794118166
and O 0 1.529261384192182e-09
exhibited O 0 1.8706915128063883e-08
a O 0 2.6893434146302297e-09
normal O 0 4.151394961127153e-08
immunoblotting O 0 6.320264560599753e-07
pattern O 0 1.6855034346008324e-07
of O 0 2.485371075611198e-10
proteins O 0 4.506595541187153e-09
of O 0 7.489691089546113e-10
the O 0 4.524641639136462e-08
FH O 1 0.9299885034561157
family O 0 5.283509381115437e-07
. O 0 4.896271548204822e-07

Factor B-Disease 1 0.9818533062934875
H I-Disease 1 1.0
deficiency I-Disease 1 0.9997379183769226
is O 0 9.576049286863508e-09
the O 0 3.393358261050139e-09
only O 0 4.3896298507206666e-07
complement B-Disease 1 1.0
deficiency I-Disease 1 1.0
associated O 0 6.3364990410264e-07
with O 0 1.2471127774915658e-07
HUS B-Disease 1 0.9991291165351868
. O 0 3.340379862493137e-06

These O 0 5.780298195645628e-08
observations O 0 8.853902500050026e-08
suggest O 0 2.8142675745357337e-08
a O 0 1.5950191167846128e-09
role O 0 1.2943031535428418e-08
for O 0 3.3974381086210315e-09
FH O 0 0.0005318540497682989
and O 0 1.3595315095926708e-08
/ O 0 1.2149075701017864e-07
or O 0 4.306685141841626e-08
FH O 0 0.0020676422864198685
receptors O 0 7.157878201269341e-08
in O 0 1.29526067649266e-09
the O 0 2.622384087658247e-09
pathogenesis O 0 3.2324598464583687e-07
of O 0 9.913947884854224e-09
idiopathic O 0 0.006065987981855869
HUS B-Disease 1 0.9993520379066467
. O 0 5.251239372228156e-07
. O 0 9.863757668426842e-07

Further O 0 2.6675358810734906e-08
evidence O 0 1.0653939952476321e-08
for O 0 2.985968416968632e-10
a O 0 7.214135400168686e-10
major O 0 3.7831249244391074e-09
ancient O 0 1.2472293065002305e-07
mutation O 0 5.362749288906343e-05
underlying O 0 2.1791167455376126e-05
myotonic B-Disease 1 0.9999979734420776
dystrophy I-Disease 1 0.9999749660491943
from O 0 1.7024330389858733e-08
linkage O 0 3.7019428873463767e-06
disequilibrium O 0 1.685904680925887e-05
studies O 0 9.281570356733937e-08
in O 0 1.0085750012933659e-09
the O 0 2.006575350321782e-09
Japanese O 0 1.2509757141287992e-07
population O 0 7.899826215407302e-08
. O 0 2.258545777067411e-07

The O 0 1.1268038178968709e-05
myotonic B-Disease 1 0.9999949932098389
dystrophy I-Disease 1 0.9999992847442627
( O 0 1.035344394040294e-05
DM B-Disease 1 1.0
) O 0 2.01886919626304e-07
mutation O 0 1.2418875030562049e-06
is O 0 1.0556643559311851e-08
an O 0 3.306706242156565e-09
unstable O 0 9.836186654865742e-05
( O 0 3.2474032352070026e-09
CTG O 0 3.516403239700594e-07
) O 0 1.7213963587892067e-09
n O 0 5.498739952258802e-08
repeat O 0 2.080101694446057e-06
, O 0 3.4846045493530653e-10
present O 0 3.186304275981655e-10
at O 0 3.848008578444251e-10
a O 0 8.480681434885895e-11
copy O 0 8.248743021965765e-09
number O 0 5.119199508740735e-10
of O 0 9.974004955282112e-11
5 O 0 2.564711776287254e-09
- O 0 1.2869973886608932e-07
37 O 0 3.0525155736427223e-09
repeats O 0 2.871471416199256e-08
on O 0 2.0364372410597298e-09
normal O 0 6.0324816253398694e-09
chromosomes O 0 1.2929313619736149e-08
but O 0 2.0356953900346753e-09
amplified O 0 6.742066016585113e-09
to O 0 6.270141628128556e-10
50 O 0 2.2304966762476397e-09
- O 0 2.3311969243877684e-08
3000 O 0 3.622921340706853e-08
copies O 0 4.672883591183563e-08
on O 0 2.9182746175138163e-07
DM B-Disease 1 0.9999972581863403
chromosomes O 0 1.6470477930852212e-05
. O 0 9.528588407192728e-07

Previous O 0 2.702655820030486e-06
findings O 0 2.882309502183489e-07
in O 0 1.090939960590731e-08
Caucasian O 0 9.118136290453549e-07
populations O 0 8.708392584821922e-08
of O 0 2.1504591440901777e-09
a O 0 1.7179769429276348e-07
DM B-Disease 1 1.0
founder O 0 1.0797143801255515e-07
chromosome O 0 5.91438379160536e-07
raise O 0 8.830825848349377e-09
a O 0 9.41071220950107e-10
question O 0 5.9902074411866124e-09
about O 0 1.9456064537237694e-10
the O 0 1.4477863352624354e-10
molecular O 0 3.8713396932621436e-09
events O 0 9.026884795204637e-10
involved O 0 2.3072554977687787e-09
in O 0 6.853827505537424e-10
the O 0 2.3006772043032697e-09
expansion O 0 3.633513472323102e-07
mutation O 0 3.548071163095301e-06
. O 0 4.2444801806595933e-07

To O 0 1.3704483592391625e-07
investigate O 0 1.4693262073706137e-07
whether O 0 2.540472010537087e-08
a O 0 2.031390167189784e-09
founder O 0 1.848890285316429e-08
chromosome O 0 2.4252690877801797e-07
for O 0 3.323899822049725e-09
the O 0 2.6280634557451776e-08
DM B-Disease 1 1.0
mutation O 0 1.6156591300386935e-06
exists O 0 2.3702575902007084e-08
in O 0 3.667966486098351e-10
the O 0 1.5673007336403089e-10
Japanese O 0 2.7901239096905783e-09
population O 0 7.004888336048509e-10
, O 0 2.757769290706591e-10
we O 0 9.692971980612697e-10
genotyped O 0 1.6101228794696e-08
families O 0 4.352346816283159e-10
using O 0 1.5737208203248088e-09
polymorphic O 0 1.193264722587628e-07
markers O 0 1.259238189277312e-07
near O 0 2.018491152000479e-08
the O 0 2.6006516939958146e-09
( O 0 2.284611388958524e-09
CTG O 0 8.074316610873211e-07
) O 0 4.097967742922037e-09
n O 0 6.774990879421239e-07
repeat O 0 4.07266452384647e-05
region O 0 1.566104685934988e-07
and O 0 2.3859243469814828e-08
constructed O 0 1.0539709364820737e-05
haplotypes O 0 3.220259168301709e-05
. O 0 9.326108738605399e-07

Six O 0 2.665527460976591e-07
different O 0 2.131878495958972e-08
haplotypes O 0 7.861884796511731e-07
were O 0 1.0115789983444756e-08
found O 0 3.1318030835336685e-08
and O 0 1.5108929574125796e-07
DM B-Disease 1 1.0
alleles O 0 3.933712832804304e-06
were O 0 9.644607246173109e-08
always O 0 2.1735243649345648e-07
haplotype O 0 1.0082928383781109e-05
A O 0 6.031316388543928e-07
. O 0 8.811655334284296e-07

To O 0 8.073971713429273e-08
find O 0 4.760106619983162e-08
an O 0 3.343494925367452e-10
origin O 0 3.281060756421539e-09
of O 0 1.1543024175386662e-10
the O 0 7.904656929014209e-10
( O 0 8.133642648289197e-10
CTG O 0 2.8122559569965233e-07
) O 0 9.773206688379332e-10
n O 0 4.7864268992725556e-08
repeat O 0 1.927605524087994e-07
mutation O 0 1.6444809958215956e-08
and O 0 2.563482759398994e-10
to O 0 4.789579496899954e-11
investigate O 0 5.425185856111625e-10
the O 0 4.2769069535930626e-11
mechanism O 0 2.82834200504567e-10
of O 0 8.424363637238308e-12
the O 0 5.153023840964721e-11
expansion O 0 1.5564042277205203e-09
mutation O 0 3.9184535616243465e-09
in O 0 3.8905819538248565e-11
the O 0 3.261440770230273e-11
Japanese O 0 7.324975070943651e-10
population O 0 1.9566255560210521e-10
we O 0 1.075421349194805e-10
have O 0 9.018620572565084e-11
studied O 0 2.543816268740784e-09
90 O 0 1.8602582807503154e-09
Japanese O 0 3.6363868360922424e-08
DM B-Disease 1 0.9999967813491821
families O 0 4.467194170132416e-09
comprising O 0 1.4052147223608813e-09
190 O 0 6.96764734797739e-09
affected O 0 1.004750771471663e-08
and O 0 5.372681410875657e-09
130 O 0 2.035381996279284e-08
unaffected O 0 7.465344538104546e-07
members O 0 3.837662987393742e-08
. O 0 2.7621788944998116e-07

The O 0 8.198647805102155e-08
results O 0 6.639150029741359e-08
suggest O 0 1.1895694207453289e-08
that O 0 3.601957898613506e-10
a O 0 5.433397620713265e-10
few O 0 2.931015874452214e-09
common O 0 2.986129565840656e-09
ancestral O 0 2.1014944451280826e-08
mutations O 0 2.2322008419450867e-07
in O 0 7.147463176870872e-10
both O 0 1.9737336209857403e-09
Caucasian O 0 7.399644346151035e-07
and O 0 2.839949386768126e-09
Japanese O 0 5.792413659833073e-09
populations O 0 3.1090954255574843e-09
have O 0 1.398857557566302e-10
originated O 0 4.0297029602065493e-10
by O 0 2.76901539891794e-11
expansion O 0 7.215690822626186e-10
of O 0 4.8710115801986476e-11
an O 0 1.8700403725535608e-10
ancestral O 0 3.731856068611705e-08
n O 0 8.238234272539557e-07
= O 0 8.123124217718214e-08
5 O 0 1.6971346550320732e-09
repeat O 0 5.070693731568099e-08
to O 0 8.496925385514942e-10
n O 0 1.5959487598138367e-07
= O 0 9.159730041119474e-08
19 O 0 4.188304369989737e-09
- O 0 8.143989305153809e-08
37 O 0 9.446883275643359e-09
copies O 0 1.7871425939119945e-07
. O 0 2.198000430553293e-07

These O 0 7.777083510518423e-08
data O 0 6.05426890842864e-08
support O 0 5.389862778315546e-09
multistep O 0 2.5186361085616227e-07
models O 0 9.868164596582574e-08
of O 0 5.224310428708634e-10
triplet O 0 3.6645306522586907e-07
repeat O 0 1.049737576863663e-07
expansion O 0 3.017712302266773e-09
that O 0 1.2929397830152567e-10
have O 0 8.02460112248049e-11
been O 0 9.466136208224896e-11
proposed O 0 4.038420431395906e-10
for O 0 4.19478590751865e-10
both O 0 2.8142084218529817e-08
DM B-Disease 1 1.0
and O 0 3.181619945280545e-07
Friedreichs B-Disease 0 1.3066855899523944e-05
ataxia I-Disease 0 3.3155145501950756e-05
. O 0 1.572075234435033e-07
. O 0 4.6872733605596295e-07

The O 0 7.040605254360344e-08
molecular O 0 4.3407862904132344e-07
basis O 0 1.2965719520252605e-07
of O 0 3.881464465393947e-07
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 2.313927938146776e-09
the O 0 4.832361177875555e-10
western O 0 2.1365924141036885e-08
Cape O 0 4.855463231479007e-08
, O 0 1.36227173985759e-09
South O 0 1.8184630690143422e-08
Africa O 0 1.1126758181490004e-07
. O 0 1.6239438593856903e-07

Deficiency B-Disease 1 0.982677161693573
of I-Disease 0 2.479974003932739e-09
the I-Disease 0 1.3273155907711498e-09
sixth I-Disease 0 2.2116335429700484e-08
component I-Disease 0 5.6419732885615304e-08
of I-Disease 0 3.3329192183906287e-10
human I-Disease 0 2.008865296332374e-09
complement I-Disease 0 1.4593796393569392e-08
( O 0 5.105451061915289e-10
C6 O 0 6.810556385516975e-08
) O 0 2.831110623713329e-10
has O 0 4.1353562241219777e-10
been O 0 1.130091242806941e-09
reported O 0 1.5045533707791492e-09
in O 0 5.368987546217063e-11
a O 0 8.922888816709218e-11
number O 0 2.1981486075794976e-10
of O 0 2.2350895440004237e-11
families O 0 1.3930158415664806e-10
from O 0 6.626338366899631e-11
the O 0 1.0788955839835523e-10
western O 0 8.420328434510793e-09
Cape O 0 2.030023793508917e-08
, O 0 1.7401668994665442e-09
South O 0 1.3391253439465345e-08
Africa O 0 7.584910832747482e-08
. O 0 1.1603700045270671e-07

Meningococcal B-Disease 1 0.9864410758018494
disease I-Disease 1 0.6129348278045654
is O 0 2.5896939703784483e-08
endemic O 0 3.7660640828107717e-08
in O 0 2.131291809703839e-09
the O 0 7.176586547252839e-10
Cape O 0 6.109285966005018e-09
and O 0 2.123633768835731e-10
almost O 0 1.4321260843885852e-10
all O 0 5.8066666058786964e-11
pedigrees O 0 1.5127751495924713e-08
of O 0 1.0830567553909987e-09
total O 0 0.0010839775204658508
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 7.968903315003217e-10
C6Q0 O 0 4.312200729827964e-08
) O 0 1.7545201402846544e-10
have O 0 1.54954341025082e-10
been O 0 9.835460224039139e-10
ascertained O 0 2.402895127318061e-08
because O 0 5.745210085450481e-09
of O 0 2.9381859167898483e-09
recurrent O 1 0.6788960695266724
disease O 0 0.0011672999244183302
. O 0 1.3622824326375849e-06

We O 0 8.339200121554313e-07
have O 0 6.125597806772021e-09
sequenced O 0 1.322179166152182e-08
the O 0 5.386099344306672e-10
expressed O 0 9.349364615829359e-10
exons O 0 2.911610152978028e-08
of O 0 1.8671285351157252e-10
the O 0 1.2497785029097486e-09
C6 O 0 1.2043062724842457e-07
gene O 0 2.832467815849782e-09
from O 0 3.9654026590119074e-11
selected O 0 1.6869870778091212e-10
cases O 0 4.0679210000504895e-10
and O 0 3.432079342946537e-10
have O 0 6.616882042287386e-10
found O 0 1.0215814860714545e-09
three O 0 9.818890145396608e-10
molecular O 0 1.7525489965919405e-06
defects O 0 0.0066057476215064526
leading O 0 8.982354415820737e-09
to O 0 2.5732374009379555e-09
total O 0 9.552953983416046e-09
deficiency O 0 1.0455973097123206e-05
879delG O 0 1.5260910402048466e-07
, O 0 3.9683933916734304e-10
which O 0 2.870964577184054e-10
is O 0 2.3464510889859014e-10
the O 0 1.371045083020661e-10
common O 0 7.523212275373226e-09
defect O 0 2.3809791116491397e-07
in O 0 3.7997480162310637e-10
the O 0 5.339996222986088e-10
Cape O 0 1.2821162798104524e-08
and O 0 7.692689263372188e-10
hitherto O 0 2.1342382083844313e-08
unreported O 0 2.0109364839981936e-08
, O 0 1.4461745689864358e-10
and O 0 1.5182746726516427e-10
1195delC O 0 8.640586912633808e-09
and O 0 2.0756946161881729e-10
1936delG O 0 7.467001239547244e-09
, O 0 5.654342619121344e-11
which O 0 5.920187257091314e-11
have O 0 1.5711558443154416e-10
been O 0 1.2738279320245738e-09
previously O 0 9.715909854435267e-09
reported O 0 5.923966206466957e-09
in O 0 1.0819913853765684e-09
African O 0 9.413984258799246e-09
- O 0 1.5699462210250203e-06
Americans O 0 3.5514054275154194e-07
. O 0 1.799253510625931e-07

We O 0 5.581417781286291e-07
also O 0 4.14712708618481e-09
show O 0 3.6929099778149066e-09
that O 0 1.3676393351147453e-10
the O 0 2.3662530268531157e-10
879delG O 0 1.2083788192285283e-07
and O 0 4.4423158485074055e-09
1195delC O 0 2.5550928057782585e-06
defects O 0 0.0009220954379998147
are O 0 1.1017083911823988e-09
associated O 0 1.3117649189098302e-08
with O 0 1.0186732346539884e-08
characteristic O 0 0.38241860270500183
C6 O 1 0.9989049434661865
/ O 0 0.0003204543318133801
C7 O 0 2.296354614372831e-05
region O 0 7.757572717537187e-08
DNA O 0 1.737959394176869e-07
marker O 0 2.2292076096164237e-07
haplotypes O 0 5.503413831320358e-07
, O 0 2.184773917335292e-09
although O 0 3.2952849338130363e-09
small O 0 3.186859220960514e-09
variations O 0 1.0320190568791077e-07
were O 0 4.55886777217529e-08
observed O 0 5.976310148980701e-07
. O 0 5.032721333009249e-07

The O 0 3.288098469056422e-07
1936delG O 0 7.965481927385554e-06
defect O 0 2.04048751584196e-06
was O 0 6.346245307042864e-09
observed O 0 2.4573494350477176e-09
only O 0 3.0830341057885846e-10
once O 0 1.7688519537983893e-09
in O 0 3.9593664458159594e-10
the O 0 3.6631073174753226e-10
Cape O 0 1.0576132858375331e-08
, O 0 2.9768701392818286e-10
but O 0 1.3983593172284259e-09
its O 0 8.027468134663707e-10
associated O 0 9.824328017771222e-09
haplotype O 0 5.333497483661631e-07
could O 0 5.111321499384758e-08
be O 0 4.839475042928143e-09
deduced O 0 4.982405812370416e-07
. O 0 1.6919423728722904e-07

The O 0 2.6497268379443994e-08
data O 0 2.9425955005990545e-08
from O 0 5.823939108751119e-10
the O 0 4.4775136376351554e-10
haplotypes O 0 5.932290747523439e-08
indicate O 0 1.6839218019981672e-08
that O 0 5.151011839288344e-10
these O 0 1.6169533767484978e-10
three O 0 5.822262116872423e-10
molecular O 0 2.9188339567554067e-07
defects O 0 2.691986082936637e-05
account O 0 2.0209480755539744e-09
for O 0 2.8583865829823196e-10
the O 0 8.027606357430273e-10
defects O 0 0.007517942693084478
in O 0 1.546608258129467e-10
all O 0 1.3399953369130913e-10
the O 0 1.8135669355157091e-10
38 O 0 7.660053702451819e-10
unrelated O 0 2.8105486826746073e-09
C6Q0 O 0 6.47470059789157e-08
individuals O 0 3.3844752000966594e-10
we O 0 4.2959499846340066e-10
have O 0 1.9102691650729753e-10
studied O 0 4.057539637614127e-09
from O 0 2.949633592930212e-10
the O 0 5.814374759438579e-09
Cape O 0 4.7443168682548276e-07
. O 0 3.13871936441501e-07

We O 0 7.690905476920307e-07
have O 0 5.327760010942484e-09
also O 0 1.272718042066856e-09
observed O 0 2.017735756254524e-09
the O 0 4.0347325480638574e-10
879delG O 0 2.244517958160941e-07
defect O 0 3.958627132760739e-07
in O 0 2.5205468823230603e-09
two O 0 4.4198706916631636e-08
Dutch O 1 0.9999827146530151
C6 B-Disease 1 1.0
- I-Disease 1 0.9999985694885254
deficient I-Disease 1 1.0
kindreds O 0 1.236267235071864e-05
, O 0 2.314934466340901e-09
but O 0 6.089853621382701e-10
the O 0 1.222129203393152e-10
879delG O 0 6.286133213961875e-08
defect O 0 6.800522811545306e-08
in O 0 1.841898022991728e-10
the O 0 1.1309747582899377e-10
Cape O 0 2.5198880759802478e-09
probably O 0 8.776015469891263e-10
did O 0 3.977919105224714e-10
not O 0 6.910254313208242e-11
come O 0 4.593705277278204e-11
from O 0 2.5876658454881962e-11
The O 0 2.8185190292795426e-10
Netherlands O 0 1.0858253318701827e-07
. O 0 1.2223309475700717e-08
. O 0 1.1207440309135563e-07

Complement B-Disease 1 0.9958992600440979
C7 I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 4.556320831738958e-08
seven O 0 4.866048453067151e-09
further O 0 9.550002566527382e-09
molecular O 0 6.376283272402361e-05
defects O 1 0.9992262125015259
and O 0 4.7059685925887607e-08
their O 0 1.1850446846040086e-08
associated O 0 3.423946850489301e-07
marker O 0 2.575725011411123e-05
haplotypes O 0 7.937331247376278e-05
. O 0 1.3851069979864405e-06

Seven O 0 1.8919797639682656e-07
further O 0 1.130525184578346e-08
molecular O 0 8.556408204185573e-08
bases O 0 3.120412088719604e-07
of O 0 1.0119342732650694e-06
C7 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 8.25983050845025e-08
described O 0 4.958345130035013e-07
. O 0 4.6450605850623106e-07

All O 0 1.9098230552572204e-08
these O 0 5.727900820318155e-09
new O 0 1.502134061581728e-08
molecular O 0 4.577566414809553e-07
defects O 0 1.6955045794020407e-05
involve O 0 1.3380377694716117e-08
single O 0 3.169239803924029e-08
- O 0 8.622973979299786e-08
nucleotide O 0 8.49192716145808e-08
events O 0 2.5595803254674365e-09
, O 0 8.206568063995334e-11
deletions O 0 2.774675378347524e-09
and O 0 1.8723889105842773e-10
substitutions O 0 1.3737210258213395e-09
, O 0 8.2087441011236e-11
some O 0 3.514606314314328e-11
of O 0 4.848256171530174e-11
which O 0 2.1684709583524864e-09
alter O 0 1.4809688764216844e-07
splice O 0 3.330216031827149e-07
sites O 0 4.9497369758455534e-08
, O 0 1.7671659691131936e-09
and O 0 5.863913354886563e-09
others O 0 5.2886917956129764e-08
codons O 0 2.4746229883021442e-06
. O 0 4.3770640445472964e-07

They O 0 1.1027058377521826e-07
are O 0 9.56024037712666e-10
distributed O 0 1.3033645274163064e-09
along O 0 2.7525262069616474e-09
the O 0 2.083787808970783e-09
C7 O 0 2.561580174642586e-07
gene O 0 2.7386969136955486e-08
, O 0 9.432149505883558e-10
but O 0 1.1998777527111315e-09
predominantly O 0 4.588761814972031e-09
towards O 0 1.9363484149437227e-09
the O 0 1.34030275766861e-09
3 O 0 2.005680954653144e-08
end O 0 2.080068810528246e-07
. O 0 2.8377695571180084e-07

All O 0 6.962641663221802e-08
were O 0 1.5920351259524068e-08
found O 0 7.0967560716894695e-09
in O 0 2.0196417871432004e-09
compound O 0 1.0777165471154149e-07
heterozygous O 0 1.8213652310805628e-06
individuals O 0 1.5167485400979785e-07
. O 0 3.9185010791698005e-07

The O 0 9.696615052234847e-06
C6 O 0 0.017114738002419472
/ O 0 0.0005721008637920022
C7 O 0 7.45796860428527e-05
marker O 0 4.320332209317712e-06
haplotypes O 0 4.985080522601493e-06
associated O 0 1.461614260733768e-07
with O 0 5.672138758683332e-09
most O 0 9.531989775268812e-08
C7 B-Disease 1 0.9077934622764587
defects I-Disease 1 0.8583232760429382
are O 0 8.71912497757421e-09
tabulated O 0 3.6908701872562233e-07
. O 0 4.426738087204285e-08
. O 0 2.397855212166178e-07

A O 0 3.986103820352582e-07
genome O 0 2.9552799674092967e-07
- O 0 4.283133989702037e-07
wide O 0 2.4743528115322988e-08
search O 0 2.988250713542584e-08
for O 0 3.2310860653694817e-09
chromosomal O 0 3.5349096378922695e-06
loci O 0 2.8348455316518084e-07
linked O 0 1.0641987273629638e-06
to O 0 2.205702109847607e-08
mental O 0 0.00013899285113438964
health O 0 4.524235919234343e-08
wellness O 0 1.9987762556183952e-08
in O 0 2.9808813750697993e-10
relatives O 0 2.1203079292320126e-09
at O 0 1.476026967317523e-09
high O 0 1.371135471828211e-08
risk O 0 2.2792877985011728e-07
for O 0 3.3043796587861607e-09
bipolar B-Disease 1 0.6087504625320435
affective I-Disease 0 0.0410725474357605
disorder I-Disease 0 0.034461744129657745
among O 0 6.885171544013247e-09
the O 0 3.5165481637733365e-09
Old O 0 6.766358069398848e-07
Order O 0 8.168864695790035e-08
Amish O 0 6.033034424035577e-06
. O 0 6.515930977002427e-07

Bipolar B-Disease 1 0.9999871253967285
affective I-Disease 1 0.999866247177124
disorder I-Disease 1 0.9999504089355469
( O 0 9.95580762719328e-07
BPAD B-Disease 1 1.0
; O 0 8.11019435786875e-06
manic B-Disease 1 0.9999916553497314
- I-Disease 1 0.9999997615814209
depressive I-Disease 1 1.0
illness I-Disease 1 0.9791133999824524
) O 0 2.8459099965516543e-08
is O 0 1.998767595878803e-09
characterized O 0 6.982614930706177e-09
by O 0 5.25567311893127e-10
episodes O 0 2.6946695541596455e-08
of O 0 6.129030616364162e-10
mania B-Disease 0 5.821645572723355e-06
and O 0 2.4109521490345287e-08
/ O 0 4.5050981611893803e-07
or O 0 7.846651328691223e-08
hypomania B-Disease 0 1.2801896446035244e-05
interspersed O 0 5.341402697922604e-07
with O 0 8.096685100156265e-09
periods O 0 5.000762257623137e-07
of O 0 4.264637354367551e-08
depression B-Disease 0 2.6774154321174137e-05
. O 0 9.256444855054724e-07

Compelling O 0 2.387566837569466e-06
evidence O 0 1.6877973507689603e-07
supports O 0 6.124583507016723e-08
a O 0 4.790296603829347e-09
significant O 0 1.227377133261598e-08
genetic O 0 1.743693616163e-07
component O 0 1.5629996141797164e-07
in O 0 4.151796684226383e-09
the O 0 4.554354671171268e-09
susceptibility O 0 1.126282882069063e-06
to O 0 8.092889913768886e-08
develop O 0 3.262247446400579e-06
BPAD B-Disease 1 0.999998927116394
. O 0 2.897909098464879e-06

To O 0 4.1878351453306095e-08
date O 0 4.615651505446294e-08
, O 0 8.232424186793708e-10
however O 0 1.1505244534859571e-09
, O 0 1.3941986454213406e-10
linkage O 0 1.1795468601860648e-08
studies O 0 3.883061427956136e-09
have O 0 1.839910723777649e-10
attempted O 0 1.6091150634167661e-09
only O 0 1.2956553885334898e-10
to O 0 2.4986893110146013e-10
identify O 0 1.7057027790201573e-08
chromosomal O 0 3.345772938700975e-07
loci O 0 2.3553944572540786e-08
that O 0 8.244271931800995e-10
cause O 0 3.1469207240064634e-09
or O 0 4.377032514213397e-09
increase O 0 5.808101111171027e-09
the O 0 6.154677212322213e-09
risk O 0 6.965071861486649e-07
of O 0 2.014359568036639e-09
developing O 0 9.280947210754675e-07
BPAD B-Disease 1 0.9999997615814209
. O 0 2.02057321985194e-06

To O 0 2.278980737457914e-08
determine O 0 1.4516423618715635e-08
whether O 0 1.3439120927216663e-09
there O 0 2.994775261111471e-10
could O 0 1.5164635103204205e-09
be O 0 4.099669770329939e-10
protective O 0 7.708585769705678e-09
alleles O 0 1.0034197472919004e-08
that O 0 2.930986287008608e-10
prevent O 0 4.666886876947274e-09
or O 0 4.1612469026119925e-09
reduce O 0 1.309934738458196e-08
the O 0 6.980147015944738e-10
risk O 0 1.3434616974450364e-08
of O 0 2.283075464792894e-11
developing O 0 7.667644297271181e-09
BPAD B-Disease 1 1.0
, O 0 8.465134843094191e-11
similar O 0 5.3281917072878215e-11
to O 0 4.0167247999933764e-11
what O 0 8.197791750985672e-11
is O 0 3.3289464934638247e-11
observed O 0 2.8136420970881204e-10
in O 0 5.3418679202277275e-11
other O 0 2.2531763121946824e-09
genetic B-Disease 1 1.0
disorders I-Disease 1 1.0
, O 0 7.192303974612457e-10
we O 0 1.476933575439432e-09
used O 0 5.482915810262057e-08
mental O 0 5.770725692855194e-06
health O 0 4.694520328030194e-08
wellness O 0 2.7806899893789705e-08
( O 0 3.363893608110402e-10
absence O 0 1.7509407257421117e-09
of O 0 1.7604434576767858e-10
any O 0 6.329553770001439e-08
psychiatric B-Disease 0 0.05683990567922592
disorder I-Disease 0 2.9046437703073025e-05
) O 0 1.4826576633097943e-09
as O 0 7.255340217504624e-10
the O 0 1.6320250706414186e-09
phenotype O 0 7.132146947697038e-06
in O 0 2.9073854435068824e-09
our O 0 1.918496694841565e-09
genome O 0 4.131928577066901e-09
- O 0 2.4266702425279618e-08
wide O 0 6.131150254162776e-09
linkage O 0 9.824256608226278e-08
scan O 0 3.091694225076935e-07
of O 0 6.51024442688275e-11
several O 0 3.215168409287372e-10
large O 0 6.306161370872587e-09
multigeneration O 0 6.990785095695173e-06
Old O 0 1.776759290805785e-07
Order O 0 4.3349257516922535e-09
Amish O 0 7.951541647344129e-08
pedigrees O 0 8.467714707194318e-08
exhibiting O 0 1.1568956459484525e-08
an O 0 1.2006630134564489e-09
extremely O 0 8.752921587529272e-08
high O 0 3.855903685234807e-07
incidence O 0 0.0015881048748269677
of O 0 1.0757982948916833e-07
BPAD B-Disease 1 1.0
. O 0 3.013290779563249e-06

We O 0 8.991269169200677e-07
have O 0 5.949012393813291e-09
found O 0 2.7666533508607927e-09
strong O 0 1.0922156512549464e-09
evidence O 0 3.2463132182414256e-09
for O 0 3.5391684027885617e-10
a O 0 3.3075135963400726e-09
locus O 0 3.3068579341488658e-06
on O 0 1.3511420604572777e-07
chromosome O 0 3.6919431295245886e-05
4p O 0 0.0001182982960017398
at O 0 5.8862266172354794e-08
D4S2949 O 0 4.0963919900605106e-07
( O 0 2.0716452997504575e-09
maximum O 0 1.6388634449526762e-08
GENEHUNTER O 0 2.6527513909968548e-06
- O 0 3.269278181505797e-07
PLUS O 0 1.0182073850728557e-07
nonparametric O 0 5.081290623820678e-07
linkage O 0 4.581182508900383e-07
score O 0 4.794010166619955e-08
= O 0 7.083735908963718e-08
4 O 0 2.7939741631399784e-09
. O 0 1.4790083602278514e-09
05 O 0 1.536853631023405e-07
, O 0 1.3865593118111974e-09
P O 0 5.85172585942928e-07
= O 0 3.915937440979178e-08
5 O 0 6.87434276169796e-10
. O 0 5.320242579820444e-10
22 O 0 7.111264355152969e-10
x O 0 2.3456300013435794e-08
10 O 0 6.269184615881329e-10
( O 0 3.584406382817207e-10
- O 0 8.889046654303456e-08
4 O 0 3.6839893358120435e-09
) O 0 7.405243640512538e-10
; O 0 1.0968126407107093e-09
SIBPAL O 0 1.8380259803052468e-07
Pempirical O 0 7.553049385933264e-08
value O 0 2.5057733665789783e-09
< O 0 7.270152035943056e-09
3 O 0 4.936033803915052e-10
x O 0 1.0143940798457152e-08
10 O 0 4.212207804776824e-10
( O 0 1.3678089216817568e-10
- O 0 2.987412983657123e-08
5 O 0 5.633483679545748e-10
) O 0 1.2079601208192514e-10
) O 0 8.393269412820814e-11
and O 0 9.179462745478872e-11
suggestive O 0 9.838991843480471e-09
evidence O 0 2.9156543845942906e-09
for O 0 2.27703175759153e-10
a O 0 8.054200639762144e-10
locus O 0 4.283440375729697e-07
on O 0 4.402521369684109e-08
chromosome O 0 6.03570842940826e-05
4q O 1 0.6871634125709534
at O 0 1.761842582936879e-08
D4S397 O 0 1.8884159658227873e-07
( O 0 7.708493843239239e-10
maximum O 0 5.3161475221941146e-09
GENEHUNTER O 0 1.5912116850813618e-06
- O 0 2.6865720315072394e-07
PLUS O 0 6.620321357786452e-08
nonparametric O 0 1.8061577122807648e-07
linkage O 0 2.323650960533996e-07
score O 0 1.954452955033048e-08
= O 0 3.580767682365149e-08
3 O 0 1.1909899733097973e-09
. O 0 5.916453438281621e-10
29 O 0 3.240714585572846e-09
, O 0 4.46533504616653e-10
P O 0 3.7270015695867187e-07
= O 0 1.8275311930437965e-08
2 O 0 6.32616792284324e-10
. O 0 4.80134432212509e-10
57 O 0 1.5611791859271307e-09
x O 0 3.6963790250865713e-08
10 O 0 1.0226011148972702e-09
( O 0 4.167925449216625e-10
- O 0 2.8718909561575856e-07
3 O 0 4.629297389868725e-09
) O 0 8.458989619875013e-10
; O 0 1.5491008475976287e-09
SIBPAL O 0 2.5940127557078085e-07
Pempirical O 0 7.403894386470711e-08
value O 0 1.8527442913196523e-09
< O 0 4.7350572351945175e-09
1 O 0 2.071043891938018e-10
x O 0 1.2801174342769173e-08
10 O 0 2.875491234011207e-10
( O 0 1.2708376018188972e-10
- O 0 2.553432842944403e-08
3 O 0 1.0535617933626895e-09
) O 0 5.91691348694745e-11
) O 0 4.5722016450699954e-11
that O 0 2.8572295571183126e-11
are O 0 1.7845105948488538e-10
linked O 0 6.243509886871834e-08
to O 0 1.0746699530272963e-08
mental O 0 4.134211849304847e-06
health O 0 2.3733390719371528e-07
wellness O 0 1.5197326774796238e-06
. O 0 2.628538027238392e-07

These O 0 3.7222022797323007e-08
findings O 0 3.392110770050749e-08
are O 0 7.101423893374204e-10
consistent O 0 1.835344654033122e-09
with O 0 1.0204885547704379e-10
the O 0 1.0552063389734911e-10
hypothesis O 0 5.8175917416747325e-09
that O 0 1.0155371682474268e-10
certain O 0 4.819345478246362e-10
alleles O 0 1.5519496798788168e-08
could O 0 5.130756708382478e-09
prevent O 0 5.415687009957537e-09
or O 0 2.19530882361596e-09
modify O 0 3.065534315283003e-08
the O 0 8.256704209230747e-10
clinical O 0 3.8885328734750146e-08
manifestations O 0 1.4526340130771587e-08
of O 0 4.392217423099254e-10
BPAD B-Disease 1 0.9999998807907104
and O 0 1.335118127165913e-09
perhaps O 0 1.890634537815572e-09
other O 0 1.5194224767256514e-09
related O 0 5.192882781557273e-07
affective B-Disease 0 0.012191783636808395
disorders I-Disease 0 0.016638515517115593
. O 0 7.67177141369757e-07

Segregation O 0 0.0003505672502797097
distortion O 0 0.000259136751992628
in O 0 3.97483245251351e-06
myotonic B-Disease 1 0.9999946355819702
dystrophy I-Disease 1 0.9999957084655762
. O 0 1.780660022632219e-05

Myotonic B-Disease 1 0.9999958276748657
dystrophy I-Disease 1 0.9999991655349731
( O 0 2.9856024411856197e-05
DM B-Disease 1 1.0
) O 0 1.4114991131464194e-07
is O 0 5.330961894145503e-09
an O 0 3.610536980502843e-09
autosomal B-Disease 1 0.6131090521812439
dominant I-Disease 1 0.9998323917388916
disease I-Disease 0 0.10555151104927063
which O 0 1.0532749783465079e-08
, O 0 3.2553329476492365e-10
in O 0 1.9943606488492804e-10
the O 0 4.236823947234569e-10
typical O 0 2.3432242812759796e-08
pedigree O 0 9.02842259620229e-07
, O 0 6.761611270889034e-10
shows O 0 3.6724978613733583e-09
a O 0 1.7799902662929412e-09
three O 0 2.092430229083675e-09
generation O 0 1.3154483724520105e-07
anticipation O 0 1.606503872153553e-07
cascade O 0 3.1763038350618444e-06
. O 0 6.021206786499533e-07

This O 0 1.638314159890797e-07
results O 0 3.173295795022568e-07
in O 0 4.0097191345012106e-08
infertility B-Disease 0 0.14807145297527313
and O 0 1.2060030485372408e-06
congenital B-Disease 1 0.9999958276748657
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 3.592688813114364e-07
CDM B-Disease 0 4.165353402640903e-06
) O 0 3.857269614826464e-09
with O 0 3.6964106775450034e-10
the O 0 7.905124888019088e-10
disappearance O 0 1.7089436710193695e-07
of O 0 5.393359092664696e-09
DM B-Disease 1 1.0
in O 0 2.549734112733404e-08
that O 0 1.1432167212888089e-08
pedigree O 0 6.905677764734719e-06
. O 0 5.506989282366703e-07

The O 0 2.5752962429237414e-08
concept O 0 1.5678581988254336e-08
of O 0 5.952675574683042e-10
segregation O 0 4.889636073812653e-08
distortion O 0 2.6793028951033193e-07
, O 0 3.4379696312036856e-10
where O 0 3.8519740175324557e-10
there O 0 8.263127682095472e-11
is O 0 5.774603017982827e-11
preferential O 0 4.316806911930371e-09
transmission O 0 1.933972271217499e-08
of O 0 6.308344818739542e-11
the O 0 1.05975062059116e-10
larger O 0 6.5568825924344765e-09
allele O 0 1.6578569272951427e-07
at O 0 3.117605062996631e-09
the O 0 2.9739999352074165e-09
DM B-Disease 1 0.9999998807907104
locus O 0 9.077297136173001e-07
, O 0 1.2824823425461318e-09
has O 0 8.635705484039136e-10
been O 0 1.0272733774741027e-09
put O 0 5.609519515559214e-10
forward O 0 5.526345492334883e-10
to O 0 3.4829034101235834e-10
explain O 0 8.897778513983212e-09
partially O 0 5.506254652232201e-08
the O 0 2.820498279376693e-10
maintenance O 0 2.1053459420272702e-08
of O 0 1.0889311674588953e-09
DM B-Disease 1 1.0
in O 0 6.498403148924581e-09
the O 0 6.5538938720521855e-09
population O 0 7.68488064295525e-08
. O 0 2.3375422131266532e-07

In O 0 1.3228444117885374e-07
a O 0 3.513600077553747e-08
survey O 0 1.0929876737009181e-07
of O 0 3.278696203423692e-09
DM B-Disease 1 1.0
in O 0 1.5902324790317834e-08
Northern O 0 1.2181374131614575e-07
Ireland O 0 1.4791523881285684e-06
, O 0 3.26806959272119e-09
59 O 0 2.478046035037096e-08
pedigrees O 0 5.874180715181865e-07
were O 0 5.5994021863625676e-08
ascertained O 0 7.788121365592815e-06
. O 0 4.983014605386415e-07

Sibships O 0 1.8765111235552467e-05
where O 0 7.445174787790165e-08
the O 0 5.89025273001198e-10
status O 0 4.111747387014475e-09
of O 0 5.325803686950792e-11
all O 0 5.534264019280144e-11
the O 0 4.4901173057443344e-11
members O 0 5.294386457022071e-11
had O 0 2.13442841179301e-09
been O 0 6.82968570586695e-10
identified O 0 1.5707070089021613e-09
were O 0 1.6430777571851962e-10
examined O 0 1.3144290100797207e-09
to O 0 6.152792858538092e-11
determine O 0 1.5836755240528078e-09
the O 0 1.2343108479750953e-10
transmission O 0 1.4332615982937114e-08
of O 0 9.249181975867771e-11
the O 0 5.46602851869693e-09
DM B-Disease 1 0.9999996423721313
expansion O 0 1.2033344987116834e-08
from O 0 7.57501505965763e-10
affected O 0 3.800047387869654e-09
parents O 0 2.215263084082153e-09
to O 0 5.874645769843312e-10
their O 0 8.132918338787931e-09
offspring O 0 7.053292279124435e-07
. O 0 4.164274969298276e-07

Where O 0 2.5058778874154086e-07
the O 0 1.273226146736306e-08
transmitting O 0 1.3992204003443476e-05
parent O 0 3.676015012388234e-06
was O 0 3.2245316106127575e-07
male O 0 4.954549694957677e-07
, O 0 2.0428688074503043e-08
58 O 0 3.344436265706463e-07
. O 0 5.55887936570798e-07

3 O 0 3.35260523343095e-07
% O 0 1.4372775858362274e-08
of O 0 1.9250680216575944e-10
the O 0 2.4771601436768265e-10
offspring O 0 8.83466722001458e-09
were O 0 1.6993503271223176e-09
affected O 0 9.228076081058134e-10
, O 0 1.0548139445232252e-10
and O 0 1.4803680503661099e-10
in O 0 8.402287199338332e-11
the O 0 7.539709828696672e-11
case O 0 2.494528583696365e-09
of O 0 8.472403334458534e-11
a O 0 1.964756801697831e-09
female O 0 9.736839956531185e-08
transmitting O 0 1.011843323794892e-05
parent O 0 4.698130737779138e-07
, O 0 8.915752580662684e-09
68 O 0 1.98516758587175e-07
. O 0 3.4213681487926806e-07

7 O 0 1.54593681145343e-06
% O 0 1.0978433095942819e-07
were O 0 6.439464783625226e-08
affected O 0 6.470034463745833e-07
. O 0 8.918823937165143e-07

Studies O 0 1.6948312122622156e-06
on O 0 1.0577625886298847e-08
meiotic O 0 8.936456765695766e-07
drive O 0 9.749216189902654e-08
in O 0 1.5362052963041606e-08
DM B-Disease 1 0.9999998807907104
have O 0 6.797031826266675e-09
shown O 0 1.2945270411179877e-09
increased O 0 7.918705691167816e-10
transmission O 0 1.3888918459770139e-08
of O 0 8.562158620994964e-11
the O 0 2.3226953693722407e-10
larger O 0 1.1489702522737844e-08
allele O 0 2.575483790678845e-07
at O 0 1.0663169902613845e-08
the O 0 1.2986553166172143e-08
DM B-Disease 1 0.9999998807907104
locus O 0 5.38432414032286e-06
in O 0 3.0563505504233035e-08
non O 0 2.8131407816545106e-06
- O 0 0.0006924409535713494
DM O 1 0.9999991655349731
heterozygotes O 0 1.1538010767253581e-05
for O 0 3.1627539698320106e-08
CTGn O 0 9.386388228449505e-06
. O 0 7.807402084836212e-07

This O 0 4.2297955360481865e-08
study O 0 1.320102871460449e-08
provides O 0 2.7390614221189935e-09
further O 0 5.157765881058651e-10
evidence O 0 1.582470821048787e-09
that O 0 3.3324359938191606e-10
the O 0 1.869984167512939e-09
DM B-Disease 1 1.0
expansion O 0 1.836501084540032e-08
tends O 0 1.8142330304726784e-08
to O 0 8.032905451926808e-10
be O 0 2.761934236872321e-09
transmitted O 0 7.550571723413668e-08
preferentially O 0 7.934971790746204e-07
. O 0 2.9274423241076875e-07

Diagnosis O 1 0.5651945471763611
of O 0 7.676421773794573e-06
hemochromatosis B-Disease 1 0.9999998807907104
. O 0 5.578785203397274e-05

If O 0 6.702770861011231e-06
untreated O 0 2.3043354303808883e-05
, O 0 5.4219118084120055e-08
hemochromatosis B-Disease 1 1.0
can O 0 0.00938083603978157
cause O 0 1.2821469681512099e-05
serious O 0 0.0009366825106553733
illness O 0 2.6423580493428744e-05
and O 0 5.804321467905993e-10
early B-Disease 0 2.4007731358466344e-09
death I-Disease 0 1.617509459705957e-09
, O 0 2.4613777682702676e-10
but O 0 3.33123040263672e-09
the O 0 1.957559891963001e-09
disease O 0 1.206679058896043e-07
is O 0 1.4346885901517226e-09
still O 0 1.0287817708842795e-08
substantially O 0 6.772756222517273e-08
under O 0 1.0548315287906007e-07
- O 0 0.43596145510673523
diagnosed O 0 0.004301850683987141
. O 0 5.148365289642243e-07

The O 0 3.095706446742952e-08
cornerstone O 0 1.2258510651008692e-07
of O 0 3.2861571797049294e-10
screening O 0 2.089432271645819e-08
and O 0 5.681675685487164e-10
case O 0 2.1874300148994053e-09
detection O 0 1.782630931757012e-08
is O 0 2.3726978715110647e-10
the O 0 1.673507721289269e-10
measurement O 0 9.639678921757877e-08
of O 0 1.0103772263292399e-09
serum O 0 1.852864244256125e-07
transferrin O 0 6.711563855787972e-07
saturation O 0 4.1663403749225836e-07
and O 0 8.747142565823651e-09
the O 0 8.684602370578887e-09
serum O 0 1.622316744942509e-06
ferritin O 0 2.4849412511684932e-05
level O 0 1.7220513655047398e-06
. O 0 7.803441235409991e-07

Once O 0 1.3028975445195101e-06
the O 0 6.396202678615737e-09
diagnosis O 0 2.112833954015514e-06
is O 0 1.7764120174845743e-09
suspected O 0 1.0667547201137495e-07
, O 0 8.346529578595607e-10
physicians O 0 4.0511674015419885e-09
must O 0 1.9829407005289568e-09
use O 0 1.0394701988047927e-08
serum O 0 3.8055623008403927e-07
ferritin O 0 1.29548989207251e-05
levels O 0 8.478055519844929e-07
and O 0 3.0249459825881786e-08
hepatic O 0 1.4481834114121739e-05
iron O 0 9.283662802772596e-05
stores O 0 3.0837984468234936e-06
on O 0 1.4677793203077272e-08
liver O 0 1.550229882241183e-07
biopsy O 0 1.3094221458231914e-06
specimens O 0 6.301869248659386e-09
to O 0 4.140723319778772e-10
assess O 0 2.4652610619568804e-08
patients O 0 5.509497746913894e-09
for O 0 6.850608275099646e-11
the O 0 3.514407376226103e-10
presence O 0 8.855265853924266e-09
of O 0 5.2157802521435315e-09
iron B-Disease 0 0.17944581806659698
overload I-Disease 0 0.00020037003559991717
. O 0 8.692658184372704e-07

Liver O 0 0.004053953103721142
biopsy O 1 0.7270678877830505
is O 0 2.452167713329345e-08
also O 0 1.3314053193269615e-09
used O 0 2.1951833684141775e-09
to O 0 1.4898914046934664e-10
establish O 0 6.089574955403521e-10
the O 0 8.157502451311416e-11
presence O 0 1.828687867799772e-09
or O 0 6.268698005129636e-09
absence O 0 4.208805304273255e-09
of O 0 3.382055469014489e-10
cirrhosis B-Disease 0 4.874067371929414e-07
, O 0 3.129602688112243e-10
which O 0 3.0095155256759654e-09
can O 0 3.582195517992659e-08
affect O 0 1.027711391543562e-07
prognosis O 0 2.0198949641780928e-06
and O 0 2.4257078123923748e-08
management O 0 2.90297720084709e-07
. O 0 2.4496486616953916e-07

A O 0 3.7052737411613634e-07
DNA O 0 8.217228355533734e-07
- O 0 1.075728050636826e-06
based O 0 2.8768218029995296e-08
test O 0 1.9231212178283386e-08
for O 0 1.4500663170213812e-10
the O 0 1.9593220101921105e-10
HFE O 0 3.599043623125908e-07
gene O 0 5.911651612677815e-09
is O 0 1.4369443135375803e-10
commercially O 0 4.158009936361395e-09
available O 0 1.6012008385857257e-09
, O 0 6.960760440266611e-11
but O 0 1.5231009509175664e-10
its O 0 4.809536102712286e-11
place O 0 1.6630525845329203e-09
in O 0 8.531625406149601e-11
the O 0 2.84409468198632e-10
diagnosis O 0 4.859466002926638e-07
of O 0 6.268084384863926e-10
hemochromatosis B-Disease 1 1.0
is O 0 9.791089183863733e-08
still O 0 7.094674714380744e-08
being O 0 4.187268132227473e-08
evaluated O 0 4.853704353990906e-07
. O 0 1.6532246149836283e-07

Currently O 0 2.9714536253777624e-07
, O 0 2.0502455289062027e-09
the O 0 9.983940063573726e-11
most O 0 3.1645235043509246e-11
useful O 0 6.387591566792139e-10
role O 0 8.072671420222832e-10
for O 0 6.631800664180787e-11
this O 0 1.4098100464821073e-10
test O 0 5.514891210367523e-09
is O 0 6.279964048783171e-11
in O 0 4.603810041525769e-11
the O 0 1.0072306877439985e-10
detection O 0 1.4919319113460006e-08
of O 0 5.263257052412484e-10
hemochromatosis B-Disease 1 1.0
in O 0 9.536278433586176e-09
the O 0 5.463388630388977e-10
family O 0 1.0814611428600074e-09
members O 0 9.636853121053335e-11
of O 0 3.6842386780255865e-11
patients O 0 2.5315993745778087e-09
with O 0 5.048143500441249e-11
a O 0 5.145395221006765e-10
proven O 0 2.9691044289847923e-08
case O 0 3.987888241852033e-09
of O 0 4.894875060834636e-10
the O 0 3.884915145135892e-08
disease O 0 3.888758783432422e-06
. O 0 3.3170300639540073e-07

It O 0 7.384911526742144e-08
is O 0 9.274133461190104e-09
crucial O 0 8.152195363209103e-08
to O 0 8.218422209438359e-08
diagnose O 1 0.5711496472358704
hemochromatosis B-Disease 1 1.0
before O 0 0.0027393170166760683
hepatic B-Disease 1 0.99989914894104
cirrhosis I-Disease 1 0.9138000011444092
develops O 0 6.651851890637772e-06
because O 0 9.407471424083269e-08
phlebotomy O 0 1.2720382983388845e-05
therapy O 0 1.4238034964364488e-06
can O 0 1.5154847687881556e-07
avert O 0 0.00012201136269140989
serious O 0 0.4752832055091858
chronic O 1 0.9998822212219238
disease O 0 5.28043310623616e-05
and O 0 1.3684464672536478e-09
can O 0 2.076943061979364e-09
even O 0 1.5468422098763313e-09
lead O 0 3.744445642439587e-09
to O 0 6.453217404889244e-10
normal O 0 3.016252136944786e-08
life O 0 2.8525402484547158e-08
expectancy O 0 1.3981819790842565e-07
. O 0 2.127799980655709e-08
. O 0 2.1635150915244594e-07

Prevalence O 0 0.003566307947039604
of O 0 2.0128435807009737e-08
the O 0 1.784236580704146e-08
I1307K O 0 2.0359448171802796e-06
APC B-Disease 0 2.533408007820981e-07
gene O 0 1.057704395179826e-07
variant O 0 4.817480885321856e-07
in O 0 4.144928844596052e-09
Israeli O 0 2.2614572969814617e-07
Jews O 0 1.4538287018694973e-08
of O 0 4.882797291494434e-11
differing O 0 4.998184532922778e-09
ethnic O 0 1.156639672927895e-08
origin O 0 5.414677772819232e-08
and O 0 5.2971621755659726e-08
risk O 0 4.29590763815213e-05
for O 0 8.769179657974746e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.4919538645917783e-06

BACKGROUND O 0 0.00040014160913415253
& O 0 1.5853613149374723e-05
AIMS O 0 8.916655360735604e-07
Israeli O 0 4.4080928773837513e-07
Jews O 0 4.248764540193406e-08
of O 0 2.5836527361988715e-10
European O 0 5.186990392758162e-09
birth O 0 5.8027973537377875e-09
, O 0 3.0617386403974933e-10
i O 0 3.4841611817881812e-09
. O 0 1.1625505419443627e-10
e O 0 1.8405890145345438e-09
. O 0 7.924685213600569e-11
, O 0 3.024750935831655e-11
Ashkenazim O 0 8.579790211626914e-09
, O 0 7.63089869071365e-11
have O 0 3.812474225206586e-10
the O 0 1.8434876958295376e-09
highest O 1 0.9998084902763367
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
incidence O 0 0.08414685726165771
of O 0 1.0397949168350351e-09
any O 0 8.093908832051966e-08
Israeli O 0 0.0016296857502311468
ethnic O 0 3.1927979762258474e-06
group O 0 1.9046192392124794e-06
. O 0 6.062184638722101e-07

The O 0 5.200530495130806e-07
I1307K O 0 7.702702532697003e-06
APC B-Disease 0 8.261333164227835e-07
gene O 0 3.123195710941218e-07
variant O 0 4.9698483053362e-06
was O 0 1.420232678128741e-07
found O 0 2.596445014546589e-08
in O 0 1.7878749147826056e-08
6 O 0 2.0865017802407237e-07
. O 0 2.7824574999613105e-07

1 O 0 2.6166253519477323e-07
% O 0 6.2800786793104635e-09
of O 0 5.6927153962993415e-11
American O 0 1.0415576179312325e-09
Jews O 0 3.017228911161851e-09
, O 0 1.8731460826870716e-10
28 O 0 5.720866558256432e-10
% O 0 1.3814506483189604e-10
of O 0 9.070458967253003e-11
their O 0 1.0991649332936504e-06
familial O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
cases O 0 3.7024935295448813e-07
, O 0 1.7171072341781723e-09
but O 0 2.449810132532093e-09
not O 0 1.2366160317967e-09
in O 0 1.210629263503904e-09
non O 0 2.1466865973707172e-07
- O 0 1.5031364455353469e-06
Jews O 0 5.518124339687347e-07
. O 0 1.9592798139456136e-07

We O 0 5.111341465635633e-07
assessed O 0 1.7340919100661267e-07
the O 0 2.8322355571930302e-09
I1307K O 0 5.395182256506814e-07
prevalence O 0 8.831240165818599e-07
in O 0 2.9732794004644347e-09
Israeli O 0 7.104546995151395e-08
Jews O 0 6.277767194973194e-09
of O 0 6.128408197580981e-11
differing O 0 3.2375204739309993e-09
ethnic O 0 9.070503459440715e-09
origin O 0 4.130551545244998e-08
and O 0 1.1884812067819439e-07
risk O 0 6.91855457262136e-05
for O 0 1.6525116734555922e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 5.2150949159113225e-06

METHODS O 0 1.5417052736665937e-06
DNA O 0 2.982556850383844e-07
samples O 0 2.2942410637938337e-08
from O 0 4.2732967164837987e-10
500 O 0 4.775734252504549e-10
unrelated O 0 2.428373058194211e-09
Jews O 0 4.271123010823885e-09
of O 0 5.990589274640357e-11
European O 0 3.1553051282884326e-09
or O 0 1.6750477671578778e-09
non O 0 6.467467983384267e-08
- O 0 1.9879364572261693e-06
European O 0 4.519197016605858e-09
origin O 0 1.0999214872242646e-09
, O 0 2.8659623285687275e-11
with O 0 1.5465987865392883e-11
or O 0 1.562266427335146e-09
without O 0 9.798871714039592e-10
a O 0 1.2983938924016059e-10
personal O 0 4.20731183226053e-09
and O 0 5.745933950862536e-09
/ O 0 4.1559506058774787e-08
or O 0 7.30876204002584e-09
family O 0 1.5270286146673584e-09
history O 0 2.4547401888952436e-09
of O 0 2.4105634155446864e-10
neoplasia B-Disease 0 1.5987075130396988e-06
, O 0 3.9135442109206053e-10
were O 0 4.107034712319546e-10
examined O 0 9.207492546181584e-09
for O 0 1.4451048691022095e-10
the O 0 3.5694991407098087e-10
I1307K O 0 4.511663220796436e-08
variant O 0 3.1840173164709995e-08
by O 0 1.7501584903545364e-10
the O 0 7.182598404931184e-10
allele O 0 3.4951958127749094e-07
- O 0 1.5596954483498848e-07
specific O 0 1.3883515670443103e-08
oligonucleotide O 0 3.952608949475689e-06
( O 0 6.1864660061417e-09
ASO O 0 6.803128940191527e-07
) O 0 6.6584111557688175e-09
method O 0 2.741386708748905e-07
. O 0 3.674710740142473e-07

RESULTS O 0 1.2212365163577488e-06
In O 0 1.6695996807314373e-09
persons O 0 1.9961425845593794e-09
at O 0 2.880872651545019e-09
average O 0 1.1387167830889666e-07
risk O 0 0.0003133928694296628
for O 0 0.0014345167437568307
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 6.114205142182527e-09
I1307K O 0 3.5476887205732055e-07
was O 0 2.8586841338551494e-08
found O 0 6.81215173159444e-09
in O 0 2.923706832191897e-09
5 O 0 5.044590167813112e-08
. O 0 1.8156841008476476e-07

0 O 0 1.3253325050754938e-06
% O 0 3.1988030002594314e-08
of O 0 5.47381917570533e-10
120 O 0 6.605183511254609e-09
European O 0 1.0118090187916096e-07
and O 0 1.672264993146655e-08
1 O 0 6.11233019753854e-08
. O 0 2.8130770601819677e-07

6 O 0 9.209874178850441e-07
% O 0 1.1910564090555908e-08
of O 0 2.8292646003791333e-10
188 O 0 1.2827864104281161e-08
non O 0 1.139764123081477e-07
- O 0 6.26927942448674e-07
European O 0 2.587482228477711e-08
Jews O 0 1.2592425768787052e-08
( O 0 8.264392503676277e-10
P O 0 5.518760417544399e-07
= O 0 6.058173340761641e-08
0 O 0 5.918545209482318e-09
. O 0 2.7439190919409384e-09
08 O 0 6.012840714220147e-08
) O 0 1.4190378649914237e-08
. O 0 1.6151371085015853e-07

It O 0 2.1341409706110426e-07
occurred O 0 4.826636086363578e-07
in O 0 2.5105681089598875e-08
15 O 0 1.276217176382488e-07
. O 0 3.6438683537198813e-07

4 O 0 1.2372557876005885e-06
% O 0 4.933450270527828e-08
of O 0 1.923963877104029e-09
52 O 0 2.5384480295542744e-07
Ashkenazi O 0 0.0005063312710262835
Israelis O 0 5.2985164074925706e-05
with O 0 5.729979690727305e-08
familial O 1 0.7202139496803284
cancer B-Disease 0 0.003494435455650091
( O 0 2.052554926024186e-08
P O 0 0.0002591631782706827
= O 0 1.0193786010859185e-06
0 O 0 2.1535964123131635e-08
. O 0 2.983983060644846e-09
02 O 0 1.9689819552581866e-08
) O 0 2.3298568629925853e-10
and O 0 4.1955700025297915e-10
was O 0 3.5118561392266656e-09
not O 0 4.559680688576151e-10
detected O 0 3.0426454689091997e-09
in O 0 1.4471955578354567e-10
51 O 0 4.259830710395818e-09
non O 0 2.1874438260738316e-08
- O 0 1.4074181819978548e-07
European O 0 5.774465794416983e-09
Jews O 0 5.6530113923258796e-09
at O 0 3.570617801429421e-09
increased O 0 5.7065083325369415e-08
cancer B-Disease 0 7.244364041980589e-06
risk O 0 1.7481972918176325e-06
. O 0 3.165337432164961e-07

Colorectal B-Disease 1 0.9924887418746948
neoplasia I-Disease 0 0.0006499715964309871
occurred O 0 1.0567017625362496e-06
personally O 0 1.8452321626227786e-07
or O 0 1.723815579168786e-08
in O 0 6.705844768362113e-10
the O 0 4.803011321996564e-10
families O 0 6.121074758169698e-10
of O 0 9.391144806247809e-11
13 O 0 6.030418941982418e-10
of O 0 1.5443091250233465e-10
20 O 0 1.568102758753298e-09
Ashkenazi O 0 9.838526437988548e-08
I1307K O 0 1.7300935795105943e-08
carriers O 0 4.388033048030593e-09
, O 0 7.410580482591911e-11
8 O 0 8.498152181957153e-11
of O 0 1.0418506335430067e-11
whom O 0 7.88344589608414e-09
also O 0 1.6383509660045092e-08
had O 0 3.164166173519334e-08
a O 0 7.172481497619287e-10
personal O 0 3.398736225790344e-08
or O 0 4.9955087177977475e-08
family O 0 2.817812472244441e-08
history O 0 9.830685598899436e-08
of O 0 2.6533074404255785e-08
noncolonic O 0 0.00044015012099407613
neoplasia B-Disease 0 0.005848554894328117
. O 0 2.9369575713644736e-06

CONCLUSIONS O 0 8.140756108332425e-06
The O 0 5.061822960783502e-08
I1307K O 0 2.188188091167831e-06
APC O 0 4.5114913405086554e-07
variant O 0 4.818551246899005e-07
may O 0 1.997183396440505e-08
represent O 0 1.7217115511058978e-09
a O 0 1.0593873556175026e-09
susceptibility O 0 7.055916739773238e-08
gene O 0 6.702628496668694e-08
for O 0 1.818241024409417e-08
colorectal B-Disease 1 1.0
, I-Disease 0 2.094846296429864e-09
or I-Disease 0 2.2401536181604342e-09
other I-Disease 0 2.032440660215684e-09
, I-Disease 0 6.525766149678702e-09
cancers I-Disease 0 0.0034901374019682407
in O 0 2.8427726839197476e-09
Ashkenazi O 0 6.912306389494915e-07
Jews O 0 1.1288638468442969e-08
, O 0 3.3860633741333857e-10
and O 0 8.430399711656378e-10
partially O 0 6.918150319279448e-08
explains O 0 7.556416825593715e-09
the O 0 3.1818833678975977e-10
higher O 0 3.029905926155152e-08
incidence O 0 0.028956172987818718
of O 0 3.9496339013567194e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 1.029693095233597e-07
European O 0 9.529169346933486e-07
Israelis O 0 2.1312953322194517e-05
. O 0 7.877367238506849e-07

Systematic O 0 1.8068845974994474e-06
analysis O 0 3.493599649573298e-07
of O 0 6.156450016447934e-09
coproporphyrinogen O 0 7.958595233503729e-06
oxidase O 0 8.049758434935939e-06
gene O 0 1.759295628289692e-05
defects O 1 0.8063719868659973
in O 0 3.284499783262618e-08
hereditary B-Disease 0 0.031606726348400116
coproporphyria I-Disease 0 0.02347358502447605
and O 0 3.6918842738487e-07
mutation O 0 2.2891084881848656e-05
update O 0 1.5160590919549577e-05
. O 0 1.9069057088927366e-06

Hereditary B-Disease 1 0.8458291888237
coproporphyria I-Disease 0 0.000776614819187671
( O 0 3.77995377220941e-07
HC B-Disease 0 2.4414686777163297e-05
) O 0 6.470453683959931e-08
is O 0 1.7917871630857007e-08
an O 0 1.2238955093835102e-07
acute O 1 0.8789742588996887
hepatic B-Disease 1 0.9998154044151306
porphyria I-Disease 1 0.9999188184738159
with O 0 6.29282681074983e-07
autosomal O 1 0.9997215867042542
dominant O 1 0.9590694308280945
inheritance O 0 0.33321815729141235
caused O 0 6.205582394613884e-06
by O 0 1.002736649269309e-08
deficient B-Disease 0 1.2974631317774765e-05
activity I-Disease 0 5.946928283151465e-08
of I-Disease 0 2.054818093455424e-09
coproporphyrinogen I-Disease 0 9.98677933239378e-06
III I-Disease 0 1.1789270502049476e-06
oxidase I-Disease 0 1.65499591275875e-06
( O 0 1.6671279468027933e-08
CPO O 0 4.942651685269084e-06
) O 0 7.917626021480828e-08
. O 0 3.110823740826163e-07

Clinical O 0 2.6510559109738097e-05
manifestations O 0 6.597240940209304e-07
of O 0 2.2376769326371004e-09
the O 0 9.842840320573032e-09
disease O 0 5.911496714361419e-07
are O 0 5.987005891050501e-10
characterized O 0 1.2946141936254207e-08
by O 0 1.1136287447754967e-08
acute O 0 0.0005906490841880441
attacks O 0 0.18119218945503235
of O 0 4.2600031946449235e-08
neurological B-Disease 1 0.9998955726623535
dysfunction I-Disease 0 0.00012161481572547927
often O 0 8.041620702670116e-08
precipitated O 0 2.883875893644472e-08
by O 0 1.7139421826239953e-10
drugs O 0 4.902716899124471e-09
, O 0 7.373809896016326e-11
fasting O 0 7.668302437480179e-09
, O 0 9.516195609293732e-10
cyclical O 0 7.0792509632156e-07
hormonal O 0 8.47611545395921e-07
changes O 0 1.6657706325418076e-08
, O 0 2.5616120336025006e-09
or O 0 1.6912710520955443e-07
infectious B-Disease 0 1.3328563909453806e-05
diseases I-Disease 0 4.054922828800045e-05
. O 0 6.007028900967271e-07

Skin O 1 0.9995085000991821
photosensitivity O 1 0.984836995601654
may O 0 0.0001639429829083383
also O 0 2.0697980218642442e-08
be O 0 6.672268071383769e-09
present O 0 2.8064039980790767e-08
. O 0 2.3065138066158397e-07

The O 0 1.377699021531953e-07
seven O 0 2.2188164194858473e-08
exons O 0 3.055899355786096e-07
, O 0 3.0832474351427663e-09
the O 0 1.4351784205501872e-09
exon O 0 3.060215476580197e-07
/ O 0 6.345255343376266e-08
intron O 0 7.391809049295262e-07
boundaries O 0 4.7918710777139495e-08
and O 0 2.9826461300785923e-09
part O 0 1.6325792939753114e-09
of O 0 1.2092510326411343e-10
3 O 0 6.215036818524311e-10
noncoding O 0 4.3687940376457846e-08
sequence O 0 3.232972556332925e-09
of O 0 1.1052963405644434e-10
the O 0 5.943769365579499e-10
CPO O 0 7.810263014107477e-08
gene O 0 7.518449862686793e-09
were O 0 8.667289108643672e-10
systematically O 0 2.976288193679011e-08
analyzed O 0 3.2678642014616344e-09
by O 0 6.675240221687417e-11
an O 0 1.0756142504453337e-10
exon O 0 6.711711364459916e-08
- O 0 5.274920411579842e-08
by O 0 5.164964900217228e-09
- O 0 3.483153534489247e-07
exon O 0 1.5222071851894725e-06
denaturing O 0 1.5184378753474448e-05
gradient O 0 5.64643642064766e-06
gel O 0 2.807933014992159e-05
electrophoresis O 0 2.4247885903605493e-06
( O 0 4.5856385355591556e-09
DGGE O 0 2.2892412232522474e-07
) O 0 8.915594928993187e-10
strategy O 0 4.424169919303722e-09
followed O 0 1.5549822540705804e-10
by O 0 3.016535285449429e-11
direct O 0 3.847568097459231e-10
sequencing O 0 4.674949316552102e-09
in O 0 5.12842546207537e-10
seven O 0 2.2096844354280165e-09
unrelated O 0 8.724052946718075e-08
heterozygous O 0 5.309006496645452e-07
HC B-Disease 0 1.0160543979509384e-06
patients O 0 1.4340332654683152e-07
from O 0 1.556285544879188e-09
France O 0 1.3356542183373676e-07
, O 0 8.62375504340207e-10
Holland O 0 1.2893167422589613e-07
, O 0 1.4511932766581026e-09
and O 0 1.0512138715057517e-08
Czech O 0 3.504154619804467e-06
Republic O 0 3.6861075614069705e-07
. O 0 5.499033477462945e-07

Seven O 0 4.5400207682178007e-07
novel O 0 2.414417963336746e-07
mutations O 0 8.735490268918511e-07
and O 0 5.715852235965713e-09
two O 0 1.316057041123031e-09
new O 0 1.6657612178505588e-08
polymorphisms O 0 2.591903694337816e-06
were O 0 9.711484949548321e-08
detected O 0 2.2430979242926696e-06
. O 0 6.209959337866167e-07

Among O 0 1.304024550563554e-07
these O 0 7.628941922632748e-09
mutations O 0 7.822099945542504e-08
two O 0 1.2106593505478713e-09
are O 0 1.5438210709817213e-09
missense O 0 8.139281817420851e-07
( O 0 1.6253740575677966e-09
G197W O 0 1.388091277476633e-07
, O 0 5.599513630549779e-10
W427R O 0 2.48404656844059e-08
) O 0 5.037393280282743e-10
, O 0 5.875998992932452e-11
two O 0 1.0708466752218371e-10
are O 0 9.641252241010534e-10
nonsense O 0 1.3287402111927804e-07
( O 0 4.156374688868425e-10
Q306X O 0 3.508082002667834e-08
, O 0 4.37349212401017e-10
Q385X O 0 1.597967447253268e-08
) O 0 2.1131002503338436e-10
, O 0 6.358391591021473e-11
two O 0 5.835110866714288e-11
are O 0 1.956177858586372e-10
small O 0 2.668705034736263e-09
deletions O 0 2.63879314843507e-07
( O 0 1.807700211742258e-09
662de14bp O 0 4.575139911366932e-08
; O 0 1.3705360180082948e-09
1168del3bp O 0 7.438758586886252e-08
removing O 0 2.3033917884163202e-08
a O 0 1.0559377816576898e-09
glycine O 0 5.067947839165754e-08
at O 0 3.81371290103516e-09
position O 0 8.092454706343233e-09
390 O 0 2.151169020692123e-09
) O 0 2.3266992499326733e-10
, O 0 1.0628538327228654e-10
and O 0 3.1727565019679105e-10
one O 0 8.783886396024343e-10
is O 0 9.426718294847092e-10
a O 0 1.756479961478874e-09
splicing O 0 7.827837293916673e-07
mutation O 0 5.909743663323752e-07
( O 0 4.819090904106815e-09
IVS1 O 0 1.2118576933062286e-06
- O 0 4.797120709554292e-07
15c O 0 3.6510691643343307e-06
- O 0 4.841573399971821e-07
- O 0 1.8245017940898833e-07
> O 0 3.19286570515942e-08
g O 0 8.866779666050206e-08
) O 0 8.319827604630348e-10
which O 0 5.722677887121108e-10
creates O 0 4.305368950241473e-09
a O 0 1.547042827176881e-09
new O 0 1.9826769559472268e-08
acceptor O 0 1.239287712451187e-07
splice O 0 1.0412687515781727e-05
site O 0 2.30208434004453e-06
. O 0 6.911146215315966e-07

The O 0 1.0469422306869092e-07
pathological O 0 5.445156716632482e-07
significance O 0 3.2538899574774405e-08
of O 0 3.746458421272081e-10
the O 0 9.213689811105041e-10
point O 0 3.683836879986302e-08
mutations O 0 9.926666422188646e-08
G197W O 0 1.4404341186491365e-07
, O 0 8.306175747208044e-10
W427R O 0 3.0098501468955874e-08
, O 0 2.7654173395674775e-10
and O 0 3.6807848435849166e-10
the O 0 1.7937001883794323e-10
in O 0 1.7803807317307019e-09
- O 0 1.8608912455420068e-07
frame O 0 3.5192281302443007e-06
deletion O 0 2.0266277545033518e-07
390delGly O 0 8.398902906492367e-08
were O 0 7.60962404200427e-10
assessed O 0 1.5910205375391229e-09
by O 0 8.927774491906959e-11
their O 0 3.5125577446670775e-10
respective O 0 3.725808994659019e-09
expression O 0 5.672160519054614e-09
in O 0 9.794574040711268e-10
a O 0 6.782070460786827e-10
prokaryotic O 0 5.10966158273618e-09
system O 0 4.0807144330301526e-09
using O 0 1.0456645327394654e-08
site O 0 1.8169728832617693e-07
- O 0 1.291930061597668e-06
directed O 0 5.409505092757172e-07
mutagenesis O 0 1.2153413990745321e-05
. O 0 6.313529183898936e-07

These O 0 3.987229035828932e-07
mutations O 0 1.289505121349066e-06
resulted O 0 3.571035023242075e-08
in O 0 1.7627963533328739e-09
the O 0 1.1660042931183057e-09
absence O 0 8.207656776448857e-09
or O 0 4.970832634398903e-09
a O 0 3.072393006675611e-09
dramatic O 0 7.290274766091898e-07
decrease O 0 5.465817025651631e-07
of O 0 7.0593335621538245e-09
CPO O 0 7.904294761829078e-06
activity O 0 8.056433102865412e-07
. O 0 5.208963216318807e-07

The O 0 3.345609655980297e-08
two O 0 3.847643537113754e-09
polymorphisms O 0 4.2566858837744803e-07
were O 0 2.662410736320453e-09
localized O 0 4.7517882961756186e-08
in O 0 2.3863966358561584e-09
noncoding O 0 4.5835946593797416e-07
part O 0 4.175956025420646e-09
of O 0 6.968212118430017e-11
the O 0 1.8427975811974306e-10
gene O 0 5.546665349243085e-09
1 O 0 1.0260593485966751e-09
) O 0 3.2799077342993144e-10
a O 0 1.8362164011520576e-09
C O 0 2.729514392285637e-07
/ O 0 4.9724658168770475e-08
G O 0 8.520514427345915e-08
polymorphism O 0 2.254506341614615e-07
in O 0 1.8727432937737376e-09
the O 0 2.1898971525047273e-09
promotor O 0 4.97579662805947e-07
region O 0 3.090237399305806e-08
, O 0 1.829050799706522e-09
142 O 0 4.135594977583423e-09
bp O 0 5.4931319937168155e-08
upstream O 0 4.154379507070871e-09
from O 0 1.9145478258320026e-10
the O 0 1.6199043495479515e-10
transcriptional O 0 1.5843379941316016e-08
initiation O 0 3.42094486072142e-09
site O 0 8.61356763692811e-09
( O 0 5.390723978315748e-10
- O 0 2.2536974952913624e-08
142C O 0 1.465740524508874e-07
/ O 0 2.5286858829076664e-08
G O 0 1.6973297434219603e-08
) O 0 1.927026038739399e-10
, O 0 4.394175995292571e-11
and O 0 2.2127789878201298e-10
2 O 0 2.6981175627049936e-10
) O 0 1.912989211483307e-10
a O 0 4.495261385351057e-10
6 O 0 2.4640844920043037e-09
bp O 0 4.141706710925064e-08
deletion O 0 2.753735373062227e-08
polymorphism O 0 8.235949877644089e-08
in O 0 9.488899666010298e-10
the O 0 3.0521529748028797e-10
3 O 0 7.111604083398504e-10
noncoding O 0 8.512700588880762e-08
part O 0 2.2677100197654454e-09
of O 0 9.686184493373773e-11
the O 0 4.0294031999899005e-10
CPO O 0 1.095768098480221e-07
gene O 0 1.9497877090657312e-08
, O 0 8.336967227684511e-10
574 O 0 1.1971398095056429e-08
bp O 0 2.3925414538439327e-08
downstream O 0 1.8326057338313717e-09
of O 0 1.9355858929537284e-11
the O 0 7.21561907446322e-11
last O 0 9.962943803287772e-10
base O 0 8.133348439187671e-10
of O 0 5.093601582184526e-11
the O 0 1.3721708214120554e-09
normal O 0 5.2754639767726985e-08
termination O 0 5.248015781944559e-07
codon O 0 1.1274962616880657e-06
( O 0 1.4598946052046813e-08
+ O 0 1.9276608043128363e-07
574 O 0 3.62971434242354e-07
delATTCTT O 0 6.875495728309033e-07
) O 0 4.4843556423757036e-08
. O 0 2.2416300282657176e-07

Five O 0 3.021129657554411e-07
intragenic O 0 2.9080665626679547e-06
dimorphisms O 0 1.887041889858665e-06
are O 0 5.429484417618369e-09
now O 0 6.984866018910907e-09
well O 0 9.647523890876641e-10
characterized O 0 3.0919515836558276e-09
and O 0 1.0172902520366733e-09
the O 0 4.5085019051427366e-10
high O 0 2.0306744730191895e-08
degree O 0 6.069728186730572e-08
of O 0 6.574787381197211e-10
allelic O 0 1.644654190613437e-07
heterogeneity O 0 1.5967799527061288e-07
in O 0 4.507644035811609e-09
HC B-Disease 0 1.171390181298193e-06
is O 0 2.984205105249771e-09
demonstrated O 0 1.5452440438323833e-09
with O 0 5.113010362323145e-11
seven O 0 4.946605625111289e-11
new O 0 8.343549462441757e-11
different O 0 1.1624064211179785e-10
mutations O 0 2.1413157913485747e-09
making O 0 2.2219735773543192e-10
a O 0 2.34438884971766e-10
total O 0 1.444732805611082e-10
of O 0 1.934712112738879e-10
nineteen O 0 4.0507057263994284e-08
CPO O 0 1.4137344805931207e-05
gene B-Disease 0 1.932108716573566e-06
defects I-Disease 0 0.0601448193192482
reported O 0 3.1894938246068705e-08
so O 0 2.462078541043411e-09
far O 0 5.433711258717722e-09
. O 0 1.4345607368682067e-08
. O 0 2.1514125592148048e-07

Coincidence O 0 1.1641358241831767e-06
of O 0 3.4254303837855105e-09
two O 0 3.0613080959085437e-09
novel O 0 3.707323159574116e-08
arylsulfatase O 0 1.3761037962467526e-06
A O 0 1.8323829564792504e-08
alleles O 0 6.500004587906005e-07
and O 0 5.580924167247758e-08
mutation O 0 1.5123156344998279e-06
459 O 0 3.8912190802875557e-07
+ O 0 2.437116961573338e-07
1G O 0 2.1612559066852555e-06
> O 0 1.1351279027849159e-07
A O 0 2.9917679444935175e-09
within O 0 6.611848291093736e-10
a O 0 2.301304702356788e-09
family O 0 3.739950571457484e-08
with O 0 9.4848367382383e-08
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
: O 0 1.939143423612677e-08
molecular O 0 4.94381175997205e-08
basis O 0 1.0316880683092222e-08
of O 0 7.2718298049778696e-09
phenotypic O 0 4.3423890019766986e-05
heterogeneity O 0 0.0003220359212718904
. O 0 4.238867404637858e-06

In O 0 2.3372726332127058e-07
a O 0 1.2717408459650414e-08
family O 0 7.839647153673468e-09
with O 0 3.8397532375888943e-10
three O 0 8.956859698372455e-10
siblings O 0 3.666018955073014e-08
, O 0 1.6649305545346493e-10
one O 0 4.676615206200552e-10
developed O 0 1.2390082737567809e-08
classical O 0 3.7243830774968956e-07
late O 0 3.8134421629365534e-06
infantile O 1 0.9857661724090576
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 0.9999998807907104
( O 0 1.8101100351941568e-07
MLD B-Disease 1 0.9999929666519165
) O 0 1.0772598812991419e-08
, O 0 1.0140086548204863e-09
fatal O 0 4.265914981260721e-07
at O 0 4.1999759226030164e-09
age O 0 4.174817380686591e-09
5 O 0 4.673877396221826e-10
years O 0 2.5796653702059302e-09
, O 0 4.3018780204739926e-10
with O 0 2.6089486127034434e-09
deficient O 0 0.00019503507064655423
arylsulfatase O 0 3.1645754461351316e-06
A O 0 2.7787864453898692e-08
( O 0 3.585762131663728e-09
ARSA O 0 2.8461490728659555e-06
) O 0 1.5789552998413114e-09
activity O 0 2.71271183294175e-09
and O 0 3.352161659364583e-09
increased O 0 2.696427792159284e-08
galactosylsulfatide O 0 4.763962351717055e-06
( O 0 5.645471645721045e-08
GS O 1 0.9999996423721313
) O 0 8.750901514531506e-08
excretion O 0 7.012467335698602e-07
. O 0 2.1805773542382667e-07

The O 0 1.936116689194023e-08
two O 0 1.9227239800301277e-09
other O 0 4.461359337515347e-10
siblings O 0 1.9707140808122858e-08
, O 0 1.2146376127120107e-09
apparently O 0 5.221944832101144e-08
healthy O 0 3.275933080360005e-09
at O 0 4.941902442823221e-10
12 O 0 1.939892552149658e-10
( O 0 8.521720828991164e-11
1 O 0 3.743608201212112e-10
/ O 0 2.971584533995042e-09
2 O 0 2.45297449019688e-10
) O 0 1.362845392094414e-10
and O 0 2.294295586846573e-10
15 O 0 1.2293510653904605e-10
years O 0 2.652292552252078e-10
, O 0 2.3410764646292215e-11
respectively O 0 5.810402714523377e-10
, O 0 1.2671343141423819e-10
and O 0 2.4988419666804873e-10
their O 0 2.3700971740758803e-10
father O 0 3.020614647297748e-09
, O 0 3.9211506264180684e-10
apparently O 0 1.1901866159291785e-08
healthy O 0 4.5922357583272344e-10
as O 0 1.0472383377146954e-10
well O 0 4.251922147702203e-10
, O 0 2.788611563886434e-10
presented O 0 7.773832244595269e-09
ARSA O 0 1.0023190043284558e-05
and O 0 3.54092755117108e-08
GS O 1 0.9999942779541016
values O 0 5.709510197959844e-09
within O 0 2.884555094784247e-10
the O 0 7.21284254545651e-10
range O 0 3.157131089892573e-08
of O 0 4.4621721428939054e-08
MLD B-Disease 1 0.9999985694885254
patients O 0 8.933269782573916e-06
. O 0 4.6080117499514017e-07

Mutation O 0 3.417473271838389e-05
screening O 0 2.500311438780045e-06
and O 0 1.015298067841286e-08
sequence O 0 1.3561231249070715e-08
analysis O 0 2.993909831161545e-08
disclosed O 0 1.0396531280321142e-07
the O 0 3.422228611604794e-10
involvement O 0 4.274855580632675e-09
of O 0 6.77451775232818e-11
three O 0 3.9600234202907814e-10
different O 0 2.6456450363809836e-09
ARSA O 0 3.211163493688218e-05
mutations O 0 1.250297003707601e-07
being O 0 2.9136917323313583e-09
the O 0 1.825021384016523e-10
molecular O 0 1.7598207335822735e-08
basis O 0 5.825297577644051e-09
of O 0 6.832659771305316e-09
intrafamilial O 0 1.665505624259822e-05
phenotypic O 0 6.194347952259704e-05
heterogeneity O 0 0.00033479335252195597
. O 0 7.904882295406424e-06

The O 0 4.0995729477799614e-07
late O 0 1.1479394288471667e-06
infantile O 0 5.869869710295461e-05
patient O 0 1.0342155292164534e-05
inherited O 0 8.157332558766939e-06
from O 0 2.6942879038927003e-09
his O 0 2.3208011068476253e-09
mother O 0 5.4160206985898185e-08
the O 0 5.426438187683402e-10
frequent O 0 7.915980404504808e-08
0 O 0 1.6894593102279032e-07
- O 0 2.8735054002027027e-05
type O 0 0.00011817901395261288
mutation O 0 2.9006603199377423e-06
459 O 0 1.239712048572983e-07
+ O 0 5.3638778751974314e-08
1G O 0 2.669694652013277e-07
> O 0 1.7040964195302877e-08
A O 0 1.7511511130052781e-09
, O 0 1.8266442525227689e-10
and O 0 1.8156295911175846e-10
from O 0 1.660744042286666e-10
his O 0 7.444670435674539e-10
father O 0 7.639353150068473e-09
a O 0 5.666545566107573e-10
novel O 0 9.278327439687928e-09
, O 0 8.185873645594199e-10
single O 0 9.372991272016407e-09
basepair O 0 2.1604510891393147e-07
microdeletion O 0 6.737350588537083e-08
of O 0 1.5437288947151018e-10
guanine O 0 4.5172946272487025e-08
at O 0 1.1940127775389442e-09
nucleotide O 0 3.775327428456876e-08
7 O 0 3.087037070415022e-09
in O 0 4.588147084483296e-10
exon O 0 7.342088537143354e-08
1 O 0 1.4101449785641762e-08
( O 0 2.6583362178200787e-09
7delG O 0 5.95309018081025e-07
) O 0 3.736613862770355e-08
. O 0 2.1056516175121942e-07

The O 0 8.01239323777736e-08
two O 0 3.5211538573776124e-08
clinically O 0 2.1617258880723966e-06
unaffected O 0 9.71291910900618e-07
siblings O 0 3.9460906009480823e-07
carried O 0 4.146623311385156e-08
the O 0 1.201431043540424e-08
maternal O 0 1.8328183841731516e-06
mutation O 0 2.7253627195023e-06
459 O 0 3.5907467577089847e-07
+ O 0 1.923145589444175e-07
1G O 0 9.486227554589277e-07
> O 0 7.474485386183005e-08
A O 0 9.632342035104102e-09
and O 0 3.064778208994312e-09
, O 0 2.3777130264690527e-10
on O 0 5.756856658045706e-10
their O 0 9.926487409828155e-10
paternal O 0 9.6718345332647e-08
allele O 0 2.685557376480574e-07
, O 0 8.220875091780044e-10
a O 0 4.021609989468544e-10
novel O 0 1.3972670132034182e-08
cytosine O 0 7.132434376444508e-08
to O 0 1.5955394783162546e-09
thymidine O 0 2.8053827350049687e-07
transition O 0 2.8065430868196017e-08
at O 0 6.564490728777628e-09
nucleotide O 0 2.3850105890232953e-07
2435 O 0 9.124616440203681e-07
in O 0 1.95017357818017e-09
exon O 0 8.899412051732725e-08
8 O 0 6.689879317178793e-09
, O 0 3.920813951285851e-10
resulting O 0 1.3279105592900464e-09
in O 0 2.651058539360207e-10
substitution O 0 4.567760836238222e-09
of O 0 6.742345570742714e-10
alanine O 0 9.600062185199931e-07
464 O 0 7.347748720576419e-08
by O 0 1.2011376782083971e-08
valine O 0 1.683218579273671e-05
( O 0 2.8851742328583896e-08
A464V O 0 2.7619021238933783e-06
) O 0 1.3436647350317799e-07
. O 0 4.94238292958471e-07

The O 0 6.15553688021464e-07
fathers O 0 2.9136656394257443e-06
genotype O 0 1.6871719708433375e-05
thus O 0 3.514803665893851e-07
was O 0 1.8875373086757463e-07
7delG O 0 9.208985829900485e-06
/ O 0 5.840547601110302e-06
A464V O 0 2.7760941520682536e-05
. O 0 9.806674370338442e-07

Mutation O 0 2.70783893938642e-05
A464V O 0 5.844526185683208e-06
was O 0 8.977579568636429e-08
not O 0 2.477936300593342e-09
found O 0 1.377005398595088e-09
in O 0 1.0133319738869773e-09
18 O 0 8.02217670070604e-09
unrelated O 0 8.843874184094602e-07
MLD B-Disease 1 0.9999996423721313
patients O 0 8.739156101000845e-07
and O 0 4.041659007469889e-09
50 O 0 1.4284146310217238e-08
controls O 0 3.4868603506765794e-06
. O 0 1.562098077556584e-06

A464V O 0 2.3072179828886874e-05
, O 0 9.531117939332034e-08
although O 0 2.5513882562222534e-08
clearly O 0 5.665275892852151e-08
modifying O 0 3.1573932801620685e-07
ARSA O 0 3.133185600745492e-05
and O 0 1.6847610595505103e-07
GS O 1 1.0
levels O 0 1.8242339194785018e-07
, O 0 7.075816599311224e-10
apparently O 0 4.216647475629998e-09
bears O 0 3.6223393173884233e-09
little O 0 7.413921143673008e-10
significance O 0 1.7714720801365047e-09
for O 0 4.940074460613175e-10
clinical O 0 4.290901856052187e-08
manifestation O 0 3.931369363385784e-08
of O 0 6.38111696815713e-09
MLD B-Disease 1 0.9999971389770508
, O 0 8.638131099303337e-09
mimicking O 0 5.232832336332649e-07
the O 0 4.838637579496208e-08
frequent O 0 7.2825041570467874e-06
ARSA O 0 0.019354814663529396
pseudodeficiency O 0 0.0001812857954064384
allele O 0 0.00013931089779362082
. O 0 3.206963583579636e-06

Our O 0 7.826635624041955e-07
results O 0 6.478394709574786e-08
demonstrate O 0 1.2953256245396005e-08
that O 0 3.1247354703722863e-10
in O 0 3.001288106929678e-10
certain O 0 3.3470632931908995e-09
genetic O 0 1.1917118172277696e-06
conditions O 0 1.6745362927395036e-06
MLD B-Disease 1 0.9999942779541016
- O 0 2.6009365683421493e-06
like O 0 3.3476204919224983e-08
ARSA O 0 5.408117067418061e-05
and O 0 2.591477787916574e-08
GS O 1 0.9999994039535522
values O 0 1.1384883258358514e-08
need O 0 7.053260198119915e-10
not O 0 1.296179413801113e-10
be O 0 4.040066892141425e-11
paralleled O 0 1.502502899874969e-09
by O 0 9.48558787072784e-10
clinical O 0 2.7807063815998845e-06
disease O 0 1.4815918802923989e-07
, O 0 2.1002020955673828e-10
a O 0 5.877784370333927e-10
finding O 0 1.0507166692264036e-08
with O 0 3.4083551536667755e-09
serious O 0 2.733135033849976e-07
diagnostic O 0 3.3067758522520307e-06
and O 0 9.551645518968144e-08
prognostic O 0 0.00011890015593962744
implications O 0 1.4068255950405728e-05
. O 0 1.2152625004091533e-06

Moreover O 0 1.0177788681176025e-05
, O 0 1.3751011351814668e-07
further O 0 2.1943142769487167e-07
ARSA O 0 0.00020324086653999984
alleles O 0 1.1196153764103656e-06
functionally O 0 1.9448334853677807e-07
similar O 0 4.84404605316513e-09
to O 0 1.48770562535816e-09
A464V O 0 9.466601369467753e-08
might O 0 1.3599281700749088e-08
exist O 0 4.3364063451178936e-09
which O 0 2.444077717989046e-10
, O 0 3.878948898194956e-11
together O 0 7.62246238350528e-11
with O 0 1.67428029773653e-10
0 O 0 2.5232031575228575e-08
- O 0 9.11735332920216e-06
type O 0 6.470100925071165e-05
mutations O 0 2.42520968640747e-06
, O 0 4.249573137826701e-09
may O 0 4.6982560064634526e-08
cause O 0 9.919772558930617e-09
pathological O 0 4.2718832560240116e-07
ARSA O 0 0.0018228115513920784
and O 0 1.2842696150983102e-06
GS O 1 1.0
levels O 0 8.080272806409994e-08
, O 0 2.2890198070335543e-10
but O 0 8.086787905980941e-10
not O 0 1.1077008199578131e-09
clinical O 0 4.567884914763454e-08
outbreak O 0 1.5807399833533964e-08
of O 0 2.0991569593675763e-10
the O 0 1.5030828137696517e-08
disease O 0 9.119666515289282e-07
. O 0 2.952445221637845e-08
. O 0 3.647626840574958e-07

Human O 0 0.00035880348877981305
MLH1 O 1 0.9424934387207031
deficiency O 1 0.9076382517814636
predisposes O 0 0.00016453229181934148
to O 0 9.75336092778889e-07
hematological B-Disease 1 0.8178449869155884
malignancy I-Disease 1 0.9994434714317322
and O 0 1.7002934100673883e-06
neurofibromatosis B-Disease 0 0.07270403206348419
type I-Disease 0 0.0019230720354244113
1 I-Disease 0 2.1407588519650744e-06
. O 0 1.5306386558222584e-06

Heterozygous O 0 0.0001255396637134254
germ O 0 0.0012957197614014149
- O 0 0.004942839499562979
line O 0 1.4633328646596055e-06
mutations O 0 6.511656920338282e-07
in O 0 2.1195436517018607e-09
the O 0 1.543205785381474e-09
DNA O 0 1.8236212326883106e-06
mismatch O 0 0.00022875344438944012
repair O 0 2.6072868877236033e-06
genes O 0 1.0919771398221201e-07
lead O 0 1.1184633308403136e-07
to O 0 8.593305977910859e-08
hereditary B-Disease 1 0.9997678399085999
nonpolyposis I-Disease 1 0.9999998807907104
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.5675581380492076e-05

The O 0 2.865197075152537e-07
disease O 0 1.8366257563684485e-06
susceptibility O 0 2.3597795006935485e-07
of O 0 4.621636962021114e-10
individuals O 0 4.089316441024948e-09
who O 0 3.8113004308115705e-08
constitutionally O 0 1.6683439696407731e-07
lack O 0 5.455831342260353e-09
both O 0 1.0718772536222332e-09
wild O 0 2.1322525967093497e-08
- O 0 3.293857298558578e-05
type O 0 1.3663765457749832e-05
alleles O 0 1.1254647915848182e-06
is O 0 5.6374553025762e-08
unknown O 0 1.2239053148732637e-06
. O 0 5.706600632038317e-07

We O 0 2.8799684059777064e-07
have O 0 3.6172507211773564e-09
identified O 0 3.951770910504138e-09
three O 0 2.857160341651621e-10
offspring O 0 5.341934450342478e-09
in O 0 8.380699467736008e-10
a O 0 4.091175043186013e-08
hereditary B-Disease 1 0.999997615814209
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 4.642828912437835e-07
who O 0 4.301078959656479e-08
developed O 0 1.667294071694414e-07
hematological B-Disease 0 0.00555208045989275
malignancy I-Disease 0 0.41974878311157227
at O 0 5.3960551582576954e-09
a O 0 3.5297845202286737e-10
very O 0 8.355146574601235e-10
early O 0 4.718468726849778e-09
age O 0 3.775699752850414e-09
, O 0 6.029656635098135e-11
and O 0 1.0669505556837322e-10
at O 0 1.4669242209830458e-10
least O 0 2.3595323611624863e-11
two O 0 2.73050922150464e-11
of O 0 7.773628095397722e-12
them O 0 1.248336573000941e-10
displayed O 0 6.461103208010854e-09
signs O 0 2.5038350059958248e-08
of O 0 1.1279722711421414e-09
neurofibromatosis B-Disease 0 0.0008853786857798696
type I-Disease 0 4.2722938815131783e-05
1 I-Disease 0 7.738700702475398e-08
( O 0 1.531918769615004e-08
NF1 B-Disease 0 2.9453547540470026e-05
) O 0 8.105201487751401e-08
. O 0 3.0746139145776397e-07

DNA O 0 3.959921286877943e-06
sequence O 0 2.182168685749275e-07
analysis O 0 5.368217514956086e-08
and O 0 6.9419265891212945e-09
allele O 0 2.9795097589158104e-07
- O 0 2.0383235721510573e-07
specific O 0 1.20284111559954e-08
amplification O 0 1.663499631376908e-07
in O 0 1.2037195684655444e-09
two O 0 2.1205546207880843e-09
siblings O 0 1.4521857849558728e-07
revealed O 0 1.6704007066437043e-07
a O 0 2.636850204851271e-08
homozygous O 0 1.9562079614843242e-05
MLH1 O 0 0.00010779207514133304
mutation O 0 2.665492047526641e-06
( O 0 5.426999294400048e-09
C676T O 0 8.669956628182263e-07
- O 0 8.377330232178792e-06
- O 0 6.956866855034605e-06
> O 0 6.284826099545171e-07
Arg226Stop O 0 9.456146472075488e-06
) O 0 6.519796613702056e-08
. O 0 2.896677528951841e-07

Thus O 0 4.0831776004779385e-07
, O 0 5.421205706568344e-09
a O 0 6.9780607958591645e-09
homozygous O 0 1.438474100723397e-06
germ O 0 0.00013821519678458571
- O 0 0.0006166438106447458
line O 0 5.159580268809805e-06
MLH1 O 0 0.00010425566142657772
mutation O 0 2.3587720079376595e-06
and O 0 1.6133721914002308e-08
consequent O 0 1.189400427392684e-05
mismatch O 1 0.9949182868003845
repair O 1 0.9971616268157959
deficiency O 1 0.7345209717750549
results O 0 3.411517823792565e-08
in O 0 1.4866787800826842e-09
a O 0 1.1456353199434943e-08
mutator O 0 0.00013047497486695647
phenotype O 0 1.2275184417376295e-05
characterized O 0 6.481966607907452e-08
by O 0 1.0800248695375103e-08
leukemia B-Disease 0 0.033090632408857346
and O 0 1.8312165650513634e-07
/ O 1 0.7287256717681885
or O 1 0.9965762495994568
lymphoma B-Disease 1 1.0
associated O 0 2.0573663277900778e-05
with O 0 8.975594312232715e-08
neurofibromatosis B-Disease 0 0.3879058063030243
type I-Disease 0 0.002735832007601857
1 I-Disease 0 2.733521000664041e-07
. O 0 5.6558938865691744e-08
. O 0 2.904754978771962e-07

Missense O 0 0.000298651255434379
mutations O 0 1.5058199096529279e-05
in O 0 1.5538541120463378e-08
the O 0 8.886207325531359e-10
most O 0 4.866241298806528e-10
ancient O 0 2.5147173232653586e-09
residues O 0 2.2412317335351872e-08
of O 0 2.5657476143692293e-10
the O 0 1.698008844641663e-09
PAX6 O 0 2.6897148472926347e-06
paired O 0 8.673399776171209e-08
domain O 0 5.765191701812e-08
underlie O 0 1.489416234790042e-07
a O 0 4.033188005791999e-09
spectrum O 0 6.147264741684921e-08
of O 0 6.6021983435859966e-09
human O 0 1.4650155435447232e-06
congenital B-Disease 1 0.9999979734420776
eye I-Disease 1 0.9999676942825317
malformations I-Disease 1 0.9996128678321838
. O 0 1.1817168342531659e-05

Mutations O 0 1.3451738595904317e-05
of O 0 7.708173654918937e-09
the O 0 9.644052667567848e-09
human O 0 4.925646379660975e-08
PAX6 O 0 2.8363128876662813e-05
gene O 0 6.177587692945963e-06
underlie O 0 0.00028509905678220093
aniridia B-Disease 1 1.0
( O 0 5.505723379428673e-07
congenital B-Disease 1 0.9999536275863647
absence I-Disease 0 1.211175373327933e-07
of I-Disease 0 4.0075437413022996e-10
the I-Disease 0 7.884314312534002e-10
iris I-Disease 0 1.0724399999162415e-06
) O 0 4.413297727268173e-09
, O 0 4.997657843119896e-10
a O 0 2.5358375399520128e-09
rare O 0 2.2849224023957504e-07
dominant O 1 0.8569517135620117
malformation B-Disease 1 0.9839054942131042
of I-Disease 0 6.018620712922029e-09
the I-Disease 0 5.240303480036346e-08
eye I-Disease 1 0.9113348126411438
. O 0 4.187031208857661e-06

The O 0 2.0305435555201257e-07
spectrum O 0 6.927563731551345e-07
of O 0 9.434601544455745e-09
PAX6 O 0 1.0746119187388103e-05
mutations O 0 2.402003019597032e-06
in O 0 2.2847736147468822e-08
aniridia B-Disease 1 1.0
patients O 0 3.2902923976507736e-06
is O 0 9.182233862148337e-10
highly O 0 2.213050409594075e-09
biased O 0 3.0524589078595454e-08
, O 0 1.6446549677695543e-10
with O 0 5.650051954075863e-11
92 O 0 1.582470821048787e-09
% O 0 1.5595176539040523e-10
of O 0 1.666667671929023e-11
all O 0 7.585858607939144e-10
reported O 0 7.384742417571033e-08
mutations O 0 9.628065811284614e-08
leading O 0 1.2559564055436567e-08
to O 0 3.881106547254376e-09
premature O 0 4.358889071909289e-08
truncation O 0 9.149026425347984e-08
of O 0 2.5964871919192944e-10
the O 0 4.87687057404429e-10
protein O 0 1.3711276558581176e-08
( O 0 7.353209152682894e-10
nonsense O 0 4.349653792701247e-08
, O 0 3.8475389541048344e-10
splicing O 0 2.7855364237439062e-08
, O 0 4.31571806069897e-10
insertions O 0 2.6114891582551536e-08
and O 0 7.108565958091617e-10
deletions O 0 1.2317015851692759e-08
) O 0 4.357621485873153e-10
and O 0 2.495117723544382e-10
just O 0 5.047414708414522e-10
2 O 0 3.10730940977777e-10
% O 0 7.438648308433216e-11
leading O 0 9.95830293226696e-11
to O 0 2.6170598674268852e-11
substitution O 0 2.575853697006636e-10
of O 0 3.5933513109487336e-11
one O 0 7.576213545412713e-10
amino O 0 5.885067100308561e-09
acid O 0 5.516437973085431e-09
by O 0 3.0006871987176e-10
another O 0 7.792642087167678e-09
( O 0 1.2283233097321045e-08
missense O 0 7.0719761424697936e-06
) O 0 1.0781585757513312e-07
. O 0 3.565380097825255e-07

The O 0 8.657515593313292e-08
extraordinary O 0 9.112001464472996e-08
conservation O 0 1.6995326035385006e-08
of O 0 4.80223250054479e-10
the O 0 1.091018497767493e-09
PAX6 O 0 2.9307750537554966e-07
protein O 0 1.1707806280014665e-08
at O 0 1.6920504997131047e-09
the O 0 4.211147541788307e-10
amino O 0 2.3284240313614646e-08
acid O 0 1.0228166757997315e-07
level O 0 1.3869858150883374e-08
amongst O 0 4.550239296463587e-09
vertebrates O 0 1.4702786543807633e-08
predicts O 0 7.478535479776838e-08
that O 0 1.1777387953770813e-09
pathological O 0 6.917306194509365e-08
missense O 0 9.821799267228926e-07
mutations O 0 4.487735623115441e-07
should O 0 2.1205626143938616e-09
in O 0 8.68426233702202e-11
fact O 0 7.580824856745494e-10
be O 0 2.6920773943395204e-10
common O 0 3.644347323916719e-10
even O 0 3.923873725941718e-10
though O 0 2.316138947300317e-10
they O 0 1.1168842933839684e-10
are O 0 6.726183499061733e-11
hardly O 0 5.7648916751418255e-09
ever O 0 2.2619571993232057e-08
seen O 0 6.835256272097467e-08
in O 0 2.7481627640213446e-08
aniridia B-Disease 1 0.9999998807907104
patients O 0 4.818928118766053e-06
. O 0 4.4162052859064715e-07

This O 0 5.147845172359666e-08
indicates O 0 3.726685093852211e-08
that O 0 3.6701153227625127e-10
there O 0 2.734716619823274e-10
is O 0 2.805972953989766e-10
a O 0 1.2617855649210696e-09
heavy O 0 1.1993038242508192e-06
ascertainment O 0 1.9551898731151596e-05
bias O 0 1.79773796844529e-05
in O 0 1.4083271215881155e-09
the O 0 2.888199679418335e-10
selection O 0 1.7612067360062156e-09
of O 0 2.1656879067855073e-10
patients O 0 1.2262258763939826e-08
for O 0 4.5515302637966215e-10
PAX6 O 0 8.795443591225194e-07
mutation O 0 5.846471395898334e-08
analysis O 0 4.258287056302379e-09
and O 0 4.5087253375264424e-10
that O 0 5.444590889247536e-10
the O 0 2.9893039155126644e-09
missing O 0 3.696887347359734e-07
PAX6 O 0 3.926533827325329e-05
missense O 0 1.9869619791279547e-05
mutations O 0 4.864046786678955e-06
frequently O 0 1.0177446938541834e-06
may O 0 2.9308057492016815e-07
underlie O 0 3.436194674577564e-06
phenotypes O 0 2.1709236079914263e-06
distinct O 0 3.7025253618594434e-07
from O 0 5.1788372701366825e-08
textbook O 0 0.00027612000121735036
aniridia B-Disease 1 0.9999995231628418
. O 0 4.802064268005779e-06

Here O 0 4.164358244906907e-07
we O 0 2.977463786635326e-08
present O 0 4.934426200975395e-09
four O 0 3.343656018728325e-09
novel O 0 1.1195348292858398e-07
PAX6 O 0 6.834722171333851e-06
missense O 0 3.439581405473291e-06
mutations O 0 9.043218938131758e-07
, O 0 1.0224529001234828e-09
two O 0 4.007986997844881e-10
in O 0 1.7330717971830722e-09
association O 0 6.572308475227828e-09
with O 0 4.437590295225391e-09
atypical O 0 1.935033196787117e-06
phenotypes O 0 8.568559678678866e-06
ectopia B-Disease 0 6.013396159687545e-06
pupillae I-Disease 0 3.981661848229123e-06
( O 0 1.0350466261854763e-08
displaced B-Disease 0 7.277619573642369e-08
pupils I-Disease 0 3.315973629014479e-07
) O 0 3.3542100652539375e-08
and O 0 5.581604227700154e-07
congenital B-Disease 1 0.9995155334472656
nystagmus I-Disease 0 3.067165380343795e-06
( O 0 2.1680699457959918e-09
searching B-Disease 0 1.6247703626959265e-08
gaze I-Disease 0 2.2835044433122675e-07
) O 0 1.3220273764602553e-09
, O 0 1.4913982548936389e-10
and O 0 2.8772467741688956e-10
two O 0 6.063902158182088e-10
in O 0 9.540239709338039e-10
association O 0 3.7082314996439436e-10
with O 0 2.2098475827014852e-10
more O 0 4.468864833739872e-09
recognizable O 0 0.02970726229250431
aniridia B-Disease 1 0.9999998807907104
phenotypes O 0 0.00017813076556194574
. O 0 1.9429551230132347e-06

Strikingly O 0 3.1959693842509296e-06
, O 0 3.2581255027253064e-08
all O 0 1.3792764708142613e-09
four O 0 2.149430189390955e-09
mutations O 0 4.344902748698587e-08
are O 0 6.516955863844487e-10
located O 0 2.4406874299387482e-09
within O 0 2.2228139329172336e-09
the O 0 4.701157685360613e-09
PAX6 O 0 3.36315815729904e-06
paired O 0 1.459524980873539e-07
domain O 0 8.522919614506463e-08
and O 0 8.605324453014873e-09
affect O 0 7.3402510736286786e-09
amino O 0 3.748933607994331e-09
acids O 0 4.390695362843644e-09
which O 0 2.5127691594128976e-10
are O 0 1.1265204047372634e-10
highly O 0 6.248365158612046e-10
conserved O 0 1.741720878634112e-09
in O 0 5.279998660512319e-10
all O 0 5.174596307000456e-10
known O 0 1.2843973884457682e-08
paired O 0 1.6661877566548355e-07
domain O 0 3.0431118602791685e-07
proteins O 0 1.7487546699612722e-07
. O 0 2.173773197000628e-07

Our O 0 7.65554659665213e-07
results O 0 1.1700912239120953e-07
support O 0 3.1265730005003434e-09
the O 0 4.320907243116068e-10
hypothesis O 0 1.009863215273299e-08
that O 0 1.449961262167676e-10
the O 0 7.691453723923658e-11
under O 0 6.289305742868123e-10
- O 0 1.2517139325041171e-08
representation O 0 1.2920586378584176e-08
of O 0 1.0110924320017034e-09
missense O 0 5.27595466337516e-06
mutations O 0 2.0199738628434716e-06
is O 0 7.458318407316256e-09
caused O 0 1.0232221292483246e-08
by O 0 6.619305659150143e-10
ascertainment O 0 7.565635087303235e-07
bias O 0 1.401196186634479e-06
and O 0 7.75357111848507e-10
suggest O 0 2.119850961435077e-09
that O 0 9.413651108625132e-11
a O 0 2.6029678412697876e-10
substantial O 0 8.488830083308585e-09
burden O 0 2.993722034716484e-07
of O 0 4.872166003977441e-10
PAX6 B-Disease 0 0.00015099614392966032
- I-Disease 0 0.10934459418058395
related I-Disease 0 1.1086714948760346e-05
disease I-Disease 0 3.1371084787679138e-06
remains O 0 7.149647984761032e-09
to O 0 5.737760822022153e-10
be O 0 7.898131593186974e-10
uncovered O 0 2.040961248894746e-07
. O 0 1.828075113508021e-08
. O 0 1.2209984845412691e-07

The O 0 1.1629601459617334e-07
chromosomal O 0 1.1241089850955177e-05
order O 0 1.9478994417454487e-08
of O 0 5.70408720257376e-10
genes O 0 4.2419305401608653e-08
controlling O 0 2.740814295520977e-07
the O 0 3.608630061435747e-09
major O 0 3.1726266058740293e-08
histocompatibility O 0 9.49449997733609e-07
complex O 0 5.294919702691914e-08
, O 0 1.7424419684886061e-09
properdin O 0 2.4241245455414173e-07
factor O 0 1.0023602925457453e-07
B O 0 8.512358249390672e-07
, O 0 1.1058347570980231e-09
and O 0 1.6701834582022457e-08
deficiency B-Disease 0 2.4244386054306233e-07
of I-Disease 0 1.481497043098745e-11
the I-Disease 0 1.7751647374275592e-10
second I-Disease 0 5.393400392961212e-09
component I-Disease 0 3.7311085776536856e-08
of I-Disease 0 1.3108238938741579e-09
complement I-Disease 0 2.396229774603853e-07
. O 0 1.6059858864991838e-07

The O 0 1.3609589188945392e-07
relationship O 0 1.609411128811189e-07
of O 0 9.857432647919495e-10
the O 0 6.724544809877386e-10
genes O 0 1.892186674012919e-08
coding O 0 2.0373168752030324e-07
for O 0 7.724462736113935e-10
HLA O 0 3.13122967554591e-08
to O 0 3.727626540772633e-10
those O 0 2.541564736446844e-10
coding O 0 2.750638117277049e-08
for O 0 4.620367699548211e-10
properdin O 0 1.437735903664361e-07
Factor O 0 1.855673481543363e-08
B O 0 2.440158120009528e-08
allotypes O 0 4.225537608704144e-08
and O 0 1.5720137414021451e-09
for O 0 1.1611305250625037e-09
deficiency B-Disease 0 3.088811340035136e-08
of I-Disease 0 1.1813643813196606e-11
the I-Disease 0 8.255739147866592e-11
second I-Disease 0 1.3104138885111638e-09
component I-Disease 0 7.490108977492582e-09
of I-Disease 0 1.0235411823655838e-10
complement I-Disease 0 8.90326212754644e-09
( O 0 5.47127232408684e-10
C2 O 0 6.390729367922177e-08
) O 0 2.639111706947972e-10
was O 0 5.170028294365636e-10
studied O 0 3.1893339080824035e-09
in O 0 2.0749503504280398e-10
families O 0 5.631216604129463e-10
of O 0 1.169360025476962e-10
patients O 0 2.9708038695730465e-08
with O 0 1.3010106769684171e-08
connective O 0 0.1309393048286438
tissue O 1 0.9992000460624695
disorders O 1 0.9929256439208984
. O 0 1.8396409586785012e-06

Patients O 0 1.0659025974746328e-05
were O 0 2.302222190664338e-09
selected O 0 1.4585941343625564e-09
because O 0 1.6685905990243555e-09
they O 0 4.6003184595022617e-10
were O 0 2.8960603359884374e-10
heterozygous O 0 4.3114440018143796e-08
or O 0 1.3244357610631141e-08
homozygous O 0 3.287649815320037e-05
for O 0 1.2418186088325456e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 2.198777337980573e-06

12 O 0 3.7836323940609873e-07
families O 0 1.173053831848847e-08
with O 0 1.194557119887918e-09
15 O 0 4.778953233142147e-09
matings O 0 9.902562396746362e-07
informative O 0 2.716244807743351e-06
for O 0 0.0002801495138555765
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
were O 0 6.009847908217125e-08
found O 0 1.6624102272544405e-07
. O 0 3.757540696369688e-07

Of O 0 3.475587462276053e-08
57 O 0 6.115711670418023e-08
informative O 0 6.630342852531612e-08
meioses O 0 2.7379638822822017e-07
, O 0 4.5142842242107406e-10
two O 0 1.3007611654458628e-10
crossovers O 0 1.5003015718662027e-08
were O 0 1.5076040416062142e-09
noted O 0 5.212488218830913e-09
between O 0 1.115431302878278e-08
the O 0 0.0006601542118005455
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
gene O 0 5.345473752527141e-08
and O 0 1.2632882517848998e-09
the O 0 8.249966265694297e-10
HLA O 0 5.887764586987032e-07
- O 0 1.144913198913855e-06
B O 0 7.605903107332779e-08
gene O 0 3.5686433808024276e-09
, O 0 1.0208466710848185e-10
with O 0 2.779741888059295e-11
a O 0 1.273948863067531e-10
recombinant O 0 3.5649083685029836e-09
fraction O 0 7.760928788513866e-09
of O 0 1.1146226164271411e-09
0 O 0 6.922360284988827e-08
. O 0 1.6246812606368621e-07

035 O 0 0.07425494492053986
. O 0 0.0001879652845673263

A O 0 6.635048066527816e-07
lod O 0 4.4906872062711045e-05
score O 0 5.726166918407216e-08
of O 0 2.9840158122240723e-10
13 O 0 9.255097799254486e-10
was O 0 4.3321712883681585e-10
calculated O 0 6.175902900196206e-09
for O 0 9.168338310772128e-10
linkage O 0 1.702426015981473e-05
between O 0 0.012694324366748333
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 1.299363994178293e-08
HLA O 0 5.198472194933856e-07
- O 0 1.6179443491637358e-06
B O 0 1.940786944487627e-07
at O 0 3.0092270342230165e-10
a O 0 6.850700562388568e-11
maximum O 0 3.7723293933034086e-10
likelihood O 0 1.6705744565470582e-09
value O 0 3.121131686434353e-10
of O 0 1.5712927486921657e-11
the O 0 3.288368882747861e-11
recombinant O 0 1.4488839017445798e-09
fraction O 0 5.804722924551697e-09
of O 0 1.2924005199366206e-09
0 O 0 9.245614052133533e-08
. O 0 1.8296105963599985e-07

04 O 0 0.0025268036406487226
. O 0 3.8229074561968446e-05

18 O 0 6.386635504895821e-07
families O 0 3.015872351852522e-08
with O 0 1.097256174809047e-09
21 O 0 2.0178205772936053e-09
informative O 0 6.464925039750824e-09
matings O 0 1.07615747424461e-07
for O 0 8.581912958049998e-10
both O 0 2.7130482305182113e-09
properdin O 0 7.225557965284679e-07
Factor O 0 1.3961086153813085e-07
B O 0 1.2381347858081426e-07
allotype O 0 1.3739398241341405e-07
and O 0 5.4545306049647024e-09
HLA O 0 1.0760769555417937e-06
- O 0 3.3947293559322134e-05
B O 0 4.1370353756065015e-06
were O 0 5.441406880635213e-09
found O 0 2.8913055061252635e-08
. O 0 1.6043541961607843e-07

Of O 0 5.299870409203322e-08
72 O 0 6.041660327582576e-08
informative O 0 5.200326924637011e-08
meioses O 0 4.47325874119997e-07
, O 0 6.53260001648448e-10
three O 0 2.1640735037298242e-10
recombinants O 0 9.221574259754561e-08
were O 0 1.4742317366867042e-09
found O 0 6.706305510917332e-10
, O 0 5.7441527229196154e-11
giving O 0 1.5701431821391054e-10
a O 0 2.1907610447957637e-10
recombinant O 0 4.355363181218763e-09
fraction O 0 1.8121061984288644e-08
of O 0 2.099538320976535e-09
0 O 0 1.4628777478264965e-07
. O 0 2.629428195177752e-07

042 O 0 0.003542102873325348
. O 0 4.927797635900788e-05

A O 0 1.0579419722489547e-06
lod O 0 8.279150642920285e-05
score O 0 8.699046105675734e-08
of O 0 7.613747410317728e-10
16 O 0 1.433788532345659e-09
between O 0 1.2914616043246951e-09
HLA O 0 3.631376159773936e-07
- O 0 2.1122134512552293e-06
B O 0 2.697645129501325e-07
and O 0 1.5363861294304115e-09
Factor O 0 5.556163085174148e-09
B O 0 9.859468796946658e-09
allotypes O 0 1.4322313113268592e-08
was O 0 3.335526577163961e-10
calculated O 0 1.4323836561302983e-09
at O 0 3.1130933941803107e-10
a O 0 1.0306347442146091e-10
maximum O 0 6.016517284379574e-10
likelihood O 0 2.1283588225173844e-09
value O 0 4.6083720173228926e-10
of O 0 1.5173619305475228e-11
the O 0 4.278383550215814e-11
recombinant O 0 1.3358415484887587e-09
fraction O 0 6.987317835438489e-09
of O 0 7.097713528025906e-10
0 O 0 5.636466227088022e-08
. O 0 1.1526165621944529e-07

04 O 0 0.004965328145772219
. O 0 5.4075451771495864e-05

A O 0 1.0872884104173863e-07
crossover O 0 2.429129892789206e-07
was O 0 1.3238143914406919e-08
shown O 0 2.6388866647408804e-09
to O 0 4.740422498983321e-10
have O 0 6.189448953364263e-10
occurred O 0 1.058779397489218e-09
between O 0 6.100383392881881e-11
genes O 0 2.2098867180631032e-09
for O 0 3.73981873247331e-10
Factor O 0 7.173798888260308e-09
B O 0 1.601394039596471e-08
and O 0 1.3711557445006406e-09
HLA O 0 1.413949775042056e-07
- O 0 8.967702456175175e-07
D O 0 2.386157802902744e-06
, O 0 2.426279177569768e-10
in O 0 1.7831733312156928e-10
which O 0 5.335244690485297e-09
HLA O 0 4.2549811496428447e-07
- O 0 2.3607253751833923e-06
D O 0 1.771605070644e-06
segregared O 0 2.328526846895329e-07
with O 0 1.497341806100394e-09
HLA O 0 4.575908008064289e-07
- O 0 8.036619760787289e-07
A O 0 3.400901960048941e-08
and O 0 6.142576580714376e-08
B O 0 3.1195866085909074e-06
. O 0 3.1407137157657417e-07

These O 0 5.1174474435811135e-08
studies O 0 6.621988291044545e-08
suggest O 0 1.4038893603185443e-08
that O 0 1.5061719926823258e-10
the O 0 6.954323228391956e-11
genes O 0 1.997837673073377e-09
for O 0 6.596719281937169e-10
Factor O 0 3.4654570413295005e-07
B O 1 0.5110337138175964
and O 0 0.44917091727256775
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 2.6588872770183514e-10
located O 0 3.741916221322583e-10
outside O 0 2.6030969046964003e-10
those O 0 1.354147072252232e-10
for O 0 6.988683243225324e-11
HLA O 0 8.636664716732412e-09
, O 0 1.1839229596688483e-10
that O 0 1.0114892257107044e-10
the O 0 5.719466913967075e-11
order O 0 3.653352897980966e-10
of O 0 5.6070242199224296e-11
genese O 0 7.524162271010937e-08
is O 0 1.323871789971065e-09
HLA O 0 6.6917579033543e-08
- O 0 1.1664112520293202e-07
A O 0 2.3208894806003855e-09
, O 0 6.310790223729157e-10
- O 0 3.656354152781205e-08
B O 0 3.883389254610847e-08
, O 0 1.5719410495496078e-10
- O 0 3.922201585737639e-08
D O 0 9.85439640999175e-08
, O 0 2.0481651097359332e-10
Factor O 0 6.021021015101269e-09
B O 0 6.55143423955451e-08
allotype O 0 1.6387281220886507e-06
, O 0 2.186198344134027e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
, O 0 9.169470738257246e-11
that O 0 3.461728473319603e-11
the O 0 1.5234090378068998e-10
genes O 0 1.566728258239891e-08
coding O 0 9.732132639328483e-06
for O 0 2.61237414633797e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 1.234100199809518e-08
Factor O 0 2.3082955991071685e-08
B O 0 1.7149053732623543e-08
allotypes O 0 1.6527950563727245e-08
are O 0 1.0512930109785046e-10
approximately O 0 1.653032988269132e-10
3 O 0 1.012740669104062e-09
- O 0 7.344427643829476e-08
- O 0 9.480622509272507e-08
5 O 0 7.671882018556175e-10
centimorgans O 0 1.7810098285053755e-08
from O 0 1.1431000590533813e-10
the O 0 3.496221645526987e-10
HLA O 0 1.0207566703002158e-07
- O 0 8.250147232047311e-08
A O 0 1.9342702994862293e-09
and O 0 2.282085187488292e-09
HLA O 0 1.933759108396771e-07
- O 0 1.978739163632781e-07
B O 0 2.1115392101478392e-08
loci O 0 1.997212839555118e-09
, O 0 8.104818899346e-11
and O 0 9.996669464440444e-11
that O 0 9.004783724231302e-11
the O 0 1.3870107840041612e-10
apparent O 0 4.881165693859657e-08
lack O 0 2.450992742097924e-09
of O 0 4.961090219191e-11
recombinants O 0 1.5657784402378638e-08
between O 0 2.1952951956283329e-10
the O 0 4.4922268682690003e-10
Factor O 0 3.0773620096624654e-08
B O 0 1.2743710442464362e-07
gene O 0 3.000845083533932e-07
and O 0 0.004639632534235716
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
gene O 0 2.586653202740763e-08
suggests O 0 6.4598468796361885e-09
that O 0 6.561454851672366e-11
these O 0 6.03506480900684e-11
two O 0 1.3423973044268678e-10
genes O 0 5.962542015680583e-09
lie O 0 1.1221194995414407e-07
in O 0 4.1775552461764676e-10
close O 0 2.8324029788251437e-09
proximity O 0 9.853471816256842e-09
to O 0 2.2755177742084243e-09
one O 0 3.97862720546982e-09
another O 0 1.453728870615123e-08
. O 0 1.500296349377095e-07

Distribution O 0 2.860102767954231e-07
of O 0 2.685545119618382e-09
emerin O 0 7.867569706832e-07
and O 0 4.0438337123305246e-09
lamins O 0 2.085112555505475e-06
in O 0 2.237583007769217e-09
the O 0 1.559372742043763e-09
heart O 0 6.267588048558537e-08
and O 0 8.890920777382405e-10
implications O 0 1.77595556039023e-08
for O 0 1.9527195416202403e-09
Emery B-Disease 0 5.010652330383891e-06
- I-Disease 0 4.647740934160538e-05
Dreifuss I-Disease 0 0.0014450082089751959
muscular I-Disease 0 5.0278129492653534e-05
dystrophy I-Disease 0 9.198520274367183e-05
. O 0 1.6468701460325974e-06

Emerin O 0 9.048197534866631e-05
is O 0 1.068591544139963e-07
a O 0 1.722822773331245e-08
nuclear O 0 4.3269074012641795e-07
membrane O 0 3.811489435179283e-08
protein O 0 1.1324437387827402e-08
which O 0 1.572505570202054e-09
is O 0 1.0564070729301989e-09
missing O 0 1.1267471400344675e-08
or O 0 3.3032894197759788e-09
defective O 0 2.480946079685964e-07
in O 0 9.663349231914253e-09
Emery B-Disease 0 0.0004521927621681243
- I-Disease 0 0.0026765242218971252
Dreifuss I-Disease 0 0.06481865048408508
muscular I-Disease 0 7.762547465972602e-05
dystrophy I-Disease 0 0.0001086107877199538
( O 0 4.066366727784043e-07
EDMD B-Disease 1 0.9999996423721313
) O 0 3.5736658787755005e-07
. O 0 5.840809080837062e-07

It O 0 1.209877922292435e-07
is O 0 2.1718860043762334e-09
one O 0 7.736656870704905e-10
member O 0 4.4305265012312134e-10
of O 0 6.567940635804348e-11
a O 0 1.2222720613408455e-09
family O 0 3.5314968727107043e-09
of O 0 2.0845380976908245e-10
lamina O 0 0.05089802294969559
- O 0 0.04073113203048706
associated O 0 2.6192662261337318e-08
proteins O 0 1.3039189727948042e-09
which O 0 3.914335522381407e-10
includes O 0 5.265003988341732e-10
LAP1 O 0 3.1053284033077944e-07
, O 0 9.670977352271848e-10
LAP2 O 0 4.5158904526942933e-07
and O 0 1.3700427459184539e-08
lamin O 0 1.2993564268981572e-05
B O 0 4.9230629883822985e-06
receptor O 0 7.391857934635482e-07
( O 0 2.9237195775522196e-08
LBR O 0 4.940200597047806e-05
) O 0 8.666652462352431e-08
. O 0 2.275042021437912e-07

A O 0 9.405504783899232e-07
panel O 0 6.381010280165356e-07
of O 0 4.407518350291184e-09
16 O 0 1.3462474690584258e-08
monoclonal O 0 2.1107061343172973e-07
antibodies O 0 1.1633196095317544e-07
( O 0 2.0580148696325296e-09
mAbs O 0 2.3974322971298534e-07
) O 0 2.1787149862007027e-09
has O 0 6.608683600362042e-10
been O 0 3.3565489276909943e-10
mapped O 0 1.6803284097477444e-08
to O 0 1.9182101740344848e-10
six O 0 1.5320282542585772e-10
specific O 0 4.1756992308350505e-10
sites O 0 1.7542198804676445e-09
throughout O 0 1.0811951334233072e-09
the O 0 4.4682485489389023e-10
emerin O 0 5.133529157319572e-08
molecule O 0 3.501482437329173e-09
using O 0 4.3754466716450224e-09
phage O 0 8.593617195629122e-08
- O 0 1.3258258491077868e-08
displayed O 0 2.2368233931757686e-09
peptide O 0 4.6813828369351995e-09
libraries O 0 1.6750284492772494e-09
and O 0 3.1097521779877013e-10
has O 0 2.46340670084777e-10
been O 0 2.956172251433742e-10
used O 0 8.788009209226288e-10
to O 0 3.4521432934475627e-10
localize O 0 1.6189338225558458e-07
emerin O 0 3.312323144655238e-07
in O 0 1.3613989935379323e-09
human O 0 1.86607218566337e-09
and O 0 2.360413553503804e-08
rabbit O 0 0.00018227325927000493
heart O 0 5.114451778354123e-05
. O 0 1.5193645594990812e-06

Several O 0 1.3457601255595364e-07
mAbs O 0 3.115870185865788e-06
against O 0 2.4672180742868477e-08
different O 0 1.2246108127555999e-08
emerin O 0 9.229982538272452e-07
epitopes O 0 1.4917461612640182e-06
did O 0 3.9888032432600085e-08
not O 0 1.4315095775430109e-09
recognize O 0 4.245781504153001e-09
intercalated O 0 1.3243751872948906e-08
discs O 0 4.197151426410528e-08
in O 0 7.788150124810045e-10
the O 0 6.085766335317544e-10
heart O 0 3.062238107531812e-08
, O 0 2.5013502380488717e-10
though O 0 1.1914988995442855e-09
they O 0 8.173096643915301e-10
recognized O 0 3.1488422980174846e-09
cardiomyocyte O 0 2.9598146156217808e-08
nuclei O 0 1.881479194665303e-09
strongly O 0 2.8952442665541867e-09
, O 0 2.6669125241518543e-10
both O 0 3.762463396395077e-10
at O 0 1.6107701839018773e-09
the O 0 2.6048502244080396e-10
rim O 0 1.8143888169674938e-08
and O 0 1.637181723523895e-09
in O 0 1.5028009947570808e-09
intranuclear O 0 5.180067432775104e-07
spots O 0 4.182530801699613e-07
or O 0 1.0793128524255735e-07
channels O 0 3.263012786192121e-06
. O 0 5.334377419785596e-07

A O 0 5.097383564134361e-06
polyclonal O 0 0.00011104826990049332
rabbit O 0 3.0877843528287485e-05
antiserum O 0 4.3940552131971344e-05
against O 0 1.2374098901091202e-07
emerin O 0 2.52616086982016e-06
did O 0 3.749157073684728e-08
recognize O 0 3.310923801791432e-08
both O 0 2.3583424102469053e-09
nuclear O 0 7.199599139084967e-08
membrane O 0 5.5381130792397926e-09
and O 0 2.553362243862267e-10
intercalated O 0 2.8372044713620426e-09
discs O 0 1.1149039025326601e-08
but O 0 9.707606940523306e-10
, O 0 3.419845309715619e-11
after O 0 4.2567237928947677e-11
affinity O 0 2.0954686597018934e-10
purification O 0 4.1075204348928196e-10
against O 0 1.8381848820858693e-10
a O 0 1.8277036828440174e-10
pure O 0 4.380941387438497e-09
- O 0 8.065414647262514e-08
emerin O 0 1.5160269128955406e-07
band O 0 3.6588430063488886e-09
on O 0 3.55434209842187e-10
a O 0 2.5925925295489094e-10
western O 0 5.410018655283011e-09
blot O 0 0.0002122306905221194
, O 0 1.584699815815327e-09
it O 0 3.0947659990232523e-09
stained O 0 1.4644310795119964e-05
only O 0 3.742532062034343e-09
the O 0 5.264042535202407e-09
nuclear O 0 9.978867865356733e-07
membrane O 0 7.077003374433843e-07
. O 0 3.209021031125303e-07

These O 0 2.8750829272894407e-08
results O 0 1.3719830604941308e-08
would O 0 5.399192204436076e-10
not O 0 2.473595495100511e-10
be O 0 1.5977555389845577e-10
expected O 0 3.247042079657092e-10
if O 0 7.483365038751799e-10
immunostaining O 0 1.840772512196054e-08
at O 0 3.4631697509723836e-10
intercalated O 0 5.202813735394329e-09
discs O 0 2.0267702183218717e-08
were O 0 1.054432319236298e-09
due O 0 6.34790109366179e-10
to O 0 1.7179679900891642e-10
a O 0 1.6928146384653786e-10
product O 0 2.007493948852357e-09
of O 0 2.424085411567578e-11
the O 0 1.7060133861157567e-10
emerin O 0 2.1840461883471107e-08
gene O 0 5.19274134802572e-09
and O 0 7.241390820311722e-10
, O 0 1.325420051490056e-10
therefore O 0 3.255339331431628e-10
, O 0 4.944700204845276e-11
cast O 0 2.4908488605035473e-09
some O 0 1.1904920105276773e-10
doubt O 0 9.209016327282882e-10
upon O 0 9.359207853165685e-11
the O 0 1.6921432310912365e-10
hypothesis O 0 2.0323678739941897e-08
that O 0 3.0577951282140248e-09
cardiac B-Disease 0 1.5446898942172993e-06
defects I-Disease 0 0.002642655512318015
in O 0 4.5880792498564915e-09
EDMD B-Disease 1 1.0
are O 0 3.645240909122549e-08
caused O 0 1.702777296941349e-08
by O 0 5.592160068346175e-10
absence O 0 5.737621489032563e-09
of O 0 3.280833937857608e-10
emerin O 0 4.865290179623116e-07
from O 0 4.238078776808152e-09
intercalated O 0 1.2901349464300438e-06
discs O 0 4.132666163059184e-06
. O 0 5.033115257901954e-07

Although O 0 6.800768233006238e-07
emerin O 0 4.277274456399027e-06
was O 0 3.645219948111844e-08
abundant O 0 7.2044867849285765e-09
in O 0 1.1727757653900994e-09
the O 0 8.026564968233174e-10
membranes O 0 5.620942289397135e-08
of O 0 1.6245890743782354e-10
cardiomyocyte O 0 2.3413344152345417e-08
nuclei O 0 2.4919799557210354e-09
, O 0 2.570631207898799e-10
it O 0 9.207224427321137e-10
was O 0 4.521093721621128e-09
absent O 0 5.514502188219694e-09
from O 0 2.7008875691514334e-10
many O 0 1.5716660195508325e-09
non O 0 1.0052207244370948e-07
- O 0 6.353502612910233e-07
myocyte O 0 2.502742518117884e-06
cells O 0 8.150190211608788e-08
in O 0 3.7441885147870835e-09
the O 0 1.0094819202777217e-08
heart O 0 3.1459317142434884e-06
. O 0 4.6482071525133506e-07

This O 0 1.540404070965451e-08
distribution O 0 9.987130233923835e-09
of O 0 3.8464750828914873e-10
emerin O 0 3.632089544680639e-07
was O 0 3.5831506650652045e-09
similar O 0 2.6159532873215596e-10
to O 0 8.918855931572267e-11
that O 0 9.561220565279527e-11
of O 0 2.5087739177753754e-11
lamin O 0 1.378528224904585e-07
A O 0 3.3054574632984668e-09
, O 0 1.571035801450904e-10
a O 0 1.2801526505512584e-10
candidate O 0 3.299473583240342e-09
gene O 0 8.079976687724866e-09
for O 0 6.104809435747427e-10
an O 0 1.1161374047219397e-09
autosomal O 0 2.918891368608456e-05
form O 0 5.850838533660863e-07
of O 0 1.6873627828317694e-07
EDMD B-Disease 1 1.0
. O 0 2.852464149327716e-06

In O 0 2.2472723060218414e-07
contrast O 0 5.615160603156255e-07
, O 0 4.718623713984016e-08
lamin O 0 5.5924105254234746e-05
B1 O 0 0.0065419478341937065
was O 0 2.8309191435482717e-08
absent O 0 2.2963861923130935e-08
from O 0 5.403715253038399e-10
cardiomyocyte O 0 4.2023660995482714e-08
nuclei O 0 7.48872341915785e-09
, O 0 6.260867935203862e-10
showing O 0 1.9126954242665306e-08
that O 0 3.128016512476961e-09
lamin O 0 6.168598247313639e-06
B1 O 0 2.0556348317768425e-05
is O 0 8.086725733491562e-10
not O 0 2.56033610979145e-10
essential O 0 4.354248350768586e-10
for O 0 7.214806529987072e-11
localization O 0 2.9140698742935456e-09
of O 0 1.1277974387713385e-10
emerin O 0 7.558583803302099e-08
to O 0 1.1118920228980755e-09
the O 0 6.122887974413516e-09
nuclear O 0 3.7914630865998333e-06
lamina O 0 2.4826887965900823e-05
. O 0 4.657489967030415e-07

Lamin O 0 0.2540852129459381
B1 O 1 0.9963862895965576
is O 0 1.5977853706772294e-07
also O 0 1.1132506472222303e-08
almost O 0 1.1392442544888581e-08
completely O 0 6.615379106733599e-07
absent O 0 2.19336854456742e-07
from O 0 1.0111102177745579e-08
skeletal O 0 1.5003928638179787e-05
muscle O 0 1.5305382476071827e-05
nuclei O 0 6.2288008848554455e-06
. O 0 1.2220090184200672e-06

In O 0 2.650000396897667e-07
EDMD B-Disease 1 0.9999972581863403
, O 0 3.3961164991325177e-09
the O 0 2.8083502190412446e-10
additional O 0 2.5828899019586515e-09
absence O 0 2.100036056162935e-08
of O 0 2.1878889810977853e-09
lamin O 0 3.100868343608454e-05
B1 O 0 0.001328198122791946
from O 0 6.684114595145729e-09
heart O 0 9.302028161073395e-07
and O 0 1.3776682017407893e-08
skeletal O 0 3.7410463846754283e-06
muscle O 0 4.510888800268731e-07
nuclei O 0 7.975418725436612e-08
which O 0 2.3329940646021896e-08
already O 0 2.0404430145504193e-08
lack O 0 5.469710462335797e-09
emerin O 0 1.4075040155603347e-07
may O 0 3.779114798874161e-09
offer O 0 9.46870581941539e-10
an O 0 5.364667737817186e-11
alternative O 0 2.419745515069849e-09
explanation O 0 1.8011061531097994e-09
of O 0 4.287802751745673e-11
why O 0 1.5549860288288642e-09
these O 0 2.4297897027736326e-10
tissues O 0 4.655266838682337e-09
are O 0 4.879848192196334e-10
particularly O 0 5.966239058352585e-09
affected O 0 3.072247878321832e-08
. O 0 2.2594131010578167e-08
. O 0 2.8826008247051504e-07

Genetic O 0 2.0281553588574752e-05
mapping O 0 1.6451497231173562e-06
of O 0 1.130676174909695e-08
the O 0 4.503383976839359e-08
copper B-Disease 0 1.8682527297642082e-05
toxicosis I-Disease 0 0.0024758276995271444
locus O 0 7.609277417941485e-06
in O 0 2.3370379409470843e-08
Bedlington O 0 1.7714428395265713e-06
terriers O 0 5.059477530267031e-07
to O 0 2.091863793296511e-09
dog O 0 2.9741658025272955e-08
chromosome O 0 1.31821124682574e-07
10 O 0 1.6737000674282854e-09
, O 0 2.371114415922193e-10
in O 0 3.478581589444474e-10
a O 0 2.216738348437275e-09
region O 0 3.369155976429283e-08
syntenic O 0 1.2597707836903282e-06
to O 0 3.398313186409041e-09
human O 0 1.3835509626858311e-08
chromosome O 0 3.7763973068649648e-06
region O 0 4.385813667795446e-07
2p13 O 0 1.1549217560968827e-05
- O 0 7.857740456529427e-06
p16 O 0 2.9704142434638925e-05
. O 0 1.0230385214526905e-06

Abnormal O 0 0.012096907943487167
hepatic B-Disease 0 0.40117698907852173
copper I-Disease 0 3.383672083145939e-05
accumulation I-Disease 0 3.04326846389813e-07
is O 0 2.121064435200992e-09
recognized O 0 4.189103286478257e-09
as O 0 3.749877297565263e-09
an O 0 2.1210132672422333e-07
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
in O 0 3.841068263454872e-08
man O 0 7.509379997827637e-07
, O 0 2.885128802532222e-09
mouse O 0 2.7357845056030783e-07
, O 0 1.5140480869035855e-08
rat O 0 4.423853170010261e-06
and O 0 6.317782208498102e-08
dog O 0 5.3202502385829575e-06
. O 0 1.2569290674946387e-06

The O 0 1.1783847497781608e-07
major O 0 1.333547601234386e-07
cause O 0 8.031764764382388e-08
of O 0 1.7611395675132258e-09
hepatic B-Disease 0 5.700937981600873e-05
copper I-Disease 0 8.043547859415412e-05
accumulation I-Disease 0 1.2588492381837568e-07
in O 0 3.0960471963936698e-09
man O 0 1.7244016703443776e-07
is O 0 3.014352767394257e-09
a O 0 7.2224830560685405e-09
dysfunctional O 0 1.5498191032747854e-06
ATP7B O 0 9.495160497863253e-07
gene O 0 1.9481451829506113e-07
, O 0 1.2323195797137032e-08
causing O 0 9.104971354645386e-07
Wilson B-Disease 0 2.4334285626537167e-05
disease I-Disease 0 2.2284741135081276e-05
( O 0 1.0444789921848496e-07
WD B-Disease 1 0.9999915361404419
) O 0 5.126597102389496e-07
. O 0 6.195726882651797e-07

Mutations O 0 2.8452743208617903e-05
in O 0 3.1688408341778995e-08
the O 0 2.874631643834391e-09
ATP7B O 0 5.430713940768328e-07
genes O 0 4.007501885894271e-08
have O 0 3.532830472607884e-09
also O 0 1.3276573174181294e-09
been O 0 3.0534472728049877e-09
demonstrated O 0 7.752081643275233e-09
in O 0 2.2572068658632816e-09
mouse O 0 7.210510375443846e-07
and O 0 3.004728341693408e-07
rat O 0 4.8418125516036525e-05
. O 0 2.05331480174209e-06

The O 0 1.4746578358426632e-07
ATP7B O 0 2.16229705074511e-06
gene O 0 1.5712569734205317e-07
has O 0 8.826279263018932e-09
been O 0 1.1919307763008646e-09
excluded O 0 4.318536195313527e-09
in O 0 1.5227639982295926e-10
the O 0 1.6085495435635977e-10
much O 0 2.0122896682295277e-09
rarer O 0 3.238665158278309e-07
human O 0 1.5540587483542367e-08
copper B-Disease 0 1.4172779629006982e-05
overload I-Disease 0 6.150112767500104e-06
disease O 0 1.5785426512593403e-06
non B-Disease 0 4.221703591156256e-07
- I-Disease 0 0.00019238849927205592
Indian I-Disease 0 2.5426686534046894e-07
childhood I-Disease 0 4.495352641242789e-06
cirrhosis I-Disease 0 2.376433985773474e-05
, O 0 6.410370012588373e-09
indicating O 0 2.5134292513939727e-07
genetic O 0 4.972019269189332e-06
heterogeneity O 0 4.581757093546912e-05
. O 0 3.929333615815267e-06

By O 0 2.621105110733879e-08
investigating O 0 1.7968869769902085e-07
the O 0 2.1993752596927152e-08
common O 0 1.0457702046551276e-06
autosomal O 1 0.8811419606208801
recessive O 1 0.7143602967262268
copper B-Disease 0 0.000778878980781883
toxicosis I-Disease 0 0.056632231920957565
( O 0 2.6009059794773748e-08
CT B-Disease 1 0.662020742893219
) O 0 5.8447962025809375e-09
in O 0 6.375079908416126e-10
Bedlington O 0 1.500722817127098e-07
terriers O 0 2.2142806699321227e-07
, O 0 8.404791862481886e-10
we O 0 4.699237110550314e-10
have O 0 2.208330740494091e-10
identified O 0 6.506796212946142e-10
a O 0 1.111815084442469e-10
new O 0 1.6649696066295405e-09
locus O 0 2.0655041055306356e-07
involved O 0 5.234370092921381e-08
in O 0 1.9495335834562866e-07
progressive O 1 0.9287177920341492
liver B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 5.576296643994283e-06

We O 0 6.376118903972383e-07
examined O 0 2.789008988202113e-07
whether O 0 1.455568376940164e-08
the O 0 5.580005790761788e-09
WD B-Disease 0 0.18737761676311493
gene O 0 4.787203238265647e-07
ATP7B O 0 5.500750830833567e-06
was O 0 1.2026736939674265e-08
also O 0 5.877996978043143e-10
causative O 0 9.507658660368179e-08
for O 0 1.2443862607014466e-09
CT B-Disease 0 0.00014573799853678793
by O 0 1.1046499270861432e-09
investigating O 0 3.5034680934131757e-08
the O 0 3.5785812091404523e-09
chromosomal O 0 0.026751607656478882
co O 0 0.0007819504244253039
- O 0 2.1266978365019895e-06
localization O 0 8.685186259071997e-08
of O 0 5.140363135147652e-10
ATP7B O 0 6.30971328519081e-07
and O 0 8.843092369481553e-10
C04107 O 0 1.2994631148899316e-08
, O 0 7.476570057507459e-11
using O 0 7.764803799936715e-10
fluorescence O 0 3.543089732715998e-08
in O 0 1.2742702448775844e-09
situ O 0 8.533850603953397e-08
hybridization O 0 7.689205716587821e-08
( O 0 3.6431815342297114e-09
FISH O 0 5.9587819123407826e-08
) O 0 1.7226684079219012e-08
. O 0 1.9277140950180183e-07

C04107 O 0 7.285253377631307e-05
is O 0 1.0250547433088286e-07
an O 0 5.6732321063179825e-09
anonymous O 0 2.00863311761168e-07
microsatellite O 0 1.3466834388964344e-05
marker O 0 8.702843956598372e-07
closely O 0 1.9250741445375752e-07
linked O 0 2.375069470872404e-06
to O 0 1.8237328447412438e-07
CT B-Disease 1 0.9958298802375793
. O 0 1.638568733142165e-06

However O 0 1.8045616343442816e-06
, O 0 1.0574139253094472e-07
BAC O 0 1.9460335352050606e-06
clones O 0 2.2749033234958915e-07
containing O 0 1.60909134905296e-08
ATP7B O 0 1.4602561577703455e-06
and O 0 4.0690717462155135e-09
C04107 O 0 7.245306932190942e-08
mapped O 0 1.0138141703919246e-07
to O 0 1.28041466318507e-09
the O 0 1.7785207750975474e-09
canine O 0 5.566751610786014e-07
chromosome O 0 1.3963232277092175e-06
regions O 0 5.829835103554615e-08
CFA22q11 O 0 1.0563753676251508e-06
and O 0 4.1170054032591e-09
CFA10q26 O 0 1.6709138606074703e-07
, O 0 3.679668791889412e-10
respectively O 0 1.8606911567076168e-09
, O 0 1.9052040500788792e-10
demonstrating O 0 2.5393662728134814e-09
that O 0 1.9043440158128533e-09
WD B-Disease 1 0.9918113946914673
cannot O 0 5.62817277227623e-08
be O 0 5.719077433852249e-10
homologous O 0 2.0873928363585037e-08
to O 0 9.085532326480461e-09
CT B-Disease 0 0.1469968557357788
. O 0 3.7496366189770924e-07

The O 0 1.1128052790354559e-07
copper O 0 1.0961230145767331e-06
transport O 0 2.2849304670558013e-08
genes O 0 3.0632840264388506e-08
CTR1 O 0 3.740290139830904e-07
and O 0 1.0322386279071338e-09
CTR2 O 0 1.38000146421291e-07
were O 0 1.2732109810897896e-09
also O 0 3.195787245946491e-10
excluded O 0 3.0434985642813217e-09
as O 0 1.0728215538158281e-10
candidate O 0 1.0999362531904922e-09
genes O 0 1.7004201380288464e-09
for O 0 2.43139369748846e-10
CT B-Disease 0 0.06111699715256691
since O 0 1.726306209093309e-08
they O 0 5.219877863282818e-10
both O 0 5.426882832004765e-10
mapped O 0 2.2104448760273954e-07
to O 0 1.6450771411768983e-08
canine O 0 4.3110021579195745e-06
chromosome O 0 4.127465945202857e-05
region O 0 4.400995294417953e-06
CFA11q22 O 0 8.242010517278686e-05
. O 0 2.0106774627492996e-06

2 O 0 1.9620034436229616e-05
- O 0 0.0005264417268335819
22 O 0 3.0201608751667663e-06
. O 0 1.1152694696647814e-06

5 O 0 5.525431697606109e-05
. O 0 9.534828677715268e-06

A O 0 2.672688026450487e-07
transcribed O 0 2.9746263408014784e-07
sequence O 0 6.689180054308963e-08
identified O 0 4.110259510525793e-08
from O 0 8.031051934587197e-10
the O 0 7.799537682373625e-10
C04107 O 0 2.6651258622223395e-07
- O 0 6.87979309077491e-08
containing O 0 6.341005942545053e-09
BAC O 0 4.873007810601848e-07
was O 0 2.5909820955405394e-09
found O 0 2.7790542089789483e-10
to O 0 7.154005859932866e-11
be O 0 1.236643704105589e-10
homologous O 0 1.6463379548525836e-09
to O 0 1.3017936728587642e-10
a O 0 3.0224917013654817e-10
gene O 0 1.2636456325765266e-08
expressed O 0 7.118402534089796e-10
from O 0 6.797662988056175e-10
human O 0 4.397643138531748e-09
chromosome O 0 4.7403054281858203e-07
2p13 O 0 7.542653861491999e-07
- O 0 1.5401285224925232e-07
p16 O 0 1.1465145632882923e-07
, O 0 1.1507989006176444e-09
a O 0 2.1178465647864186e-09
region O 0 2.508031649028908e-08
devoid O 0 4.764712002724991e-08
of O 0 5.387968959880141e-10
any O 0 1.245873537669695e-08
positional O 0 1.329040969721973e-06
candidate O 0 1.7757205341695226e-06
genes O 0 4.786409135704162e-06
. O 0 2.4766320620983606e-06

Molecular O 0 7.887457286415156e-06
analysis O 0 3.98865921624747e-07
of O 0 1.4029329920006717e-09
the O 0 1.8350400088351648e-09
APC B-Disease 0 3.340725385214682e-08
gene O 0 2.2111358077836485e-08
in O 0 1.2391163650704584e-09
205 O 0 3.287475180968613e-09
families O 0 1.6138945735377774e-09
: O 0 5.488476340076431e-10
extended O 0 9.888848850891918e-09
genotype O 0 0.00035469120484776795
- O 0 0.00014128696057014167
phenotype O 0 3.1837703318160493e-06
correlations O 0 2.929844526988745e-07
in O 0 1.1277355715932913e-09
FAP B-Disease 0 1.5944419118341102e-08
and O 0 1.0161553543053259e-10
evidence O 0 4.354596960798318e-10
for O 0 4.256504523847404e-11
the O 0 4.768505035279702e-11
role O 0 2.5086903665538784e-09
of O 0 2.33161268070603e-10
APC B-Disease 0 3.2388559390028604e-08
amino O 0 2.083411310138672e-08
acid O 0 5.072986297705029e-08
changes O 0 1.0491571345028206e-07
in O 0 0.00012009294732706621
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
predisposition O 0 0.0010200715623795986
. O 0 3.073437255807221e-06

BACKGROUND O 0 4.977064600097947e-05
/ O 0 2.233582745247986e-05
AIMS O 0 3.7296860000424203e-07
The O 0 1.6380063971865866e-09
development O 0 5.335000441419879e-09
of O 0 6.068709268447492e-08
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 4.179382617763849e-09
a O 0 6.727277068740989e-10
variable O 0 2.6028466493244196e-08
range O 0 7.054770545522615e-09
of O 0 9.613854157208834e-10
extracolonic O 0 7.065161298669409e-06
manifestations O 0 2.1559635570156388e-05
in O 0 1.3058160220680293e-05
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 2.859661094589683e-07
FAP B-Disease 0 1.0725668744271388e-06
) O 0 5.943591396828651e-09
is O 0 6.761159965229524e-10
the O 0 2.235393536942354e-10
result O 0 3.553795036026486e-09
of O 0 9.255234773020149e-11
the O 0 1.886232947612143e-09
dominant O 0 0.00014572688087355345
inheritance O 0 0.06443436443805695
of O 0 2.580680984465289e-06
adenomatous B-Disease 1 1.0
polyposis I-Disease 1 0.9999998807907104
coli I-Disease 1 1.0
( O 0 6.137950663287484e-07
APC B-Disease 0 2.5843630737654166e-06
) O 0 5.196013574959579e-08
gene O 0 2.2633871594734956e-06
mutations O 0 1.7996317183133215e-05
. O 0 1.3333344668353675e-06

In O 0 7.40320231784608e-08
this O 0 1.5863480529176854e-09
study O 0 2.3442914276472493e-09
, O 0 3.2251920578652005e-10
direct O 0 2.4240414120413334e-09
mutation O 0 4.885338711346776e-08
analysis O 0 1.0342414036301761e-08
of O 0 9.981616921894698e-11
the O 0 3.790229796685196e-10
APC B-Disease 0 1.1832919533105724e-08
gene O 0 7.347535468937849e-09
was O 0 1.4666257097672997e-09
performed O 0 1.2673501137427934e-09
to O 0 2.709013291468665e-10
determine O 0 3.796825254198666e-08
genotype O 0 5.866600531589938e-06
- O 0 6.922643933648942e-07
phenotype O 0 2.696204717267392e-07
correlations O 0 5.0198938339462984e-08
for O 0 3.382384372585534e-10
nine O 0 1.1695546753287545e-09
extracolonic O 0 3.8987813866242504e-08
manifestations O 0 8.561710451715498e-09
and O 0 3.9559316933335253e-10
to O 0 2.3737117826883036e-10
investigate O 0 8.140491836172714e-09
the O 0 9.778837739560231e-10
incidence O 0 8.112252203318349e-07
of O 0 4.923208507534582e-10
APC B-Disease 0 8.748431667982004e-08
mutations O 0 2.1218508550191473e-07
in O 0 9.944950640772277e-09
non O 0 4.2997598939109594e-05
- O 1 0.9997583031654358
FAP O 1 0.999925971031189
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 3.950159680243814e-06

METHODS O 0 3.877057224599412e-06
The O 0 2.7904395238920188e-08
APC B-Disease 0 1.9388816951959598e-07
gene O 0 6.097612015310006e-08
was O 0 6.541593045028549e-09
analysed O 0 2.0454265836633567e-08
in O 0 8.795169037512096e-10
190 O 0 6.3267631134067415e-09
unrelated O 0 5.0522931616114874e-08
FAP B-Disease 0 2.3636039259145036e-07
and O 0 2.9731888062656253e-09
15 O 0 1.1565514768108187e-08
non O 0 6.854382718302077e-06
- O 1 0.99989914894104
FAP O 1 0.9999774694442749
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 8.353081852874311e-07
using O 0 4.132285269520253e-08
denaturing O 0 3.4898428566521034e-05
gradient O 0 9.922935532813426e-06
gel O 0 0.00012883833551313728
electrophoresis O 0 7.65695767768193e-06
, O 0 4.357631588902677e-09
the O 0 5.097744448789854e-10
protein O 0 8.193235423448186e-09
truncation O 0 4.4120798747826484e-07
test O 0 2.012955633290403e-07
, O 0 3.7603681279918533e-10
and O 0 3.937113135510373e-10
direct O 0 1.410080407993064e-08
sequencing O 0 6.376715191436233e-07
. O 0 3.0303053222269227e-07

RESULTS O 0 4.548030119622126e-06
Chain O 0 5.994027105771238e-07
terminating O 0 1.6758706067321327e-07
signals O 0 6.838529031938378e-08
were O 0 1.7273824592933806e-09
only O 0 2.964387624260212e-10
identified O 0 9.48452605342709e-09
in O 0 7.557220960130451e-10
patients O 0 3.269135628869435e-09
belonging O 0 1.7460516366085699e-09
to O 0 8.223823844133449e-10
the O 0 1.85795689944257e-09
FAP B-Disease 0 2.2286867817911116e-07
group O 0 6.6043015500838465e-09
( O 0 3.830573080954025e-10
105 O 0 4.699588718182213e-09
patients O 0 9.315125026887472e-08
) O 0 1.482369960115193e-08
. O 0 1.9057080180573394e-07

Amino O 0 6.5818094299174845e-06
acid O 0 2.0385834886837984e-06
changes O 0 2.9331534534549064e-08
were O 0 8.727073508296712e-10
identified O 0 1.6189231066832122e-09
in O 0 1.5542349351971296e-10
four O 0 3.5737365844390467e-10
patients O 0 2.862108772205829e-09
, O 0 2.4370288773112314e-11
three O 0 3.330832831771602e-11
of O 0 2.6673484601613673e-11
whom O 0 3.135447457225382e-09
belonged O 0 6.852340472818241e-09
to O 0 3.4246253055592035e-10
the O 0 6.284005538148563e-10
non O 0 2.928162814441748e-07
- O 0 2.635619239299558e-06
FAP O 0 7.462148232662003e-07
group O 0 1.0074050038610949e-07
of O 0 2.313292242206444e-07
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 2.4864297301974148e-05
. O 0 6.154468223940057e-07

Genotype O 1 0.9964422583580017
- O 1 0.9756184220314026
phenotype O 0 9.158906323136762e-05
correlations O 0 3.9337655834970064e-06
identified O 0 2.1732341792812804e-07
significant O 0 3.093474987281297e-08
differences O 0 1.541024801099411e-07
in O 0 1.9018611130405816e-09
the O 0 2.686711964017263e-10
nature O 0 2.0276624823623024e-09
of O 0 8.980188120899513e-11
certain O 0 2.7272120117771692e-09
extracolonic O 0 6.612912670789228e-07
manifestations O 0 1.5179583101598837e-07
in O 0 9.39394873000765e-09
FAP B-Disease 0 4.977419507667946e-07
patients O 0 2.8438101651317993e-08
belonging O 0 2.5679276483003832e-09
to O 0 1.2906662405498537e-09
three O 0 5.861386043193306e-09
mutation O 0 2.608945806059637e-06
subgroups O 0 2.225951902801171e-06
. O 0 8.181914950000646e-07

CONCLUSIONS O 0 1.2296098248043563e-05
Extended O 0 1.391229716318776e-06
genotype O 0 0.00026760040782392025
- O 0 3.570824264897965e-05
phenotype O 0 8.709104690751701e-07
correlations O 0 1.7584828526651108e-07
made O 0 1.4022882854902718e-09
in O 0 1.9430847209012114e-10
this O 0 6.446706363183452e-11
study O 0 4.917699580886392e-10
may O 0 7.160808057626866e-10
have O 0 5.665624219775012e-11
the O 0 1.1758386798954579e-11
potential O 0 2.2990047365833988e-10
to O 0 2.385038173902121e-11
determine O 0 2.9228466869035685e-10
the O 0 1.0088568001831444e-11
most O 0 3.347270724485263e-11
appropriate O 0 1.8816900815288307e-10
surveillance O 0 3.9253578165698855e-09
and O 0 3.1863103822082905e-10
prophylactic O 0 3.8642816946321545e-08
treatment O 0 3.26438165387799e-09
regimens O 0 9.265134437441702e-09
for O 0 5.702485358916043e-11
those O 0 3.440396578735516e-10
patients O 0 3.556412275784737e-09
with O 0 2.8696614529089004e-10
mutations O 0 1.5373844064470177e-07
associated O 0 1.0422079199656764e-08
with O 0 2.278592869942031e-09
life O 0 2.6468634928278334e-07
threatening O 0 6.425039464375004e-05
conditions O 0 7.815052413207013e-06
. O 0 1.422842501597188e-06

This O 0 5.049345475072187e-08
study O 0 1.245921055215149e-08
also O 0 8.542881402284763e-10
provided O 0 4.899050054518739e-10
evidence O 0 1.7231374105364239e-09
for O 0 3.4128422310431006e-10
the O 0 5.900541721892694e-10
pathological O 0 6.169393884647434e-08
nature O 0 9.06441588455209e-09
of O 0 2.2008250777361127e-10
amino O 0 1.7462022938730115e-08
acid O 0 3.8807382196637263e-08
changes O 0 7.2180075250116715e-09
in O 0 1.4719812035934865e-09
APC O 0 1.6745151043551232e-08
associated O 0 3.104988488544791e-09
with O 0 3.3912600505559e-10
both O 0 3.464948994391648e-09
FAP B-Disease 0 2.6019836241175653e-07
and O 0 1.3588858926993908e-08
non O 0 8.58683415572159e-06
- O 1 0.9997633099555969
FAP O 1 0.9999760389328003
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 8.564205018046778e-06
. O 0 6.204181346447513e-08
. O 0 3.787614559769281e-07

Inherited B-Disease 1 0.9999676942825317
colorectal I-Disease 1 1.0
polyposis I-Disease 1 0.9999905824661255
and O 0 0.04287552088499069
cancer B-Disease 1 0.9979531764984131
risk O 0 0.00022662983974441886
of O 0 5.325484053742002e-09
the O 0 2.4257262865035045e-08
APC O 0 4.275284481991548e-06
I1307K O 0 1.4582671610696707e-05
polymorphism O 0 6.1278413340915e-05
. O 0 1.9035551304114051e-06

Germ O 0 0.006242968607693911
- O 0 0.011405272409319878
line O 0 1.017577801576408e-06
and O 0 1.0759168667107133e-08
somatic O 0 3.259341383454739e-07
truncating O 0 9.025616805047321e-07
mutations O 0 5.078728122498433e-07
of O 0 2.693818779153645e-10
the O 0 8.8283291788116e-10
APC B-Disease 0 1.7668501328671482e-08
gene O 0 1.214033762408917e-08
are O 0 7.960805903373114e-10
thought O 0 6.6326046876952205e-09
to O 0 4.885578164248727e-09
initiate O 0 2.260423343614093e-06
colorectal B-Disease 1 1.0
tumor I-Disease 0 0.00010233633656753227
formation O 0 3.43084730047849e-06
in O 0 4.6825352910673246e-05
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 0 0.0004065942484885454
sporadic O 1 0.9991387128829956
colorectal O 1 1.0
carcinogenesis O 1 0.9891214966773987
, O 0 8.344116508851585e-07
respectively O 0 2.064107093247003e-06
. O 0 8.421405937042437e-07

Recently O 0 6.546852546307491e-06
, O 0 1.5451828261348055e-08
an O 0 5.6498423717243895e-09
isoleucine O 0 5.155889812158421e-05
- O 0 2.8483882488217205e-05
- O 0 5.41809413334704e-06
> O 0 6.130305223450705e-07
lysine O 0 1.5096211427589878e-06
polymorphism O 0 4.086733042640844e-06
at O 0 5.55784076539112e-08
codon O 0 4.466809286896023e-07
1307 O 0 5.558767384172825e-07
( O 0 1.3260805786785568e-09
I1307K O 0 4.969716371761024e-08
) O 0 3.451346153315882e-10
of O 0 6.189398993328155e-11
the O 0 4.68241667661573e-10
APC B-Disease 0 9.631919262176325e-09
gene O 0 1.2291669904129776e-08
has O 0 3.2060090138230635e-09
been O 0 1.205369248857835e-09
identified O 0 2.0770976050243917e-09
in O 0 2.503545981635824e-10
6 O 0 5.530405022824425e-10
% O 0 3.930750447356246e-10
- O 0 8.10875775414388e-08
7 O 0 3.845164187055161e-09
% O 0 3.5876757120689717e-10
of O 0 1.5973412870184944e-10
the O 0 7.111349731303562e-09
Ashkenazi O 0 7.682156137889251e-06
Jewish O 0 4.5775752255394764e-07
population O 0 2.1499893421150773e-07
. O 0 3.897811780007032e-07

To O 0 1.3126764031312632e-07
assess O 0 6.026336905051721e-07
the O 0 5.857183627000495e-09
risk O 0 5.6643468582251444e-08
of O 0 8.457662348249073e-11
this O 0 9.150780133637682e-10
common O 0 2.3262177961669295e-08
APC B-Disease 0 2.1012706952205917e-07
allelic O 0 5.470609494295786e-07
variant O 0 6.885863967909245e-06
in O 0 1.7360213178108097e-07
colorectal O 1 1.0
carcinogenesis O 0 0.0018414153018966317
, O 0 4.826431254656427e-09
we O 0 1.2713957664445275e-09
have O 0 1.8606760576744819e-10
analyzed O 0 1.8781520783051064e-09
a O 0 2.848828950519078e-10
large O 0 7.170269267220419e-09
cohort O 0 1.704314911421534e-07
of O 0 9.740137585367847e-10
unselected O 0 1.9228487872169353e-05
Ashkenazi O 0 1.8316217392566614e-05
Jewish O 0 1.1583775716417222e-07
subjects O 0 7.168822691028254e-08
with O 0 4.6999653058321655e-09
adenomatous B-Disease 0 2.463542296027299e-05
polyps I-Disease 0 1.9749564671656117e-05
and O 0 7.382682909451432e-09
. O 0 2.4767137674075457e-08
or O 1 0.9141110777854919
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, I-Disease 0 3.0135938189346234e-09
for O 0 9.860704475173065e-10
the O 0 1.1224015494804007e-08
APC O 0 1.962973101399257e-06
I1307K O 0 4.271771103958599e-06
polymorphism O 0 1.9417273506405763e-05
. O 0 9.405925993632991e-07

The O 0 4.183819442005188e-07
APC O 0 1.0481135177542455e-06
I1307K O 0 1.5125623349376838e-06
allele O 0 1.2459969411793281e-06
was O 0 2.743496452239924e-08
identified O 0 1.2267615367989038e-08
in O 0 5.875441244640456e-10
48 O 0 1.8588679484565773e-09
( O 0 1.722492426470268e-10
10 O 0 2.0720712645694306e-10
. O 0 3.896004907577577e-10
1 O 0 9.733638339781692e-10
% O 0 4.2151335200024675e-10
) O 0 4.059015901169971e-10
of O 0 3.3815844568962916e-10
476 O 0 6.462079227276263e-07
patients O 0 5.370449684960477e-07
. O 0 2.0903854647258413e-07

Compared O 0 2.7358680654288037e-07
with O 0 1.0425474927799883e-09
the O 0 3.107167301230618e-10
frequency O 0 6.843814048806962e-08
in O 0 5.649903878079954e-10
two O 0 1.6246509693118583e-10
separate O 0 2.553723676967934e-09
population O 0 2.473884208598065e-09
control O 0 1.6423808091303727e-08
groups O 0 1.1588517923044606e-09
, O 0 2.5405372250375535e-10
the O 0 5.127662738857452e-10
APC O 0 3.891256028509815e-08
I1307K O 0 6.79857663499206e-08
allele O 0 6.919364636814862e-08
is O 0 8.122713612834787e-10
associated O 0 7.976050375724242e-10
with O 0 5.258026652965597e-11
an O 0 1.4460532771209955e-10
estimated O 0 6.351052572739491e-09
relative O 0 4.266028952315537e-07
risk O 0 1.596988568053348e-06
of O 0 2.1670938377127413e-09
1 O 0 1.3393022868513071e-07
. O 0 4.23211162114967e-07

5 O 0 6.84980841469951e-06
- O 0 4.9135844164993614e-05
1 O 0 9.699256224848796e-07
. O 0 6.332548423415574e-07

7 O 0 4.900947715213988e-06
for O 0 5.853400466548919e-07
colorectal B-Disease 1 1.0
neoplasia I-Disease 0 0.09219881892204285
( O 0 1.9939745854458124e-08
both O 0 2.640801355369149e-08
P O 1 0.7797879576683044
= O 0 0.00027134211268275976
. O 0 1.8831465808943904e-07
01 O 0 3.6077281038160436e-06
) O 0 4.6563084055151194e-08
. O 0 1.6595525664797606e-07

Furthermore O 0 8.532676929462468e-07
, O 0 8.141671337114076e-09
compared O 0 1.0309562981092313e-08
with O 0 1.0715052178866813e-09
noncarriers O 0 4.077472794961068e-07
, O 0 1.7620366277171229e-09
APC O 0 2.1123730320482537e-08
I1307K O 0 6.494019544334151e-08
carriers O 0 2.8044080835343266e-08
had O 0 1.9305697041005487e-09
increased O 0 5.07420050421814e-10
numbers O 0 2.091855577646129e-09
of O 0 7.348008312924037e-10
adenomas B-Disease 0 0.00033703568624332547
and O 0 0.00019303584122098982
colorectal B-Disease 1 1.0
cancers I-Disease 1 0.9625076055526733
per O 0 4.5098307310809105e-08
patient O 0 1.9284404118025122e-07
( O 0 4.8754595916022936e-09
P O 0 0.000479271198855713
= O 0 1.30106229789817e-06
. O 0 1.151089179529663e-08
03 O 0 7.749837038772966e-08
) O 0 3.217634492180821e-10
, O 0 3.338535350949634e-11
as O 0 5.171564565475961e-11
well O 0 1.8655729738803473e-10
as O 0 3.126553738130866e-10
a O 0 8.581912958049998e-10
younger O 0 1.5169389300240255e-08
age O 0 1.89492066482444e-08
at O 0 2.79093956834231e-08
diagnosis O 0 1.1651549357338808e-05
. O 0 4.924067980027758e-07

We O 0 8.898662713363592e-07
conclude O 0 1.0881286982566962e-07
that O 0 2.3978166119320576e-09
the O 0 1.1708938263410573e-09
APC O 0 7.26965581065997e-08
I1307K O 0 1.632527784067861e-07
variant O 0 2.661404892023711e-07
leads O 0 3.578869822717934e-08
to O 0 5.957346616014547e-09
increased O 0 1.0517577209157025e-07
adenoma B-Disease 1 1.0
formation O 0 1.9827073316491806e-08
and O 0 7.190315565175354e-10
directly O 0 8.003205875795061e-10
contributes O 0 1.148137251938408e-09
to O 0 1.9034132603401588e-10
3 O 0 5.391196933324238e-10
% O 0 5.530521041130498e-10
- O 0 3.723622654661085e-08
4 O 0 1.8596836293127694e-09
% O 0 2.9014399216542586e-10
of O 0 1.3873813209386299e-10
all O 0 2.056230563596273e-08
Ashkenazi O 0 0.01065788883715868
Jewish O 1 0.9362969398498535
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 4.0457057366438676e-06

The O 0 2.8291864850871207e-08
estimated O 0 2.208489036092942e-08
relative O 0 5.5500439799516244e-08
risk O 0 3.1423047630596557e-07
for O 0 1.132380522683718e-09
carriers O 0 3.932089143177109e-08
may O 0 3.3763785101115218e-09
justify O 0 6.420992182398777e-09
specific O 0 9.210350815358481e-10
clinical O 0 7.497412468637776e-09
screening O 0 3.1385467558209257e-09
for O 0 6.434397459287311e-11
the O 0 3.4875349136376244e-11
360 O 0 4.2087067164686687e-10
, O 0 4.368920850095215e-11
000 O 0 3.05761277408223e-10
Americans O 0 5.808341585478161e-10
expected O 0 1.7376949879022163e-10
to O 0 9.659322647292967e-11
harbor O 0 4.440418255313716e-09
this O 0 8.294757242177653e-11
allele O 0 1.3384257258053367e-08
, O 0 3.858886266083772e-10
and O 0 3.8410130631660877e-10
genetic O 0 1.1792881338124062e-08
testing O 0 6.395104890088987e-09
in O 0 5.548405832001002e-11
the O 0 3.959537905884325e-11
setting O 0 3.820430638512562e-10
of O 0 5.851148038304999e-11
long O 0 6.629960580539773e-09
- O 0 1.5845019163407414e-07
term O 0 2.277152049146025e-07
- O 0 7.490383779895637e-08
outcome O 0 5.553832505000855e-09
studies O 0 1.6557002435746426e-09
may O 0 3.6521269342060236e-10
impact O 0 1.4996712760506625e-09
significantly O 0 2.5904697054102144e-08
on O 0 0.001260294346138835
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
prevention O 0 4.330374636651868e-08
in O 0 6.369124672112036e-10
this O 0 2.844909863242151e-09
population O 0 5.7169128098166766e-08
. O 0 2.0800251832042704e-07

Localization O 0 7.204267603810877e-06
of O 0 1.0612870582349387e-08
human O 0 8.145259577929664e-09
BRCA1 O 0 8.44307749048312e-07
and O 0 5.27676924377829e-09
its O 0 2.1521826543136058e-09
loss O 0 9.02876990949153e-08
in O 0 9.254516042389582e-10
high O 0 2.8479254865487746e-07
- O 0 6.404535088222474e-05
grade O 0 4.893745426670648e-06
, O 0 4.420441790387031e-09
non B-Disease 0 6.831664336459653e-07
- I-Disease 0 0.07217837125062943
inherited I-Disease 1 0.9964889287948608
breast I-Disease 1 0.9999110698699951
carcinomas I-Disease 1 1.0
. O 0 7.286129857675405e-06

Although O 0 3.239631780616037e-07
the O 0 3.997453035253784e-09
link O 0 1.0928980742619387e-07
between O 0 9.251026611423185e-09
the O 0 2.4053347758012933e-08
BRCA1 O 0 0.1313331127166748
tumour B-Disease 1 1.0
- O 0 1.6576211692154175e-06
suppressor O 0 1.167263121715223e-06
gene O 0 6.383012305377633e-07
and O 0 1.0678010653464298e-07
hereditary B-Disease 1 0.9986928105354309
breast I-Disease 1 1.0
and I-Disease 1 0.9999991655349731
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
is O 0 2.3397352943987926e-09
established O 0 1.1420459022914997e-09
, O 0 1.1211166023317176e-10
the O 0 4.292434116481836e-11
role O 0 3.460035369329262e-09
, O 0 1.7480132619152045e-10
if O 0 4.4967962686826013e-10
any O 0 1.51124807112879e-10
, O 0 6.89844154022623e-11
of O 0 3.3418802447560125e-11
BRCA1 O 0 2.0096888420084724e-07
in O 0 4.067550740671777e-09
non B-Disease 0 4.865051596425474e-05
- I-Disease 1 0.5434243083000183
familial I-Disease 1 0.9967683553695679
cancers I-Disease 1 0.9998090863227844
is O 0 1.3540997656491527e-07
unclear O 0 8.299529667965544e-07
. O 0 4.7035462102940073e-07

BRCA1 O 0 0.00068102334626019
mutations O 0 1.566171704325825e-05
are O 0 1.3275415433611215e-08
rare O 0 2.856591052591284e-08
in O 0 7.397454648838675e-09
sporadic B-Disease 0 1.3774883882433642e-05
cancers I-Disease 1 0.9996811151504517
, O 0 3.975615392448617e-09
but O 0 2.037168655988353e-08
loss O 0 1.8529147993717743e-08
of O 0 3.3747030170339087e-10
BRCA1 O 0 7.094762395354337e-07
resulting O 0 2.4796820596861835e-08
from O 0 1.4996827113478162e-09
reduced O 0 1.5381374396383762e-08
expression O 0 1.3563404621663722e-08
or O 0 1.4146842808315796e-08
incorrect O 0 1.245567631258382e-07
subcellular O 0 5.473939381772652e-07
localization O 0 6.011762820889999e-08
is O 0 3.423560601678588e-10
postulated O 0 1.9826005281942116e-09
to O 0 1.0192104799022772e-10
be O 0 9.640364201368712e-11
important O 0 1.7657499074008598e-10
in O 0 7.314350791709501e-10
non B-Disease 0 3.760609104119794e-07
- I-Disease 0 0.0008625880000181496
familial I-Disease 1 0.9557378888130188
breast I-Disease 1 0.9999904632568359
and I-Disease 1 0.9999152421951294
ovarian I-Disease 1 1.0
cancers I-Disease 1 1.0
. O 0 5.330926342139719e-06

Epigenetic O 0 2.7162834157934412e-05
loss O 0 2.257857886434067e-05
, O 0 4.8162056565104194e-09
however O 0 1.359320656035834e-09
, O 0 1.661593224122626e-10
has O 0 2.9593430483920713e-10
not O 0 1.9714074817045457e-10
received O 0 1.5615178594607926e-10
general O 0 1.5592618862747543e-10
acceptance O 0 5.096210564659032e-09
due O 0 3.621013044963206e-09
to O 0 4.6164128075787403e-10
controversy O 0 5.0626507430706624e-09
regarding O 0 1.8706585169780965e-09
the O 0 8.90487072968682e-10
subcellular O 0 2.5096832700910454e-07
localization O 0 4.9910514832163244e-08
of O 0 6.557879794755195e-10
BRCA1 O 0 7.539130564282459e-08
proteins O 0 2.295211354308435e-09
, O 0 1.909551405887555e-10
reports O 0 3.3680411237746455e-10
of O 0 1.4904705941676255e-11
which O 0 3.4587602226743286e-10
have O 0 1.9194948408518542e-10
ranged O 0 4.5781900492869454e-10
from O 0 5.6436112727542564e-11
exclusively O 0 1.555223172466924e-09
nuclear O 0 7.734627871514022e-08
, O 0 4.209635764973463e-11
to O 0 2.5781378767963936e-11
conditionally O 0 7.148789116229182e-09
nuclear O 0 1.965657325797565e-08
, O 0 6.04277045068713e-11
to O 0 8.705589721325069e-11
the O 0 1.0160066121756017e-09
ER O 0 3.7302621080925746e-07
/ O 0 1.6032551286571106e-08
golgi O 0 1.958652120492843e-07
, O 0 4.765234318249156e-10
to O 0 3.5773853324094773e-10
cytoplasmic O 0 6.282453313133374e-08
invaginations O 0 3.2799025007079763e-07
into O 0 6.920034323343316e-09
the O 0 1.5220745552824155e-08
nucleus O 0 5.541290306609881e-07
. O 0 4.3099313984384935e-07

In O 0 9.100104136905429e-08
an O 0 1.335128230195437e-09
attempt O 0 1.756943213138129e-08
to O 0 8.463508227585237e-10
resolve O 0 8.631477754761363e-09
this O 0 7.16278494850009e-11
issue O 0 1.4479915044773861e-09
, O 0 2.1238728831196596e-10
we O 0 6.305171385001529e-10
have O 0 1.0568304009694884e-09
comprehensively O 0 1.5643580297819426e-07
characterized O 0 4.19913703808561e-08
19 O 0 1.7743539970638267e-08
anti O 0 5.633037289953791e-07
- O 0 7.380836905213073e-06
BRCA1 O 0 5.733540820074268e-05
antibodies O 0 5.93041750107659e-06
. O 0 8.566570954826602e-07

These O 0 1.1896084117779537e-07
reagents O 0 8.263886002168874e-07
detect O 0 2.2511128463520436e-06
a O 0 1.4372364631753953e-08
220 O 0 5.015902715399534e-08
- O 0 3.7753062542833504e-07
kD O 0 1.5998193703126162e-06
protein O 0 2.4010399002349914e-08
localized O 0 6.133866037316693e-08
in O 0 1.040858510492626e-09
discrete O 0 1.3395857934028754e-07
nuclear O 0 7.776621941957274e-07
foci O 0 1.326190641748326e-07
in O 0 1.3000226450898822e-09
all O 0 7.533546564353344e-10
epithelial O 0 4.404293463267095e-08
cell O 0 4.2045869008688896e-07
lines O 0 1.9195962863705063e-07
, O 0 1.910808455907187e-10
including O 0 9.178324766878632e-11
those O 0 3.00202668279681e-10
derived O 0 1.1434456936854076e-08
from O 0 3.4415748473293206e-08
breast B-Disease 0 0.046534132212400436
malignancies I-Disease 0 0.017343273386359215
. O 0 1.492076194153924e-06

Immunohistochemical O 0 0.0023534924257546663
staining O 0 0.000776618137024343
of O 0 3.945025284224357e-08
human O 0 1.1493653317984354e-07
breast O 0 2.0822268197662197e-05
specimens O 0 3.6674359193966666e-07
also O 0 2.554611810978713e-08
revealed O 0 5.087803174319561e-07
BRCA1 O 0 6.845420102763455e-06
nuclear O 0 6.126190328359371e-07
foci O 0 5.588592557614902e-07
in O 0 9.216541307921489e-09
benign O 0 6.699555797240464e-06
breast O 0 0.00015590146358590573
, O 0 3.5218526761582325e-08
invasive B-Disease 0 0.00027789422892965376
lobular I-Disease 1 0.999843955039978
cancers I-Disease 1 0.9999743700027466
and O 0 1.9439360698925157e-07
low B-Disease 0 6.38223355053924e-05
- I-Disease 1 0.5898348093032837
grade I-Disease 0 0.4023693799972534
ductal I-Disease 1 0.9970133304595947
carcinomas I-Disease 1 1.0
. O 0 1.639542642806191e-05

Conversely O 0 4.599030580720864e-05
, O 0 1.819592938545611e-07
BRCA1 O 0 3.8159050745889544e-06
expression O 0 1.1767001950602207e-07
was O 0 3.0486766888770944e-08
reduced O 0 1.3187037239958954e-08
or O 0 8.641690918409495e-09
undetectable O 0 5.566592449213204e-07
in O 0 5.010180048614643e-10
the O 0 3.208405208177112e-10
majority O 0 7.904464638386344e-09
of O 0 3.4305286389368916e-10
high O 0 2.3659717385271506e-07
- O 0 1.2523485565907322e-05
grade O 0 1.144015982390556e-06
, O 0 1.9385140159755565e-09
ductal B-Disease 0 7.426477168337442e-06
carcinomas I-Disease 1 1.0
, O 0 3.3736105020665264e-09
suggesting O 0 1.3396133091703177e-08
that O 0 5.846911843576663e-10
absence O 0 9.199711548113498e-10
of O 0 1.1258008414394283e-10
BRCA1 O 0 2.6428730848238047e-07
may O 0 4.323151614471499e-09
contribute O 0 1.2487462452970277e-10
to O 0 5.915570810977044e-11
the O 0 5.472396841232907e-11
pathogenesis O 0 2.0400721112423525e-09
of O 0 2.936110382600887e-11
a O 0 3.709370310911453e-10
significant O 0 5.160612381871488e-09
percentage O 0 1.1994761450750957e-07
of O 0 3.561598793666576e-09
sporadic B-Disease 0 0.056290239095687866
breast I-Disease 1 0.9999889135360718
cancers I-Disease 1 0.999671220779419
. O 0 1.6987571882509656e-07
. O 0 6.347398198158771e-07

